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Preface  to  ”Polyphenols  for  Cancer  Treatment  or 
Prevention”
The current special issue book focuses on the impact of an important plant-based, dietary
micronutrient, polyphenols, on cancer treatment and prevention. The range and type of research
presented is wide and varied, including original research, a number of comprehensive review articles
on specific polyphenols, polyphenol pharmacokinetics, specific cancer types, or polyphenols and
cancer prevention and treatment in general.
This special issue was inspired by my students who, from time to time, expressed their frustration
with the level of scientific evidence within the field of nutrition research with respect to health benefits
of food bioactives. Although it is recognised that nutritional health is personal and is more than
the sum of individual dietary components, it can be difficult to obtain interpretable results from a
systemic approach, in part due to the number of variables that cannot be controlled for. Evidence
of effect is more easily interpretable from tissue culture, animal model and human trials utilising
individual dietary components or a limited combination of dietary components. For this reason these
are the study types presented in this book.
Polyphenols are a broad group of plant-based chemical compounds. They are particularly well
known for their inhibitory effects on cancer cells, and for their anti-oxidant activity. Polyphenols have
been tested alone, in combination, and with conventional cancer drugs and are of interest as they have
been found to induce apoptosis, inhibit proliferation, angiogenesis and metastasis, and modulate the
immune system in cancer cells/tissues. Polyphenols are readily consumed in a diet rich in fresh fruit
and vegetables and an increase in consumption could be encouraged by robust scientific evidence of
health benefits.
Comprehensive reviews are presented on the use of polyphenols, both singularly and in
combination, for the prevention and treatment of breast cancer (Braakhuis et al. 2016), as well as
mechanism involved (Abdal Dayem et al. 2016), and for cancers in general (Zhou et al. 2016 and
Niedzwiecki et al. 2016). In addition, the double edged sword of the influence of polyphenols on
DNA damage, a reduction in damage in response to low doses and an increase in damage in response
to high doses, is discussed in depth by Asqueta and Collins (2016). A review article of particular
interest was that prepared by Benvenuto et al. 2016 on the response of asbestos induced malignant
mesothelioma to the immune modulatory effects of polyphenols. Treatment options for malignant
mesothelioma are limited, and in addition to providing a profile of up and down regulated cytokines,
Benvenuto et al (2016) suggest ways in which the challenge of polyphenol bioavailability can be
overcome. This article generated a high almetrix score and was widely publicised in the USA.
A number of articles have been included in this book that speak specifically to the anti-
carcinogenic effects of specific polyphenols such as quercetin (Khan et al., 2016) and its glycoside
form quercitrin (Truong et al. 2016), tea catechins (Xiang et al. 2015), resveratrol (Li et al. 2016; Pavan
et al. 2016); curcumin (Pavan et al. 2016; Bimonte et al. 2016); mangiferin (Gold-smith et al. 2016);
citrus extracts (Cirmi et al. 2016); olive leaf extract (oleurpein) (Boss et al. 2016); Elderflower extracts
(Schrder et al. 2016), Chinese Bayberry Anthocyanin Extract (Wang et al. 2016); cuminaldehyde
(Tsai et al. 2016); Punica granatum Juice (Tibulla et al. 2016); and rosemary extract (Moore et al. 2016).
ix
Lastly, a number of articles included in this book include a discussion on polyphenol
bioavailability, but Mandalari et al., Cao et al., Darag et al., Benvenuto et al. and Granja et al.
specifically address polyphenol bioavailability, bioaccessibility, toxicology and nano-delivery.
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Abstract: Background: Activated STAT3 signaling is critical for human medulloblastoma cells. SHP2,
SOCS3 and PIAS3 are known as the negative regulators of STAT3 signaling, while their relevance to
frequent STAT3 activation in medulloblastomas remains unknown. Methods: Tissue microarrays
were constructed with 17 tumor-surrounding noncancerous brain tissues and 61 cases of the classic
medulloblastomas, 44 the large-cell medulloblastomas, and 15 nodular medulloblastomas, which
were used for immunohistochemical profiling of STAT3, SHP2, SOCS3 and PIAS3 expression patterns
and the frequencies of STAT3 nuclear translocation. Three human medulloblastoma cell lines
(Daoy, UW228-2 and UW228-3) were cultured with and without 100 μM resveratrol supplementation.
The influences of resveratrol in SHP2, SOCS3 and PIAS3 expression and SOCS3 knockdown in
STAT3 activation were analyzed using multiple experimental approaches. Results: SHP2, SOCS3 and
PIAS3 levels are reduced in medulloblastomas in vivo and in vitro, of which PIAS3 downregulation
is more reversely correlated with STAT3 activation. In resveratrol-suppressed medulloblastoma
cells with STAT3 downregulation and decreased incidence of STAT3 nuclear translocation, PIAS3 is
upregulated, the SHP2 level remains unchanged and SOCS3 is downregulated. SOCS3 proteins are
accumulated in the distal ends of axon-like processes of resveratrol-differentiated medulloblastoma
cells. Knockdown of SOCS3 expression by siRNA neither influences cell proliferation nor STAT3
activation or resveratrol sensitivity but inhibits resveratrol-induced axon-like process formation.
Conclusion: Our results suggest that (1) the overall reduction of SHP2, SOCS3 and PIAS3 in
medulloblastoma tissues and cell lines; (2) the more inverse relevance of PIAS3 expression with
STAT3 activation; (3) the favorable prognostic values of PIAS3 for medulloblastomas and (4) the
involvement of SOCS3 in resveratrol-promoted axon regeneration of medulloblastoma cells.
Keywords: medulloblastoma; STAT3 signaling; STAT3 negative regulators; PIAS3; resveratrol
1. Introduction
Medulloblastoma is the most frequent primary brain malignancy in childhood and is characterized
by rapid and aggressive intracranial growth and high recurrence incidence [1]. Although the
combination of operation with adjuvant radiotherapy and/or chemotherapy has been adapted in
clinical settings [2], the outcome of medulloblastomas remains poor due to the difficulty in removing
the highly aggressive tumor radically and the long-term side effects of conventional anticancer
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therapies [3,4]. It is therefore urgently necessary to investigate the critical molecular alterations
related with medulloblastoma formation and progression and to explore more effective therapeutic
approaches with lesser toxicities for better management of medulloblastomas.
Several signaling pathways are known to be involved in the formation and progression of
medulloblastomas [5–7], of which STAT3 signaling seems most crucial because selective inhibition of
STAT3 activation suppresses growth and induces apoptosis of medulloblastoma cells [5,8,9]. However,
the underlying mechanism by which STAT3 signaling is inhibited by resveratrol remains largely
unknown. It has been found that several factors can negatively regulate STAT3 signal transduction.
For instance, induction of SHP-1 and SHP-2 tyrosine phosphatases inhibit constitutive and inducible
STAT3 activation and loss of protein tyrosine phosphatase leads to aberrant STAT3 activation and
promotes gliomagenesis [10,11]. Similarly, PIAS3 down-regulation is associated with increased STAT3
activation and poor prognosis of malignant mesothelioma patients [12]. In some types of human
malignancies, an interplay between STAT3 signaling and SOCS3 has been found in the form of feedback
control [13,14]. Nevertheless, no comprehensive study is so far available concerning the statuses of
those negative regulators in medulloblastoma tissues and their relevance with STAT3 activation.
Resveratrol (3,5,4′-trihydroxy-trans-stilbene), a naturally occurring polyphenol found in grapes,
peanuts and the root of polygonum cuspidatum, has preventive and therapeutic effects on many
kinds of human cancers including brain malignancies [15]. More importantly, the in vitro and
in vivo anticancer doses of resveratrol have little toxic effect on the normal tissues and cells [16–18].
For example, resveratrol in 100 μM is sufficient to cause growth arrest and apoptosis of human
medulloblastoma and glioblastoma cells in vitro [16,19] and rat orthotopic glioblastomas in vivo
without affecting glial cells and neurons [18]. These findings thus suggest that resveratrol would be of
potential practical value in improving the therapeutic outcome of medulloblastomas. Our previous
studies demonstrate that STAT3 signaling is the critical molecular target of resveratrol although other
signaling pathways are inhibited concurrently in resveratrol-treated medulloblastoma cells [19–21].
However, the reasons for resveratrol-caused STAT3 inactivation remain to be clarified. The current
study aims to address these issues using medulloblastoma microarrays to profile SHP2, SOCS3 and
PIAS3 expression patterns in medulloblastoma tissues and resveratrol-sensitive medulloblastoma cell
lines to elucidate the impact(s) of resveratrol in SHP2, SOCS3 and PIAS3 expression when exerting its
inhibitory effect on STAT3 signaling and cell proliferation.
2. Experimental Section
2.1. Medulloblastoma Specimens and Microarray Construction
The protocol of this study had been reviewed by the Ethics Committee of Dalian Medical
University before conducting the experiments. The archived 120 paraffin-embedded medulloblastoma
specimens were kindly provided by the Clinical Pathology Departments, the First Affiliated Hospital of
Dalian Medical University and Shen-Jing Hospital of China Medical University at Shenyang. This study
was approved by the hospital institution review board and the informed consent was obtained from
all patients before tissue sample collection. The tissue microarrays were constructed in duplicate with
120 medulloblastoma and, where possible, the noncancerous tumor-surrounding brain tissue blocks
by the method described previously [22].
2.2. Tissue Microarray-Based Immunohistochemical Staining
The expression levels and intracellular distribution patterns of STAT3, SHP2, SCOS1, SOCS3
and PIAS3 in the three subtypes (the classical, the large-cell and the nodular) of medulloblastomas
were profiled immunohistochemically, using paraffin sections of the constructed medulloblastoma
microarrays. The antibodies used were the rabbit anti-human p-STAT3 (Proteintech, Chicago, IL, USA),
SCOS1, SCOS3, PIAS3 and SHP2 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) antibodies at
dilutions of 1:120, 1:100, 1:100, 1:120 and 1:100, respectively. Color reaction was developed using 3,
2
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3′-diaminobenzidine tetrahydrochloride (DAB). The sections without the first antibody incubation
were used as the background control. According to the labeling intensity, the staining results were
evaluated by two researchers, and scored as negative (−) if no immunolabeling was observed in target
cells, weakly positive (+) if the labeling was faint, moderately positive (++) if the labeling was stronger,
and strongly positive (+++) if the labeling was distinctly stronger than (++).
2.3. Cell Culture and Resveratrol Treatments
Human medulloblastoma UW228-2 and UW228-3 cell lines were kindly provided by Dr. Keles
GE, Department of Neurosurgery, Washington University at Seattle. Human medulloblastoma DAOY
cell line was obtained from the Cell Culture Facility, Chinese Academy of Sciences Cell Bank, Shanghai.
The three cell lines were cultured in DMEM (Gibco Life Science, Grand Island, NY, USA) supplemented
with 10% fetal bovine serum (Gibco, Grand Island, NY, USA) under 37 ◦C and 5% CO2 condition
and were plated onto culture dishes (Nunc A/S, Roskilde, Denmark) at a density of 5 × 104/ml, and
incubated for 24 h before further experiments. For paralleled H/E staining, Immunocytochemical (ICC)
labeling and transferase-mediated deoxyuridine triphosphate-biotin nick end labeling TUNEL assay
(Promega, Madison, WI, USA), dozens of cell-bearing coverslips were concurrently prepared under
the exact same experimental conditions using Nest-Dishes (Nest Biotech., Inc., Wuxi, China; China
invention patent No. ZL200610047607.0) and collected regularly during drug treatments. Resveratrol
(Res; Sigma-Aldrich, St. Louis, MO, USA) was dissolved in dimethylsulfoxide (DMSO; Sigma-Aldrich,
St. Louis, MO, USA) and diluted with culture medium to the optimal working concentration (100 μM)
just before use. The cells were treated by 100 μM RA for 72 h, while the cells under normal culture
condition and treated by 0.2% DMSO were used as normal and background controls, respectively.
Cell numbers and viabilities were checked in 12 h intervals and the cell-bearing coverslips were fixed in
cold acetone or 4% paraformaldehyde (pH 7.4) for morphological, immunocytochemical examinations
and TUNEL assay. The experimental groups were set in triplicate and the experiments as well as the
following examinations were repeated for three times to establish confidential conclusion.
2.4. Immunocytochemical Staining
Immunocytochemical (ICC) staining for p-STAT3, SOCS1, SOCS3, PIAS3 and SHP2 was performed
on the coverslips of the three medulloblastoma cell lines collected from different experimental groups.
The antibodies and their dilutions are the same as that used in immunohistochemical staining for
tissue microarray sections. The cell-bearing coverslips without the first antibody incubation were used
as the background control.
2.5. Protein Preparation and Western Blotting
Total cellular proteins were prepared from the cells under different culture conditions. The sample
proteins (15 μg/lane) were separated by electrophoresis in 10% sodium dodecylsulfate–polyacrylamide
gel electrophoresis and transferred to polyvinylidene difluoride membrane (Amersham,
Buckinghamshire, UK). The membrane was blocked with 5% skimmed milk in TBS-T (10 mM Tris–Cl,
pH 8.0, 150 mM NaCl and 0.5% Tween 20) at 4 ◦C overnight, rinsed three times with TBS-T and followed
by 3 h incubation at room temperature with the first antibody, and 1 h incubation with HRP-conjugated
anti-rabbit IgG (Zymed Lab Inc., San Francisco, CA, USA). The bound antibody was detected using
the enhanced chemiluminescence system (Roche, Penzberg, Germany). After removing the labeling
signal by incubation with stripping buffer (62.5 mM Tris–HCl, pH 6.7, 100 mM 2-mercaptoethanol,
2% SDS) at 55 ◦C for 30 min, the membrane was reprobed with other antibodies one-by-one until all of
the parameters were examined.
2.6. RNA Isolation and RT-PCR
Total cellular RNAs of the experimental groups were extracted using Trizol solution (Life Technology,
Grand Island, NY, USA). The sample RNAs were subjected to reverse transcription/RT and then
3
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polymerase chain reaction/PCR using the primers specific for STAT3, PTP, SOCS1, SOCS3 and
PIAS3 according to producer’s protocols (Takara Inc., Dalian Branch, Dalian, China). The sequences
of PCR primers for each of the gene transcripts were listed in Table 1. The PCR products were
resolved on ethidium bromide-stained 1.5% agarose gel and photographed under UV illumination
(UVP, LLC, Upland, CA, USA). β-actin products generated from the same RT solutions were used as
quantitative control.







56 ◦C 477 bp [16]R: 5′-TGCTTCTGTCTGGACCATCC-3′
SOCS3
F: 5′-GAGCCCCCTCCTTCCCCTCGC-3′
56 ◦C 264 bp [21]R: 5′-GGTCCAGGAACTCCCGAATG-3′
PIAS3
F: 5′-ACGCTGTTGGCCCCTGGCAC-3′
56 ◦C 411 bp [22]R: 5′-GGGGCTCGGCCCCATTCTTGG-3′
β-actin
F: 5′-GCATGGAGTCCTGTGGCAT-3′
58 ◦C 326 bp [17]R: 5′-CTAGAAGCATTTGGGGTGG-3′
2.7. siRNA Knockdown of SOCS3 Expression
UW228-3 cells were selected to elucidate the impact(s) of SOCS3 down-regulation in cell
growth, STAT3 activation and resveratrol sensitivity by SOCS3-specific siRNA transfection
(siSOCS3-1: 5′-CCAAGAACCTGCGCATCCA-3′; siSOCS3-2: 5′-AGAGCCTATTACATCTACT-3′) [23].
The mock oligonucleotides (sense-50-UUCUCCGAACGUGUCACGUTT-30 and antisense-50-
ACGUGACACGUUCGGAGA) and β-actin siRNAs (sense-50-UGAAGAUCAAGAUCAUUGCdTdT-30
and antisense-50-GCAAUGAUCUUGAUCUUCAdTdT-30) were used as negative and positive
controls of transfection efficiency [24]. Those siRNAs were synthesized by Genepharma Company,
Shanghai, China. Briefly, UW228-3 cells were conventionally cultured in 6-well plates to 60% to
70% confluence and then transfected with 0.3 nmol siRNA/well for 2 or 3 days using 4 mL
X-tremeGENE siRNA transfection reagent according to manufacturer’s manual (Roche, Penzberg,
Germany). After confirming the efficiency of SOCS3 inhibition by RT-PCR, the transfectants were
incubated in the medium without or with 100 μM resveratrol for 72 h; afterward, the cells were
examined by morphological staining, viable and nonviable cell counting, STAT3- and SOCS3-oriented
immunolabeling. The results were compared with those obtained from the normally cultured cells and
the cells treated by mock oligonucleotides.
2.8. Statistical Analyses
The results obtained from tissue microarray based immunohistochemical profiling were evaluated
with the independent-samples t-test and ANOVA. Data were presented as mean ± standard deviation
(SD) of separate experiments (n ≥ 10). When required, p-values are stated in the figure legends.
3. Results
3.1. Frequent STAT3 Activation in Medulloblastomas
According to the criteria of World Health Organization classification system [25], 120 medulloblastoma
specimens were classified into three histological subtypes as classical (61 cases), large-cell (44 cases)
and nodular (15 cases). The levels and intracellular distribution patterns of p-STAT3 in the three
subtypes were analyzed according to the results of tissue microarray-based immunohistochemical
staining. It was found that nuclear translocation of p-STAT3 could be observed in 63.9% (39/61) of
the classical, 81.8% (36/44) of the large-cell, 53.3% (8/15) of the nodular medulloblastomas and 23.5%
(4/17) of tumor-surrounding brain tissues (Figure 1). Statistical analyses (ANOVA) reveal that the
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staining densities and the frequencies of p-STAT3 nuclear translocation are significantly different
between the three medulloblastoma subtypes and the tumor-surrounding brain tissues (p = 0.000).
Figure 1. Incidences of p-STAT3 nuclear translocation in noncancerous brain tissues and the three
histological subtypes of medulloblastomas.
3.2. Differential SHP2, SOCS3 and PIAS3 Expression Patterns
The results of immunohistochemical staining were summarized in Table 2 and shown in
Figures 2 and 3. It was revealed that the frequencies of p-SHP2 cytoplasmic labeling were significantly
different between the tumor-surrounding brain tissues (17/17; 100%) and the classical (32/61;
52.5%; p = 0.016), the large-cell (27/44; 61.4%; p = 0.000) or the nodular medulloblastomas (2/15;
13.3%; p = 0.000). The frequencies of SOCS3 cytoplasmic detection were 100% (17/17) in the
tumor-surrounding brain tissues, 80.3% (49/61) in the classical, 90.9% (40/44) in the large-cell and
80.0% (12/15) in the nodular medulloblastomas (Figure 3). Statistical analyses showed no significant
differences between the tumor-surrounding brain tissues and the classical (p > 0.05), the large-cell
(p > 0.05) or the nodular medulloblastomas (p > 0.05). In the case of PIAS3, significant differences
of nuclear PIAS3 detection were evidenced between the tumor-surrounding brain tissues (58.8%;
10/17) and the classical (21.3%; 13/61; p = 0.000), the large-cell (15.9%; 7/44; p = 0.000) or the nodular
medulloblastomas (6.70%; 1/15; p = 0.000).










p− + ≥++ − + ≥++ − + ≥++ − + ≥++
(%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%)
Noncancerous
15 14 1 0 0 4 11 0 1 14 5 7 3
(93.3) (6.7) (0.0) (0.0) (26.7) (73.3) (0.0 (6.7) (93.3) (33.3) (46.7) (20.0)
MB
112 12 45 55 0.000
#
54 36 22 0.000
#
17 37 58 0.003
#
88 11 13 0.001
#(10.7) (40.2) (49.1) (48.2) (32.1) (19.7) (15.2) (33.0) (51.8) (78.6) (9.8) (11.6)
Large
46 2 16 28 0.000
*
18 15 13 0.001
*
4 12 30 0.000
*
35 6 5 0.000
*(4.3) (34.8) (60.9) (39.1) (32.6) (28.3) (8.7) (26.1) (65.2) (76.1) (13.0) (10.9)
Classic
58 5 26 27 0.000
&
29 21 8 0.001
&
11 21 26 0.004
&
45 5 8 0.000
&(8.6) (44.8) (46.6) (50.0) (36.2) (13.8) (19.0) (36.2) (44.8) (77.6) (8.6) (13.8)
Nodular
8 5 3 0 7 1 0 2 4 2 8 0 0
(62.5) (37.5) (0.0) (87.5) (12.5) (0.0) (25.0) (75.0) (25.0) (100) (0.0) (0.0)
#: Noncancerous vs. Large; *: Noncancerous vs. Classic; &: Noncancerous vs. Nodular.
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Figure 2. Immunohistochemical illustration (20×) of expression levels and intracellular distribution
patterns of STAT3, SHP2, SOCS3 and PIAS3 in the three medulloblastoma subtypes and the
tumor-surrounding cerebellum tissues. The arrows indicate the regions shown in the insets with
higher magnification (40×).
Figure 3. Fractionation of STAT3 nuclear translocation and SHP2, SOCS3 and PIAS3 expression levels
in the tumor-surrounding noncancerous brain tissues (Upper left) and the large-cell (Upper right),
classical (Low left) and nodular medulloblastomas (Low right). * Statistical analyses show significant
reduction of their detection rates in comparison with that of the tumor-surrounding brain tissues
(p = 0.000).
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3.3. STAT3 Activation and SOCS3 and PIAS3 Down-Regulation
The concurrent p-STAT3 nuclear translocation and p-SHP2, SOCS3 and/or PIAS3 down-regulation
are summarized in Figure 3, followed by correlative analyses to elucidate the relevance of p-STAT3
nuclear translocation and the expression levels of p-SHP2, SOCS3 and PIAS3, respectively. Statistical
correlations were established between p-STAT3 nuclear translocation and the level of SOCS3 (R = 0.333;
p = 0.047) or PIAS3 expression (R = −0.494; p = 0.002) but not p-SHP2 down-regulation (R = 0.02;
p > 0.05) in the large-cell medulloblastomas. Inverse correlation could be established between p-SHP2
(R = −0.35; p = 0.029), SOCS3 (R = 0.495; p = 0.001) or PIAS3 expression (R = −0.352; p = 0.020) and
p-STAT3 nuclear translocation in the classic medulloblastomas. The corresponding data of the nodular
group were not analyzed due to the limited case number.
3.4. Inhibited STAT3 Signaling in Resveratrol-Suppressed Cells
Growth suppression, remarkable morphological alteration and frequent cell death were observed
in UW228-2, UW228-3 and DAOY cells in a time-related fashion after 100 μM resveratrol treatment,
and the majority of resveratrol-treated cells died of apoptosis at the 72-h time point [9,16]. As shown
in Figure 4, high levels of STAT3 expression and distinct STAT3 nuclear translocation were observed in
the three normally cultured medulloblastoma cell lines; the inhibitory effects of resveratrol on STAT3
signaling were evidenced in terms of reduction of STAT3 nuclear immunostaining (Figure 4) and
down-regulated STAT3 expression (Figure 5).
Figure 4. Immunocytochemical demonstration of STAT3, p-SHP2, SOCS3 and PIAS3 expression in
three human medulloblastoma cell lines without (NC) and with 100 μM resveratrol treatment (Res) for
48 h (20×). Arrows in the immunofluorescent images (40×) indicate SOCS3 accumulation in the distal
end of the axon-like processes of the three resveratrol-treated medulloblastoma cell lines. The inset
images are the normally cultured cells.
3.5. Differential Responses of PIAS3, SOCS3 and SHP2 to Resveratrol
The results of immunocytochemical staining (Figure 4), RT-PCR (Figure 5A) and Western blotting
(Figure 5B) demonstrated that the level of PIAS3 was low in normally cultured UW228-2, UW228-3
and DAOY cells, which became increased with distinct nuclear labeling after resveratrol treatment for
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48 h. SOCS3 levels were reduced in resveratrol-treated cells (Figure 5), accompanied with preferable
accumulation of SOCS3 proteins in the distal end of the axon-like long process (Figure 4). SHP2 was
expressed in the three cell lines and its level remained almost unchanged in resveratrol-treated cells.
Figure 5. The results of RT-PCR (A) and Western blotting (B) and their grayscale analyses for STAT3,
p-SHP2, SOCS3 and PIAS3 expression in three human medulloblastoma cell lines without and with
100 μM resveratrol treatment for 48 h.
3.6. SOCS3 Knockdown Caused Process Shortening
The results of RT-PCR demonstrate that the level of SOCS3 transcription is remarkably suppressed
(Figure 6A), accompanied with decreased SOCS3 immuno-labeling in SOCS3 siRNA transfected cells
(Figure 6B). H/E staining (data not shown) and viable:nonviable cell counting (Figure 6C) reveal
that neither morphological alteration nor distinct cell death are found in the transfected population.
p-STAT3-oriented immunocytochemical staining demonstrates p-STAT3 nuclear translocation in
normally cultured transfectants and its remarkable reduction after resveratrol treatment (Figure 6D).
After being treated by 100 μM resveratrol, the SOCS3 siRNA transfectants show distinct growth arrest
in a time-related fashion (Figure 6C) without forming long axon-like processes (Figure 6B,D). SOCS3
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level and growth of UW228-3 cells treated by 10 μM mock oligonucleotides are similar to those of
normally cultured cells (Figure 6A,B).
Figure 6. Knockdown of SOCS3 expression and its influence in STAT3 activation, resveratrol-sensitivity
and axon-like process regeneration of medulloblastoma UW228-3 cells. (A) RT-PCR demonstration of
SOCS3 downregulation in SOCS3-specific siRNA transfected UW228-3 cells (siRNA). The normally
cultured (C), and mock RNA transfected (mock) cells are used as controls; (B) Immunofluorescent
illustration (20×) of SOCS3 expression and intracellular distribution in normally cultured (C), mock
RNA transfected (mock) and SOCS3-specific siRNA transfected UW228-3 cells (siRNA) before (N)
and after resveratrol treatment (Res); (C) Viable:nonviable cell counting (mean cell number/visual
field) reveals no influence of SOCS3 knockdown in the proliferation and resveratrol sensitivity of
UW228-3 cells. N, UW228-3 cells without siRNA transfection; siRNA, normally cultured SOCS3 siRNA
transfected UW228-3 cells; siRNA+Res, 100 μM resveratrol-treated UW228-3 cells with SOCS3 siRNA
transfection; (D) SOCS3 knockdown exerts little effect on STAT3 activation in normally cultured cells
(C) and resveratrol-caused STAT3 inactivation of UW228-3 cells (Res).
4. Discussion
Severe short- and long-term adverse effects and frequent drug resistance are the major therapeutic
dilemma in the management of childhood medulloblastomas [2–4]. It is therefore necessary to
explore safer and more effective anti-medulloblastoma drugs. Our previous studies demonstrate
that resveratrol efficiently suppresses growth and induces neuronal-like differentiation and extensive
apoptosis of human medulloblastoma cells [9,19–21]. More importantly, this polyphenol compound
has little harmful effect on rat glial cells and neurons in vitro and in vivo [16,18], suggesting its
suitability for treating this sort of pediatric malignancy and the need to investigate the molecular
event(s) occurring in resveratrol-treated medulloblastoma cells.
STAT3 signaling plays a pivotal role in regulating differentiation and proliferation of neuronal
cells [26] and its activation is closely related with brain cancer formation [27,28]. Accordingly, our
current study reveals that STAT3 nuclear translocation is frequently observed in classical and large-cell
medulloblastomas in comparison with the tumor-surrounding brain tissues. According to the clinical
data, the prognoses of medulloblastomas vary in a subtype-related manner. For instance, the patients
with nodular tumors usually have relatively better prognoses, while the fates of the patients with
classic and especially large-cell tumors are extremely poor [29]. Because some cancer prognostic factors
such as VEGF, Bcl-2 and survivin are the downstream genes of STAT3 signaling, the constitutive
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STAT3 activation may lead to unfavorable outcomes for the large-cell and classic medulloblastomas.
In this context, it would be worthwhile to elucidate the statuses of STAT3 regulatory factors and their
correlations with STAT3 activation in medulloblastomas.
It has been recognized that STAT3 signaling can be regulated positively [28,29] or
negatively [10–14]. Multiple factors have been identified as STAT3 signaling promoters, including
IL-6 [30] and LIF [31] which are over expressed in medulloblastomas [32]. Nevertheless, we found that
LIF was up-regulated in resveratrol-treated medulloblastoma cells with STAT3 inactivation presumably
due to the feedback loop of STAT3 and LIF in those cells [9]. Alternatively, this finding suggests the
presence of additional factor(s) that might negatively regulate STAT3 signaling. However, no report is
so far available concerning the statuses of intrinsic STAT3 inhibitory factors in medulloblastomas and
the impacts of resveratrol in their expression.
Several molecular factors are supposed to negatively regulate STAT3 signaling in different
manners. PIAS3 inhibits STAT3 signaling by interrupting the interaction of p-STAT3 with its target
genes [12]; SHP2 is a non-receptor type protein tyrosine phosphatases and its phosphorylated form
(p-SHP2) interferes STAT-3 activation by dephosphorylating the active STAT-3 complexes in the
cytoplasm and in nucleus [10]. SOCS3 works in a classic negative feedback loop to attenuate STAT3
activity by suppressive binding with phosphorylated JAK [14] and/or facilitating ubiqitination of
JAK in the cytoplasm [33]. To shed light on the potential link(s) of these three negative regulators to
STAT3 activation, their expression patterns in the three subtypes of medulloblastomas were profiled by
tissue microarray-based immunohistochemical staining. The results revealed the general reductions
of p-SHP2, SOCS3 and especially PIAS3 levels in the three medulloblastoma subtypes with frequent
p-STAT3 nuclear translocation. It was also found that p-SHP2 downregulation was inversely correlated
with STAT3 activation in classic but not large-cell medulloblastomas, suggesting differential regulation
of STAT3 signaling in the histological subtypes of medulloblastomas. It would be therefore necessary
to clarify whether the downregulation of those negative regulators is directly linked to or merely the
paralleled molecular events with STAT3 activation. Alternatively, it would be more convincing if the
levels of SHP2, SOCS1/SOCS3 and/or PIAS3 are altered accordingly in medulloblastoma cells with
suppressed STAT3 signaling.
Our previous results clearly demonstrated that resveratrol can attenuate STAT3 activation of
medulloblastoma cells via inhibiting STAT3 transcription and nuclear translocation [9]. Therefore,
the resveratrol-treated medulloblastoma cells would be an ideal model to evaluate the role of SHP2,
SOCS3 or PIAS3 in regulating STAT3 signaling. It is found that upon resveratrol treatment, PIAS3 is
up-regulated and translocalized in nuclei, SOCS3 level is reduced and SHP2 remains unchanged in the
three medulloblastoma cells so far checked. These findings thus suggest that of the three so-called
STAT3 negative regulators examined here, PIAS3 rather than the other two proteins may be more
correlated with resveratrol-caused STAT3 inactivation.
It has been proposed that SOCS3 is up-regulated as a feedback response to STAT3 activation [13,14].
Therefore, it would be possible that SOCS3 level is reduced in resveratrol-treated medulloblastoma cells
with suppressed STAT3 signaling. The maintenance of STAT3 activation in SCOS3 siRNA transfected
UW228-3 cells is in accordance with this notion. It has been evidenced that resveratrol inhibits
growth and induces neuronal-like differentiation of human medulloblastoma cells [9]. Our finding
of preferable accumulation and intracellular rearrangement of SOCS3 to the synapse-like end of the
long processes indicates the involvement of this protein in axon regeneration [34]. This speculation is
elucidated and proved by treating SOCS3 siRNA transfected UW228-3 cells with resveratrol, because
the transfectants remain sensitive to resveratrol but fail to form axon-like long processes. These findings
also suggest SOCS3 as a potential indicator of resveratrol-promoted neuronal differentiation of
medulloblastoma cells.
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5. Conclusions
Taken together, the expression patterns of three STAT3 negative regulators and their correlation
with STAT3 activation in human medulloblastomas are investigated in this study. The results reveal that
PIAS3 downregulation is more reversely correlated with STAT3 activation. PIAS3 upregulation and
nuclear translocation in resveratrol-treated medulloblastoma cells with suppressed STAT3 signaling
further suggests the negative regulatory effects of PIAS3 on STAT3 signaling and the potential value of
PIAS3 in evaluating the prognosis of medulloblastoma patients. Inhibition of resveratrol-induced long
process formation by SOCS3 siRNA transfection suggests the active role of SOCS3 in axon regeneration.
In the future, we will further elucidate the influence of PIAS3 manipulation in the survival and
resveratrol sensitivities of medulloblastoma cells.
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Abstract: Herein we investigated the effect of elderflower extracts (EFE) and of enterolactone/enterodiol
on hormone production and proliferation of trophoblast tumor cell lines JEG-3 and BeWo, as well
as MCF7 breast cancer cells. The EFE was analyzed by mass spectrometry. Cells were incubated
with various concentrations of EFE. Untreated cells served as controls. Supernatants were tested for
estradiol production with an ELISA method. Furthermore, the effect of the EFE on ERα/ERβ/PR
expression was assessed by immunocytochemistry. EFE contains a substantial amount of lignans.
Estradiol production was inhibited in all cells in a concentration-dependent manner. EFE upregulated
ERα in JEG-3 cell lines. In MCF7 cells, a significant ERα downregulation and PR upregulation were
observed. The control substances enterolactone and enterodiol in contrast inhibited the expression of
both ER and of PR in MCF7 cells. In addition, the production of estradiol was upregulated in BeWo
and MCF7 cells in a concentration dependent manner. The downregulating effect of EFE on ERα
expression and the upregulation of the PR expression in MFC-7 cells are promising results. Therefore,
additional unknown substances might be responsible for ERα downregulation and PR upregulation.
These findings suggest potential use of EFE in breast cancer prevention and/or treatment and warrant
further investigation.
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1. Introduction
A growing body of data points to health benefits of phytoestrogens in diet and to possible
pharmaceutical applications [1]. The two main groups of phytoestrogens, isoflavones and lignans,
are polyphenolic compounds derived from plants with a molecular structure that closely resembles
mammalian estrogens [2]. Due to their molecular structure, these compounds can bind and interact
with human estrogen receptors (ER) resulting in both estrogen and anti-estrogen effects [3]. Thus,
it is assumed that some phytoestrogens can be classified as selective estrogen receptor modulators
(SERM) [4,5].
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Isoflavones are mostly found in legumes, with the most common representative being soy
and its derivative products [6], making them more common in Asian diets, whereas lignans, more
common in occidental diets, are usually found in seeds and fiber-rich cereals [7,8]. Their role in the
pathogenesis of hormone-dependent malignancies, especially breast cancer, has been investigated using
chemically pure isolates or product extracts in several in vitro or in vivo models [9–11]. Their effects
as hormonally-active diet components have been excessively and controversially discussed [12,13].
Isoflavone extracts and supplements are often used for the treatment of menopausal symptoms and
for the prevention of age-associated conditions, such as cardiovascular diseases and osteoporosis in
postmenopausal women [12].
In humans the most important lignans are secoisolariciresinol and matairesinol [14].
After oral intake they are transformed by intestinal aerobe and anerobe flora into bioavailable
enterolignans enterodiol and enterolactone [15].
Clinical studies proved that a high exposition to enterolignans reduced the risk of breast cancer
by 16% [16]. Moreover, increased blood concentrations of enterolactone in postmenopausal women
are related with a significant reduction of breast cancer mortality [17].
With the goal of identifying potential sources of phytoestrogens and selecting those with beneficial
functions, our group has tested, in prior trials, the phytoestrogen properties of pumpkin and flax seed
lignan and isoflavone extracts on the proliferation of trophoblast and breast cancer cell lines [18,19].
Moreover, the effect of the phytoestrogens genistein and daidzein on human term trophoblasts and
their influence on fertility was investigated [20].
Elder flower (Sambucus nigra) is a historically-significant herbal medicinal plant used for centuries
as a cold remedy. It is used as a general nutritive tonic and due to its strong taste as a flavor
enhancer in meals and beverages. Elder extracts possess significant antioxidant activity and have been
shown to impair angiogenesis. The anthocyanins present in elderberries protect vascular epithelial
cells against oxidative insult, and reduce low-density lipoprotein (LDL) and cholesterol, therefore,
preventing vascular disease [21]. Elder extracts boost cytokine production [22]. The influenza A
virus subtype H1N1 inhibition activities of the elder flavonoids compare favorably to the known
anti-influenza activities of oseltamivir and amantadine [23]. The terpenes extracted from elder flower
show notably strong antimicrobial effects in vitro upon methicillin-resistant Staphylococcus aureus [24].
Moreover elder flower could improve bone properties by inhibiting the process of bone resorption and
stimulating the process of bone formation [25].
Due to the interesting characteristics of elder flower described above, this in vitro study aims to
identify the distribution of lignans and isoflavones in elder flower extracts (EFE) and evaluate the
potential phytoestrogen effects of EFE on tumor trophoblast BeWo and JEG-3 cells and the ER-positive
MCF7 breast cancer cell lines, and compare those with the effects of enterodiol and enterolactone.
2. Materials and Methods
2.1. Preparation of the EFE
In total six EFE from the species Sambucus nigra were produced. Three lignan-isolations were
prepared as previously described [26] and, afterwards, dissolved in 100% ethanol. In the aim to verify
the previously-reported increased lignan concentration in elder flowers [27] the molecular–chemical
composition of the extract was further analyzed by pyrolysis-field ionization mass spectrometry by
using an LCQ-Advantage (Thermo Finnigan’s, Arcade, NY, USA). The peaks were identified by ion
trap technology in electrospray ionisation (ESI) mode. The source voltage was set at 4.5 kV, while
the mass detection range was 150–2000 amu. For the production of the three flavonoid extracts, the
method previously described by Franz and Koehler was used [28].
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2.2. Cell Lines
For the current work the chorion carcinoma cell lines JEG-3 and BeWo, and the breast carcinoma
cell line MCF7, were used. All cell lines were obtained from the European Collection of Cell Cultures
(ECACC, Salisbury, UK). The cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) without
phenol red (Biochrom AG, Berlin, Germany) supplemented with 10% heat-inactivated fetal calf serum
(PAA Laboratories GmbH, Pasching, Austria), 100 μg/mL Penicillin/Streptomycin (Biochrom AG)
and 2.5 μg/mL Amphotericin B (Biochrom AG). Cultures were maintained in a humidified incubator
at 37 ◦C with a 5% CO2 atmosphere. Prior to cell culture, the levels of estrogen or progesterone in the
medium were measured, using an automated Immulite (DPC Biermann, Freiburg, Germany) hormone
analyzer, in order to exclude their presence.
2.3. Effect of EFE on Cell Lines
For all experiments, the cells were seeded on Quadriperm tissue slides with or without added
lignan and flavonoid EFE separately. In brief, cells were seeded at a concentration of 400,000 cells per
slide. The cells were left to attach for 24 h. Then, the medium was replaced by medium supplemented
with lignan and flavonoid EFE separately at final effective concentrations of 10, 50, and 100 μg/mL.
Since the original EFE was diluted in 100% ethanol, medium supplemented with 100% ethanol at
a concentration of 5 μg/mL (this being the maximum ethanol concentration achieved during these
experiments) served as the internal control. In addition, enterolactone and enterodiol (Sigma-Aldrich,
Taufkirchen, Germany) were added to the same cell cultures as used for EFE in concentrations of 10,
50, and 100 μg/mL, respectively. After the cells were cultured for 72 h, 1 mL from each supernatant
was stored at −80 ◦C for estradiol analysis. The remaining supernatant was then discarded and the
slides were washed in phosphate-buffered saline (PBS), fixed in acetone for 10 min, and left to dry at
room temperature. Cells treated with equal concentrations of estradiol (10, 50, and 100 μg/mL) served
as external controls.
2.4. Estradiol Determination in the Cell Culture Medium
For the determination of estradiol in the culture medium, a competitive enzyme immuno-assay
(EIA) was applied as described previously [29]. The measurements were performed using
an automated Immulite 2000 (DPC Biermann, Freiburg, Germany) hormone analyzer.
2.5. Immunocytochemistry for the ERα, ERβ, and Progesterone Receptor (PR)
For immuno-detection of the steroid receptors ERα, ERβ, and PR, the Vectastain R Elite
Avidin/Biotin Complex (ABC) Kit (Vector Laboratories, Burlingame, CA, USA) was used according to
the manufacturer’s protocol. After being air dried, the slides were rinsed in PBS for 5 min and incubated
with the ABC normal serum for 60 min in a humidified environment. The slides were then washed
and incubated with the respective primary antibodies. Salient features of the antibodies used are
presented in Table 1. The slides were then incubated with the diluted biotinylated secondary antibody
(30 min), followed by incubation with the ABC reagent (30 min), and the ABC substrate (15 min).
A PBS wash (5 min) was applied between steps. Finally, the slides were counterstained with Mayer’s
acidic hematoxylin (30 s), rinsed with water, and covered with Aquatex. The intensity and distribution
patterns of the specific immunocytochemical staining was evaluated using a semi-quantitative method
(IRS score) as previously described [30]. Briefly, the IRS score was calculated as the product of the
optical staining intensity (0 = no staining; 1 = weak staining; 2 = moderate staining; and 3 = strong
straining) multiplied by staining extent (0 = no staining; 1% ≤ 10% staining; 2 = 11%–50% staining;
3 = 51%–80% staining and 4 ≥ 80% staining). The percentage of positively-stained cells was estimated
by counting approximately 100 cells.
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Table 1. Antibodies used for expression analysis of steroid hormone receptors.
Salient Features of the Antibodies Used in the Present Study
Antibody (Source) Origin Dilution in PBS Temperature
Anti-ERcr (Dako, Germany) Mouse monoclonal 1:150 1 h RT
Anti-ERβ (Serotec, Germany) Mouse monoclonal 1:600 O/N 4 ◦C
Anti-PR (Dako, Germany) Mouse monoclonal 1:50 1 h RT
ER = estrogen receptor; PR = progesterone receptor; O/N = overnight; RT = room temperature.
2.6. Statistical Analysis
The results are presented as mean ± sem of three independent experiments. Statistical analysis
was performed using the Wilcoxon’s signed rank tests for pairwise comparisons. Each observation
with p < 0.05 was considered statistically significant.
3. Results
3.1. EFE Contains Phytoestrogen Compounds
Mass spectrometry was performed to identify the different substrates and to determine
their proportions in EFE. The results showed that the EFE contains phytoestrogen compounds.
Lignan dimers (LDIM) were found with a total intensity of 2.6%, lignans (LIGNA) with 1.3%,
isoflavones (ISOFL) with 0.6%, and flavones (FLAVO) with 0.1%. Figure 1 demonstrates the distribution
of the different substance classes found in EFE. With a total intensity of 18.1% the most abundant
substance class in EFE were lipids, including alcanes, alcenes, fatty acids, waxes, and fats (LIPID).
Monolignoles (PHLM) were found with an intensity of 13.4% and carbohydrates (CHYDR) with 11.1%.
Nitrogen (NCOMP) compounds were found with a total intensity of 6%, amino acids and peptides
with 5.4% (PEPTI), isoprenoid compounds (ISOPR) with 1.5%, other polyphenolic (POLYO) with 5.2%,
and low molecular compounds (LOWMW) with 4.7%.
Figure 1. Cont.
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Figure 1. Characteristic diagram of mass spectrometry analysis results of the EFE using both the
microwave extraction (A) and the extraction method modified from Luyengi et al. [26] (B); moreover,
the different substances extracted are presented (C).
3.2. EFE Lignan and Flavonoid Extracts Induce the Inhibition of Estradiol Secretion in JEG-3, BeWo, and
MCF7 Cells in a Dose-Response Pattern and the Inhibition of Progesterone Secretion in JEG-3 Cells
To assess the estradiol and progesterone secretion, all three cell lines were cultured for 72 h in the
presence of different EFE concentrations. An automated hormone analyzer was used to determine the
estradiol and progesterone concentration in the medium by applying a competitive EIA. All cell lines
were incubated with elder flower flavonoid and lignan extracts. The EFE lignan and flavonoid extracts
demonstrated a statistical significant inhibition in estradiol secretion in a dose-response pattern in
all three cell lines (Figure 2). Only statistical significant data is demonstrated in the figures. The cell
culture medium with 10% FCS did not contain any measurable amounts of estrogen and progesterone,
as determined with the automated hormone analyzer Immulite (DPC Biermann, Freiburg, Germany).
In JEG-3 cells, the estradiol production was inhibited from 5634.96 ± 235.77 pg/mL in the control
to 4547.48 ± 145.89 pg/mL, 1283.88 ± 29.78 pg/mL, and 1030.43 ± 24.50 pg/mL when the EFE
lignan concentration was 10 μg/mL, 50 μg/mL, and 100 μg/mL, p = 0.018, respectively (Figure 2A).
EFE flavonoids had a similar effect using the same concentrations, as the estradiol production was
inhibited from 5634.97 ± 235.77 pg/mL in the control to 5049 ± 187.28 pg/mL, 1264.5 ± 151.26 pg/mL,
and 1137 ± 138.08 pg/mL (Figure 2B).
In JEG-3 cell lines progesterone secretion was also significantly inhibited using EFE lignan
extracts from 87.95 ± 1.36 pg/mL in the control to 84.88 ± 1.98 pg/mL, 66.22 ± 2.25 pg/mL, and
45.98 ± 1.92 pg/mL when the EFE concentration was 10 μg/mL, 50 μg/mL and 100 μg/mL.
The cultivation of the BeWo cell line with EFE lignan extracts resulted again in an inhibition
of estradiol secretion from 245.25 ± 16.25 pg/mL in the control to 230.85 ± 8.17 pg/mL,
231.95 ± 6.1 pg/mL, and 206.81 ± 5.69 pg/mL when the EFE concentration was 10 μg/mL, 50 μg/mL,
and 100 μg/mL (Figure 2C). The differences between the stimulated cells and the control were only
significant at a concentration of 100 μg/mL, with p = 0.05.
In MCF7 cell lines the EFE flavonoid concentrations of 10 μg/mL and 50 μg/mL first
provoked a transient increased secretion of estradiol from 146.37 ± 9.91 pg/mL in the control to
185.44 ± 4.28 pg/mL at 10 μg/mL and 164.07 ± 3.16 pg/mL at 50 μg/mL (Figure 2D). Then, at
100 μg/mL, the estradiol secretion was inhibited to 140.21 ± 2.22 pg/mL, p = 0.08 respectively.
Using the same concentrations with EFE flavonoid-extracts, progesterone secretion was also
significantly inhibited in JEG-3 cells (Figure 2E) from 104.83 ± 5.13 pg/mL in the control to
77.94 ± 1.32 pg/mL, 56.18 ± 1.7 pg/mL, and 47.76 ± 1.56 pg/mL (p = 0.043).
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Figure 2. Estradiol and progesterone concentration in the tissue culture medium of JEG-3, BeWo,
and MCF7 cells in the absence or presence of EFE. The effective EFE concentrations were 10 μg/mL,
50 μg/mL, and 100 μg/mL. Significantly different observations are highlighted with an asterisk.
3.3. EFE Flavonoid Extracts up Regulates ERα in JEG-3 Cells
JEG-3 cell lines that were cultivated with EFE flavonoid in the concentrations of 10 μg/mL,
50 μg/mL, and 100 μg/mL an upregulation of ERα was demonstrated. The IRS score of ERα was
increased from 1 ± 0 in the control to 1.33 ± 0.23, 1.67 ± 0.54, and 2.167 ± 0.44. At 100 μg/mL
statistical significance was demonstrated, p = 0.015, respectively (Figure 3A).
Figure 3. Upregulation of ER α and progesterone receptor by elder flower flavonoids in JEG-3
and MCF7 cells. The effective EFE concentrations were 10 μg/mL, 50 μg/mL, and 100 μg/mL.
Significantly different observations are highlighted with an asterisk.
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3.4. EFE Flavonoids Downregulate ER α and EFE Lignans and Flavonoids Upregulate the PR in a
Dose-Response Pattern Predominantly in Lower Concentrations in MCF7 Cells
MCF7 cells that were exposed to EFE flavonoids with the concentrations of 10 μg/mL, 50 μg/mL,
and 100 μg/mL responded significantly with a downregulation of ER α at the concentrations of
10 μg/mL (3.5 ± 0.55) and 50 μg/mL (6.3 ± 0.88) compared to the control (11.33 ± 0.73, p = 0.002 and
0.004), (Figure 4A).
MCF7 cells that were exposed to EFE lignan and flavonoid extracts with the concentrations
of 10 μg/mL, 50 μg/mL, and 100 μg/mL responded significantly in an upregulation of the PR in
a dose-response pattern (Figure 4B). The upregulation of the progesterone IRS score significantly
reached a peak at the EFE lignan concentration of 10 μg/mL (8 ± 0.98) compared to the control
(3.3 ± 0.36, p = 0.002). As the EFE concentration increased, the IRS score decreased at 50 μg/mL to
7.66 ± 1.04, and at 100 μg/mL to 5.83 (Figure 4B).
The same phenomenon was observed using EFE flavonoids where the IRS score increased from
2.66 ± 0.46 in the control to 6 ± 0 at 10 μg/mL (p = 0.002), and then decreased to 4.83 ± 0.59 (p = 0.026)
at 50 μg/mL, and to 2.83 ± 0.44 at 100 μg/mL (Figure 3B).
Figure 4. Representative microphotographs of MCF7 cells grown in the absence or presence of
elder flower extract (at effective EFE concentrations of 10 μg/mL, 50 μg/mL, and 100 μg/mL), after
immuno-detection of ER-α (A) and PR (B); and presentation of the immunocytochemistry results by
the semi-quantitative immunoreactivity score (IRS). Significantly different observations are highlighted
with an asterisk.
3.5. Enterolactone Downregulates Expression of ERα and PR in a Dose-Response Pattern in MCF7 Cells
MCF7 cells that were exposed to enterolactone at concentrations of 10 μg/mL, 50 μg/mL, and
100 μg/mL responded significantly with a downregulation of ER α at concentrations of 50 μg/mL (IRS
score 2.5) and 100 μg/mL (IRS score 0) compared to the control (IRS score 5, p = 0.027 and 0.024) (see
Figure 5). MCF7 cells that were exposed to enterolactone at concentrations of 10 μg/mL, 50 μg/mL, and
100 μg/mL responded with a dose-response-related downregulation of the PR. The downregulation
of the PR was significant at enterolactone concentrations of 50 μg/mL (IRS score 4) and 100 μg/mL
downregulation (IRS score 2) compared to the control (IRS score 9, p = 0.028 for both concentrations).
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Figure 5. Representative microphotographs of MCF7 cells grown in the absence or presence of
enterolactone at concentrations of 10 μg/mL, 50 μg/mL, and 100 μg/mL), after immuno-detection of
ER-α (A) and PR (B); and presentation of the immunocytochemistry results by the semi-quantitative
immunoreactivity score (IRS). Significantly different observations are highlighted with an asterisk.
3.6. Enterodiol Downregulates Expression of ERα and PR Only at High Concentrations in MCF7 Cells
MCF7 cells that were exposed to enterodiol at concentrations of 10 μg/mL, 50 μg/mL, and
100 μg/mL responded with a significant downregulation of ERα only at 100 μg/mL (IRS score 0)
compared to the control (IRS score 5, p = 0.023) (Figure 6). MCF7 cells that were exposed to enterodiol at
concentrations of 10 μg/mL, 50 μg/mL, and 100 μg/mL responded with a significant downregulation
of the PR at 100 μg/mL (IRS score 0) compared to the control (IRS score 5.5, p = 0.023).
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Figure 6. Representative microphotographs of MCF7 cells grown in the absence or presence of
enterodiol at concentrations of 10 μg/mL, 50 μg/mL, and 100 μg/mL), after immuno-detection of
ER-α (A) and PR (B) ; and presentation of the immunocytochemistry results by the semi-quantitative
immunoreactivity score (IRS). Significantly observations are highlighted with an asterisk.
3.7. Enterolactone Inhibits Estradiol Secretion in JEG-3 Cells and Induce Estradiol Secretion in BeWo and
MCF7 Cells in a Dose-Response Pattern
In JEG-3 cells, the estradiol production was inhibited from 211.8 ± 8.88 pg/mL in the control to
190.9 ± 7.9 pg/mL, and 149.59 ± 7 pg/mL at enterolactone concentrations of 10 μg/mL and 50 μg/mL,
p = 0.028, respectively (Figure 7).
The cultivation of the BeWo cell line with enterolactone resulted again in an upregulation
of estradiol secretion from 75.07 ± 2.33 pg/mL in the control to 94.66 ± 6.39 pg/mL,
137.66 ± 10.04 pg/mL, and 173.53 ± 9.56 pg/mL when the enterolactone concentration was 10 μg/mL,
50 μg/mL, and 100 μg/mL. The differences between the stimulated cells and the control were
significant at all concentration levels of enterolactone, p = 0.028, respectively.
In MCF7 cells the concentrations of 10 μg/mL, 50 μg/mL and 100 μg/mL provoked an increased
secretion of estradiol from 52.65 ± 7.90 pg/mL in the control to 75.22 ± 2.11 pg/mL at 10 μg/mL,
123.93 ± 3.93 pg/mL at 50 μg/mL, and 172.12 ± 10.05 pg/mL at 100 μg/mL, p = 0.028, respectively.
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Figure 7. Estradiol concentration in the tissue culture medium of JEG-3, BeWo and MCF7 cells in
the absence or presence of enterolactone. The effective enterolactone concentrations were 10 μg/mL,
50 μg/mL, and 100 μg/mL. Significantly different observation are highlighted with an asterisk.
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3.8. Enterodiol Induces Estradiol Secretion in JEG-3, BeWo, and MCF7 Cells at Distinct Concentrations
In JEG-3 cells, the estradiol secretion was significantly enhanced from 79.85 ± 1.14 pg/mL in the
control to 86.37 ± 1.07 pg/mL, when the concentration was 50 μg/mL enterodiol, p = 0.028 (Figure 8).
The cultivation of the BeWo cell line with enterodiol resulted again in a significant upregulation
of estradiol secretion from 63.71 ± 0.68 pg/mL in the control to 72.71 ± 0.79 pg/mL, and
84.37 ± 4.63 pg/mL at the enterodiol concentrations of 50 μg/mL and 100 μg/mL, respectively.
The differences between the stimulated cells and the control were significant at both concentration of
enterodiol, p = 0.028, respectively.
In MCF7 cells the concentrations of 50 μg/mL and 100 μg/mL provoked an increased secretion
of estradiol from 35.64 ± 1.32 pg/mL in the control to 53.28 ± 0.39 pg/mL at 50 μg/mL, and
56.94 ± 2.54 pg/mL at 100 μg/mL, p = 0.028, respectively.
Figure 8. Cont.
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Figure 8. Estradiol concentration in the tissue culture medium of JEG-3, BeWo and MCF7 cells in
the absence or presence of enterodiol. The effective enterodiol concentrations were 50 μg/mL and
100 μg/mL. Significantly different observation are highlighted with an asterisk.
4. Discussion
To our knowledge, this is the first study evaluating the phytoestrogen properties of EFE on BeWo,
JEG-3, and MCF7 cells regarding the estrogen and progesterone response. Prior to this study it was
uncertain if EFE contains phytoestrogen compounds. Although mass spectrometry proved that EFE
contains lignans and isoflavones, the subgroups of each class were not identified and, thus, precision
is lacking. EFE proved to be richer in lignans than in isoflavones (presented in Figure 1). This may
explain why more significant results were found using the lignan EFE. However, further studies with
isolated fractions of the subgroups of EFE lignans and isoflavones could clarify if one subgroup is
more potent than the other. Therefore, it would be interesting to isolate and identify the different
lignans and isoflavones in the EFE that cause phytoestrogen activity for further characterization.
Before further evaluation in an animal model, in vitro evaluation of the various components’ effects as
single substances is required.
In a previous study of our group, the phytoestrogen properties of pumpkin seed extract were
tested on the same cells, which resulted in an unexpected estrogen secretion in all cell lines [18].
As hormone-dependent tumors react with proliferation when exposed to estrogens, pumpkin seeds,
thus, could provoke carcinogenic effects.
In contrast, EFE was the first of the potential phytoestrogens previously tested by our group,
which had an inhibitory effect on the estradiol secretion of all three cell lines.
The effect on JEG-3 and BeWo cells was observed to be dose-dependent. Interestingly, in MCF7
cells, estrogen secretion was higher following the administration of intermediate phytoestrogen
concentrations than in controls or with the highest EFE concentration tested. The degree to which
the inhibition of estrogen secretion results in a decreased cell proliferation has to be tested in
further investigations using EFE. In addition, it is possible that at the highest EFE concentration
estrogen secretion was decreased due to cytotoxic effects of the extract itself, as other studies suggest
that phytoestrogens cause cytotoxicity and decrease growth in MCF7 tumors. For example, in
a study by Bergman et al. [31] ovariectomized mice were treated with continuous release of estrogen.
MCF7 tumors were established and mice were fed with basal diet or 10% flaxseed, and two groups that
were fed basal diet received daily injections with enterodiol or enterolactone (15 mg/kg body weight).
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The regimens containing flax seeds or enterodiol or enterolactone injections resulted in decreased
estrogen-induced growth and angiogenesis in solid tumors by decreasing the secretion of VEGF.
It is of interest that EFE induces not only an inhibition of estradiol secretion, but also
an upregulation of the ERα in JEG-3 cells. It could be assumed that, if EFE causes an inhibition
on the trophoblast estrogen secretion, the cells react by increasing ERα expression in order to obtain
stimulation even in a low-estrogen environment. A recent study by Lim et al. [32] outlined that the
flavonoid apigenin reduces survival of JEG-3 cells by inducing apoptosis via the PI3K/AKT and
ERK1/2 MAPK pathways. Therefore, it seems likely that the phytoestrogens also found in EFE could
trigger non-genomic estradiol receptor signal transduction causing apoptosis in JEG-3 cells. In contrast
to the effects of EFE on JEG-3 cells, another study by our group [33] demonstrated that the two
well-known phytoestrogens genistein and daidzein provoked a reduced progesterone production
and a stimulation of the estrogen production in JEG-3 cells. Therefore, regarding the other extracts
investigated by our group, the characteristics of EFE seem to be favorable for further research due to
the properties of decreased estrogen secretion and increased ERα expression in JEG-3 cells.
MCF7 cells that were exposed to EFE extracts responded with a significant downregulation of
ERα and an upregulation of PR, both predominantly in lower concentrations of EFE. Why the lower
concentrations provoked a stronger effect on receptor expression remains unknown. Although it is,
again, possible that higher concentrations of EFE resulted in cytotoxic effects leading to cell damage
and, therefore, to decreased cellular function. Nevertheless, the fact that lower EFE concentrations
resulted in a decreased expression of the ERα receptor and an increase in the progesterone receptor
could be beneficial for clinical use as low blood concentrations of phytoestrogens are easier to achieve
by dietary intake alone. It is important to mention that the concentrations used in this study were
extremely high (non-physiological). The highest level of enterolactone that has been measured in
serum/plasma in humans is 2 μmol/L (over 16 times less than the enterolactone concentration used).
Furthermore, estradiol levels in adult females reach levels only as high as 300 pg/mL in the luteal phase
(30,000 times less than the external control). Therefore, before realistic interpretation, our findings
must be reevaluated in further studies using more physiologically relevant doses.
Our current findings partially concur with a previously-described downregulation of ERα and
upregulation of PR on the MCF7 cells when treated with other potential phytoestrogen compounds
such as flax and pumpkin isoflavone and lignan extracts or mixtures [19,34]. Interestingly, it has
been demonstrated that estradiol has similar effects on the MCF7 ERα and on PR, as it causes
a downregulation of ERα and an upregulation of PR [35,36]. Therefore, whether EFE causes MCF7 cell
proliferation or inhibition has to be tested in future investigations. In a study by Stendahl et al., it was
demonstrated that high progesterone receptor expression correlates with a better effect of adjuvant
tamoxifen in premenopausal breast cancer patients [37]. This suggests clinical trial evaluation of
elderflower as a combination partner for tamoxifen.
It is unclear whether the lignans present in the EFE require any metabolic processing prior to
exerting biological effects and whether the cell culture systems used are capable of completing this
conversion. For example secoisolariciresinol diglycoside (SDG) is the primary lignan in flaxseed;
however, in vitro studies use bioavailabile enterodiol and enterolactone when investigating effects of
flaxseed lignans. This is because in vitro systems do not have the components necessary to convert
SDG to enterodiol and enterolactone. Therefore, additional in vivo studies could provide valuable
information regarding EFE metabolism prior to the conduction of further in vitro studies. Nevertheless,
the pattern of hormone secretion and receptor expression of enerolactone and enterodiol tested
on JEG-3, BeWo, and MCF7 cells were different to those of EFE. Therefore, it is probable that the
lignans in EFE are not related to the enterolignans. Enterolactone and enterodiol in contrast to
EFE inhibited not only the expression of the ER but also PR in MCF7 cells. Moreover contrary
to EFE, both control substances upregulated estradiol production in BeWo and MCF7 cells in
a concentration-dependent manner.
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5. Conclusions
Our results clearly demonstrate beneficial features of EFE in the setting of hormone
receptor-positive breast cancer MCF7 cells by inhibition of estrogen secretion, downregulation of
Erα, and upregulation of PR. Decreased local and circulating estrogen concentrations are certainly
considered an advantage in treating breast cancer. In that view, EFE could be related to reduced tumor
cell proliferation, possibly suggesting a protective effect on breast cancer. Nevertheless, the results and
the conclusions made must be interpreted with caution as this is an in vitro cell culture study. In this
setting, the use of plant extracts instead of chemically pure agents may be advantageous as it may
more accurately reflect the effects of phytoestrogen-rich diets.
If the effects of EFE can be attributed solely to potential phytoestrogen activity remains unsolved.
To which degree other non-estrogenic pathways play a role can currently not be clarified. For example,
mass spectrometry demonstrated a high amount of lipids in EFE. Lipids can inhibit cell proliferation
through activation of PPARα and PPARγ (peroxisome proliferator-activated receptors) which bind
as transcription factors to the retinoid X receptors and, thus, regulate the expression of various
genes [38,39]. In MCF7 breast cancer cells PPARγ activates p53 by stimulating the transcription
factor NFkB (nuclear factor kappa-light-chain-enhancer of activated B-cells), which is a gene promoter
of p53 and, thus, induces apoptosis [40]. Therefore, the following additional investigations are
necessary to obtain further insight of the promising anti-carcinogenic effects of EFE: the results
of hormone secretion and receptor expression of EFE should be correlated with DNA synthesis
performance (BRDU proliferation assay), metabolic activity (MTT assay), and cytotoxicity (LDH assay)
tests. Cytotoxicity could be evaluated in detail by immunohistochemistry or reverse transcriptase
quantitative (RTQ)-PCR quantification of apoptosis-induced markers (for example, p53, p21, BCL2,
Caspase 8/9). Then, as a possibility to determine the role of hormone receptor-mediated cell
response, EFE could be tested on malignant ER-negative cells (e.g., BT-20). Furthermore, fractional
chromatography could provide information of the individual substances and their impact on breast
cancer cells. Finally, after further in vitro investigations, properly designed animal studies could
highlight a potential role of EFE in trophoblast and breast cancer prevention and/or treatment.
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Abstract: Multiple myeloma (MM) is a clonal B-cell malignancy characterized by an accumulation of
clonal plasma cells (PC) in the bone marrow (BM) leading to bone destruction and BM failure. Despite
recent advances in pharmacological therapy, MM remains a largely incurable pathology. Therefore,
novel effective and less toxic agents are urgently necessary. In the last few years, pomegranate
has been studied for its potential therapeutic properties including treatment and prevention of
cancer. Pomegranate juice (PGJ) contains a number of potential active compounds including organic
acids, vitamins, sugars, and phenolic components that are all responsible of the pro-apoptotic effects
observed in tumor cell line. The aim of present investigation is to assess the antiproliferative and
antiangiogenic potential of the PGJ in human multiple myeloma cell lines. Our data demonstrate
the anti-proliferative potential of PGJ in MM cells; its ability to induce G0/G1 cell cycle block and
its anti-angiogenic effects. Interestingly, sequential combination of bortezomib/PGJ improved the
cytotoxic effect of the proteosome inhibitor. We investigated the effect of PGJ on angiogenesis and cell
migration/invasion. Interestingly, we observed an inhibitory effect on the tube formation, microvessel
outgrowth aorting ring and decreased cell migration and invasion as showed by wound-healing
and transwell assays, respectively. Analysis of angiogenic genes expression in endothelial cells
confirmed the anti-angiogenic properties of pomegranate. Therefore, PGJ administration could
represent a good tool in order to identify novel therapeutic strategies for MM treatment, exploiting its
anti-proliferative and anti-angiogenic effects. Finally, the present research supports the evidence that
PGJ could play a key role of a future therapeutic approach for treatment of MM in order to optimize
the pharmacological effect of bortezomib, especially as adjuvant after treatment.
Keywords: Punica granatum juice; multiple myeloma; proliferation; angiogenesis
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1. Introduction
Multiple myeloma (MM) is a clonal B-cell malignancy characterized by accumulation of clonal
plasma cells (PC) in the bone marrow (BM) leading to bone destruction and BM failure [1–3].
MM encompasses a spectrum of clinical variants ranging from benign Monoclonal Gammopathies of
Undetermined Significance (MGUS) and smoldering/indolent MM, to more aggressive, disseminated
forms of MM and plasma cell leukemia. Despite recent advances in proteasome inhibitor and
immunomodulatory drug-based therapies [4,5], and MM remains largely incurable [2,6]. The genetic
complexity of myeloma is due to intraclonal heterogeneity in the myeloma-propagating cell [7,8].
Multiple mutations in different pathways trigger a deregulation of the intrinsic biology of the PC,
leading to the features of myeloma [7–9]. The sequential acquisition of multiple genetic events can
lead to disease progression and the development of treatment-resistant disease [8,9]. Therefore,
novel effective and less toxic agents are urgently necessary in order to treat patients affected by
multiple myeloma. The development of novel therapeutic compounds without significant adverse side
effects is considered an important area for immunopharmacological studies. A wide variety of natural
compounds possesses significant cytotoxic as well as chemopreventive activity, through induction
of cancer cell apoptosis [10]. Over 60% of currently used anticancer agents are derived from natural
sources, including plants, marine organisms and microorganisms.
Punica granatum L., also known as pomegranate, belonging to the Punicaceae family, has been
gaining popularity as a nutraceutical food having potential beneficial effects on health, including
prevention and/or treatment of oncologic diseases, cardiovascular and neurological disorders,
metabolic diseases [11,12]. Moreover, pomegranate has been studied for its potential therapeutic
properties including treatment and prevention of cancer [13,14]. Pomegranate fruit is widely consumed
fresh as well as in processed forms, such as juice, jams, sauce, and wine. The pharmacological
effects of PGJ are related to a large number of phytochemicals, including hydrolyzable tannins and
related compounds (ellagitanin, punicalagin, pedunculagin, punicalin, gallagic acid, ellagic acid and
gallic acid), flavonoids (anthocyanins and catechins), flavonols (quercetin and kaempferol), flavones
(apigenin and luteolin), and conjugated fatty acids (punicic acid), present in discrete anatomical parts,
such as peel (pericarp or husk), juice, and seeds [13,15]. PGJ, extracts, and phytoconstituents have
been extensively studied preclinically for their anticarcinogenic and cancer chemopreventive effects in
colon, lung, skin, and prostate cancer [16].
Based on numerous in vitro studies, several pomegranate products and phytoconstituents
exhibited cytotoxic, antiproliferative, proapoptotic, antiangiogenic, antiinvasive, and antimetastatic
effects against estrogen receptor-positive and -negative breast carcinoma cells [17–25].
Pomegranate seed oil and fermented juice concentrate suppressed 7,12-dimethyl benz(a)anthracene
(DMBA)-induced precancerous mammary gland lesions ex vivo [26] and pomegranate extract
inhibited the growth of xenografted BT-474 tumors in vivo [23].
Recently, some authors reported for the first time that a pomegranate formulation (emulsion)
containing the most bioactive phytochemicals present in the whole fruit affords a remarkable
chemopreventive effect against DMBA-induced mammary tumorigenesis in rats [27].
The aim of the present investigation is to assess the antiproliferative and antiangiogenic potential
of PGJ in human multiple myeloma cell lines.
2. Experimental Section
2.1. Reagents and Compounds
Recombinant human VEGF-A (VEGF-A165 isoform) was obtained from Peprotech (Rocky Hill, NJ,
USA). The serum-free endothelial cell basal medium (EBM) was obtained from ScienceCell Research
Laboratories (San Diego, CA, USA). The proteosome inhibitor bortezomib (BTZ) was used at 30 nM
(Takeda, Italy).
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2.2. Pomegranate Juice
Pomegranate juice (PGJ) was extracted by plants of five-year-old Wonderful varieties.
The plants were produced under organic agricultural practices in an experimental farmland of
the section of National Research Council—Institute for Agricultural and Forest Systems in the
Mediterranean (ISAFOM).
Pomegranate fruits were harvested at physiological maturity in October 2014 and randomly
collected from each of four geographical orientation of tree. The fruits were stored at 4 ◦C for three
days. After manual separations of the arils, the PGJ was obtained by mechanical press. Subsequently,
the PGJ was centrifuged at 5000 rpm for 5 min at room temperature and then filtered by sterile
syringe with filters 0.22 μm (Invitrogen, Paisley, UK). Afterwards, each aliquot (20 mL) of the juice was
collected into specific vials and stored at −20 ◦C.
2.3. Phenolic Compounds by HPLC Analysis
After being thawed at room temperature, the sample of the PGJ was analyzed using a liquid
chromatography system Dionex UltiMate 3000 (Thermo Fisher Scientific, Waltham, MA, USA),
including a solvent rack, a quaternary pump with an integrated four-channel degasser, a thermostatted
column compartment, an autosampler and a four wavelength UV-Vis detector. Separation was
performed on a column Dionex Acclaim 120, C18, 3 μm (4.6 × 150 mm) (Thermo Fisher Scientific,
Waltham, MA, USA) with a gradient program at a flow rate of 0.8 mL·min−1. Column temperature
was maintained at 30 ◦C and the injection volume was 20 μL. The mobile phases consisted of water
and formic acid (95:5, v/v) (eluent A) and methanol (eluent B). The gradient started with 1% B to
reach 20% B at 20 min, 40% B at 30 min, 95% B at 35 min and 1% B after 41 min. The chromatograms
were recorded simultaneously at 280, 360 and 520 nm. Calculation of concentrations was based on the
external standard method. The HPLC analysis was replicated three times and the average values are
reported in Table 1.













2.4. Cell Cultures and Cell Viability Assay
MM cell lines KMS26, MM1S and U266 (established from peripheral blood of a multiple myeloma
patients in refractory and terminal stage) were cultured in suspension using RPMI1640 medium
supplemented with 10% or 20% fetal bovine serum (FBS) and 1% penicillin/streptomycin at 37 ◦C and
5% CO2. Human lymphocytes and monocytes were isolated, after informed consent, from fresh buffy
coat of healthy volunteers provided by the Transfusional Centre of E. Muscatello Hospital—Augusta
(SR). Monocytes and lymphocytes then were purified from the lymphomonocytic population by
positive isolation using magnetic beads coated with goat anti-mouse CD14+ IgG and anti-mouse CD3+
IgG respectively (MiltenyiBiotec GmbH, Bergisch Gladbach, Germany) [28].
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Human Brain Microvascular Endothelial Cells (HBMEC) (Innoprot, Elexalde Derio, Spain) were
grown in monolayer in EBM supplemented with 5% fetal bovine serum (FBS), 1% endothelial cell
growth supplement (ECGS), 100 U/mL penicillin and 100 mg/mL streptomycin. In studies involving
serum-starvation, serum was reduced at 1% v/v.
Cell viability was assessed using ATPlite 1step assay (PerkinElmer, Milan, Italy) according to the
manufacturers’ protocol. ATPlite TM 1step is an Adenosine TriPhosphate (ATP) monitoring system
based on firefly (Photinus pyralis) luciferase. ATP is a marker for cell viability because it is present in
all metabolically active cells. Because ATP concentration declines rapidly when cells undergo necrosis
or apoptosis, monitoring ATP is a good indicator of proliferation effects [29–31].
This analysis is a patented luminescence test that analyzes cell proliferation and cytotoxicity in
mammalian cells considering the light release induced by ATP-luciferase-D-luciferin reaction.
This luminescence assay is an alternative to colorimetric, fluorometric and radioisotopic assays
for the quantitative evaluation of proliferation and cytotoxicity of cultured mammalian cells. ATP
monitoring can be used to assess the cytocidal, cytostatic and proliferative effects of a wide range of
drugs, biological response modifiers and biological compounds.
ATPlite 1 step (PerkinElmer, Waltham, Massachusetts MA, USA) is a true homogeneous high
sensitivity ATP monitoring 1-step addition assay kit for the quantification of viable cells. Because
the kit needs no stabilization of the luminescence signal, high throughput is preserved. Briefly,
the 96-well black culture plate was taken from the incubator and equilibrated at room temperature
for 30 min. Subsequently, to each well containing 100 μL of the cell suspension (5 × 105 cells/mL),
100 μL of reconstituted reagent was added and the plate was shaken for 20 min at 700 rpm using orbital
shaker (Stuart Scienti c, Staffordshire, UK). The luminescence was measured using Victor3 (PerkinElmer,
Milan, Italy). Viability of the cells was expressed as percentage of vitality of untreated cells.
MTT assay: To quantify cell viability in endothelial cells, the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl
tetrasodium bromide (MTT) assay was used (Chemicon, Temecula, CA, USA). 10,000 cells/well were
plated in 96-well plates and grown in complete medium, in the absence or in the presence of PGJ
(3%, 6% or 12% v/v) for 24–48 or 72 h. At the end of treatment, the cells were incubated with MTT for
4 h; then, 100 μL dimethyl sulfoxide was added and the absorbance was read at 590 nm, as previously
described [32].
2.5. Cell Cycle Analysis
Cells were washed and resuspended in cold 80% ethanol to obtain a final concentration of
0.5 × 106 cells/mL for 1 h at 4 ◦C. The ethanol-fixed cells were centrifuged to remove ethanol
and the pellet was resuspended in propidium iodide-staining reagent (0.1% Triton X-100), 0.1 mm
Ethylenediaminetetraacetic acid (EDTA), 0.05 mg/mL RNase A and 50 mg/mL propidium iodide).
Cells were stored in the dark at room temperature for about 3 h. Cells were then analyzed with a
flow cytometer (FC500 Beckman Coulter; Beckman Coulter S.p.A., Milano, Italy) and the data were
processed by the ModFit program (Verity Software House, version 4.0, Topsham ME 04086, US).
2.6. Cell Invasion Assay
In order to perform cell invasion/migration experiments, harvested cells (1 × 106 cells/mL)
were seeded into 8.0-μm-pore transwell inserts (Corning Life Sciences, Lowell, MA, USA) coated
with Matrigel in the absence (control cells) or in the presence of PGJ (3% or 6% v/v) in medium
containing 1% FBS. Cells migration was stimulated by addition of VEGF (50 ng/mL) to the lower well
of the Boyden chamber. After 24 h, the cells were fixed with 95% ethanol and the invading cells were
stained with 1× crystal violet. Invaded cells were stained with 0.1% crystal violet and counted after
scanning membranes (×100 total magnification) by using ImageJ software (ImageJ 1.50e, National
Institutes of Health, NIH, Bethesda, MD, USA). The membranes were also dissolved in acetic acid
the density of invading cells was measured by reading the absorbance at 590 nm using a plate reader
(Synergy 2-BioTek, Winooski, VT, USA).
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2.7. Tube Formation Assay
The ability of cells to migrate and organize into capillary-like structures was carried out by using
Matrigel (BD, Franklin Lakes, NJ, USA). Briefly, the cells were shifted to medium containing 1% serum
for the 24 h. Next, the cells at 1 × 104 were suspended in 200 μL of the same medium containing either
PGJ at different concentrations or PGJ plus VEGF (50 ng/mL). The mixtures were seeded in 96-well
plates covered with polymerized growth factor-reduced Matrigel matrix (BD, Franklin Lakes, NJ,
USA), incubated for 4 h (37 ◦C, 5% CO2) and photographed at 100× magnification using an inverted
Leica DM IRB microscope (Leica, Buffalo Grove, IL, USA) equipped with a Charge-Coupled Device
(CCD) camera as previously described [33].
2.8. Aortic Ring Assay
Aortic rings were obtained by cross-sectioning the thoracic aorta of New Zealand white male
rabbits at 1-mm intervals. Rings were placed individually on the bottom of 24-well plates, pre-coated
with 150 μL of Matrigel. After 10 min, wells were rinsed with 150 μL of endothelial cell basal medium
and incubated with the same medium containing 1% FBS in the absence or in the presence of VEGF-A
(50 ng/mL) and the compound under test. The medium was changed in control and treated cells
three times a week starting from day two. Aortic rings were observed daily for signs of angiogenic
sprouting. The angiogenic response was measured by counting the length of neovessels sprouting out
of the rings after 14 days. PGJ was renewed every two days during the assay.
2.9. Wound Healing Assay
Twenty-four well tissue culture plates were seeded with HBMEC to a final density of 150,000 cells
per well, and these were maintained at 37 ◦C and 5% CO2. Cells were cultured in 1% serum medium
supplemented or not with 3% or 6% PGJ, or with PGJ added to VEGF-A (50 ng/mL)-stimulated
cells. As described before, VEGF-A alone was used as a positive control, and 1% serum medium
was a negative control. Wound closure was monitored within 24 h to 48 h of seeding. Confluent
HBMEC monolayer was scratched with a p200 pipet tip. The wounds were photographed at 40× using
phase-contrast microscope. After 24 h and 48 h, endothelial cells invading the wound were quantified
by computerized analysis of the digitalized images. For each image acquired, areas of scratch were
measured using ImageJ tools. The migration of cells toward the wounds was expressed as percentage
of wound closure, as previously described [34].
2.10. Gene Expression Analysis
RNA was extracted by Trizol reagent (Invitrogen, Carlsbad, CA, USA). First strand cDNA was
then synthesized with Applied Biosystem (Foster City, CA, USA) reverse transcription reagent [29].
PPARγ mRNA expression was assessed by TaqMan Gene Expression, Applied Biosystem and
quantified using a fluorescence-based real-time detection method by 7900HT Fast Real Time PCR
System (Life Technologies, Carlsbad, CA, USA). For each sample, the relative expression level of
PPARγ (Hs01115514_m1) mRNA was normalized using Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) (Hs02758991_g1) as an invariant control [35]. Analysis of angiogenic genes was performed
using TaqMan Low Density Array Human Angiogenic Panel (Life Technologies, Carlsbad, CA, USA)
that contains assays for 93 human genes in addition to three endogenous controls (18S, ACTB, GAPDH).
2.11. Statistical Analysis
Statistical significance between two groups was analyzed by Student’s t-test. One-way and
two-way analysis of variance (ANOVA), followed by Tukey’s post hoc test, was used for multiple
comparisons. p values < 0.05 were considered statistically significant.
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3. Results
3.1. Effect of Pomegranate Juice on Multiple Myeloma Cell Viability
The anticancer activity of the PGJ was tested in U266, KMS26 and MM1S cell lines at different
concentrations (3%, 6% and 12% of juice). After 24 h of treatment, we observed the inhibition of cell
proliferation in a dose-dependent manner (p < 0.0001) (Figure 1A). The KMS26 cells showed a major
sensitivity to the 12% PGJ exposure with 20% of proliferation only (p < 0.001). As showed in Figure 1B
for U266 cell line, 6% and 12% PGJ induced G0/G1 cell cycle arrest in a dose-dependent manner
(untreated: 50.58% ± 7%; 6% PGJ: 65.8% ± 5.2%; 12% PGJ: 73% ± 3%; p < 0.05), with a decrease of the
percentage of cells in G(2)/M and S phase. In healthy lymphocytes and monocytes, the PGJ treatment
did not show any effects (Figure 1A).
3.2. Pomegranate Juice Induces PPARγ Expression in Multiple Myeloma Cells
PGJ polyphenols can regulate the activation of PPARγ in several cancer cells [36]. It has been reported
that this protein induces inhibition of cell proliferation in MM [37]. We observed a significant increase
of PPARγ mRNA expression in U266 cells after treatment con PGJ in a dose-dependent manner. PGJ
induced up-regulation of PPARγ of about 20 and 30 fold, respectively, at 6% and 12% (p < 0.0001) (Figure 1C),
suggesting that this molecular mechanism may contribute to a PGJ anti-proliferative effect on MM cells.
3.3. Pomegranate Juice Inhibits Angiogenesis
Since angiogenesis is associated with progression of MM [38], we first examined the effect of
PGJ on HBMEC cell viability. As shown in Figure 2A, PGJ inhibited cell proliferation in a dose- and
time-dependent manner by 18% and 19% at 48 h and 72 h, respectively, in the presence of 3% PGJ.
Moreover, inhibitions by 29%, 31% and 32% at 24 h, 48 h, and 72 h, respectively, in the presence of
6% PGJ, were found. Since PGJ significantly reduced cell viability at 12%, this dose was not used for
the subsequent tests. The direct effect of PGJ on angiogenesis was tested by using the tube formation
and ex vivo rabbit aortic ring assays. We studied the effect of VEGF-A alone or in combination with
3% or 6% PGJ, on tubule formation of HBMEC by using the Matrigel assay. The results in Figure 2B
show that the tubular networks formed on Matrigel vary in the different environments. The number
of the interconnections between the tubes provides information on the way the HBMEC organize them
and grow. In panel a (control), some cells are joined by projections or direct cell contact. Cellular
projections that do not result in contact with other cells are also visible (arrows). In the presence of
VEGF-A (panel b) the cells show sprouts which connect with similar projections originating from other
cells to form a cell–cell contact. Some cells forming polygon structures are also visible (arrowheads).
In the presence of 3% (panel c) or 6% (panel e) PGJ, the cells show few sprouts. Both 3% and 6% PGJ
suppressed the formation of tube-like structures in presence of VEGF-A (panels d and f). As expected,
the VEGF-A treatment significantly induced an enhancement of both tube length and number of branch
points by 1.7 and 2.0 fold, respectively, in comparison to control unstimulated cells (Figure 2C,D).
The total length and the number of branch points were significantly reduced by both concentrations
of PGJ respect to VEGF-A-treated cells (p < 0.0001). The incubation of the cells with 3% or 6% PGJ
in the presence of VEGF-A significantly reduced tube total length by 1.7 fold after both treatments
in comparison to VEGF-A-treated cells. Moreover, fewer branch points between cells incubated
with 3% or 6% PGJ plus VEGF-A was observed, with a reduction by 2.2- and 2.3-fold, respectively,
in comparison to growth factor stimulated cells. Moreover, PGJ in the presence or not of VEGF-A
totally inhibited the formation of enclosed spaces in Matrigel (mesh number, panel e). The ex vivo
rabbit aortic ring assay (Figure 3) showed an evident new vessel sprouting of endothelial tubes
from aorta rings when the incubations were carried out in presence of VEGF (panel d). Total length
was about 6 fold greater with VEGF-A than controls cells (panel a) or 3% and 6% PGJ treated cells
(panels b and c). Panels e and f show the effects of both 3% and 6% PGJ, respectively, on VEGF-treated
cells. As shown in the bar graph inset, there is a dose-dependent effect, with a higher concentration of
PGJ leading to a greater reduction of outgrowth of vascular shoots.
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Figure 2. (A) Effect of PGJ on HBMEC viability. Cells (1 × 104 cells/well) were cultured in complete
medium in the absence or in the presence of PGJ at 3% or 6% or 12% (v/v). Cell viability was
assessed by MTT assay. Values are expressed as mean ± SD of three independent experiments, each
involving six different wells per condition. (* p < 0.05 vs. respective control); (B) Effect of PGJ on
VEGF-A-induced HBMEC in vitro angiogenesis. Tube formation was evaluated with light microscopy
and representative fields are shown. Panel (a): Control cells; panel (b): VEGF-A stimulated cells;
panels (c) and (e): Cells treated with 3% and 6% PGJ, respectively; panels (d) and (f): Cells treated with
3% and 6% PGJ, respectively, in the presence of VEGF-A; Quantitative analysis of tube formation was
indicated as tube length (C) and number of branch points (D) expressed as percentage of control cells.
Image analysis of the total length and the number of branch points in the whole photographed area
(representing central 70% of the well) were carried out by using Angiogenesis Analyzer tool for ImageJ
(ImageJ 1.50e, National Institutes of Health, NIH, Bethesda, MD, USA). Values are expressed as
a mean ± SD of three independent experiments performed in duplicate. Statistically significant
differences by one-way analysis of variance (ANOVA) followed by Tukey’s test (p < 0.05) are
indicated: (*) VEGF-A-stimulated cells vs. control; (§) 3% and 6% PGJ plus VEGF-A-treated cells
vs. VEGF-A-stimulated cells.
3.4. Effect of Pomegranate Juice on Cell Invasion and Migration
Since endothelial cell migration is essential for the formation of new blood vessels during
neo-angiogenesis, we evaluated the effects of PGJ treatment on the migratory and invasive properties
of endothelial cells by using, respectively, the wound-healing and the transwell assays (Figure 4).
As shown in panel A, the presence of VEGF-A in the medium increased HBMEC migration in
comparison to control cells. Quantitative analysis showed in panel b revealed a VEGF-dictated
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increase of cell migration by almost 1.7- and 2.0-fold after 24 h and 48 h, respectively, compared with
control cells. The incubation with VEGF-A plus 3% and 6% PGJ reduced the cell migration (panel a);
this reduction was estimated at almost 6.0 fold when both 3% or 6% PGJ, respectively, were added to
VEGF-A-treated cells for both 24 h and 48 h.
The effect of PGJ on HBMEC migration was also assessed by using transwell migration assays
(panels c, d and e). A reduction of the number of invaded cells by 30% and 40% after 3% or 6% PGJ,
respectively, was found in comparison to VEGF-treated cells.
a. Control cells  
b. 3% PGJ 
c. 6% PGJ 
d. VEGF-A 
e. VEGF-A + 3% PGJ 
f. VEGF-A + 6% PGJ d 
a b b c 












































Figure 3. Developing microvessels from the intimal/subintimal layers of the aortic wall. Rabbit
thoracic aortic rings were isolated and embedded on Matrigel, in the absence of VEGF-A ((a): untreated;
(b): 3% PGJ; (c): 6% PGJ) or in the presence of 50 ng/ml VEGF-A ((d): VEGF-A alone; (e): 3% PGJ;
(f): 6% PGJ). After 14 days, the angiogenic response was measured by counting the lenght of neovessels
sprouting out of the rings. Representative photographs from a single experiment that was performed
three times are shown. Statistically significant differences by one-way ANOVA followed by Tukey’s test
(p < 0.05) are indicated: (*) VEGF-A-stimulated cells vs. control; (§) 3% and 6% PGJ plus VEGF-A-treated
cells vs. VEGF-A-stimulated cells.
3.5. Effect of Pomegranate Juice on Angiogenic Genes Expression
To confirm the anti-angiogenic properties of PGJ, we analyzed the expression of mRNA angiogenic
genes in HBMEC cells after treatment with VEGF-A alone or in combination with 3% and 6% PGJ.
Compared to cells exposed to VEGF-A alone, we observed that several angiogenic genes were
downregulated in cells treated with VEGF-A in combination with PGJ (Table 2).
3.6. Combination of Pomegranate Juice with Proteosome Inhibitor Bortezomib
For its anti-proliferative and anti-angiogenic properties, we tested in vitro the combination of
PGJ with the proteasome inhibitor BTZ, a first-line drug used for MM therapy. We observed that
combination of PGJ (6%) with BTZ inhibited the cytotoxicity of the drug in MM cells (Figure 5A). It may
be linked to the G0/G1 cell cycle arrest induced by PGJ that could protect MM cells from BTZ cytotoxic
effects. For this reason, we used alternating BTZ/PGJ or PGJ/BTZ combinations for treatment of
24 h each one. Before the addition of the second compound, cells were washed and resuspended in
drug-free medium. Pre-treatment with PGJ inhibited cytotoxic effect of BTZ (Figure 5B), probably
for the same mechanism that led to the failure of concurrent combination PGJ-BTZ. On the contrary,
treatment with PGJ after BTZ improved the cytotoxic effect in MM cell lines (p < 0.0001).
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Figure 4. (A”) Effect of PGJ on VEGF induced HBMEC migration (wound healing assay).
Images of scratch photographed with at ×40 using phase-contrast microscope at different time point,
0, 24 and 48 h. (a) Control cells, 1% serum; (b) VEGF-A + 1% serum; (c) 3% PGJ; (d) 6% PGJ;
(e) VEGF-A + 3% PGJ; (f) VEGF-A + 6% PGJ; (B”) migration of HBMEC cells after wounding evaluated
as percentage of wound closure respect to 48 h VEGF-A treated cells considered as 100% wound closure.
The results are expressed as mean ± standard deviation. Statistically significant differences by one-way
ANOVA followed by Tukey’s test (p < 0.05) are indicated: (#) non stimulated cells vs. control at 24 h;
(*) 3% and 6% PGJ vs. control at 24- and 48 h; (**) VEGF-A-stimulated cells vs. respective control at at
24- and 48 h; (§) 3% and 6% PGJ plus VEGF-A-treated cells vs. VEGF-A-stimulated cells at 24- and 48 h;
(C”) effect of PGJ on VEGF-A induced HBMEC invasion. Harvested HBMEC (1 × 106 cells/mL) were
allowed to migrate through transwell membranes towards 50 ng/mL VEGF in the absence or in the
presence of PGJ for 24 h. Cells that had migrated to the underside of the transwell membrane were
fixed and evaluated with light microscopy. Representative fields are shown at 100× magnification;
(D”) average number (displayed as percentage of control) of HREC migrated in three different wells in
each condition (n = 5 different fields of the same membrane); and (E”) quantitative analysis of invaded
cells, which were eluted using 10% acetic acid and measured optical density value at 590 nm. Data
are the mean ± SD of three independent experiments. Statistically significant differences by one-way
ANOVA followed by Tukey’s test (p < 0.05) are indicated: (*) 3% and 6% PGJ plus VEGF-A-treated cells
vs. VEGF-A-stimulated cells.
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Table 2. Effect of 6% PGJ on the expression levels of angiogenic genes in HBMEC. Reported data are
expressed by relative quantification (fold change) using a 2−ΔΔCt method. VEGF-A treated cells was of
the control.
Genes VEGF PGJ + VEGF p Value
VEGF 43 0.036 p < 0.001
ADAMST1 23 0.041 p < 0.001
CXCL12 16 0.136 p < 0.001
CXCL2 9 0.038 p < 0.001
FGF2 32 0.011 p < 0.001
FIGF 12 0.065 p < 0.05
IL12A 9 0.030 p < 0.001
IL8 21 0.007 p < 0.01
MMP2 5 0.031 p < 0.001
PDGFB 15 0.116 p < 0.001
VEGFB 19 0.028 p < 0.001
VEGFC 18 0.008 p < 0.001
Figure 5. (A) the survival assay in U266 cell line treated with Bortezomib (BTZ) alone and
in combination with PGJ. Bars represent the mean ± SEM of four independent experiments.
*** p < 0.0001 versus untreated cells; and (B) the survival assay in U266 cell line treated alternating
BTZ/PGJ or PGJ/BTZ combinations for treatment of 24 h each one. Bars represent the mean ± SEM of
four independent experiments. * p < 0.05; ** p < 0.001; *** p < 0.0001.
4. Discussion
It is well-known that Punica granatum extracts contain bioactive compounds with anti-cancer
actions leading to their use in a number of randomized clinical trials for prostate cancer [39].
Accumulated experimental evidence demonstrates that PGJ inhibits tumor proliferations [40] and
induces apoptosis through a nuclear factor-kB-dependent mechanism in vitro and in mice [41].
Previous studies in vitro have also shown that pomegranate metabolites were able to inhibit prostate
cancer cell proliferation [42]. The treatment with PGJ showed anticancer effects also in some cancer
lines of colon (HT29 and HCT116), liver (HepG2 and Huh7), and breast (MCF-7 and MDA-MB-231) [43].
Our data demonstrated the anti-proliferative potential of PGJ in MM cells and its ability to improve the
cytotoxic effect of the proteosome inhibitor BTZ. PGJ contains a number of potential active compounds
including organic acids, vitamins, sugars, and phenolic components that are all responsible of the
pro-apoptotic effects of PGJ observed in tumor cell lines. The phenolic components include phenolic
acids: principally, hydroxybenzoic acids (such as gallic acid and ellagic acid) [44], hydroxycinnamic
acids (such as caffeic acid and chlorogenic acid) [45], anthocyanins, including glycosylated forms
of cyanidin, delphinidin, and pelargonidin [46], gallotannins and ellagitannins [44]. However, the
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concentration and the contents of these compounds vary due to growing region, climate, cultivation
practice, and storage conditions [45,47]. In particular, it has been reported that the anthocyanins,
which are major components of PGJ, were found to have binding affinity against eicosanoid receptors
(e.g., peroxisome proliferator-activated receptors α and γ), by this way regulating gene expression and
suppressing chemically induced carcinogenesis [48]. Several data demonstrated that the pomegranate
leaves, stem and flower extracts modulate cell cycle progression and induce apoptosis in human MM
cells through G2/M and S phase cell cycle arrest and mitochondrial membrane permeabilization [49].
It has also been reported that pomegranate induces apoptosis in leukemia cell lines and its polyphenols
are responsible for these pro-apoptotic properties [50]. Our results confirm the anti-proliferative effect
of PGJ in MM cell lines with a block of cell cycle in G0/G1 phase. Moreover, it upregulated PPARγ
mRNA expression, which has been reported to induce apoptosis in MM cells [51,52] and be involved in
the induction of G0/G1 phase cell cycle arrest [53]. In addition, accumulated evidence demonstrated
that PGJ inhibits tumor angiogenesis and cell invasion [40] Angiogenesis is a constant hallmark of MM
progression with prognostic potential [38,54]. In the bone marrow, increased vascularization correlated
with a poor prognosis for MM patient [38]. Moreover, it has been reported that MM tumor progression
is dependent on endothelial progenitor cells-trafficking (targeting vasculogenesis to prevent progression
in multiple myeloma). For this reason, we investigated the effect of PGJ on angiogenesis and cell
migration/invasion. Interestingly, we observed an inhibitory effect on the tube formation, microvessel
outgrowth aorting ring and decreased cell migration and invasion as showed by wound-healing and
transwell assays, respectively. Analysis of angiogenic genes expression in endothelial cells confirmed
the anti-angiogenic properties of pomegranate. Therefore, PGJ administration could represent a good
tool in order to identify novel therapeutic strategies for MM treatment, exploiting its anti-proliferative
and anti-angiogenic effects.
Furthermore, we assessed the effect of PGJ treatment in combination with the proteosome inhibitor
BTZ. Our results demonstrated that the concurrent administration of PGJ-BTZ on MM cells in vitro
reduced the cytotoxic effect of proteosome inhibitor. We hypothesized that block of cell cycle in
GO/G1 induced by PGJ could protect MM cells from bortezomib activity. We therefore evaluated
sequential exposure of MM cells to the two compounds and found that the sequence of PGJ followed
by BTZ did not add any cytotoxic effect to BTZ alone, thus confirming our hypothesis. On the contrary,
by exposing MM cells to BTZ followed by PGJ, we observed an increase cytotoxic effect.
This is a pre-clinical model of potential benefits of bortezomib-PGJ combination. We propose
using the entire pomegranate juice as a nutraceutical means, able to induce a modulation of the
well-known pharmacological function of bortezomib in multiple myeloma, due to the metabolic
relationships of individual components present in the whole pomegranate juice and not to a single one.
Indeed, several previous studies have well shown that the single phytochemical agents are not able to
induce the same effects of the entire pomegranate juice [55,56].
A phase 1 study has been planned to verify potential side effects in patients undergoing treatment,
since the effect of PGJ on CYP450 or biochemical interactions is unknown. Most recently, it has
been reported that the proteasome-inhibitory and anticancer activity of bortezomib can be blocked
by green tea polyphenols, quercetin, myricetin and ascorbic acid through their interaction with the
structure of a boronic acid to form boronic ester complexes [57,58]. It is worth noting that the drug has
been administered in combination with a variety of antitumor agents in patients with cancer without
significant alterations to its pharmacokinetic or pharmacodynamic profile (as reviewed by [4]).
5. Conclusions
In conclusion, the current work supports the evidence that PGJ could play a key role of a future
nutraceutical approach for treatment of multiple myeloma in order to optimize the pharmacological
effect of BTZ, especially as an adjuvant after treatment. Other stimulating studies are necessary in
this field in order to better clarify all of the biochemical mechanisms that supervise these interesting
antiproliferative and antiangiogenic effects. Future and stimulating studies of PGJ in combination with
BTZ or other anti-MM agents are warranted.
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Abstract: To investigate the antitumor effect of anthocyanins extracted from Chinese bayberry fruit
(Myrica rubra Sieb. et Zucc.), a nude mouse tumor xenograft model was established. Treatments with
C3G (cyanidin-3-glucoside, an anthocyanin) significantly suppressed the growth of SGC-7901 tumor
xenografts in a dose-dependent manner. Immunohistochemical staining showed a significant increase
in p21 expression, indicating that the cell cycle of tumor xenografts was inhibited. qPCR screening
showed that C3G treatment up-regulated the expression of the KLF6 gene, which is an important
tumor suppressor gene inactivated in many human cancers. Western blot showed that C3G treatments
markedly increased KLF6 and p21 protein levels, inhibited CDK4 and Cyclin D1 expression, but did
not notably change the expression of p53. These results indicated that KLF6 up-regulates p21 in
a p53-independent manner and significantly reduces tumor proliferation. This study provides
important information for the possible mechanism of C3G-induced antitumor activity against gastric
adenocarcinoma in vivo.
Keywords: Chinese bayberry; anthocyanin; SGC-7901 cell; tumor xenograft; KLF6 gene
1. Introduction
Anthocyanins are the most abundant water-soluble pigment found in fruit, vegetables and beans.
It has been well established that anthocyanins from different sources exhibit multiple functional
properties including antioxidant [1], anticancer [2], anti-obesity [3] and anti-diabetic effects [4]. It has
been demonstrated in our laboratory that the proliferation of human SGC-7901, BGC-823 and AGS
gastric cancer cells in vitro was inhibited by anthocyanins from Chinese bayberry fruit [5].
Gastric cancer, also called stomach cancer, is the fourth most frequently diagnosed cancer in
humans and the third leading cause of cancer death worldwide [6]. It ranks second as the most
frequently diagnosed cancer and is the leading cause of cancer death in China today, second only to
lung cancer [7]. Further epidemiological and experimental studies showed that diet pattern variations
play an important role in the etiology of gastric cancer [8,9], and a reverse association between fruit
intake and gastric cancer risk has been widely reported [10–13].
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Chinese bayberry (Myrica rubra Sieb. et Zucc.) is a subtropical native Chinese fruit with high
nutrient and health values. The red-colored Chinese bayberry pulp is a rich source of anthocyanins,
especially cyanidin-3-glucoside (C3G) [14], which has been well characterized as having anticancer
activity in vitro [15] and in vivo [16]. Previous studies have demonstrated that the in vitro anticancer
activities of anthocyanins are exerted through mechanisms of promotion of apoptosis [17], inhibition
of cell cycle [18] and cell invasion [5,19]. However, the antitumor effects of C3G in vivo have been less
clearly demonstrated.
Krüppel-like transcription factor 6 (KLF6) is a novel tumor suppressor gene and is involved in
the pathogenesis of many cancers [20]. In addition to gastric cancer [21], functional inactivation of
KLF6 was observed in a number of other human cancers including prostate [20], colorectal [22,23],
ovarian [24], liver [25,26], and breast cancer [27]. With different cell types and contexts, KLF6
exhibits growth inhibition activity through several major cancer pathways such as p53-independent
up-regulation of p21 [20], disruption of Cyclin D1 and CDK4 interaction [28] and induction of
apoptosis [23]. Although the tumor-suppressing activity of the KLF6 gene is well known, it has
not been reported whether natural nutrients such as anthocyanins could affect KLF6 expression.
In this study, it was first discovered that C3G, a major component of anthocyanins from Chinese
bayberry, could suppress the growth of SGC-7901 tumor xenografts through up-regulating KLF6
gene expression.
2. Materials and Methods
2.1. Materials and Chemicals
Chinese bayberry (Myrica rubra Sieb. et Zucc c.v. Dongkui) fruits were harvested at commercial
maturity from Xianju County, Zhejiang Province, China. The SGC-7901 gastric cancer cell line
was obtained from the Department of Surgery, Second Affiliated Hospital, School of Medicine,
Zhejiang University.
C3G standards were purchased from Sigma-Aldrich Co. LLC (Shanghai, China). RIPA (Radio
Immunoprecipitation Assay) lysis buffer was purchased from the Beyotime Institute of Biotechnology
(Hangzhou, China). Anti-KLF6, anti-caspase3, anti-p21, anti-p53, anti-Cyclin D1, anti-CDK4 antibodies
were obtained from Proteintech (Chicago, IL, USA). All the other reagents were of analytical grade
and purchased from Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China). Double-distilled
water (ddH2O) was used in all experiments. All samples for HPLC (High Performance Liquid
Chromatography) analyses were filtered through a 0.22 μm membrane before injection.
2.2. Purification and Identification of C3G from Chinese Bayberry Fruit
Fifty grams of fresh Chinese bayberry fruit pulp was extracted ultrasonically with 80% aqueous
methanol (1% formic acid) in a material-to-solvent ratio of 1:10 (w/v) three times. The supernatants
from three extractions were combined and evaporated under reduced pressure at 36 ◦C to remove the
methanol. A phenolic-rich extract (PRE) was obtained by solid-phase extraction (SPE) using a Sep-pak
C18 cartridge (12 cc, 2 g sorbent; Waters Corp., Milford, MA, USA). Sugars and organic acids were
removed by eluting with ddH2O. Phenolics were eluted with 10% aqueous methanol after eluting with
5% aqueous methanol.
The purity of C3G was determined by HPLC (2695 pump, 2996 diode array detector; Waters Corp.,
Milford, MA, USA) coupled with a Waters SunFire C18 analytical column (4.6 × 250 mm) at a column
temperature of 25 ◦C. The HPLC analyses were performed as per previously published procedures [29]
with some modifications. The mobile phase consisted of 0.1% (v/v) formic acid in water (eluent A)
and of acetonitrile: 0.1% formic acid (1:1, v/v) (eluent B). The gradient program was as follows: 0 to
40 min, 10% to 38% of B; 40 to 60 min, 38% to 48% of B; 60 to 70 min, 48% to 100% of B; 70 to 75 min,
100% to 10% of B; 75 to 80 min, 10% of B. Then 10 μL samples were injected and were detected from
200 to 600 nm. Anthocyanins were calculated as C3G equivalent at 515 nm.
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LC-MS (Liquid Chromatograph-Mass Spectrometer) experiments were performed according
to our previous publication [5]. Briefly, an Agilent 6430 Triple Quadrupole LC/MS system
(Agilent Technologies Inc., Santa Clara, CA, USA) was used for LC-MS. Multiple reaction monitoring
(MRM) was used for analytical identification and electrospray ionization (ESI) was in positive mode.
The operation conditions were as follows: capillary 4000 V, nebulizer 35 psi, dry gas flow rate 9 L/min
at 350 ◦C. An Agilent MassHunter Workstation was used to carry out data acquisition and processing.
The 1H-NMR (Hydrogen-Nuclear Magnetic Resonance) (500.18 MHz) spectra were obtained on
a Bruker Avance 500 instrument (Bruker Biospin, Fallanden, Switzerland). Extracts (15 mg) were
dissolved in 0.5 mL deuterated methanol (CD3OD) in a 5 mm tube at variable temperatures; δ (parts
per million) and the coupling constants (J) in Hertz were presented as chemical shifts.
2.3. Animal and Tumor Xenograft Studies
Balb/c nude mice (weighing 19–21 g) were used for building a model and were maintained at
23–25 ◦C and 50%–60% humidity in the Laboratory Animal Center of Zhejiang University (Hangzhou,
China). Balb/c-nu mice were randomly allocated to four groups: a model group (drinking water),
low-dose group (C3G, 25 mg·kg−1·bw−1·day−1), high-dose group (C3G, 125 mg·kg−1·bw−1·day−1)
and positive control group (tegafur, 10 mg·kg−1·bw−1·day−1) (three mice in each group). Mice were s.c.
injected with 2 × 106 SGC-7901 cells on the right groin and were housed under a regular 12 h light/12 h
dark cycle. After 18 days, the mice were sacrificed for the assay of tumorigenicity (e.g., body weight
and tumor volume). All experiments were carried out in accordance with the ethical guidelines of the
Animal Experimentation Committee in the College of Medicine, Zhejiang University. Our experiment
ethic approval code is ZJU20160443.
2.4. Immunohistochemical Staining
The tumor tissues were removed from each mouse and the samples were subsequently fixed in
4% (v/v) paraformaldehyde/PBS (Phosphate Buffer Saline) and embedded in paraffin for staining.
The paraffin sections were deparaffinized in xylene, rehydrated in a 10 mM citrate buffer (pH 6.0),
and heated in a microwave oven for 15 min to restore the antigens. To suppress endogenous peroxidase
within the tissues, the samples were treated with 3% peroxide for 5 min and then with a blocking
solution for 30 min. Slides were incubated with the primary antibody and secondary antibody in
a humid chamber for 60 min. Tissue staining was visualized with a 3,3′-diaminobenzidine substrate
chromogen solution and the images were taken by using a microscope set (Zeiss, Germeny) at
a 200× magnification.
2.5. Quantitative Real-Time PCR and Western Blot Assay
Total RNA was isolated from tumor tissues using Trizol reagent (Invitrogen, Waltham, MA, USA)
according to the manufacturer’s protocol. Equal amounts of total RNA (1.0 μg) were used to synthesize
cDNA with the iScriptTM cDNA Synthesis kit (Bio-Rad, Hercules, CA, USA). Quantitative real-time
PCR was performed in triplicate using a SYBR Green Master I kit (Roche, Basel, Switzerland) and
the LightCycler480 real-time PCR System (Roche, Basel, Switzerland). Gene-specific primers were
used as mentioned in Table 1. The RNA quality was detected by OD260/OD280 and gel electrophoresis.
The fold change of the treatment group versus control group for each target gene was calculated
using the 2−ΔΔCt method and was evaluated as the effect of treatment on relative gene expression.
Expression was normalized against expression of the housekeeping gene β-actin.
Tumor tissues were lysed using RIPA buffer containing 1% PMSF (Phenylmethanesulfonyl
Fluoride), and protein inhibitor (cOmplete mini, Roche, Los Angeles, CA, USA). The protein
concentration was determined using the Pierce BCA Protein Assay Kit (Thermo Scientific, Waltham,
MA, USA). The concentration was adjusted to 1 μg/μL using PBS and 5× loading buffer. Equal
amounts (40 μg) of protein were separated on a 10% SDS (Sodium Dodecyl Sulfate)-polyacrylamide
gel and transferred onto PVDF (Polyvinylidene Fluoride) membranes. After blocking the membrane
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with 5% nonfat dried milk for 1.5 h, the protein abundance was detected with antibodies against KLF6
(1:1000 dilutions), p21 (1:1000 dilutions), p53 (1:1000 dilutions), Cyclin D1 (1:1000 dilutions), CDK4.
(1:1000 dilutions), followed by incubation with peroxide-conjugated anti-rabbit immunoglobulin.
β-actin was used as a loading control.
Table 1. Primer sequences used in quantitative real-time PCR.





Cyclin D1 GAACACGGCTCACGCTTACC GCCCAGACCCTCAGACTTGC
β-actin TGACGTGGACATCCGCAAAG CTGGAAGGTGGACAGCGAGG
2.6. Statistics
Statistical analyses were carried out using SPSS version 19.0 (IBM, Armonk, NY, USA). Data were
analyzed by one-way ANOVA. Multiple comparison between the groups was performed using the
LSD (Least Significant Difference) method. OriginPro 8.0 software packages (OriginLab Corporation,
Northampton, MA, USA) was used for plotting the experimental data. Values were expressed as the
mean ± standard deviation.
3. Results
3.1. Purification of C3G Extracted from Chinese Bayberry
The identification and quantification of C3G extracted and purified from Chinese bayberry
was accomplished by HPLC, LC-MS and 1H-NMR (Figure 1). HPLC identification was carried out
according to the retention time and peak area compared with those of standard C3G. HPLC analysis
of the identified anthocyanin compounds showed that the retention time of cyanidins-3-glucoside
was 15.6 to 17.9 min. The HPLC chromatograms of Chinese bayberry pulp showed impurity peaks
(Figure 1A), while purified C3G extracts did not have any other significant peaks (Figure 1B). The purity
was determined with a standard curve chart and C3G with a purity of 88.81% was achieved.
Figure 1. Cont.
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Figure 1. HPLC chromatograms of Chinese bayberry pulp (A) and purified C3G from Chinese bayberry
(B) (λ = 280 nm) and LC-MS2 spectrum of purified C3G (C).
Further identification of C3G was confirmed by LC-MS (Figure 1C) and 1H-NMR (Table 2).
Among all the LC-MS2 products, ions at m/z 287.0 were present in great abundance which was related
to the loss of one hexose ([M − 162]+) molecule, furnishing the cyanidin aglycone, the main body
structure of C3G. The ions at m/z 136.9 and 240.6 resulted from the ring-cross cleavage of cyanidin.
The 1H-NMR spectrum showed the presence of one cyaniding nucleus and one hexose (Table 2).
Therefore, all HPLC, LC-MS and 1H-NMR data confirmed the purified extract was C3G.
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3.2. C3G Suppressed the Growth of SGC-7901 Tumor Xenografts
A tumor xenograft model was established to study the inhibition effects of C3G on tumor
growth in vivo. Through preliminary tests (data not shown), we chose 25 mg·kg−1·bw−1·day−1
and 125 mg·kg−1·bw−1·day−1 as our C3G treatment doses and selected 18 days as the duration of
this experiment. The effects of C3G on tumor size were monitored every alternate day. After eight
days of cancer cell injection treatment, the average tumor volume in the control group began to appear
significantly different from that of other treatment groups, reaching up to 230.8 mm3 (Figure 2A).
At 18 days before the sacrifice, the average tumor volume in the control group had increased to
771.5 mm3, while the C3G treatment groups with low dose and high dose grew to 384.1 mm3 and
276.0 mm3, respectively, compared to the tegafur-treated group (positive control), which was 211.7 mm3
(Figure 2A).
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Figure 2. Effects of purified C3G on tumorigenesis in vivo. (A) The volumes of tumors were monitored
at the indicated times; (B) tumor weights were measured after rats were sacrificed; (C) photographs of
individual tumor xenografts removed from mice; (D) the body weights were monitored every alternate
day after treatments; (E) the liver index and (F) the spleen index. The index was calculated as liver
weight (mg)/body weight (g); and spleen weight (mg)/body weight (g), respectively. Values are
mean ± SEM of three mice. ** p < 0.01, *** p < 0.001.
The inhibitory effect of C3G on tumor growth was evaluated based on tumor xenograft size when
tumor tissues were removed and weighed after sacrifice. The tumor weight and size of treatment
groups were significantly lower than those of the control group (Figure 2B,C). Inhibition rates of the low
C3G dose group, the high dose group and the drug group were 30.4%, 45.1% and 53.0%, respectively.
Experimental results showed no significant changes in body weight, liver index and spleen index
between the control group and C3G treatment groups (Figure 2D–F), indicating that C3G extracted
from Chinese bayberry has little toxicity to mice. However, compared with the control group and
C3G treatment groups, the body weight and liver index of the tegafur group was significant decreased
(Figure 2D,E), showing the positive drug had some toxic effects or side effects on the liver and whole
body of mice.
3.3. C3G Inhibited the Cell Cycle of SGC-7901 Tumor Xenografts
Expressions of caspase 3 and p21 in tumor tissues were determined by immunohistochemistry
staining. The negative cellular nuclei were stained blue, while the positive nuclei were stained dark
brown. Immunohistochemical studies showed clear positive p21 staining in cell nuclei in C3G treatment
groups with a dose-dependent manner. In contrast, the positive caspase 3 staining, which appeared
in the cytoplasm, showed no marked change among different treatments (Figure 3). These results
indicated that anthocyanin C3G from Chinese bayberry could suppress the growth of tumor xenografts
by inhibiting the cell cycle but with less induction of apoptosis.
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Figure 3. Caspase 3 and p21 immunochemical staining of tumor xenografts sections
(200× magnification) (n = 3).
3.4. Gene Expression Analysis
To elucidate the in vivo mechanism of C3G inhibition of the cell cycle in SGC-7901 cell tumor
xenografts, the effects of C3G on expression of cancer-related genes, including KLF6, p21, Cyclin D1,
CDK4 and p53, were further evaluated. Both mRNA levels, measured by quantitative real-time PCR,
and protein levels, measured by Western blot, were analyzed to determine these effects. As indicated in
Figure 4A, results showed that the KLF6 and p21 genes were up-regulated in a dose-dependent manner
in C3G treatment groups. The relative mRNA expression of KLF6 in the low dose and high dose
groups was about 1.61- and 2.06-fold higher than in the control group. Similarly, p21 was up-regulated
2.19- and 3.48-fold in the low dose group and high dose group, respectively. Both Cyclin D1 and CDK4
gene expressions in C3G treatment groups were inhibited significantly. In comparison with the control
group (Figure 4A), Cyclin D1 gene expression was decreased 0.62- and 0.26-fold and the CDK4 gene
was down-regulated 0.69- and 0.32-fold, respectively. However, there were no obvious changes in the
expression of p53, the master tumor suppressor gene, between the treatment groups and the control
(Figure 4A). The protein expressions of various genes as measured by Western blot analysis were
in accordance with their qPCR analysis (Figure 4B). KLF6 and p21 protein levels were significantly
increased, indicating the critical role of KLF6 in the tumor xenograft suppression in vivo. However,
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Figure 4. Effects of purified C3G on gene expression and protein expression in tumor xenografts.
(A) Relative mRNA expression of KLF6, p21, CDK4, Cyclin D1, p53 after C3G treatments; (B) protein
expression of KLF6, p21, CDK4, Cyclin D1, p53 after C3G treatments. Values are mean ± SEM of
measurements from three mice. ** p < 0.01, *** p < 0.001.
4. Discussion
A nude mouse tumor xenograft model was established to study the in vivo anticancer effect of
high-purity anthocyanin C3G from Chinese bayberry. Results showed that C3G inhibited the growth
of SGC-7901 cell tumor xenografts in a dose-dependent manner. The inhibition rates of low dose
and high dose groups were 30.4% and 45.1%, respectively. Compared with the positive drug tegafur
treatment, the C3G treatment did not show any toxic effects or other side effects. Immunohistochemical
staining indicated that the tumor-suppressing effect was due to cell cycle inhibition but lower apoptosis
induction. Through qPCR and Western blot, it was established that C3G treatment could up-regulate
KLF6 gene expression and the downstream effector p21 in a p53-independent manner. As a consequence,
it is concluded that C3G activity on tumor growth inhibition was probably through KLF6-mediated
p21 induction, by disruption of the Cyclin D1 and CDK4 interaction, thus blocking the cell cycle.
The Krüppel-like family (KLF) of transcription factors is characterized by three contiguous
C2H2-type zinc finger motifs at the carboxy terminus which comprise the DNA-binding domain [30,
31]. KLF6 is a member of the KLF family that consists of four exons and encodes a nuclear core promoter
element-binding protein [32]. KLF6 is a tumor suppressor based on its inactivation and somatic
mutations in a variety of cancers such as prostate [20], gastric [21], ovarian [24], breast [27], liver [25,26],
and colorectal cancer [22,23]. KLF6’s growth-suppressive activity is linked to p53-independent
transactivation of p21 [20] and inhibition of the Cyclin D1/CDK4 complex [28]. This study could be
the first report that KLF6 can be up-regulated by anthocyanin C3G extracted from Chinese bayberry,
thus reducing the mouse tumor growth burden.
In vitro effects of C3G are well studied and it is known that C3G can suppress tumor cell
proliferation by various mechanisms such as apoptosis induction [17], cell cycle inhibition [18],
peroxidation inhibition [33] and migration inhibition [5,19], etc. Several signaling pathways
have been implicated, such as inhibiting Ras signaling [16], down-regulating the expressions of
CDKs [34], abolishing ethanol-mediated p130Cas/JNK interaction [19], elevating the Bax/Bcl-2
ratio [17], and inducing signaling by p38/p53 and c-jun [35]. Mulberry anthocyanins containing
46.13% of cyanidine-3-gluoside induce apoptosis in gastric cancer cell AGS by up-regulating p53 and
other apoptosis-mediated gene expression [35]. However, the in vivo experiment from this study did
not show any significant change of p53 expression in tumor tissues, either at the mRNA or protein level,
illustrating that the mechanism of the antitumor effect of C3G in vitro and in vivo might be different.
There have been multiple reports about antitumor effects of anthocyanins extracted from natural
products. Baked purple-fleshed potato reduced the colon CSCs number via induction of apoptosis [36].
Anthocyanins extracted from Korean wild berry, Meoru, could inhibit hepato-carcinoma cell metastasis
via the AMPK pathway [37]. Delphinidin-3-glucoside suppressed breast carcinogenesis in vivo through
decreasing HOX transcript antisense RNA (HOTAIR) transcript [38]. Pomegranate polyphenolics
showed cytotoxicity in vitro and in vivo through the PI3K/AKT pathway [39]. A diet containing
anthocyanins from black raspberries inhibited NMBA-induced rat esophagus tumor development
by reducing NF-κB and COX-2 expression [40]. Anthocyanin-rich extract from roselle could inhibit
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N-Nitrosomethylurea–induced leukemia in vivo [41]. A diet with anthocyanin-enriched potato P40
prevented rats from colorectal cancer [42]. Furthermore, although its tumor inhibition capacities
are clearly indicated [16,35,43,44], the reported in vivo C3G antitumor mechanisms are nuanced in
different animal models and different purities of C3G. However, reports expatiating the mechanism of
C3G suppressing tumor growth in vivo are limited [16,35,43,44], which is partly due to the difficulty
of separating and purifying high-purity C3G.
In this study, by using high-purity C3G and a tumor xenograft model, it was demonstrated that
C3G treatment could up-regulate KLF6 gene expression and KLF6 exhibited tumor growth–suppressing
activity by cell cycle inhibition with a p53-independent up-regulation of p21 and disrupted the
Cyclin D1 and CDK4 interaction. However, further progress could be made by studying the oral
administration of C3G, its metabolism and digestion in mice to investigate the target points of C3G.
Since the KLF6 gene belongs to the transcription factor Krüppel-like family, the antitumor function of
other KLF family members could also be studied.
5. Conclusions
In conclusion, C3G treatment showed in vivo antitumor effects in dose-dependent manner,
where significantly tumor growth inhibition was observed in nude mouse xenograft model. C3G
treatments also showed no toxic effects or other side effects compared with the positive drug tegafur
treatment. The tumor-suppressing effect was due to cell cycle inhibition but lower apoptosis induction
through Immunohistochemical staining test. Further q-PCR and Western blot results showed that
C3G treatment could up-regulate the KLF6 gene expression and the downstream effector p21 in
a p53-independent manner. These results might provide important information concerning the possible
mechanism of C3G-induced antitumor activity against gastric adenocarcinoma in vivo and shed light
on the potential application of food anthocyanins in cancer prevention.
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Abstract: Resveratrol, a natural polyphenol present in most plants, inhibits the growth of numerous
cancers both in vitro and in vivo. Aberrant expression of YAP has been reported to activate multiple
growth-regulatory pathways and confer anti-apoptotic abilities to many cancer cells. However, the
role of resveratrol in YES-activated protein (YAP) expression and that of YAP in pancreatic cancer
cells’ response to gemcitabine resistance remain elusive. In this study, we found that resveratrol
suppressed the proliferation and cloning ability and induced the apoptosis of pancreatic cancer cells.
These multiple biological effects might result from the activation of AMP-activation protein kinase
(AMPK) (Thr172) and, thus, the induction of YAP cytoplasmic retention, Ser127 phosphorylation, and
the inhibition of YAP transcriptional activity by resveratrol. YAP silencing by siRNA or resveratrol
enhanced the sensitivity of gemcitabine in pancreatic cancer cells. Taken together, these findings
demonstrate that resveratrol could increase the sensitivity of pancreatic cancer cells to gemcitabine
by inhibiting YAP expression. More importantly, our work reveals that resveratrol is a potential
anticancer agent for the treatment of pancreatic cancer, and YAP may serve as a promising target for
sensitizing pancreatic cancer cells to chemotherapy.
Keywords: pancreatic cancer; resveratrol; AMPK; YAP; gemcitabine
1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant and lethal tumors,
with an overall five-year survival rate less than 7% [1]. Over recent decades, the prognosis of patients
with this malignancy has not improved due to aggressive local invasion, metastases, and resistance to
chemotherapy [2]. Currently, surgical resection is the only opportunity for curing pancreatic cancer at
an early stage. Unfortunately, only approximately 20% of patients are eligible for surgical resection
at the time of diagnosis, with most patents losing the opportunity for radical surgery. At present,
gemcitabine is the first-line chemotherapeutic agent for pancreatic cancer patients. However, a low
response rate to gemcitabine is common in the clinic, and less than 20% of patients experience the
ideal effects of gemcitabine [3]. In recent years, FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil,
and leucovorin) has become the recommended frontline chemotherapeutic regimen for metastatic
pancreatic cancer patients [4]. However, the seriously adverse reaction and acquired drug resistance
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associated with FOLFIRINOX limits its cytotoxic efficacy. Therefore, a novel target for enhancing
current chemotherapy is clearly needed to improve the outcomes of patients with pancreatic cancer.
The Hippo pathway was first discovered by genetic mosaic screens in Drosophila melanogaster [5,6],
and increasing evidence has demonstrated that the Hippo pathway also limits organ size in mammalian
systems [7,8]. The YES-associated protein (YAP), a main component of the Hippo pathway, has been
proved to be overexpressed and to participate in the tumorigenesis of a variety of cancers, including
breast cancer [9], lung cancer [10], ovarian cancer [11], liver cancer [12], and pancreatic cancer [13,14].
YAP functions as an oncogene and promotes the survival of cancer cells by regulating cancer cell
proliferation and apoptosis. The abnormal overexpression of YAP has also been reported to be linked
to disease progression and poor prognosis in breast cancer patients [15]. However, whether aberrant
YAP expression causes resistance of pancreatic cancer cells to chemotherapy is currently unclear. We
hypothesized that overexpression of YAP might be closely correlated to the sensitivity of gemcitabine
treatment in pancreatic cancer cells.
Resveratrol (trans-3,4',5-trihydroxystilbene, Res) is a natural polyphenolic phytoalexin that was
first isolated by Takaoka from the roots of white hellebore in 1939. Since then, resveratrol has been
widely found in plants (such as grape skin, red wine, berries, and peanuts) and in traditional Chinese
medicines (such as Rheum officinale Baill and Polygonum cuspidatum) [16,17]. Numerous studies
have shown that resveratrol exhibits antioxidant activity, anti-inflammatory activity, and protective
activity against cardiac diseases and metabolic disorders [18]. Over the past several years, many
reports have demonstrated that resveratrol acts as a cancer chemo-preventive agent to induce growth
inhibition, cell cycle arrest, apoptosis, and changes in biomarker expression in several human cancer
cell lines [19–21]. Our previous study showed that resveratrol plays an important role in suppressing
the proliferation of pancreatic cancer cells via the PI-3K/Akt/NF-κB signaling pathway [22] and the
hedgehog signaling pathway [23,24]. However, whether resveratrol can inhibit YAP expression and its
molecular mechanism have not been elucidated.
In the present study, we tested the hypothesis that resveratrol is able to inhibit YAP expression via
activation of the AMP-activated protein kinase (AMPK) pathway and inhibit the proliferation ability of
pancreatic cancer cells. YAP is associated with resistance to gemcitabine chemotherapy and targeting
YAP via resveratrol can enhance the sensitivity of pancreatic cancer cells to gemcitabine. Our findings
indicate that YAP is a novel molecular target for improving the efficacy of current chemotherapeutic
regimens for patients with pancreatic cancer and improving their long-term outcomes.
2. Materials and Methods
All experimental protocols were approved by the Ethical Committee of the First Affiliated Hospital
of Medical College, Xi’an Jiaotong University, Xi’an, China.
2.1. Reagents
Resveratrol (>99% pure) and MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium
bromide) were purchased from Sigma-Aldrich (St. Louis, MO, USA), and gemcitabine was purchased
from Selleck Chemicals (Houston, TX, USA). Resveratrol and gemcitabine were initially dissolved
in Dimethyl Sulfoxide (DMSO) at stock concentrations of 50 mM and 10 mM, respectively. Working
dilutions for resveratrol and gemcitabine were prepared in culture medium immediately before use,
and DMSO was used as control in all experiments. The antibodies used in this study are listed in
Supplementary Materials Table S1.
2.2. Cell Lines and Cell Culture
The human pancreatic cancer cell lines Panc-1 and BxPC-3 were purchased from the Type
Culture Collection of the Chinese Academy of Sciences (Shanghai, China). Panc-1 and BxPC-3 were
cultured in Dulbecco's Modified Eagle Medium (DMEM) or RPMI-1640, respectively, containing 10%
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dialyzed heat-inactivated fetal bovine serum (FBS) (HyClone, Logan, UT, USA), 100 U/mL penicillin
and 100 μg/mL streptomycin in a humidified atmosphere containing 5% CO2 at 37 ◦C.
2.3. Cell Viability Assay
Cancer cell lines (Panc-1, BxPC-3) were plated into 96-well plates at a density of 5000 cells/well
and treated with various concentrations (0, 25, 50, 100, and 200 μM) of resveratrol and various
concentrations (0, 1, 2, 5, 10, and 20 μM) of gemcitabine for designated lengths of time (24, 48, and
72 h). After being transfected with siRNA for 48 h, cells were plated in 96-well plates at a density
of 5000 cells/well and treated with 2 μM gemcitabine for 72 h. Cell viability was assessed by the
MTT assay. Ten microliters of 5 mg/mL MTT was added into each well after media were removed
and incubated at 37 ◦C for 4 h. Then, 100 μL DMSO was added to each well, and the optical density
(OD) was measured at 490 nm on a multifunction microplate reader (POLARstar OPTIMA; BMG,
Offenburg, Germany). The proliferation inhibition rate was calculated according to the following
equation: Proliferation inhibition rate = (1 − OD sample/OD control) × 100%.
2.4. Apoptosis Assay
Cell apoptosis was assessed by flow cytometry with an Annexin V-FITC/7-AAD apoptosis
detection kit from Becton, Dickinson and Company (BD) (Franklin Lakes, NJ, USA) according to
the manufacturer’s instructions. Briefly, cancer cells were seeded into 6-well plates at a density
of 1 × 105 cells per well, after being starved overnight, and each treatment was applied for 48 h.
Then, cells were trypsinized, washed with phosphate buffered saline (PBS) and stained with Annexin
V and 7-AAD. The percentage of apoptotic cells was quantified by flow cytometry using a FACSCalibur
(BD Biosciences, San Diego, CA, USA) instrument. The total apoptosis rate was calculated by summing
the rate of populations stained with Annexin V-FITC+/7-AAD- (early apoptotic cells) and Annexin
V-FITC+/7-AAD+ (late apoptotic cells).
2.5. Immunofluorescence Staining
Cells were fixed in 4% formaldehyde diluted in phosphate buffered saline (PBS) for 15 min,
permeabilized with 0.3% Triton X-100, treated with blocking buffer (5% BSA in PBS), and then incubated
overnight with the primary antibody at 4 ◦C. Cells were then incubated with the Red conjugated
secondary antibody from Jackson Immunoresearch Laboratories (West Grove, PA, USA) for 1 h at room
temperature. Slides were mounted and examined using a Zeiss Instruments confocal microscope.
2.6. Gene Silencing by Small Interfering RNA
Loss-of-function analysis was performed using siRNAs targeting AMPK and YAP, which were
purchased from GenePharm (Shanghai, China). The siRNA sequences are provided in Supplementary
Materials Table S2. Each siRNA (100 nM) was transfected into pancreatic cancer cells using
Lipofectamine 2000 according to the manufacturer’s instructions. The knockdown of each target
gene was confirmed by Western blot analysis. The cells were used for subsequent experiments 48 h
after transfection.
2.7. Western Blot Analysis
Total proteins were extracted by RIPA lysis buffer (Beyotime, Guangzhou, China), and the
concentration of proteins was determined using the BCA protein assay kit (Pierce, Rockford, IL, USA)
according to the manufacturer’s instruction. The proteins were then subjected to SDS-PAGE using
a 10% polyacrylamide gel with a 5% stacking gel. The proteins were subsequently transferred to
polyvinylidene difluoride (PVDF) membranes. The membranes were blocked with 5% fat-free milk in
Tris-buffered saline-Tween (TBS-T) for 2 h and then incubated with the primary antibodies (listed in
Supplementary Materials Table S1) at 4 ◦C overnight. Then, the membranes were incubated with a
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secondary antibody (diluted 1:10,000) for 2 h at room temperature. Chemiluminescence detection of
bound antibodies was performed using an enhanced chemiluminescence (ECL) PLUS system and a
Molecular Imager ChemiDoc XRS System (Bio-Rad Laboratories, Hercules, CA, USA).
2.8. Real-Time PCR
Total RNA was extracted using the Fastgen1000 RNA isolation system (Fastgen, Shanghai, China)
according to the manufacturer’s protocol. Total RNA was reverse-transcribed into cDNA using the
Prime Script RT reagent kit (TaKaRa, Dalian, China). Real-time PCR was used to quantitatively
examine the expression of YAP, CTGF and CYR61 at the mRNA level. Real-time PCR was conducted
according to a previous report [25]. The PCR primer sequences for YAP, CTGF, CYR61, and β-actin
are shown in Supplementary Materials Table S3. The expression of each target gene was determined
using β-actin as the normalization control. Relative gene expression was calculated using the 2−ΔΔCt
method [26].
2.9. Colony Formation Assay
One thousand cells were seeded into a 35-mm petri dish and allowed to adhere overnight.
The next day, a different treatment was applied to the dishes for 24 h, after which the medium was
replaced with drug-free medium. Cells were further cultured for two weeks to allow colonies to form.
At the indicated time point, colonies were fixed with 4% paraformaldehyde and then stained with
0.1% crystal violet solution, rinsed, and then imaged. The number of colonies larger than 0.5 mm
in diameter was counted using a microscope (Nikon Eclipse Ti-S, Tokyo, Japan) at a magnification
of 400×.
2.10. Statistical Analysis
Each experiment was performed at least three times. Data are presented as means ± standard
deviation. Differences were evaluated using Student’s t-test, with p < 0.05 considered to be statistically
significant.
3. Results
3.1. Resveratrol Inhibits the Proliferation of Pancreatic Cancer Cells
First, we examined the effects of resveratrol on the viability of cancer cells. Pancreatic cancer
cells Panc-1 and BxPC-3 were treated with increasing doses of resveratrol (0, 25, 50, 100, and 200 μM).
At the indicated time points (24, 48, and 72 h), the cell viability was assessed by the MTT assay.
As shown in Figure 1, resveratrol decreased the growth of cancer cell lines in a dose- and
time-dependent manner. The 50% inhibitory concentration (IC50) for both BxPC-3 and Panc-1 cells
was approximately 50 μM resveratrol, which exhibited no cytotoxic effects on the BxPC-3 and Panc-1
cells. These results were in accord with our previous results. Therefore, cells were treated with 50 μM
resveratrol in subsequent experiments.
3.2. Resveratrol Inhibits Clone Formation and Induces Apoptosis of Pancreatic Cancer Cells
To address the underlying mechanism governing the inhibitory effect of resveratrol (Res) on
pancreatic cancer cell viability, we measured Res-induced apoptosis in BxPc-3 and Panc-1 cells by flow
cytometry. The flow cytometric analyses were conducted after Panc-1 and BxPC-3 cells were treated
with or without resveratrol (50 μM) for 48 h. As shown in Figure 2A,B, treatment of cancer cells with
resveratrol caused an increase in the apoptotic population compared with that of the untreated control
cells. Next, we detected the effect of resveratrol on the clone formation ability of cancer cells Panc-1
and BxPC-3. As shown in Figure 2C,D, treatment with 50 μM resveratrol markedly decreased the
number of colonies compared with the untreated control cells. These results demonstrate that Res has
a potent effect against clone formation and induces apoptosis of cancer cells.
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Figure 1. Resveratrol inhibits the proliferation of pancreatic cancer cells. (A) The structure of resveratrol
(Res); (B,C) Panc-1 and BxPC-3 pancreatic cancer cells were treated with increasing concentrations of
resveratrol (0, 25, 50, 100, and 200 μM) for 24 h, 48 h, or 72 h to analyze the inhibition ratio for cancer
cell proliferation; (D) Micrographs of Panc-1 and BxPC-3 cells after being treated with the indicated
concentrations of resveratrol for 48 h; representative images were captured (magnification, 100×; Scar
bar: 100 μm).
Figure 2. Resveratrol inhibits clone formation and induces apoptosis of pancreatic cancer cells.
(A,B) The effects of resveratrol on Panc-1 and BxPC-3 cells apoptosis were detected by flow cytometry;
(C,D) The effects of resveratrol on the colony-forming ability of Panc-1 and BxPC-3 cells. Images are
representative of three independent experiments (Scale bar: 1 cm). Column: Mean, bar: SD, * p < 0.05,
** p < 0.01.
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3.3. Resveratrol Inhibits YAP Expression of Pancreatic Cancer Cells
Increasing evidence has suggested that overexpression of YAP plays a key role in cancer cell
survival and progression [27]. In particular, YAP can be phosphorylated at Ser127 and forms a
more stable complex with the 14-3-3 proteins; therefore, it is retained in the cytoplasm and subject
to degradation [28]. To determine whether resveratrol affects the YAP expression of cancer cells,
Panc-1 and BxPC-3 cells were treated with resveratrol (0, 25, 50, and 100 μM) for 24 h. The protein
expression of YAP and p-YAP (Ser127) in the pancreatic cancer cells exposed to resveratrol was
evaluated by Western blot analysis. As shown in Figure 3A,B, resveratrol treatment up-regulated
the level of p-YAP (Ser127), and the total level of YAP was significantly inhibited by resveratrol in
a dose-dependent manner. Connective tissue growth factor (CTGF) and cysteine-rich angiogenic
inducer 61 (CYR61) are two YAP-mediated downstream effectors that play an important role in
tumor progression [29,30]. We therefore examined the expression of YAP, CTGF and CYR61 in
response to treatment with resveratrol. The results showed that the mRNA levels of YAP, CTGF,
and CYR61 were downregulated upon treatment with resveratrol (50 μM) (Figure 3C,D). Additionally,
the nuclear translocation of YAP was decreased due to the effect of resveratrol, as demonstrated by
immunofluorescence (Figure 3E). Together, these data indicate that resveratrol inhibits YAP expression
of cancer cells via YAP phosphorylation at Ser127.
Figure 3. Resveratrol inhibits YAP expression of pancreatic cancer cells. (A,B) The effects of resveratrol
on the protein expression of YAP and p-YAP (Ser127) were examined by Western blot analysis using
β-actin as an internal loading control; (C,D) The effects of resveratrol on the mRNA expression of YAP,
connective tissue growth factor (CTGF) and CYR61 were examined by real-time PCR with β-actin
as the normalized reference gene. The data represent the results of three independent experiments;
(E) Immunofluorescence staining of YAP in Panc-1 and BxPC-3 cells after treatment with resveratrol
(50 μM) for 24 h. YAP staining is shown in red, and nuclear DNA staining by DAPI is shown in blue.
(Magnification, 400×; Scale bar: 20 μm). Column: mean, bar: SD, * p < 0.05, ** p < 0.01.
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3.4. Knockdown of AMPK Rescues Resveratrol Induced Suppression of YAP in Pancreatic Cancer Cells
Previous studies have established that resveratrol can activate the AMPK pathway [31].
The activation of AMPK leads to the suppression of YAP expression [32]. Based on the abovementioned
promising findings, we speculated that the effect of resveratrol on cancer cell YAP inhibition may be
mediated by AMPK signaling. To test this hypothesis, we further examined the effect of resveratrol on
the activity of AMPK signaling. Immunoblotting results revealed that the phosphorylation level of
AMPK (p-AMPK) in pancreatic cancer cells was significantly increased in response to resveratrol
treatment in a dose-dependent manner (Figure 4A,B). To verify that resveratrol-inhibited YAP
expression in cancer cells is mediated by AMPK signaling, siRNA technology was developed to
knock down AMPK expression. We found that knocking down AMPK expression alone did not affect
the expression of YAP or the phosphorylation level of p-YAP in Panc-1 and BxPC-3 cells (Figure 4C,D).
However, resveratrol induced the activation of p-AMPK and p-YAP, and inhibition of YAP was restored
by AMPK knockdown (Figure 4C,D). Additionally, the immunofluorescence results indicated that the
nuclear translocation and total level of YAP was inhibited by resveratrol and that this inhibition effect
was restored by AMPK knockdown (Figure 4E). Together, these data suggest that AMPK signaling is
involved in resveratrol-suppressed YAP expression in pancreatic cancer cells.
3.5. Knockdown of YAP Increased Gemcitabine Sensitivity in Pancreatic Cancer Cells
First, we used the MTT assay to examine the effects of gemcitabine on the proliferation of the
Panc-1 and BxPC-3 cell lines. As shown in Figure 5A,B, we found that BxPC-3 was sensitive whereas
Panc-1 was resistant to gemcitabine, in accord with previous findings [33]. Therefore, we used Panc-1
in further experiments. To evaluate the effects of YAP on cell survival and resistance to chemotherapy,
we treated Panc-1 cells, which express high levels of YAP natively and are resistant to gemcitabine,
with 2 μM gemcitabine in the presence of either siControl or siYAP and confirmed the silencing
of YAP in the cells using Western blot analysis (Figure 5H). MTT assay results showed that
the proliferation capacity was lower in siYAP cells than in siControl cells after treating them
with gemcitabine (Figure 5C). Furthermore, silencing of YAP increased the apoptotic response to
treatment with gemcitabine (2 μM) in Panc-1 cells (Figure 5D,E). The clone ability was significantly
decreased after silencing YAP, and siYAP enhanced the gemcitabine inhibition effect on clone ability
(Figure 5F,G). Together, these data suggest that YAP silencing enhances the sensitivity of gemcitabine
in gemcitabine-resistant pancreatic cancer cells.
Figure 4. Cont.
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Figure 4. Knockdown of AMP-activated protein kinase (AMPK) rescues resveratrol-induced
suppression of YES-associated protein (YAP) of pancreatic cancer cells. (A,B) The effects of resveratrol
on the activation of AMPK (Thr172) in Panc-1 and BxPC-3 cells were measured by Western blot analysis;
(C,D) After transfection with siAMPK or siControl for 48 h, Panc-1 and BxPC-3 cells were treated with
resveratrol (50 μM) for 24 h. The protein expression levels of YAP, p-YAP (Ser127), AMPK and p-AMPK
(Thr172) were examined by Western blot analysis using β-actin as an internal loading control; (E) YAP
in Panc-1 and BxPC-3 cells was stained for immunofluorescence after transfection with siAMPK or
siControl for 48 h and then treated with resveratrol (50 μM) for 24 h. YAP staining is shown in red, and
nuclear DNA staining by DAPI is shown in blue (Magnification, 400×; Scale bar: 20 μm).
Figure 5. Cont.
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Figure 5. Knockdown of YAP increases gemcitabine sensitivity in pancreatic cancer cells. (A,B) Panc-1
and BxPC-3 cells were treated with increasing concentrations of gemcitabine (0, 1, 2, 5, 10, and 20 μM) for
24 h, 48 h, or 72 h to analyze the inhibition ratio for cancer cell proliferation; (C) After being transfected
with siControl or siYAP for 48 h, cells were plated in 96-well plates and treated with 2 μM gemcitabine
for 72 h. Cell viability was assessed by the MTT assay; (D,E) The effects of siControl or siYAP on Panc-1
cancer cells apoptosis after treatment with 2 μM gemcitabine for 48 h was detected by flow cytometry;
(F,G) The effects of siControl or siYAP combined with gemcitabine on the colony-forming ability of
Panc-1 cells. Images are representative of three independent experiments (Scale bar: 1 cm); (H) The
efficiency of siRNAs targeting YAP in Panc-1cells was evaluated by Western blot analysis. Column:
Mean, bar: SD, * p < 0.05, ** p < 0.01.
3.6. Inhibition of YAP Activity by Resveratrol Enhanced the Sensitivity of Pancreatic Cancer Cells
to Gemcitabine
To determine whether resveratrol increases the susceptibility of Panc-1 cells to gemcitabine, we
treated Panc-1 cells with 50 μM resveratrol and 2 μM gemcitabine. The MTT assay results showed
that the proliferation capacity was significantly lower in the resveratrol and gemcitabine therapy
group than in the resveratrol alone or gemcitabine alone group (Figure 6A). The protein expression of
YAP and p-YAP (Ser127) in Panc-1 exposed to resveratrol and gemcitabine was evaluated by Western
blot analysis. As shown in Figure 6B, resveratrol treatment up-regulated the level of p-YAP (Ser127),
and the total level of YAP was significantly inhibited by resveratrol. However, gemcitabine had no
effect on YAP expression. Next, we measured the apoptosis rate in Panc-1 cells by flow cytometry.
Flow cytometric analyses were conducted after Panc-1 cells were treated with or without resveratrol
(50 μM) and gemcitabine (2 μM) for 48 h. As shown in Figure 6C,D, treatment of cancer cells with
resveratrol caused an increase in apoptotic population compared with the untreated control cells,
but almost all cells underwent apoptosis in the resveratrol and gemcitabine combined therapy group.
Next, we detected the clone formation ability of Panc-1 cancer cells after treatment with resveratrol and
gemcitabine. As shown in Figure 6E,F, treatment with resveratrol and gemcitabine markedly decreased
the number of colonies compared with the number measured for the gemcitabine or resveratrol alone
cells. Taken together, these results demonstrate that resveratrol has a potent effect in enhancing the
sensitivity of pancreatic cancer cells to gemcitabine by inhibiting YAP expression.
Figure 6. Cont.
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Figure 6. Inhibition of YAP activity by resveratrol enhances the sensitivity of pancreatic cancer cells
to gemcitabine. (A) Panc-1 cells were treated with gemcitabine (2 μM) and resveratrol (50 μM) for
72 h. Cell viability was assessed by the MTT assay; (B) Panc-1 cells were treated with gemcitabine
(2 μM) and resveratrol (50 μM) for 24 h. The protein expression levels of YAP and p-YAP (Ser127) were
examined by Western blot analysis using β-actin as an internal loading control; (C,D) Panc-1 cells were
treated with gemcitabine (Gem) (2 μM) and resveratrol (50 μM) for 48 h. Apoptosis was detected by
flow cytometry; (E,F) The combined effects of Res and Gem on Panc-1 cell clones’ colony-forming
ability was detected. Images are representative of three independent experiments (Scale bar: 1 cm).
Column: Mean, bar: SD, * p < 0.05, ** p < 0.01.
4. Discussion
In this study, we observed that resveratrol inhibited pancreatic cancer cell proliferation and clone
formation and induced cell apoptosis, which was accompanied by the activation of p-AMPK and p-YAP
and a decreased level of YAP in BxPc-3 and Panc-1 cells. Moreover, the results suggest that AMPK
signaling is essential in resveratrol-suppressed YAP expression in pancreatic cancer cells. Furthermore,
we found that YAP silencing enhances the sensitivity of gemcitabine in gemcitabine-resistant Panc-1
cancer cells. Resveratrol has a synergistic effect with gemcitabine in Panc-1 cells by inhibiting YAP
expression. Our findings suggest that resveratrol is a potential drug for adjuvant therapy or a
complementary alternative medicine for the management of pancreatic cancers via activation of
AMPK and inhibition of YAP.
Despite great advances in modern medicine over the past several years, pancreatic cancer is still
associated with an extremely high mortality rate [1]. Currently, gemcitabine [3] and FOLFIRINOX [4]
are considered first-line drugs for treating pancreatic cancer, but their efficacy is still low because
of a seriously adverse reaction and because acquired drug resistance limits their cytotoxic efficacy.
Therefore, we must find a novel target for enhancing current chemotherapy to improve the outcomes
of patients with pancreatic cancer.
Resveratrol is a natural polyphenolic phytoalexin that is widely found in plants and in traditional
Chinese medicines [16,17]. Resveratrol has been shown to directly inhibit the proliferation and viability
of human pancreatic cancer cells in vitro in a dose- and time-dependent manner [22]. Accordingly,
our results demonstrated that resveratrol inhibited cell proliferation and clone formation and induced
cell apoptosis. Interestingly, we found that Panc-1 and BxPC-3 cells respond differently to gemcitabine
(BxPC-3 being more sensitive). But their biochemical and functional response to resveratrol appears
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to be the same. As we know, BxPC-3 and Panc-1 cells have many differences such as K-ras mutation
types (BxPC-3 is a K-ras wild cell while Panc-1 is a K-ras mutant cell) [34] and epithelial-mesenchymal
transition (EMT) regulated genes (E-cadherin and Zeb-1) [35] which could affect gemcitabine sensitivity
in pancreatic cancer cells. Our previous reports have shown that resveratrol could inhibit the EMT of
pancreatic cancer cells via suppression of the PI3K/Akt/NF-kappaB pathway in Panc-1 and BxPC-3
cells [22]. Furthermore, resveratrol could also inhibit pancreatic cancer stem cell characteristics
in human and Kras (G12D) transgenic mice by inhibiting pluripotency maintaining factors and
epithelial-mesenchymal transition [36]. However, the specific mechanism needs to be further explored.
The AMPK system is traditionally considered a sensor of cellular energy status and a regulator
of metabolism [37]. Recent studies have provided novel evidence that AMPK may function as a
suppressor of cell proliferation. Indeed, activation of AMPK has been shown to benefit a variety
of malignant tumors by inhibiting the proliferation of tumor cells [38,39]. In this respect, our
results demonstrated that resveratrol could activate AMPK (Thr172) and suppress the proliferation
of pancreatic cancer cells, indicating the anti-proliferative action of AMPK in pancreatic cancer cells.
The effect of AMPK on cell proliferation appears to be mediated through multiple mechanisms,
mainly the regulation of cell cycle progression, inhibition of protein synthesis, and de novo fatty acid
biosynthesis [40,41]. Previous reports have suggested that AMPK activation stabilizes and increases
AMOTL1 steady-state protein levels, contributing to YAP inhibition [42]. Accordingly, our results
demonstrated that resveratrol induces YAP cytoplasmic retention and S127 phosphorylation and
inhibits YAP transcriptional activity and YAP-dependent transformation via activation of AMPK.
Knockdown of AMPK rescues resveratrol-induced suppression of YAP in pancreatic cancer cells.
Some reports have suggested that glucose starvation and energy stress could result in phosphorylation
of YAP and contribute to its inactivation [43]. Harris et al. [44] demonstrated that resveratrol could
inhibit glycogen synthesis, which may serve as the underlying mechanism in the inhibition of YAP.
However, Jung-Soon Mo [32] and his colleagues also found that AMPK inhibits YAP activity through
phosphorylation of serine 94. Whether resveratrol could induce YAP phosphorylation at serine 94 need
further investigation.
As an oncogene, YAP is abundantly expressed in many types of cancers [15,27], and tremendous
progress has been made toward our understanding of the roles of YAP in tumorigenesis, size control,
and stem cell renewal and differentiation [45,46]. However, YAP’s function in chemotherapeutic
drug response is largely unknown in pancreatic cancer cells. Ciamporcero et al. [47] demonstrated
that YAP overexpression protected, whereas YAP knockdown sensitized, urothelial cell carcinoma
(UCC) cells to chemotherapy and radiation effects by increasing the accumulation of DNA damage
and apoptosis. Verteporfin, a pharmacological YAP inhibitor, could inhibit tumor cell proliferation
and restore sensitivity to cisplatin. In our study, we found that the chemotherapeutic sensitivity of
pancreatic cancer to gemcitabine can be increased by YAP inhibition in vitro. YAP may participate in
regulating the chemosensitivity of pancreatic cancer to chemotherapy. As a dietary and synthetic agent
that is a pharmacological YAP inhibitor, resveratrol may exhibit greater efficacy and lower toxicity for
the prevention and treatment of pancreatic cancer. However, its more specific mechanisms and safety
require further investigation.
5. Conclusions
In conclusion, the present study demonstrated that resveratrol suppressed the proliferation
and cloning ability and induced the apoptosis of pancreatic cancer cells. These multiple biological
effects might result from the activation of AMPK (Thr172), thus, inducing YAP cytoplasmic retention
and S127 phosphorylation, and inhibiting YAP transcriptional activity by resveratrol. YAP silencing
by siRNA or resveratrol could enhance the sensitivity of gemcitabine in pancreatic cancer cells.
These results suggest that resveratrol is a potential anticancer agent for the treatment of pancreatic
cancer. However, whether other mechanisms are involved in the anti-tumor effects of resveratrol and
its safety in humans warrant further study.
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Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/8/10/546/s1,
Table S1: A list of the utilized primary antibodies, Table S2: The siRNA sequences, Table S3: Primers sequences for
real-time PCR analysis.
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Abstract: The goal of the present study was to quantify the rate and extent of polyphenols released in
the gastrointestinal tract (GIT) from natural (NS) and blanched (BS) almond skins. A dynamic gastric
model of digestion which provides a realistic simulation of the human stomach was used. In order to
establish the effect of a food matrix on polyphenols bioaccessibility, NS and BS were either digested
in water (WT) or incorporated into home-made biscuits (HB), crisp-bread (CB) and full-fat milk
(FM). Phenolic acids were the most bioaccessible class (68.5% release from NS and 64.7% from BS).
WT increased the release of flavan-3-ols (p < 0.05) and flavonols (p < 0.05) from NS after gastric plus
duodenal digestion, whereas CB and HB were better vehicles for BS. FM lowered the % recovery of
polyphenols, the free total phenols and the antioxidant status in the digestion medium, indicating that
phenolic compounds could bind protein present in the food matrix. The release of bioactives from
almond skins could explain the beneficial effects associated with almond consumption.
Keywords: almond skin; food matrix; simulated human digestion; polyphenols; bioaccessibility
1. Introduction
The presence of polyphenols in almond skin has been related to several health benefits associated
with almond (Prunus dulcis Miller D.A. Webb) consumption [1–3]. The antioxidant and free-radical
scavenging activity of almond skin polyphenols has been reported [4]. It has been shown that
flavonoids and phenolic acids, including flavonols, flavanols, flavanones and simple phenolic acids
identified in almond skins may play a role in reducing risk factors against chronic inflammatory
diseases and ageing disorders [5,6]. A range of biological effects of flavonoids, including anticancer,
antiviral, antimutagenic and anti-inflammatory activities, have been reported [7,8]. Nevertheless,
one of the major limiting factors affecting the beneficial effects of polyphenols is their bioaccessibility
and subsequent absorption in the gastrointestinal tract (GIT), together with their bio-transformation
by the gut microbiota enzymes [9].
This process depends on the physico-chemical properties of the food matrix and its changes during
digestion. We refer to bioaccessibility as the proportion of a nutrient or phytochemical compound
‘released’ from a complex food matrix during digestion and therefore becoming potentially available for
absorption in the GIT. A number of studies have reported that food matrix affects polyphenol release
in the gut as well as the efficacy by which they are transported across the mucosal epithelium [10,11].
The presence of a food matrix (muffin) decreased the bioaccessibility of certain bioactive compounds,
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such as protocatechuic acid and luteolin, from raw shelled and roasted salted pistachios during
simulated human digestion [12]. Interaction with other food nutrients and the formation of complexes
mainly with protein and fat is also known to affect bioaccessibility of phenolic acids [13]. The influence
of digestion conditions, such as pH, temperature, bile salts, gastric and pancreatic enzymes on the
bioaccessibility of certain polyphenols has been reported [14,15]. Milk has been found to affect
bioaccessibility of epicatechin metabolites [16]. We have previously identified a combination of
flavonols, flavan-3-ols, hydroxybenzoic acids and flavanones present in almond skin [1]: the major
flavonoids were (+)-catechin, (−)-epicatechin, kaempferol and isorhamnetin, both as aglycones or
conjugated with rhamnose (Rha) and glucose (Glc). The total phenolic content, expressed as mg gallic
acid equivalents (GAE) per 100 g of fresh skin, was higher in natural almond skin (NS, 3474.1 ± 239.8)
than blanched almond skin (BS, 278.9 ± 12.0). The blanching process is known to remove most of the
water-soluble flavonoids and other polyphenols [1]. BS, obtained by industrial blanching, currently
represents a commercially available product. Our previous investigation on the release of almond skin
polyphenols during simulated human digestion using a static model demonstrated higher percentages
of polyphenols released from NS compared to BS [17].
The aim of the present study was to assess the effect of a range of food matrices on the rate and
extent of polyphenol bioaccessibility from NS and BS during simulated human digestion. A dynamic
gastric model (DGM) was used to simulate the human stomach [12,18]. Gastric digesta were then
subjected to a duodenal phase in order to simulate the full human upper GIT.
2. Materials and Methods
2.1. Production of Test Meals
Natural almonds with intact skin were kindly provided by the Almond Board of California and
stored in the dark. NS was removed using liquid-nitrogen as previously reported and milled [17].
BS, provided by ABCO laboratories, was obtained by hot water blanching, dried and powdered.
Home-made biscuits (HB) containing NS or BS were prepared using the following ingredients:
white flour (200 g), butter at room temperature (100 g), sugar (sucrose, 100 g), eggs (one standard egg)
and baked at 180 ◦C for 12 min. For the digestion experiments, 25 g of HB containing 2 g of either NS
or BS were used. Home-made crisp-bread (CB) containing NS or BS was prepared using the following
ingredients: baking soda (5 g), hot water (400 mL), salt (1.2 g), fennel seed (1 g), white flour (250 g) and
baked at 230 ◦C for 2–4 min. For the digestion experiments, 34 g of CB containing 2 g of either NS or
BS were used.
2.2. Chemicals and Enzymes
Egg L-α-phosphatidylcholine (PC, lecithin grade 1, 99% purity) was obtained from Lipid Products
(South Nutfield, Surrey, UK). Porcine gastric mucosa pepsin, bovine α-chymotrypsin, pancreatic
α-amylase, porcine colipase, porcine pancreatic lipase and bile salts were obtained from Sigma (Poole,
Dorset, UK). Lipase for the gastric phase of digestion was a gastric lipase analogue of fungal origin
(F-AP15) from Amano Enzyme Inc. (Nagoya, Japan). All flavonoid and other phytochemical standards
were obtained from either Sigma-Aldrich (Poole, UK) or Extrasynthese (Genay, France). All solvents
were HPLC grade, water was ultra-pure grade, and other chemicals were of AR quality.
2.3. Simulated Human Digestion
Eight meals were prepared as follows and subjected to in vitro gastric and gastric plus duodenal
digestion: WT (200 mL) containing either NS (2 g) or BS (2 g), HB (25 g) containing either NS (2 g)
or BS (2 g) added to water (240 mL), CB (34 g) containing either NS (2 g) or BS (2 g) added to water
(240 mL), FM (200 mL) containing either NS (2 g) or BS (2 g).
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2.4. Gastric Digestion
Individual meals were fed onto the DGM in the presence of priming acid (20 mL), as previously
reported [18]. In order to replicate the conditions found in the human stomach, samples were
processed in two zones: within the fundus/main body of the DGM, where the meals were subjected
to inhomogeneous mixing while gastric acid and enzyme secretions were added; in the antrum,
where physiological shear and grinding forces were applied in order to mimic the antral shearing and
rate of delivery to the duodenum. The composition of the simulated gastric acid solution has also been
previously reported [12]. The simulated gastric enzyme solution was prepared by dissolving porcine
gastric mucosa pepsin and a gastric lipase analogue from Rhizopus oryzae in the above described
salt mixture (no acid) at a final concentration of 9000 U/mL and 60 U/mL for pepsin and lipase,
respectively. A suspension of single-shelled lecithin liposomes was added to the gastric enzyme
solution at a final concentration of 0.127 mM.
A total of six samples (G1–G6) were ejected from the antrum of the DGM at regular intervals
during each run (see Table 1 for sampling details) in order to replicate the predicted gastric emptying
regimes under physiological conditions. Samples digested in WT were ejected from the antrum of the
DGM every 4 min: the amount of gastric acid secretion was 1.5 ± 0.1 mL and 1.6 ± 0.1 mL for NS and
BS respectively; the amount of gastric enzyme secretion was 2.8 ± 0.1 mL and 2.7 ± 0.1 mL for NS
and BS respectively. Samples digested in HB were ejected from the antrum of the DGM every 4 min:
the amount of gastric acid secretion was 6.4 ± 0.1 mL and 6.3 ± 0.1 mL for NS and BS respectively;
the amount of gastric enzyme secretion was 11.2 ± 0.2 mL and 11.4 ± 0.1 mL for NS and BS respectively.
Samples digested in CB were ejected from the antrum of the DGM every 5 min: the amount of gastric
acid secretion was 17.6 ± 0.2 mL and 18.2 ± 0.2 mL for NS and BS respectively; the amount of gastric
enzyme secretion was 13.8 ± 0.1 mL and 14.2 ± 0.2 mL for NS and BS respectively. Samples digested
in FM were ejected from the antrum of the DGM every 6 min: the amount of gastric acid secretion was
4.4 ± 0.2 mL and 4.6 ± 0.2 mL for NS and BS respectively; the amount of gastric enzyme secretion was
13.1 ± 0.3 mL and 13.8 ± 0.2 mL for NS and BS respectively. A control digestion without addition of
gastric enzymes was performed for each meal. Each gastric sample was weighed, its pH recorded and
adjusted to 7.0 with NaOH (1 M) in order to inhibit gastric enzyme activity.
Table 1. Simulated human digestion parameters.
Matrix
DGM 1 DGM 2 DGM 3 DGM 4 DGM 5 DGM 6 DD TDT
Sampling Time (min)
Water 4 8 12 16 20 24 120 144
Home-made
biscuit 4 8 12 16 20 24 120 144
Crisp bread 5 10 15 20 25 30 120 150
Full-fat milk 6 12 18 24 30 36 120 156
DGM = Gastric sample; DD = Duodenal digestion; TDT = Total digestion time.
2.5. Duodenal Digestion
Individual gastric samples (23 g, G1 to G6) were transferred upon ejection, to a Sterilin plastic tube
for duodenal digestion with the addition of simulated bile solution (2.5 mL) and pancreatic enzyme
solution (7.0 mL) and incubated at 37 ◦C under shaking conditions (170 rpm) for 2 h. Simulated bile
was prepared fresh daily. It contained lecithin (6.5 mM), cholesterol (4 mM), sodium taurocholate
(12.5 mM), and sodium glycodeoxycholate (12.5 mM) in a solution containing NaCl (146.0 mM),
CaCl2 (2.6 mM) and KCl (4.8 mM).
Pancreatic enzyme solution contained NaCl (125.0 mM), CaCl2 (0.6 mM), MgCl2 (0.3 mM),
and ZnSO4·7H2O (4.1 μM). Porcine pancreatic lipase (590 U/mL), porcine colipase (3.2 μg/mL),
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porcine trypsin (11 U/mL), bovine α-chymotrypsin (24 U/mL) and porcine α-amylase (300 U/mL)
were added to the pancreatic solution.
2.6. Poliphenols Extraction from Samples before and after Dynamic in Vitro Digestion
All original samples (WT, HB, CB and FM containing NS or BS) and aliquotes obtained from
each sample subjected to a dynamic in vitro gastric digestion (NSWT G, NSHB G, NSCB G, NSFM G,
BSWT G, BSHB G, BSCB G, BSFM G) and gastric plus duodenal digestion (NSWT G + D, NSHB G + D,
NSCB G + D, NSFM G + D, BSWT G + D, BSHB G + D, BSCB G + D, BSFM G + D), were harvested and
centrifuged to separate the residual material from the supernatant. The volume of each supernatant
was measured; the residues were dried in a forced air heated oven (T ◦C < 40 ◦C) and brought to
constant weight.
Each residue was extracted with hexane (1:5, w/v) to remove the lipid fraction. The procedure
was repeated 3 times. Afterwards it was extracted with a methanol/water mixture (70:30) (1:10, w/v)
by shaking for 5 min and sonicating for 10 min. After centrifugation at 12,074 rcf for 10 min,
the supernatant was collected. The procedure was repeated 3 times. The supernatants were pooled.
In order to precipitate proteins, MeOH (8 mL) and 2M NaOH (600 μL) were added in 10 mL extract.
Samples were stirred vigorously and after centrifugation at 5916 rcf for 5 min the supernatant was
brought to dryness in a rotavapor. Finally, the residue was resuspended with 10 mL of 1% HCl in MeOH
and extracted, using a separatory funnel, with the same volume of ethyl acetate. The extraction was
repeated 4 times. The ethyl acetate fractions were combined and evaporated to dryness in a rotavapor.
The residue was weighed, solubilised in MeOH, filtered through a Nalgene 0.22 μM nylon filter and
subjected to total phenol, radical scavenging activity and HPLC analysis.
For NS and BS digested in water no protein precipitation step was perfermed, given that they
were not incorporated into any food matrix.
2.7. Polyphenols Release and Radical Scavenging Activity
Total phenol content was determined colorimetrically by the Folin-Ciocalteu method as modified
by Singleton, Orthofer and Lamuela-Raventos [19] using gallic acid as a reference compound.
Total phenol content was expressed as mg of gallic acid equivalents (GAE) per 100 g of sample.
The anti-radical activity was determined using the stable 2,2-diphenyl-1-picrylhydrazyl radical (DPPH)
and the procedure previously described [20]. Results were expressed as mg of extract needed to
scavenge 50 μmol of the initial DPPH concentration (SE50). The determination of phenolics and
flavonoids was carried out using a Shimadzu high performance liquid chromatography system
equipped with an UV–Vis photodiode-array detector (DAD) (SPD-M10AVP, Shimadzu, Kyoto, Japan)
and a fluorescence detector (1046A Hewlett Packard, Palo Alto, CA, USA), as previously reported [17].
2.8. Statistical Analysis
All assays were performed in triplicate and expressed as means ± standard deviation (SD).
Data analysis was performed using ANOVA tests using SigmaPlot software version 12.0 for Windows
(SPSS Inc., Hong Kong, China). To isolate the group or groups that differ from the others, a multiple
comparison procedure (Tukey Test) was used. Results were considered statistically significant
at p < 0.05.
3. Results
3.1. Polyphenols Release during Simulated Digestion
The polyphenolic content of the baseline meals (NS WT, NS HB, NS CB and NS FM, BS WT, BS HB,
BS CB and BS FM) is reported in Table 2. As expected, the NS meals had a total phenol content nearly
ten times higher than the BS meals.
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The release of polyphenols as a percentage of the original amount present in each meal (Table 2)
after simulated gastric plus duodenal digestion is reported in Figure 1. No polyphenols were detected
in blank samples of each meal not containing almond skin. As expected, a high release of bioactive
compounds was observed from both NS and BS in WT (Figure 1A).
Table 2. Baseline polyphenols content of natural skins and blanched skins in water (W); home-made
biscuits (HB); crisp-bread (CB) and full-fat milk (FM). Values were given as μg/g and represent averages
(±SD) of triplicate measurements.
Natural Skin
Sample Phenolic acids Flavonols Flavan-3-ols Flavanones Total phenols
W 2.15 ± 0.11 14.31 ± 1.05 2.37 ± 0.18 3.43 ± 0.22 22.26
HB 17.85 ± 1.02 115.30 ± 8.32 20.82 ± 1.65 30.44 ± 2.21 184.41
CB 12.53 ± 0.89 83.89 ± 4.22 14.72 ± 1.12 21.78 ± 1.44 132.92
FM 2.07 ± 0.12 13.95 ± 1.22 2.15 ± 0.12 3.22 ± 0.17 21.39
Blanched Skin
Sample Phenolic acids Flavonols Flavan-3-ols Flavanones Total phenols
W 0.31 ± 0.02 1.28 ± 0.05 0.62 ± 0.03 0.22 ± 0.02 2.43
HB 2.25 ± 0.14 9.82 ± 0.59 5.18 ± 0.21 1.73 ± 0.102 18.98
CB 1.78 ± 0.12 7.24 ± 0.35 3.65 ± 0.25 1.31 ± 0.09 13.98
FM 0.29 ± 0.01 1.19 ± 0.08 0.60 ± 0.02 0.19 ± 0.01 2. 27
The % release from NS and BS in WT during the gastric phase of digestion was higher for
phenolic acids (47.1% from NS and 45.3% from BS) compared with the other classes of polyphenols,
with a further increase in the duodenal phase of digestion (68.5% from NS and 64.7% from BS). Lower %
release from BS in WT was observed with flavanones after both gastric (29.3%) and gastric plus
duodenal incubation (48.2%). Higher release of flavonols (65.6%) and phenolic acids (59.4%) was
observed after in vitro gastric plus duodenal digestion from NS (Figure 1A). The % of recovery,
calculated from the amount of polyphenols present in the medium at the end of each step of digestion,
confirmed the data obtained from the % of release (Figure 2). This data demonstrated a different
bioaccessibility across the various classes of polyphenols in the absence of an interfering food matrix.
In accordance with our previous investigation [1], high release of polyphenols was detected when NS
and BS were incubated in WT. However, the static and dynamic digestion models used affected the
rate and extent of bioactives potentially available for absorption in the gut.
The % of release and recovery of polyphenols from NS and BS incorporated into HB are reported in
Figures 1B and 2, respectively. Phenolic acids were the class of polyphenols mostly released from NS in
the gastric phase, followed by flavonols and flavanones, with an average % release of 40.72 in the gastric
compartment. Flavonols had the highest % release from BS in the gastric phase (48.5), followed by
flavanones and phenolic acids. For both NS and BS, the gastric + duodenal digestion (G + D) produced
only a slight increase in polyphenol release over that observed in the gastric compartment. In addition,
higher percentages of phenolic acids and flavonols were released from NSHB G + D.
Higher % of release of phenolic acids, flavonols, flavan-3-ols and flavanones were observed in
BSCB G compared with NSCB G, whereas the opposite behaviour was detected in the duodenal phase
(Figure 1C). A higher release of phenolic acids was observed in BSCB G (52.7%) compared with BSWT
G (45.3%), as well as flavonols both in the gastric (51.4 in BSCB G vs. 33.9 in BSWT G) and in the
duodenal phase (63.9 in BSCB G + D vs. 52.3 in BSWT G + D) and flavanones both in the gastric (47.6 in
BSCB G vs. 29.3 in BSWT G) and in the duodenal phase (59.8 in BSCB G + D vs. 48.2 in BSWT G + D).
The % release data were confirmed by % recovery values (Figure 2).
The % of release and recovery of flavonoids and phenolic acids from NS and BS incorporated into
FM are reported in Figures 1D and 2, respectively. The highest % release from NS was detected with
flavonols after gastric plus duodenal digestion, followed by flavanones and phenolic acids. About 60%
of phenolic acids and flavanones were released from BS in FM after simulated digestion.
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Figure 1. Release of flavonoids and phenolic acids from natural almond skin (NS) and blanched
almond skin (BS) in water (A); home-made biscuits (B); crisp-bread (C) and full-fat milk (D). Values are
given as % phenolic acids, flavanols, flavan-3-ols and flavanones released from the initial amounts
presents in the meals (Table 2) during in vitro gastric (G) and gastric + duodenal (G + D) digestion.
Values represent averages (±SD) of triplicate measurements. Matching symbols across the four panels
indicate significantly different (p < 0.01) samples. † Phenolic acid release in BS-G + D significantly
different between A, B and D; †† Flavonols release in BS-G + D significantly different between A, C and
D; ** Flavonols release in BS-G + D significantly different between A and C; ¶ Flavonols release in
BS-G + D significantly different between A and B; ‡‡ Flavan-3-ols release in BS-G significantly different
between A, B and C; & Flavanones release in BS-G significantly different between A and D; ¥ Flavanones
release in BS-G significantly different between A and B; Flavanones release in NS-G significantly
different between A and D; Ω Flavanones release in NS-G significantly different between A and B;
‡ Phenolic acid release in BS-G + D significantly different between B and C; * Flavan-3-ols release
in BS-G + D significantly different between B and C; ¥¥ Flavanones release in BS-G + D significantly
different between B, C and D; § Phenolic acid release in NS-G + D significantly different between C
and D; || Flavonols release in BS-G significantly different between C and D. §§ Flavan-3-ols release in
BS-G significantly different between C and D; | Flavan-3-ols release in BS-G + D significantly different
between C and D; ¶¶ Flavan-3-ols release in NS-G+D significantly different between C and D.
78
Nutrients 2016, 8, 568
Figure 2. Recovery of total phenolic compounds in the digestion medium from natural almond skin
(NS) and blanched almond skin (BS) in water (WT), home-made biscuits (HB), crisp-bread (CB) and
full-fat milk (FM). Values are given as % of total phenolic compounds calculated from the amount of
polyphenols present in the medium at the end of each step of digestion. Values represent averages
(±SD) of triplicate measurements. † p < 0.01 vs. BS (CB); ‡ p < 0.01 vs. BS (FM); § p < 0.01 vs. NS (CB);
|| p < 0.01 vs. NS (FM); ¶ p < 0.01 vs. NS (HB); ** p < 0.01 vs. BS (FM); †† p < 0.01 vs. NS (FM).
Statistical analysis of Figure 1 showed significant differences in the % of bioactives released from
the tested meals: higher release (p < 0.05) of phenolic acid was detected from NS in CB vs. FM after
G + D, flavan-3-ols from NS in WT vs. FM after G + D and flavonols from NS in WT vs. HB after
G + D; higher release (p < 0.01) of flavan-3-ols was also observed from NS in CB vs. FM after G + D;
higher release (p < 0.05) of flavan-3-ols was found from NS in CB vs. FM after G; higher release
(p < 0.01) of flavanones from BS in HB vs. WT after G and vs. FM after G + D and flavan-3-ols from BS
in CB vs. HB after G + D; higher release (p < 0.01) of flavanones from BS in FM, CB and HB vs. WT
after G + D and of flavonols in CB vs. FM after G; higher release (p < 0.05) of phenolic acids from BS in
CB vs. WT after G. This data confirmed the presence of a food matrix affected the release of bioactives
from almond skin during simulated digestion. Overall WT and CB were good vehicles for the release
of polyphenols from NS, whereas HB and CB were optimal for polyphenols bioaccessibility from BS.
This could be due to the previous loss of water soluble polyphenols from BS during the industrial
blanching process.
Statistical analysis of Figure 2 showed significant differences in the % recovery of polyphenols
from the tested meals: higher recovery was observed from both NS and BS in CB vs. HB (p < 0.05)
and vs. FM (p < 0.01) after G + D; higher recovery was also detected from NS in CB vs. WT (p < 0.01),
FM (p < 0.01) and HB (p < 0.01) after G, as well as NS in WT vs. HB (p < 0.05); lower recovery (p < 0.01)
was observed with BS in WT vs. CB and FM vs. HB after G. The recovery data also confirmed WT was
a good vehicle for bioactives bioaccessibility from NS, whereas CB was optimal for BS.
Significantly (p < 0.01) lower % recoveries were obtained with FM from both NS and BS after
gastric plus duodenal digestion. We believe the % recovery demonstrated that milk protein were able
to bind the free polyphenols present in the digestion medium and the interaction between phenolic
compounds and proteins was more pronounced in milk rather than biscuits [21]. Furthermore,
complexes made by protein and tannin are less well digested and the amino acid profile may
be damaged.
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The same trend was also detected when comparing the kinetics (%) of release for flavan-3-ols from
NS in WT and FM during the full digestion process (Figure 3). When NS was digested in WT, a steady
release of flavan-3-ols over time was observed, corresponding to a significant increase detected for the
initial 5 gastric digestion samples. In the presence of FM, the dynamics of release were very similar to
WT but at a significantly slower rate.
Figure 3. Kinetic of release of flavan-3-ols from natural almond skin (NS) in water and full-fat milk.
Values are given as % of flavan-3-ols released from the initial amounts of flavan-3-ols in the meals
(Table 2) during in vitro gastric (samples 0 to 6, see Table 1 for sampling time) and gastric + duodenal
(DD) digestion. Values represent averages (±SD) of triplicate measurements. SD were always <10%.
Water (WT), full-fat milk (FM). † p < 0.01 vs. NS (FM).
3.2. Antioxidant Profile during Digestion
The total phenolic content, measured by the Folin-Ciocalteu method, from all the tested meals
during digestion is reported in Figure 4A,B. A decrease in the total phenols was observed post in vitro
gastric and gastric plus duodenal digestion for both NS and BS in WT, HB, CB and FM. In agreement
with the polyphenols release data, significant differences were observed across the four food matrices.
A corresponding increase in free total phenols in the digestion medium, expressed as mg GAE/200 mL
medium, was observed for WT, HB and CB (Figure 5). However, much lower than expected values of
free total phenols were detected in FM, in agreement with the polyphenols recovery data. This data
demonstrated that phenolic compounds could bind protein present in the food matrix, thus hindering
the antioxidant potential in vitro [21].
In agreement with the total phenolic content, the radical scavenging activity, measured by DPPH,
was lower after digestion (Figure 6). As shown in panel A, no statistically significant difference
was observed in NS across all matrices; however in panel B, a statistically significant difference
in WT vs. CB, HB and FM for sample 6 (last gastric sample) was observed. A corresponding
increase of the antioxidant status was detected in the digestion medium, with the exception of FM;
a statistically significant difference (p < 0.01) was observed in BS digestion media when comparing FM
vs. WT, CB and HB and in NS when comparing FM vs. WT and CB (Figure 7).
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Figure 4. Total phenolic content in natural (NS, panel (A)) and blanched (BS, panel (B)) almond
skin before and after simulated human digestion. Values are expresses in mg GAE/g and they
represent mean ± SD of three different experiments. 0 to 6: gastric samples (see Table 1 for sampling
time). DD: sample post in vitro gastric + duodenal digestion. Water (WT), home-made biscuits (HB),
crisp-bread (CB) and full-fat milk (FM).
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Figure 5. Free total phenols measured in the digestion medium of natural almond skin (A) and
blanched almond skin (B) after in vitro gastric and gastric + duodenal digestion. Values are expressed
as mg GAE/200 mL medium. 0 to 6: gastric samples (see Table 1 for sampling time). DD: sample post
in vitro gastric + duodenal digestion. Water (WT), home-made biscuits (HB), crisp-bread (CB) and
full-fat milk (FM).
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Figure 6. Radical scavenging activity measured in natural (NS, panel (A)) and blanched (BS, panel (B))
almond skin before and after simulated human digestion. Values are expresses as mg of sample
containing the amount needed to scavenge 50 μmol of the initial DPPH solution (SE50) and they
represent mean ± SD of three different experiments. 0 to 6: gastric samples (see Table 1 for sampling
time). DD: sample post in vitro gastric + duodenal digestion. Water (WT), home-made biscuits (HB),
crisp-bread (CB) and full-fat milk (FM). † p < 0.01 vs. CB at the same sampling time; ‡ p < 0.01 vs. HB at
the same sampling time; § p < 0.01 vs. FM at the same sampling time.
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Figure 7. Radical scavenging activity measured in the natural almond skin digestion medium
(panel (A)) and the blanched almond skin (BS) digestion medium (panel (B)) after in vitro gastric and
gastric + duodenal digestion. Values are expressed as mg of extract needed to scavenge 50 μmol of the
initial DPPH• concentration (SE50). 0 to 6: gastric samples (see Table 1 for sampling time). DD: sample
post in vitro gastric + duodenal digestion. Water (WT), home-made biscuits (HB), crisp-bread (CB) and
full-fat milk (FM). † p < 0.01 vs. CB at the same sampling time; ‡ p < 0.01 vs. HB at the same sampling
time; § p < 0.01 vs. FM at the same sampling time.
4. Discussion
The data presented here has demonstrated that bioaccessibility of polyphenols from almond skin
was significantly affected by the type of food matrix used. Given the lack of understanding of the fate
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of antioxidant compounds in the human body, research focused on the bioaccessibility of polyphenols
from solid matrices are extremely important in order to better understand the beneficial effect on
the host.
We have previously shown that polyphenols from almond skin were bioaccessible in the upper
GIT during simulated human digestion in a static system and most of the release occurred in the gastric
phase of digestion [1]. However, in the present study, a considerable further loss of polyphenols was
observed during the duodenal phase over that detected in the gastric environment across all the food
matrices used (Figure 1). The amount of individual polyphenols released from NS and BS are quite
different, although a similar rate was detected across the two skin samples. The use of a dynamic
model of digestion (DGM), where the digestion products are removed during the time course of the
experiment, has likely affected the rate and release of almond skin polyphenols. A similar trend was
observed with lipid bioaccessibility from natural raw and roasted almonds after mastication [22].
A study on polyphenols bioaccessibility from apples indicated the release was mainly achieved during
the gastric phase (65% of phenolics and flavonoids), with a slight increase (<10%) during intestinal
digestion [23].
In vitro digestion of the cocoa insoluble water fraction, source of polyphenols, lead to a 51%
release of the total phenols from the insoluble material, without a reduction of the total antioxidant
capacity [24].
In our previous study investigating bioaccessibility of bioactives from pistachios, more of 90%
of polyphenols were released in the gastric compartment, with little or no increase in the duodenal
phase [12]. The lower % of bioaccessibility in almonds (Figure 1) could be due to the properties of their
cell walls, which is known to affect lipid and protein bioaccessibility in the gut [22,25]. Almond skins
contain high amount of dietary fiber and several cell wall bound phenolics, including p-hydroxybenzoic
acid, vanillic acid and t-ferulic acid [17]. We have previously shown that complex carbohydrates present
in dietary fiber can directly interact with antioxidants and therefore interfere with their bioaccessibility
in the gut [26,27]. Furthermore, the polyphenols structure plays a crucial role in relation to their
adsorption, which was improved by low degree of hydroxylation and reduced by methylation or
methoxylation. An increased degree of polymerization determined enhanced absorption for certain
polyphenolic classes, including procyanidins [28]. However, the role of glycosylation still remains
controversial [13,28]. Dietary fiber can reduce fat bioaccessibility in the GIT and pectin was found to
strongly lower β-carotene bioavailability [29].
The high dietary fiber content in almond skin, as well as the significant amounts of lipids,
could have affected the release of phytochemicals, especially in the absence of a food matrix.
Dietary fiber could also reduce the rate of antioxidant absorption by physically trapping the bioactive
compounds within its matrix in the chyme, thus restricting enzyme diffusion [30]. Therefore, it is
hypothesised that certain polyphenols, mainly phenolic acids which are bound to dietary fiber, are not
released in the upper GIT but reach the large bowel where they can be metabolised by the gut
microbiota. This could also be due to a dietary fiber specific effect on gastrointestinal physiology
(e.g., motility and/or secretion) [28]. The polyphenols-carbohydrates interaction could exert positive
effects on lipid metabolism and increase the antioxidant activity in the large intestine [13,28].
A number of studies have reported on the effects of a food matrix in a simulated gastrointestinal
environment: the findings demonstrated that green tea polyphenols were protected more by
the interaction with dairy products, which could help maintain their antioxidant activity during
digestion [31] and cheese was identified as an effective matrix for polyphenols protection during
gastrointestinal digestion [32]. Stanisavljevic et al. [11] have investigated the changes in polyphenols
content and antioxidant activity of chokeberry juice subjected to in vitro gastric digestion in the
presence of a food matrix: the results demonstrated a decrease in the total phenolic content, anthocyanin
content and DPPH radical scavenging activity immediately after addition of the food matrix. However,
the fat content in cocoa samples increased the released of phenolic compounds during duodenal
digestion [33]. Lesser et al. [34] have shown that high fat content in meals could either enhance or
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reduce the absorption of certain flavonoids; polyphenols could also affect the fat adsorption process at
the emulsification stage by a direct interaction with phosphatidylcholine or by incorporation within
the lipid layer, thus leading to physicochemical property changes of emulsions directly related to
lipase activity and fat adsorption decrease, as suggested for tea polyphenols [28]. Moreover, several
studies suggested that polyphenols were able to create a positive antioxidant environment at the
gastrointestinal level fighting the harmful products of lipid peroxidation [28]. All these interactions
could contribute to the well-known beneficial effects of polyphenols.
Another important aspect to discuss is the polyphenols ability to bind proteins, thus affecting the
amino acids availability and leading in some cases to protein denaturation (e.g., α-amylase, trypsin,
lysozyme) or to their lower digestibility (e.g., β-lactoglobulin) [28,35]. This often affects enzyme activity
in a positive way (α-amylase inhibition which could be connected to the prevention of dental injuries)
or negative way (when digestive enzymes are involved). It is known, in fact, that protein-polyphenol
interactions might influence their adsorption, even though proteins could be carriers of polyphenols
through the gastrointestinal tract, thus protecting them from oxidative reactions and increasing their
availability at the large intestine [28,35].
In the present study, the fat and protein content in the milk matrix have significantly lowered
the release of phenolic acids and flavan-3-ols after simulated human digestion from both NS and
BS compared with water, whereas the home-made biscuits decreased bioaccessibility of flavonols
(Figure 3). In a recent study [36] the addition of milk decreased the total phenolic, flavonoid and
anthocyanin content, although it had no effect on the polyphenols being absorbed in vitro.
It has also been suggested, with respect to what is mentioned above, that the presence of digestible
carbohydrates, lipids and other antioxidant compounds may have a beneficial impact on polyphenols
bioaccessibility [37]. This could explain the high bioaccessibility detected when almond skins were
incorporated in bread.
Even if the bioaccessibility of each antioxidant differs greatly, the potential synergistic effect
amongst polyphenols could affect their bioactivity and influence on glycoprotein transporters across
the mucosal epithelium. It is well established that a variety of factors, including chemical structure,
food matrix, digestion enzymes and interaction with the gut microbiota can directly influence
polyphenols bioaccessibility and rate of absorption [38]. A number of studies have indicated
some unique technological strategies, including micro-encapsulation, which increase polyphenols
bioavailability and therefore increase their beneficial health benefits [39–41].
5. Conclusions
In summary, the results of the present study indicate that the presence of a food matrix had
a significant effect on polyphenol bioaccessibility from almond skin in both the gastric and duodenal
environments. The dietary fiber present in almond skin may act as barrier to prevent a total release of
phytochemicals during digestion. Further studies are warranted in order to investigate absorption of
bioactives, which could explain the beneficial health effects associated with almond consumption.
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Abbreviations
The following abbreviations are used in this manuscript:
NS natural almond skin
BS blanched almond skin




NSWT G natural almond skin in water post in vitro gastric digestion
NSHB G natural almond skin in home-made biscuits post in vitro gastric digestion
NSCB G natural almond skin in crisp-bread post in vitro gastric digestion
NSFM G natural almond skin in full-fat milk post in vitro gastric digestion
NSWT G + D natural almond skin in water post in vitro gastric plus duodenal digestion
NSHB G + D natural almond skin in home-made biscuits post in vitro gastric plus duodenal digestion
NSCB G + D natural almond skin in crisp-bread post in vitro gastric plus duodenal digestion
NSFM G + D natural almond skin in full-fat milk post in vitro gastric plus duodenal digestion
BSWT G blanched almond skin in water post in vitro gastric digestion
BSHB G blanched almond skin in home-made biscuits post in vitro gastric digestion
BSCB G blanched almond skin in crisp-bread post in vitro gastric digestion
BSFM G blanched almond skin in full-fat milk post in vitro gastric digestion
BSWT G + D blanched almond skin in water post in vitro gastric plus duodenal digestion
BSHB G + D blanched almond skin in home-made biscuits post in vitro gastric plus duodenal digestion
BSCB G + D blanched almond skin in crisp-bread post in vitro gastric plus duodenal digestion
BSFM G + D blanched almond skin in full-fat milk post in vitro gastric plus duodenal digestion
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Abstract: Quercitrin is found in many kinds of vegetables and fruits, and possesses various bioactive
properties. The aim of the present study was to elucidate hepatoprotective mechanisms of quercitrin
isolated from Toona sinensis (Juss.) M.Roem. (syn. Cedrela sinensis Juss.), using acetaminophen
(APAP)-treated HepG2 cell and animal models. In an in vitro study, quercitrin suppressed the
production of reactive oxygen species and enhanced expression of nuclear factor E2-related factor 2
(Nrf2), activity of antioxidant response element (ARE)-reporter gene, and protein levels of NADPH:
quinone oxidoreductase 1 (NQO1), catalase (CAT), glutathione peroxidase (GPx), and superoxide
dismutase 2 (SOD-2) in APAP-treated HepG2 cells. In an in vivo study, Balb/c mice were orally
administered with 10 or 50 mg/kg of quercitrin for 7 days and followed by the injection with single
dose of 300 mg/kg APAP. Quercitrin decreased APAP-caused elevation of alanine aminotransferase
and aspartate aminotransferase levels, liver necrosis, the expression of pro-inflammatory factors
including inducible nitric oxide synthase, cyclooxygenase 2 and inerleukin-1β, and phosphorylation
of kinases including c-Jun N-terminal kinase and p38. Quercitrin restored protein levels of Nrf2,
NQO1 and activities and expressions of CAT, GPx, SOD-2. The results suggested that quercitrin
attenuates APAP-induced liver damage by the activation of defensive genes and the inhibition of
pro-inflammatory genes via the suppressions of JNK and p38 signaling.
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1. Introduction
Acetaminophen (APAP, marketed as Paracetamol® or Tylenol®), a widely used over-the-counter
analgesic and antipyretic drug, is safe and effective at therapeutic dose. However, it can cause acute
liver failures such as serve hepatic necrosis, hepatic lesions and cirrhosis, and even death when taken
in high doses. APAP-induced hepatotoxicity is initiated by formation of excess reactive intermediate
N-acetyl-p-benzoquinone imine (NAPQI), which is produced by metabolism of liver cytochrome P450s
(CYPs) including CYP2E1, CYP3A4 and CYP1A2 [1]. NAPQI depletes cellular glutathione (GSH) and
adenosine triphosphate (ATP), causes mitochrondrial dysfunction and damage, and finally causes DNA
fragmentation and apoptosis. Acetaminophen also contributes to overproduction of reactive oxygen
species (ROS) [2]. In addition, lipid peroxidation resulting from oxidative stress has been demonstrated
to contribute to the initiation and progression of APAP-induced liver damage [3]. Furthermore,
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accumulating evidence indicates that acetaminophen overdose triggers the transcriptional activation
of pro-inflammatory mediators and cytokines such as inducible nitric oxide (iNOS), cyclooxygenase 2
(COX-2), tumor necrosis factor α (TNF-α), and interleukin 1β (IL-1β) [2,4].
N-acetylcysteine (NAC) is used as a clinical antidote for APAP poisoning [5,6]. NAC protects liver
from APAP-induced injury by restoring hepatic glutathione and scavenging free radicals [7]. However,
NAC therapy has considerable limitations because the therapeutic effect of this drug is quite narrow
and it could cause some side-effects such as nausea, anaphylactic reaction, headaches and diarrhea [7,8].
Thus, alternative and effective agents are needed to prevent APAP-induced hepatotoxicity.
Toona sinensis (Juss.) M.Roem. (syn. Cedrela sinensis Juss.), a member of the Meliaceae family,
is an upland tree that has been used as traditional medicine and nutritious food for a long time in
China and Korea. T. sinensis leaves contain a variety of bioactive compounds such as gallic acid,
methyl gallte, kaemferol, quercetin, rutin, quercitrin, palmitic acid and linoleic acid, etc. [9–12]. Of
these compounds, quercitrin (3-rhamnosyl quercetin) (Figure 1), a glycoside of quercetin, has been
found as a main bioactive constituent in T. sinensis leaves [13,14]. The sugar portion bound to the
aglycone in quercitrin has been demonstrated to increase solubility of quercitrin and consequently
improve the absorption by interacting with the sodium dependent glucose transport receptor in the
small intestine [15,16]. Pharmacological studies have shown that quercitrin has antioxidant [17,18],
anti-inflammatory [19,20], and anti-allergic [21] activities. Quercitrin has been demonstrated to exert
a protective effect against UV-induced cell death and apoptosis [22,23]. Furthermore, quercitrin has
been studied as an anti-cancer agent against non-small cell lung cancer through the modulation
of immune response [24]. Our group previously reported that quercitrin from T. sinensis leaves
potently scavenged free radicals and induced antioxidant enzymes in H2O2-treated HepG2 cells [9].
However, the protective mechanisms of quercitrin against APAP-induced hepatotoxicity have not
been investigated.
Figure 1. Chemical structure of quercitrin.
In the present study, we examined the hepatoprotective effects of quercitrin in both cell line
and animal models of hepatotoxicity challenged by APAP. The stimulating activity of quercitrin
on cellular defensive genes including transcription factor nuclear factor E2-related factor 2 (Nrf2),
antioxidant response element (ARE)-reporter gene and antioxidant enzymes was determined. The
inhibitory effects of quercitrin on liver damage markers of alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) as well as inflammatory targets of iNOS, COX-2 and IL-1β were
evaluated in APAP-induced hepatotoxic mice. In addition, the modulation of mitogen activated protein
kinases (MAPKs) by quercitrin was examined.
2. Materials and Methods
2.1. Chemicals
Acetaminophen, silymarin, MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide],
dimethyl sulphoxide (DMSO), polyethylene glycol (PEG), and triton X-100 were purchased from
Sigma-Aldrich (St. Louis, MO, USA). 21,71-dichlorodihydrofluorescein diacetate (DCFH-DA) was
purchased from Molecular Probe Inc. (Eugene, OR, USA). The colorimetric ALT and AST assay kits
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were supplied by Young-Dong Co. (Seoul, Korea). Anti-Nrf2 (sc-13032), anti-NQO1 (sc-25591),
anti-SOD-2 (sc-18504), anti-GPx (sc-30147), anti-COX-2 (sc-1745), anti-iNOS (sc-651), anti-IL-1β
(sc-7884), anti-β-actin (sc-1616), and horseradish peroxidase-conjugated anti-goat immunoglobulin
IgG (sc-2350) antibodies were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA).
Anti-p-ERK (9101), anti-p-JNK (9251), anti-p-p38 MAPK (9211), anti-CAT (14097), and horseradish
peroxidase-conjugated anti-rabbit immunoglobulin IgG (7074) were purchased from Cell Signaling
Technology (Beverly, MA, USA). All other reagents used in this study were of the highest grade
commercially available.
2.2. Preparation of Quercitrin
Quercitrin from powder of T. sinensis (Juss.) M.Roem. leaves, kindly provided by Slow-life
Chamjook Farm Corporation (Hamyang, Korea), was isolated according to previous literature [9]. A
voucher specimen (Jeong, W.S. 001) of the raw material was deposited at the Herbarium of Kyungpook
National University (KNU), Daegu, Korea. Briefly, the powder of T. sinensis was extracted three times
with 95% ethanol (EtOH) for 24 h in room temperature and concentrated by rotary evaporation at
40 ˝C. After concentration, the concentrate was suspended in 10% EtOH and then fractionated with
a series of organic solvents, including h-hexane, DCM, ethylacetate (EtOAc), n-butanol, and water
in sequence. The EtOAc-solution fraction, the most potent antioxidant fraction to both scavenging
radicals and antioxidant enzyme activity, was applied onto a silica gel open column. The column
was eluted with solvent mixtures of DCM/methanol under gradient conditions to yield 17 fractions.
The most potent subfraction (Fr. 10) was purified by recycling preparatory high-performance liquid
chromatography (HPLC) and structural analyses were performed using 1H- and 13C-nuclear magnetic
resonance (NMR) analysis.
2.3. Cell Culture
Human hepatoma cell line HepG2, obtained from American Type Culture Collection (ATCC,
Rockville, MD, USA), was maintained DMEM containing 10% fetal bovine serum (FBS), 100 units/mL
penicillin, 100 μg/mL streptomycin, 1% essential amino acids, 1% glutamax in humidified atmosphere
of 5% CO2 at 37 ˝C. The medium was renewed once every two days.
2.4. Cell Viability Assay
Cell viability was examined using MTT assay. Briefly, HepG2 cells were cultured in a 24-well
plate at density of 1 ˆ 105 cells/well. After starvation, cells were treated with a series of various
concentrations of quercitrin in the presence of 10 mM APAP for 24 h and then incubated with 5 mg/mL
MTT for additional 4 h. The dark blue formazan crystal was solubilized in DMSO and followed
by measurement of absorbance at 570 nm with a microplate reader (BioTek Instruments, Winooski,
VT, USA).
2.5. ROS Formation Assay
Level of intracellular ROS was measured using DCFH-DA. In viable cells, the DCFH-DA is
cleaved by esterase to DCFH and followed oxidizing by ROS to form a highly florescent molecule, DCF.
Briefly, HepG2 cells were seeded onto 96-well plates at density of 2 ˆ 104 cells/well and then treated
either vehicle (DMSO, 0.1%) or various concentrations of quercitrin in the presence of 10 mM APAP
for 24 h. After washing twice with phosphate-buffered saline (PBS), the cells were incubated with
20 μM DCF-DA for 1 h at 37 ˝C in darkness. The fluorescence that is representative of intracellular
reactive oxygen species level was measured at 485/20 nm excitation and 528/20 nm emission using a
fluorescence multidetection reader (Synergy HT, BioTek, VT, USA).
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2.6. Assay of Reporter Gene Activity
HepG2-C8 cell line, kindly donated by Ah-Ng Tony Kong (Rutgers University, New Brunswick,
NJ, USA), was established by the table transfection of HepG2 cells with p-ARE-T1-luciferase reporter
gene as previously described [25]. After starvation, the HepG2-C8 cells were treated with various
concentrations of quercitrin for 24 h and then ARE-luciferase activity was measured using a luciferase
kit from Promega (Promega Corp., Madison, WI, USA) according to the manufacturer’s instructions.
Luciferase activity was normalized against total protein concentration, determined by a BCA protein
assay kit (Pierce, Rockford, IL, USA), and expressed as a fold induction over that in vehicle-treated cells.
2.7. Animals and Experimental Design
Thirty male Balb/c mice (6 weeks old, 20–25 g) were obtained from Hyochang Science (Daegu,
Korea) and allowed free access to standard laboratory diet and distilled water ad libitum for at least
one week prior to the experiment. The animal room was environmentally controlled at 25 ˘ 2 ˝C,
55%–60% humidity, 12 h light/dark cycle. This animal experiment was approved by the Animal Care
and Used Committee of Inje University with protocol number 2013-50 (Gimhae, Korea). The mice
were randomly divided into six groups with five mice each. Group I (control group) received 50% PEG
as a vehicle for 7 days. Group II (quercitrin group) was only administered 50 mg/kg quercitrin for
7 days. Group III (APAP group) received 50% PEG for 7 days. Group IV and V (quercitrin + APAP
group) were orally gavaged with 10 or 50 mg/kg of quercitrin, respectively, for 7 consecutive days.
Group VI (APAP + silymarin group) was orally administered 50 mg/kg of silymarin (SIL), which is
frequently used as a natural hepatoprotectant by its antioxidant and anti-inflammatory properties [26]
for 7 days. After 1 h last administration, a single dose of APAP (300 mg/kg) was injected to mice in
groups III-VI. After 24 h APAP challenge, all mice were sacrificed to obtain blood and livers for further
biochemical analysis.
2.8. Measurement of Plasma ALT and AST Levels
Blood samples from mice were centrifuged at 3000ˆ g, 4 ˝C for 10 min to obtain serum supernatant.
The ALT and AST activities in serum were measured using commercially available kits (Young-dong
Pharm, Seoul, Korea).
2.9. Assay for Antioxidant Enzymes Activity
Liver tissues were collected and homogenized in phosphate buffer (pH 7.0) and then tissue
homogenates were centrifuged at 10,000ˆ g, 4 ˝C for 10 min to obtain separately supernatant and
pellet for further experiments. The protein concentration was determined using a BCA protein assay
kit (Pierce, Rockford, IL, USA). CAT activity was determined by the method of Aebi [27]. GPx activity
was performed according to the method of Bongdanska et al. [28]. SOD activity was determined by the
method of Oyanagui [29]. Enzyme activities were expressed in relation to the vehicle-treated control.
2.10. Western Blot Analysis
Cells and liver tissues were homogenized in RIPA buffer and then centrifuged at 10,000ˆ g, 4 ˝C
for 10 min to obtain supernatant. Total protein concentration of each sample was determined using a
BCA protein assay kit (Pierce, Rockford, IL, USA) according to the manufacturer’s instructions. Equal
amounts of protein were resolved on SDS-PAGE gels and then transferred onto PVDF membranes
(Millipore, Bedford, MA, USA) using a semidry transfer system (Bio-rad, Hercules, CA, USA). After
blocking with 5% non-fat milk in PBST (0.1% Tween 20 in PBS) for 2 h at 4 ˝C, the membranes
were incubated overnight with appropriate primary antibodies at 4 ˝C. Then, the membranes were
washed five times with PBST and hybridized with horseradish peroxidase-conjugated anti-rabbit or
anti-goat immunoglobulin IgG secondary antibodies for 3 h at 4 ˝C. After washing five times with
93
Nutrients 2016, 8, 431
PBST, blots were visualized using enhanced chemiluminescence western blotting reagent (Santa Cruz
Biotechnology, Santa Cruz, CA, USA).
2.11. Statistical Analysis
Data were expressed as means ˘ SD. Statistical comparisons were evaluated using analysis of
variance (ANOVA) followed by Tukey’s test. p < 0.05 was considered as significant.
3. Results
3.1. Protective Effect of Quercitrin against Oxidative Stress in APAP-Induced HepG2 Cells
To investigate the effect of quercitrin on the APAP-induced ROS formation, we measured the
intracellular level of ROS using a redox-sensitive fluorescence reagent, DCF-DA. As shown in Figure 2A,
exposure of HepG2 cells to APAP remarkably elevated the ROS production by over 2-fold at 24 h when
compared to the control. Pre-treatment of quercitrin, however, inhibited the increase of APAP-induced
ROS level. The presence of 10, 25, 50 μg/mL quercitrin significantly decreased the ROS formation in
HepG2 cells by 0.5-, 0.5-, and 1.3-fold, respectively, compared to APAP-treated cells alone. Enhanced
oxidative stress can result in apoptosis and cell death; thus, we tested whether quercitrin rescue
APAP-induced cell death using MTT assay. Consequently, 10 mM APAP reduced 30% cell viability,
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Figure 2. Protective effects of quercitrin on acetaminophen (APAP)-treated HepG2 cells. (A) Effect of
quercitrin on APAP-mediated reactive oxygen species (ROS) formation; (B) Effect of quercitrin on cell
viability using MTT assay at 24 h. Effect of quercitrin on protein expressions of (C) catalase (CAT);
(D) glutathione peroxidase (GPx); and (E) superoxide dismutase 2 (SOD-2) in APAP-treated HepG2
cells. ROS was presented as the fold induction of vehicle-treated control. Cell viability was normalized
as 100% for control (without any treatments). Protein expression levels were normalized with β-actin.
All data represent means ˘ SD of at least three independent experiments. Significant differences were
(##) p < 0.01 or (#) p < 0.05 as compared with the control; (**) p < 0.01 or (*) p < 0.05 as compared with
the APAP group.
Antioxidant enzymes including CAT, GPx, and SOD constitute the primary part of enzymatic
antioxidant defense system against oxidative stress via directly eliminating ROS. Thus, the effects
of quercitrin on expression levels of antioxidant enzymes were examined. The results showed that
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APAP significantly reduced protein expressions of GPx and SOD but not CAT compared with control
(Figure 2C–E). However, pretreatment with quercitrin for 1 h blocked the effect of APAP on the
decreased expression of antioxidant enzymes. Overall, these results obviously suggested that quercitrin
prevents APAP-induced ROS formation and cell death through the induction of antioxidant enzymes
in HepG2 cells.
3.2. Upregulation of Nrf2/ARE-Mediated Phase II Detoxifying Enzymes by Quercitrin in APAP-Treated
HepG2 Cells
To further confirm the role of quercitrin in protection of cells from APAP toxicity, the activation
of Nrf2/ARE pathway was evaluated. Nrf2 is considered as a key transcriptional factor responsible
for the regulation of phase II detoxifying and/or antioxidant enzymes, which protect cells from cell
death-induced APAP toxicity. The basal levels of protein expression of Nrf2 were detected in HepG2
cells. Compared with untreated control, APAP was able to significantly decrease the Nrf2 protein level
for up to 24 h (Figure 3A). Further, we investigated the inhibitory effect of quercitrin on APAP-induced
the reduction of Nrf2 expression. Results showed that quercitrin has the potential to induce Nrf2
for 24 h. The quercitrin concentration at ě25 μg/mL caused a significant increase in protein level
of Nrf2. In particular, quercitrin concentration at 50 μg/mL resulted in a strong up-regulation of
Nrf2 at 24 h by 1.6-fold compared to control and 2.0-fold compared with APAP alone. In addition, in
order to elucidate whether the activation of Nrf2 induces ARE-mediated phase II detoxifying and/or
antioxidant enzymes using ARE-reporter gene activity assay, HepG2-C8 cells, stably transfected with
a pARE-TI-luciferase reporter gene were exposed to quercitrin for 24 h. As illustrated in Figure 3B,
quercitrin enhanced the ARE-luciferase activity. The luciferase activity by quercitrin at the highest
concentration of 50 μg/mL reached 2.6-fold compared with that by vehicle-treated control. This result
demonstrated the role of Nrf2 in up-regulation of ARE-mediated phase II enzymes. Furthermore,
the effect of quercitrin on protein level of a phase II detoxifying enzyme, NQO1, was examined in
APAP-treated HepG2 cells. The result showed that treatment with APAP resulted in the decrease of
NQO1 protein level; however, pre-treatment of quercitrin restored the APAP-reduced expression level
of NQO1, even more than in the control at quercitrin concentration of 25 μg/mL (Figure 3C). These
data suggest that quercitrin promotes hepatoprotective system through the activation of Nrf2 and





























Figure 3. Up-regulation of nuclear factor E2-related factor 2 (Nrf2)/antioxidant response element
(ARE)-mediated phase II detoxifying enzyme in APAP-treated HepG2 cells. (A) Effect of quercitrin on
protein expression of Nrf2; (B) Effect of quercitrin on ARE-luciferase activity; (C) Effect of quercitrin
on protein level of quinone oxidoreductase 1 (NQO1). Luciferase activity was normalized with total
protein content and expressed as fold induction of normal control. Protein expression levels were
normalized with β-actin. All data represent means ˘ SD of at least three independent experiments.
Significant differences were (##) p < 0.01 or (#) p < 0.05 as compared with the control; (**) p < 0.01 or
(*) p < 0.05 as compared with APAP group.
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3.3. Protective Effect of Quercitrin against APAP-Induced Hepatotoxicity in Vivo
To further investigate the role of quercitrin in protecting liver from APAP-induced toxicity, Balb/c
mice were administered quercitrin at a dose of 10 and 50 mg/kg before injection of 300 mg/kg APAP.
As shown in Table 1, APAP significantly increased liver weight within 24 h compared with the control
and quercitrin alone groups, whereas body weights were comparable among all experimental groups.
Oral pre-administration of quercitrin (10 and 50 mg/kg) or SIL (50 mg/kg) reduced the APAP-induced
increase of liver weight. In addition, injection of 300 mg/kg APAP highly elevated 14- and 3-fold of
serum ALT and AST activities, respectively, compared to the vehicle-treated group, implying that a
high dose of APAP caused liver toxicity (Figure 4A,B). Quercitrin treatment significantly prevented the
APAP-induced elevation of ALT and AST levels. Similarly, 50 mg/kg of SIL, considered as a positive
control in this study, was found to attenuate the ALT and AST activities. Further, the administration of
50 mg/kg quercitrin alone was unlikely to significantly alter the basal activity of these transaminases,
suggesting no liver damage caused by quercitrin. Histological (H&E) analysis further revealed that
APAP-induced severe hepatic lesions such as hydropic degeneration, inflammation, and hemorrhage
were improved by quercitrin pretreatment. Also, a similar result was observed in the positive control
group, SIL (Figure 4C). These results prove that quercitrin may be a potential agent in the prevention
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Figure 4. Protective effects of quercitrin on APAP intoxicated mice. Mice were orally administered
quercitrin of 10 or 50 mg/kg once a day for seven days. The control group received the same volume
of saline. After the seventh gavage of quercitrin or saline, animals received a single injection of APAP
(300 mg/kg). All mice were sacrificed at 24 h after APAP injection to obtain blood and liver. Serum
ALT (A) and AST (B) levels; and H&E staining (C). All data represent means ˘ SD of five mice in each
group. Significant differences were (##) p < 0.01 as compared with the control; (**) p < 0.01 or (*) p < 0.05
as compared with APAP group.
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I Control 20.12 ˘ 0.49 23.02 ˘ 1.36 1.42 ˘ 0.09 6.19 ˘ 0.30
II Quercitrin (50mg/kg) 19.62 ˘ 0.59 23.40 ˘ 0.45 1.53 ˘ 0.11 6.55 ˘ 0.53
III APAP (300 mg/kg) 19.68 ˘ 0.40 23.37 ˘ 0.90 1.65 ˘ 0.11 7.21 ˘ 0.36 #
IV Quercitrin(10 mg/kg) + APAP 20.20 ˘ 0.34 24.1 ˘ 0.41 1.50 ˘ 0.10 6.20 ˘ 0.31 *
V Quercitrin(50 mg/kg) + APAP 19.92 ˘ 0.38 23.02 ˘ 0.97 1.47 ˘ 0.09 6.40 ˘ 0.28 *
VI Silymarin(50 mg/kg) + APAP 19.68 ˘ 0.85 23.42 ˘ 0.92 1.50 ˘ 0.10 6.38 ˘ 0.19 *
(#) p < 0.05 as compared with the control, (*) p < 0.05 as compared with APAP group.
3.4. Protective Effect of Quercitrin against APAP-Induced Hepatotoxicity through Enhancement of Activity and
Expression of Antioxidant Enzymes
To examine whether quercitrin activates antioxidant defense system in APAP-treated mouse
models, we measured activity and protein level of antioxidant enzymes including CAT, GPx,
and SOD-2, which importantly contribute to the protection of cells/tissues from oxidative stress
through directly neutralizing and eliminating ROS. The results indicated that injection of mice to
300 mg/kg APAP resulted in the reduction in activities of three antioxidant enzymes. Quercitrin
pre-administration, however, prevented the APAP-induced decrease of CAT, GPx, and SOD-2 enzyme
activities (Figure 5A–C). It is likely that quercitrin, SIL (50 mg/kg), also significantly increased the
activities of these enzymes when compared to APAP-treated mice. Interestingly, oral administration of
50 mg/kg quercitrin alone was shown to enhance the CAT and SOD-2 activities but not GPx activity
compared to the vehicle-treated control. In order to further confirm the inductive effect as well as
the role of quercitrin on liver protection against APAP-induced oxidative stress, protein expression
levels of antioxidant enzymes including CAT, GPx, and SOD-2 were determined. The results showed
that treatment of 300 mg/kg APAP caused slightly reduced protein expressions of these antioxidant
enzymes. However, as expected, quercitrin significantly induced the APAP-abolished CAT, GPx, and
SOD-2 proteins, even more than those in the control group (Figure 5D–F). This result is consistent with
SIL, which also enhanced the expressions of antioxidant enzymes in APAP-treated mice. Overall, our
study supports the use of quercitrin in preventing APAP-mediated liver toxicity.
3.5. Upregulation of NQO1 Expression by Nrf2-Mediated Quercitrin in APAP-Treated Mice
As demonstrated, quercitrin up-regulated Nrf2-mediated phase II detoxifying enzyme in HepG2
cells, thus we confirmed the inductive effect of quercitrin on protein levels of NQO1 in an APAP-treated
mouse model. Similar to the in vitro result, exposure of mice to APAP caused a significant attenuate
of NQO1 protein level (Figure 6B) but was unlikely to suppress protein expression of Nrf2 after
24 h challenge (Figure 6A) when compared to the untreated control. The presence of quercitrin
restored the APAP-reduced protein expression of both Nrf2 and NQO1. Further, the levels of Nrf2
and NQO1 expression induced by quercitrin were even higher than those induced by a positive
control, SIL (50 mg/kg) (Figure 6A,B). These results demonstrate the role of quercitrin in the activation
of Nrf2/ARE-mediated phase II detoxifying enzyme, implying protection of cells/tissues against
APAP-induced toxicity.
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Figure 5. Effects of quercitrin on activities and protein expressions of hepatic antioxidant enzymes
in APAP intoxicated mice. The hepatic activities of CAT (A); GPx (B) and SOD-2 (C) were measured
as described in Materials and Methods section. The protein levels of CAT (D); GPx (E) and SOD-2
(F) were determined using Western blot analysis. Protein expression levels were normalized with
β-actin. All data represent means ˘ SD of five mice in each group. Significant differences were
(#) p < 0.05 as compared with the control; (**) p < 0.01 or (*) p < 0.05 as compared with APAP group.
Figure 6. Effects of quercitrin on expressions of Nrf2 and NQO1 in APAP intoxicated mice. The protein
levels of Nrf2 (A) and NQO1 (B) were measured by Western blot analysis as described in Materials
and Methods section. Protein expression levels were normalized with β-actin. All data represent
means ˘ SD of five mice in each group. Significant differences were (#) p < 0.05 as compared with the
control; (**) p < 0.01 or (*) p < 0.05 as compared with APAP group.
3.6. Quercitrin Attenuates Inflammatory Response in APAP-Treated Mice
In further studies, we evaluated the effects of quercitrin on APAP-induced expression of
pro-inflammatory mediators and cytokines implicated in hepatotoxicity. APAP treatment significantly
increased protein expression for the pro-inflammatory mediators and cytokine such as iNOS, COX-2
and IL-1β compared to vehicle-treated control, whereas animals receiving quercitrin alone did not show
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elevated levels of these hepatic inflammatory factors (Figure 7A–C). APAP-enhanced protein expression
of iNOS, the enzyme mediating production of nitric oxide, was also inhibited by the presence of
quercitrin (Figure 7A). Expression of pro-inflammatory mediator COX-2 that was up-regulated in mice
exposing APAP intoxication was reduced in mice pre-treated with quercitrin (Figure 7B). Additionally,
quercitrin administration resulted in a decrease in the APAP-induced IL-1β protein level (Figure 7C).
Figure 7. Effects of quercitrin on inflammatory response in APAP intoxicated mice. The hepatic
inducible nitric oxide (iNOS) (A); cyclooxygenase 2 (COX-2) (B) and interleukin 1β (IL-1β) (C) levels
were evaluated by Western blot analysis. Protein expression levels were normalized with β-actin. All
data represent means ˘ SD of five mice in each group. Significant differences were (#) p < 0.05 as
compared with the control; (**) p < 0.01 or (*) p < 0.05 as compared with APAP group.
Figure 8. Effects of quercitrin on MAP kinases in APAP intoxicated mice. The phosphorylations of ERK,
JNK and p38 MAPK were analyzed by Western blotting. Protein expression levels were normalized
with β-actin. All data represent means ˘ SD of five mice in each group. Significant differences were
(##) p < 0.01 or (#) p < 0.05 as compared with the control; (**) p < 0.01 or (*) p < 0.05 as compared with
APAP group.
3.7. Activation of Cytoprotective Mechanisms by Quercitrin through Regulation of MAPK Pathways in
APAP-Treated Mice
To investigate role of quercitrin on the modulation of MAPKs in APAP-treated mice,
phosphorylation levels of MAPKs including ERK, JNK, and p38 MAPK were determined using
western blotting. As shown in Figure 8, exposure of APAP (300 mg/kg) increased the phosphorylation
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levels of ERK, JNK, and p38 MAPK in the liver by 2-, 3-, and 4-fold, respectively, when compared to the
control group. This suggested that MAPKs involved in APAP-caused hepatotoxicity. On other hand,
treatment of quercitrin (50 mg/kg) alone resulted in a significant elevation of phosphorylated ERK and
JNK but not phosphorylated p38. Oral administration of quercitrin or SIL, however, strongly inhibited
the JNK and p38 MAPK phosphorylations, whereas ERK phosphorylation was slightly decreased at
50 mg/kg quercitrin and there was no change at 50 mg/kg SIL. Overall, our results indicate that the
inhibition of APAP-induced phosphorylation levels of JNK and p38 MAPK by quercitrin contributes
to protection of liver from toxicity.
4. Discussion
The present study demonstrated the role of quercitrin from T. sinensis in the protection of
cells/tissues from APAP-induced toxicity. Quercitrin attenuated the ROS formation and cell death
induced by APAP overdose through the restoration of antioxidant enzymes as well as enhancement of
Nrf2/ARE pathway-mediated cytoprotecive enzymes in HepG2 cells. Moreover, oral administration
of quercitrin exhibited protective effects against APAP-caused liver injury in mice, which is consistent
with an in vitro test. Indeed, quercitrin pretreatment prevented APAP toxicity, as evidenced by much
less liver injury and decreased serum ALT and AST levels. Quercitrin restored the APAP-induced
reduction of activities and protein expressions of antioxidant enzymes, including CAT, GPx, and
SOD-2 as well as protein level of phase II enzyme NQO1 through the activation of transcription
factor Nrf2. In addition, quercitrin exerted the anti-inflammatory property through inhibiting the
expression of pro-inflammatory mediators and cytokine such as iNOS, COX-2, IL-1β in APAP-treated
liver. Furthermore, inhibition of APAP-mediated phosphorylation levels of JNK and p38 MAPK were
considered as a protective mechanism of quercitrin from APAP toxicity in liver. These results, for
the first time, demonstrate that antioxidant and anti-inflammatory properties of quercitrin potently
contribute to the prevention of APAP-induced liver injury.
Reactive oxygen species (ROS) including free radicals such as superoxide (O2¨ ´), hydroxyl
radical (¨ OH), peroxyl radical (RO2¨ ) and non-radical species such as hydrogen peroxide (H2O2) are
implicated in the development of various diseases such as aging, cancer, atherosclerosis, fibrosis, and
inflammation [30–32]. The accumulation of ROS results in oxidative stress, lipid peroxidation, protein
inactivation, DNA damage, loss of cell function, and finally apoptosis and necrosis [33]. Increased
oxidative stress and massive impairment of antioxidant defense systems are well-known as the main
mechanisms of APAP-caused hepatotoxicity [34]. The major reactive oxygen species generated by
APAP toxicity is superoxide (O2¨ ´), which dismutates to molecular oxygen and hydrogen peroxide
or reacts with nitric oxide (NO) to produce peroxynitrite (ONOO´), a potent oxidant and nitrating
species [35]. A variety of phenomena such as lipid peroxidation, increased ALT and AST, reduced
levels of cellular antioxidant enzymes, and DNA damages was observed in APAP toxicity. In this
study, we confirmed that ROS levels were dramatically increased, whereas protein expressions and
activities of CAT, GPx, and SOD-2 in HepG2 cells and mouse livers significantly decreased after
APAP treatment. In addition, HepG2 cell death and liver necrosis were elevated, suggesting that
APAP-induced ROS formation results in loss of cell function and ultimately apoptosis. However,
quercitrin could inhibit ROS formation and consequently reduce hepatic cell death as well as liver
necrosis caused by APAP toxicity. Quercitrin also remarkably abolished plasma ALT and AST levels,
which coincided with the decrease of APAP-mediated oxidative damage. Furthermore, the levels of
antioxidant enzymes including CAT, GPx, and SOD-2 were restored by pretreatment of quercitrin in
APAP-treated HepG2 cells and livers of mice. These results indicate that quercitrin protects cells/livers
from APAP-induced oxidative stress through the suppression of ROS production and enhancement of
an antioxidant defense system.
Recent studies have demonstrated that transcription factor Nrf2 importantly contributes to cellular
defense mechanisms from APAP toxicity [36,37]. Treatment of Nrf2 knockout mice (Nrf2-/-) with
APAP results in enhanced hepatotoxicity and mortality compared to wild-type [36]. NAC treatment
100
Nutrients 2016, 8, 431
produced a low efficacy in Nrf2-/- mice, although NAC still exhibited the effective protection against
APAP toxicity in wild-type mice [37,38]. Additionally, hepatocyte-specific Kelch-like ECH-associated
protein-1 (keap1) gene knockout mice that highly express detoxifying enzymes are significantly more
resistant to APAP toxicity than wild-type animals [39]. Consequently, up-regulation of phase II
antioxidant/detoxifying enzymes by Nrf2/ARE pathway plays a critical role in preventing hepatic
damage caused by APAP. To clarify the underlying hepatoprotective mechanism of quercitrin, we
investigated the inductive effect of quercitrin on the Nrf2/ARE pathway. The results suggested that
protein level of Nrf2 was enhanced by the pre-treatment of quercitrin in both in vitro and in vivo
models. Quercitrin also significantly increased the ARE-reporter gene activity in HepG2-C8 cells.
Furthermore, quercitrin restored the APAP-induced reduction of phase II enzyme NQO1, which are
capable of scavenging oxidative stress and detoxifying/eliminating toxic chemicals. NQO1 has been
demonstrated to be capable of lowering NAPQI availability by the conversion of NAPQI back to the
parent APAP, prevent adenosine triphosphate (ATP) depletion as well as mitochondrial dysfunction
caused by APAP [40,41]. Our findings strongly indicate that quercitrin enhances the hepatic defense
system through the activation of Nrf2/ARE-mediated phase II detoxifying/ antioxidant enzymes.
Uncontrolled inflammation initiates the progression of tissue damage and results in the
development of many diseases such as Alzheimer’s disease, cardiovascular disease, atherosclerosis and
cancer [42,43]. During the inflammatory response, pro-inflammatory mediators and cytokines such
as iNOS, COX-2, IL-1β, and TNF-α were up-regulated and accumulated in the liver [44]. Numerous
evidence has showed that APAP causes early damage, which triggers an inflammatory response with
the production of pro-inflammatory factors and innate immune cell infiltration in the liver [45–48].
Thus, inhibition of these mediators and cytokines production is an important mechanism for treatment
of inflammation, contributing to preventing APAP-induced hepatotoxicity. In the current study, we
confirmed that APAP intoxication resulted in increased expression levels of iNOS, COX-2 as well as
IL-1β in the liver. However, mice pre-administered quercitrin exhibited the inhibitory effect on protein
expressions of iNOS, COX-2, and IL-1β. These results, for the first time, imply that the hepatoprotective
effect of quercitrin may be due to its anti-inflammatory property.
MAP kinases including ERK, JNK, and p38 MAPK play a crucial role in transduction
extracellular signals to cellular responses including cellular proliferation, differentiation, development,
inflammation and apoptosis in response to various signals produced by growth factors, hormones,
cytokines, and xenobiotics as well as oxidative stress [49,50]. A massive study demonstrated that MAP
kinases directly implicate in the mechanism of APAP-caused hepatocellular injury. During APAP
overdose, JNK is phosphorylated and translocates into mitochondria early in APAP hepatotoxicity
in mice, resulting in an initial oxidative stress, induction of mitochorial permeability transition,
and inhibition of bioenergetics [35,51]. Additionally, activated JNK can trigger Bax activation,
which is responsible for the initial apoptosis-inducing factor (AIF) and endonuclease G release from
the mitochondria and early DNA damage, as well as induce iNOS expression, which promotes
peroxynitrite formation [52,53]. Furthermore, inhibition of JNK activation or jnk gene knockout in
mice decreased the liver injury, nuclear DNA fragmentation, and prevented the development of
mitochondrial oxidative stress after APAP overdose [51,52,54]. Different from JNK inhibitor, the
inhibitors of ERK and p38 MAPK exhibited no protection against APAP toxicity either in vitro or
in vivo [52]. Although activations of ERK and p38 MAPK were observed, the roles of ERK and
p38 MAPK in APAP-caused heptotoxic mechanism have not been clearly investigated. Overall, the
inhibition of JNK phosphorylation contributes to reduction of liver injury induced by APAP challenge.
In the present study, we also investigated the inhibition of JNK phosphorylation and concluded it
could play a part in the hepatoprotective mechanism of quercitrin against APAP-mediated damage.
5. Conclusions
In conclusion, quercitrin protects against APAP-induced liver injury by enhancing the cellular
defense system and lowering inflammatory response. Activation of Nrf2/ARE pathway-mediated
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cytoprotective proteins by quercitrin may contribute to neutralizing ROS, eliminating toxicants and
finally preventing cell death and liver necrosis. Quercitrin also exhibits anti-inflammatory properties
through the inhibition of pro-inflammatory mediators including iNOS and COX-2 as well as a cytokine
IL-1β in APAP-caused inflammation. Furthermore, the suppression of JNK phosphorylation by
quercitrin was identified as a protective mechanism against apoptosis. Our study revealed that
quercitrin may have safe therapeutic potential in protecting cell/liver from APAP toxicity.
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Abstract: Cinnamomum verum, also called true cinnamon tree, is employed to make the seasoning
cinnamon. Furthermore, the plant has been used as a traditional Chinese herbal medication.
We explored the anticancer effect of cuminaldehyde, an ingredient of the cortex of the plant, as
well as the molecular biomarkers associated with carcinogenesis in human colorectal adenocarcinoma
COLO 205 cells. The results show that cuminaldehyde suppressed growth and induced apoptosis,
as proved by depletion of the mitochondrial membrane potential, activation of both caspase-3
and -9, and morphological features of apoptosis. Moreover, cuminaldehyde also led to lysosomal
vacuolation with an upregulated volume of acidic compartment and cytotoxicity, together with
inhibitions of both topoisomerase I and II activities. Additional study shows that the anticancer
activity of cuminaldehyde was observed in the model of nude mice. Our results suggest that the
anticancer activity of cuminaldehyde in vitro involved the suppression of cell proliferative markers,
topoisomerase I as well as II, together with increase of pro-apoptotic molecules, associated with
upregulated lysosomal vacuolation. On the other hand, in vivo, cuminaldehyde diminished the
tumor burden that would have a significant clinical impact. Furthermore, similar effects were
observed in other tested cell lines. In short, our data suggest that cuminaldehyde could be a drug for
chemopreventive or anticancer therapy.
Keywords: cuminaldehyde; antiproliferative; topoisomerase I; topoisomerase II; lysosomal
vacuolation; xenograft
1. Introduction
Colorectal cancer is one of the most common malignancies [1]. Nevertheless, it is not sensitive to
conventional chemotherapeutic drugs and there is a need for better management of the disease.
Over the past three decades, various approaches have been used for prevention and treatment of
cancer, such as traditional Chinese medicine (TMC). The therapeutic usage described in classic books
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of Chinese materia medica are still informative even the present-day; for example, Artemisia annua.
Artemisinin, an ingredient of the plant, was discovered by Tu Youyou, a Chinese scientist, who
was awarded half of the 2015 Nobel Prize in Medicine for her discovery of its effect against
Plasmodium falciparum malaria.
Moreover, contemporary epidemiological and experimental studies have unremittingly suggested
a correlation between regularly eating vegetables and fruits and avoidance of lifestyle disorders,
including tumors and heart disorders [2,3]. Phytochemicals, e.g., flavonoids and polyphenols of which
plants are rich sources, appear to possess desirable characters required for avoiding malignancy
and may have great possibility as antiproliferative drugs [4–9]. Indeed, the common seasoning
cinnamon is manufactured from the true cinnamon tree. In addition, the plant has been applied
for the treatment of dyspepsia, circulatory disorders, and inflammation, such as gastroenteritis [2,3].
Cuminaldehyde, an ingredient of true cinnamon tree’s bark, may be the compound that has this effect.
Cuminaldehyde exists in the true cinnamon tree in a high concentration, and it is also found in the shoot
of Artemisia salsoloides, leaf of Aegle marmelos, and essential oil from cumin [10]. The chemical is stable,
soluble in ethanol, and available commercially. Until now, very little research on cuminaldehyde
has been published. Therefore, the current study intended to explore the anticancer activity of
cuminaldehyde and clarify its mechanisms in human colorectal adenocarcinoma COLO 205 cells.
Malignancy is a hyperproliferative disease. Various genetic and epigenetic aberrations are needed
to convert normal cells into transformed ones. These abnormalities regulate different pathways which
collaborate to enable malignant cells endowed with an extensive capabilities needed for proliferating,
metastating, and killing their host [11]. Although antiproliferative drugs are possibly able to act
through various mechanisms, apoptosis has been shown to be the most common and preferred
mechanism through which many anticancer agents kill and eradicate cancer cells [12].
Apoptosis-inducing antiproliferative agents may act by targeting mitochondria. The drugs may
alter mitochondria through various mechanisms. They may cause the development of pores on
membranes, leading to swelling of mitochondria, or increase membrane permeability, resulting in the
discharge of pro-apoptotic cytochrome from the organelle into the cytosolic compartment. Cytochrome
c interacts with protease activating factor-1 together with deoxyadenosine triphosphate, which then
interacts with pro-caspase-9 resulting in the formation of apoptosome. Then the inactive pro-caspase-9
is activated by the formed apoptosome into active caspase-9. Next, the active form caspase-9 acuates
caspase-3, resulting in a proteolytic cascade [13–15].
Topoisomerases, enzymes controlling the DNA’s topological status, are involved in conserving
the integrity of the genome [16]. They relax intertwined DNA by transitory protein-linked breaks
of only one (topoisomerase I) or two (topoisomerase II) strands of the double-stranded DNA [17].
Topoisomerase I plays a role in DNA processing by engaging systems of tracking and being involved
in conserving the integrity of the genome [16]. Upregulated enzyme’s catalytic activity, protein, and
mRNA have been demonstrated across human cancers [18]. Indeed, topoisomerase I is involved in the
chromosomal instability of colorectal cancer (CRC) and the expression levels of the enzyme has been
suggested as prognostic markers [19–21] in CRC. Topoisomerase II is upregulated during cell growth
and peaks at G2/M. Topoisomerase II gene copy number is also elevated in CRC and considered as a
potential predictive biomarker for anticancer treatment [20]. In addition to cell cycle regulation, the
enzyme has been demonstrated to be another main target of antiproliferative agents [22–25]. What
is more, apoptotic cell death was shown to be the ultimate effective pathway of death in cancer
subsequent to suppression of topoisomerase [26].
This diversification of machineries of carcinogenesis implies that there could be various processes
that are crucially objective for avoidance of cancer. In an effort to investigate the activities and latent
machineries of cuminaldehyde in human colorectal adenocarcinoma COLO 205 cell, we performed a
series of tests to study the effects of cuminaldehyde on growth as well as activities of topoisomerase
I and II in human colorectal COLO 205 cells. Our results prove that cuminaldehyde suppressed the
activities of both topoisomerase I and II and increased lysosomal vacuolation with upregulated volume
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of acidic compartment together with cytotoxicity. Lastly, cuminaldehyde induced apoptosis, resulting
in the suppression of cell proliferation, in vitro as well as in vivo.
2. Materials and Methods
2.1. Materials
We purchased RPMI-1640 and fetal bovine serum (FBS) from GIBCO BRL (Gaithersburg, MD,
USA), together with dimethyl sulfoxide and cuminaldehyde from Sigma-Aldrich, Inc. (St. Louis,
MO, USA).
2.2. Cell Culture
Human colorectal adenocarcinoma COLO 205 cells (American Type Culture Collection CCL-222,
American Type Culture Collection, Manassas, VA, USA) were purchased via BCRC (Bioresource
Collection and Research Center, Hsinchu, Taiwan) on 27 July 2010 and stored in liquid nitrogen until
usage. The cells were incubated in the medium of RPMI-1640, complemented with penicillin 10
U/mL, amphotericin B 0.25 μg/mL, streptomycin 10 μg/mL, and FBS 10% (v/v) at 37 ˝C with 5%
carbon dioxide.
2.3. Cell Viability XTT Test
We incubated the cells in the culture plate with 96 wells at the concentration of ten thousand cells
per well. After being incubated for 24 h, we treated the cells with cuminaldehyde at the concentration
of 10, 20, 40, 80, or 160 μM for 12, 24, or 48 h. We determined cell viability using the Cell Proliferation
Kit II (XTT) (Roche Applied Science, Mannheim, Germany) according to the supplier’s instructions.
The value of absorbance was evaluated by a spectrophotometer (Tecan infinite M200, Tecan, Männedorf,
Switzerland) using 492 nm wavelength with a reference of 650 nm wavelength.
2.4. Lactate Dehydrogenase Cytotoxicity Test
We incubated the cells in the culture plate with 96 wells at the concentration of ten thousand
cells per well. After being incubated for 24 h, cells were incubated with various cuminaldehyde’s
concentrations for 48 h. Lactate dehydrogenase’s activity was evaluated by LDH-Cytotoxicity Kit
(BioVision, Milpitas, CA, USA) according to the supplier’s instructions. The samples’ absorbance at
490 nm wavelength was evaluated by a spectrophotometer (Tecan infinite M200, Tecan, Männedorf,
Switzerland). Data are presented as the percent of activity’s variation relative to untreated control.
2.5. Test for Nuclear Fragmentation
Nuclear fragmentation test using acridine orange was performed to investigate the possible
mechanism of suppressive effect of cuminaldehyde on growth in human colorectal COLO 205 cells.
We cultured the cells with various cuminaldehyde concentrations for 48 h and stained the cells with
acridine orange (5 μg per mL) at 25 ˝C. The cells were then examined by the Nikon ECLIPSE Ti
fluorescence microscope [27].
2.6. Comet Test
Comet test is an electrophoretic assay and has been employed to study the injury of DNA in
eukaryotic cells individually. The assay is comparatively easy to achieve, versatile, and sensitive.
The sensitivity’ limit is approximately 50 strand breakages per diploid cell. This test was achieved
following Olive’s alkaline protocol (with 41,6-diamidino-2-phenylindole staining) [28]. The cells were
then observed using the Nikon ECLIPSE Ti fluorescence microscope with C-FL Epi-Fl Filter Cube
and analyzed with automated analytical software (Comet Assay 2.0, Perceptive Instruments, Bury St.
Edmunds, UK) following the manufacturer’s instructions.
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2.7. Test for Volume of Acidic Compartments
Increase of the volume of acidic compartment is a general phenomenon of the cells subjected to
necrotic or apoptotic death of the cell. Moreover, upregulated volume of the acidic compartment may
be an implication of cells that are about to die [29]. To investigate the activities of cuminaldehyde in
the cell, the volume of acidic compartment test for lysosomes was achieved as reported formerly [27]
with modification. Briefly, human colorectal COLO 205 cells were seeded in 6 cm dishes at the
density of 6000/cm2 (instead of 6250/cm2) 24 h before cuminaldehyde was added. After incubation
with cuminaldehyde for another 48 h (instead of 24 h), the cells were washed twice with PBS
(phosphate-buffered saline) and incubated for 4 min with 4 mL staining solution. The rest of the
experiment was performed similarly. The optical density (OD) at 540 nm of samples was determined by
a spectrophotometer (Tecan infinite M200, Tecan, Männedorf, Switzerland). All tests were performed
in triplicate.
2.8. Mitochondrial Membrane Potential Test
Mitochondrial dysfunction plays a crucial role in the initiation of apoptotic cell death.
Actually, the opening of the transition pore creates depolarization of the mitochondrial membrane
potential and releasing of apoptogenic factors [30]. To investigate the mitochondria’s role of
in cuminaldehyde-caused apoptotic cell death, we observed the variations in mitochondrial
membrane potential.
The potential of mitochondrial membrane was determined by the reagent JC-1, a
mitochondrial-specific fluorescent compound (Invitrogen, Carlsbad, CA, USA.) according to the
protocol described previously [31]. The JC-1 reagent is monomer and the mitochondrial membrane
potential is less than 120 millivolt. Under such a condition, the dye emits green fluorescence
(wavelength of 540 nm) after excitement by blue light (wavelength of 490 nm). In addition, the
dye becomes dimmer (J-aggregate) at a mitochondrial membrane potential of more than 180 millivolt
and emits red fluorescence (590 nm) after excitation by green light (540 nm). Human colorectal
COLO 205 cells were treated with various cuminaldehyde concentrations for 48 h, harvested, and
then stained with JC-1 at the concentration of 25 μM at 37 ˝C for 30 min. Finally, the samples were
examined using a spectrophotometer and a fluorescence microscope. Changes in the percentage of
red (wavelength of 590-nm)/green (wavelength of 540-nm) fluorescence represent the variations of
membrane potential [32].
2.9. Caspase Activity Test
Proteins of mitochondrial called SMACs (second mitochondria-derived activator of caspases) are
discharged into the cytosolic compartment after the increased membranes’ permeability. Then, SMAC
interacts with the inhibitor of apoptosis proteins (IAPs), thereby making IAPs inactive, which then
abolishes IAPs from inhibiting caspases [33,34] that demolish the cell subsequently.
To farther explore the details in cuminaldehyde-caused apoptotic cell death, the variations in
activities of the crucial caspases implicated in apoptotic cell death were determined. The assay is
established on the evaluation of the AFC chromophore following division from DEVD- and LEHD-AFC
through caspase-3 and -9, respectively. The released AFC emits a yellow-green fluorescence. Human
colorectal COLO 205 cells were treated with various concentrations of cuminaldehyde for 48 h and
activities of the caspases were measured by Fluorometric Assay Kit (BioVision, Milpitas, CA, USA)
according to the supplier’s instructions. The light emission was determined by a spectrophotometer
(Tecan infinite M200, Tecan, Männedorf, Switzerland). Data are presented as the percent of activity’s
variation relative to control.
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2.10. Test for Topoisomerase I and II Activities
Topoisomerase I and II extracts from the cells were prepared according to the methods of TopoGEN
(Port Orange, FL, USA). Briefly, cells from two 100 mm dishes were pelleted at 800ˆ g for 3 min at 4 ˝C,
resuspended in 3 ml of ice cold TEMP buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 4 mM MgCl2,
0.5 mM PMSF). The sample was then pelleted as described above, resuspended in 3 mL of TEMP
and kept on ice for 10 min. The sample was then homogenized using tight fitting homogenizer with
eight strokes. Nuclei were pelleted by centrifugation at 1500ˆ g for 10 min at 4 ˝C, resuspended in
1 mL of cold TEMP, transferred to a microfuge tube, and pelleted in Microfuge at 1500ˆ g at 4 ˝C for
2 min, sequentially. The nuclear pellet was resuspended in a small volume (no more than 4 pellet
volumes) of TEP (same as TEMP but lacking MgCl2). An equal volume of 1 M NaCl was added. The
sample was then vortexed, kept on ice for 60 min, and centrifuged at 100,000ˆ g for 1 h at 4 ˝C. Tests
for topoisomerase I as well as II activities were performed according to the methods described by
Har-Vardi et al. [35].
2.11. In Vivo Tumor Xenograft Study
The study has been approved by the Institutional Animal Care and Use Committee (IACUC) of
China Medical University that conforms to the provisions of the Declaration of Helsinki (the animal
ethical approval number: 97-108-N). Nude mice (male, 6 weeks old, BALB/c Nude) were from the
National Science Council Animal Center (Taipei City, Taiwan, Republic of China). The animals were
raised under pathogen-free conditions under China Medical University’s regulations and ethical
guidelines for the use and care of laboratory animals. Human colorectal COLO 205 cells (5 ˆ 106 cells
in 200 μL of culture medium) were subcutaneously injected into the mice’s flanks. Treatment was
started when the tumors reached about 75 mm3. Thirty-two mice were divided randomly into four
groups (eight mice/group). Cuminaldehyde-treated mice received intratumoral injection of 5, 10, or
20 mg/kg/day of cuminaldehyde in a 200 μL volume (the solutions were prepared from stock solution
of cuminaldehyde in dimethyl sulfoxide and diluted into appropriate concentrations in PBS) daily.
The mice in the control group were treated with an equal volume of vehicle. After transplantation,
body weight as well as tumor size were monitored at weekly intervals. Tumor size was measured
using calipers, and tumor volume was calculated using the hemiellipsoid model formula (1):
tumor volume “ 1/2p4π/3q ˆ pl/2q ˆ pw/2q ˆ h (1)
where l = length, w = width, and h = height.
Specimens (tumor masses) at the end of the experiment (42 days after the treatment) were
investigated by terminal deoxynucleotidyl transferase dUTP nick end labeling test using the
Quick Apoptotic DNA Ladder Detection Kit (Chemicon, Temecuba, CA, USA) according to the
supplier’s instructions.
2.12. Statistical Analysis
Results are presented by means plus/minus standard error. The statistical significance was
determined by ANOVA (one-way analysis of variance), followed by the Bonferroni t-test for multiple
comparisons. A p value lower than 0.05 was regarded as statistically significant.
3. Results
3.1. Cuminaldehyde’s Effects on Cell Morphological Changes
When human colorectal COLO 205 cells were incubated with 20 μM of cuminaldehyde for 48 h,
blebbing of the plasma membrane was found. In addition, cell shrinkage and cell detachment also
occurred (Figure 1C).
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Figure 1. Cuminaldehyde’s chemical structure and effects on cellular morphology, proliferation, as
well as lactate dehydrogenase releasing in human colorectal COLO 205 cells. (A) Chemical structure;
(B) and (C) Cuminaldehyde’s effect on cellular morphology; Cells were treated without (B) and
with 20 μM (C) cuminaldehyde for 48 h. Cell detachment, shrinkage, and blebbing of plasma
membrane (arrows) were found when the cells were incubated with 20 μM of cuminaldehyde;
(D) Cuminaldehyde’s effect on growth. Human colorectal COLO 205 cells were treated with
cuminaldehyde at the specified circumstances. Proliferation suppressive effect was determined using
the XTT test; (E) Cuminaldehyde’s effect on the lactate dehydrogenase releasing in the cells. The
supernatant was gathered after 48 h of incubation with the indicated cuminaldehyde concentrations.
Absorptions of light were determined by a spectrophotometer (Tecan infinite M200, Tecan, Männedorf,
Switzerland). Results are shown by means plus/minus standard error of the mean, n equal to 3.
*, Statistically significant (p less than 0.05) from the control group. CuA, cuminaldehyde.
3.2. Cuminaldehyde Inhibited Human Colorectal COLO 205 Cell Proliferation
Different methods have been used for quantifying cell growth; for instance, DNA synthesis as well
as metabolic activity. Although radioactive labelling of synthesized DNA is the most accurate assay for
DNA quantification, the disadvantages of this assay are the hazards and hassle of using radioactivity.
An alternative method quantifying growth is the metabolic activity. The assay is established on the
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cleavage of a salt (the tetrazolium, e.g., XTT and MTT) into formazan by cell’s dehydrogenases which
then modifies culture medium’s color. This assay is easier, faster, and does not require the use of
radioactive materials.
We investigated cuminaldehyde’s potential cell proliferation inhibitory activity in human
colorectal COLO 205 cells by the XTT test. As demonstrated in Figure 1D, cuminaldehyde inhibited cell
proliferation in a dose- as well as time-dependent manner. The IC50 value following 48 h of treatment
was 16.31 μM.
3.3. Cuminaldehyde Caused Cytotoxicity in Human Colorectal COLO 205 Cells
The first morphological evidence of apoptotic phenomenon is retraction of the cell, loss of
adherence, followed by convolution of cytoplasm and membrane of the plasma, together with blebbing.
Finally, the cell disintegrated into small particles called apoptotic bodies, leading to the release of the
cell’s content into the bathing medium [36]. One way of studying loss of integrity of the membrane is
determining the releasing of enzyme lactate dehydrogenase into the supernatant medium [37]. The
assay was initially employed to test cellular death developed through necrosis [38]. Then, the assay
was shown to accurately quantify apoptosis [39–41].
Cuminaldehyde was cytotoxic, as proved by the elevation of lactate dehydrogenase activity in the
bathing medium (Figure 1E).
3.4. Cuminaldehyde Caused Nuclear Fragmentation in Human Colorectal COLO 205 Cells
Apoptosis is the most frequent and preferred mechanism through which various anticancer drugs
kill cancer cells [12]. Moreover, apoptosis also has been shown to be the major machinery of the
death of cancer caused by several polyphenols [42–45]. In the nucleus, apoptosis is characterized by
endonuclease activation, resulting in cleavage of nucleic acid into fragments.
Acridine orange is a dye with nucleic acid-selective metachromatic characteristic and valuable for
quantifying apoptosis, determinations of cell cycle, proton-pump activity, and pH gradients [46]. When
acridine orange inserts into double-stranded DNA, it fluoresces green. In addition, when interacting
with RNA or single-stranded DNA, acridine orange fluoresces orange. Apoptotic cells which contain
a high fraction of the nucleic acid in the denaturated status exhibit an orange fluorescence along
with a diminished green one relative to interphase non-apoptotic cells. In addition, when acridine
orange are in an acidic environment (e.g., cellular lysosomes), the dye becomes protonated as well as
sequestered. Under such an acidic environment, when excited by the blue light, the dye fluoresces
orange [47]. The test of nuclear fragmentation is established on acridine orange’s characters and
examined microscopically.
When human colorectal COLO 205 cells were treated with cuminaldehyde at the concentration
of 20 μM for 48 h, the result of staining using acridine orange demonstrated that COLO cells
demised partially through apoptosis, along with fragmentation and nuclear condensation. In addition,
orange-stained lysosomal vacuoles were observed. On the other hand, no significant chromosomal
fragmentation was found in the control group (Figure 2A).
DNA strand breakage was also explored using the comet test after treatment with various
cuminaldehyde concentrations. As demonstrated in Figure 2C,D, treatment with cuminaldehyde led
to increased tail intensity as well as moment.
Given that nuclear condensation, fragmentation, blebbing of the plasma membrane and the
formation of apoptotic body are apoptosis’s morphologic characteristics [48], the morphological
changes observed in the study prove that treatment with cuminaldehyde did lead to apoptosis in
human colorectal COLO 205 cells (Figures 1C and 2B).
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Figure 2. Cuminaldehyde caused nuclear fragmentation in human colorectal COLO 205 cells.
(A and B) Acridine orange staining; COLO 205 cells were incubated without (A) with 20 μM
(B) cuminaldehyde, respectively, for 48 h, then stained using acridine orange. The orange vacuoles
in COLO cells demonstrate that they existed acidic; (A) Typical picture of control cells accompanying
intact nucleus with green fluorescence that implicates a good cell viability; (B) Typical picture of test
cells incubated with cuminaldehyde with lysosomal vacuolation (arrows) and nuclear fragmentation
(arrow heads) were found; (C and D) Comet test. Cuminaldehyde’s effect on intensities of tail (C) as
well as moment (D). Human colorectal COLO 205 cells were incubated with cuminaldehyde at the
indicated concentrations for 48 h. Data are shown as means plus/minus standard error of the mean,
n = 125. *, Significant difference (p < 0.05) from the control. CuA, cuminaldehyde.
3.5. Cuminaldehyde Increased Volume of Acidic Compartment in Human Colorectal COLO 205 Cells
Neutral Red has been used to stain lysosomes and quantify the volume of acidic compartment
in cells [27,49,50]. As demonstrated in Figure 3A,B, positive neutral red staining suggests that
incubation with cuminaldehyde resulted in acidic vacuoles in human colorectal COLO 205 cells.
Moreover, Figure 3C shows that the treatment increased the volume of the acidic compartment in a
quantity-dependent manner in the cells.
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Figure 3. Cuminaldehyde increased the volume of the acidic compartment in human colorectal COLO
205 cells. After treatment without and with 20 μM cuminaldehyde, respectively, for 48 h, human
colorectal COLO 205 cells were stained using neutral red. (A) Human colorectal COLO 205 cells
without treatment: There were no observable vacuoles in the cell; (B) Human colorectal COLO 205
cells treated with cuminaldehyde at the concentration of 20 μM for 48 h. The blebbing (black arrows)
and acidic red-stained vacuoles (red arrows) in cells happened; (C) Cuminaldehyde increased volume
of acidic compartment in a quantity-dependent manner. After treating the cells using the specified
concentrations of cuminaldehyde for 48 h, results were evaluated by a spectrophotometer. Results are
shown by means plus/minus standard error of the mean, n equal to 3. *, Statistically significant (p less
than 0.05) from the control group. CuA, cuminaldehyde.
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3.6. Cuminaldehyde Caused Apoptosis via the Mitochondrial Pathway in Human Colorectal COLO 205 Cells
We then investigated the mitochondria’s role of in the cuminaldehyde-caused apoptosis in
human colorectal COLO 205 cells. Initial apoptotic cell death frequently involves mitochondrial
depolarization, followed by releasing of mitochondrial apoptogenic molecules into cytosol. Therefore,
we explored mitochondrial dysfunction by determining mitochondrial membrane potential in
cuminaldehyde-treated human colorectal COLO 205 cells using the mitochondria-specific dye JC-1
with a spectrophotometer. Figure 4A shows that cuminaldehyde caused the loss of mitochondrial
membrane potential, as suggested by downregulation of mitochondrial membrane potential in a
quantity-dependent manner.
Figure 4. Cuminaldehyde caused apoptosis via the mitochondrial pathway in human colorectal
COLO 205 cells. (A) Cells were treated with the specified cuminaldehyde concentrations for 48 h and
mitochondrial membrane potential was evaluated using JC-1 spectrophotometrically; (B) Activations of
caspase-3 as well as -9. After treating the cells using the specified concentrations of cuminaldehyde for
48 h, activities of caspases-3 and -9 were determined using a spectrophotometer. Results are expressed
by means plus/minus standard error of the mean, n equal to 3. *, Statistically significant (p less than
0.05) from the control group. CuA, cuminaldehyde.
Caspases are cysteine proteases that play critical roles in apoptosis. Figure 4B shows that the
activities of caspase-3 and -9 elevated in a quantity-dependent manner in cuminaldehyde-treated
human colorectal COLO 205 cells.
3.7. Cuminaldehyde Suppressed Topoisomerase I Activity in Human Colorectal COLO 205 Cells
The effect of cuminaldehyde on activity of topoisomerase I in human colorectal COLO 205 cells
was performed with increasing cuminaldehyde concentration (Figure 5A, lane 3–5) or camptothecin
(a known specific suppressor of type I topoisomerase and used as a positive control, lane 6) [51].
Figure 5A shows the transformation of the intertwined plasmid pUC 19 into the unrestrained form
declined in a quantity-dependent manner under the existence of cuminaldehyde or camptothecin
(please correlate lane 3–6 to lane 2). These data suggest that cuminaldehyde suppressed the DNA
loosening activity topoisomerase I the human colorectal COLO 205 cell nuclear proteins.
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Figure 5. Cuminaldehyde inhibited topoisomerase I as well as II activities in human colorectal COLO
205 cells. (A) Cuminaldehyde inhibited topoisomerase I activity. Nuclear proteins of COLO 205 cells
interacted with the indicated cuminaldehyde concentrations in a topoisomerase I’s specific reaction
mixture (lanes 3–5), or 60 μM of camptothecin (CPT, a specific topoisomerase I inhibitor and used
as positive control, lane 6), or the vehicle (1% dimethyl sulfoxide, lane 2). Lane 1, pUC19 DNA
only; (B) Cuminaldehyde inhibited topoisomerase II activity. DNA relaxation test (upper panel)
and decatenation test (lower panel). Nuclear proteins of COLO 205 cells were added to a specific
topoisomerase II reaction mixture with the specified cuminaldehyde concentrations (lanes 3–5) or
60 μM of camptothecin (a specific suppressor of topoisomerase II and used as positive control, lane 6),
or the vehicle (one percent dimethyl sulfoxide, lane 2). Lane 1, Interwined pUC19 DNA (upper panel)
or kinetoplast DNA (lower panel) only. kinetoplast DNA is an extensive chain of plasmids. When
kinetoplast DNA is examined using electrophoretic analysis, it gets the gel only a lightly (figure not
demonstrated). Consequent to topoisomerase II’s decatenation, small monomeric circles of nucleic acid
were produced (lower panel, lane 2–6). This is the representative of six experiments. CPT, camptothecin;
CuA, cuminaldehyde; kDNA, kinetoplast; S & R, Interwined and the unrestrained forms of the pUC
19 plasmid, respectively; VP-16, etoposide.
3.8. Cuminaldehyde Suppressed Activity of Topoisomerase II in Human Colorectal COLO 205 Cells
The effect of cuminaldehyde on topoisomerase II activity in human colorectal COLO 205 cells
was investigated using increasing concentration of cuminaldehyde (Figure 5B, lane 3–5) or etoposide
(a known inhibitor of topoisomerase II and used as a positive control, lane 6) [52]. Figure 5B, upper
panel, shows transformation of the interwined plasmid pUC 19 into the unrestrained form declined in
a quantity-dependent manner under the existence of cuminaldehyde or etoposide (please correlate
lane 3–6 to lane 2). The data suggest that cuminaldehyde suppressed DNA relaxation activity of
topoisomerase II in the human colorectal COLO 205 cell nuclear proteins. In addition, this effect was
further evaluated using the decatenation test. The decatenation effect involves the releasing of mini
circular DNA (monomers) from the kinetoplast, an extensive chain of plasmids. Nuclear proteins
in human colorectal COLO 205 cells enclosed type II topoisomerase that transformed kinetoplast to
monomeric DNA (Figure 5B, lower panel, please correlate lane 2 to lane 1). The transformation of
kinetoplast into monomeric DNA declined in a quantity-dependent manner under the existence of
cuminaldehyde (please correlate lane 3–5 to lane 2) or etoposide (please correlate lane 6 to lane 2). The
data suggest cuminaldehyde suppressed the topoisomerase II’s decatenation activity in the human
colorectal COLO 205 cell nuclear proteins.
3.9. Cuminaldehyde Suppressed Growth of Human Colorectal COLO 205 Xenograft in a Nude Mice Model
To investigate if cuminaldehyde suppresses proliferation of the human colorectal COLO 205
xenograft, 5 ˆ 106 human colorectal COLO 205 cells in 200 μL of culture medium were used for
subcutaneous injection. Figure 6A, left panel, shows that, in comparison with tumors of control mice
(orange arrows), obvious tumor burden reduction was found in the tumors of the mice injected with
20 mg/kg/day of cuminaldehyde (blue arrows). Tumor growth inhibition was found in all groups
with cuminaldehyde injection (5, 10, and 20 mg/kg/day of cuminaldehyde, respectively). On the other
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hand, significant growth inhibition was observed only in mice injected with 10 and 20 mg/kg/day of
cuminaldehyde, where about 48.9% and 69.4%, respectively, decreases in tumor volume were found
(Figure 6B,C). None of the cuminaldehyde injections resulted in any significant decrease in body
weight and/or diet consumption relative to the control group. The mechanism of cuminaldehyde’s
antiproliferative effect in vivo was explored. We gathered the human colorectal COLO 205 xenograft
from vehicle and cuminaldehyde-treated mice, then investigated the cause of the death by the terminal
deoxynucleotidyl transferase dUTP nick end labeling assay. Figure 6A, right panel, demonstrates
that, in comparison with tumors of control mice (white arrows), elevated terminal deoxynucleotidyl
transferase dUTP nick end labeling-positive cells that suggest apoptotic death were found in the
cancers of the cuminaldehyde-injected mice (yellow arrows).
Figure 6. Cuminaldehyde suppressed growth and caused apoptosis in human colorectal COLO 205
xenograft. The mice with pre-established cancers (n = 8 per group) were treated using intratumoral
injection with the specified cuminaldehyde concentrations. Tumor volumes were recorded by calipers
and apoptosis was evaluated by terminal deoxynucleotidyl transferase dUTP nick end labeling
test. (A) Left panel, Representative of tumor-bearing mice from the control (orange arrows) and
20 mg/kg/day of cuminaldehyde-injected (blue arrows) groups; (A) Right panel, cuminaldehyde
caused apoptosis in human colorectal COLO 205 xenograft using terminal deoxynucleotidyl transferase
dUTP nick end labeling test. Representative of terminal deoxynucleotidyl transferase dUTP nick end
labeling test of tumors from the control (white arrows) and 20 mg/kg/day of cuminaldehyde-injected
(yellow arrows) groups; (B) Mean of tumor volume observed at the specified number of days after
the start of treatment; (C) Cuminaldehyde’s effects on tumor weight observed at the endpoint of the
experiment. Tumor weight per mouse was collected and analyzed. Results are shown by means
plus/minus standard error of the mean, n = 8. *, Statistically significant (p less than 0.05) from the
control group. CuA, cuminaldehyde.
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4. Discussion
In addition to providing taste and flavor to foods, certain spices have been used as remedies
in traditional medicine [53]. True cinnamon tree is used to manufacture the seasoning cinnamon
and has been used for more than 5000 years by both of the two most ancient forms of medicine
in the words: Ayurveda and traditional Chinese herbal medicines for various applications such as
adenopathy, rheumatism, dermatosis, dyspepsia, stroke, tumors, elephantiasis, trichomonas, yeast,
and virus infections [54]. Cuminaldehyde, an ingredient of the cortex of the plant, possesses various
activities, including: (i) suppressions of melanin formation (through inhibiting the oxidation of
L-3,4-dihydroxyphenylalanine catalyzed by tyrosinase) [55], lipoxygenase [56], aldose reductase,
α-glucosidase [57], alpha-synuclein fibrillation (possibly by the interaction with amine groups through
cuminaldehyde’s aldehyde group as a Schiff base reaction) [58]; and (ii) insulinotropic and β-cell
protective action (through the closure of the ATP-sensitive K channel and the increase in intracellular
Ca2+ concentration) [59].
Although cuminaldehyde exists in true cinnamon tree in a high concentration (100 PPM), it is also
found in the shoot of Artemisia salsoloides (1000 PPM), leaf of Aegle marmelos (300 PPM), and essential
oil from cumin [10]. Essential oil from cumin with the major constituents of cuminaldehyde, cymene,
and terpenoids has been reported to possess: (i) antibacterial, antifungal, and insecticidal [60] activities;
(ii) antioxidant capacity; (iii) anticancer activity [61,62] with glutathione-S-transferase activating,
β-glucuronidase and mucinase inhibiting properties [60].
In this research, we initially explored the effects of cuminaldehyde on the proliferation of human
colorectal COLO 205 cells. We observed that cuminaldehyde suppressed the growth of human
colorectal COLO 205 cells in a concentration- as well as time-dependent manner (Figure 1D). Although
cells may die through necrotic or other mechanisms, apoptosis is the preferred and most common
mechanism through which different anticancer drugs kill as well as remove cancer cells [12]. Moreover,
apoptosis was demonstrated to be the main machinery of tumor cell demise caused by several
polyphenols [42–45].
Our data demonstrate that cuminaldehyde caused apoptotic cell death, as suggested by loss of
mitochondrial membrane potential, increase of caspase-3 and -9 (Figure 4), along with morphological
features of apoptosis, including apoptotic body formation, fragmentation, and nuclear condensation
as demonstrated in different stainings as well as comet assay (Figures 1–3).
Our data also suggest that cuminaldehyde generated vacuolation associated increased volume of
the acidic compartment. Increase of volume of the acidic compartment has been demonstrated to be
an ordinary event observed in cells that are subjected to apoptotic or necrotic cell demise and could be
an indication of failing cells [29]. Because apoptotic cell death is an ordered process, an upregulated
volume of acidic compartment could cause the self-digestion in the course of cell death [29].
In addition to cell cycle control, topoisomerase has been demonstrated to be another main target
of anticancer drugs [22–25]. The chemotherapeutic agent etoposide kills tumor cells by stabilizing
the transient intermediate division complex. The resulting accumulation of division complexes may
lead to the development of permanent DNA strand divisions that fragment the chromosome leading
to the stimulation of death pathways [63]. Furthermore, apoptosis has been demonstrated to be the
most efficient death-pathway in cancer cells subsequent to the suppression of topoisomerase II [26].
Clinically, topoisomerase has been suggested as a potential predictive biomarker in CRC [20,64].
Topoisomerase I seems to be involved in the chromosomal instability pathway of sporadic CRC [21]
and high frequency of gene gain of the topoisomerase I and II genes in CRC [20,65]. CRC patients with
low topoisomerase I expression were statistically favorably associated with overall survival [19].
Our findings prove that cuminaldehyde inhibited activities of topoisomerase I and II in a
quantity-dependent manner (Figure 5), which, in part, could be a machinery causing the cells to
move toward apoptosis. Although most of inhibitors of topoisomerase are specifically targeting either
type I or II topoisomerase [66], our results clearly show that cuminaldehyde inhibited activities of
topoisomerase I along with II in human colorectal COLO 205 cells.
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Our results clearly demonstrated that cuminaldehyde possesses antiproliferative activity in
human colorectal COLO 205 cells. Furthermore, cuminaldehyde thiosemicarbazone has been shown to
possess antiproliferative with anti-topoisomerase II activity in U937 cells [67]. However, some other
tumor cell lines did not show the same negative effect of the plant extracts containing cuminaldehyde
on cell proliferation [58]. Possible explanation for these contradictory phenomena could be the extracts
also possess antioxidant [61] and/or other activities. Therefore, further research is needed to clarify
the specific latent mechanisms of the suppression, possible mutagenic effects, as well as other side
effects for clinical usage of cuminaldehyde as an anticancer and/or chemopreventive drug against
human colorectal adenocarcinoma and/or other malignancies.
Treatment-associated cytotoxicity and other side effects of antiproliferative drugs are the main
concerns of anticancer therapy. Consequently, the perfect anticancer agent would discriminatorily
destroy malignant cells but not the healthy ones. Our results show that none of the therapy with
cuminaldehyde caused any observable decline in body weight or consumption of diet relative to
the control mice. Our data present persuasive evidence of the protecting activity of cuminaldehyde
against human colorectal COLO 205 xenograft growth in the current study using nude mice model
without any detectable side effect; this implies that cuminaldehyde has an antiproliferative effect
in human colorectal COLO 205 cells and this agent may potentially serve as an anticancer and/or
chemopreventive drug.
5. Conclusions
Collectively, our data clearly suggest that the antiproliferative effect of cuminaldehyde in human
colorectal COLO 205 cells in vitro involved inhibition of cell growth markers, topoisomerase I and II,
together with upregulation of proapoptotic molecules, associated with increased lysosomal vacuolation.
In vivo, cuminaldehyde diminished the tumor burden and may have significant clinical impact.
The present study provides fundamental knowledge on the cancer inhibitory activity of
cuminaldehyde in human colorectal COLO 205 cells that implicates a model for the exploration
of possible antiproliferative drugs against human colorectal adenocarcinoma. Indeed, similar effects
were observed in other tested cell lines, including human hepatocellular carcinoma SK-Hep-1 and Hep
3B, lung squamous cell carcinoma NCI-H520 and adenocarcinoma A549, and T-lymphoblastic MOLT-3.
Our results present a rationalization for further developing cuminaldehyde as an effective and safe
anticancer and/or chemopreventive drug. A future direction would be to synthesize the derivatives of
cuminaldehyde and examine the protective effects of cuminaldehyde and their derivatives in vitro. We
would then extend the study to examine the effects of these agents in a mouse model and use these
systems for new drug design and discovery based on parental compound cuminaldehyde as a lead for
safer and potent chemopreventive and/or anticancer usage.
Acknowledgments: We thank Alice Y. Yu for her excellent technical assistance. This work was supported by
grants from St. Mary’s Hospital Luodong (grant # SMHRF104001) and China Medical University Beigang Hospital
(grant # CMUBH R103-002 and CMUBH R103-006).
Author Contributions: Jaw-Ming Cherng and Kuen-daw Tsai conceived and designed the study; Jonathan Cherng,
Yi-Heng Liu, and Ta-Wei Chen performed the experiment; Shu-mei Yang and Ho-Yiu Wong analyzed the data
and evaluated the literature. All authors have contributed to the interpretation of results and the writing of
the manuscript.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Tanzer, M.; Liebl, M.; Quante, M. Molecular biomarkers in esophageal, gastric, and colorectal
adenocarcinoma. Pharmacol. Ther. 2013, 140, 133–147. [CrossRef] [PubMed]
2. Tanaka, S.; Yoon, Y.H.; Fukui, H.; Tabata, M.; Akira, T.; Okano, K.; Iwai, M.; Iga, Y.; Yokoyama, K.
Antiulcerogenic compounds isolated from chinese cinnamon. Planta Medica 1989, 55, 245–248. [CrossRef]
[PubMed]
119
Nutrients 2016, 8, 318
3. Reddy, A.M.; Seo, J.H.; Ryu, S.Y.; Kim, Y.S.; Kim, Y.S.; Min, K.R.; Kim, Y. Cinnamaldehyde and
2-methoxycinnamaldehyde as NF-κB inhibitors from Cinnamomum cassia. Planta Medica 2004, 70, 823–827.
[CrossRef] [PubMed]
4. Shukla, S.; Meeran, S.M.; Katiyar, S.K. Epigenetic regulation by selected dietary phytochemicals in cancer
chemoprevention. Cancer Lett. 2014, 355, 9–17. [CrossRef] [PubMed]
5. Priyadarsini, R.V.; Nagini, S. Cancer chemoprevention by dietary phytochemicals: Promises and pitfalls.
Curr. Pharm. Biotechnol. 2012, 13, 125–136. [CrossRef] [PubMed]
6. Surh, Y.J. Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer 2003, 3, 768–780. [CrossRef]
[PubMed]
7. Yang, C.S.; Landau, J.M.; Huang, M.T.; Newmark, H.L. Inhibition of carcinogenesis by dietary polyphenolic
compounds. Annu. Rev. Nutr. 2001, 21, 381–406. [CrossRef] [PubMed]
8. Watson, W.H.; Cai, J.; Jones, D.P. Diet and apoptosis. Annu. Rev. Nutr. 2000, 20, 485–505. [CrossRef]
[PubMed]
9. Middleton, E., Jr.; Kandaswami, C.; Theoharides, T.C. The effects of plant flavonoids on mammalian cells:
Implications for inflammation, heart disease, and cancer. Pharmacol. Rev. 2000, 52, 673–751. [PubMed]
10. Duke, J.A. Dr. Duke’s Phytochemical and Ethnobotanical Databases. Available online: https://phytochem.
nal.usda.gov/phytochem/chemicals/show/6429?et=C (accessed on 21 May 2016).
11. Artandi, S.E.; DePinho, R.A. Telomeres and telomerase in cancer. Carcinogenesis 2010, 31, 9–18. [CrossRef]
[PubMed]
12. Aleo, E.; Henderson, C.J.; Fontanini, A.; Solazzo, B.; Brancolini, C. Identification of new compounds
that trigger apoptosome-independent caspase activation and apoptosis. Cancer Res. 2006, 66, 9235–9244.
[CrossRef] [PubMed]
13. Pop, C.; Timmer, J.; Sperandio, S.; Salvesen, G.S. The apoptosome activates caspase-9 by dimerization.
Mol. Cell 2006, 22, 269–275. [CrossRef] [PubMed]
14. Zou, H.; Henzel, W.J.; Liu, X.; Lutschg, A.; Wang, X. Apaf-1, a human protein homologous to C. elegans
CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 1997, 90, 405–413. [CrossRef]
15. Li, P.; Nijhawan, D.; Budihardjo, I.; Srinivasula, S.M.; Ahmad, M.; Alnemri, E.S.; Wang, X. Cytochrome c and
dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997,
91, 479–489. [CrossRef]
16. McClendon, A.K.; Osheroff, N. DNA topoisomerase II, genotoxicity, and cancer. Mutat. Res. 2007, 623, 83–97.
[CrossRef] [PubMed]
17. Heck, M.M.; Earnshaw, W.C. Topoisomerase II: A specific marker for cell proliferation. J. Cell Biol. 1986, 103,
2569–2581. [CrossRef] [PubMed]
18. Husain, I.; Mohler, J.L.; Seigler, H.F.; Besterman, J.M. Elevation of topoisomerase I messenger RNA, protein,
and catalytic activity in human tumors: Demonstration of tumor-type specificity and implications for cancer
chemotherapy. Cancer Res. 1994, 54, 539–546. [PubMed]
19. Negri, F.V.; Azzoni, C.; Bottarelli, L.; Campanini, N.; Mandolesi, A.; Wotherspoon, A.; Cunningham, D.;
Scartozzi, M.; Cascinu, S.; Tinelli, C.; et al. Thymidylate synthase, topoisomerase-1 and microsatellite
instability: Relationship with outcome in mucinous colorectal cancer treated with fluorouracil. Anticancer Res.
2013, 33, 4611–4617. [PubMed]
20. Sonderstrup, I.M.; Nygard, S.B.; Poulsen, T.S.; Linnemann, D.; Stenvang, J.; Nielsen, H.J.; Bartek, J.;
Brunner, N.; Norgaard, P.; Riis, L. Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch
repair-proficient colorectal cancers. Mol. Oncol. 2015, 9, 1207–1217. [CrossRef] [PubMed]
21. Azzoni, C.; Bottarelli, L.; Cecchini, S.; Ziccarelli, A.; Campanini, N.; Bordi, C.; Sarli, L.; Silini, E.M. Role
of topoisomerase I and thymidylate synthase expression in sporadic colorectal cancer: Associations with
clinicopathological and molecular features. Pathol. Res. Pract. 2014, 210, 111–117. [CrossRef] [PubMed]
22. Naowaratwattana, W.; De-Eknamkul, W.; De Mejia, E.G. Phenolic-containing organic extracts of mulberry
(Morus alba L.) leaves inhibit HepG2 hepatoma cells through G2/M phase arrest, induction of apoptosis, and
inhibition of topoisomerase IIα activity. J. Med. Food 2010, 13, 1045–1056. [CrossRef] [PubMed]
23. Baikar, S.; Malpathak, N. Secondary metabolites as DNA topoisomerase inhibitors: A new era towards
designing of anticancer drugs. Pharmacogn. Rev. 2010, 4, 12–26. [PubMed]
120
Nutrients 2016, 8, 318
24. Bandele, O.J.; Clawson, S.J.; Osheroff, N. Dietary polyphenols as topoisomerase II poisons: B ring and C ring
substituents determine the mechanism of enzyme-mediated DNA cleavage enhancement. Chem. Res. Toxicol.
2008, 21, 1253–1260. [CrossRef] [PubMed]
25. Sudan, S.; Rupasinghe, H.P. Flavonoid-enriched apple fraction AF4 induces cell cycle arrest, DNA
topoisomerase II inhibition, and apoptosis in human liver cancer HepG2 cells. Nutr. Cancer 2014, 66,
1237–1246. [CrossRef] [PubMed]
26. El-Awady, R.A.; Ali, M.M.; Saleh, E.M.; Ghaleb, F.M. Apoptosis is the most efficient death-pathway in tumor
cells after topoisomerase II inhibition. Saudi Med. J. 2008, 29, 558–564. [PubMed]
27. Fan, C.; Wang, W.; Zhao, B.; Zhang, S.; Miao, J. Chloroquine inhibits cell growth and induces cell death in
A549 lung cancer cells. Bioorg. Med. Chem. 2006, 14, 3218–3222. [CrossRef] [PubMed]
28. Olive, P.L.; Banath, J.P. The comet assay: A method to measure DNA damage in individual cells. Nat. Protoc.
2006, 1, 23–29. [CrossRef] [PubMed]
29. Ono, K.; Wang, X.; Han, J. Resistance to tumor necrosis factor-induced cell death mediated by PMCA4
deficiency. Mol. Cell Biol. 2001, 21, 8276–8288. [CrossRef] [PubMed]
30. Ly, J.D.; Grubb, D.R.; Lawen, A. The mitochondrial membrane potential (Δψm) in apoptosis; an update.
Apoptosis 2003, 8, 115–128. [CrossRef] [PubMed]
31. Reers, M.; Smiley, S.T.; Mottola-Hartshorn, C.; Chen, A.; Lin, M.; Chen, L.B. Mitochondrial membrane
potential monitored by JC-1 dye. Methods Enzymol. 1995, 260, 406–417. [PubMed]
32. Martin, E.J.; Forkert, P.G. Evidence that 1,1-dichloroethylene induces apoptotic cell death in murine liver.
J. Pharmacol. Exp. Ther. 2004, 310, 33–42. [CrossRef] [PubMed]
33. Fesik, S.W.; Shi, Y. Controlling the caspases. Science 2001, 294, 1477–1478. [CrossRef] [PubMed]
34. Deveraux, Q.L.; Reed, J.C. Iap family proteins—Suppressors of apoptosis. Genes Dev. 1999, 13, 239–252.
[CrossRef] [PubMed]
35. Har-Vardi, I.; Mali, R.; Breietman, M.; Sonin, Y.; Albotiano, S.; Levitas, E.; Potashnik, G.; Priel, E. DNA
topoisomerases I and II in human mature sperm cells: Characterization and unique properties. Hum. Reprod.
2007, 22, 2183–2189. [CrossRef] [PubMed]
36. Andrade, R.; Crisol, L.; Prado, R.; Boyano, M.D.; Arluzea, J.; Arechaga, J. Plasma membrane and nuclear
envelope integrity during the blebbing stage of apoptosis: A time-lapse study. Biol. Cell 2010, 102, 25–35.
[CrossRef] [PubMed]
37. Lobner, D. Comparison of the LDH and MTT assays for quantifying cell death: Validity for neuronal
apoptosis? J. Neurosci. Methods 2000, 96, 147–152. [CrossRef]
38. Koh, J.Y.; Choi, D.W. Quantitative determination of glutamate mediated cortical neuronal injury in cell
culture by lactate dehydrogenase efflux assay. J. Neurosci. Methods 1987, 20, 83–90. [CrossRef]
39. Gwag, B.J.; Lobner, D.; Koh, J.Y.; Wie, M.B.; Choi, D.W. Blockade of glutamate receptors unmasks neuronal
apoptosis after oxygen-glucose deprivation in vitro. Neuroscience 1995, 68, 615–619. [CrossRef]
40. Koh, J.Y.; Gwag, B.J.; Lobner, D.; Choi, D.W. Potentiated necrosis of cultured cortical neurons by
neurotrophins. Science 1995, 268, 573–575. [CrossRef] [PubMed]
41. Li, J.; Zhang, J. Inhibition of apoptosis by ginsenoside RG1 in cultured cortical neurons. Chin. Med. J. (Engl.)
1997, 110, 535–539. [PubMed]
42. Miura, T.; Chiba, M.; Kasai, K.; Nozaka, H.; Nakamura, T.; Shoji, T.; Kanda, T.; Ohtake, Y.; Sato, T.
Apple procyanidins induce tumor cell apoptosis through mitochondrial pathway activation of caspase-3.
Carcinogenesis 2008, 29, 585–593. [CrossRef] [PubMed]
43. Liu, J.R.; Dong, H.W.; Chen, B.Q.; Zhao, P.; Liu, R.H. Fresh apples suppress mammary carcinogenesis
and proliferative activity and induce apoptosis in mammary tumors of the sprague-dawley rat. J. Agric.
Food Chem. 2009, 57, 297–304. [CrossRef] [PubMed]
44. Yoon, H.; Liu, R.H. Effect of selected phytochemicals and apple extracts on NF-κB activation in human breast
cancer MCF-7 cells. J. Agric. Food Chem. 2007, 55, 3167–3173. [CrossRef] [PubMed]
45. Zheng, C.Q.; Qiao, B.; Wang, M.; Tao, Q. Mechanisms of apple polyphenols-induced proliferation inhibiting
and apoptosis in a metastatic oral adenoid cystic carcinoma cell line. Kaohsiung J. Med. Sci. 2013, 29, 239–245.
[CrossRef] [PubMed]
46. White, K.; Grether, M.E.; Abrams, J.M.; Young, L.; Farrell, K.; Steller, H. Genetic control of programmed cell
death in drosophila. Science 1994, 264, 677–683. [CrossRef] [PubMed]
121
Nutrients 2016, 8, 318
47. Darzynkiewicz, Z. Differential staining of DNA and RNA in intact cells and isolated cell nuclei with acridine
orange. Methods Cell Biol. 1990, 33, 285–298. [PubMed]
48. Wyllie, A.H.; Kerr, J.F.; Currie, A.R. Cell death: The significance of apoptosis. Int. Rev. Cytol. 1980, 68,
251–306. [PubMed]
49. Cover, T.L.; Puryear, W.; Perez-Perez, G.I.; Blaser, M.J. Effect of urease on HeLa cell vacuolation induced by
Helicobacter pylori cytotoxin. Infect. Immun. 1991, 59, 1264–1270. [PubMed]
50. Patel, H.K.; Willhite, D.C.; Patel, R.M.; Ye, D.; Williams, C.L.; Torres, E.M.; Marty, K.B.; MacDonald, R.A.;
Blanke, S.R. Plasma membrane cholesterol modulates cellular vacuolation induced by the Helicobacter
pylori vacuolating cytotoxin. Infect. Immun. 2002, 70, 4112–4123. [CrossRef] [PubMed]
51. Pommier, Y. Diversity of DNA topoisomerases I and inhibitors. Biochimie 1998, 80, 255–270. [CrossRef]
52. Li, T.K.; Liu, L.F. Tumor cell death induced by topoisomerase-targeting drugs. Annu. Rev. Pharmacol. Toxicol.
2001, 41, 53–77. [CrossRef] [PubMed]
53. Srinivasan, K. Role of spices beyond food flavoring: Nutraceuticals with multiple health effects. Food Rev. Int.
2005, 21, 167–188. [CrossRef]
54. Duke, J.A.; Duke, P.-A.K.; duCellier, J.L. Duke’s Handbook of Medicinal Plants of the Bible; CRC Press: Boca Raton,
NY, USA, 2008.
55. Nitoda, T.; Fan, M.D.; Kubo, I. Effects of cuminaldehyde on melanoma cells. Phytother. Res. 2008, 22, 809–813.
[CrossRef] [PubMed]
56. Tomy, M.J.; Dileep, K.V.; Prasanth, S.; Preethidan, D.S.; Sabu, A.; Sadasivan, C.; Haridas, M. Cuminaldehyde
as a lipoxygenase inhibitor: In vitro and in silico validation. Appl. Biochem. Biotechnol. 2014, 174, 388–397.
[CrossRef] [PubMed]
57. Lee, H.S. Cuminaldehyde: Aldose reductase and α-glucosidase inhibitor derived from Cuminum cyminum L.
seeds. J. Agric. Food Chem. 2005, 53, 2446–2450. [CrossRef] [PubMed]
58. Morshedi, D.; Aliakbari, F.; Tayaranian-Marvian, A.; Fassihi, A.; Pan-Montojo, F.; Perez-Sanchez, H.
Cuminaldehyde as the major component of Cuminum cyminum, a natural aldehyde with inhibitory effect on
alpha-synuclein fibrillation and cytotoxicity. J. Food Sci. 2015, 80, 2336–2345. [CrossRef] [PubMed]
59. Patil, S.B.; Takalikar, S.S.; Joglekar, M.M.; Haldavnekar, V.S.; Arvindekar, A.U. Insulinotropic and β-cell
protective action of cuminaldehyde, cuminol and an inhibitor isolated from Cuminum cyminum in
streptozotocin-induced diabetic rats. Br. J. Nutr. 2013, 110, 1434–1443. [CrossRef] [PubMed]
60. Aruna, K.; Sivaramakrishnan, V.M. Anticarcinogenic effects of the essential oils from cumin, poppy and
basil. Phytother. Res. 1996, 10, 577–580. [CrossRef]
61. Allahghadri, T.; Rasooli, I.; Owlia, P.; Nadooshan, M.J.; Ghazanfari, T.; Taghizadeh, M.; Astaneh, S.D.
Antimicrobial property, antioxidant capacity, and cytotoxicity of essential oil from cumin produced in Iran.
J. Food Sci. 2010, 75, 54–61. [CrossRef] [PubMed]
62. Chen, Q.; Hu, X.; Li, J.; Liu, P.; Yang, Y.; Ni, Y. Preparative isolation and purification of cuminaldehyde
and p-menta-1,4-dien-7-al from the essential oil of Cuminum cyminum L. by high-speed counter-current
chromatography. Anal. Chim. Acta 2011, 689, 149–154. [CrossRef] [PubMed]
63. Baldwin, E.L.; Osheroff, N. Etoposide, topoisomerase II and cancer. Curr. Med. Chem. Anticancer Agents 2005,
5, 363–372. [CrossRef] [PubMed]
64. Gilbert, D.C.; Chalmers, A.J.; El-Khamisy, S.F. Topoisomerase I inhibition in colorectal cancer: Biomarkers
and therapeutic targets. Br. J. Cancer 2012, 106, 18–24. [CrossRef] [PubMed]
65. Smith, D.H.; Christensen, I.J.; Jensen, N.F.; Markussen, B.; Romer, M.U.; Nygard, S.B.; Muller, S.; Nielsen, H.J.;
Brunner, N.; Nielsen, K.V. Mechanisms of topoisomerase I (TOP1) gene copy number increase in a stage III
colorectal cancer patient cohort. PLoS ONE 2013, 8, e60613. [CrossRef] [PubMed]
66. Denny, W.A.; Baguley, B.C. Dual topoisomerase I/II inhibitors in cancer therapy. Curr. Top. Med. Chem. 2003,
3, 339–353. [CrossRef] [PubMed]
67. Bisceglie, F.; Pinelli, S.; Alinovi, R.; Goldoni, M.; Mutti, A.; Camerini, A.; Piola, L.; Tarasconi, P.; Pelosi, G.
Cinnamaldehyde and cuminaldehyde thiosemicarbazones and their copper(II) and nickel(II) complexes: A
study to understand their biological activity. J. Inorg. Biochem. 2014, 140, 111–125. [CrossRef] [PubMed]
© 2016 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Effect of Tea Polyphenol Compounds on Anticancer
Drugs in Terms of Anti-Tumor Activity, Toxicology,
and Pharmacokinetics
Jianhua Cao 1, Jie Han 2, Hao Xiao 1, Jinping Qiao 1,* and Mei Han 1,*
1 Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry,
Beijing Normal University, Beijing 100875, China; caojianhua0303@163.com (J.H.C.);
201521150080@mail.bnu.edu.cn (H.X.)
2 Analytical Center, Beijing Normal University, Beijing 100875, China; 13701290930@139.com
* Correspondence: qiao_jinping@bnu.edu.cn (J.Q.); hanmei@bnu.edu.cn (M.H.); Tel.: +86-10-6220-07786 (J.Q.)
Received: 1 August 2016; Accepted: 21 November 2016; Published: 14 December 2016
Abstract: Multidrug resistance and various adverse side effects have long been major problems in
cancer chemotherapy. Recently, chemotherapy has gradually transitioned from mono-substance
therapy to multidrug therapy. As a result, the drug cocktail strategy has gained more recognition
and wider use. It is believed that properly-formulated drug combinations have greater therapeutic
efficacy than single drugs. Tea is a popular beverage consumed by cancer patients and the general
public for its perceived health benefits. The major bioactive molecules in green tea are catechins,
a class of flavanols. The combination of green tea extract or green tea catechins and anticancer
compounds has been paid more attention in cancer treatment. Previous studies demonstrated that the
combination of chemotherapeutic drugs and green tea extract or tea polyphenols could synergistically
enhance treatment efficacy and reduce the adverse side effects of anticancer drugs in cancer patients.
In this review, we summarize the experimental evidence regarding the effects of green tea-derived
polyphenols in conjunction with chemotherapeutic drugs on anti-tumor activity, toxicology, and
pharmacokinetics. We believe that the combination of multidrug cancer treatment with green tea
catechins may improve treatment efficacy and diminish negative side effects.
Keywords: tea polyphenol; anticancer agent; synergistic anticancer activity; toxicology; pharmacokinetics
1. Introduction
Tea made from the plant species Camellia sinensis is the most widely consumed beverage other than
water. Tea is divided into three subtypes based on fermentation levels: green (unfermented), oolong
(partially fermented), and black (highly to fully fermented). Among the various types of tea, green tea is
believed to have better antioxidant and health benefits than black and oolong teas [1]. Previous studies
reported that green tea could lower the risk of cardiovascular disease, improve brain function, promote
fat loss, and combat cancer and type II diabetes, among many other health benefits [2–5]. Green tea
is also associated with many therapeutic effects, including anti-blood coagulation, the reduction of
hypertension, oxidative damage repair, HIV treatment, and cancer prevention and treatment [6–9].
Green tea contains substantial amounts of polyphenols, caffeine, theanine, polysaccharides,
and other compounds. Caffeine is a functional alkaloid in tea products. Medicinally it can be used
as a cardiac, cerebral, and respiratory stimulant, among other uses. Tea polyphenols are a class of
bioactive molecules in green tea, categorized as epistructured catechins or nonepistructured catechins.
Epistructured catechins include epicatechin (EC), epicatechin gallate (ECG), epigallocatechin (EGC),
and epigallocatechin gallate (EGCG). Nonepistructured catechins include catechin (C), catechin gallate
(CG), gallocatechin (GC), and gallocatechin gallate (GCG). EGCG is the most abundant polyphenol in
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green tea; a typical catechin profile in an extract from green tea leaf is comprised of 10%–15% EGCG,
6%–10% EGC, 2%–3% ECG, and 2% EC. Figure 1 shows the chemical structures of the main polyphenol
ingredients in green tea [1,10].
Figure 1. The chemical structures of the main polyphenols in green tea.
Nutritional supplements are commonly integrated into chemotherapeutic strategies for cancer
treatment. Combination chemotherapy is an approach to cancer treatment that utilizes multiple
medications. This approach can overcome the disadvantages of monotherapy and enhance therapeutic
effects in cancer treatment [11]. Due to their various health benefits, green tea polyphenols are
increasingly used for cancer prevention or as an adjuvant in chemotherapy. Previous studies
have demonstrated that combining chemotherapeutic drugs with green tea could reduce cancer
risk, improve survival rates among cancer patients, and decrease chemotherapy-associated side
effects [12–15].
In this paper, we mainly reviewed the experimental data regarding the effects of tea polyphenols
in conjunction with chemotherapeutic drugs on anti-tumor activity, toxicology, and pharmacokinetics.
We believe that the combination of green tea catechins and anticancer drugs may enhance cancer
treatment efficacy and diminish negative side effects.
2. Synergistic Anticancer Activity of Tea Polyphenols and Chemotherapeutic Agents
The combination of green tea catechins and anticancer drugs is a new treatment strategy that
has been widely accepted by cancer researchers [11]. Although anticancer drugs and tea polyphenols
are very different in terms of structure and function, tea polyphenols can synergistically enhance
the effects of anticancer drugs and make them 10–15 times more effective than monotherapy [11].
Some studies have also reported beneficial effects of EGCG or green tea extract with anticancer drugs,
such as bleomycin, cisplatin, tamoxifen, and bortezomib [16–19]. We have also studied the effect of
green tea extract on 5-fluorouracil (5-FU) in cancer cells and animals. Our results demonstrated that
green tea catechins with anticancer agents are more effective than monotherapy [15]. The effects of tea
polyphenols or tea extracts on the therapeutic efficacy of anticancer agents are listed in Table 1.
124
Nutrients 2016, 8, 762
2.1. Combination of Tea Polyphenols and Bleomycin
Bleomycin is frequently used in the treatment of various cancers [10]. However, the monotherapy
strategy has often failed to produce therapeutic benefit due to multidrug-resistant cancer. Green tea
polyphenols have been used as an adjuvant in bleomycin therapy. Alshatwi et al. [10] reported
a synergistic anticancer effect with a combination of tea polyphenols and bleomycin. Various
concentrations of tea polyphenols, bleomycin, or tea polyphenols combined with bleomycin were
added to cervical cancer cells (SiHa), and then the cell growth, intracellular reactive oxygen species,
poly-caspase activity, early apoptosis and expression of caspase-3, caspase-8, caspase-9, Bcl-2, and p53
were observed. This study showed that tea polyphenols combined with bleomycin synergistically
inhibited cervical cancer cell viability and proliferation through the induction of apoptosis. Other
studies have also suggested that tea polyphenols may increase antitumor activity of bleomycin [18].
2.2. Combination of Tea Polyphenols and Cisplatin
Cisplatin is often the first chemotherapeutic agent used to treat many forms of cancer.
Unfortunately, cisplatin resistance often develops during the course of treatment. Both preclinical
and clinical studies have shown that multiple mechanisms drive tumor resistance to cisplatin. The
synergistic effect of cisplatin and tea polyphenols has been studied in vitro and in vivo [20–22]. Tea
polyphenols combined with cisplatin can decrease proliferation and induce apoptosis in breast cancer
cells. Additionally, tea polyphenols plus cisplatin may minimize or slow the development of drug
resistance, which may also reduce drug toxicity and improve therapeutic efficacy [18]. The combination
of EGCG with cisplatin has increased beneficial effects on cell cycle arrest, modulation of ROS- and
apoptosis-related gene expression and potent antioxidant activity when compared with monotherapy.
EGCG may also reduce oxidative stress, inhibit proliferation, and sensitize ovarian cancer cells to
cisplatin. The combination of tea polyphenols and cisplatin can synergistically inhibit the growth of
various cancer cells, such as MCF-7 breast cancer cells and non-small cell lung cancer (NSCLC) A549
cells. Additionally, we found that, compared with cisplatin monotherapy, the combination of cisplatin
and EGCG can significantly decrease tumor size in animal models—the data will be reported in the
near future.
2.3. Combination of Tea Polyphenols and Ibuprofen
Ibuprofen is a non-selective nonsteroidal anti-inflammatory drug (NSAID) [23], which may inhibit
the growth of prostate cancer cells in both in vitro and in vivo xenograft models. The synergistic
effect of EGCG and ibuprofen (EGCG+ibuprofen) treatment on DU-145 prostate cancer cells has
been investigated. This study showed that EGCG + ibuprofen treatment resulted in greater growth
inhibition than ibuprofen or EGCG alone. EGCG + ibuprofen treatment acts synergistically to block
proliferation and promote apoptosis in DU-145 prostate cancer cells [23].
2.4. Combination of Tea Polyphenols and Tamoxifen
Tamoxifen is an anti-estrogenic compound used for the prevention of breast cancer. Green tea is
often used as a supplement in breast cancer treatment and prevention [4]. Co-administration of green
tea and tamoxifen improves experimental outcomes in breast cancer cell lines and animal models.
Green tea increased the inhibitory effect of tamoxifen on the proliferation of estrogen receptor-positive
MCF-7, ZR75, and T47D human breast cancer cells in vitro [24,25]. The combination of EGCG (75 and
100 μM) and tamoxifen (5–200 μM) significantly increased apoptosis in PC-9 cells compared to EGCG
or tamoxifen alone [26]. When MCF-7 xenograft-bearing mice were treated with both green tea and
tamoxifen, their tumor sizes were significantly diminished, and more cancer cell apoptosis occurred in
tumor tissue [27,28].
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2.5. Combination of Tea Polyphenols and Bortezomib
Bortezomib exerts its antitumor effects by reversibly blocking the 26S proteasome [29]. EGCG
interferes with bortezomib’s anticancer activity [30]. EGCG’s negative impact on bortezomib efficacy
was concentration-dependent in CWR22 xenograft-bearing breast cancer mice. Only very high levels
of EGCG antagonized bortezomib’s antitumor activity, while low levels of EGCG had no adverse
effects in CWR22 mice [31]. This example demonstrates the negative interaction of EGCG and an
anticancer drug.
2.6. Combination of Tea Polyphenols and Other Anticancer Drugs
Tea extract or tea polyphenols also synergistically enhance the anticancer activity of other
chemotherapy drugs, such as Paclitaxel, sulindac, celecoxib, curcumin, luteolin, docetaxel, retinoids,
and so on [32–35]. Our group has studied the effects of green tea extract and 5-fluorouracil
treatment in SW480, BIU-87, and BGC823 human cancer cell lines; a daily dose of green tea
(equivalent to <6 cups daily in humans) did not alter the cytotoxicity of 5-FU treatment in these
cells [15].
Table 1. The effects of green tea catechins on anticancer compounds in anti-tumor activity.
Anticancer Drugs Experiment Effects Reference
Bleomycin
SiHa cervical cancer cells or uterine cervical
cancer cells were treated with tea
polyphenol and bleomycin; poly-caspase
activity, early apoptosis, and the expression
of caspase-3, caspase-8, caspase-9, Bcl-2,






Some cancer cells—such as human SW480,
BIU-87, BGC823, and Hep3B—were treated
with green tea and 5-FU; the cytotoxicity,











Cancer cells YCU-N861, YCU-H891, Hep3B,
SW480, BIU-87, BGC823, et al. were
coadministered cisplatin with tea









DU-145 cells were treated with EGCG and
ibuprofen; cell death analysis,
immunoblotting, RT-PCR analysis, and








Cancer cells PC-9, MCF-7, and
MDA-MB-231were treated with tea
polyphenols and tamoxifen; some factors












PC-9 cancer cells were treated with
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Table 1. Cont.
Anticancer Drugs Experiment Effects Reference
Bortezomib
Cancer cells 26S and CWR22 were treated
with bortezomib and tea polyphenols; cell




A549 and MCF-7 cancer cells were treated
with celecoxib and tea polyphenols; the cell








Cancer cells H292, A549, H460, and Tu212










PC-3ML cancer cells were treated with










Cancer cells PC-9, A549, NCI-H460, and ER
alpha-breast cancer cells were treated with
curcumin and tea polyphenols; the cell









Cancer cells PC-3, LNCaP, and CWR22Rv1
were treated with quercetin and tea









PC-3ML cancer cells were treated with
paclitaxel and tea polyphenols; the cell










Cancer cells BEL-7404/DOX, PC-3ML,
IBC-10a, and PCa-20a were treated with
doxorubicin and tea; the cell proliferation









Cancer cells ALVA-41, PC-3, and MCF-7
were treated with resveratrol and green tea;







Cancer cells PC-3 AP-1, HT-29, SKOV-ip1,
SKOVTR-ip2 were treated with
sulforaphane and EGCG; the cell activity








EGFR (epidermal growth factor receptor); MMP-2, MMP-9 (a family of matrix metalloproteinases);
EMMPRIN (extracellular matrix metalloproteinase inducer); hTERT (human telomerase reverse transcriptase);
ER (estrogen receptor).
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2.7. Combination of Caffeine and Anticancer Drugs
Caffeine is another ingredient in tea. Caffeine can inhibit the activities of both ATM and ATR—two
important protein kinases involved in DNA damage-induced cell cycle arrest and apoptosis. It has been
reported that caffeine increased the cisplatin-induced apoptosis in both HTB182 and CRL5985 lung
cancer cells by inhibiting ATR and inducing ATM activation [45]. Caffeine could enhance the antitumor
effect of cisplatin; when the dosing period of caffeine was increased, the synergistic effect was increased
in osteosarcoma-bearing rats [46]. Significant inhibition of tumor growth and prolongation of survival
time were also found in sarcoma-bearing mice [47]. Caffeine significantly decreased mutagenicity
of the anticancer aromatic drugs daunomycin, doxorubicin, and mitoxantrone. Caffeine decreased
the anticancer drug vinblastine-induced chromosomal aberrations and mitotic index in bone marrow
cells [48].
3. Ameliorating Toxicity Induced by Chemotherapeutic Agents
Two major problems in cancer chemotherapy are adverse side effects and multidrug resistance.
Chemotherapy can cause fatigue, nausea, vomiting, and more serious side effects in cancer patients.
Previous studies found that anticancer drugs caused serious adverse effects via antioxidant defense
abnormalities against reactive oxygen species (ROS) [5,49]. Antioxidants may protect against
chemotherapy-induced toxicity. Due to their antioxidant and ROS-scavenging properties, green
tea polyphenols could circumvent the adverse effects of ROS and chemotherapy and enhance
treatment efficacy (Table 2). Additionally, P-glycoprotein (P-gp) plays an important role in multidrug
resistance [50]. EGCG was found to inhibit the transport activity of P-gp and may be an effective P-gp
modulator [51]. EGCG also increased chemotherapy drug accumulation in multidrug resistant cells.
Doxorubicin is a potent broad-spectrum chemotherapeutic agent. However, the clinical use of
doxorubicin has been seriously limited by its undesirable side effects, especially dose-dependent
myocardial injury, which can lead to lethal congestive heart failure [52]. Treatment with green
tea ameliorated the cardiotoxicity of doxorubicin. Doxorubicin-induced oxidative stress, heart
and liver morphological changes, and metabolic disorders were also mitigated by green tea
in male Wistar rats [53]. The mechanism underlying these effects is currently unknown, but
it may involve the modulation of enzymes required for lipid synthesis, such as HMG-CoA
(3-hydroxy-3-methylglutary-coenzyme A) reductase [54].
Table 2. A combination of green tea catechins and anticancer compounds ameliorating the toxicity
induced by chemotherapeutic agents.
Anticancer Drugs Experiment Effects Reference
Doxorubicin
Wistar albino rats with
cardiotoxicity induced by
doxorubicin were treated with green
tea. AST, CK, LDH, LPO,
cytochrome P450, blood glutathione,
tissue glutathione, and enzymatic
and non-enzymatic antioxidants
were evaluated along with
histopathological studies.








levels to the normal levels.
[52]
Doxorubicin (DOX)
Neonatal Rats with cardiotoxicity
induced by doxorubicin were
treated with EGCG; LDH, MnSOD,





stress by attenuating ROS
production and apoptosis,






Nutrients 2016, 8, 762
Table 2. Cont.
Anticancer Drugs Experiment Effects Reference
Doxorubicin
Rats were treated with doxorubicin
and different doses of EGCG.















AST (aspartate transaminase); CK (creatine kinase); LDH (lactate dehydrogenase); LPO (lipid peroxidation);
MnSOD (superoxide dismutase).
4. Pharmacokinetic Effect on Chemotherapeutic Agents
Based on food–drug interactions, green tea polyphenols may affect the expression or activities
of drug-metabolizing enzymes and drug transporters [55,56]. It is currently unknown whether green
tea consumption will alter the pharmacokinetics and bioavailability of a chemotherapeutic agent in
cancer patients. Alterations in the pharmacokinetic parameters may also alter the drug’s efficacy or
toxicity [57]. Therefore, anticancer drugs should contain warnings on the potential pharmacokinetic
interaction of drugs and EGCG.
In our previous study, we reported that green tea extracts increase the bioavailability of
5-FU in rats [15]. The maximum plasma concentrations (Cmax) and the area under the plasma
concentration-time curves (AUC) of 5-FU in rats increased significantly following administration
of green tea extract for 14 days. The half-life of 5-FU in plasma was also substantially prolonged [19].
Green tea may decrease the activity of dihydropyrimidine dehydrogenase (DPD)—the initial and
rate-limiting enzyme of 5-FU metabolism. Reduced DPD activity may result in decreased 5-FU
metabolism, leading to higher plasma concentrations.
Co-administration of EGCG and irinotecan (CPT-11) altered the pharmacokinetics of CPT-11 and
its metabolite, SN-38, in Sprague–Dawley rats [58]. When the animals were pretreated with EGCG,
the CPT-11 and SN-38 AUC in plasma were increased by 57.7% and 18.3%, respectively, while the AUC
in bile were decreased by 15.8% and 46.8%, respectively. Therefore, the plasma-to-bile distribution ratio
(AUCbile/AUCplasma) was significantly reduced, while the half-lives of CPT-11 and SN-38 in plasma
were substantially prolonged. EGCG may inhibit the transport of CPT-11 and SN-38 into the biliary
tract by modulating P-gp and reduce hepatobiliary excretion of CPT-11 and SN-38. The increased
plasma concentrations of CPT-11 and SN-38 may be associated with enhanced pharmacological effects
or toxicity.
Sunitinib is a novel oral antitumor agent. Plasma concentrations of sunitinib in rats significantly
decreased with co-administration of EGCG [59]. The related pharmacokinetic parameters of plasma
sunitinib (such as AUC0–∞ and Cmax) were markedly reduced by the co-administration of EGCG. In
the sunitinib with EGCG group, the mean Cmax decreased by 47.7% compared with the sunitinib
with water group, while AUC0–∞ significantly decreased by 51.5%. These results indicate that EGCG
markedly reduced the bioavailability of sunitinib. Therefore, it is necessary for patients receiving
sunitinib therapy to avoid consuming green tea or EGCG dietary supplements.
5. Human Trials
The aims of the clinical trials are to study the effectiveness of green tea extract in treating
cancer patients. A total of 100 clinical trials involving both green tea and cancer are listed in
clinicalTrials.gov [60]. Some results proved that green tea contains ingredients that may prevent
or slow the growth of certain cancers. For example, in the clinicalTrial NCT00685516 (a multicenter,
randomized, phase II trial), 113 men diagnosed with prostate cancer were randomized to consume six
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cups daily of brewed green tea, black tea, or water (control) prior to radical prostatectomy. The prostate
tumor markers of cancer development and progression were determined by tissue immunostaining of
proliferation (Ki67), apoptosis (Bcl-2, Bax, Tunel), inflammation (nuclear and cytoplasmic nuclear factor
kappa B (NFκB)) and oxidation (8-hydroxydeoxy-guanosine (8OHdG)). Blood and urine samples,
as well as tissue from diagnostic biopsy and radical prostatectomy specimens were evaluated by
high performance liquid chromatography and ELISA analysis; the concentrations of total and free tea
polyphenols (i.e., EGCG, EC, EGC, and ECG), theaflavins, and conjugated/colonic tea metabolites
were also detected [61]. The estimated study completion date is August 2017; some primary data
have been published [62]. The results showed that green tea can change NFκB and systemic oxidation,
and future longer-term studies are warranted to further examine the role of green tea for prostate
cancer prevention and treatment.
6. Conclusions
The benefits of combining tea polyphenols with anticancer compounds are now widely accepted
by cancer researchers. Previous studies have demonstrated that a combination of chemotherapeutic
drugs and green tea extract could enhance therapeutic effects and reduce the adverse side effects
of anticancer drugs most of the time. Several papers have also reported the potential for negative
interactions between tea polyphenols and anticancer drugs. In this article, we provided a brief
overview of the pharmacodynamics, toxicology, and pharmacokinetic interactions between green tea
and anticancer drugs. We believe that the combination of green tea and anticancer drugs may be
important in enhancing therapeutic efficacy while diminishing negative side effects.
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Abstract: Polyphenols are a very broad group of chemicals, widely distributed in plant foods, and
endowed with antioxidant activity by virtue of their numerous phenol groups. They are widely
studied as putative cancer-protective agents, potentially contributing to the cancer preventive
properties of fruits and vegetables. We review recent publications relating to human trials, animal
experiments and cell culture, grouping them according to whether polyphenols are investigated in
whole foods and drinks, in plant extracts, or as individual compounds. A variety of assays are in
use to study genetic damage endpoints. Human trials, of which there are rather few, tend to show
decreases in endogenous DNA damage and protection against DNA damage induced ex vivo in
blood cells. Most animal experiments have investigated the effects of polyphenols (often at high
doses) in combination with known DNA-damaging agents, and generally they show protection.
High concentrations can themselves induce DNA damage, as demonstrated in numerous cell culture
experiments; low concentrations, on the other hand, tend to decrease DNA damage.
Keywords: polyphenols; flavonoids; human studies; in vitro; in vivo; DNA damage; DNA protection
1. Introduction
For many years now it has been recognised that fruits and vegetables play an important role in
preventing or alleviating the effects of various chronic diseases, notably cardiovascular disease and
various cancers. The mechanism(s) of this protection is still not clear. A common explanation is the
so-called antioxidant hypothesis; oxidative stress is a factor in many diseases; fruits and vegetables
contain various phytochemicals with antioxidant properties, and so these are likely to be the agents of
protection. This is clearly a simplistic hypothesis; phytochemicals have been shown to have a wide
array of influences on the physiological processes of human cells, and reducing them to sources of
antioxidant activity is misguided and misleading. A meta-analysis of clinical trials indicates that
antioxidant phytochemicals taken as supplements have no beneficial effect on mortality and may
even increase it [1]. In natural plant foods, of course, phytochemicals of different kinds are present,
acting in concert, often in all likelihood synergistically, and so studies of whole foods or extracts are
particularly valuable. The reductionist approach (looking at individual components) is still popular,
however, as evidenced by the large number of studies of individual phytochemicals, and by the
growing catalogue of plant species that have been extracted and tested for potential health-promoting
effects using a range of molecular markers. DNA damage is one of the most commonly employed
such markers, in the reasonable belief that a decrease in DNA damage—as the initiating event of
carcinogenesis—must signify a decrease in cancer risk.
Currently, the most popular assay for DNA damage at the cellular level is single cell gel
electrophoresis, or the comet assay [2]. It is based on the ability of a strand break (SB) to relax
Nutrients 2016, 8, 785 134 www.mdpi.com/journal/nutrients
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supercoiling in a loop of DNA, thus allowing the DNA to extend to the anode during electrophoresis
forming a comet-like image in which the relative intensity of the comet tail reflects the break
frequency. Strand breakage is a feature of some but not all kinds of DNA-damaging agent.
Reactive oxygen species, in particular, tend to cause damage to DNA bases. An example of base
oxidation is 8-oxo–7,8-dihydroguanine (8-OH–Gua). This is converted to a SB by the action of
formamidopyrimidine DNA glycosylase (Fpg)—a bacterial repair enzyme, and a simple modification
of the comet assay, incorporating an enzymic digestion of the DNA after lysis of cells in agarose—allows
the detection of oxidised purines. An analogous enzyme, endonuclease III (or Nth) converts oxidised
pyrimidines to SBs. In the search for antioxidant protection of cells against such damage, it is surprising
that so few published studies actually use the enzyme-modified comet assay.
The measurement of resistance to H2O2-induced damage is a good marker of cellular antioxidant
status. Typically, cells are exposed in vitro to 50–100 μM H2O2 for a brief period, and the yield of SBs is
measured with the basic comet assay; the lower the break frequency, the higher the antioxidant status.
The base 8-OH–Gua and the nucleosides 8-OH–Guo and 8-OH–dGuo can be detected in tissues,
but are more commonly measured in urine, plasma or serum, using high performance liquid
chromatography (often linked with mass spectrometry) and antibody-based techniques (ELISA or
immunohistochemistry). In the tables and text that follow, we use the abbreviation 8-OH–G to cover all
three compounds, as the oxidised base is the common factor. They are markers of oxidative stress [3,4];
free 8-OH–Gua can arise through cellular DNA base excision repair, though the origin of the oxidised
nucleosides is not certain.
γ-H2AX is the phosphorylated form of histone H2AX, which appears at the site of DNA
damage (particularly double SBs); it is detected by immunocytochemistry [5], or sometimes by
immunofluorescence combined with flow cytometry [6], and is a sensitive damage indicator.
Unrepaired DNA damage can result in alterations at the level of chromosomes. Classically,
chromosome aberrations (chrom abs) were studied as an index of genomic instability, but now the
presence of micronuclei (MN: fragments of chromosomes or whole chromosomes that segregate
as discrete bodies at mitosis) is a more common marker [7]. Both chrom abs and MN have been
confirmed—in long-term human clinical studies—as prospective markers of cancer risk [8,9].
Here, we summarise the results of recent investigations of effects of polyphenols—a very broad
class of phytochemicals—on DNA damage, at the level of humans, in animal experiments, and in
in vitro studies using cultured (usually human) cells.
2. Methods
In this review, we have concentrated on papers published from 2010 to the present. We used
PubMed with the followings terms in the title or abstract: polyphenols/polyphenol/flavonoids/
flavonoid combined with DNA damage/DNA protection/DNA repair. We found a total of 386 papers.
We have concentrated on papers where the effect of polyphenols, in the form of real food, plant extract
or pure compound, is tested in cell culture, animals and humans. We have excluded papers where only
gene expression was studied, papers specifically focused on other diseases than cancer, and papers, for
example, with deficient experimental design. Papers in which the main interest is in the induction of
apoptosis were also excluded.
The reports are summarised in tables according to whether they deal with whole foods (or drinks)
(Table 1), with extracts of plants (Table 2), or with single phytochemicals (Table 3). Studies are
further classified as ‘in humans’, ‘in vivo’ (animal studies), or ‘in vitro’ (experiments with cultured
cells). Extracts and phytochemicals are, where possible, grouped according to functional, chemical
or botanical relationships (such as ‘tea and coffee related compounds’, or ‘flavonoids’, or ‘Lamiaceae’).
We have generally excluded in vitro experiments with plants or compounds appearing in just one or
two publications, unless they fall into one of these groups.
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3. Results
3.1. Whole Foods and Drinks
Relatively few investigations of effects of whole foods on genetic damage endpoints have been
published. A variety of fruit-derived drinks as well as tea (though this could be considered an extract),
and dark chocolate, were tested in human supplementation trials. A decrease in urinary 8-OH–G was
seen in overweight or obese adults supplemented with orange juice [10] but levels of plasma 8-OH–G
in triathletes were too low to see any effect of Aronia-citrus juice [11]. De-alcoholised wine given daily
for one month was without effect on DNA SBs or Fpg-sites in peripheral blood mononuclear (PBMN)
cells of post-menopausal women [13]. However, a daily blueberry drink taken for 6 weeks protected
PBMN cells from H2O2-induced damage, but had no effect on SBs or DNA repair capacity [14].
Malhomme de la Roche et al. [15] found that ingestion of green tea protected PBMN cells challenged
ex vivo with UV(A)/VIS (ultraviolet(A)/visible) radiation, but only in some subjects, described as
responders. Alleva et al. [16] gave a honey supplement to humans exposed to pesticides, and found,
after two weeks’ supplementation, lower levels of EndoIII- and Fpg-sensitive sites in lymphocytes as
well as an enhanced capacity for DNA repair. Dark chocolate induced a transient protection against
H2O2-induced DNA damage in PBMN cells ex vivo [12].
Most of the animal studies have looked at the possible protection afforded by polyphenol-rich
foods or drinks against DNA damage induced by treating the animals (rats or mice) with known
carcinogens such as doxorubicin (Dox), n-nitrosodiethylamine, or sodium arsenite. Protection was
claimed with Chrysobalanus icaco fruit [17], Piquia pulp [19], Açai pulp [20], and tea [18,22]; but cloudy
apple juice actually increased SBs and had no effect on nitrosamine-induced damage [21]. Treatment
of hyperlipidemic rats with spinach increased the resistance of blood cells ex vivo to H2O2-induced
damage [23].
Experiments with cultured cells and whole foods/drinks are understandably rarely performed.
Incubation of PBMN cells with green tea decreased DNA damage at low concentrations but increased it
at the highest concentration tested (representing 71 mM catechins) [24]. Various honeys afforded slight
protection of HepG2 cells against SBs produced by treatment with certain organic carcinogens [26].
A Chinese herbal preparation caused SBs in mouse lymphoma cells and rat fibroblasts, but at extreme
concentrations (1–13 mg/mL) [25].
3.2. Extracts of Plants
3.2.1. Tea-Related Extracts
One human trial and several animal experiments have been reported with tea-related extracts.
Post-menopausal women with osteoporosis were supplemented with green tea polyphenols for
6 months; the level of urinary 8-OH–G decreased [27]. Xu et al. [28] found a decrease in 8-OH–G in
rats given a very high dose of green tea polyphenols. Protective effects of green tea extracts against
genetic damage were reported by Garcia-Rodriguez et al. [30] in mice treated with Cr(IV); and by
Pu et al. [31] in rats treated with acrylonitrile. Katiyar et al. [29] found that green tea polyphenols
promoted the repair of UV-induced DNA lesions in mice proficient in nucleotide excision repair (NER),
but not in NER- mice. Two studies with cultured cells have found increases in DNA SBs induced
by green tea extract; Prasad et al. [35] in melanoma cell lines (though at rather high concentrations),
and Durgo et al. [36] in a human laryngeal carcinoma cell line.
3.2.2. Lamiaceae Family Plants
The Lamiaceae family includes many plants used as culinary herbs, and so they have been grouped
together here. All publications in our search deal with effects in cell culture.
Calo et al. [39] tested an extract of Thymus vulgaris (and thymol in parallel) on keratinocytes
irradiated with UV(A) or UV(B); they found a decrease in SBs, though no effect on MN or γ-H2AX
146
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foci. A similar protective effect was reported by Cornaghi et al. [38] in a human skin model exposed
to UV(B). A citrus and rosemary extract (but at high concentrations) decreased the frequency of MN
induced by X-rays in human lymphocytes, and decreased UV(B)-induced SBs in keratinocytes [37].
This last group also tested lemon balm extract on UV(B)-irradiated keratinocytes and found a
decrease in SBs (at a high concentration) and in γ-H2AX foci at a more moderate concentration [40].
Thirugnanasampandan et al. [42] studied three Lamiaceae species; HepG2 cells were incubated for 4 h
with an extract before treating with CdCl2. Dose-dependent decreases in SBs were seen with all three
(though even the lowest concentration tested was high). An extract of Ocimum sanctum (a form of basil)
was tested by Venuprasad et al. [41] on human neuroblastoma cells; it protected against H2O2-induced
SBs (at a high concentration).
3.2.3. Honey-Related Extracts
In parallel experiments to their human honey trial, Alleva et al. [16] showed that pre-treatment
of cells with honey extract protected against pesticide-induced DNA damage and inhibition of DNA
repair. Propolis extract (at high concentration) decreased the frequency of γ-ray-induced SBs in
fibroblasts [50], and yet—at a much lower concentration—it caused oxidative damage (SBs measured
with Fpg and EndoIII together in the comet assay) in a human cancer cell line, which was suppressed
by antioxidants or catalase and so was imputed to the production of H2O2 [51].
3.2.4. Fruits and Berries
All papers on extracts of fruits and berries reviewed here describe cell culture experiments and
with one exception they have made use of high to extremely high extract concentrations. The extract
of one Australian fruit (among several studied) caused an increase in MN [48]. Other reports are
of protection against oxidation damage caused by H2O2 [43,44,46]; or tert-butyl-hydroperoxide
(t-BOOH) [45,49]. The exception to usage of high doses is a report by Bellion et al. [47] with apple
polyphenol extracts; they found that 24 h pre-incubation of Caco2 cells decreased the DNA damage
induced by menadione (low concentrations actually giving the greatest protection).
3.2.5. Miscellaneous Plant Extracts
Animal experiments with various plant extracts have shown protection against SB production
in liver cells of pyrogallol-treated rats (at very high doses of extract) [34]; accelerated rejoining of
γ-ray-induced DNA SBs [33]; and a decrease in pyrimidine dimers in the skin of UV(B)-irradiated
mice [32].
4. Isolated Phytochemicals
4.1. Compounds Related to Tea and Coffee
Compounds tested—caffeic acid, chafuroside B, chlorogenic acid, ellagic acid, epicatechin,
epicatechin gallate, epigallocatechin gallate, theaflavin.
One human trial with epigallocatechin gallate in prostate cancer patients showed no significant
effect on 8-OH–G in leukocytes [52]. Animal studies with single polyphenols have generally involved
treating mice or rats with a known DNA-damaging agent and looking for protection against DNA
breaks, MN and chrom abs. Generally, protection is seen [54,57] though in some cases at rather
high doses [56,63]. Pretreatment of rats with epicatechin reduced the level of DNA breaks induced
in bone marrow cells by the topoisomerase poison etoposide [55]. High concentrations have also
been used in in vitro experiments with cultured cells, and have given increases in SBs and γ-H2AX
foci [71] and in γ-H2AX and 8-OH–G [58]. Kumar et al. [79] found that a combination of ellagic
acid with curcumin (25 μM each) caused SBs while the separate compounds had no significant effect.
A decrease in (background) SBs with epigallocatechin gallate or epicatechin gallate was reported by
Durgo et al. [36] at 48 but not 72 h. At more reasonable concentrations, the results are mixed: decreases
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in UV(B)-induced SBs [70] and cyclobutane pyrimidine dimers [72]; decreases in H2O2-induced SBs
and MN [74]; a decrease in SBs induced by cumene hydroperoxide [75]; but SBs and Fpg-sites increased
in tetradecanoyl phorbol acetate (TPA)-stimulated neutrophils [78] and an increase in SBs with ellagic
acid in prostate cancer cells was reported by Vanella et al. [73] at concentrations of 9 μM in one of the
cell lines but higher concentrations in two other lines.
4.2. Curcumin
Curcumin was examined alongside epicatechin by Papiez [55]; at high concentration (up to
0.2 g/kg/day), it decreased DNA damage in the bone marrow of rats treated with etoposide.
In cultured cells, curcumin at rather high concentrations caused SBs [85,86] and γ-H2AX foci [83].
The production of SBs in combination with ellagic acid was noted above [79]. Lewinska et al. [81]
reported a pro-oxidant effect of curcumin at concentrations of 10 μM (and below), indicated by an
increase in 8-oxo–G in smooth muscle cells. Sebastia et al. [80] compared effects of curcumin on human
lymphocytes, both stimulated by TPA and unstimulated, and γ-irradiated. In non-cycling cells, the
phytochemical was radioprotective (decreasing the level of premature chromosome condensation),
whereas in cycling cells it acted as a radiosensitiser, increasing the frequency of chrom abs.
4.3. Resveratrol
At high concentration, in human lymphocytes, resveratrol decreased the frequency of chromosome
aberrations caused by aflatoxin [87]. At a lower concentration, it protected human epithelial cells
against SBs and MN induced by sodium arsenite [88], and rat astrocytes against SBs caused by
ethanol [91]. However, a low dose enhanced the frequency of γ-H2AX foci after ionising irradiation
of prostate epithelial cells [90]. A moderately high concentration applied to colon cancer cells
caused γ-H2AX foci, apparently as a result of topoisomerase II poisoning [89]. SBs as well as
Fpg-sites were increased in non-cycling cells but decreased in TPA-stimulated, cycling cells [78].
In contrast, Sebastia et al. [80] found that, as with curcumin, effects of resveratrol on irradiated
lymphocytes differed depending on whether the cells were non-cycling (showing a decrease in
premature chromosome condensation), or cycling (in which it had the opposite effect, acting as
a radiosensitiser, increasing chromosome aberrations).
4.4. Flavonoids
Kozics et al. [97] performed a useful comparative study of 10 flavonoids, concluding that
their effectiveness at protecting against B(a)P-induced SBs and MN depended on their chemical
structure. Tested over a relatively low concentration range, fisetin, quercetin, galangin, kaempferol
and luteolin (in order of decreasing effectiveness) were more effective than chrysin,7-hydroxyflavone,
7,8-dihydroxyflavone or baicalein, while rutin was without effect.
Among the flavonoids, quercetin appears most often in this survey. At low concentrations, SBs
induced by aflatoxin B1 (AFB1), methyl methanesulphonate (MMS), Dox, HgCl2 or methyl mercury in
HepG2 cells were decreased [100,101]. At high concentrations, quercetin and also rutin (glycoside of
quercetin with rutinose) caused massive γ-H2AX foci, probably reflecting lethality [94], and yet they
decreased DNA damage (SBs) induced by food mutagens PhIP and IQ [96].
Quercitrin, the rhamnose glycoside of quercetin, protected mouse epidermal cells against
UV(B)-induced SBs [102]. Rutin at low concentrations showed the same protective effect as quercetin
on HepG2 cells treated with AFB1, MMS or Dox [100]; at much higher concentrations, it caused SBs,
but still protected against MN induced by B(a)P [93].
The myricetin rhamnoside, myricitrin, at high concentrations, induced MN in TK6 cells;
the aglycone myricetin, being more cytotoxic, was tested at lower concentrations, and gave equivocal
results [65]. Kaempferol at high concentrations induced SBs [95,99], as did fisetin [98]. Galangin and
chrysin caused base oxidation at the moderate concentration of 20 μM [51], while a low concentration
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of naringin was protective against cadmium-induced chromosome aberrations [92]. Apigenin at a high
concentration decreased SBs, chrom abs and MN [69].
5. Discussion and Conclusions
Many of the papers that we have reviewed report experiments with high or very high
concentrations of phytochemicals. When investigating the role of phytochemicals in normal human
nutrition, the aim should always be to study concentrations close to those likely to be present in
humans as a result of dietary intake. As a rule of thumb, we have assumed this concentration to
be in the low micromolar range. Many papers quote concentrations in μg/mL. To convert these
concentrations to micromolar, again as a rule of thumb, we have assumed a molecular weight of 500;
then 1 μg/mL = 2 μM. We would regard a concentration of over 20 μM or 10 μg/mL as high, and
over 50 μM or 25 μg/mL as very high. Clearly, in functional foods or phytochemical supplements, the
concentration is likely to be higher than in natural foods, and experiments showing genotoxicity of
phytochemicals at high doses should at least serve as a warning to designers of functional foods.
It is always instructive to carry out experiments over a range of concentrations. Often, in the
case of micronutrients in general, the dose–response curve is U-shaped, i.e., a beneficial effect at low
concentrations changes to a detrimental effect at higher concentrations, and this tendency is clear in
many of the reports described here.
Of course, if genotoxicity is specifically directed to cancer cells while healthy cells are unaffected,
it is regarded as beneficial, and it is evidently the aim of some of the papers that we have reviewed
to identify plant extracts or particular polyphenols that have such targeted action and so might have
potential value as therapeutic agents. The differential response of cycling vs non-cycling cells to certain
polyphenols might be exploited therapeutically in targeting dividing cancer cells.
With such a wide-ranging set of phytochemicals, not to mention the variety of test systems,
experimental designs and assays applied in their study, it is difficult to generalise. However, high
concentrations are likely to show DNA-damaging effects, while also in many cases protecting cells
against damaging effects of other agents, apparently acting as pro-oxidants when present alone,
but as anti-oxidants in combination. This is not a novel observation: many years ago, Duthie et al.
reported DNA-damaging effects of quercetin at 50 μM [103] alongside an ability to protect cells against
H2O2-induced DNA damage at concentrations of 10–50 μM [104]. Low concentrations are generally
protective, in some cases even decreasing the already low background level of cellular DNA damage.
To summarise, results reported in the recent literature, on the whole, lend support to the
hypothesis that dietary polyphenols protect the body against the effects of reactive oxygen species
on DNA integrity, but do so reliably only when present at low concentrations. We recommend that
greater attention be paid to the concentrations used, particularly in in vitro experiments, if the results
are to be extrapolated to issues of human health. An important consideration when extrapolating
is that plant foods contain a variety of micronutrients which might be expected to act in concert,
whereas most experiments are carried out with single compounds. In this respect, there are clear
advantages in using plant extracts or whole foods, though this approach does present practical
difficulties. We also recommend that, since oxidative damage to DNA, and its prevention, are of major
concern, the modified comet assay incorporating Fpg or EndoIII should be employed, since it provides
increased sensitivity and specificity.
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Abbreviations
SB strand break
Fpg formamidopyrimidine DNA glycosylase
EndoIII endonuclease III (Nth)
8-OH–Gua (8-OH–G) 8-oxo–7,8-dihydroguanine
PBMN peripheral blood mononuclear
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Abstract: Cancer cells display enhanced growth rates and a resistance to apoptosis. The ability
of cancer cells to evade homeostasis and proliferate uncontrollably while avoiding programmed
cell death/apoptosis is acquired through mutations to key signaling molecules, which regulate
pathways involved in cell proliferation and survival. Compounds of plant origin, including food
components, have attracted scientific attention for use as agents for cancer prevention and treatment.
The exploration into natural products offers great opportunity to evaluate new anticancer agents
as well as understand novel and potentially relevant mechanisms of action. Rosemary extract
has been reported to have antioxidant, anti-inflammatory, antidiabetic and anticancer properties.
Rosemary extract contains many polyphenols with carnosic acid and rosmarinic acid found in highest
concentrations. The present review summarizes the existing in vitro and in vivo studies focusing on
the anticancer effects of rosemary extract and the rosemary extract polyphenols carnosic acid and
rosmarinic acid, and their effects on key signaling molecules.
Keywords: rosemary extract; carnosic acid; rosmarinic acid; cancer; proliferation; survival;
cell signaling
1. Introduction
Arguably the most fundamental traits of cancer cells are their enhanced proliferative and
decreased apoptotic capacities [1]. Normal cells tightly control the production and release of
growth factors, which regulate cell growth/proliferation, thereby ensuring cellular homeostasis and
maintenance of normal tissue architecture. In cancer cells, these signals are deregulated and thus,
homeostasis within the cell is disrupted. Proliferation of cancer cells may be enhanced in a number
of ways. Cancer cells may produce growth factors to which they can respond via the expression of
cognate receptors. The level of receptor proteins displayed on the surface of cancer cells can also
be elevated, rendering these cells hyperresponsive to growth factors; the same outcome can result
from alterations to the receptor molecules that facilitate activation of downstream signaling pathways
independent of growth factor binding [1]. Alternatively, cancer cells can signal normal neighbouring
cells resulting in mutations/alterations in signaling pathways. These alterations stimulate the release
of growth factors which are supplied back to the cancer cells, enhancing their proliferation [2,3].
Growth factor receptors (GFR), such as epidermal GFR (EGFR) are plasma membrane proteins with
intrinsic tyrosine kinase (TK) activity. Growth factor binding enhances the tyrosine kinase activity
of the receptor causing receptor autophosphorylation. The phosphorylated tyrosine residues of the
receptor act as docking sites for intracellular proteins containing Src-homology 2 (SH2) domains,
leading to stimulation of intracellular signaling cascades such as the phosphatidylinositol 3-kinase
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(PI3K-Akt) and the Ras-mitogen activated protein kinase (Ras-MAPK) cascades, that result in enhanced
proliferation and inhibition of apoptosis/enhanced survival.
The development of cancer is divided into three stages: initiation, promotion and progression.
Initiation involves a change to the genetic makeup of a cell which primes the cell to become cancerous.
During the stage of promotion various factors permit a single mutated cell to survive (resist apoptosis)
and replicate, promoting growth of a tumor. Finally, as the cancerous cell replicates and develops
into a tumor, the disease state progresses. As normal, healthy cells progress to a neoplastic state they
acquire a series of hallmark capabilities which enable them to become malignant. The 6 hallmarks
of cancer proposed by Hanahan and Weinberg include sustaining proliferative signaling, evading
growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis,
and activating invasion and metastasis [1]. As tumors progress and become more aggressive
they will begin to exhibit more of these hallmarks. Current anticancer agents may be classified
as chemopreventive or chemotherapeutic depending on which stage of carcinogenesis they target.
To explore the chemopreventive potential of anticancer agents, cells in culture or animal models can be
exposed to an anticancer agent before being exposed to a carcinogen. This provides evidence of the
effect of an anticancer agent on the initiation and promotion stages of cancer. Alternatively, cells in
culture or animal models may be exposed to a carcinogen to establish a neoplastic state prior to being
treated with an anticancer agent and this provides evidence of the effect of an anticancer agent on the
progression of cancer.
Many pharmaceutical agents have been discovered by screening natural products from plants.
Some of these drugs such as the chemotherapeutics etoposide, isolated from the mandrake plant and
Queen Anne’s lace, and paclitaxel and docetaxel, isolated from the wood and bark of the Nyssaceae tree,
are currently successfully employed in cancer treatment [4]. The exploration into natural products offers
great opportunity to evaluate new chemical classes of anticancer agents as well as study novel and
potentially relevant mechanisms of action. Many labs, including ours have shown metformin, a drug
derived from the lilac, has anticancer properties [5]. In addition, the polyphenol resveratrol, found
in high concentrations in wine, has been shown to have anticancer effects in vitro and in vivo [6–10].
Importantly, metformin and resveratrol exhibit both chemopreventive and chemotherapeutic effects.
The plant Rosmarinus Officinalis L. a member of the mint family Lamiaceae, is native to the
Mediterranean region and has many culinary and medicinal uses. The main polyphenols found
in rosemary extract (RE) include the diterpenes carnosic acid (CA) and rosmarinic acid (RA) [11].
Rosemary extract and its polyphenols CA and RA have recently been explored and found to exert
potent anticancer effects (reviewed recently in [12–14]). To establish a systematic literature review we
used the online search engine Pubmed. We searched the key phrases: rosemary extract and cancer,
carnosic acid and cancer, rosmarinic acid and cancer. We also included subtypes of cancer such as breast
cancer, colon cancer, etc., as keywords in our search. All studies pertaining to our topic and published
after the year 2000 were included in the current review. In the following sections, in vitro and in vivo
studies on the effects of RE and its main polyphenols have been summarized and sorted by cancer
cell type, in chronological order from earliest to most recent. Chronology was chosen as the sorting
method to highlight how the literature has progressed and what knowledge is currently available.
Initially we focused on the studies examining the anticancer effects of RE, we then highlighted studies
in which mechanisms of action have been investigated and separately summarized the studies using
the polyphenols CA and RA. The studies presented in the text are also summarized, organized and
presented in a table format to allow the reader to extract the information easily.
This is a comprehensive systematic review and adds to the existing literature by summarizing all
relevant studies using RE, CA and RA in each cancer subtype. The review is organized by experimental
treatment (RE, CA, RA), type of cancer (histology) and the study model (in vitro or in vivo) resulting
in a clear, detailed and inclusive summary of the existing literature. This review also focuses on the
mechanistic data provided by these studies, which will be beneficial for future research to help focus
efforts on identifying the main mechanisms involved in the anticancer action of RE, CA and RA.
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2. Anticancer Effects of Rosemary Extract (RE): In Vitro Studies
Several in vitro studies using colon cancer cell lines have shown RE to exhibit anticancer properties
(Table 1). Exposure of CaCo-2 colon cancer cells to RE drastically decreased colony formation at
30 μg/mL (24 h) [15]. Yi, et al. (2011) examined the anti-tumorigenic effect of several culinary and
medicinal herbs on SW480 colon cancer cells and found RE to significantly decrease cell growth at a
concentration of 31.25 μg/mL (48 h), with an IC50 of approximately 71.8 μg/mL [16]. Cell proliferation
was dramatically decreased and cell cycle arrest was induced in HT-29 and SW480 cells using extracts
that were standardized to CA (25%–43%) or to total polyphenol content (10 μM) [17–19]. Cell growth
of SW620 and DLD-1 colon cancer cells was significantly inhibited by RE at 30 μg/mL (48 h), with an
IC50 as low as 34.6 μg/mL. Furthermore, RE enhanced the inhibitory effects of the chemotherapeutic
drug 5-fluorouracil (5-FU) on proliferation and sensitized 5-FU resistant cells [20].
In SW620 and DLD-1 colon cancer cells RE inhibited cell viability dose-dependently resulting
in significant inhibition at concentrations as low as 20 μg/mL, and an IC50 around 25 μg/mL (48 h).
This study used 5 different RE’s, containing increasing levels of carnosol (CN: 1%–3.8% w/w) and CA
(10%–30% w/w). Inhibition of cell viability was correlated with increasing CA content. Furthermore,
CA alone (at doses found in RE) decreased cell viability and this effect was potentiated by the
addition of CN (at doses found in RE). However, the inhibition seen using RE was greater than the
response seen with CA or CN alone or in combination suggesting that chemicals other than CA and
CN present in RE, also contribute to its anticancer effects [21]. Similarly, RE inhibited cell viability
in HT29, SW480 and HGUE-C-1 colon cells at comparable doses (1.5–100 μg/mL; 48 h) and the
authors reported that individual fractions of RE containing CA and other polyphenols, while potent,
were not as potent as the complete extract [22]. Using HCT116 and SW480 cells, 10–100 μg/mL RE
standardized to 23% CA (24–72 h) inhibited cell viability and induced apoptosis [23]. Valdes, et al.
have shown, using HT-29 colon cells, that 30–60 μg/mL RE (24–72 h) inhibits cell proliferation
(IC50 16.2 μg/mL). Moreover, RE induced cell cycle arrest, necrosis, cholesterol accumulation and ROS
accumulation [24–26]. These studies provide evidence for the role of RE as an anticancer agent in colon
cancer cells, capable of consistently inhibiting cell growth and viability at relatively low concentrations
in the 20–100 μg/mL range.
Table 1. Anticancer effects of Rosemary Extract (RE). In vitro studies: colon cancer.
Cancer Cell Dose/Duration Findings Mechanism Reference
CaCo-2 (Colorectal
adenocarcinoma) 0.1–30 μg/mL (3–24 h)
↓ cell colony formation.
Long and short term
antioxidant effects
↓ H2O2-induced DNA strand













RE containing 10 μM
total polyphenols (72 h)
↓ cell proliferation





1.95–62.5 μg/mL (48 h)
3 RE’s standardized to
25.9%, 36.2%, 42.4% CA
↓ cell proliferation





RE containing 10 μM
total polyphenols (48 h)
↓ cell proliferation
SW480 more sensitive
↑ cell cycle arrest
↑ antioxidant and xenobiotic
effects Modulates: Nrf2, ER







20–110 μg/mL (24–48 h)
↓ cell proliferation
IC50 36.4 and 34.6 μg/mL




Modulates TYMS and TK1.
↑ PARP cleavage [20]
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Table 1. Cont.





20–120 μg/mL (48 h) ↓ cell viabilityIC50 25 μg/mL
↑ PARP cleavage.
↑ GCNT3.














(24 h, 48 h, 72 h)










adenocarcinoma) 30 μg/mL (2–72 h)
↓ cell proliferation



















adenocarcinoma) 30–60 μg/mL (6 h, 24 h)
↓ cell proliferation
↑ cell cycle arrest
↑ H2O2 in media
↑ ROS levels
↑ HO-1 and CHOP expression
[26]
H2O2 (hydrogen peroxide), 5-FU (fluorouracil), TYMS (thymidylate synthase), TK1 (thymidine kinase 1), PARP
(poly ADP ribose polymerase), GCNT3 (glucosaminyl (N-acetyl) transferase 3), miR-15b (microRNA-15b). GI50
(50% growth inhibition), TGI (total growth inhibition), Nrf2 (nuclear factor erythroid 2-related factor 2), casp
(caspase), UPR (unfolded protein response), ER (endoplasmic reticulum), HO-1 (heme oxygenase protein-1),
CHOP (C/EBP homologous protein).
In rat RINm5F insulinoma cells, RE significantly inhibited cell proliferation at 25 μg/mL (24 h),
viability at 12 μg/mL (24 h) and increased apoptosis at 25 μg/mL (24 h) [27] (Table 2). Exposure
of pancreatic cancer cells PANC-1 and MIA-PaCa-2 to RE containing increasing concentrations of
CN (1%–3.8% w/w) and CA (10%–30% w/w) resulted in significant inhibition of cell viability with
an IC50 of 50 μg/mL (48 h) and 30 μg/mL (48 h) respectively. The RE containing 25.66% w/w CA
(sub-max) caused maximal inhibition compared to other RE’s in PANC-1 cells, significantly inhibiting
cell viability to approximately 60% at 40 μg/mL (48 h) [21].
Breast cancer can be classified under three subtypes based on the sensitivity of the tumors to
chemotherapeutic agents. The subtypes are (i) estrogen receptor positive (ER+), which express ERα
and therefore respond to estrogens; (ii) human epidermal growth factor receptor 2 positive (HER2+)
which overexpress HER2 and can be either ER+ or ER−; (iii) triple negative (TN) which lack expression
of ERα, progesterone receptor and HER2. One study used MCF-7 (ER+) breast cancer cells and a
cigarette smoke solution (in PBS) collected from a cigarette with or without 40 mg RE added to the
filter. The control used in this experiment was cells stimulated with 2.5 μM benzopyrene for 12–18 h
and exposed to 1:19 v/v cigarette smoke solution for 2 h without an RE filter. The presence of RE in
the filter lead to considerably reduced benzopyrene levels and associated DNA adduct formation [28]
(Table 2).
RE inhibited cell proliferation in breast cancer cells with an IC50 of 90 μg/mL and 26.8 μg/mL
in MCF-7 (ER+) and MDA-MB-468 (TN) cell lines respectively [29] (Table 2). In a similar study,
dose-dependent inhibition of cell viability by 6.25–50 μg/mL (48 h) RE was seen in MDA-MB-231
(TN) and MCF-7 (ER+) breast cancer cells and MCF-7 cells had an IC50 of ~24.02 μg/mL. There is
a discrepancy seen in the reported IC50 values which may be attributed to the different extraction
methods used for the preparation of rosemary extract; supercritical CO2 [30] and ethanol extraction [29].
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Furthermore, MCF-7 cells were used in 2 additional studies and while both were found to inhibit
cell proliferation, the IC50 values varied greatly from 187 μg/mL [31] to 9.95–13.89 μg/mL
(RE standardized to 25%–43% CA) [18]. In agreement with the aforementioned studies, the RE
resulting in a higher IC50 value was obtained from an alcohol based, methanol extraction [31].
The effects of RE at 1–120 μg/mL (48 h) were explored in all three breast cancer subtypes, ER+,
HER2+ and TN. RE caused dose-dependent inhibition of cell viability in all subtypes of breast cancer
cells. Furthermore RE enhanced the effectiveness of the monoclonal antibody (mAb) trastusumab
and the chemotherapeutic drugs tamoxifen and paclitaxel, used in the treatment of breast cancer [32].
Taken together, these studies suggest a role for RE to inhibit pancreatic and breast cancer cell viability
and proliferation, and induce apoptosis at concentrations in the 10–100 μg/mL range.
Table 2. Anticancer effects of Rosemary Extract (RE). In vitro studies: pancreatic and breast cancer.
Cancer Cell Dose/Duration Findings Mechanism Reference









20–120 μg/mL (48 h) ↓ cell viability ↑ PARP-cleavage [21]
MCF-7 (ER+)
(Breast adenocarcinoma)
40 mg RE powder filter
(inserted into cigarette)
(2 h)
↓ BP levels and associated










6.25–50 μg/mL (48 h) ↓ cell viability IC50~20.42 μg/mL [30]
MCF-7
(Breast adenocarcinoma) 1–250 μg/mL (48 h)




1.95–62.5 μg/mL (48 h)
3 REs standardized to
25.9%, 36.2%, 42.4% CA











10–120 μg/mL (48 h)










TNFα (tumor necrosis factor), PARP (poly ADP ribose polymerase), BP (benzopyrene), Fos (FBJ murine
osteogenic sarcoma virus), HER2 (human epidermal growth factor receptor 2), ERBB2 (HER2/neu gene), ERα
(estrogen receptor α).
Rosemary extract (6.25–50 μg/mL; 48 h) inhibited viability of DU145 and PC3 prostate cancer
cells [30] (Table 3). In agreement with these data, significant inhibition of LNCaP and 22RV1
prostate cancer cell proliferation and viability, and an induction of apoptosis were seen with RE
(50 μg/mL standardized to 40% CA; 24–48 h) [33]. RE was able to combat the enhanced prostate
specific antigen (PSA) levels measured in cell culture media, indicative of prostate cancer, inhibiting
levels to less than a fifth of what was seen in the control group. Correspondingly, levels of the androgen
receptor, to which PSA binds, were significantly decreased by 50 μg/mL RE [33]. The inhibitory
effects on both androgen sensitive and insensitive cell lines are important and suggest potential
chemotherapeutic effects in different prostate cancer subtypes.
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Using 5637 bladder cancer cells Mothana, et al. (2011) showed that RE inhibited cell proliferation
with an IC50 of 48.3 μg/mL (48 h) [31] (Table 3). Exposure of A2780 ovarian cancer cells to 0.08%
(0.8 mg/mL; 48 h) RE containing media resulted in significant inhibition of proliferation and induction
of apoptosis and cell cycle arrest. Cisplatin is a chemotherapeutic agent used often in cancer treatment
however, as with many chemotherapeutics, patients often develop resistance to treatment. At 0.08%
RE enhanced the sensitivity of A2780 and cisplatin-resistant A2780CP70 cell lines to growth inhibition
by cisplatin treatment, suggesting that RE may be of use in combination with cisplatin or potentially
other chemotherapeutic drugs in patients who have developed an acquired resistance [34]. In HeLa
cervical cancer cells, RE inhibited cell proliferation with an IC50 of 23.31 μg/mL (72 h) [35] and RE
standardized to CA (25%–43%) inhibited cell proliferation with an IC50 of ~10 μg/mL (48 h) [18],
suggesting that standardized extracts containing higher concentrations of CA may have greater
anticancer effects. Furthermore, in human ovarian cancer cells SK-OV3 and HO-8910 rosemary
essential oil (0.0625%–1%) inhibited cell viability with an IC50 of 0.025% and 0.076% in each cell
line respectively (48 h) (Table 3) [36]. This study noted that the rosemary essential oil was more
potent than its individual components (α-pinene, β-pinene, 1,8-cineole) when tested alone at the
same concentrations.
Table 3. Anticancer effects of Rosemary Extract (RE). In vitro studies: prostate, ovarian, cervical and
bladder cancer.









































adenocarcinoma) 1.56–400 μg/mL (72 h)




1.95–62.5 μg/mL (48 h)
3 REs standardized to
25.9%, 36.2%, 42.4% CA











CHOP (C/EBP homologous protein), PSA (prostate specific antigen), Bax (Bcl-2 associated X protein), casp
(caspase), hsp70 (heat shock protein 70).
In human liver Hep-3B cells, RE at 0–50 μg/mL (24–48 h) dose-dependently decreased cell
viability [30,37] with an IC50 of 22.88 μg/mL [30] (Table 4). Cell viability was inhibited in Bel-7402
liver cells by rosemary essential oil with an IC50 of 0.13% (1.3 mg/mL; 48 h) [36] and in HepG2
liver cells by RE with an IC50 of 42 μg/mL (48 h) [38]. The latter study also found that of the
4 different extracts tested, those with higher concentrations of CA resulted in more potent inhibition of
cell proliferation [38]. In lung cancer cells, RE decreased viability of NCI-H82 small cell carcinoma
cells (6.25–50 μg/mL; 48 h) [30] and decreased proliferation of A549 non-small cell carcinoma cells
(2.5–200 μg/mL) [39] with an IC50 or 24.08 μg/mL and 15.9 μg/mL in each cell line respectively
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(Table 4). In a V79 normal hamster lung fibroblast cell line RE was cytotoxic at 30 μg/mL (24 h) [15].
The cytotoxicity of RE in normal fibroblasts raises questions about its potential as a successful treatment
option however, further research is required to fully examine the cytotoxicity issue in normal tissues.
Table 4. Anticancer effects of Rosemary Extract (RE). In vitro studies: liver and lung cancer.
Cancer Cell Dose/Duration Findings Mechanism Reference
Hep-3B
(Hepatocellular carcinoma) 0.5–5 μg/mL (24 h) ↓ cell viability ↑ TNFα [37]
Hep-3B
(Hepatocellular carcinoma) 6.25–50 μg/mL (48 h)
↓ cell viability














(Lung carcinoma; SCLC) 6.25–50 μg/mL (48 h)
↓ cell viability
IC50 ~24.08 [30]
V79 (Normal hamster lung) 0.1–30 μg/mL (3–24 h)
Cytotoxic to cells at










(Lung adenocarcinoma) 2.5–200 μg/mL (48–72 h)
↓ cell proliferation
↓ cell survival






mTOR (mammalian target of rapamycin), PARP (poly(ADP-ribose) polymerase).
Vitamin D analogues (VDA) are commonly used in clinical differentiation therapy of acute
myeloid leukemia (AML) to attempt to restore a defect in the capacity of myeloid progenitor cells
to mature into non-replicating adult cells. However, pharmacologically relevant doses have been
found to result in many adverse events such as hypercalcemia and attempts to circumvent these
adverse events have been unsuccessful. RE containing 10 μM equivalent of CA, or 10 μM CA alone
(96 h) potentiated the ability of vitamin D derivatives to inhibit cell viability and proliferation, induce
apoptosis and cell cycle arrest and increase differentiation of WEHI-3BD murine leukemic and human
HL-60 leukemic cells [40,41] (Table 5). A study examining the human leukemia HL-60 and K-562
cell lines and the murine RAW264.7 macrophage/monocyte cell line found significant inhibition of
proliferation with an IC50 of 0.14% (1.4 mg/mL) and 0.25% (2.5 mg/mL) for the HL-60 and K-562
cells, respectively. In addition 0.1% (1 mg/mL; 72 h) RE significantly increased differentiation of HL-60
cells [29]. RE inhibited viability at 50 μg/mL (48 h) in K-562 leukemia cells [30]. Similar effects of RE
(50 μg/mL; 24 h) were reported by others that lead to decreased proliferation of K-562 cells [42].
Table 5. Anticancer effects of Rosemary Extract (RE). In vitro studies: leukemia.










↑ cell cycle arrest
↑ cell differentiation
↑ apoptosis
↑ G1 phase [41]
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Table 5. Cont.















↔ basal TNFα, IL-1β,
iNOS or COX2
















K-562 (Human leukemia) 6.25–50 μg/mL (48 h) ↓ cell viability IC50~12.50 μg/mL [30]
K-562 (Human leukemia),





VDA (vitamin D analogue), LPS (lipopolysaccharide), NO (nitric oxide), TNFα (tumor necrosis factor α),
IL-1β (interleukin 1β), iNOS (inducible nitric oxide synthase), COX2 (cyclooxygenase 2), ROS (reactive oxygen
species), NADP (nicotinamide adenine dinucleotide phosphate), Rb2 (retinoblastoma-related gene 2).
3. Anticancer Effects of Rosemary Extract (RE): In Vivo Animal Studies
A limited number of studies have examined the effects of RE administration on tumor growth
in animals in vivo (Table 6). Administration of RE (1 mg/mL) in the drinking water ad libitum for
32–35 days resulted in a significant decrease in tumor size in nude mice xenografted with SW620
colon cancer cells [21]. A similar study using HCT116 colon cancer xenografted athymic nude mice
fed 100 mg/kg/day RE dissolved in olive oil (4 weeks) significantly decreased tumor size in treated
animals compared to control [23]. Biochemical analysis of serum samples collected from Sprague
Dawley rats with N-methylnitrosourea-induced colon cancer showed significant anticancer effects by
both high (3333.3 mg/kg/day) and low (1666.6 mg/kg/day) dose RE after 4 months of treatment with
significant alteration of gene and protein signaling and aggregation of lymphoid cells [43]. A significant
reduction in tumor volume was seen in mice xenografted with 22RV1 prostate cancer cells by RE
(100 mg/kg/day) which was administered, dissolved in olive oil for 22 days [33].
In a diethylnitrosamine (DEN)-induced liver cancer model in F344 rats, RE at 100 mg/kg/day
(5 days) was administered intragastrically with an intraperitoneal (i.p) injection of DEN on day 4.
From this point, rats were fed a normal diet for 3 weeks until undergoing partial hepatectomy.
Examination of liver tissue suggested RE may exert some protective antioxidant effects [44].
In accordance with this, use of Swiss mice exposed to 6 Grays (Gy) ionizing radiation (IR) in
their liver once, followed by treatment with 1000 mg/kg RE fed orally, daily for 5 days suggested
protective, antioxidant activity by RE. A delayed onset of IR-induced mortality and attenuated
increases in glycogen and protein levels were seen in livers of mice exposed to IR and fed RE,
compared to IR-exposed mice not fed RE [45]. Caution should be taken however, due to the high
concentration (1000 mg/kg) used [45] which is at least 10 times greater than what has been found to
exert potent anticancer effects in other studies. Taken together, these studies suggest a role for RE
inhibiting chemical- or IR-induced carcinogenesis by exerting protective, antioxidant effects on healthy
tissues. Thus, RE may display radio-protective effects, which would benefit healthy tissue during
radiation treatment.
In WEHI-3BD myeloid leukemia xenografted mice fed 1% w/w RE in their food ad libitum
(29 days), investigators noted a significant decrease in both tumor volume and incidence. Furthermore,
RE showed an additive effect when combined with Vitamin D analogues (VDA) [41]. In WEHI-3BD
xenografted mice administered RE (4% w/w in food) for up to 15 weeks combined with VDAs, median
survival time was significantly increased and white blood cell count decreased to levels comparable to
those seen in the control group of healthy mice [40].
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Using a 7,12-dimethylbenz(a)anthracene (DMBA)-induced skin cancer nude mouse model, RE
(500 or 1000 mg/kg/day; 15 weeks) administered orally in water resulted in a significant decrease
in tumor number, diameter, weight and decrease in tumor incidence and burden, and an increase in
latency period compared to control mice treated with DMBA only [46,47]. One group of mice, which
were administered RE for 7 days prior to the first application of DMBA, showed a 50% reduction
in tumor growth compared to the DMBA-only treated mice, suggesting potent chemo protective
effects [47].
Table 6. Anticancer effects of Rosemary Extract (RE). In vivo studies.
Animal Model Dose/Duration Findings Mechanism Reference
SW620 colon xenograft
(nude mice)
1 mg/mL in drinking
water (32–35 days) ad
libitum




100 μL olive oil by oral
gavage (4 weeks)




(low dose) RE or
3333.3 mg/kg/day
(high dose) RE orally
(4 months)
Both RE showed comparable











100 mg/kg/day in olive












Injected i.p with 20
mg/kg DEN on day 4.
Fed normal diet until
week 3 (underwent
partial hepatectomy)
↑ antioxidant activity ↓ GST positive foci [44]
Swiss mice exposed to
γ-IR (liver)
6Gy γ-IR (once) followed




Attenuated negative IR effects
Protective effect on liver
and blood
↓ LPx levels
↑ GSH levels [45]
Myeloid leukemia
inoculated mice
1% RE w/w in food ad
libitum (29 days)
↓ tumor volume






4% w/w in food ad
libitum (15 weeks)
RE alone ↔ median survival
time RE+VDA























↑ GSH levels [47]
miR-15b (microRNA 15b), PSA (prostate specific antigen), CHOP (C/EBP homologous protein), VDA
(vitamin D analogue), WBC (white blood cell), GST (glutathione S transferase), IR (ionizing radiation), LPx
(lipid peroxidase), GSH (glutathione), DEN (diethylnitrosamine), DMBA (7,12-dimethylbenz(a)anthracene),
NMN (N-methylnitrosourea), cyt C (cytochrome C), PCDP4 (programmed cell death protein 4), CEA
(carcinoembryonic antigen), CCSA-4 (colon cancer specific antigen 4), LPx (lipid peroxidase), GSH (glutathione).
4. Mechanisms of Anticancer Effects of Rosemary Extract (RE): In Vitro Studies
Many studies have examined the anti-proliferative and colony forming abilities of RE in vitro
in colon [15–20,24–26], pancreas [27], breast [18,29,31,32], prostate [33], cervical [18,35], bladder [31],
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ovarian [34], lung [39] and leukemia [29,40–42] cell lines however, little is known concerning the
underlying mechanism. RE was shown to have an inhibitory effect on AKT1 mRNA and protein
expression, a protein involved in the PI3K/Akt survival signaling pathway, in a leukemic cell
line [42] however, no measure of Akt activity was mentioned. No effect on ERK2 protein levels,
involved in cell proliferation and differentiation, were seen in these cells. Cell cycle arrest prevents
further division by proliferating cells and RE was shown to induce cell cycle arrest in a number of
cancer cell lines [17,19,24,25,33,34,41] and increase retinoblastoma-related gene 2 (Rb2) [42] which
regulates entry into cell division. Recently, Moore, et al. (2016) found RE inhibited activation of
the Akt/mTOR/p70S6K signaling pathway which was associated with a significant decrease in cell
proliferation and survival [39].
The viability of various cancer cell lines was shown to be significantly inhibited by treatment with
RE which many studies attributed to enhanced apoptosis and cell death. Increased poly ADP ribose
polymerase (PARP) cleavage, which is an established indicator of enhanced apoptosis, was seen in
colon [20,21], pancreas [21], breast [32] and lung [39] cancer cell lines following treatments with RE.
Alternatively, RE enhanced nitrate accumulation (i.e., increased nitric oxide production) and TNFα
production in pancreatic [27] and liver [37] cancer cells, indicative of enhanced cell death capabilities
and nitric oxide-induced apoptosis. In ovarian cancer cells [34] enhanced apoptosis was associated with
increased gene expression of mitochondrial-regulated apoptosis proteins cytochrome c, involved in the
electron transport chain, and heat shock protein 70 (hsp70) which is involved in protein folding and
protecting the cell from heat stress and toxic chemicals. Other mechanisms of apoptosis by RE include
enhanced protein expression of pro-apoptotic Bax and cleaved-caspase 3 [23,33], increased expression
of binding immunoglobulin protein (BiP) and CCAAT/-enhancer-binding protein homologous
protein (CHOP) proteins which induce endoplasmic reticular stress [25,33], and the unfolded protein
response [24–26,33] in prostate and colon cancer cells. Interestingly, in normal prostate epithelial
cells RE treatment resulted in a decrease in endoplasmic reticular stress related protein PRKR-like
endoplasmic reticulum kinase (PERK), suggesting RE selectively induces endoplasmic reticular stress
in prostate cancer cells but spares normal prostate cells [33]. Similarly, in breast cancer cells [32] RE
decreased expression of estrogen receptor α (ERα) in the ER+ subtype and human epidermal growth
factor receptor 2 (HER2) in the HER2+ subtype, and it was suggested the decreased receptor expression
was correlated with enhanced apoptosis in these cell subtypes. Correspondingly, increased levels of
Fos, an oncogenic transcription factor, were detected in ER+ and HER2+ cell lines, and this event is
thought to precede apoptosis and correspond to the PARP-cleavage seen in these cells. Although RE
was also capable of inducing anticancer effects in triple negative (TN) breast cancer cells, its mechanism
has yet to be elucidated [32].
Induction of apoptosis by endoplasmic reticular stress has been found by several studies
in colon cancer cells [19,23,24,26] and has been shown to involve translocation of nuclear factor
erythroid 2-related factor 2 (Nrf2) into the nucleus and induction of p38 MAPK and PERK activity.
The Nrf2/antioxidant response element (ARE) signaling pathway has been considered to protect cells
against carcinogenesis and attenuate cancer development by neutralizing ROS and carcinogens and
members of this pathway, including sestrin-2 and heme oxygenase-1 (HO-1), are upregulated by RE in
colon cancer cells [23,25]. Overall, the majority of existing studies indicate that the anticancer effects of
RE may be due largely to induction of apoptosis.
Antioxidants are molecules, which scavenge harmful free radicals, protecting cells from oxidative
DNA damage and potentially death. RE has been shown to exert antioxidant effects in colon [15],
breast [28], and leukemia [29,40] cell lines. Colon cancer cells pretreated with RE followed by
treatment with hydrogen peroxide, often used in cell culture to induce oxidative DNA damage,
showed reduced DNA double-strand breaks and oxidative damage compared to control cells treated
with hydrogen peroxide only. Similarly, RE reduced oxidative damage induced by methylene blue
(oxidizes purines) in these cells [15]. RE treatment resulted in increased levels of antioxidants and
NAPD(H)-quinone reductase (oxidoreductase involved in the transfer of electrons from a reduced
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molecule to an oxidized molecule) which decreased reactive oxygen species (ROS) levels, and inhibited
lipopolysaccharide (LPS)-stimulated production of the free radical nitric oxide (NO) in leukemia cell
lines [29,40]. In an in vitro model of cigarette smoking, the use of an RE containing cigarette filter
considerably reduced benzopyrene (carcinogen) levels and associated DNA adduct formation in breast
cancer cells [28]. An effect of RE treatment, to inhibit ROS levels in cancer cells, may be viewed as a
beneficial and not an anticancer effect for cancer cells. Traditionally treatments for cancer should result
in apoptosis/killing of cancer cells. The antioxidant properties exerted by RE treatment indicate a
potential for RE as a preventative strategy which may target the initiation and promotion stages of
cancer. Antioxidants work to restore damaged DNA back to normal and protect the cell from further
damage thus, preventing the potential mutation into a cancer cell and subsequent tumor formation.
In addition to the antiproliferative, apoptotic and antioxidant mechanisms noted above, some
evidence indicates that RE may (i) exert anti-inflammatory effects [29] through inhibition of
interleukin-1 (IL-1) and cyclooxygenase 2 (COX2) molecules; (ii) aid in the reversal of acquired
drug resistance [34] by inhibiting P-glycoprotein levels (involved in drug resistance); and (iii) alter
metabolic-related genes [21] such as glycosyltransferase (GCNT3) which forms glycosidic linkages
in a variety of macromolecules and its potential epigenetic regulator microRNA-15b. Induction of
autophagy [26] and alterations to cholesterol metabolism [24] may also be mechanisms of RE in colon
cancer cells.
5. Mechanisms of Anticancer Effects of Rosemary Extract (RE): In Vivo Animal Studies
Limited evidence exists regarding RE’s mechanism in vivo however, few studies list potential
antioxidant effects and serum biomarkers for RE’s anticancer effects. Increases in glutathione (GSH),
an antioxidant, and reductions in lipid peroxidase (LPx), an oxidizing agent resulting in free radical
production and cell damage, have been recorded in IR-induced mouse liver [45] and DMBA-induced
mouse skin cancer [46,47] models treated with RE. Similarly, RE decreased glutathione-S transferase
(GST) positive foci, which are associated with oxidative damage from the reduction of GSH [40],
in a rat DEN-induced liver cancer model however, results were not significant and should be taken
with caution [44].
Serum samples from mice xenografted with prostate cancer cells and fed RE in their diet showed
a decrease in prostate-specific antigen (PSA) levels (high levels would be suggestive of prostate cancer)
and examination of tissue samples showed decreased androgen receptor and CHOP expression,
indicative of an induction of apoptosis associated with endoplasmic reticular stress [33]. Similarly,
HCT116 colon cancer xenografted mice showed increased Nrf2 and Sestrin-2 expression which are
indicative of endoplasmic reticular stress and can lead to enhanced apoptosis [23]. A significant
decrease in microRNA-15b (miR-15b) plasma levels after administration of RE in colon cancer
xenografted mice suggested circulating miR-15b levels may act as a minimally invasive method
to monitor the antitumor effects of RE in vivo [21]. Furthermore, rats with N-methylnitrosourea
(NMN)-induced colon cancer fed RE, showed significant alterations in cell death modulating proteins
including cytochrome c, programmed cell death protein 4 (PCDP4), carcinoembryonic antigen (CEA)
and colon-cancer specific antigen-4 (CCSA-4) [43]. Sufficient evidence exists to support the potential
use of RE in chemotherapeutics however, it is still not well understood whether the anticancer effects
seen by RE are attributable to individual polyphenols within the extract or rely on the combination of
all the components within the extract combined. The next section of this review explores the role of
two of RE’s main polyphenols, CA and RA, and their potential contribution to RE’s anticancer effects.
6. Anticancer Effects of Carnosic Acid (CA): In Vitro Studies
Treatment of different colon cancer cells with CA resulted in significant inhibition of cell viability
using concentrations ranging from 1 to 400 μM, and having IC50 values in the 20–90 μM range
(Table 7). In addition, CA induced apoptosis and cell cycle arrest in Caco-2 cells [48,49] and inhibited
cell adhesion and migration in Caco-2, HT-29 and LoVo cells [49] by inhibiting activity of the cell
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cycle regulator cyclin A [48] and by inhibiting MMP-9, uPA and COX-2 activity, associated with cell
adhesion and migration properties [49]. Similarly, in SW480 colorectal cancer cells with hyperactive
β-catenin which is oncogenic, CA targeted β-catenin for proteasomal degradation and this suggests
a potential for CA to be used as a small molecule oncogenic β-catenin inhibitor [50]. In SLW620
and DLD-1 cells CA inhibited cell viability and this was associated with downregulation of miR-15b
and enhanced GCNT3 activity which are associated with regulation of metabolic related genes [21].
Furthermore, in HT-29 colon cells CA inhibited cell proliferation and enhanced cell cycle arrest, which
was correlated with altered expression of an array of transport and biosynthesis genes and altered
activity of detoxifying enzymes and metabolites. Of note, levels of GSH, an important antioxidant, were
enhanced and levels of N-acetylputrescine, which are toxic in high doses, were decreased [51]. In HT-29
cells co-cultured with 3T3-L1 adipocytes, CA attenuated the negative effects of the adipocytes on the
colon cancer cells by inhibiting triglyceride accumulation and downregulating expression of the Ob-R
receptor [52]. In these cells CA also inhibited cell viability by decreasing phosphorylation of the cell
survival regulators Akt and Bcl-xL and enhancing Bax expression. Furthermore, cell cycle arrest was
induced by inhibition of cyclin D1 and CDK4 [52]. Similarly, a fraction of rosemary extract which was
found to consist mainly of CA (98.7% pure) was tested on HT-29, SW480 and HGUE-C-1 colon cancer
cells and significantly inhibited cell viability. Among several different fractions of the RE that were
tested, the fraction containing CA was found to be among the most active and it was suggested that
synergism between many components of the extract plays a role in rosemary’s anticancer effects [22].
Inhibition of cell proliferation and increased cell cycle arrest by CA in HT-29 cells was found to be
orchestrated by the unfolded protein response and triggered by endoplasmic reticular stress [24]
which can lead to apoptosis and thus destruction of cancerous cells. Enhanced cholesterol and ROS
accumulation in CA treated cancer cells was also shown to contribute to the inhibition of proliferation
seen [24]. Similarly, activity of pro-apoptotic markers including p53, Bax, caspases and PARP were
enhanced and anti-apoptotic markers MDM2, Bcl-2 and Bcl-xL were decreased in HT-29, HCT116 and
SW480 colon cells [53]. Levels of ROS and H2O2 were increased in vitro in the cell medium [25,53] by
CA which can trigger cellular stress and thus cancer cell death. The signaling molecules STAT3 and
survivin play a key role in regulating cell survival and CA inhibited activity of these molecules in colon
cancer cells [53]. These studies provide strong evidence that CA at relatively low doses (1–100 μM) is
capable of inhibiting colon cancer cell growth and survival by modulating expression of key signaling
molecules and altering cell metabolism.
In breast cancer cells, including MCF-7, MDA-MB-231 and MDA-MB-468, CA inhibited
cell proliferation and enhanced apoptosis at concentrations of 1.5–150 μM [30,54–56] (Table 8).
The inhibitory effects of CA were found to be dependent on increasing levels of the antioxidant
glutathione in breast cancer cells and accordingly, expression of genes involved in glutathione
biosynthesis (CYP4F3, GCLC) and transport (SLC7A11) were significantly increased as well [54].
Importantly, the sensitivity of CA was found to be associated with HER2 expression and thus the
MCF-7 cells were more sensitive to the CA treatment, compared to the triple-negative MDA-MB-468
cell line which does not express HER2 [54]. In the triple negative MDA-MB-361 cell line CA induced
TRAIL-mediated apoptosis through down-regulation of c-FLIP and Bcl-2 expression and through
CHOP-dependent upregulation of DR5, Bim and PUMA expression (ER stress associated proteins) [56]
suggesting that CA is capable of inhibiting breast cancer cell survival through different mechanisms
depending on the mutations that are present.
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Table 7. Anticancer effects of Carnosic Acid (CA). In vitro studies: colon cancer.
Cell Type Dose/Duration Findings Mechanism Reference
Caco-2 (Colorectal
adenocarcinoma) 1–50 μM CA (48 h)
↓ cell proliferation
↑ cell cycle arrest
↑ cell doubling time
IC50 23 μM






1–388 μM CA (48 h)
↑ apoptosis
↓ cell adhesion and migration
IC50 26.4–92.1 μM
(high in Caco2)
↓ MMP-9 and uPA activity,
COX-2 expression [49]
SW480 (Colorectal


















5–35 μg/mL (15–105 μM)
CA (24–72 h)
↓ cell proliferation
↑ cell cycle arrest









adenocarcinoma) 1–10 μM CA (24–48 h)
↓ cell viability
↑ cell cycle arrest
↓ triglyceride accumulation of
3T3-L1 adipocytes










30–60 μg/mL (24–48 h)
CA fraction of RE
(98.7% purity)
↓ cell viability [22]
HT-29
(Colorectal adenocarcinoma)
12.5 μg/mL (37.6 μM)
CA (2–72 h)
↓ cell proliferation














20–100 μM CA (24 h) ↓ cell viability↑ apoptosis
↑ p53, Bax, casp 3, casp 9,
PARP cleavage
↑ ROS generation
↓ MDM2, Bcl-2, Bcl-xL





μM) CA (24 h) ↓ cell proliferation
↑ H2O2
↑ ROS [25]
MMP-9 (matrix metallopeptidase 9), uPA (urokinase plasminogen activator), COX-2 (cyclooxygenase 2),
BCL9-β (B-cell CLL/lymphoma 9), GCNT3 (glucosaminyl (N-Acetyl) transferase 3), GSH (glutathione),
CDK4 (cyclin-dependent kinase 4), Bcl-xL (B-cell lymphoma-extra large), Bax (Bcl-2-like protein 4), Ob-R
(leptin receptor), ROS (reactive oxygen species), UPR (unfolded protein response), ER (endoplasmic reticulum),
casp (caspase), p53 (tumor protein p53), PARP (poly(ADP-ribose) polymerase), MDM2 (mouse double minute 2
homolog), Bcl-2 (B-cell CLL/lymphoma 2), STAT3 (signal transducer and activator of transcription 3), H2O2
(hydrogen peroxide).
Inhibition of cell viability by CA was shown in rat insulinoma (RINm5F) and human (MIA-PaCa-2,
PANC-1) pancreatic cancer cells at doses of 6–300 μM [21,27]. In prostate cancer cells, lower
doses of CA (<100 μM) inhibited cell viability and enhanced apoptosis [30,57,58]. Induction of
apoptosis in PC-3 prostate cells was associated with activation of both intrinsic and extrinsic apoptotic
pathways. Inhibition of caspase 8 and 9, Bcl-2, Bid, IAP, p-Akt, p-GSK3 and NF-κB and activation of
caspase 3 and 7, PARP, Bax, cytochrome c and PP2A all contribute to enhanced apoptosis within
these cells [58]. The use of a pan-caspase inhibitor attenuated the apoptotic effects of CA and
provides strong evidence for the involvement of caspases in the apoptotic mechanism of CA in
prostate cancer cells [58]. Low doses of CA both alone and in combination with other phytonutrients
such as curcumin showed potent anticancer effects in LNCaP, PC3 and DU145 prostate cells and
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inhibited androgen receptor activity. The inhibition of proliferation of these cells was associated with
an inhibition of the EpRE/ARE antioxidant transcription system and inhibition of PSA secretion [57].
Furthermore, CA inhibited proliferation of A2780 ovarian cancer cells and enhanced the sensitivity
of a resistant A2780CP70 cell line to cisplatin, a potent chemotherapeutic agent [34]. Carnosic acid
has potent anticancer effects on its own but also acts synergistically with other compounds including
phytonutrients and chemotherapeutics and this represents a promising route for future cancer therapies
using combinations of anticancer agents at lower doses.
Table 8. Anticancer effects of Carnosic Acid (CA). In vitro studies: breast, pancreatic, prostate and
ovarian cancer.















↑ cell cycle arrest IC50:






(Breast adenocarcinoma) 20–60 μM CA (24 h) ↑ apoptosis [55]
MDA-MB-361













2–18 μg/mL (6.02–54.15 μM)





(18.8–150 μM) CA (48h) ↓ cell viability [30]
PC3 (Prostate
adenocarcinoma) 20–100 μM CA (0–72 h)
↓ proliferation
↑ apoptosis
↓ casp 8, casp 9, Bcl-2,
Bid, IAP, p-Akt,
p-GSK3, NF-κB
↑ casp 3, casp 7, PARP





















CYP4F3 (leukotriene-B(4)omega-hydroxylase 2), GCLC (glutamate-cysteine ligase catalytic subunit), SLC7A11
(solute carrier family 7 member 11), CDKN1A (cyclin-dependent kinase inhibitor 1A), TRAIL (TNF-related
apoptosis-inducing ligand), c-FLIP (cellular FLICE (FADD-like-IL-1β-converting enzyme)-inhibiting protein),
DR5 (death receptor 5), Bim (Bcl-2-like protein 11), PUMA (p53 upregulated modulator of apoptosis), CHOP
(C/EBP homologous protein), casp (caspase), Bcl-2 (B-cell CLL/lymphoma 2), Bid (BH3 interacting-domain),
IAP (inhibitor of apoptosis), p-Akt (phosphorylated protein kinase B), p-GSK3 (phosphorylated glycogen
synthase kinase 3), NF-κB (nuclear factor kappa B), PARP (poly (ADP-ribose) polymerase), Bax (Bcl-2-like
protein 4), cyt c (cytochrome c), PP2A (protein phosphatase 2A), EpRE (electrophile responsive element), ARE
(antioxidant response element), PSA (prostate specific antigen).
In Hep-3B, HepG2 and SK-HEP1 human liver cancer cells, CA inhibited cell viability and
enhanced apoptosis [30,55,56,59] (Table 9). In Hep-G2 cells the formation of autophagic vacuoles and
autolysosomes contributed to enhanced cell death by CA and this was induced through inhibition of the
Akt/mTOR cell survival pathway [59]. Furthermore, in SK-HEP1 cells CA induced TRAIL-mediated
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apoptosis by altering apoptotic markers such as c-FLIP, Bcl-2, DR5, Bim, PUMA and CHOP [56].
Rat liver clone 9 cells are often used as a model for screening hepatotoxicity and CA was found to
enhance activity of enhancer element GPEI which regulates the pi class of glutathione S-transferase
and modulates antioxidant and detoxification systems within the cell [60]. CA was found to exert
a protective effect in these non-cancerous liver cells which was modulated by the Nrf2/p38 MAPK
signaling pathway [60,61]. Furthermore, CA inhibited viability of small-cell lung cancer NCI-H82
cells [30].
Table 9. Anticancer effects of Carnosic Acid (CA). In vitro studies: liver, lung, skin and kidney cancer.




(18.8–150 μM) CA (48 h) ↓ cell viability [30]
HepG2
(Hepatocellular carcinoma) 20–100 μM for (12–48 h)
↓ proliferation
↑ apoptosis
↑ autophagic vacuoles and
autolysosomes
↑ LC-3
↓ p-Akt, p-mTOR [59]
SK-HEP1
(Hepatocellular carcinoma) 20–60 μM CA (24 h) ↑ apoptosis [55]
SK-HEP1






↑ DR5, Bim, PUMA, CHOP
[56]
Rat clone 9
(Normal rat liver) 1–20 μM CA (24 h)

















(18.8–150 μM) CA (48 h) ↓ cell viability [30]
HT-1080 (Fibrosarcoma) 25–100 μM CA (4–72 h)
↑ apoptosis
↑ cell cycle arrest
↑ chromatin condensation and






25–100 μM CA (4–72 h)
↓ cell survival
↑ apoptosis
↑ cell cycle arrest





B16F10 (Skin melanoma) 2.5–10 μM CA (12 h)




↓ MMP-9, TIMP-1, uPA,
VCAM-1
↓ p-Src, p-FAK, p-Akt
[63]
Caki (Kidney clear cell
carcinoma) 20–60 μM CA (24 h)
↑ apoptosis Promotes ROS
production
↑ PARP cleavage, casp 3,
ATF4, CHOP [55]









↑ DR5, Bim, PUMA, CHOP
[56]
LC3 (light chain 3), p-mTOR (phosphorylated mammalian target of rapamycin), TRAIL (TNF-regulated
apoptosis-inducing ligand), c-FLIP (cellular FLICE (FADD-like-IL-1β-converting enzyme)-inhibiting protein),
Bcl-2 (B-cell CLL/lymphoma 2), DR5 (death receptor 5), Bim (Bcl-2-like protein 11), PUMA (p53 upregulated
modulator of apoptosis), CHOP (C/EBP homologous protein), GSTP (Glutathione S-transferase P), Nrf2 (nuclear
factor E2-related factor-2), NQO1 (NAD(P)H-quinone oxidoreductase 1), p-ERK (phosphorylated extracellular
signal-regulated kinases), MMP-2 (matrix metalloproteinase-2), MMP-9 (matrix metallopeptidase-9), TIMP-1
(TIMP metallopeptidase inhibitor 1), uPA (urokinase plasminogen activator), VCAM-1 (vascular cell adhesion
protein 1), p-Src (proto-oncogene tyrosine-protein kinase Src), p-FAK (phosphorylated focal adhesion kinase),
PARP (poly(ADP-ribose)polymerase), casp (caspase).
In several models of skin cancer, including HT-1080, BEAC, HUVEC and B16F10 cells, CA
inhibited cell survival, cell migration and cell adhesion, enhanced apoptosis and induced cell cycle
arrest [62,63] (Table 9). Chromatin condensation and DNA fragmentation were seen in HT-1080 cells
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which lead to apoptosis [62]. In human umbilical and bovine aortic endothelial cell lines, CA inhibited
tubulogenesis and MMP-2 expression suggesting anti-angiogenic properties of CA which would be
beneficial in anticancer therapies [62]. Inhibition of the epithelial-mesenchymal transition in B16F10
melanoma cells suggests a possible mechanism for the inhibition of cell migration by CA. Inhibition
of cell migration markers MMP-9, TIMP-1, uPA and VCAM-1 was seen in this cell line using low
doses of CA (10 μM). Inhibition of phosphorylation of signaling molecules Akt, FAK and Src were
also associated with inhibition of the epithelial-mesenchymal transition and cell migration in B16F10
cells [63]. In Caki, kidney cancer cells, CA induced apoptosis through ROS-mediated endoplasmic
reticular stress. Activity of apoptotic markers PARP, caspase 3, ATF4 and CHOP was increased in these
cells [55]. Similarly, TRAIL-mediated apoptosis was induced in Caki, AHCN and A498 kidney cells
through modulation of endoplasmic reticular stress related proteins c-FLIP, Bcl-2, DR5, Bim, PUMA
and CHOP [56].
In T98G glioblastoma cells CA promotes production of nerve growth factor and this was found
to be regulated by the Nrf2 signaling pathway [64,65] (Table 10). Nerve growth factor is involved in
the regulation of growth and the maintenance and survival of certain target neurons, and thus can
act to protect neural cells from toxic agents that may cause cancer. In IMR-32 neuroblastoma cells CA
induced apoptosis by activation of caspases, PARP and the p38 MAPK pathway and inhibited cell
viability, which was associated with decreased ERK activation [66]. Interestingly however, in SH-SY5Y
neuroblastoma cells CA attenuated apoptosis induced by the neurotoxic compounds methylglyoxal
and amyloid β, exerting a cytoprotective effect [67,68]. This protective effect was associated with
increased activation of PI3K/Akt signaling, inhibition of cytochrome c release and inhibition of caspase
cascades which results in a pro-survival effect on the cell [36,67]. Similarly, in U373MG astrocytoma
cells CA inhibited amyloid β peptide production and release and this was associated, at least partially,
with activation of the α-secretase TACE/ADAM17 [69]. The use of CA may have potential in the
prevention of amyloid β-mediated diseases. Furthermore, in GBM glioblastoma cells, CA promoted
apoptosis by inducing cell cycle arrest and degradation of cyclin B1, RB, SOx2 and GFAP, molecules
involved in cell survival and maturation processes [70].
Table 10. Anticancer effects of Carnosic Acid (CA). In vitro studies: brain and neural cancer.
Cell Type Dose/Duration Findings Mechanism Reference
T98G (Glioblastoma) 5–100 μM CA (0–48 h) ↑ NGF synthesis [64]
T98G (Glioblastoma) 2–50 μM CA (24 h) ↑ NGF synthesis↑ Nrf2, HO-1, TXNRD1 [65]
IMR-32




↑ casp 3, casp 9, PARP, p-p38
↓ p-ERK [66]
U373MG




(Neuroblastoma) 1 μM CA (12 h)
↑ antioxidant defense
↑ detoxification systems
Blocked activation of apoptosis
↑ PI3K/Akt




(Neuroblastoma) 10 μM CA (1 h) ↓ apoptosis ↓ caspase cascade [68]
GBM (Glioblastoma) 17.5–40 μM CA (48 h)
↓ cell survival








NGF (nerve growth factor), Nrf2 (nuclear factor E2-related factor 2), HO-1 (heme oxygenase-1), TXNRD1
(thioredoxin reductase 1), casp (caspase), PARP (poly(ADP-ribose)polymerase), p-ERK (phosphorylated
extracellular signal-regulated kinases), TACE (TNF-α converting enzyme), ADAM17 (ADAM metallopeptidase
domain 17), PI3K (phosphatidylinositol-4,5-bisphosphate 3-kinase), Akt (protein kinase B), cyt c (cytochrome
c), CDK (cyclin dependent kinase), RB (retinoblastoma), SOX2 (sex determining region Y-box 2), GFAP (glial
fibrillary acidic protein).
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Leukemia is a cancer that usually develops in the bone marrow and results in a high number of
white blood cells that are not fully developed being released into the bloodstream. Most treatment
options for leukemia involve agents that promote the differentiation of these immature white blood
cells into mature, differentiated cells. Unfortunately, there are many side effects associated with higher
doses of these differentiating agents and strategies are required to lower the dose necessary to see
anticancer effects. One such agent which is used is 1α25-dihydroxyviatmin D (1,25D). Many studies
have found that low doses of CA (5–10 μM) are able to potentiate the pro-differentiation effects of
1,25D and help sensitize leukemia cells including human HL-60, U937, MOLM-13 and mouse WEHI-3B
cells [40,41,71–78] to its anticancer effects (Table 11). Furthermore, CA inhibited cell viability and
induced apoptosis and cell cycle arrest in these cells using a multitude of different strategies. In
HL-60 cells, CA enhanced expression of the vitamin D and retinoic acid receptors thus, enhancing the
sensitivity of cells to 1,25D [71], and enhanced expression of cell cycle regulators p21Waf1, p27Kip1 which
may have tumor suppressor functions [72]. Carnosic acid also increased levels of the antioxidant GSH
and phase II enzyme NADP(H)-quinone reductase which help protect cells from chemically-induced
carcinogenesis, and enhanced signaling through MAPK pathways including ERK and JNK which
are involved in the proliferation and differentiation of cells [40,73–75,79]. In K562 leukemia cells CA
inhibited cell viability and sensitized resistant cells to adriamycin, a chemotherapeutic agent [30,80].
Similarly, CA enhanced the activity of doxercaliferol, an agent which helps prevent the common
problem of calcification associated with administration of vitamin D derivatives such as 1,25D, and
decreased levels of microRNA181a which are linked to cell proliferation [81]. Antioxidant effects were
also produced by CA in U937, HL-60 and NB4 leukemic cells which exhibited increased GSH and
NADPH levels and CA ameliorated arsenic trioxide-induced cytotoxic effects [79]. Activation of the
Nrf2/ARE signalling pathway which can alter cell survival was also seen [77,79]. The authors suggest
that the Nrf2/ARE pathway likely plays an important role in the cooperative induction of leukemia cell
differentiation by 1,25D and CA [77]. Importantly, in HL-60 cells CA increased PTEN expression and
caspase cleavage and inhibited phosphorylation of Bad and Akt which are associated with enhanced
apoptosis [62,82]. The strong inhibitory effects of CA on the PTEN/Akt survival pathway make it a
good candidate to be combined with other therapies for leukemia treatment.
Table 11. Anticancer effects of Carnosic Acid (CA). In vitro studies: leukemia.
Cell Type Dose/Duration Findings Mechanism Reference
HL-60 (Myeloid
leukemia) 10 μM CA (0–48 h)
CA potentiated effects of 1,25D
↑ differentiation
↓ proliferation
↑ cell cycle arrest
↑ vitamin D receptor,




2.5–10 μM CA (0–48 h)
CA potentiated effects of 1,25D
↑ differentiation
↓ proliferation
↑ cell cycle arrest IC50 6–7μM
↑ p21Waf1, p27Kip1 [72]
HL-60-G
(Myeloid leukemia) 10 μM CA (0–48 h)




↑ Raf/MAPK/ERK, AP-1 [73]
HL-60
(Myeloid leukemia) 10 μM CA (0–72 h)
CA potentiated effects of 1,25D






10 μM CA (0–96 h)
CA potentiated effects of 1,25D
↑ differentiation
↓ proliferation
↑ cell cycle arrest
[41]
WEHI-3B D (Murine
myeloid leukemia) 10 μM CA (48–96 h)








K562 (Myeloid leukemia) 2.5–50 μM CA (24–72 h) ↓ cell viability CA sensitizedresistant cells to Adriamycin [80]
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Table 11. Cont.










(18.8– μM) CA (48 h) ↓ cell viability [30]
U937
(Myeloid leukemia) 10 μM CA (96 h)
CA potentiated effects of 1,25-D





10 μM CA (48 h)
Enhances activity of 1,25D







10 μM CA (48 h)
Enhances activity of
doxercalciferol




(Myeloid leukemia) 5–25 μM CA (24–72 h)
↓ viability
↑ apoptosis
↑ cell cycle arrest





(Myeloid leukemia) 25–100 μM CA (4–72 h)
↓ cell survival
↑ apoptosis
↑ cell cycle arrest IC50 5.7 μM






10 μM CA (96 h) CA potentiated effects of 1,25-D↑ differentiation [78]
NB4 (Human





Activation of Nrf2 [79]
1,25-D (1α25-dihydroxyviatminD), GSH (glutathione), Raf (rapidly accelerated fibrosarcoma), MAPK
(mitogen-activated protein kinase), ERK (extracellular signal-regulated kinases), AP-1 (activator protein 1),
JNK (c-jun N-terminal kinases), ROS (reactive oxygen species), c-jun (v-jun sarcoma virus 17 oncogene), ATF2
(activating transcription factor 2), Nrf2 (nuclear factor E2-regulated factor-2), ARE (antioxidant response
element), HPK1 (hematopoietic progenitor kinase 1), casp (caspase), PTEN (phosphatase and tensin homolog).
7. Anticancer Effects of Carnosic Acid (CA): In Vivo Animal Studies
The above studies in vitro provide strong evidence for the anticancer effects if CA in various
cancer cell lines. Several studies using animal models have also explored the effects of CA in vivo
and found significant anticancer effects which supports future research exploring the anticancer
mechanisms of CA in both animal and human models (Table 12). In DMBA-induced models of oral
cancer using hamsters, it was shown that using 10 mg/kg/day CA administered orally for 14 weeks,
caused the number of tumors on the animals to significantly decrease. Furthermore, expression
of detoxification enzymes was enhanced [83], markers of apoptosis including p53, Bax, Bcl-2 and
caspases were increased [84], and regulators of cell growth including COX-2, c-fos, KF-κB and cyclin
D1 were decreased [84]. Using the same hamster model, 750 μg CA dissolved in 0.1mL saline (20 μM)
administered daily for 11 weeks significantly slowed the progression of lesions and oral cancer
development [85]. In mice xenografted with prostate samples from human biopsies, 100 mg CA
dissolved in 100 μL of cottonseed oil administered daily for 25 days decreased tumor growth [86].
Azoxymethane was used to induce colon cancer in mice and 0.01%–0.02% CA fed with a high fat
(45%) diet for 11 weeks decreased both tumor size and number of tumors, and modulated signaling
molecules involved in cell metabolism and cell growth [52]. Serum samples taken from the mice after
treatment showed decreased levels of insulin, leptin and IGF-1 and analysis of tissue samples showed
a decrease in the associated insulin and leptin receptors, as well as decreased activity of ERK and
expression of cyclin D1 and Bcl-xL which regulate cell survival [52]. In K562 leukemia inoculated mice
fed 1% CA with standard powder diet, there was a decrease in the number of leukemic cells which was
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partially attributed to enhanced apoptosis [87]. Furthermore, survival time of the animals increased
significantly [87]. Overall, CA shows significant anticancer effects in mouse and hamster models of
several types of cancer and this evidence provide support of its potential to be used against cancer
in humans.
Table 12. Anticancer effects of Carnosic Acid (CA). In vivo studies.











10 mg/kg/day CA orally
for (14 weeks) ↓ # of tumors
↑ p53, Bax, Bcl-2,
casp 3, casp 9







in 100 μL cottonseed oil
daily (25 days)
↓ tumor growth [86]
DMBA-induced oral
cancer-hamster
750 μg CA dissolved in
0.1 mL saline (20 μM)
daily for (11 weeks)
↓ progression of cancer and
development of lesions [85]
AOM-induced colon
cancer-mice
0.01%–0.02% CA fed with
a high fat (45%) diet for
(11 weeks)
↓ # of tumors
↓ tumor size
↓ insulin, leptin and IGF-1
serum levels compared to
mice fed HFD alone
↓ insulin receptor, leptin





1% (v/v) CA with
standard powdered rodent
diet Ad libitum




Bax (Bcl-2-like protein 4), Bcl-2 (B-cell CLL/lymphoma 2), casp (caspase), COX2 (cyclooxygenase 2), NF-κB
(nuclear factor kappa B), IGF-1 (insulin-like growth factor 1), HFD (high fat diet), p-ERK (phosphorylated
extracellular signal-regulated kinase), Bcl-xL (B-cell lymphoma-extra large), # (number).
8. Anticancer Effects of Rosmarinic Acid (RA): In Vitro Studies
Treatment of HT29 colon cancer cells with RA (5–20 μM) lead to a reduction in COX2 promoter
activity and COX2 protein levels [88] (Table 13). In HCT15 and CO115 colon cancer cells, RA
(10–100 μM) induced apoptosis and decreased levels of phosphorylated-ERK which regulates cell
proliferation [89]. Rosmarinic acid (55–832.6 μM) decreased ROS levels which was associated with
decreased migration and adhesion rates in Ls174-T colon cells [90]. Furthermore, treatment of
CO115 cells with RA (50 μM) protected against BCNU-induced DNA damage, suggesting potential
chemopreventive effects [91]. Treatment of MCF-7 and MDA-MB-231 breast cancer cells with RA
(0–300 μM) decreased cell viability [30,92–94] (Table 13). Rosmarinic acid decreased methyltransferase
activity, which inhibits hyper-methylation of DNA, associated with disease [93], and sensitized a
resistant cell line (MCF-7/Adr) to the chemotherapeutic agent Adriamycin [94].
In DU145 and PC3 prostate cancer cells RA (17.3–138.8 μM) decreased cell viability [30] and in
A2780 and A2790CP70 ovarian cancer cells RA (6.9–27.8 μM) lead to a reduction in cell proliferation
and increased the sensitivity of cisplatin-resistant cells [34] (Table 13). In SCG7901/Adr gastric cancer
cells, RA (0.096–60 μM) was found to decrease cell viability, drug resistance, expression and activity of
p-glycoprotein [95]. Furthermore, treatment of MKN45 gastric cancer cells with RA (200–300 μM) lead
to a decrease in cell viability, the Warburg effect/glucose uptake and pro-inflammatory cytokines [96].
In B16 melanoma cells, RA (1–100 μM) was found to increase melanin content, tyrosinase expression
and CREB phosphorylation [97].
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Table 13. Anticancer effects of Rosmarinic Acid (RA). In vitro studies: colon, breast, prostate, ovarian,
gastric and skin cancer.
Cell Type Dose and Duration Findings Mechanisms Reference
HT-29 (Colorectal
adenocarcinoma) 5–20 μM RA (1 h)
↓ TPA induced COX2





10–100 μM RA (48 h)
↑ apoptosis of HCT15
(50 μM) and CO115
(100 μM)





(55.5–832.6 μM) RA (24 h)
↓ migration rate
↓ adhesion IC50 70 μg/mL ↓ ROS [90]
CO115 (Colorectal




adenocarcinoma) 60 μM RA (24 h) ↓ cell viability [92]
MCF7 (Breast













0.08–10 mM RA EC values:
0.74 mM (in wt) and
0.81 mM (in Adr resistant)
0.08–0.32 mM RA effective












(6.9–27.8 μM) RA (48 h)





(Gastric carcinoma) 0.096–60 μM RA (48 h)




↓ activity of p-glycoprotein
[95]
MKN45





cytokines (IL-6 and STAT3)
[96]
B16 (Skin melanoma) 1–100 μM RA (48 h) ↑ melanin content↑ tyrosinase expression
↑ phosphorylation
of CREB [97]
TPA (12-O-tetradecanoylphorbol-13-acetate), COX2 (cyclooxygenase 2), ERK (extracellular signal-regulated
kinases), ROS (reactive oxygen species), BCNU (1,3-bis-(2-chloroethyl)-1-nitosourea), IL-6 (interleukin-6), STAT3
(signal transducer and activator of transcription 3) CREB (cAMP response element-binding protein) wt (wild
type), Adr (Adriamycin).
Treatment of HepG2 liver cancer cells with RA (25–250 μM) decreased ochratoxin and
aflatoxin-mediated cell damage, apoptosis, ROS levels and caspase 3 activation [98] (Table 14),
suggesting that RA can exert protective effects and prevent cytotoxicity induced by toxic agents.
Alternatively, in HepG2 cells without the presence of cytotoxic agents, RA (13.9 and 27.8 μM) lead
to an increase in apoptosis, which was associated with an increase in caspase 8, NFBIA, TNFSF9
and Jun mRNA and a decrease in Bcl-2 mRNA levels [99]. Thus, RA has several potential anticancer
mechanisms in liver cells. In Hep-3B liver cancer cells, RA (17.3–138.8 μM) was found to decrease cell
viability [30], while treatment of HepG2 liver cancer cells with RA (20–80 μM) showed no significant
changes to cell viability but an increase in Nrf2 nuclear translocation, ARE-luciferin activity, MRP2
levels, intracellular ATP levels and efflux of p-glycoprotein was seen [100]. In NCI-H82 and A549
lung cancer cells RA (10–500 μM) decreased cell growth [30,101] which was associated with decreased
hCOX2 activity, suggesting an anti-inflammatory role of RA [101].
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Table 14. Anticancer effects of Rosmarinic Acid (RA). In vitro studies: liver and lung cancer.
Cell Type Dose and Duration Findings Mechanisms Reference
HepG2 (Hepatocellular
carcinoma) 25–250 μM RA (24 h)
↓ OTA- and AFB-induced
cell damage and apoptosis
↓ DNA and protein
synthesis inhibition induced
by OTA- and AFB-
↓ ROS production




(13.9–27.8 μM) RA (72 h) ↑ apoptosis
↑ casp 8, NFBIA, TNFSF9
and Jun mRNA
↓ Bcl-2 mRNA expression
[99]
HepG2 (Hepatocellular








(24 h or 4 days) ↔cell viability
↑ translocation of Nrf2
↑ ARE-luciferin activity







(17.3–138.8 μM) RA (48 h) ↓ cell viability [30]
A549 (Lung
adenocarcinoma)
10–500 μM RA (48 h)
IC50 198.12 ↓ cell proliferation ↓ hCOX2 activity [101]
OTA (ochratoxin), AFB (Aflatoxin), ROS (reactive oxygen species), casp (caspase), NFBIA (nuclear factor
of kappa light polypeptide gene enhancer in B-cells inhibitor-alpha), TNFSF9 (tumor necrosis factor ligand
superfamily-member 9), Jun (v-jun sarcoma virus 17 oncogene), Bcl-2 (B-cell CLL/lymphoma 2), Nrf2 (nuclear
factor E2-related factor-2), ARE (antioxidant response element), MRP2 (multidrug resistance-associated
protein 2), ATP (adenosine triphosphate), hCOX2 (human cyclooxygenase 2).
Treatment of K562 leukemia cells with RA inhibited cell viability [30] and reversed the induction
of hyperosmosis-induced apoptosis and associated ROS/RNS production [102] (Table 15). In U937
leukemia cells, RA (60 μM) enhanced TNF-α induced apoptosis and decreased TNF-α induced-NF-κB
activation and ROS production [92]. Surprisingly AKT1 and ERK2 levels, which regulate cell survival,
were not affected by RA treatment in U937 or K562 cells [42]. Rosmarinic acid (40 μM) increased
macrophage differentiation induced by ATRA which was mediated by an increase in CD11b expression
on the cell surface [103]. In HL-60 leukemia cells, RA (50–150 μM) inhibited cell growth and induced
apoptosis, which was associated with decreased dNTP levels [104]. CCRF-CEM, CEM/ADR5000
leukemia cells treated with RA (3–100 μM) developed increased cytotoxicity, apoptosis, necrosis, cell
cycle arrest and caspase-independent apoptosis which was mediated by increased PARP cleavage
and blockage of p65 nuclear translocation [105]. In agreement with other studies, RA (0.07–2.2 mM)
exerted DNA protective and anti-carcinogenic effects in HL-60 leukemia cells [106].
Table 15. Anticancer effects of Rosmarinic Acid (RA). In vitro studies: leukemia.
Cell Type Dose and Duration Findings Mechanisms Reference















0.2 mM RA (48 h) Not tested on proliferation ↔ AKT1↔ ERK2 [42]
NB4 (Human
promyelocytic leukemia) 40 μM RA (72 h)
↑ ATRA-induced
macrophage differentiation ↑ expression of CD11b [103]
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Table 15. Cont.
Cell Type Dose and Duration Findings Mechanisms Reference
HL-60 (Myeloid leukemia) 50–150 μM RA (24–72 h)
↓ cell growth
↑ apoptosis
IC50 147 μM (24 h), 74 μM
(48 h), 69 μM (72 h)





3–100 μM RA (72 h)
↑ cytotoxicity
↑ apoptosis and necrosis







HL-60 (Myeloid leukemia) 0.07–2.2 mM RA (72 h) DNA protection andanticarcinogenic effects [106]
ROS (reactive oxygen species), RNS (reactive nitrogen species), TNF-α (tumor necrosis factor-alpha), NF-κB
(nuclear factor kappa-light-chain-enhancer of activated B cells), Akt (protein kinase B), ERK (extracellular
signal-regulated kinases), ATRA (all-trans retinoic acid), dNTP (deoxy-nucleoside triphosphate), PARP
(poly(ADP-ribose) polymerase).
9. Anticancer Effects of Rosmarinic Acid (RA): In Vivo Animal Studies
Apart from the in vitro studies using different cancer cell lines, several studies using RA in animal
cancer models have been performed. Administration of 0.25–1.35 mg of RA (30 min) prior to TPA
treatment was found to decrease myeloperoxidase activity and COX2 induction in mice [107] (Table 16).
Using 1–4 mg/kg RA (20 days) in Lewis lung carcinoma xenografted mice lead to decreased tumor
growth [90] and 100 mg/kg RA (14 weeks) reduced DMBA-induced tumor formation in the buccal
pouches of hamsters [108]. Administration of 360 mg/kg RA from weeks 4 to 12 of the animal’s life
decreased the frequency of large adenomas in mice [109]. Rats given 2.5–10 mg/kg RA for 16 weeks,
showed a decrease in development of DMH-induced aberrant crypt foci by decreasing DMH-induced
elevation of bacterial enzymes [110]. Administration of 100 mg/kg RA 1 week before DMBA treatment
in mice decreased skin tumors by increasing the levels of phase I (cyt p450) and phase II (GST, GR, GSH)
detoxification agents and restoring levels of caspase 3, caspase 9, p53 and Bcl-2 [111]. Venkatachalam,
et al. found that 2.5, 5 and 10 mg/kg RA given to rats for 4 weeks, decreased DMH-induced colon
tumor formation, number of polyps, antioxidant status, CYP450 content, PNPH activity and reversed
the markers of oxidative stress [112]. Hamsters given 1.3 mg/mL RA for 2 weeks were found to have
a decreased incidence of tumors induced by DMBA, decreased tumor grade scoring and increased
tumor differentiation [113]. Rosmarinic acid administered at 2 mg/kg for 14 days to mice had an
anti-Warburg effect, mediated through decreased glucose uptake [96]. Furthermore, administration of
5 mg/kg RA for 30 weeks was found to decrease DMH-induced colon tumor formation in rats through
decreased TNF-α, IL-6 and COX2 levels [110]. Taken together, these studies provide evidence for RA’s
anticancer effects in animal models and suggest several mechanisms which may be responsible for the
inhibition of tumor growth and progression.
Table 16. Anticancer effects of Rosmarinic Acid (RA). In vivo studies.
Animal Model Dose and Duration Findings Mechanisms Reference
Seven-Nine week old male
Balb/c mice




↓ myeloperoxidase activity ↓ COX2 induction [107]
C57BL/6 mice implanted
with Lewis lung carcinoma
1, 2 and 4 mg/kg RA
(20 days) ↓ tumor growth [90]








360 mg/kg RA (8 weeks) ↓ the frequency oflarge adenomas
↑ levels of parent
compound in plasma [109]
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Table 16. Cont.







↓ DMH induced aberrant
crypt foci
↓ DMH induced increase
in bacterial enzymes [110]
DMBA induced skin





↑ status of phase I (cyt
p450) detoxification agents
↑ status of phase II (GST,
GR, GSH) detoxification
agents. Restored activity




cancer (Male Wistar rats)
2.5, 5 and 10 mg/kg RA
(4 weeks)
↓ DMH induced aberrant
crypt foci, number of polyps,
reversed the markers of
oxidative stress, antioxidant
status, CYP450 content and
PNPH activity
[112]
Five month old Syrian
hamsters
1.3 mg/mL RA (2 weeks)
pretreatment
↓ incidence of tumors
↑ differentiation









2 mg/kg RA via celiac
injection daily (14 days) ↓ Warburg effect ↓ glucose uptake [114]
DMH induced colon
cancer (Male Wistar rats)
5 mg/kg RA orally
(30 weeks)






TPA (12-O-tetradecanoylpheorbol-13-acetate), COX2 (cyclooxygenase 2), DMBA
(7,12-dimethylbenz(a)anthracene), DMH (1,2-dimethylhydrazine), p53 (tumor protein p53), casp (caspase), Bcl-2
(B-cell CLL/lymphoma 2), CYP450 (cytochrome p450), GST (Glutathione S-transferase), GR (glucocorticoid
receptor), GSH (glutathione), PNPH (p-nitrophenol hydroxylase), TNF-α (tumor necrosis factor alpha),
IL-6 (interleukin-6).
10. Dosage and Bioavailability
The effects of RE have been studied in many cancer cell lines and although the concentrations
used in the in vitro studies are variable (0.1–500 μg/mL) it appears that the concentrations in the
range of 0.1–100 μg/mL are most effective. Similar to in vitro studies, the reported doses of RE used
in vivo are within a wide range (1 mg/mL drinking water −3333.3 mg/kg/day). This high variability
suggests the need for more systematic studies to identify effective RE doses in vivo. One study has
examined the levels of RE components in the plasma and tissue samples of animals administered
with RE. Administration of a single dose of RE (100 mg/mL water) enriched in CA (40% w/w) by
intragastric gavage in rats was followed by measurements of RE compounds and metabolites in plasma,
liver, small intestine content and brain. The researchers tentatively identified 26 compounds and the
main metabolites detected in plasma, liver and gut were glucuronide conjugates of CA, carnosol and
rosmanol [115]. Metabolites were detected as early as 25 min after oral administration and most of the
compounds remained present at substantial concentrations (micromolar range) for several hours [115].
Doolaege, et al. reported that 64.3 mg/kg (193.43 mM) CA orally administered to rats resulted in a
plasma concentration of 0.015 mg/mL (45.12 μM) [116]. Another study reported that ingestion of
360 mg/kg/day RA after 8 weeks resulted in a plasma concentration of 1.1 μM [117]. The reported
plasma concentrations of CA, carnosol and their metabolites were in the micromolar range indicating
that absorption and bioavailability are likely not barriers for these components of RE [114,115,118].
Another important issue that must be systematically examined in well-designed studies are the
potential toxicity of chronic administration of RE and RE polyphenols. Rosemary extract has already
been approved as a safe food additive by the European Food and Safety Authority (EFSA) [119] and
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is considered to be generally recognized as safe by the United States Food and Drug Administration
(FDA) (21CFR182.10). In a study reviewed by the EFSA, rosemary was found to have low acute and
sub-chronic toxicity in rats and the only effect at high doses was a slight increase in relative liver
weight, which has been shown to be reversible. Overall, 90 day RE administration (180–400 mg/kg/day,
equivalent to 20–60 mg/kg/day of carnosol plus CA) in rats revealed no observed adverse effect
levels (NOAEL) (reviewed in [119]). Furthermore, an acute single dose of 24 and 28.5 g/kg RE to
female and male mice respectively or the daily administration of 11.8 and 14.1 g/kg to female and
male mice respectively for 5 days resulted in no gross macroscopic lesions observed on autopsy
besides fatty liver in mice subjected to repeat administration of the extract indicating low acute toxicity
(reviewed in [119]). In another study, it was reported that an LD50 of 169.9 mg/kg/day RA was found
in mice implanted with Lewis lung carcinoma cells [90]. One study performed in humans used a
powdered RE mixed with citrus extract (1:1 ratio) (Nutroxsun™) which was consumed daily (250 mg)
for 3 months. Results showed a protective effect against UV-induced skin damage. Significant results
were seen after 8 weeks and continued to increase after 85 days of treatment [120]. Overall, the limited
in vivo studies report doses of RE or RE components that are relatively high and showed minimal
to no adverse effects, indicating low toxicity. Nonetheless, further research should be performed to
confirm maximum recommended doses of RE and RE components.
In humans, to achieve RE polyphenol levels that will provide health benefits high intake of
rosemary would be required, which is not practical. A more reasonable direction for the potential
future use of RE and its polyphenols as anticancer agents would be to develop easily ingestible and
soluble pills containing RE or RE components. Overall, the studies available currently suggest that
RE and its polyphenols CA and RA are good candidates for drug development and further research
examining the effective doses in animals is required before any clinical studies in humans are initiated.
In addition, systematic studies in animals to examine if chronic administration results in any toxicity
are required before clinical human studies.
It should be noted that in recent years, scientists have recognized that the gut microbiota plays an
important role in overall health and disease prevention. Although certain plant bioactive compounds
may be poorly bioavailable, the gut bacteria may generate metabolites that are more potent than the
parent compounds. A recent study found that administration of RE rich in CA (40% w/w) in rats had
a selective effect on caecum microbiota (increased the Blautia coccoides and Bacteroides/Prevotella
groups and reduced the Lactobacillus/Leuconostoc/Pediococccus group), decreased β-glucosidase
activity and increased fiber fecal elimination [121]. These data are associated with the decreased body
weight and the improvement of the metabolic and inflammatory status seen with RE [121]. Although
the above study suggests a potential prebiotic effect of RE administration against metabolic disorders
and obesity, there are no studies specifically examining the effect of gut microbiota on RE metabolites.
11. Conclusions
It should be noted that the levels of polyphenols and bioactive compounds present in RE may be
affected by many factors such as the plant growing conditions (soil, climate, exposure to stressors).
Additionally, the extraction method and storage of RE may affect its potency. Water, methanol, ethanol
and supercritical carbon dioxide extraction are methods which have been used in different studies and
evidence suggests that methanol (alcoholic-solvent) extraction may lead to RE with higher potency
(lower IC50) [31]. Since the source and extraction method of RE may affect its potency/biological
activity, this issue should be taken into consideration when future studies are planned.
In recent years, focus has shifted towards establishing new targeted cancer treatments that can
modulate specific pathways often mutated in cancer. RE and its polyphenols CA and RA may be
used as chemicals to target specific pathways leading to induction of apoptosis and decreased cell
survival. In addition, RE, CA and RA may be used as neutraceuticals to enhance the anticancer effects
of current chemotherapeutics. This could allow for lower doses to be used and less toxicity induced in
healthy surrounding tissue. Although studies examining signalling molecules and pathways targeted
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by RE, CA and RA are limited, the existing studies provide supporting evidence for the use of these
compounds both on their own and in combination with other cancer therapies.
Overall, RE, CA and RA have been shown to have various potent and effective anticancer
properties. However, more systematic studies are required in animals before human studies are
initiated. The in vivo animal studies should find (1) the doses to be administered; (2) the best route of
administration; (3) the plasma levels of CA, RA and other RE bioactive ingredients; (4) the signaling
molecules/pathways affected; and (5) any possible toxic effects associated with chronic administration.
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Abstract: Resveratrol and curcumin are natural products with important therapeutic properties
useful to treat several human diseases, including cancer. In the last years, the number of studies
describing the effect of both polyphenols against cancer has increased; however, the mechanism of
action in all of those cases is not completely comprehended. The unspecific effect and the ability to
interfere in assays by both polyphenols make this challenge even more difficult. Herein, we analyzed
the anticancer activity of resveratrol and curcumin reported in the literature in the last 11 years,
in order to unravel the molecular mechanism of action of both compounds. Molecular targets and
cellular pathways will be described. Furthermore, we also discussed the ability of these natural
products act as chemopreventive and its use in association with other anticancer drugs.
Keywords: cancer; resveratrol; curcumin; polyphenols; anticancer
1. Introduction
Over the last years, the number of searchers involving polyphenols has increased meaningly.
The major reason for that includes the presence of these compounds in our diet contributing to
prevention of several diseases. In addition, potent antioxidant properties of polyphenols reduce
oxidative stress-associated with some diseases, including cancer. It has been described that polyphenols
inhibit carcinogenesis and induce tumor cell death [1].
Among the polyphenols, the interest in two of them has increased in the last years. Papers describing
curcumin and/or resveratrol are present in almost fifteen thousand of publications in the last ten years.
Both polyphenols have been described as promising anticancer compounds; however, the mode of
action for them are still unclear and not fully comprehended [2].
Curcumin (diferuloylmethane) is an active ingredient of the perennial herb Curcuma longa,
also known as turmeric. The yellow color of this polyphenol is chemically related to its major
fraction, which contains curcuminoids [3]. Curcumin has been used for a long time in countries such
as China and India as traditional medicines. This ancient remedy has brought the attention of scientific
community for a wide range of beneficial properties including anti-inflammatory, antioxidant and
chemopreventive [4,5].
By the other hand, resveratrol (trans-3,5,4′-trihydroxystilbene) is a stilbene phytoalexin synthetized
by a variety of plants, specially vine in response to fungi infections and ultraviolet radiation [6].
This compound is found at high concentration in grapes and red wine, which antioxidant effect is well
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established in several different assays. Resveratrol has been investigated as potential compound for
the treatment of several diseases, regulation of immune system and chemoprevention [7,8].
In clinical studies, the common issue regarding both compounds is the reduced aqueous
solubility and low bioavailability [3,9–11]. In order to overcome these limitations, studies have
been conducted using several strategies. For curcumin, for example, these strategies include:
(a) complexation with metal ions, such as Zn2+, Cu2+, Se2+ and Mg2+ [12]; (b) co-administration with
piperine, which inhibits the phase II metabolism of curcumin and increases its bioavailability [13,14];
(c) Pharmaceutical technologies such as micelles formation and nanoencapsulation were used to
increase the bioavailability of curcumin [15–23]. Resveratrol has been extensively studied aiming
to enhance its aqueous solubility and bioavailability and a number of techniques were used
to achieve this goal [24], including: (a) nanoencapsulation [25–28]; (b) prodrug approach [29];
and (c) co-administration with piperine [30]. These polyphenols have exhibited very low or
not-observed toxic effects at daily intake of 0–3 mg·kg−1 body weight for curcumin [3] and
0.073 mg–5 g for resveratrol [31]. However, in humans at high doses either curcumin and resveratrol
can cause side effects such as diarrhea, skin rash, and headaches [3,31–34].
Another concern about these both polyphenols is the ability to perturb membranes and alter
protein function, that leads to false-results in a series of assays described in the literature [35–37].
Therefore, this review article proposes to investigate the real mechanisms involved in the anticancer
effect of resveratrol and curcumin in order to clarify the mode of action of both compounds as
anticancer drugs useful for prevention and treatment.
2. Cell Proliferation
The antiproliferative effects of curcumin and resveratrol are associated with the modulation of
transcription factors, protein kinases, cell cycle regulatory proteins, and inhibition of angiogenesis [9,10].
Some targets related to its effect are presented as following (Figure 1).
Figure 1. Effects of curcumin and resveratrol in cellular proliferation and angiogenesis.
2.1. Transcription Factors
2.1.1. NF-κB
Nuclear Factor-kappa B (NF-κB) is a pro-inflammatory transcription factor that regulates
the expression of more than 200 genes, which are involved in innate and adaptive immunity,
cellular transformation, proliferation, antiapoptosis, angiogenesis, invasion and metastasis [38].
Moreover, NF-κB regulates several pro-inflammatory cytokines including, IL-1, IL-2, IL-6, TNF-α and
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monocyte chemotactic protein 1 (MCP-1). These cytokines are released in chronic inflammation states
associated to various cancers [39–42].
NF-κB is found in an inactive state in the cytoplasm and its activation occurs through the action
of a variety of stimuli, such as, carcinogens, mitogens, chemotherapeutic agents, radiation, hypoxia,
protein kinases, and degradation of the NF-κB cytoplasmic inhibitor (I-κB) [43–45]. Subsequently its
activation, NF-κB translocate to the cell nucleus and binds to the target DNA gene promoter region [46].
Luciferase assay was performed transfecting series of plasmids into PC-3 cells with luciferase
reporter gene. The data showed down regulation of NF-κB blocking the development and progression
of prostate cancer cells (PC-3) [47].
Curcumin showed a potent antiproliferative effect on melanoma cell lines by NF-κB inhibition.
Three melanoma cell lines were treated with curcumin and it has shown a decreasing of NF-κB binding
activity through electrophoretic mobility shift assay (EMSA), and an inhibition of cell viability in
a dose-dependent manner with IC50 ranging from 6.1 μM to 7.7 μM [48].
2.1.2. AP-1
The activating protein-1 (AP-1) transcription factor is related to control an extensive range of
cellular processes, including cell proliferation. Dysfunctions in the AP-1 transcription factor levels are
associated to the growth and progression of many types of cancer [49]. AP-1 showed to be required for
binding in the involucrin (hINV), which is a marker of keratinocyte differentiation [50].
Using a High-Throughput Cell-Based Assay, it was identified potentials AP-1 inhibitors. In this
assay, curcumin has shown inhibiting AP-1 in the dose-dependent manner with IC50 values of
100 μM [51].
In a different study, using fluorescent cell-staining assay it was shown that curcumin also
suppress the in vitro growth of PC-3 cells. By a luciferase assay, it was determined the intracellular
signal pathway via inhibition of androgen-induced AP-1 activity in prostate cancer cells (PC-3).
Flow cytometry data indicated that curcumin arrested 57.29% of PC-3 cells in G2/M phase, and reduced
to 23.89% of cells in the S phase [47].
2.1.3. EGR—Early Growth Response
The Early Growth Response gene (EGR-1) is activated by stress, injury, mitogens and
differentiation [52]. This gene regulates the expression of other genes, which are involved in the
control of growth and apoptosis such as: p21, p53, PTEN, Gadd45 [53].
Curcumin suppressed proliferation in human high-metastatic NSCLC cells 95D by EGR-1 in
a dose-dependent manner. NSCLC cells transfected with EGR-1 siRNA notably inhibited EGR-1
expression, specifically siRNA3 [52]. Also, it has been found that curcumin inhibits human colon
cancer cell growth via suppressing EGR-1 [54].
2.1.4. β-Catenin
The β-catenin is located in three cellular pools (cell membrane, cytoplasm and nucleus), mainly in
the cell membrane [55]. The main event of the activation of Wnt/β-catenin pathway is the nuclear
translocation of beta-catenin, which binds to T-cell factor (TCF) in the nucleus [56]. The intracellular
levels of beta-catenin are regulated by the phosphorylation of GSK-3β. Curcumin showed suppressing
this phosphorylation in LNCaP prostate cancer cells, inducing the degradation of beta-catenin affecting
the cell proliferation [56].
Curcumin suppressed cell growth by inhibiting the activation of Wnt/β-catenin pathway in
desmoplastic cerebellar medulloblastoma (DAOY) cells. In this study, the expression of nuclear
beta-catenin was significantly decreased; however, there was no effect on the expression of cytoplasmic
beta-catenin levels. In addition, curcumin promote the activation of GSK-3β and its downstream target
cyclin D1. The authors concluded that curcumin could be useful in the medulloblastoma treatment [57].
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2.2. Protein Kinases
Protein kinases are a group of tyrosine or serine/threonine kinase enzymes whose function
is to modify others proteins by attaching phosphate groups through the phosphorylation process.
Tyrosine phosphorylation has a vital role in several important cellular pathways of eukaryote
physiology, as well as in human diseases [58,59].
Protein kinases mediate most of the intracellular signal-transduction pathways in eukaryotic cells,
control metabolism, transcription, mRNA processing, cell division, apoptosis and differentiation.
Moreover, tyrosine phosphorylation mediated by protein kinases also regulate communication
between neighboring cells, motility of cells and transport of molecules to within the cell [60,61].
Deregulation in tyrosine phosphorylation has been associated to a variety of cellular disorders and
human diseases, such as cancer, diabetes, cardiovascular disorders, inflammatory diseases and immune
deficiencies [62–65]. Specifically related to cancer, several studies have shown that deregulation of
several protein kinases, including MAPK, Raf kinase, Akt, mTOR, MLK3, Src kinase, AMPK and
protein kinase D are associated to a variety of cancers, such breast, gastric, thyroid, prostate, lung,
liver and colorectal cancer [66–74].
2.2.1. EGFR—Epidermal Growth Factor Receptor
Also known as ErbB1 or HER1, EGFR is a member of the ErbB family of receptors. The structure
of EGF receptor is represented by an extracellular ligand-binding domain, a single transmembrane
region with hydrophobic characteristics, and an intracellular module including the tyrosine kinase
domain [75].
The EGFR pathway contributes in many ways to cancer proliferation and angiogenesis to many
types of cancer. Curcumin decreased expression of EGFR, and also EGFR mRNA levels in bladder
cancer cells [76].
An autophosphorylation activity of the EGFR tyrosine kinase have been observed after
a short-term treatment of curcumin in dose and time dependent manner in human epithelial cancer
cells (A431). Curcumin was able to inhibit EGFR tyrosine kinase in a concentration of 1 μM after 4 h of
cell exposoure. The exact molecular mechanism of this short-term inhibition remains unknown [75].
2.2.2. Polo-Like Kinase (PLK)
Polo-like kinases are important proteins on regulation of the cell cycle. It is related to spindle
assembly, which has been found in high levels in colorectal cancer than normal colon tissues [77].
Curcumin downregulates PLK resulting in inhibition of the cell growth. It was characterized that
curcumin promote cell cycle arrest in the G2/M phase and decrease the expression of some genes
including tubulin genes and p53 related to colon cancer [78]. In some cancer cell lines, inhibition of
PLK leads to cellular senescence correlating to the number of cells arrested in mitosis [79].
2.2.3. Phosphatidylinositol 3-Kinase (PI3K) Pathway
PI3K is a protein that acts in the mechanism of cell survival. Its expression or activation is
upregulated in diseases, such as diabetes and cancer. Akt is a mediator of PI3K signaling and affects
directly the apoptosis process, targeting related proteins [80].
The influence of PI3K/Akt pathway and the effect of RES on cell growth were evaluated in
different cancers cells. PI3K and MAPK are associated with HIF-1α accumulation and increase of
VEGF expression, leading to angiogenesis [81]. In a study conducted to evaluate the influence of the
RES in the accumulation of HIF-1α and VEGF expression in human tongue squamous cell carcinoma
and hepatoma cells induced by hypoxia condition, it was observed that resveratrol was able to reduce
the accumulation of HIF-1α and the expression of VEGF through inhibition of Akt and p42 and p44
MAPK phosphorylation [82].
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In another study using human diffuse large B-cell lymphoma, it was observed that the resveratrol
inhibited Akt phosphorylation following downstream targets, such as p70 S6K, S6 ribosomal and
FOXO-3a. More specifically, it provides an improved comprehension of one possible mechanism
of action, which involves the inhibition of PI3K pathway. This inhibitory effect exhibited a direct
relationship with a decreased activity in the glycolysis pathway and may be the cause of cell cycle
arrest in G0/G1 phase according authors observations [83].
The exposure of prostate cancer cells to resveratrol demonstrated that inhibition of the PI3K
pathway reduces the phosphorylation of GSK-3 protein, which is related with the modulation of
expression of cyclin D1, and decreases the activation NF-κβ [84,85].
2.2.4. MAPK (p38 e ERK)
Resveratrol effects on MAPK are described in the literature. Using breast cancer cells, it was
demonstrated that this polyphenol causes cycle cell arrest in S/G2M phase and upregulates the
levels of phosphorylated p38 e ERK and increase p21 and p53R2 levels [86]. Another study using
the same type of cancer cells also demonstrated the activity of resveratrol in the activation of p38.
Resveratrol caused cycle cell arrest in G0/G1 phase. It also increased the activation of p38, p21 and
p53 levels and decreased pRb hyperphosphorylated. Additionally, it was observed inhibition of ER
expression, related to p53 activity. ER is described to play an important role in breast cancer cell
proliferation [87].
2.3. Phosphodiesterases (PDEs)
Phosphodiesterases consist of a family containing 11 isoenzymes, which are responsible for
hydrolyze two important second messengers that regulate cellular responses to external stimuli:
the cyclic adenosine-3′,5′-monophosphate (cAMP) and the cyclic guanosine-3′,5′-monophosphate (cGMP).
These isoenzymes play an important role in cancer, and were found to be upregulated in
angiogenesis and various types of tumors. For curcumin, it was found modifications in the pattern
of PDE1A expression at transcriptional level. After curcumin treatment, the expression of PDE1A
was dramatically reduced in B16F10 melanoma cancer cells. These findings indicate that PDE1A
has an important role in the anti-proliferative effects of curcumin, and its inhibition may recover
normal intracellular signaling contributing to the treatment [88]. Other isoforms (PDE2 and PDE4)
were described to be upregulated in human umbilical vein endothelial cells (HUVECs). In these cells,
the inhibition of PDE2 and PDE4 activities decrease the angiogenesis and cell proliferation [89].
2.4. Angiogenesis
Angiogenesis is involved in several biological processes. Nonetheless, its involvement in
pathological processes, notably in tumor growth and metastasis still have been extensively
investigated [90]. Some important pro-angiogenic and anti-angiogenic factors include: VEGF, MMPs,
FGF (fibroblast growth factor) and HGF (hepatocyte growth factor). However, among these factors,
VEGF and its receptors were described to be key regulators of both physiological and pathological
vasculogenesis and angiogenesis [91,92].
VEGF is an important and multifunctional signaling glycoprotein that comprises a family of
structurally related mitogens: VEGF-A, VEGF-B, VEGF-C, VEGF-D and placental growth factor (PIGF).
These growth factors regulate a family VEGF receptors tyrosine kinases (VEGFR-1, VEGFR-2 and
VEGFR-3) and promote endothelium regeneration, blood vessel regeneration and increase vascular
permeability. However, VEGF-A (commonly known as VEGF) is the central member of the VEGF
family and the majority of angiogenic effects related to these growth factor family are attributed to the
interaction of VEGF-A with VEGFR-2 [93,94].
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HIF-1/VEGF/bFGF
Cancer tumors activate hypoxia-inducible factor (HIF) under hypoxic conditions as a survival
mechanism that ultimately leads to angiogenesis progression. It has been reported the effect of
curcumin on vascular endothelial cells under hypoxic conditions using human umbilical vein
endothelial cells (HUVECs). Specifically, curcumin downregulates HIF-1α protein and VEGF
expression by blocking hypoxia-stimulated angiogenesis [95] and demonstrates anti-proliferative
and anti-angiogenic properties [96].
During the tumor development, VEGF is a critical pro-angiogenic stimulator for neovascularization.
The VEGF-VEGFR-2 complex is required to maintain a subset of vasculatures in healthy tissues and
organs. Curcumin can block the VEGF-VEGFR-2 signaling pathways in HUVECs by suppressing the
phosphorylation of VEGFR-2 induced by VEGF [97].
The effects of resveratrol against VEGF alter cell proliferation in endometrial cancer [98],
myeloma [99], osteosarcoma [100], renal cancer [101] and melanoma [102]. High levels of VEGF
were observed in endometrial carcinoma cells cultured in vitro under hypoxia conditions. However,
after resveratrol treatment it was observed a reduced level of VEGF in a dose dependent manner,
suggesting an anti-angiogenic activity when angiogenesis is induced under hypoxia [98].
The cellular viability of osteosarcoma cells and human renal cancer cells was evaluated in the
presence of resveratrol. It was observed a dose dependent inhibition of growth in both cells, with no
detectable VEGF and VEGF mRNA even at high doses of resveratrol (up to 40 μmol/L) [100,101].
Resveratrol also inhibited in a dose dependent manner the proliferation, migration and tube
formation of HUVEC induced by co-culture with myeloma cell. In order to comprehend the mechanism
that resveratrol acts in angiogenesis, it was determinate the levels of VEGF, basic fibroblast growth
factor (bFGF) and metalloproteinases 2 and 9 (MMP-2 and MMP-9) [99]. Interestingly, it was found
that resveratrol inhibited the expression of VEGF and bFGF, besides to suppress the expression of
MMPs, which may explain its effect in the angiogenesis [99].
Additionally, studies to characterize the antiangiogenic effect of RES were evaluated in a chick
chorioallantoic membrane (CAM) model. Resveratrol reduced the angiogenesis in the membrane
induced by fibroblast growth factor-2 (FGF-2). Moreover, the tumor growth in the CAM model was
inhibited, as well as, the angiogenesis. The level of p53 was quantified and a significant reduction was
determinated after treatment using resveratrol. This results suggest an apoptotic effect induced by
resveratrol, which might be responsible to stop tumor growth and angiogenesis [103].
2.5. Cell Cycle Regulators
The cell cycle is divided into four main phases: G1-S-G2-M. The G1 phase, also known as GAP 1,
is the first growth stage of the cell cycle. During the S (synthesis) stage, the chromosomes of somatic
cells are replicating. The G2 phase (GAP 2) is the final sub-phase of interphase in the cell cycle, prior to
mitosis (M phase) [104].
Cyclin B1 is overexpressed in many tumors and is needed to forward cells from G2 phase
to M phase during the cellular cycle. It was demonstrated that after 24 h of curcumin treatment,
protein and mRNA levels of cyclin B1 were downregulated. In addition, flow cytometry data have
shown arrested effect on cell cycle involving G2/M phase in small cell lung cancer (SCLC) cells [105].
Curcumin inhibits cyclin-dependent kinase 2 (CDK2) activity in vitro and decrease the
proliferation of colon cancer cells, indicating G1 cell cycle arrest in a dose-dependent manner.
The percentage of sh-CKD2-transfected HCT116 colon cancer cells in G1 phase was higher
after curcumin treatment that those of control groups. Computational molecular docking studies
have demonstrated a very good binding affinity between CDK2 and curcumin with a score of
−12.69 kcal/mol, validating previous in vitro data [106].
Resveratrol has been described to cause cell cycle arrest in different types of cancers, mainly at
low concentrations. Cycle cell arrest between the G1 and S phases were observed in prostate cancer
cells [107], pituitary prolactinoma [108], human epidermoid carcinoma [109] and lung cancer cells [110].
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Similar results were found in these studies, showing that resveratrol decreased the levels of cyclins
(D1 and D3) and of CDK (4 and 6). In addition, resveratrol increased the expression of p21 and p27.
Furthermore, the inhibition of cell proliferation of pituitary prolactinoma cells, an estrogen-dependent
tumor, caused by resveratrol persists after the end of the exposure of this compound, which indicates
an irreversible suppressive effect [108]. The phosphorylation of pRb was inhibited in two different
type of cells exposured to resveratrol [108,109]. Resveratrol was described to inhibit kinases, therefore,
authors assumed that a reduction of cyclin D1 levels could be associated with this effect [109].
The exposition of hepatocarcinoma cells to resveratrol induces cell accumulation in S phase,
by a reversible process. Regarding cell cycle regulators, it was observed reduction in the levels of
cyclin D1 and p21. However, the levels of phosphorylated CDK2 and Chk2 have been increased.
PI3K pathway may be related, in part, with cell cycle arrest in S phase [111].
In addition, it was observed that resveratrol treatment of oral squamous carcinoma cells resulted
in cell cycle arrest in G2/M phase. It was also observed an increase in cyclin A and B levels,
possibly related to the high expression of protein kinase Myt-1 [112].
2.6. SIRT
Sirtuin family is composed by seven sirtuins types, defined as NAD+-dependent histone
deacetylases. SIRT-1 is responsible for deacetylation of transcriptional factors, DNA repair proteins
and signaling factors. It regulates important biological activity, including cell survival, gene expression,
metabolism and senescence [113].
Resveratrol has been described as a potential SIRT activator, since this compound inhibited cell
proliferation in a SIRT-1 dependent way. In this study, the anti-proliferative effect of this compound
was studied only in gastric cancer cells that could express SIRT-1. It was observed that resveratrol
treatment caused a G1 phase arrest, decrease the levels of cyclin D1, CDK4 and CDK6 and increase
the levels of p21. In knockout cells that can express SIRT-1, resveratrol was not capable to inhibit cell
proliferation [114].
Similary, in a study using breast cancer cells, resveratrol inhibited cell proliferation by stimulating
SIRT-1. Activation of AMPK pathway leads to mTOR activation, which stimulates the cell proliferation.
It was observed that resveratrol can block AMPK phosphorylation by SIRT-1 activity overexpressed in
tumor cells [115].
The effects of resveratrol on cell proliferation of hepatocarcinoma cell under high concentration
of glucose were evaluated in another study. The results showed that high glucose concentration
upregulated activated STAT-3 and enhanced cellular viability. Resveratrol was able to suppress
proliferation and activation of STAT-3 and Akt [116].
2.7. Others Targets
Others proteins, enzymes, and transcription factors involved in cell proliferation and described as
target for curcumin and resveratrol are described in Tables 1 and 2.
Table 1. Antiproliferative targets for curcumin.
Target Effect Cancer Type Reference
GRP78 downregulation Colon [117]
EphA2 downregulation Melanoma [118]
SOCS1 & 3 upregulation Leukemia [119]
Nrf2 downregulation Breast [120]
miR-15a/16-1 downregulation Leukemia [121]
DLEC1 upregulation Colon [122]
Skp2 downregulation Glioma [123]
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Table 2. Antiproliferative targets for resveratrol.
Target Effect Cancer Type Reference
PKC downregulation gastric [124]
eEF1A2 downregulation ovarian [125]
pro-IGFII upregulation breast [126]
PTEN upregulation breast [127]
MIC-1 upregulation pancreas [128]
6-PF1K inhibition breast [129]
RNF20 activation breast [130]
Nox5 upregulation lung [131]
uH2B downregulation glioma [132]
3. Metastasis
Although several advances have been achieved in the last years against cancer, the mortality rate
related to metastasis is still about 90% [133–135]. Therefore, cellular pathways involved in metastasis
have been extensively described as promising therapeutic target for a variety of cancers [136–138].
Metastasis is the spread and growth process of solid cancers cells from the original neoplasm to distant
organs through several cellular mechanisms, such as angiogenesis, invasion and proliferation [139,140].
The process involved in metastasis is fairly complex and begins when primary cancer cells break away
from their original tumor environmental and invade through the basement membrane reaching the
circulation. Subsequently, these metastasizing cells will reach and settle microenvironment in distant
organs [141]. This metastatic progression depends on several biochemical, genetic and epigenetic
factors in the original tumor cells and association to the new microenvironment [142].
Curcumin and resveratrol modulate many of these cellular pathways, including transcription
factors, proteins, enzymes and growth factors (Figure 2) [143]. Although the precise mechanism
of action of polyphenols remains unclear, several studies have highlighted the inhibitory effect of
these compounds in a number of molecular targets and signaling pathways involved in cancer
metastasis [144–147]. In this section, we highlighted the major cellular targets involved in metastasis
that curcumin and resveratrol have the ability to modulate.
Figure 2. The control of metastasis by curcumin and resveratrol.
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3.1. NF-κB Signaling Pathway
Curcumin is able to modulate NF-κB signaling pathway directly and indirectly by downregulation
or upregulation some key factors. Aggarwal and coworkers demonstrated that curcumin inhibited
tumor cell invasion through inhibition of I-κB kinase complex (IKK) and protein kinase B (Akt) in
human myeloid leukemia and human embryonic kidney cells. The inhibition of IKK and Akt blocks
the phosphorylation of p65, which led to a suppression of cellular events required for NF-κB gene
expression. As a result, the inhibition of NF-κB by curcumin resulted in downregulating of several
NF-κB-regulated gene products involved in cellular proliferation and metastasis including COX-2,
cyclin D1, c-myc, MMP-9, VEGF and intercellular adhesion molecule-1 [148].
Similarly, it was also demonstrated that curcumin inhibits translocation of NF-κB from
the cell nucleus by inhibition of the I-κB kinase complex in both, breast and prostate cancer
cells [149,150]. The authors have demonstrated that inhibition of NF-κB activity reduces the expression
of inflammatory cytokines, such as, CXCL1 and CXCL2. Some cancer cells with potential to metastasize
to lung overexpress these inflammatory cytokines and promotes infiltration of inflammatory cells,
which lead to angiogenesis and metastasis process [151]. Moreover, in vivo experiments using mice
demonstrated that curcumin was able to reduce the number of lung metastases formed from circulating
prostate cancer cells after 35 days of treatment [150].
In fact, several studies have demonstrated the narrow relationship between curcumin and
NF-κB signaling pathway in cancer metastasis. Narasimhan and Ammanamanchi have shown that
curcumin was able to block the invasion of breast carcinoma cells using a matrigel invasion experiment.
They have concluded that curcumin reduced the expression and transcriptional activity of NF-κB
p65 protein and decreased the levels of the Recepteur d’Origine Nantais tyrosine kinase (RON) [152].
RON plays an important role in cell proliferation, differentiation and metastasis. Its overexpression in
patients with breast cancer is associated to a poor prognostic [153].
Zong and colleagues also demonstrated the potential therapeutic application of curcumin to
inhibit metastatic progression of breast cancer cells. They investigated the urokinase-type plasminogen
activator (uPA), a serine protease protein that plays an important role in tumor growth and metastasis.
The authors found that curcumin was able to reduce uPA expression through downregulating NF-κB
activity [154].
In a different work, the inhibition of the human astroglioma cells invasion and metastasis was
reported for curcumin. The authors proposed that mechanism of action involves the downregulation
of NF-κB, which resulted in an inhibition of matrix metalloproteinase-9 [155]. Interestingly, an in vivo
study using human prostate adenocarcinoma LNCaP xenograft cells demonstrated that curcumin was
able to reduce metastatic process in mice though inhibition of NF-κB activity leading to a reduction in
the expression of its related genes, including VEGF, Bcl-2, Bcl-XL, uPA, cyclin D1, MMP-2, MMP-9,
COX-2 and IL-8 [156].
By the other hand, the activity of resveratrol against NF-κB during metastasis is also described
by several groups. Chen and colleagues have reported that resveratrol successfully inhibited
epithelial-mesenchymal transition in mouse melanoma model and reduced cancer migration and
metastasis. The authors concluded that resveratrol downregulated NF-κB activity and influenced
in epithelial-mesenchymal transition [157]. In another study, it was demonstrated that resveratrol
was able to block the migration and invasion of human metastatic lung and cervical cancer cells.
Resveratrol inhibited the activity of NF-κB and AP-1 leading to reduction in MMP-9 expression [158].
Liu and coworkers also demonstrated the effect of resveratrol on NF-κB inhibition and its downstream
events in human lung adenocarcinoma cell metastasis [159].
Heme oxygenase 1 (HO-1) is an important enzyme involved in angiogenesis and tumor metastasis
and its activity have been associated to matrix metalloproteinases expression [160]. Resveratrol
suppressed NF-κB activity leading to inhibition of HO-1 and subsequently downregulating the
expression of MMP-2 and MMP-9 in lung cancer cells [159]. Resveratrol was also reported
acting as an inhibitor of cancer invasion and metastasis of human hepatocellular carcinoma cells.
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The authors have demonstrated that resveratrol suppressed TNF-α-mediated MMP-9 expression
through downregulation of NF-κB signaling pathway activity [161].
Ryu and coworkers have reported the antimetastatic activity of resveratrol in human glioma
cancer cells induced by TNF-α overexpression. Resveratrol suppressed NF-κB activation and
downregulated the expression of urokinase plasminogen activator (uPA), thereby leading to a reduction
of TNF-α-induced cell invasion [162]. Adhesion molecules, such as intracellular adhesion molecule-1
(ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), E-cadherin and E-selectin plays a central role
in endothelial adhesion of a number of cancer cells and are closely related to cancer invasion and
metastasis [163,164]. Therefore, the inhibition of cellular pathways related to adhesion molecules have
been considering as a promising anti-metastasis target [165]. Park and colleagues have demonstrated
the anti-metastatic activity of resveratrol in human fibrosarcoma cells. Resveratrol blocked cancer cell
adhesion to endothelial cells through inhibition of ICAM-1 expression; however, they observed that
this downregulation of ICAM-1 expression was due to suppression of NF-κB activation. Therefore,
indirectly the inhibition of NF-κB pathway has an important role in ICAM-1 expression [166].
3.2. Matrix Metalloproteinase (MMP)
Matrix metalloproteinases (MMPs), collectively called matrixins, represents a group of enzymes
with proteolytic activity that exist in the extracellular matrix (ECM) and are involved in most of the
physiological conditions, including embryogenesis, reproduction, organ development, wound healing,
angiogenesis and apoptosis [167,168]. These zinc-dependent endopeptidases also plays a vital role
in the spread and dissemination of cancer and are closely related to tumor metastasis process [169].
The proteolytic activity of MMPs involves the ECM degradation and evidences have shown that the
expression of specific MMPs, such as MMP-2 (Gelatinase A) and MMP-9 (Gelatinase B), are associated
with a wide range of human cancers [170–173].
Several studies have shown the potential use of curcumin in cancer metastasis by reducing
the expression and activity of matrix metalloproteinases. Chen and colleagues have demonstrated
that curcumin suppressed migration and invasion of human endometrial carcinoma cells.
Curcumin successfully reduced the expression of MMP-2 and MMP-9 through downregulation of the
extracellular signal regulated kinase (ERK) signaling pathway [174]. This protein kinase is involved in
the biosynthesis of MMP and plays a vital role to regulate the proliferation and invasion of endometrial
carcinoma cells [175]. Another study demonstrated that curcumin also suppress the tumor growth and
metastasis in prostate cancer cells by inhibition of MMP-9. Furthermore, curcumin also inhibited the
expression of cellular matriptase, a membrane-anchored serine protease that is associated to a number
of tumors with poor prognosis [176].
Indeed, MMP-2 and MMP-9 are the main enzymes associated with metastasis whose activities are
inhibited by curcumin. This inhibitory activity may occur through different pathways. For instance,
it was demonstrated that curcumin inhibited lung cancer cells invasion by modulating the
PKCα/Nox-2/ROS/ATF-2 signaling pathway leading to downregulation of MMP-9 expression.
During the metastasis process, the activation of MMP-9 gene promoter enhances MMP-9
transcription [177]. Another study pointed out that Rac1/PAK1 pathway is a promising target in MMPs
activation pathway. The authors have demonstrated that curcumin reduces lung cancer cell metastasis
through inhibition of MMP-2 and MMP-9 expression mainly by downregulation of Rac1/PAK1 [178].
Banerji and coworkers demonstrated the effect of curcumin on MMP-2 activity in murine melanoma
cells. They observed a reduction in membrane type-1 matrix metalloproteinase (MT1-MMP) and
focal adhesion kinase (FAK) production, leading to a reduction of MMP-2 expression after 15 days of
curcumin treatment [179]. FAK and MT1-MMP plays a vital role in intracellular signaling pathway and
studies have associated its activity to MMP expression [180,181]. Further, the same research group has
demonstrated that curcumin was able to reduce tumor cell invasion and metastasis in human laryngeal
squamous carcinoma cells. The authors suggested that curcumin inhibited MMP-2 expression through
modulation of FAK and MT1-MMP signaling pathway [182]. Liao and colleagues also demonstrated
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the inhibitory effect of curcumin in MMP-2 expression on lung cancer cells due to downregulation of
the expression of glucose transporter 1 (GLUT-1) and MT1-MMP [183].
For resveratrol, studies have demonstrated its anti-metastatic effect against several types of
cancers by downregulation of MMP expression and its enzymatic activities, mainly MMP-2 and
MMP-9. Among the types of cancer that resveratrol was active, we included glioblastoma [184],
breast [185,186], multiple myeloma [99,187] and hepatocellular carcinoma [188].
3.3. E-Cadherin
The epithelial cell–cell adhesion molecule cadherin 1, also known as epithelial cadherin
(E-cadherin) is a transmembrane glycoprotein that mediates cell-cell adhesion through calcium-dependent
binding between two E-cadherin molecules at surface of adjacent cells [189,190]. E-cadherin is essential
for the epithelial cell behavior and evidence have shown that loss of its function is associated with
the proliferation of a number of cancers, including lung [191], pancreatic [192], oral [193], liver [194],
gastric [195], prostate [196] and ovarian [197]. The cellular function of E-cadherin depends on the
interaction with the catenin protein family, such as α-, β- and p120 catenins [198]. β-catenin is a key
cytoplasmic protein that acts in association with α-catenin and creates a link between E-cadherin and
the actin cytoskeleton [189,199].
Chen and colleagues described the cell invasion and metastasis inhibitory activity of curcumin in
a mice lung cancer [200]. Specifically, curcumin up-regulated the expression of E-cadherin through
activation of the tumor suppressor DnaJ-like heat shock protein 40 (HLJ1), which has been associated
with cell proliferation, invasion and metastasis against a variety of human cancers [201]. The authors
also suggested that curcumin modulates HLJ1 by enhancing the JNK/JunD expression [200]. Further,
the same research group demonstrated the anti-metastatic effect of curcumin against colorectal cancer
cells using in vivo assays [202]. Curcumin played its activity by upregulation of E-cadherin expression
leading to an inhibition of mesenchymal transition (EMT). EMT-related genes has been associated with
cancer progression and metastasis [203]. Likewise, not only E-cadherin overexpression was observed
for curcumin activity, but also the suppression of Sp-1 transcriptional activity and the inhibition of
focal adhesion kinase (FAK) phosphorylation [202]. Curcumin was able to block papillary thyroid
cancer cells migration and invasion in a dual pathway, by increasing E-cadherin expression and
inhibition of MMP-9 activity [204–206]. Zhang and coworkers have shown the potential application
of curcumin in reducing progression and metastasis of colon cancer cells through the overexpression
of E-cadherin. Moreover, the authors demonstrated that others signaling pathways were involved,
including downregulation of vimentin, inhibition of Wnt signaling pathway and downregulation of
CXCR4 [207].
3.4. Protein Kinases
Du and colleagues have reported the effect of curcumin in the inhibition of cancer invasion and
metastasis in human prostate-associated fibroblasts. Curcumin suppressed the MAOA/mTOR/HIF-1α
signaling pathway thereby leading to a downregulation of reactive oxygen species (ROS),
CXC chemokine receptor 4 (CXCR4) and interleukin-6 (IL-6) receptor, which has been associated to
migration of prostate carcinoma cells [208]. The inhibition of the Akt/mTOR/P70S6K kinase-signaling
pathway by curcumin was also reported in human melanoma cells. Curcumin reduced the
phosphorylation of this kinase-signaling pathway leading to an inhibition of cell invasion. The authors
have demonstrated that curcumin was able to reduce melanoma growth against an in vivo melanoma
model [209].
Guan and coworkers have reported the antiproliferative and antimetastatic activity of curcumin
in breast cancer cells. They concluded that for these cells, curcumin increased AMP-kinase
phosphorylation leading to a reduction of Akt protein expression and subsequently cell migration
suppression [210].
199
Nutrients 2016, 8, 628
Another study has demonstrated that curcumin inhibited cell growth and invasion through
downregulation of S-phase kinase associated protein 2 (Skp2)-pathway in glioma cancer cells.
The authors concluded that the suppression of Skp2 activity promotes an upregulation of p57 [123],
which acts as an regulator of apoptosis, differentiation and migration in tumorigenesis and its inhibition
is related to tumor growth [211].
Mitogen-activated protein kinase (MAPK) pathway comprises a family of protein kinases,
including extracellular-signal regulated kinases (ERK), c-Jun N-terminal Kinase (JNK) and p38 MAPK.
These protein kinases plays an important role in the regulation of genes involved in cell migration
and invasion [212]. Several in vitro and in vivo studies have reported the anti-metastatic activity of
resveratrol through downregulation of MAPK pathways against cancers, such as ovarian [213,214],
oral [215], breast [216,217], fibrosarcoma [218], hepatocellular carcinoma [219] and osteosarcoma [220].
Akt/protein kinase B (PKB) is another important serine/threonine kinase that plays a central role
in many signaling pathways involved in cell growth, proliferation and tumorigenesis, such as PI3K,
PTEN, NF1, LKB1, TSC2, FOXO and eIF4E [221,222]. Resveratrol have been described as an inhibitor
of the Akt signaling pathway in a number of human cancer, including cutaneous melanoma [223],
glioblastoma [224], pancreatic [225], and breast [226]. In most cases, the inhibition of this pathway
leads to a reduction in MMP expression, and consequently inhibition of cancer invasion and metastasis.
3.5. Vascular Endothelial Growth Factor (VEGF)
Kalinski and colleagues have reported the angiogenesis and anti-metastatic activity of curcumin
in human chondrosarcoma cells. Curcumin inhibited interleukin-1 (IL-1) signaling by blocking the
recruitment of IL-1 receptor associated kinase (IRAK) to the IL-1 receptor. IL-1 plays a central role
in inflammatory, immune and malignant processes and its downstream events are associated with
activation of NF-κB and metastasis-related genes, such as, VEGF-A [227]. Curcumin was also described
with anti-metastatic activity through mice gastric cancer model. The authors reported that curcumin
downregulated the expression of vascular endothelial growth factor receptor 3 (VEGFR-3) and its
mRNA, prospero homeobox 1 (Prox-1) and podoplanin. This compound leads to a suppression of
lymphatic vessel density, which is associated with poor prognosis in gastric cancer [228].
3.6. Hedgehog Signaling Pathway
The Hedgehog signaling pathway is an important family of proteins recognized for its
importance in a number of cellular events including, proliferation, survival and differentiation [229].
Cumulative evidence strongly suggests its regulatory effect in the development of cancer angiogenesis
and metastasis by modulating the expression of central proteins and transcription factors involved
in cancer invasion, such as Snail protein, E-cadherin, angiogenic factors, cyclins, anti-apoptotic and
apoptotic genes [230,231].
It was demonstrated the effect of resveratrol on metastatic prostate cancer cells by modulating
the Hedgehog pathway. The authors have demonstrated that resveratrol-treated cells resulted in
inhibition of epithelial-mesenchymal transition, exhibited an enhancement of E-cadherin expression
and reduction of vimentin expression. In addition, resveratrol inhibited the expression of the
transcription factor glioma-associated oncogene homolog 1 (Gli-1) [232], which plays an important role
in the downstream events upon Hedgehog activation [233]. Gao and colleagues also demonstrated
the anti-metastatic activity of resveratrol against gastric cancer cells by modulation of the Hedgehog
signaling pathway through downregulation of Gli-1 expression. Moreover, resveratrol upregulated the
expression of E-cadherin gene, decrease Snail protein and N-cadherin expression [234].
In different study, the role of Hedgehog pathway was once again described. Authors have
found that the beneficial effect of resveratrol in the inhibition pancreatic cancer cells migration and
invasion by suppression of this signaling pathway. Resveratrol was able to reduce Gli-1 expression and
hypoxia-induced reactive oxygen species production leading to a downregulation of Hedgehog activity
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and thereby inhibiting the cell invasion. Furthermore, resveratrol also inhibited HIF-1α, uPA and
MMP-2 expression [235].
3.7. STAT-3 Signaling Pathway
Signal transducer and activator of transcription-3 (STAT-3) is a transcription factor that belongs to
the STAT protein family [236]. This signaling pathway is present in cytoplasm in their inactive state
and upon activation-dependent tyrosine phosphorylation; this transcription factor translocates into
the cell nucleus and binds to specific enhancer elements for transcription process initiation. A number
of stimuli are known to activate STAT-3 pathway, including cytokines, growth factors and oncogenic
proteins. Currently, there is cumulative evidence that point out its important role in metastasis process
of a variety of human cancers, such as leukemias, lymphomas, head and neck, breast, lung, gastric,
hepatocellular, colorectal and prostate cancers [237]. STAT-3 target genes are involved in several
cellular events related to cancer metastasis, such as invasion, cell survival, angiogenesis and tumor-cell
immune evasion [238].
Lee-Chang and coworkers have reported the in vivo anti-metastatic activity of resveratrol against
metastatic lung cancer. The authors described that resveratrol downregulates STAT-3 activity and
reduces the tumor-evoked regulatory B cells (tBregs) production and activity [239]. tBregs is thought
to be an important mediator in the protection of metastatic cancer cells by modulation of CD4+ T cells
to inactivate antitumor NK cells and the effector CD8+ T cells conversion [240].
Resveratrol was also reported as an inhibitor of tumor growth and metastasis against
tumor-associated macrophages. The mechanism seems to be through inhibition of lymphangiogenesis
and M2 macrophage activation and differentiation [241]. M2 macrophage activation has been associated
to tumor growth and metastasis in tumor-associated macrophages [242]. The authors demonstrated
the inhibitory effect of resveratrol on STAT-3 phosphorylation during M2 macrophage differentiation.
This effect blocks the differentiation process, decreases VEGF-C-induced migration/invasion,
and capillary-like tube formation in lymphatic endothelial cells by modulation of IL-10, MCP-1 and
TGF-β1 [241]. Wang and colleagues also reported the inhibitory effect of resveratrol in the STAT-3
phosphorylation in human glioblastoma cells leading to a reduction of hypoxia-induced migration
and invasion [243]. Mechanistically, resveratrol inhibited cancer metastasis through upregulation
of microRNA-34a activity, which act as an important tumor suppressor and is downregulated by
STAT-3 [243,244].
3.8. Others
For resveratrol and curcumin, not only those mechanisms described above are responsible to
inhibit the metastasis process, but different biochemical signaling pathways has shown an important
contribution to modulate this process as well. For instance, Chen and colleagues reported the
effect of curcumin to prevent cancer progression and metastasis using an in vivo lung cancer model.
In this work, it was demonstrated that curcumin downregulated the expression of Cdc42 and Rho
GTPase protein that plays an important role in proliferation, invasion and metastasis [245]. In fact,
several studies have associated the overexpression of Cdc42 and the progression of a variety of human
cancers [246]. The same research group has demonstrated the anti-metastatic activity of curcumin in
non-small cell lung cancer by decreasing the expression of early growth response protein 1 (EGR-1),
and thereby reducing the adherens junctions and Wnt signaling pathway activity. This signaling
pathway is essential for cancer cells detach from the epithelium and achieve metastasis to distant
tissues [52].
Integrin β4 (ITG β4) is a heterodimeric transmembrane receptor that act as structural link between
cells or cells to the extracellular matrix. Cumulative evidences reveal that ITG β4 is associated in several
signaling pathways leading to a variety of cellular events, including cell apoptosis, differentiation,
cancer invasion and metastasis [247]. It was demonstrated that curcumin successfully inhibited the
201
Nutrients 2016, 8, 628
palmitoylation process of ITG β4 in breast cancer cells. This process is a post-translational modification
and it is essential for ITG β4 signaling activity that promote a reduction in cancer invasion [248].
Dorai and coworkers have reported the anti-metastatic activity of curcumin in bone cancer.
Curcumin was able to inhibit metastasis process from bone cancer to prostate using an in vivo model.
The authors suggested that curcumin upregulated the bone morphogenic protein-7 (BMP-7), which act
as a metastasis inhibitory protein and its upregulation promoted a modulation of transforming
growth factor-β (TGF-β) function [249]. TGF-β plays a vital role in the cycle of bone metastasis.
Studies have shown that its binding with BMP-7 leads to increased expression of E-cadherin and
therefore, the inhibition of bone cancer metastasis [250].
Curcumin also inhibited in vivo tumor progression and metastasis in colorectal cancer. The study
concluded that curcumin reduced miR-21 transcriptional regulation and expression through inhibition
of activator protein-1 (AP-1) [251]. miR-21 is a microRNA that plays an important role in cellular
proliferation, differentiation and apoptosis and studies have associated its overexpression in a variety
of human cancer, including glioblastoma, ovarian carcinoma, hepatocellular carcinomas, head and neck
cancer and chronic lymphocytic leukaemia [252]. In another study, curcumin suppressed migration of
cancer glioma cells by decreasing miR-21 expression [253].
Phosphatase of regenerating liver-3 (PRL-3) is a tyrosine phosphatase and cumulative evidence
have associated its overexpression with a number of human cancer metastasis [254,255]. Wang and
collaborators have demonstrated that curcumin inhibits in vivo metastasis through downregulation of
PRL-3 expression in melanoma cells. Specifically, the inhibition of PRL-3 cause a reduction of Src and
STAT-3 phosphorylation [256].
Several others proteins, enzymes, and transcription factors have been described as a target for
resveratrol leading to inhibition of cancer metastasis. Some examples reported in the literature are
presented in Table 3.
Table 3. Antimetastatic targets for resveratrol.
Target Effect Cancer Type Reference
MTA-1/HDAC downregulation prostate [257]
EGFR downregulation ovarian [258]
MALAT-1 downregulation colorectal [259]
TGF-β1/Smads downregulation colorectal [260]
α5β1 integrins/hyaluronic acid downregulation/upregulation ovarian [261]
tensin upregulation erythroleukemia [262]
TGF-β1 downregulation lung [263]
COX-2 downregulation colon adenocarcinoma [264]
interleukin-18 downregulation hepatic melanoma [265]
4. Cellular Death
4.1. Apoptosis
An important event in the intrinsic apoptotic pathway, or mitochondrial pathway, is the change
in mitochondrial membrane potential that leads to an increase in permeabilization of the outer
mitochondrial membrane and the release of the proteins found in the space between the inner and
outer mitochondrial membranes. The regulation of this permeabilization is coordinated by proteins of
the Bcl-2 family and others components [266]. Bcl-2 is an antiapoptotic protein inserted in the outer of
mitochondrial membrane. It has your antiapoptotic properties by regulating the activity of Bax and
Bak, for example. These two proteins are able to move to the mitochondria, disrupt the function of
Bcl-2, allow the permeabilization of the outer mitochondrial membrane and release the content of the
intermembrane space [267].
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Cytochrome c is an example of the released content of the mitochondrial intermembrane space.
Once in the cytosol, cytochrome c binds to the C-terminal region of Apaf-1 (apoptotic protease
activating factor-1), a cytosolic protein with an N-terminal caspase-recruitment domain (CARD),
a nucleotide-binding domain and a C-terminal domain [268]. The association of dATP with Apaf-1 is
facilitated by this binding and exposes its N-terminal CARD, which now is able to oligomerize
and become a platform on which the initiator caspase-9 is activated through a CARD-CARD
interaction [269]. This complex is called apoptosome and it is the responsible for caspase-3, that it is
able to induce apoptosis [270,271].
Smac/DIABLO and Omi/HtrA2 are two others examples of the released mitochondrial proteins.
They facilitate caspase activation by inhibiting the IAPs (inhibitor of apoptosis proteins), an endogenous
inhibitor of caspases [272]. XIAP, cIAP1, cIAP2, survivin and livin (ML-IAP) are examples of IAPs.
AIF (apoptosis inducing factor) is another protein of the mitochondrial intermembrane space that
induces apoptosis caspase-independent. After an apoptotic insult, AIF translocate to the nucleus and
induces chromatin condensation and DNA fragmentation. On the other hand, an overexpression of
Bcl-2 blocks the AIF redistribution, inhibiting this apoptotic pathway [273]. A general scheme about
apoptosis is presented in Figure 3.
Figure 3. General scheme about curcumin and resveratrol effects in apoptosis.
The ability of resveratrol to direct target mitochondria was shown in bladder cancer cells and
neuroblastoma cell lines. Experiments with intact cancer cell and isolated mitochondria were run
and both of them resulted in a loss of mitochondrial membrane potential. Thus, it was shown that
resveratrol was able to induce the release of cytochrome c and Smac/diablo in the intact cancer
cell. An interesting result came from the neuroblastoma cell lines, which demonstrated that isolated
mitochondria cytochrome c was not able to be released, indicating that the cytoplasmic content is
important for this process [274,275].
In breast cancer cells [276] and glioma cells [277], resveratrol has demonstrated potential to
activate caspase-3 and increase its activity. In breast cancer cell study, the cleavage of caspase-3 into its
active form was observed. In addition, the role of caspase-3 in apoptosis was tested using a caspase-3
inhibitor, resulting in a decrease of cell death. Beyond that, in glioma cells study was also demonstrated
the induction in the caspase-3 mRNA expression.
In human lung adenocarcinoma, has been demonstrated that the resveratrol-induced apoptosis
is predominantly via intrinsic pathway and caspase-independent. It was demonstrated that in these
cells AIF is the protein released from mitochondria. Also, resveratrol was able to induce Bak, but not
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Bax, activation and, when the first one is silenced, the release of AIF is prevented and the apoptosis
is inhibited, indicating that Bak has an essential role in this caspase-independent AIF signaling
pathway [278,279].
4.1.1. ROS
Curcumin is capable to activate antioxidant enzymes, such as, glutathione-S-transferase (GST),
quinine reductase and hemeoxygenase-1 [280]. There are a lot of works demonstrating that apoptotic
induced effect by curcumin is due to reactive oxygen species (ROS) formation. It was reported
that both papillary thyroid cancer cell line and cutaneous T cell lymphoma cells have a previous
increased levels of ROS that is responsible to promote loss of mitochondrial membrane potential
(MMP). These deregulations culminated in Bcl-2 reduction, cleavage of poly ADP-ribose polymerase
(PARP) and apoptosis induction [281,282].
Curcumin has increased the levels of ROS and superoxide radicals (SOR) against human lung
adenocarcinoma epithelial cells, leading to high levels of lipid peroxidation. They described that the
antioxidant agent—N-acetyl cysteine—has prevented curcumin-induced ROS formation and apoptosis.
They suggested that ROS formation induced by curcumin was able to activate the apoptosis in these
cells [283].
In diffuse large B cell lymphoma cells lines (DLBCL) was demonstrated that resveratrol-induced
apoptosis is related to release of ROS (reactive oxygen species). In a sequence of events, the ROS
released is able to inactive Akt and FOXO1, GSK3 and Bad. Inactivated Bad allows a change in Bax
protein conformation, which leads to variations in mitochondrial membrane potential, release of
cytochrome c and apoptosis via intrinsic pathway. Moreover, ROS release also results in up-regulation
of DR5, a death receptor, which increased the apoptosis in DLBCL, demonstrating, in this cell,
that resveratrol is able to induce apoptosis via intrinsic and extrinsic pathway [284].
In SGC7901 cells, resveratrol was able to induce apoptosis and developed a pro-oxidant role,
inducing the generation of reactive oxygen species. A treatment of this cells with a scavenger eliminated
the pro-apoptotic effect of resveratrol, indicating that the pro-oxidant role of this polyphenol is essential
for the apoptosis [285].
4.1.2. Calcium Homeostasis
Calcium also appears to be an important role in apoptosis induces for curcumin. This polyphenol
promoted apoptosis in color cancer cells through the increase in [Ca2+] and ROS formation.
These effects promote a reduction in MMP and generate caspase-3 activation. The use of an intracellular
calcium chelator promote a reversion in apoptosis [286]. A similar result was observed in human
leukemia cells and was also verified that the caspase-3 inhibitor (z-VAD-fmk) was capable to block
curcumin-induced apoptosis [287].
In a different study, the levels of ROS and intracellular [Ca2+] increased by curcumin have shown
an important contribution to cause apoptosis. The use of the mitochondrial uniporter inhibitor (RU-360)
partially suppressed curcumin-induced apoptosis. Moreover, the use of SKF-96365, a store-operated
Ca2+ channel blocker, blocked the elevation of mitochondrial calcium, promoting a potentiation in
curcumin-induced apoptosis [288].
Using human hepatocellular carcinoma J5 cells, it was also demonstrated for curcumin the
ability to induce apoptosis through Ca2+-regulated mitochondria-dependent pathway. In vitro assays
have demonstrated an increased level of cytoplasmatic cytochrome c, corroborating with reduced
mitochondrial membrane potential hypothesis. Once again, for these cells it was observed an increase
in ROS formation and cytoplasmic calcium accumulation. BAPTA, an intracellular calcium chelator,
was capable to reduce curcumin-induced apoptosis, suggesting that this process is calcium dependent
in these cells lines [289].
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In mesothelioma cells (REN cells), resveratrol was able to induce a transient intracellular [Ca2+]
elevation possibly by T-type Ca2+ channels. Experiments were run toward to Cav 3.2 isoform of this
channel because its shown to be highly expressed in REN cells. The results have demonstrated that
it is the major responsible for Ca2+ entry. Besides, Cav 3.2 siRNA inhibited the effect of resveratrol,
which indicates the role of this channel. A comparison between normal cells and mesothelioma cells
was studied and a difference in the peak levels of calcium have demonstrated a higher sensibility of
cancer cells to resveratrol-induced changes. Furthermore, in cancer cells resveratrol was able to inhibit
proliferation whereas in normal cells it was ineffective [290].
4.1.3. Bcl-2 Family
In follicular lymphoma cell lines, curcumin inhibited the cellular proliferation and induced
apoptosis through the increase in bcl-2 family proteins. The authors demonstrated a reduction in
Bcl-xL levels for all cell lines. In addition, they characterized cell line-dependent changes in the level
of Mcl-1, bcl-w, Bak, and Bok. All these process promotes increased levels of ROS. Curcumin also
increase the lysosomal membrane permeability [291].
Similar observations were made for other cancer cell lines, including glioblastoma, colorectal,
lung and endometrial carcinoma [292,293]. In human prostate cancer cells, it was observed reduction
of pro-apoptotic proteins and induction of caspase 3 and PARP cleavage [294]. Yu and Shah (2007)
verified through transfected human endometrial adenocarcinoma HEC-1-A cells the possibility of
proto-oncogene Ets-1 promote Bcl-2 regulation [295]. The authors observed that curcumin was capable
to downregulate the Ets-1 gene and reduce Bcl-2 expression. For HEC-1-A cells, it was found DNA
fragmentation induced by curcumin in a dose-dependent manner.
The in vivo effect of Curcumin on Bcl-2 and Bax expression was described using nude mice
prostate cancer (PC3 cell line) [296]. Three groups were treated with different concentrations of this
compound and showed an expressive reduction in tumor volume at all concentrations compared to
control groups.
Huang and colleagues have shown the apoptotic effect of resveratrol in nasopharyngeal carcinoma
cells. In their study, Bcl-2 was downregulated and Bax protein was upregulated. The expressive
increase in the Bax/Bcl-2 ratio is responsible for the apoptosis due to the apoptotic properties of Bax.
Besides that, it was also observed the release of cytochrome c due to the disruption of the mitochondrial
membrane potential, and the activation of caspase-9 and -3. The last one responsible to cause DNA
fragmentation and apoptosis [297].
Corroborating with previous results, Wang and co-workers have demonstrated in human
leukemia cells the apoptotic effect of resveratrol and its ability to interfere in the regulation of proteins
of Bcl-2 family. The ratio Bax/Bcl-2 increases, which induces the permeabilization of the outer
mitochondrial membrane and the release of pro-apoptotic proteins. In their study, it was shown the
decrease of cytochrome c level of the intermembrane space in the mitochondria and its increase in the
cytosol. In addition, caspase-3 activity was increased as well [298].
Cholangiocarcinoma, human acute leukemia, liver and pancreatic cancer cell lines have
demonstrated to be sensitive to resveratrol. In all four-cell lines, this polyphenol was able to induce
apoptosis by reducing Bcl-2 levels and increase caspase-3 activity. Furthermore, in pancreatic cells
was also demonstrated an up-regulation in Bax and downregulation in Bcx-xL and XIAP, and in liver
cancer cells an increase in p53 expression protein was also detected [299–301].
4.1.4. p53 Family
The TP53 gene is responsible for p53 protein codification, which is a transcription factor involved
in cellular regulation, as well as, tumor suppression. Its effect occurs due to activation of repair proteins
or induction of apoptosis, when cellular damages are irreversible [302–304]. This factor are present in
both intrinsic and extrinsic pathways, and acts on the changes of mitochondrial membrane potential
as cell sensitization to apoptosis [304].
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According to He and co-workers [57], curcumin can ameliorate the general health state of patients
with colorectal cancer through the increase of p53 expression in tumor cells. This study conducted with
126 patients, revealed that curcumin promotes an increase in weight body of the individuals when
compared to control group (vehicle). After surgery, immunoblotting assay revealed that anti-apoptotic
protein Bcl-2 was reduced and Bax was elevated. TNF-α level was also lower than control group,
probably for p53 modulation. Thus, the authors have suggested that curcumin can be used in the
treatment to ameliorate cachexia in these patients.
In breast cancer, it was demonstrated that resveratrol was not able to induce p53 protein expression,
but expressively increased the phosphorylation in Ser15, resulting in a higher level of phospho-p53.
When phosphorylated, p53 protein reduce its interaction with MDM2, an oncoprotein that regulates it
negatively, what results in cell cycle arrest or apoptosis [305].
Notch-1 is a transmembrane receptor that mediates intracellular signalling involved in cell
differentiation and cell survival [306]. In glioblastoma cells were demonstrated that Notch-1 activation
and p-53 restoration by resveratrol was correlated. Glioblastoma cells were treated with a Notch-1
inhibitor (MRK-003) and resulted in a decrease of p53 restoration and significantly inhibition of p53
translocation to the nucleus, which indicates that Notch-1 activated is able to augment p53 expression
and restore its function. In these cells, the activation of Notch-1-p53 signaling pathway indicates to be
an initiating factor of apoptosis induced by resveratrol, with increased Bax expression and decreased
Bcl-2 expression [307].
p73 is another transcription factor, belonging to p53 family, related to apoptosis and cancer
progression. The p73 presents several functions in nervous system. Structurally, it is more complex
than p53 because the conserved region in DNA-binding domain is also more complex [303]. p73 is
responsible to perform the transcription of two isoform of proteins: TAp73 (related with tumor
suppression and chemotherapy induced-apoptosis); and DNp73 (present in tumor cells and associated
with chemoresistance) [308,309]. A research with p73 transfected Hep3B (p53-deficient) showed
apoptosis induction when treated with curcumin at concentrations ranging from 40 to 80 μM.
Western blot data have revealed an increase of TAp73 and reduction of DNp73 protein in the same
concentrations necessary to induce apoptosis. MMP (mitochondrial membrane potential) were
reduced and it was accompanied for cytochrome c release, cleavage of pro-caspase-9, pro-caspase-3,
and pro-PARP [310].
4.1.5. Extrinsic Pathway (Receptor-Mediated Pathway)
The extrinsic pathway is mediated by triggering cell surface death receptors of the tumor
necrosis factor (TNF) receptor superfamily (TNF-R1, Fas/CD95, TRAIL-R1/DR4 and TRAIL-R2/DR5).
After that, an adaptor, FADD (Fas-associated death domain protein), for example, binds to the
receptor and a trimerized receptor-ligand complex (DISC—death-inducing signaling complex) is
shaped. Thus, DISC recruits the initiator caspase-8, which is now activated [311]. In type I cells,
caspase-8 activation is sufficient to apoptosis occurrence as a direct consequence, with activating
downstream caspases such as caspase-3. In type II cells, the apoptosis is dependent on the amplification
of death receptors via the mitochondrial pathway. The link between these two pathways occurs via
Bid cleavage by caspase-8. The truncated bid interacts with Bax, promoting cytochrome c release and
downstream events [312].
TRAIL (TNF-related apoptosis-inducing ligand) is the ligand of the death receptors DR4 and
DR5. Some types of cells, like LNCaP (prostate cancer), are resistant to TRAIL-induced apoptosis.
Shankar et al. have studied the resveratrol and curcumin ability to sensitize this prostate cancer cells
to TRAIL. The results have demonstrated that these polyphenols were able to sensitize the cells to
TRAIL, and they were also able to upregulate the TRAILs receptors, DR4 and DR5. Furthermore,
the death receptor pathway was demonstrated to be involved in sensitization of TRAIL-resistant cells
by resveratrol and curcumin [313,314].
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An in vivo study with curcumin corroborates with the data above. LNCaP cells were xenografted
in Balb nude mice and treatments with curcumin, TRAIL and curcumin + TRAIL was evaluated.
Curcumin alone is able to induce apoptosis in tumor cells, while TRAIL is ineffective. When together,
they are able to increase the cell death to values higher than curcumin alone, demonstrating that this
natural product sensitize TRAIL-resistant cells [156].
In chondrosarcoma cells, curcumin was able to induce the cleavage of caspase-3, -7 and -8,
but not -9, which indicates the activation of extrinsic pathway. Furthermore, it was also demonstrated
an increase in Fas, FasL and DR5 expression by curcumin treatment, and transfection with siRNA
of this components reduced apoptosis. p53 was also evaluated in this study, and it was shown to be
able to participate of death receptor increased expression. Taken together, these results suggest that
curcumin-induced cell death in chondrosarcoma cells occurs by extrinsic pathway [315].
In anaplastic large-cell lymphoma, resveratrol has induced apoptosis in a dose-dependent manner.
In the same study, it was demonstrated that this phytoalexin was also able to induce the expression of
the death receptor Fas/CD95 about twice folds when cells were treated with 25 μM of resveratrol for
48 h, indicating that extrinsic pathway may be a mechanism of this cellular apoptosis [316].
A link between intrinsic and extrinsic apoptotic pathway induced by resveratrol was demonstrated
in multiple myeloma and T-cell leukemia cells. In the death receptor pathway, resveratrol induced the
association of membrane rafts and Fas/CD95 and translocated DR4 and DR5 (TRAIL-receptors) to rafts.
FADD, procaspase-8 and -10 were also translocated into rafts, as well as its actives forms. These data
indicate that the constituents of DISC (FADD, Fas/CD95 and procaspase-8) are recruited into rafts,
and this apoptotic complex in death receptor signaling is activated. Furthermore, Bid, which is a linker
between Fas signaling and mitochondria was also translocated to raft. This data indicates a connection
between intrinsic and extrinsic apoptotic pathway, which was demonstrated by blocking Fas/CD95
downstream signaling what prevented loss in membrane mitochondrial potential [317].
Endoplasmatic Reticulum (ER) Stress
Curcumin promotes apoptosis induction at a dose and time-dependent manner in human lung
cancer cells. Besides the upregulation of the pro-apoptotic proteins Bax and Bad, an increased
level of ROS accompanied for ER stress in these cells after treatment with curcumin was observed.
These alterations conduce to MMP (mitochondrial membrane potential) modification and caspase-3
activation. The authors concluded that an activation of extrinsic pathway through increased FAS/CD95
expression promotes caspase-8 activation. This data was confirmed by using a caspase-8 inhibitor,
which decreased the apoptosis in these cells [318].
4.1.6. NF-κβ
The levels of NF-κβ are increased in pancreatic carcinoma cells. It was demonstrated that
curcumin reduces this levels, promotes apoptosis and inhibits cellular proliferation. Reduction in the
levels of I-κB kinase (IKK), NF-κβ, as well as, cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE-2),
and interleukin-8 (IL-8) were observed after treatment using curcumin [319].
Similar results were obtained using melanoma cells, where curcumin inhibited NF-kβ and IKK
independently from B-Raf mutations or PI3K/Akt pathway. The authors did not found a direct
correlation between IL-8 and NF-κβ for melanoma cells, and they hypothesized that IL-8 regulation
could occur through AP-1 transcription factor [48].
In a different study using glioblastoma cells, curcumin was selective against cancer cells and
promoted a reduction in NF-κβ and IKK leading to apoptosis [320].
Sun et al. have investigated the role of the inhibition of NF-κB in resveratrol-induced apoptosis
in human multiple myeloma cells. When activated, p65 subunit of NF-κB is translocated to the
nucleus, which lead the researches to evaluate its presence in the cytoplasm. As result, they found
the vast majority of NF-κB in this compartment, where it could not function as transcription factor.
Furthermore, the targets genes of NF-κB were also evaluated, and as expected, they were down
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regulated. Bcl-2, Bcl-xL, XIAP, c-IAP and VEGF are proteins resultant from the target genes activated
by NF-κB [321].
Another example of the role of NF-κB in resveratrol-induced apoptosis was demonstrated in
human breast cancer cells. EMSA experiments have shown a decrease in the p65(RelA)/p50 binding to
the DNA at resveratrol levels that induces apoptosis. This result may be attributed to the lower level
of NF-κB activated in nucleus due to the increase of the protein I-κB in the cytosol. These data were
confirmed through the dose-dependent increased level of p65/(RelA) immunoprecipitated by an anti
I-κB antibody. In this case, Bcl-2 was down regulated [322].
A study with multiple myeloma cells has demonstrated the ability of resveratrol to suppress
the constitutively active IKK, which is necessary for NF-κB activation. Furthermore, resveratrol also
inhibited the appearance of subunit p65 in the nucleus [323].
4.1.7. PI3K, Akt/mTOR
Phosphotydilinositol-3 kinase (PI3K) is a lipid kinase family, which is activated by receptors
with protein tyrosine kinase activity (RPTK). When RPTK is activated, PI3K associates with
the receptor leading to the catalytic subunit activation and formation of the second messenger
phosphatidylinositol-3,4,5-trisphosphate (PIP3). PIP3 recruits signaling proteins with pleckstrin
homology (PH) domains to the membrane, including PDK1 and Akt. Akt activated has the ability to
modulate the function of various substrates that are involved in cell survival, cell cycle progression
and cellular growth [221].
Akt/PI3K is an important pathway for apoptosis regulation. In breast cancer cells, curcumin induced
an Akt and glycogen synthase kinase 3b (GSK3B) phosphorylation. This kinase is involved in
apoptosis process [324]. However, curiously in both cells: T-cell acute lymphoblastic leukemia
(T-ALL) malignant cells and upper aero-digestive tract cancer cell; curcumin promotes the
de-phosphorylation/inactivation of Akt, FOXO transcription factor and GSK3 [325,326].
FOXO transcription factors have been correlated with induction and cancer regulation.
Pancreatic cancer cells treated with curcumin, presented an increased in FOXO1 (Forkhead box O1)
expression, which is correlated with inhibition in phosphorylation/activation of PI3K and Akt [327].
mTOR, an Akt upstream modulator, was inhibited in vitro by curcumin using uterine leiomyosarcoma
cells. Western Blot data revealed that curcumin has restrained p70S6 and S6 phosphorylations;
both ribosomal proteins are downstream targets of mTOR. Interestingly, in the presence of a mTOR
inhibitor (rapamycin), it was not observed apoptosis [328]. In vivo assay, using female nude mice,
shows that curcumin decreases m-TOR and S6 phosphorylation leading to a reduction in tumor
size [329].
In a time-dependent manner, resveratrol was able to reduce Akt phosphorylation, decrease the
level of Akt protein and the phosphorylation of caspase-9, sequentially, in human breast cancer cells.
Assuming that caspase-9 is a site for Akt and now it is activated, it indicates that this is one of the
pathways for resveratrol-induced apoptosis [330].
Another pathway involving Akt activity and resveratrol-induced apoptosis was studied in
human chronic myeloid leukemia cells. Hsp70, a heat shock protein, is responsible for helping
the cell to maintain protein homeostasis and scape apoptosis and, in the cited cells, is overexpressed.
The expression of Hsp genes is regulated by transcription factors of HSF (heat shock factor) family.
In this study, resveratrol was able to decrease the phosphorylation of Akt, which is essential for its
activity. GSK3B is a target of Akt and its phosphorylated form is inactive. Assuming that Akt is not
able to phosphorylate GSK3B, then it is able to prevent HSF-1 to enter the nucleus and activate Hsp70
expression [331,332].
Studies have demonstrated that Akt is a direct regulator of miR21 expression [333]. PC-3M-MM2
cells exhibit a high level of phosphorylated Akt, which it is shown, in this study, to be
decreased by resveratrol as well as miR-21 expression. To corroborate with this supposition,
this androgen-independent human prostate carcinoma cells was treated with LY294002, a well-known
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inhibitor of Akt activity. The results demonstrated that the expression of miR-21 was also decreased,
indicating that Akt may be a target for cancer treatment [334].
Dai et al. have studied in chondrosarcoma cells the ability of resveratrol to interfere in PI3K
activity. By western blot analysis, it was demonstrated that the PI3K, Akt and AMPK levels decreased
significantly in a concentration of resveratrol enough to cause apoptosis. This result suggest that the
inhibition of PI3K pathway by resveratrol may be a molecular mechanism to suppress cancer cell
proliferation [335].
4.1.8. Telomerase
Telomerase is a reverse transcriptase, responsible to regulation of telomeric length of chromosomes,
doing addition of repetitive sequences with guanine. This enzyme is expressed in proliferations cells,
as germinal cells and cancer [336].
High levels of telomerase are found in tumor cells, and studies suggest this target as potential
for anticancer drug development. In human leukemia cells and acute myeloblastic leukemia cells
curcumin has inhibited telomerase activity, at dose and time-dependent manner. This activity is
probably due to suppression of translocation of the catalytic subunit of telomerase (TERT—telomerase
reverse transcriptase) from nucleus to cytosol. Curcumin induced apoptosis by increasing Bax and
reducing Bcl-2, which promotes activation of caspase-3 and release of cytochrome c. The authors
have suggested that a relationship between curcumin-induced apoptosis parameters and telomerase
inhibition can exist [337,338].
Similar results were obtained using brain tumor cells. Khaw and collaborators identified that
curcumin binds to cell surface and hen seeps into the cytoplasm in order to initiate the apoptotic cascade.
TRAP assay and PCR revealed that curcumin inhibited telomerase activity through the inhibition in
hTERT mRNA expression. This effect provokes a reduction of a telomere size. Moreover, caspase-3 and
caspase-7 levels are increased [339].
A study carried out with MCF-7 cells has demonstrated the effect of resveratrol in telomerase
activity. In a dose dependent manner, resveratrol was able to decrease the cellular viability and induce
apoptosis. These events were related to resveratrol ability to down regulated TLMA, reduce the level
of hTERT (catalytic subunit of human telomerase reverse transcriptase) of the nuclear compartment,
where it is able to elongate the telomere and increase its levels in the cytoplasm, indicating that this
phitoalexin is able to interfere in the process of translocation of this subunit to the nucleus [340].
In A431 epidermoid carcinoma cells, resveratrol was able to inhibit telomerase activity in a dose
independent manner. Moreover, resveratrol was also able to decrease the expression of hTERT by
inhibition of RNA transcription [341].
4.1.9. JAK/STAT
STAT-3 (Signal transducer and activator of transcription 3) is a protein that has a dual role in
normal cells, as cytoplasmic signaling proteins and as nuclear transcription factors that activates
diverse genes. Among the genes regulated by STATs are the genes that control proliferation, apoptosis,
angiogenesis and immune responses [342]. Simplistically, JAK2 is a tyrosine kinase responsible for the
phosphorylation and activation of STAT-3, which is now able to enter into the nucleus and activate its
target genes [343].
In human leukemia cells curcumin reduced the nuclear expression of STAT-3, 5a and 5b in
dose and time-dependent manner. In addition, STAT-5a and 5b was followed by truncated isoforms
formation, indicating that curcumin was able to induce the cleavage of STAT-5 into its dominant
negative variants (lacking the STAT5 C-terminal region). However, it was not observed modifications
in STAT-1 expression, only reduction in its transactivation. STAT-3, 5a and 5b phosphorylation was
maintained and mRNA of Jak-2 was reduced as well as cyclin D1 and v-src gene expression [344].
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Similar results were obtained in other researches with primary effusion lymphoma, Hodgkin’s
lymphoma, cutaneous T-cell lymphoma and melanoma cells. These studies have found that curcumin
reduces phosphorylation in Jak-2 or Jak-1 and STAT-3. These regulations provoke an apoptosis
induction, reduction in Bcl-2, activation in caspase-3 and PARP cleavage [345–348].
In head and neck tumor cells, STAT-3 is overexpressed in comparison to others tumor cells. It was
shown that resveratrol has inhibited the constitutive activation of STAT-3 and JAK2, the tyrosine kinase
of the Janus family responsible for the STAT-3 phosphorylation. Beyond that, resveratrol inhibited
STAT-3-DNA binding, because of the decreased phosphorylation level, which inhibits STAT-3 to
translocate to the nucleus. Furthermore, resveratrol was also able to induce the expression of SOCS-1
(suppressor of cytokine signaling 1) protein and mRNA. SOCS-1 is a negative regulator of STAT-3
by inhibiting JAK2. STAT-3 is also known for its expression regulation of various genes products
involved in anti-apoptosis (Bcl-2, Bcl-xL, survivin and others), which was found to be downregulated
in resveratrol treatment [349].
In NK leukemia cells, resveratrol, in a time and dose-dependent manner, inhibited constitutively
phosphorylation of STAT-3 and JAK2, which resulted in a decrease of downstream anti-apoptotic
proteins MCL1, surviving and Bcl-10 [350].
In bladder and ovarian cancer cells, beyond the inhibition of STAT-3 expression and phosphorylation,
it was demonstrated the reduction of STAT-3 into the nucleus. In consequence of this event,
STAT-3 downstream anti-apoptotic products genes were suppressed [351,352].
4.1.10. miRNA
miRNAs are portions of RNA that can not be transcript in proteins, and lately several works have
established its role in many diseases, including cancer. Despite of this importance, until now is not
known its exact function in many human diseases [353].
According to the literature, Bcl-2 is a target of miRNA15a and miRNA16 [354]. In human breast
adenocarcinoma (MCF-7 cells), it was observed a downregulation in Bcl-2 and upregulation of mi-R15a
and mi-R16 when exposed to different concentration of curcumin. In breast carcinoma cell lines, it was
also found that curcumin was capable to upregulate these miRNA and the use of anti-miRNA15a and
anti-miRNA16 promoted a renovation of Bcl-2 expression. Thus, curcumin can induce miR-15a and
miR-16 expression and it can probably serve as potential gene therapy targets for Bcl-2-overexpressing
tumors [355].
Curcumin increased miRNA16 in A549 human lung adenocarcinoma cell line, but promoted
a significantly downregulation in miRNA186*. Authors observed that the use of an inhibitor for
mRNA186*, not only reduce cellular proliferation but also promote apoptosis, indicating that miR-186*
may play an oncogenic role in the development of lung cancer. Moreover, it was observed that
modifications in miR-186* levels cause changes in caspase-10 levels. This enzyme appears to be
increased in cell treated with curcumin [356].
Another study showed the relationship between curcumin and miRNA186* in treatment of
multidrug-resistant cells of lung carcinoma (A549/DDP cells). These cells are sensitive to curcumin
treatment, which can modify miRNA186* expression. The authors concluded that mRNA-186* can be
a target for lung cancer susceptible to curcumin treatment [357].
In human glioma cells, resveratrol was able to inhibit the expression of the microRNA 21 (miR-21)
that is found to be overexpressed in this type of cancer. Furthermore, it was studied the involvement of
miR-21 and the resveratrol-induced apoptosis in these cells. It was found that the downregulation of
miR-21 expression decreases the phosphorylation of I-kB and nuclear p65 protein levels, which leads
to an inactivation of NF-κB signaling and, consequently, apoptosis [358].
Bcl-2 is a key regulator of apoptosis and it has been reported to be positive regulated by miR-21.
To analyze if this is the mechanism involved in resveratrol-induced apoptosis in pancreatic cancer
cells, Liu et al. have studied this purpose. Real-time PCR has demonstrated the ability of resveratrol to
decreased the expression of miR-21, and western blot has demonstrated that Bcl-2 is downregulated
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by resveratrol, but it is restored by overexpression of miR-21. These results indicate that in pancreatic
cancer cells the apoptosis induced by resveratrol is due to inhibiting miR-21 regulation of Bcl-2
expression [359].
A study realized by Zhou et al. in bladder cancer cells, resulted in the same data that Liu et al.
demonstrating the ability of resveratrol to reduce miR-21 and Bcl-2. Furthermore, this study was able to
indicate that Akt also participates of this process. It was demonstrated that resveratrol inhibits miR-21
expression, and as a consequence decreases Akt phosphorylation and Bcl-2 expression. The inhibition
of Bcl-2 was counteracted by an Akt stimulator, demonstrating that in these cells, resveratrol is
able to induce apoptosis by the regulation of Akt/Bcl-2 signaling pathway by inhibiting miR-21
expression [360].
4.2. Autophagy
This kind of cellular death are characterized for the formation of vesicles with cellular organelles
(autophagosome), that promote an auto phagocytic process [361,362]. An important difference
when compared to apoptosis, is that autophagy do not promote chromatin condensation and it
is accompanied by massive autophagic vacuolization of the cytoplasm [362]. At cellular level the
autophagic death can be considered as reversible process, once the stimuli is removed the cellular
death process is interrupted [362].
Curcumin can induce autophagy in glioma cell lines, regulated by simultaneous inhibition of
the Akt/mTOR/p70S6K pathway and stimulation of the ERK1/2 pathway. The last one regulates
extracellular signalization, and when are activated promote autophagy. In vivo models using nude
mice have revealed that curcumin reduced the tumor size by inducing autophagy. The mechanism
seems to be related to LC3, an autophagosome-specific protein, that was increased in tumor treated for
this polyphenol [363].
AMP is a kinase involved in metabolism of eukaryotic cells and its deregulation seems to be
related with cancer process [364]. Similarly, in human adenocarcinoma cell line curcumin has promoted
an autophagy process that was not observed in human normal lung cells. In this study, the authors
observed an increased phosphorylation of AMP (AMPK) and acetylCoA carboxylase. The use of
a si-RNA knockdown of a catalytic subunit of AMP kinase (AMPKα1) promotes a reduction in LC3-II,
suggesting that this pathway is important to autophagy in these cell lines [365].
An in vitro and in vivo study with breast cancer stem-like cells has demonstrated the ability of
resveratrol to decreased the cell viability in both systems. Thus, the cell death by autophagy was
studied. It was demonstrated that resveratrol treatment increased the number of autophagossomes,
upregulated the expression of LC3-II, Beclin1 and Atg 7, which are required for autophagossome
formation, and GFP-LC3-II puncta formation assay demonstrated an increase in the percentage of
cells with autophagossomes compared with control. It was also demonstrated that resveratrol induces
autophagy, at least partially, via suppressing Wnt/βcatenin signaling pathway [366].
In melanoma cells, resveratrol treatment has induced a dose and time-dependent accumulation
of LC3-II, significantly upregulation of Beclin-1 and induction of the formation of LC3 puncta,
suggesting that resveratrol induces autophagy in these cells, and this event is regulated by ceramides,
which regulates Akt/mTOR pathway. Interestingly results appeared when the conversion of LC3-I in
LC3-II and Beclin-1 formation were inhibited. The cytotoxic effect of resveratrol increased as well as
the apoptosis. It indicates that, in this case, autophagy acts as a resistance mechanism against apoptotic
cell death, and inhibition of this event could be a novel strategy of treatment [367].
Others apoptotic targets have been studied for curcumin (Table 4) and resveratrol (Table 5).
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Table 4. Others apoptotic targets for curcumin.
Target Effect Cancer Type Reference
AP-2γ inhibition testicular [368]
MST1 activation melanoma [369]
Hexoquinase-2 downregulation colorectal [370]
Skp2/Her2 downregulation breast [371]
GADD45/153 upregulation lung [372]
Proteasome inhibition colon [373]
Aurora A downregulation bladder [374]
AMPK activation colon [375]
Cdc27/APC3 inhibition medulloblastoma [376]
HDAC 4 inhibition medulloblastoma [377]
PKC downregulation liver [378]
Sp1 inhibition lung [379]
Microtúbulo inhibition breast [380]
Ras/ERK signaling activation gastric [381]
Fatty acid synthase inhibition liver [382]
Table 5. Others examples of apoptotic targets for resveratrol.
Target Effect Cancer Type Reference
5-LOX downregulation mammary [383]
COX 2 upregulation ovarian [384,385]
ΔNp63 downregulation nasopharyngeal [386]
Hexoquinase 2 downregulation hepatocellular [387]
MTA1 downregulation prostate [388]
Specificity protein 1 inhibition mesothelioma [389]
GADD45α/Annexin A1 upregulation leukemia [390]
p21 upregulation breast [391]
ASPP1 upregulation breast [392]
TIGAR downregulation Lung/breast [393]
Casein kinase (CK2) downregulation prostate [394]
IRE1α/XBP1 upregulation Multiple myeloma [395]
Androgen receptor downregulation prostate [396]
Caspase-6 upregulation colon [397]
CHOP upregulation colon [398]
Cathepsin L/B activation Cervical/colorectal [399,400]
ATF3 upregulation colorectal [401]
Fatty acid synthase downregulation breast [402]
Hedgehog signaling downregulation pancreas [403]
Tristetraprolin activation glioma [404]
SphK1/S1P downregulation leukemia [405]
Proteasome activation leukemia [406]
Pentose phosphate and talin-FAK pathway downregulation colon [407]
5. Perspectives
The antitumoral properties of resveratrol and curcumin have been described in a number of
studies using different types of cancers, including lung, breast, colon, leukemia, lymphoma, melanoma,
multiple myeloma, neuroblastoma, osteosarcoma, ovarian, pancreatic, and prostate [107,108,277,278].
The majority of these studies have evaluated the anticancer properties of resveratrol or curcumin
by itself (no-association) through in vitro or in vivo assays [408,409]. These studies conducted to
hypothesis about the mechanism of action, whereby these polyphenols acted in the cell through
down- or upregulation of important proteins, transcription factors and cytokines. Nevertheless,
these polyphenols present non-specific action, considering the wide range of molecular targets that they
can act. These non-specific activities are in fact, very different from the traditional chemotherapeutics
that hit only one (or very few targets) in most of the cases [410]. This plurality of molecular targets
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associated to polyphenols have been generating divergent opinions in literature about the real
contribution that such phytochemicals may have in anticancer therapy [37,145,410–413]. Nonetheless,
there are a number of reviews in literature that highlight the cancer chemoprevention effect exerted by
these polyphenols [414–419]. This chemopreventive effect has been associated to the anti-inflammatory
properties of these phytochemicals, especially through the antioxidant activity [420–423].
Not only those targets discussed in this review, but also ability to complex with the DNA was
described for both polyphenols. Using infrared spectroscopy, it was demonstrated that curcumin is
able to interact with guanine, adenine and thymine, and the backbone PO2 in the DNA structure.
It was also shown the ability of curcumin to complex the RNA molecule, which maintain its A-RNA
conformation upon curcumin complexation [424,425].
Furthermore, there are a variety of studies involving these polyphenols in combination with
approved anti-cancer drugs and its implication in anticancer combination therapy. These studies
highlight the application of curcumin and resveratrol along with anticancer drugs aiming to improve
the efficacy of the treatment. We highlighted in Table 6 some examples of polyphenols and anticancer
drugs in combination regimens evaluated in vitro or in vivo.
Table 6. Combination therapy of polyphenols and approved anti-cancer drugs.
Polyphenol Drug Cancer Type Reference
curcumin cisplatin lung [426]
curcumin cisplatin head and neck [427]
curcumin valproic acid leukemia [428]
curcumin gemcitabine pancreatic [429]
curcumin 5-fluorouracil breast [430]
curcumin 5-fluorouracil gastric [431]
curcumin 5-fluorouracil + oxaliplatin colon [432]
curcumin bevacizumab liver [433]
curcumin imatinib leukemia [434]
curcumin paclitaxel brain [435]
curcumin oxaliplatin colorectal [436]
curcumin temozolomide glioblastoma [437]
curcumin gefitinib lung [438]
resveratrol cisplatin ovarian [439]
resveratrol cisplatin colorectal [440]
resveratrol 5-fluorouracil colorectal [441]
resveratrol 5-fluorouracil melanoma [442]
resveratrol doxorubicin breast [443]
resveratrol doxorubicin leukemia [444]
resveratrol melphalan breast [445]
resveratrol temozolomide glioma [446]
resveratrol gemcitabine pancreatic [447]
resveratrol paclitaxel neuroblastoma [448]
resveratrol tamoxifen breast [449]
resveratrol cyclophosphamide breast [450]
The combinations of polyphenols (resveratrol and curcumin) within anticancer drugs have
demonstrated in several cases a synergic effect and it seems to be a useful strategy to treat cancer.
Studies involving humans to test both polyphenols against cancer is being performed.
Tables 7 and 8 describe the current studies registered in US at different stages. It is possible to
observe a high number of studies recruiting volunteers, which reveals the interest in both polyphenols
by scientific community. Not only treatment against cancer but also chemoprevention and palliative
care is being investigated (Tables 7 and 8).
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Table 7. Human studies using curcumin in cancer.
Cancer Treatment
Intervention Study Status NCT Number
Curcumin and





Curcumin, capecitabine and radiation therapy followed by





Curcumin Trial of curcumin in advanced-pancreatic cancer Completed NCT00094445(Phase II)
Curcumin
Phase II study of curcumin versus placebo for





Avastin/folfiri in combination with curcumin in colorectal




curcumin Gemcitabine With Curcumin for Pancreatic Cancer Completed
NCT00192842
(Phase II)




Phase III Trial of Gemcitabine, Curcumin and Celebrex in
Patients with Metastatic Colon Cancer Unknown NCT00295035
Curcumin and
Docetaxel
Multicenter Study Comparing Taxotere Plus Curcumin Versus
Taxotere Plus Placebo Combination in First-line Treatment of








Docetaxel With or Without a Phytochemical in Treating






Phase III trial of gemcitabine, curcumin and celebrex in





Curcumin and cholecalciferol in treating patients with
previously untreated stage 0-II Chronic lymphocytic leukemia




Pilot study of curcumin (diferuloylmethane derivative) with
or without bioperine in patients with multiple myeloma Completed NCT00113841
Curcumin Use of curcumin for treatment of intestinal adenomas infamilial adenomatous polyposis (FAP) Recruiting NCT00927485
Anthocyanins
and curcumin
Randomized window of opportunity trial of anthocyanin






Pilot study of curcumin formulation and Ashwagandha
extract in advanced osteosarcoma Unknown
NCT00689195
(Phase I/II)
Curcumin Turmeric effect on reduction of serum prolactin and relatedhormonal change and adenoma size in prolactinoma patients Unknown
NCT0134429
(Phase I)
Adverse Effects Management Induced by Chemotherapy
Intervention Study Status NCT Number
Curcumin Curcumin for the Prevention of Radiation-induced Dermatitisin Breast Cancer Patients Completed
NCT01042938
(Phase II)
Curcumin Radiosensitizing and Radioprotectve Effects of Curcumin inProstate Cancer Completed NCT01917890
Curcumin and
FOLFOX
Combining Curcumin With FOLFOX Chemotherapy in
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Table 7. Cont.
Adverse Effects Management Induced by Chemotherapy




An Open-label Prospective Cohort Trial of Curcumin Plus




Prophylactic Topical Agents in Reducing Radiation-Induced
Dermatitis in Patients with Non-inflammatory Breast Cancer





Curcumin Effect of curcumin addition to standard treatment ontumor-induced inflammation in endometrial carcinoma Recruiting
NCT02017353
(Phase II)
Curcumin Curcumin for prevention of oral mucositis in childrenusing chemotherapy Completed
NCT00475683
(Phase III)




Intervention Study Status NCT Number





Curcumin Curcumin in Preventing Gastric Cancer in Patients withChronic Atrophic Gastritis or Gastric Intestinal Metaplasia Not yet recruiting
NCT02782949
(Phase II)
Curcumin Sulindac and plant compounds in preventing colon cancer Completed NCT00003365
Curcumin Curcumin for the chemoprevention of colorectal cancer Completed NCT00118989(Phase II)
Curcumin and
sulindac
The effects of curcuminoids on aberrant crypt foci in the
human colon Unknown NCT00176618
Curcumin Randomized trial of adjuvant curcumin after prostatectomy Recruiting NCT02064673
Table 8. Human studies using resveratrol in cancer.
Cancer Treatment
Intervention Study Status NCT Number
Resveratrol Resveratrol for patients with colon cancer Completed NCT00256334(Phase I)




A biological study of resveratrol’s effects on










Adverse Effects Management Induced by Chemotherapy




A clinical study to assess the safety,
pharmacokinetics, and pharmacodynamics of




Intervention Study Status NCT Number
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6. Conclusions
Curcumin and resveratrol are natural products with promising anticancer activity. Both compounds
can act against proliferation, metastasis and cellular death through different mechanisms. Not only
in vitro, but also in vivo data have demonstrated the potential of these polyphenols to treat and
prevent cancer. In addition, the association of these polyphenols with current anticancer drugs
has demonstrated synergic effect useful to improve the treatment. Different groups worldwide are
conducting several clinical trials aiming to investigate the beneficial effects of curcumin and resveratrol
in humans. Therefore, the use of resveratrol and curcumin seems to contribute to anticancer therapy.
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Abstract: Fruits and vegetables have long been recognized as potentially important in the prevention
of cancer risk. Thus, scientific interest in nutrition and cancer has grown over time, as shown
by increasing number of experimental studies about the relationship between diet and cancer
development. This review attempts to provide an insight into the anti-cancer effects of Citrus fruits,
with a focus on their bioactive compounds, elucidating the main cellular and molecular mechanisms
through which they may protect against cancer. Scientific literature was selected for this review
with the aim of collecting the relevant experimental evidence for the anti-cancer effects of Citrus
fruits and their flavonoids. The findings discussed in this review strongly support their potential as
anti-cancer agents, and may represent a scientific basis to develop nutraceuticals, food supplements,
or complementary and alternative drugs in a context of a multi-target pharmacological strategy in
the oncology.
Keywords: Citrus; cancer; flavonoids; nutraceuticals; functional foods; natural product; complementary
and alternative medicines
1. Introduction
Cancer and heart disease are two of the main pathologies worldwide, and the most common
causes of death in old age. The decline in death rates over the last century has resulted in a large
proportion of people beginning to live up to eighty years old or more, and an increased incidence
of chronic diseases. Thus, cancer represents a crisis for public health, with an estimated 14 million
cases globally with a total of 8.2 million deaths for cancer in 2012 [1]. The two most important ways
to reduce cancer risk are the avoidance of cancer-causing agents and finding preventive strategies to
stop cancer onset. Obviously, death to cancer can be reduced by the discovery of new drugs or novel
therapeutic approaches, designed to stop the development of clinical cancer in the first instance.
Despite the ongoing development of synthetic drugs that represent the mainstay of pharmaceutical
care, the plant kingdom still remains an attractive source of novel anti-cancer drugs. It provides
biologically active molecules for use in pharmaceuticals applications, and it has been estimated
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that about 70% of anti-cancer drugs originate to some extent from natural sources [2]. Moreover,
both observational and experimental studies suggest that regular consumption of fruits and vegetables
may play an important role in reducing degenerative diseases such as cancer [3–5]. Recently, it has been
suggested that, among tissues, a third of the variation in cancer risk is attributable to environmental
factors or hereditary predisposition, and that changes in lifestyle can play a very important role in the
development of certain types of cancer [6]. About 30%–40% of cancer incidence could be prevented
by an healthy diet, doing regular physical activity, and maintaining correct body weight [7]. Overall,
a high dietary intake vegetables and fruits (>400 g/day) could prevent at least 20% of all cancer
cases [7,8].
The cancer protective effects of vegetables and fruits may be due to the presence of bioactive
molecules acting through different mechanisms including the following: inhibition of carcinogen
activation, stimulation of carcinogen detoxification, scavenging of free radical species, control of
cell-cycle progression, inhibition of cell proliferation, induction of apoptosis, inhibition of oncogene
activity of, inhibition of angiogenesis and metastasis, and inhibition of hormone or growth-factor
activity [4,9–12].
Citrus fruits (CF), i.e., oranges, lemons, limes, bergamot, grapefruits, and tangerines, are popular
all over the world. CF are the main winter fruits consumed in the Mediterranean diet, meaning they
are the main source of dietary flavonoids. They are rich in vitamins and flavonoids, and have long
been hypothesized to possess a protective effect against cancer.
This review is an attempt to provide an insight into the anti-cancer effects of CF, with a focus on
their bioactive compounds, elucidating the main cellular and molecular mechanisms by which they
may protect against cancer.
2. The Citrus Flavonoids
Flavonoids are pigments commonly present in the genus Citrus that are responsible for flower
and fruit color. They are low molecular weight polyphenolic compounds, widely found in the plant
kingdom as secondary metabolites. They are characterized by a common C6-C3-C6 structure consisting
of two benzene rings (A and B) linked through a heterocyclic pyran ring (C) (Figure 1).
Figure 1. Basic chemical structure of Citrus flavonoids.
Flavonoids containing an hydroxyl group in position C-3 of the C ring are classified as
3-hydroxyflavonoids (flavonols, anthocyanidins, leucoanthocyanidins, and catechins), and those
lacking it as 3-desoxyflavonoids (flavanones and flavones). At present, more than 9000 flavonoids have
been characterized, some of which are clinically used. The large number of compounds arises from
various combinations of multiple hydroxyl and methoxyl groups substituting the basic flavonoids
skeleton. Flavonoids are divided into six classes on the basis of their chemical structures: flavones,
flavanones, flavonols, isoflavones, anthocyanidins, and flavans. Flavonoids are mainly present in
plants as glycosides, while aglycones (the forms lacking sugar moieties) occur less frequently. Therefore,
a large number of flavonoids result from many different combinations of aglycones and sugars, among
which mainly D-glucose and L-rhamnose bound to the hydroxyl group at the C-3 or C-7 position.
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More than sixty types of flavonoids have been identified in CF: flavanones are the flavonoids
most widely present, followed by flavones, flavonols, and anthocyanins (the latter only in blood
oranges). Some flavonoids, such as hesperidin, naringin, and polymethoxylated flavones (PMFs)
are characteristic compounds contained in Citrus while others like rutin and quercetin are common
throughout the plant kingdom [13]. Figure 2 shows the main structural formula of some flavonoids
isolated from CF, and their chemical substituents.
Figure 2. Structural formula of some flavonoids isolated from Citrus fruits and their chemical substituents.
Flavanones (2,3-dihydro-2-phenylchromen-4-one) occur almost exclusively in CF and are present
in both the glycoside or aglycone forms (Figure 3). Naringenin and hesperetin are the most
important flavanones present in aglycone forms, while the glycosidic forms are grouped into two
types: neohesperidosides and rutinosides. Glycosylation occurs at position 7, either by rutinose or
neohesperidose, disaccharides formed by a glucose and a rhamnose molecule differing only in the type
of linkage (1 → 6 or 1 → 2). Naringin, neoeriocitrin, neohesperedin, and poncirin consist of a flavanone
with neohesperidose (rhamnosyl-α-1,2 glucose), and they have a bitter taste; while hesperidin,
narirutin, eriocitrin, and didymin consist of a flavanone with rutinose (rhamnosyl-α-1,6 glucose),
and have no taste. Flavanones, usually present in diglycoside form, give CF their characteristic taste.
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Figure 3. Classification of Citrus flavonoids.
Flavonols (3-hydroxy-2-phenylchromen-4-one) may be considered to be the 3-hydroxy derivatives
of flavones. Glycosylation occurs preferentially at the 3-hydroxyl group of the central ring, and the
predominant types are 3-O-monoglycosides. The most common flavonol aglycones are quercetin and
kaempferol, while rutin and rutinosides are the main glycosidic forms.
The most abundant flavones (2-phenylchromen-4-one) present in the aglycone form are luteolin,
diosmetin, and apigenin, while diosmin and neodismin represent the principal flavones present in the
rutinoside and neohesperidoside forms, respectively. The PMFs tangeretin and nobiletin are present in
smaller quantities.
Anthocyanins (2-phenylchromenylium), are metabolites of flavones structurally derived from
pyran or flavan. In CF, they are present only in blood oranges. Anthocyanidins are anthocyanins with
a sugar group, in which glycosylation with glucose, arabinose, or galactose almost always occurs at
the 3-position.
The most abundant Citrus flavonoids are flavanones, e.g., hesperidin, naringin, or neohesperidin.
However, there are flavones, e.g., diosmin, apigenin, or luteolin, that generally display higher biological
activity, despite occuring in much lower concentrations. Of note are apigenin, which has shown
particularly good anti-inflammatory activity, and diosmin and rutin that are important venotonic agents
present in several pharmaceutical products. The beneficial effects of flavonoids are mainly due to their
anti-oxidant properties which can play a key role in fighting several degenerative diseases. However,
there is recent increasing evidence linking the pharmacological activity of Citrus flavonoids to their
ability to inhibit the activity of intracellular signaling molecules, such as phosphodiesterases, kinases,
topoisomerases, and other regulatory enzymes [14]. Blocking protein kinases and lipid-dependent
signaling cascades results in alterations in the phosphorylation state of target molecules, with the
consequent modulation of gene expression implicated in many degenerative diseases including
cancer. Many studies designed to uncover a structure–activity relationship have demonstrated that
anti-oxidant, enzyme-inhibitory, or anti-proliferative activities of some flavonoids are dependent
upon particular structural factors. The structure oxidation state (flavanone, flavone, etc.), substituents
(position, number, and nature of groups in both the A and B rings of the flavonoid structure), and the
presence of glycosylation may be important determinant features of flavonoid activity [15,16]. More
specifically, studies on melanoma cell lines using several flavonoids of Citrus origin have shown the
presence of the C2–C3 double bond on the C ring, conjugated with the 4-oxo function, to be critical
for this biological activity [17]. Moreover, the presence of three or more hydroxyls in any of the rings
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of the flavonoid skeleton significantly increased the anti-proliferative activity observed in melanoma
B16-F10 cell cultures [18].
3. Preclinical Studies
Carcinogenesis is a multi-step process of genetic and epigenetic alterations leading to the
progressive transformation of normal cells towards malignancy. The process of carcinogenesis can be
divided into three main stages: (i) initiation, a phase in which cellular exposition to a carcinogenic
agent leads to irreversible alterations, usually at the DNA level. In this phase cells react to carcinogens
by the activation of enzymes involved in the metabolism of xenobiotics that, while aiming to inactivate,
may generate a mutagenic compound responsible for DNA damage and mutations, thereby initiating
cancer development; (ii) the tumor promotion stage is characterized by the proliferation of abnormal
cells that may initiate a pre-neoplastic focus. In this phase over-activation and/or over-expression of
enzymes involved in the synthesis of nucleotides and DNA (e.g., ornithine decarboxylase), as well as
in the regulation of the differentiation process (DNA polymerase or topoisomerases) occur. Moreover,
oxidative stress caused by the overproduction of reactive oxygen species (ROS) induces further cell
damage and genome instability; (iii) progression is the final stage of carcinogenesis. It is characterized
by an uncontrolled proliferation of tumor cells which also acquire the ability to invade neighboring
tissues and to form metastasis at distant sites, coupled with a loss of capacity for apoptosis or
senescence. Hence, metastasis is the spread of cancer cells from a primary tumor to distant sites
in the cancer patient’s body. Angiogenesis is the first step of the metastatic process that leads to the
formation of new blood capillaries by outgrowth or sprouting of pre-existing blood vessels. It allows
the tumor to be fed and facilitates the access of tumor cells to the bloodstream. Indeed, tumor vessels
are more permeable than normal ones, since tumor-associated endothelial cells are enlarged and loosely
connected. Therefore, the metastatic process is the end result of a complex series of events depending
on the ability of tumor cells to detach from the primary tumor, migrate, and invade connective
tissues, entering the vascular or lymphatic system, through which vital organs are reached where they
proliferate to form a distant metastasis. The tendency of a primary tumor to form metastasis is the
hallmark of malignant cancer, and has important diagnostic, prognostic, and therapeutic implications.
Interest in nutrition and cancer has grown considerably, as evidenced by the rapid proliferation
of studies examining nutritional exposure in relation to cancer risk [19]. A large body of in vitro and
in vivo studies have shown that fruits and vegetables may have an important role in the maintenance
of a healthy lifestyle and the reduction of cancer risk. Their potential health benefits are probably
due to the presence of secondary metabolites ubiquitous in the plant kingdom that are considered
non-nutritional but which are essential for the maintenance of health. Thus, in the last decade,
bioactive compounds including flavonoids, carotenoids, ascorbic acid, and limonoids have been
intensively investigated for their potential antioxidant, anti-inflammatory, and anti-cancer activities.
Several compounds are responsible for Citrus antitumoral effects; of these, vitamin C is considered
an important micronutrient through which CF exert their antioxidant effects by trapping free radicals
and reactive oxygen molecules, thus protecting against oxidative damage, inhibiting the formation
of carcinogens and protecting DNA from damage [20]. Flavonoids also exhibit antioxidant and free
radical scavenging properties, interfering with the oxidative/anti-oxidative potential of the cell [21].
Furthermore, there are numerous reports showing flavonoids to be able to act at various stages of
carcinogenesis, and specifically to interact with proteins involved in cancer development.
Growing experimental evidence supports the view that Citrus flavonoids exert their anti-cancer
effects through a number of different mechanisms. They may act as suppressing agents, preventing the
formation of new cancers from pro-carcinogens or as blocking agents, disenabling carcinogens from
achieving initiation, as well as preventing the onset of the tumor promotion stage. Moreover, Citrus
flavonoids may function as transformation agents, facilitating the biotransformation of carcinogens
into inactive metabolites. Finally, they behave as both anti-angiogenic and anti-metastatic agents,
preventing the formation of new vessels and metastasis [14,22]. Table 1 shows the principal
cancer-related processes modulated by Citrus flavonoids.
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Table 1. Main mechanisms through which Citrus flavonoids may act as anti-cancer drugs.
Mechanism by Which Citrus Flavonoids May Fight against Cancer
Antioxidant activity, thus counteract oxidative stress
Anti-inflammatory effect
Phase II enzyme induction, hence enhancing detoxification
Phase I enzyme inhibition, thus stopping activation of carcinogens
Inhibition of cell proliferation
Inhibition of oncogene and/or induction of tumor suppressor gene
Induction of cell-cycle arrest
Induction of apoptosis
Inhibition of signal transduction pathways
Anti-angiogenic effect
Inhibition of cell adhesion, migration and invasion
3.1. Initiation Phase Inhibition by Citrus Flavonoids
In the last twenty years, there has been an increasing awareness that flavonoids and other
naturally-occurring substances in plants have protective effects against environmental mutagens/
carcinogens and endogenous mutagens [23]. In support of this, there are numerous experimental
findings suggesting that certain Citrus flavonoids may exert preventive effects against DNA
damage induced by a variety of carcinogens [24]. Naringenin and rutin prevent the accumulation
of ultraviolet radiation-B (UV-B)-induced DNA damage [25] by a mechanism that may involve
the ability of flavonoids to neutralize free radicals generated near DNA, promoting mutations.
The radical scavenging property of flavonoids is also responsible for quercetin protective effect against
mercury-induced DNA damage and oxidative stress in a human-derived liver cell line (HepG2), that
seems to be due to the maintenance of redox status [26]. Moreover, it has been observed that naringenin
at low doses (10–80 μM) can stimulate DNA repair following oxidative damage in a human lymph node
prostate cancer cell line (LNCaP), leading to a significant increase in the levels of several major enzymes
in the DNA base excision repair pathway [27]. In in vivo experiments, naringenin has demonstrated
its capability to inhibit N-diethylnitrosamine (NDEA)-induced hepatocarcinogenesis [28,29]. Naringin
has been found to reduce the rate of micronuclei formed by ifosfamide in mouse blood cells [30] and
to exert protective action against DNA deterioration induced by daunorubicin in mouse hepatocytes
and cardiocytes, suggesting that this flavonoid may be useful in reducing the adverse effects found
in anthracycline treatments [31]. Moreover, it accelerated the regression of pre-neoplastic lesions in
rats exposed to 1,2-dimethylhydrazine (DMH) [32]. Experiments performed using in vivo models
of genotoxicity induced by cyclophosphamide show that the antioxidative activity of hesperidin
(100, 200, and 400 mg/kg body weight (BW) administered by gavages for five consecutive days)
may reduce the frequency of micronucleated polychromatic erythrocytes (MnPCEs) induced by
chemotherapy drugs [33]. Furthermore, in the presence of a mammalian metabolic activation system,
naringin, apigenin, hesperetin, and other flavonoids (300 μg/plate) have been shown to produce
antimutagenic effects against aflatoxin B1 (1 μg/plate), with an inhibition rate of more than a 70% in
Salmonella typhimurium. In this study, the structure–activity relationship analysis suggests the flavonoid
configuration containing the free 5-, 7-hydroxyl group to be essential [34].
Flavonoids may also inhibit the first phase of carcinogenesis through an increase in detoxification
processes by modulating enzyme activity resulting in the decreased carcinogenicity of xenobiotics.
For example, naringenin inhibits the activity of aromatase (CYP19) in Chinese hamster ovary
(CHO) cells, thereby decreasing estrogen biosynthesis and inducing antiestrogenic effects, which
are important in breast and prostate cancers [35]. Quercetin has instead proven to be a potent
non-competitive inhibitor of sulfotransferase 1A1, suggesting a role for potential chemopreventive
agents in sulfation-induced carcinogenesis [36]. The chemopreventive potential of diosmin, naringenin,
naringin, and rutin against CYPlA2-mediated mutagenesis of heterocyclic amines produced by high
temperature cooking of meat was hinted by Bear and Teel [37]. Several reports have described
the potential anti-mutagenic properties of apigenin. For instance, exposure to apigenin prior to
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a carcinogenic insult has been shown to offer a protective effect in both murine skin and colon cancer
models [38], as well as to prevent the genotoxic effects of benzo(α)pyrene (BP) in vivo. Indeed,
Khan et al. [39] demonstrated that apigenin (2.5 and 5 mg/kg orally) reverts BP-induced depletion in
the levels of glutathione (GSH), quinone reductase (QR), and glutathione-S-transferase (GST), while
also reducing DNA strand breaks and damage. Increased GSH by apigenin also enhances endogenous
defense against oxidative stress [40]. Moreover, topical application of apigenin has been proven to
reduce dimethyl benzanthracene-induced skin tumors by strongly inhibiting epidermal ornithine
decarboxylase, an enzyme that plays a key role in tumor promotion [41]. In addition, apigenin
administration has been reported diminish the incidence of UV light-induced cancers and to increase
tumor-free survival in vivo [42]. Moreover, apigenin as well naringenin, suppress colon carcinogenesis
in azoxymethane (AOM)-treated rats [43].
The antigenotoxic activity of hesperidin was investigated by Nandakumar et al., [44]. They reported
that daily administration of hesperidin at a concentration of 30 mg/kg BW for 45 days prevented
7,12-dimethylbenz(α)anthracene (DMBA)-induced experimental breast cancer formation, presumably
by the regulation of both phase I and phase II metabolizing enzymes, and through its strong
antioxidant activity. The results also revealed that the flavanone may act both by modulating
the energy reservoir of the cell and by maintaining oxidative phosphorylation. Also, the aglycone
hesperetin has been reported to modulate xenobiotic-metabolizing enzymes during DMH-induced
colon carcinogenesis [45]. Tangeretin, a pentamethoxy flavone present in significant amounts in CF
peel, was found to suppress DMBA-induced breast cancer in rats [46].
Chronic inflammation is closely connected to the carcinogenic process. Indeed, nobiletin has
been shown to inhibit DMBA/tetradecanoyl-13-phorbol acetate (TPA)-induced skin tumor formation
by reducing the number of tumors per mouse, manifesting its potential in inflammation-associated
tumorigenesis [47]. The studies discussed above are summarized in Table 2.
Table 2. Studies investigating the ability of Citrus flavonoids to inhibit the initiation phase
of carcinogenesis.
Initiation Phase
Flavonoid Concentration/Dose Experimental Model Reference
Quercetin 0.1–5.0 μM HgCl2/MeHg-treated HepG2 cells [26]
Naringenin 10–80 μM Ferrous sulfate-exposed LNCaP cells [27]
Naringenin 200 mg/kg NDEA-treated rats [28]
Naringenin 200 mg/kg NDEA-treated rats [29]
Naringin 50–500 mg/kg Ifos-treated mice [30]
Naringin 50–500 mg/kg Dau-treated mice [31]
Naringin 10–200 mg/kg DMH-injected rats [32]
Hesperidin 50–400 mg/kg Cyclophosphamide-treated mice [33]
Naringin, apigenin, hesperetin 300 μg/plate Aflatoxin B1-exposed Salmonella typhimurium TA100 [34]
Diosmin, naringenin, naringin, rutin 0.25–1.0 μM Heterocyclic amines-exposed Salmonella typhimurium TA98 [37]
Apigenin 10–100 μM 308 and HCT116 cells [38]
Apigenin 2.5 and 5 mg/kg BP-treated mice [39]
Quercetin, kaempferol, myricetin,
apigenin 5–25 μM COS-1 cells [40]
Apigenin 1–50 μM DMBA/TPA-exposed mice [41]
Apigenin 5 and 10 μmoles in200 μL UV-A/B-exposed SKH-1 mice [42]
Apigenin, naringenin 0.1% and 0.02% AOM-treated rats [43]
Hesperidin 30 mg/kg DMBA-treated rats [44]
Hesperetin 20 mg/kg DMH-treated rats [45]
Tangeretin 50 mg/kg DMBA-treated rats [46]
Nobiletin 160 and 320 nM DMBA/TPA-exposed mice [47]
AOM: azoxymethane; BP: benzo(α)pyrene; Dau: daunorubicin; DMBA: 7,12-dimethylbenz(α)anthracene; DMH:
1,2-dimethylhydrazine; Ifos: ifosfamide; NDEA: N-diethylnitrosamine; TPA: tetradecanoyl-13-phorbol acetate.
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3.2. Inhibition of Tumor Development
A great number of in vitro studies have demonstrated that Citrus flavonoids reduce the growth
of several types of tumor cells in cultures. Tangeretin, nobiletin, quercetin and taxifolin have
anti-proliferative effects on squamous cell carcinoma HTB43 [48], as well as on many other tumoral
cell lines. Tangeretin, a PMF present mainly in the peel of tangerine and other CF, induced apoptosis
in human myeloid leukaemia HL-60 cells, without causing cytotoxicity in human peripheral blood
mononuclear cells [49,50]. Tangeretin and nobiletin (another PMF widely found in the mandarin epicarp)
also inhibited the proliferation of both human breast cancer cell lines (MDA-MB-435 and MCF-7) and
a human colon cancer cell line (HT-29) in a concentration- and time-dependent manner, by blocking cell
cycle progression at the G1 phase without inducing cell death [51]. This study showed tangeretin IC50
values of 30–40 μM for breast and colon cell lines, and slightly higher values for nobiletin, while in other
reports tangeretin exhibited much greater potency [49,50]. However, this discrepancy could be caused
by differences related to both cell type and experimental procedures. The inhibition of the activity of
cyclin-dependent kinases 2 (Cdk2) and 4 (Cdk4), accompanied by an increase in Cdk inhibitors p21 and
p27 seems to be the mechanism through which tangeretin arrests cell cycle progression at the G1 phase
in colon adenocarcinoma COLO 205 cells [52]. Yoshimizu et al. [53] documented the growth-inhibitory
action of nobiletin, both alone and in combination with cisplatin, in various human gastric cancer
cell lines (TMK-1, MKN-45, MKN-74, and KATO-III), through the induction of apoptosis and cell
cycle deregulation. Interestingly, orange peel extract (OPE) containing 30% polymethoxyflavones,
such as tangeretin (19.0%), heptamethoxyflavone (15.24%), tetramethoxyflavone (13.6%), nobiletin
(12.49%), hexamethoxyflavone (11.06%) and sinensitin (9.16%), inhibited tumorigenesis in Apc(Min/+)
mice by increasing apoptosis [54]. OPE also decreased the development of hyperplastic lesions in
mouse mammary glands [55]. The reduction of mammary cancer cell growth caused by tangeretin may
be related to the inhibition of mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated
kinase (ERK) phosphorylation and of other proteins like adducin α and γ, protein kinase Cδ, signal
transducer and activator of transcription (STAT) 1 and 3, and stress-activated protein kinase (JNK) [56].
Tangeretin and nobiletin also inhibited the proliferation of both SH-SY5Y neuroblastoma cells [57]
and brain tumor cells [58], reducing also invasion, migration, and adhesive properties. Moreover,
it has been reported that tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through
the downregulation of the phosphoinositide 3-kinase (PI3K)/protein kinase B (also known as Akt)
signaling pathway, suggesting a potential approach for the treatment of drug-resistant cancers [59].
Tangeretin also induced apoptosis in gastric cancer AGS cells through the activation of both extrinsic
and intrinsic signaling pathways [60]. Nobiletin and the coumarin auraptene have been reported
to counteract prostate carcinogenesis both in vitro and in vivo. In particular, nobiletin inhibited the
growth of several prostate cancer cell lines with IC50 values of around 100 μM, by a mechanism
involving apoptosis and cell cycle arrest at the G0/G1 phase, as well as inhibited development
of prostate adenocarcinomas in a transgenic rat model [61]. The preventive effects of nobiletin
on prostate cancer have recently been confirmed in a study that also reported the ability of this
flavonoid to reduce the risk of colon cancer [62]. Furthermore, nobiletin reduces AOM-induced rat
colon carcinogenesis [63] and, like quercetin (100 ppm), is able to decrease preneoplastic lesions
and serum levels of both leptin and insulin in an in vivo model of colon carcinogenesis, suggesting
a promising role in preventing tumors associated with obesity [64,65]. Experiments performed using
both in vitro and in vivo models showed the anti-proliferative property of nobiletin on lung cancer
cells. The mechanism involves the activation of the apoptotic process and cell cycle arrest at the
G2/M phase due to decreased Bcl-2 and increased Bax protein expression, both of which positively
correlated with elevated expression of p53 [66]. As reported by Ohnishi et al. [67], nobiletin treatment
suppressed HepG2 and MH1C1 hepatocarcinoma cell growth by inducing cell cycle inhibition and
apoptosis, but without apparent effects in the early stages of in vivo hepatocarcinogenesis. In glioma
cells, it suppresses proliferation by inhibiting Ras activity and mitogen-activated protein/extracellular
signal-regulated kinase (MEK/ERK) signaling cascade, probably via a Ca2+-sensitive protein kinase C
(PKC)-dependent mechanism [68]. There are more recent results that demonstrate the ability of
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nobiletin to inhibit cell growth and migration via cell-cycle arrest and suppression of the MAPK and
Akt pathways [69]. In human gastric p53-mutated SNU-16 cells, nobiletin was found to be effective in
inhibiting cell proliferation, inducing apoptosis, and enhancing the efficacy of 5-Fluorouracil (FU) [70].
Its anti-cancer effects have also been demonstrated in acute myeloid leukemia cells [71], where it
was responsible for the induction of cell-cycle arrest and apoptosis. Moreover, orally administrated
nobiletin inhibited colitis-associated colon carcinogenesis in AOM/dextran sulfate sodium-treated
mice [72].
Apigenin is a flavone present mainly in fruits and vegetables, and among Citrus species it is
abundant in grapefruit. It possesses anti-inflammatory and free radical scavenging activity, and as
a candidate anti-cancer agent, is capable of reducing cancer cell proliferation of without affecting
normal cells. It has been reported that apigenin possesses growth inhibitory properties in breast
cancer, inducing apoptosis by: (i) the involvement of the caspase cascade [73]; (ii) inhibiting STAT3 and
nuclear factor kappa B (NF-κB) signaling in HER2-overexpressing breast cancer cells [74]; (iii) reducing
the activity of both PI3K and Akt kinase [75] and regulating the p14ARF-Mdm2-p53 pathway [76].
Apigenin is reported to exert growth inhibitory effects by increasing the stability of p53, leading
to cell cycle arrest in many cancer cell lines, including rat neural and liver epithelial cells, as well
as human breast, ovarian, cervical, prostate, colon, and thyroid cancers [77]. In epidermal cells
and fibroblasts reversible G2/M and G0/G1 arrest is also mediated by the inhibition of p34 (Cdc2)
kinase activity [78,79], while in breast carcinoma the G2/M phase cell cycle arrest after apigenin
treatment led to a significant decrease in cyclins (B1, D1, and A) and cyclin-dependent kinase
(Cdk1 and 4) protein levels [80]. In pancreatic cancer cell lines, apigenin caused both time- and
concentration-dependent inhibition of DNA synthesis and cell proliferation through G2/M phase cell
cycle arrest caused by the suppression of cyclin B-associated Cdc2 activity [81,82]. Moreover, in the
same cell lines, it inhibited the glycogen synthase kinase-3β/NF-kB signaling pathway and upregulated
the expression of cytokine genes, which potentially contributed to its anti-cancer properties [83].
In addition, apigenin has been shown to induce WAF1/p21 levels, resulting in G1 phase cell cycle
arrest in androgen-responsive (LNCaP) and androgen-refractory (DU145) human prostate cancer
cells [84,85]. Indeed, the apoptosis observed in these cell lines appeared to be correlated with: (i) the
alteration in Bax/Bcl-2 ratio; (ii) the down- regulation of the constitutive expression of NF-kB/p65;
(iii) the release of cytochrome c; (iv) the induction of apoptotic protease activating factor-1 (Apaf-1),
which leads to caspase activation and PARP-cleavage [84,85]. Apigenin-induced growth inhibition by
different mechanisms has also been reported in colon [86,87], prostate [88], and neuroblastoma [89,90]
cancer cells. In endothelial cells, the anti-proliferative effect exerted by the flavanone is due to the
blocking of cells in the G2/M phase, as a result of the accumulation of the hyperphosphorylated
form of retinoblastoma protein [91]. Diosmin, another important Citrus flavone (mostly due to its
venotonic activity), occurs naturally as a glycoside, and after ingestion is rapidly transformed by
intestinal flora to its aglycone form, diosmetin. Diosmin has been shown to inhibit Caco-2 and HT-29
colon cancer cell growth [92]. In the hepatocellular carcinoma HA22T cells, it inhibited cell viability,
reduced cellular proliferative proteins, and induced cell cycle arrest in the G2/M phase through
p53 activation and inhibition of the PI3K-Akt-mouse double minute 2 homolog (MDM2) signaling
pathway. In addition, it suppressed tumor growth through protein phosphatase 2 (PP2A) activation in
HA22T-implanted xeno-graft nude activation [93]. The effectiveness of diosmin as an anti-cancer agent
has also been demonstrated in DU145 prostate cancer cells, where it promotes genotoxic events and
apoptotic cell death [94]. Moreover, it has been shown that diosmin may reduce the development of
esophageal cancer induced by N-methyl-N-amylnitrosamine (MNAN) when given during the initiation
phase [95], decreases oral carcinogenesis initiated by 4-nitroquinoline 1-oxide (4-NQO) [96], counteracts
N-butyl-N-(4-hydroxybutyl)nitrosamine (OH-BBN)-induced urinary-bladder carcinogenesis [97], and
prevents AOM-induced rat colon carcinogenesis, either alone or in combination with hesperidin [98].
In these cases [95–98], rats were fed a diet containing diosmin (1000 ppm), hesperidin (1000 ppm),
or diosmin + hesperidin (900 ppm and 100 ppm, respectively), and the cancer inhibition found could be
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related to the suppression of the increased cell proliferation caused by the carcinogens in the affected
mucous membranes.
Quercetin is a water-soluble flavonol, widely distributed in nature and the most common dietary
flavonol. It represents the aglycone form of a number of other flavonoid glycosides, such as rutin
and quercitin. In CFit is present mainly in lemon peel. Experimental data have shown quercetin
to be a potential anti-carcinogenic agent against several human tumor cell lines, including HL-60
(promyelocytic leukemia cells), A431 (epithelial carcinoma cell line), SK-OV-3 (ovary adenocarcinoma),
HeLa (cervical carcinoma) and HOS (osteosarcoma) [99]. The inhibitory effect of quercetin on HL-60
growth may be due to the induction of apoptosis mediated by an up-regulation of pro-apoptotic Bax
and post-translational modification (phosphorylation) of anti-apoptotic Bcl2 [100]. This flavonol also
demonstrated concentration-dependent anti-proliferative activity against both meningioma [101]
and colon cancer cells (CRC) [102]. Growth inhibition of several CRC cells has been reported
and numerous mechanisms explaining the in vitro anti-proliferative effect of quercetin have been
proposed [103]. Interestingly the combination of quercetin and low-frequency ultrasound selectively
induced cytotoxicity in skin and prostate cancer cells, while having minimal effect on corresponding
normal cell lines [104]. Quercetin has been reported to induce cell growth inhibition in MDA-MB-231
breast cancer cells by inhibition of the F-box protein S-phase kinase-associated protein 2 (Skp2) and
induction of p27 expression, thereby blocking cell cycle progression [105]. Moreover, several reports
have shown that if quercetin is associated with antineoplastic drugs it may then play a relevant role in
development of chemotherapeutic combinations. For example, in human breast cancer cells, quercetin
inhibits lapatinib-sensitive and -resistant breast cancer cell growth by modifying levels of factors
that regulate cell cycle G2/M progression and apoptosis, such as cyclin B1, p-Cdc25c (Ser216), Chk1,
caspase 3, caspase 7, and PARP [106]. In breast cancer cells, it potentiated the antitumor effects of
doxorubicin, attenuating unwanted cytotoxicity to non-tumoral cells [107], and markedly increased
the effect of adriamycin in a multidrug-resistant MCF-7 human breast cancer cell line [108] and in
MCT-15 human colon carcinoma cells [109].
Naringin and naringenin are two of the most abundant flavanones in CF, although the amounts
differ. Naringenin is the aglycone and is a metabolite of naringin (naringenin-7-neohesperoside),
the main flavonoid of grapefruit. Diverse biological and pharmacological properties, including
anti-carcinogenic activity, have been reported for both of these flavanones. Kanno et al. [110]
showed the anti-proliferative effect of naringenin in a range of human cancer cell lines (breast,
stomach, liver, cervix, pancreas, and colon) as well as its ability to inhibit tumor growth in sarcoma
S-180-implanted mice. The same authors reported that the exposure of human promyeloleukemia
HL-60 cells to naringenin at concentrations up to 0.5 mM induced apoptosis via the activation of
NF-κB, while a higher concentration (1 mM) reduced intracellular ATP levels, causing mitochondrial
dysfunctions leading to necrosis [111]. Naringenin-induced inhibition of colon cancer cell proliferation
has also been reported by Frydoonfar et al. [112]. A mechanism through which naringenin might
cause a reduction of breast cancer growth seems to be the impairment of glucose uptake. Indeed,
in MCF-7 cells, the flavanone impaired the insulin-stimulated glucose uptake, thus decreasing the
availability of glucose concentration in the culture medium and inhibiting proliferation [113]. In human
leukemia THP-1 cells, naringenin exerts an anti-proliferative effect in a concentration-dependent
manner, inducing apoptosis through the modulation of the Bcl-2 family, mitochondrial dysfunction,
activation of caspases, and PARP degradation that correlate with inactivation of the PI3K/Akt
pathway [114]. Using the same cell line, Shi et al. [115] have demonstrated naringenin may enhance
curcumin-induced apoptosis through inhibition of the Akt and ERK pathways, and by activating
the JNK and p53 pathways. In human epidermoid carcinoma A431 cells, the ability of naringenin to
induce apoptotic cascade and cell cycle arrest in the G0/G1 phase has been demonstrated [116].
Several in vitro studies have demonstrated the naringenin-induced intrinsic apoptotic pathway
initiated by the caspase cascade [111,114,117]. It has also been reported activation of the apoptosis
extrinsic pathway, triggered by ligands binding plasma membrane death receptors. Indeed, it has
been observed that naringenin enhances tumor necrosis factor-related apoptosis-inducing ligand
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(TRAIL)-induced apoptosis in TRAIL-resistant A549 human lung cancer cells by the upregulation
of TRAIL receptor 5 (death receptor 5, DR5, also named TRAIL-R2)) without inhibition of cell
growth in human normal lung fibroblast WI-38 cells [118]. Moreover, naringenin (50 μM) and other
flavonoids, among which hesperetin and apigenin, produced a more than three-fold increase in
mitoxantrone accumulation by inhibition of breast cancer resistance protein (BCRP; an ATP-binding
cassette transporter conferring multidrug resistance to a number of important anti-cancer agents)
in BCRP-overexpressing MCF-7 (breast cancer) and NCI-H460 (lung cancer) cells, whereas the
glycoside form (naringin) had no significant effects [119]. The presence of the 2,3-double bond in
the C ring of flavonoids, as well as ring B being attached at position 2, hydroxylation at position
5, lack of hydroxylation at position 3, and hydrophobic substitution at positions 6, 7, 8, or 40,
are structural properties important for potent flavonoid–BCRP interaction, and critical for potent
BCRP inhibition [120]. Some studies have suggested that naringenin also inhibits the P-glycoprotein
(P-gp), thus improving antitumor activity both in vitro [121] and in vivo [122,123]. Conversely, other
experimental studies indicate that naringenin modulates drug efflux pathways by inhibiting the
activity of multidrug resistance-associated proteins (MRPs) but not P-gp [124]. Similarly, Zhang and
collaborators [124] have claimed that doxorubicin in combination with naringenin enhanced antitumor
activity in vivo, while others have asserted that the pharmacokinetics of intravenously administered
doxorubicin (the plasma concentration, biliary, and urinary clearance and tissue distribution) is not
altered by pre-treatment with naringin, naringenin, and quercetin [125]. A number of in vivo studies
on the antitumor effects of naringenin have also been performed. These found that it suppresses
colon carcinogenesis through the aberrant crypt stage in AOM-treated rats [43], reduces tumor size
and weight loss in N-methyl-N’-nitro-N-nitrosoguanidine-induced gastric carcinogenesis [126,127],
promotes apoptosis in cerebrally-implanted C6 glioma cells rat model [128] and, like naringin, inhibits
oral carcinogenesis [129].
Several findings have identified naringin to be a promising chemotherapeutic agent for diverse
types of cancers. Naringin (750 μM) showed an anti-proliferative effect on SiHa human cervical
cancer cells through cell cycle arrest in the G2/M phase and apoptosis induction via disruption
of mitochondrial transmembrane potential, and the activation of both the intrinsic and extrinsic
pathways [130]. By contrast, naringin (1 mM) induced growth inhibition and apoptosis by suppressing
the NF-κB/COX-2-caspase-1 pathway on HeLa cells [131]. Recently, the role of glycoconjugates in
cancer cells has been a focus because of their regulatory effects on malignant phenotypes. A study
by Yoshinaga [132] reported naringin to suppress HeLa and A549 cell growth through the alteration
of glycolipids. This effect may largely be due to the attenuation of epidermal growth factor receptor
(EGFR) signaling through GM3 ganglioside accumulation. Triple-negative (ER-/PR-/HER2-) breast
cancer is an aggressive cancer with poor prognosis and a lack of targeted therapies. In this kind
of tumor, Li et al. [133] demonstrated that naringin inhibited cell proliferation and promoted cell
apoptosis and G1 cycle arrest. These effects were accompanied by increased p21 levels and decreased
survival by modulation of the β-catenin pathway.
Moreover, 100 μM naringin resulted in a significant concentration-dependent growth inhibition of
5637 bladder cancer cells together with of cell-cycle blocking [134]. In this cell line, the naringin-induced
anti-proliferative effect seems to be linked to the activation of Ras/Raf/ERK-mediated p21WAF1
induction, which in turn leads to a decrease in the levels of cyclin D1/CDK4 and cyclin E-CDK2
complexes, causing G1-phase cell-cycle arrest [134]. Recently, naringin has been investigated
regarding its ability to induce autophagy. Several studies have reported that autophagy promotes
cancer cell death in response to various anti-cancer agents on apoptosis-defective cells [135,136].
Accordingly, over-activation of autophagy in cancer cells has been proposed to be an important death
mechanism occurring in the tumor progression phase, where apoptosis is limited [136]. In AGS gastric
adenocarcinoma cells, naringin showed autophagy-mediated growth inhibition by suppressing the
PI3K/Akt/mTOR cascade through MAPKs activation [137]. Naringin has been demonstrated to
reduce glioblastoma cell proliferation by inhibiting the FAK/cyclin D1 pathway, and promoting cell
apoptosis by influencing the FAK/bads pathway [138].
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Furthermore, an in vivo study documented that grapefruit pulp powder (13.7 g/kg) or isolated
naringin (200 mg/kg) or limonin (200 mg/kg) protect against AOM-induced aberrant crypt foci
(ACF) by suppressing proliferation and elevating apoptosis through anti-inflammatory activities,
suggesting that the consumption of grapefruit or its flavonoids may help to suppress colon cancer
development [139]. Camargo et al. [140] showed that the treatment of rats bearing Walker 256
carcinosarcoma (W256) with 25 mg/kg of naringin reduced tumor necrosis factor-α (TNF-α) and
interleukin-6 (IL-6) levels and tumor growth by ~75%. Very recently, it has been proven that
naringin prevent intestinal tumorigenesis in a adenomatous polyposis coli multiple intestinal neoplasia
(Apc(Min/+)) mouse model [141].
Another important Citrus flavanone is hesperidin (hesperetin-7-rutinoside), the principal
flavonoid in sweet orange and lemon, being the glycosides form of hesperetin (free state). It is
water-soluble as a glycoside conjugate due to the presence of the sugar in its structure, which on
ingestion releases its aglycone hesperetin. Along with other flavonoid compounds, hesperidin has
been widely reported to possess venotonic and vasculo-protective pharmacological properties, and it is
effectively used as a supplement in patients suffering from blood vessel disorders including capillary
fragility and excessive permeability [142]. Both hesperidin and hesperetin have shown anti-cancer
activities, although the latter exhibited higher anti-proliferative activity in vitro. Chen et al. [143]
showed hesperetin to exert stronger cytotoxic activity than hesperidin in the HL-60 human leukemia
cell line. Moreover, at the same concentrations (40 and 80 μM), hesperetin induced apoptosis, while
hesperidin did not. The Authors suggest that the rutinoside group at C-7 causes the reduction of
apoptotic induction on HL-60 cells by hesperidin. This hypothesis is strengthened by evidence
that the aglycone naringenin also induces anti-proliferative and pro-apoptotic effects, but not the
glycone naringin. Furthermore, hesperetin inhibits the expression of CDK2, CDK4, and cyclin D,
thus inducing cell cycle arrest in the G1 phase, which in turn reduces MCF-7 cell proliferation in
a concentration-dependent manner [144]. Moreover, hesperetin (5 to 100 μM) inhibits human colon
adenocarcinoma HT-29 cellular growth and induces apoptosis via the Bax-dependent mitochondrial
pathway, involving oxidant/antioxidant imbalance [145]. It also enhances Notch1 levels, that in
turn decreases the expression of the neuroendocrine tumor markers ASCL1 and CgA, causing
inhibition of human gastrointestinal carcinoid (BON) cell growth [146]. Furthermore, hesperetin
exerts anti-proliferative and pro-apoptotic effects in human cervical cancer SiHa cells, via both
death receptor- and mitochondria-related mechanisms [147], while it induces ROS-mediated cell
death in hepatocarcinoma cells [148]. In the same study, the Authors showed that hesperetin
significantly inhibited the growth of xenograft tumors [148]. Hesperidin (20 mg/kg BW) suppressed
cell proliferation markers, angiogenic growth factors, COX-2 mRNA expression, enhanced apoptosis,
and reduced aberrant crypt foci in DMH-induced colon carcinogenesis in rats [149,150].
Anti-proliferative activity has also been described for the glycone hesperidin: Patil et al. [151]
found that it inhibits cell cycle progression in Panc-28 human pancreatic carcinoma cells, while
Park et al. [152] described its cytotoxic and pro-apoptotic effects on SNU-C4 human colon cancer cells.
In HepG2 hepatocarcinoma cells, its ability to induce apoptosis via both mitochondrial and death
receptor pathways has been demonstrated [153], as well as the non-apoptotic programmed cell death
namely paraptosis [154]. Hesperidin also inhibits proliferation of Ramos Burkitt’s lymphoma cells
and sensitizes them to doxorubicin-induced apoptosis through the inhibition of both constitutive and
doxorubicin-mediated NF-κB activation in a PPARγ-independent manner [155]. In hematopoietic
malignancies, hesperidin promoted p53 accumulation and downregulated constitutive NF-κB activity
in both PPARγ-dependent and -independent pathways [156]. Induction of apoptosis by hesperidin
has also been reported in human mammary carcinoma MCF-7 [157,158] and human cervical cancer
HeLa cells [159].
Other reports have shown that hesperidin and neohesperidin increase the sensitivity of
Caco-2 cells to doxorubicin, which is consistent with decreased Pgp activity demonstrated in
drug-resistant human leukaemia cells (CEM/ADR5000) at non-toxic concentrations (0.32–32 μM) [160].
Inhibition of Pgp has also been described for hesperetin and quercetin in breast cancer resistance
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protein (BCRP/ABCG2)-overexpressing cell lines [161]. Moreover, hesperidin has been reported
suppress proliferation of both human breast cancer and androgen-dependent prostate cancer cells
through mechanisms other than antimitotic ones, suggesting a possible interaction with androgenic
receptors [162].
Encouraging results in vivo of carcinogenesis inhibition by hesperidin have also been observed.
The compound (500 ppm/kg BW) was found to inhibit 4-NQO-induced oral carcinogenesis and to
decrease the number of lesions, polyamine levels in tongue tissue, and cell proliferation activity [163].
Later, the same group reported the inhibition of 4-NQO, AOM, MNAN, and OH-BBN-initiated
tumorigenesis by hesperidin alone or in combination with diosmin, as described above [95,97].
Moreover, when administered subcutaneously to CD-1 mice, hesperidin inhibited TPA-induced
tumor promotion, although it did not inhibit DMBA-induced tumor initiation [164]. Later, they
documented the protective effect of hesperidin against the TPA-stimulated infiltration of neutrophils,
suggesting its potential as a chemopreventive agent against tumor promoter-induced inflammation
and hyperplasia [165]. Daily administration of hesperetin (20 mg/kg BW) per os for 15 weeks inhibited
rat colon carcinogenesis during and after DMH initiation [166]. Further, in rats with DMBA-induced
mammary gland tumors, pretreatment with hesperetin (50 mg/kg BW/day) significantly reduced
the tumor burden and the overexpression of the proliferating cell nuclear antigen (PCNA), as well as
restoring the decreased Bcl-2 and increased Bax expression. By contrast, in the liver of mice treated with
DMBA, at a dosage of 10 mg/kg BW, it prevented DNA fragmentation and decreased Bax expression
and cleaved caspase-3, caspase-9 and PARP [167]. This study suggests that hesperetin may act as either
pro-apoptotic or anti-apoptotic agent depending on the circumstance [167]. Attenuation of BP-induced
lung cancer afforded by hesperidin supplementation (25 mg/kg BW) has also been reported [168].
Finally, dietary administration of hesperetin at 1000 ppm and 5000 ppm significantly deterred xenograft
growth in athymic mice ovariectomized and transplanted with aromatase-overexpressing MCF-7 cells,
while no such effect was observed in mice treated with apigenin or naringenin. Western blot analysis
indicated that cyclin D1, CDK4, and Bcl-XL were reduced in the tumors of hesperetin-treated mice,
and there are also results suggesting that the flavonone reduces plasma estrogen [169].
Didymin and poncirin are two flavanones that have been investigated less. However, studies
have shown their ability to induce the extrinsic apoptosis pathway in human non-small cell lung
cancer cells [170] and gastric cancer cells [171], respectively.
Anthocyanidins and anthocyanins occur ubiquitously in the plant kingdom and confer the bright
red, blue, and purple colors to fruits and vegetables. In CF, they are found most commonly in oranges,
predominantly as mixture of them. Several investigations have shown the antiproliferative effects of
anthocyanidins and anthocyanins both in vitro (towards multiple cancer cell types) and in vivo [172].
The main characteristics of the studies presented in this section are reported in Table 3.
Table 3. Studies on the ability of Citrus flavonoids to inhibit tumor development.
Promotion Phase
Flavonoid Concentration/Dose Experimental Model Reference
Quercetin, taxifolin,
nobiletin, tangeretin 2–8 μg/mL HTB43 cells [48]
Tangeretin 50–100 μM HL-60 cells [49]
Tangeretin 2.7–27 μM HL-60 cells [50]
Tangeretin, nobiletin
54 μM (tangeretin)
MDA-MB-435, MCF-7, and HT-29 cells [51]
100–200 μM for MDA-MB-435
60 μM for MCF-7
200 μM for HT-29 (nobiletin)
Tangeretin 10–50 μM COLO 205 cells [52]
Nobiletin 20–200 μM TMK-1, MKN-45, MKN-74, and KATO-III cells [53]
Tangeretin 10−7–10−4 M T47D cells [56]
Nobiletin 20–30 μM H2O2-treated SH-SY5Y cells [57]
Tangeretin, nobiletin IC50 4 mg/mL Brain tumor cells [58]
Tangeretin 150 μM A2780/CP70 and 2008/C13 cells [59]
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Table 3. Cont.
Promotion Phase
Flavonoid Concentration/Dose Experimental Model Reference
Tangeretin 5–240 μM AGS cells [60]
Nobiletin 1 × 10−7–5 × 10−4 mol/L TRAP rats [61]
Nobiletin 0.05% PhIP-treated rats [62]
Nobiletin 0.01%–0.05% AOM-treated rats [63]
Chrysin, quercetin, nobiletin 100 ppm AOM-treated mice [64]
Nobiletin 100 ppm AOM/DSS-treated mice [65]
Nobiletin 1.25–80 μM A549 cells [66]
Nobiletin 10−3 M MH1C1 and HepG2 cells [67]
Nobiletin 10–100 μM C6 cells [68]
Nobiletin 20–100 μM U87 and Hs683 cells [69]
Nobiletin 0–200 μM AGS, MKN-45, SNU-1, and SNU-16 cells [70]
Nobiletin 0–160 μM HL-60, U937, THP-1, OCI-AML3, and MV4-11 cells [71]
Nobiletin 0.05 wt% AOM/DSS-treated CD-1 mice [72]
Apigenin 1–100 μM MDA-MB-453 cells [73]
Apigenin 0–40 μM MCF-7, MCF-7 HER2, SK-BR-3 cells [74]
Apigenin 10–70 μM MDA-MB-453, BT-474, SKBr-3, MCF-7,and HBL-100 cells [75]
Apigenin 0–60 μM HT-29 and MG63 cells [77]
Apigenin 10–50 μM HDF cells [78]
Apigenin IC50: 7.8 μg/mL for MCF-7 and8.9 μg/mL for MDA-MB-468 cells MCF-7 and MDA-MB-468 cells [80]
Apigenin 1–100 μM BxPC-3 and MiaPaCa-2 cells [81]
Apigenin 6.25–100 μM AsPC-1, CD18, MIA PaCa2, and S2-013 cells [82]
Apigenin 10–100 μM BxPC-3 and PANC-1 cells [83]
Apigenin 10–80 μM LNCaP cells [84]
Apigenin 1–20 μM DU145 cells [85]
Apigenin 0–80 μM SW480, HT-29, and Caco-2 cells [86]
Apigenin 10–10 μM HCT-116, SW480, HT-29, and LoVo cells [87]
Apigenin 20–50 μg/mouse 22Rv1 and PC-3 cells-implanted mice [88]
Apigenin 50 μM SH-SY5Y cells [89]
Apigenin 15–60 μM and 25 mg/kg NUB-7, LAN-5, and SK-N-BE cells and NUB-7inoculated xenograft mice [90]
Flavonids 25–250 μM HT-29, Caco-2, LLC-PK1, and MCF-7 cells [92]
Diosmin 0–120 μM and 15 mg/kg HA22T cells and HA22T xenograft mice [93]
Diosmin 50–250 μM DU145 cells [94]
Diosmin, hesperidin 1000 ppm MNAN-injected rats [95]
Diosmin, hesperidin 1000 ppm 4-NQO-exposed rats [96]
Diosmin, hesperidin 500–1000 ppm OH-BBN-exposed rats [97]
Diosmin, hesperidin 1000 ppm AOM-injected rats [98]
22 flavonoids 0–10 μM HL-60, A431, SK-OV-3, HeLa, HOS cells [99]
Quercetin 0–100 μM Caco-2 and HT-29 and IEC-6 cells [102]
Quercetin 0–50 μM Prostate and skin cells [104]
Quercetin 0–50 μM MDA-MB-231, MDA-MB-453, AU565, BT483, BT474,and MCF-7 cells [105]
Quercetin 0–10 μM SK-Br-3 and SK-Br-3-Lap R cells [106]
Quercetin 2.5–40 μM MDA-MB-231, MCF-7, and MCF-10A cells [107]
Quercetin 1–10 μM MCF-7ADR-resistant cells [108]
Naringenin 0–1 mM HL-60 cells [110]
Naringenin 0.02–2.85 mmol HT-29 cells [112]
Naringenin 10 μM MCF-7 cells [113]
Naringenin 0–400 μM THP-1 cells [114]
Naringenin 50–750 μM HaCaT and A431 cells [116]
Naringenin 0.1–0.5 mM HL-60 cells [117]
Naringenin 100 μM A549, H460, and WI-38 cells [118]
Naringenin, hesperetin,
apigenin 50 μM MCF-7 and NCI-H460 cells [119]
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Table 3. Cont.
Promotion Phase
Flavonoid Concentration/Dose Experimental Model Reference
Naringenin, kaempferol 25–100 μM HK-2 cells [121]
Naringenin 10 mg/kg Rats [122]
Naringenin, naringin 0.7 mg/kg (naringenin) and2.4–9.4 mg/kg (naringin) Rats [123]
Naringenin 100 μM A549, MCF-7, HepG2, and MCF-7/DOX cells [124]
Naringin, naringenin,
quercetin
50 mg/kg (naringin or naringenin)
and 100 mg/kg (quercetin) Rats [125]
Naringenin 200 mg/kg MNNG-treated rats [126]
Naringenin 200 mg/kg MNNG-treated rats [127]
Naringenin 50 mg/kg C6 cells-injected rats [128]
Naringin, naringenin 2.5% Hamsters [129]
Naringin 250–2000 μM SiHa cells [130]
Naringin 1000 μmol/L HeLa cells [131]
Naringin 0–3200 μM HeLa and A549 cells [132]
Naringin 50–200 μM and 100 mg/kg MDA-MB-231, MDA-MB-468, and BT-549cells/MDA-MB-231 xenograft mice [133]
Naringin 0–150 μM 5637 and T24 cells [134]
Naringin 1.2–3 mM AGS cells [137]
Naringin 50–200 μM MDA-MB-231, MDA-MB-468, and BT-549 cells [138]
Naringin 200 mg/kg AOM-injected rats [139]
Naringin 10.25–35 mg/kg W256 rats [140]
Naringin 150 mg/kg Apc(Min/+) mice [141]
Hesperetin, hesperidin,
naringenin, naringin 40–80 μM HL-60, THP-1, and PMN cells [143]
Hesperetin 0–200 μM MCF-7 cells [144]
Hesperetin 5–100 μM HT-29 cells [145]
Hesperetin 0–125 μmol/L BON cells [146]
Hesperetin 125–1000 μM SiHa cells [147]
Hesperetin 0–600 μM and 10–40 mg/kg HepG-2, SMMC-7721, and Huh-7/hepatocellularcarcinoma xenograft mice [148]
Hesperetin 20 mg/kg DMH-injected rats [149]
Hesperidin, hesperitin,
rutin, neohesperidin 25–100 μg/mL Panc-28 cells [151]
Hesperidin 1–100 μM SNU-C4 cells [152]
Hesperidin 0–200 μM HepG2 cells [153]
Hesperidin 0.1–2 mM HepG2 cells [154]
Hesperidin 0–100 μM Ramos cells [155]
Hesperidin 10–100 μM NALM-6 cells [156]
Hesperetin 0–200 μM MCF-7, MCF-10A, HMEC and MDA-MB-231 cells [157]
Hesperidin 20–100 μM MCF-7 cells [158]
Hesperidin 0–100 μM HeLa cells [159]
Hesperidin 0.32–32 μM Caco-2, CCRF-CEM and CEM/ADR5000 cells [160]
Hesperetin, quercetin 30 μM K562, K562/BCRP, MCF7/WT, and MCF7/MR cells [161]
Hesperidin 0–100 μM MCF-7, LNCaP, PC-3 and DU-145 cells [162]
Hesperidin 500 ppm 4-NQO-treated rats [163]
Hesperidin 1% DMBA/TPA-treated mice [164]
Hesperetin 20 mg/kg DMH-treated rats [166]
Hesperetin 10–50 mg/kg DMBA-treated rats [167]
Hesperidin 25 mg/kg BP-exposed mice [168]
Hesperetin 1000–5000 ppm MCF-7 xenograft mice [169]
Didymin 0–20 μM A549 and H460 cells [170]
Poncirin 50–200 μM AGS cells [171]
4-NQO: 4-nitroquinoline 1-oxide; AOM: azoxymethane; DMH: 1,2-dimethylhydrazine; DSS: dextran sulfate
sodium; MNAN: N-methyl-N-amylnitrosamine; MNNG: N-methyl-N′-nitro-N-nitrosoguanidine OH-BBN:
N-butyl-N-(4-hydroxybutyl)nitrosamine; PhIP: 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.
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3.3. Inhibition of Tumor Progression: Focus on Angiogenesis and Metastatization
Both development and progression of solid neoplasms requires rapid and persistent growth of new
blood vessels (neo-angiogenesis) around the cancer tissue to supply the growing tumor with nutrients and
oxygen. Cancer cells can stimulate angiogenesis by secreting angiogenesis-promoting growth factors,
such as the vascular endothelial growth factor (VEGF), the most important endothelial cell-selective
mitogen in vitro. VEGF also produces a substantial increase in vascular permeability that allows tumor
cells access to the bloodstream, thereby linking angiogenesis and metastases with a poor prognosis [91].
It has been reported that some flavonoids, including naringin, apigenin, and rutin, are able to
inhibit VEGF release in MDA human breast cancer cells [173], and VEGF and transforming growth
factor-β1 (TGF-β1) in the GL-15 glioblastoma cell lines [174]. Several findings suggest that apigenin
can be considered a natural anti-angiogenic compound. Indeed, it reduces VEGF transcriptional
activation via hypoxia-inducible factor 1 (HIF-1) pathway in A549 lung cancer cells, and inhibits
angiogenesis in the tumor tissues of nude mice [175]. The inhibition of HIF-1 and VEGF expression has
been described in different cancer cells in normoxic or hypoxic conditions [176]. The Authors described
the inhibition of tumor angiogenesis using both chicken chorioallantoic membrane and Matrigel plug
assays [176]. Apigenin-induced reduction of neo-angiogenesis in the human umbilical vein endothelial
cell (HUVEC) seems to be mediated by inhibition of matrix-degrading proteases [177]. Recently,
it has been shown that apigenin may act by modulating the inflammatory cytokine IL-6/activators of
transcription 3 (STAT3) (IL-6/STAT3) signaling pathways in HUVEC cells. Angiogenesis inhibition
resulted in modulation of the activation of extracellular signal-regulated kinase-1/2 (ERK 1/2)
signaling triggered by IL-6, as well as in a marked reduction in the proliferation, migration,
and morphogenic differentiation of endothelial cells. These effects were coupled with reduced
expression of the IL-6 signal transducing receptor-alpha (IL-6Rα) and suppression of cytokine signaling
(SOCS3) protein, as well as the secretion of extracellular matrix metalloproteinase (MMP)-2 [178].
Other Citrus flavonoids have been evaluated for their potential anti-angiogenic capability.
Lam et al. [179] demonstrated the anti-angiogenic activity of some polymethoxylated flavonoids,
including hesperetin and nobiletin, both in vitro (HUVEC cells) and in vivo (the zebrafish embryo
model). The structure–activity relationship (SAR) analysis indicated that a flavonoid with
a methoxylated group at the C3′ position offers stronger anti-angiogenic activity, whereas the absence
of a methoxylated group at the C8 position causes lower lethal toxicity in addition to enhancing
anti-angiogenic activity. Anti-angiogenic activity of nobiletin in vitro and in vivo previously reported
by Kunimasa et al. [180], gave an in-depth description of the mechanisms underlying its inhibitory
action on multiple functions of the proliferation, migration, and tube formation of HUVEC cells.
Wang et al. [181] reported nobiletin to inhibit tumor growth and angiogenesis by reducing VEGF
expression of K562 cells xenograft in nude mice. Moreover, quercetin inhibited tube formation in
HUVEC cells and suppressed the angiogenic process in a chick chorioallantoic membrane assay [182].
Interestingly, the flavonoid quercetin possessed strong inhibitory effects on vessel formation and on
endothelial cell proliferation, and concomitantly showed strong antioxidant activity [183].
Many studies have reported that flavonoids, many of which are abundant in the Citrus genus,
are an effective natural inhibitor of cancer invasion and metastasis [184]. In particular, tangeretin and
nobiletin appear to be able to inhibit the progression phase of carcinogenesis.
In MCF-7/6 breast cancer cells, tangeretin was found to upregulate the function of the
E-cadherin/catenin complex, which consequently led to firm cell–cell adhesions and inhibited cell
invasion [185]. In brain tumor cells, nobiletin, and to a lesser extent, tangeretin, exhibited inhibitory
activity on the adhesion, migration, invasion, and secretion of MMP-2/MMP-9. In glioblastoma,
nobiletin inhibited human U87 and Hs683 glioma cell growth and migration by arresting cell cycle
and suppressing the MAPK and Akt pathways [69]. Naringin inhibited the invasion and migration
of glioblastoma U87 MG cells by increasing the expression of tissue inhibitors of metalloproteinases
(TIMP-1 and TIMP-2), thereby decreasing the expression and proteinase activity of MMP-2 and MMP-9
and enhancing the focal adhesion kinase (FAK)/MMPs pathway [138]. Moreover, naringin inhibited
cell migration and invasion of chondrosarcoma cells via vascular cell adhesion molecule 1 (VCAM-1)
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down-regulation by increasing miR-126 [186], while in bladder cancer cells it downregulated the
Akt and MMP-2 pathways [187]. In an experimental model of pulmonary metastasis generated
by inoculating albino Swiss mice with highly metastatic murine melanoma cells B16F10, diosmin
reduced the number of metastatic nodules in the lung more effectively than tangeretin and rutin [188].
Furthermore, oral administration of naringenin or hesperitin reduced the number of lung metastases
in C57BL6/N mice inoculated with B16F10 cells, and increased survival time after tumor cell
inoculation [189]. In addition, in a breast cancer resection model that mimics clinical situations
after surgery, orally administered naringenin significantly decreased the number of metastatic tumor
cells in the lung and extended the life span of tumor resected mice. Both in vitro and in vivo
experimental results have further demonstrated that relief of immunosuppression caused by regulatory
T cells might be the fundamental mechanism underlying metastasis inhibition by naringenin [190].
Some reports have illustrated the mechanisms by which nobiletin may reduce tumor invasion and
metastasis in vitro. In human fibrosarcoma HT-1080 cells stimulated with TPA, it directly inhibited the
phosphorylation of mitogen-activated protein/extracellular signal-regulated kinase (MEK), thereby
suppressing either the sequential phosphorylation of extracellular regulated kinases (ERK) and the
expression of MMP [191]. MMP-1 and -9 expression were suppressed by nobiletin in fibrosarcoma
cells with an associated increase in tissue inhibitors of MMPs [192]. Additionally, MMP-7 was
down-regulated in colorectal cells [193], while MMP-2 in human nasopharyngeal carcinoma cells [194].
Nobiletin exerts antimetastatic effects on human breast cancer cells [195] through the down-regulation
of both CXC chemokine receptor type 4 (CXCR4) and MMP-9 via a mechanism involving NF-κB
inhibition and MAPKs activation. Minagawa et al. [196] showed that pro-MMP-9 activity was inhibited
by nobiletin in gastric cell lines, and reported a significant reduction in the peritoneal dissemination
of stomach cancer nodules when the polymethoxylated flavone was administered subcutaneously
to severe combined immune deficient (SCID) mice. Moreover, nobiletin has been shown to reduce
adhesion, invasion, and migration of highly metastatic human gastric adenocarcinoma AGS cells by
inhibiting the activation of FAK and PI3K/Akt signals, which in turn downregulates MMP-2 and -9
expression and activity [197]. Finally, nobiletin inhibited the epithelial–mesenchymal transition of
human non-small cell lung cancer cells by antagonizing the TGF-β1/Smad3 signaling pathway, thus
prohibiting the growth of metastatic nodules in the lungs of nude mice [198].
Treatment of MDA-MB-231 breast tumor cells with apigenin (ranging from 2.5 to 10 μg/mL) led
to a partial decrease in urokinase-plasminogen activator (uPA) expression and completely inhibited
phorbol 12-myristate 13-acetate (PMA)-induced MMP-9 secretion [199]. Apigenin also inhibited
hepatocyte growth factor (HGF)-induced migration and invasion and decreased HGF-stimulated
integrin β4 and Akt phosphorylation in MDA-MB-231 cells. It also inhibited HGF-promoted metastasis
in nude mice and in chick embryos [200]. In prostate cancer, the motility and invasion of PC3-M
cells were inhibited by apigenin through a FAK/Src signaling mechanism [201]. In ovarian cancer,
it inhibited FAK-mediated migration and invasion of A2780 cells, and repressed spontaneous metastasis
formation on the ovaries of nude mice following inoculation with A2780 cells [202]. In cervical cancer,
apigenin inhibited the motility and invasiveness of HeLa cells [203]. Moreover, its administration
significantly decreased the incidence of cancer metastasis in AOM-induced intestinal adenocarcinoma
in rats [204]. Noh et al. [205] further reported that this flavone inhibited PMA-induced migration and
invasion of human cervical carcinoma Caski cell line via the suppression of p38 MAPK-dependent
MMP-9 expression. Finally, intraperitoneal administration of apigenin and quercetin into syngeneic
mice injected with B16-BL6 melanoma cells resulted in a significant delay in tumor growth and lungs
metastases, with flavonoids being more effective than tamoxifen [206].
Over the last decade, there has been extensive researches into the potential anti-invasive role
of quercetin. In breast cancer, the invasive activity of PMA-induced MCF-7 cells was blocked by
the flavonol by reducing MMP-9 expression and by blocking activation of the protein kinase C
(PKC)/ERK/AP-1 signaling cascade [207]. In MDA-MB-231 cells the anti-invasive effect was mediated
by inhibiting MMP-3 activity [208]. In PC-3 prostate cancer cells, quercetin (50 and 100 μM for
24 h) decreased MMP-2/MMP-9 expression [209] and downregulated the mRNA of uPA, uPA
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receptor (uPA-R), EGF, and EGF receptor (EGF-R), thereby inhibiting invasion and migration [210].
In human glioblastoma U87 cells, quercetin blocked PMA-induced migration and invasion by inhibiting
ERK-dependent COX-2 activation and MMP-9 activity [211], while in the DAOY medulloblastoma cell
line, it reduced both Met-induced cell migration and HGF-mediated Akt activation [212]. Moreover,
quercetin decreased the invasiveness of A431 epidermal cancer cells by increasing EGF-depressed
E-cadherin, by down-regulating both epithelial–mesenchymal transition (EMT) markers and MMP-9,
leading to the restoration of cell–cell junctions [213]. In addition, it inhibited cell–matrix adhesion,
migration, and invasion of HeLa cells [214] and inhibited the motility and invasion of murine
melanoma B16-BL6 cells by decreasing pro-MMP-9 via the PKC pathway [215]. The administration of
quercetin to DMBA-induced mammary carcinoma rats has been reported to significantly decrease both
tissue type plasminogen activator (t-PA) and u-PA [216]. Lastly, didymin was observed to suppress
phthalate-mediated breast cancer cell proliferation, migration, and invasion, suggesting that it is
capable of preventing phthalate ester-associated cancer aggravation [217]. Table 4 summarizes the
essential features of the studies on the anti-angiogenic and anti-metastatic activity of Citrus flavonoids.
Table 4. Studies on the ability of Citrus flavonoids to inhibit angiogenesis and metastasis and
their characteristics.
Progression Phase
Flavonoid Concentration/Dose Experimental Model Reference
Flavonoids 0.1–100 μmol/L MDA, U343, and U118 cells [173]
Rutin 50–100 μM GL-15 cells [174]
Apigenin 0–20 μM A549 cells [175]
Apigenin 0–30 μM PC-3, DU145, LNCaP, OVCAR-3, HCT-8, MCF-7 cells [176]
Apigenin 5 mg/L HUVEC cells [177]
Apigenin 25 μM HUVEC, HMVECs-d-Ad cells [178]
Hesperetin and nobiletin 0–100 μM and 30 μM HUVECs cells and zebrafish [179]
Nobiletin 0–128 μM and 100 μg/egg HUVEC and HDMEC cells and CAM [180]
Nobiletin 12.5–50 mg/kg K562 cells xenograft mice [181]
Quercetin 0–100 μM and 50–100 nmol/10 μL/egg HUVEC cells and CAM [182]
Quercetin 3.13–50 μg/mL HUVEC cells [183]
Naringin 0–30 μM JJ012 and SW1353 cells [186]
Neringenin 0–300 μM TSGH-8301 cells [187]
Tangeretin, rutin, and diosmin 20 mg/animal B16F10-inoculated mice [188]
Naringenin and hesperitin 10 μM/20 mg/g of pellets B16-F10 cells/B16-F10-inoculated C57BL6/N mice [189]
Naringenin 0–200 μM and 100 mg/kg 4T1 cells/4T1-injected BALB/c and C57BL/6 mice [190]
Nobiletin 64 μM TPA-stimulated HT-1080 cells [191]
Nobiletin 0–64 μM TPA-stimulated HT-1080 cells [192]
Nobiletin 0–100 μM Caco-2, HT-29, Colo205, Colo320DM, LS174T, and LS180 cells [193]
Nobiletin 0–200 μM MDA-MB-231 cells [195]
Nobiletin 0–256 μM/16–64 μM TMK-1, MKN-45, and St-4 cell/TMK-1-injected mice [196]
Nobiletin 0–4.5 μM HepG2, Caco-2, and AGS cells [197]
Apigenin 2.5–10 μg/mL MDA-MB231 cells [199]
Apigenin 0–320 μM MDA-MB-231, A549, SK-Hep1 cells [200]
Apigenin 0–50 μM PC3-M, C4-2B, and DU145 cells [201]
Apigenin 20/40 μM A2780 cells [202]
Apigenin 10–50 μM HeLa cells [203]
Apigenin 0.75–1.5 mg/kg AOM-treated rats [204]
Apigenin 5–20 μM PMA-exposed SK-Hep1 and MDA-231 cells [205]
Apigenin and quercetin 1–10,000 nM/25–50 mg/kg B16-BL6-injected mice [206]
Quercetin 80 μM TPA-treated MCF-7 cells [207]
Quercetin 0–100 μmol/L MDA-MB-231 cells [208]
Quercetin 50–100 μM PC-3 cells [209]
Quercetin 25–125 mM PC-3 cells [210]
Quercetin 50 μM TPA-exposed U87 cells [211]
Quercetin 1–20 μM HGF-exposed DAOY cells [212]
Quercetin and luteolin 10–20 μM A431 cells [213]
Quercetin 20 to 80 μM/L HeLa cells [214]
Quercetin 3.3 × 10−1 mM B16-BL6 cells [215]
Quercetin 25 mg/kg DMBA-treated rats [216]
DMBA: 7,12-dimethylbenz(α)anthracene; HGF: hepatocyte growth factor; TPA: tetradecanoyl-13-phorbol acetate.
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4. Anti-Cancer Properties of Citrus Juices and Extracts
As described above, a number of studies have investigated the anti-cancer effect of single Citrus
flavonoids as pure compounds. However, few studies have focused on the biological activity of Citrus
juices and extracts. A very interesting paper [218] explains why a single bioactive compound may
not replicate the same effect as the phytocomplex in which it is contained. Indeed, often, even at
high concentrations, no single active principle can replace the combination of natural phytochemicals
present in an extract in achieving the same magnitude of pharmacological effect. Liu [218] suggests that
the additive and synergistic effects of phytochemicals in fruits and vegetables are responsible for these
potent antioxidant and anti-cancer activities, and that the benefits of a diet rich in fruits and vegetables
is attributable to the complex mixture of phytochemicals present in whole foods. This concept has
been supported through data obtained employing several nutraceuticals by Surh [10].
In line with this, some preclinical studies have indicated that Citrus juices and extracts may
reduce cancer formation and progression. To the best of our knowledge, So et al. [219] were the
first to show that concentrated Citrus sinensis (orange) juice inhibits the development of mammary
tumors induced by 5 mg of DMBA in rats, also suggesting the anti-cancer properties of naringin
and quercetin. Two years later, the same Authors [220] showed that a double-strength orange
juice administration inhibited DMBA-induced mammary tumorigenesis in rats more effectively than
double-strength grapefruit juice. Moreover, Miyagi and coworkers [221] showed that orange juice
inhibits AOM-induced colon cancer in male rats, suggesting that flavonoids and limonoid glucosides
might be responsible for this anti-cancer activity. Citrus reticulata (mandarin) juice has also long been
investigated regarding its antitumoral activity. In particular, studies have demonstrated the capability
of mandarin juice to suppress the chemically-induced carcinogenesis in colon, tongue, and lung cancers,
especially when it is supplemented with added amounts of flavonoids, such as beta-cryptoxanthin
and hesperidin [222–225]. Recently, we have investigated the effects of a flavonoid-rich extract
from mandarin juice (MJe) on three human anaplastic thyroid carcinoma cell lines (CAL-62, C-643,
and 8505C cells), showing that MJe reduced cell proliferation through a block of the cell cycle in the
G2/M phase, accompanied by low cell death due to autophagy. Moreover, MJe reduced activity of
MMP-2, thus decreasing cell migration [226]. In another study, Vanamala and coworkers [139] showed
that grapefruit juice and limonin produce suppressive effects on AOM-induced colon carcinogenesis by
lowering inducible nitric oxide synthases iNOS and cyclooxygenase-2 COX-2 levels and upregulating
apoptosis, thereby reducing the formation of aberrant crypt foci. Furthermore, methanolic extract of
lemon fruit triggered apoptosis of MCF-7 human breast cancer cells [227]. An analogous effect was
achieved on the same cell line using lemon seed extract [228].
In recent years, Citrus bergamia (bergamot) fruit has attracted attention due to its potential
anti-cancer effects. In particular, we have shown that bergamot juice (BJ) to reduce the growth rate of
different cancer cell lines by different molecular mechanisms, depending on cancer type. In SH-SY5Y
human neuroblastoma cells, BJ stimulated the cell cycle arrest in the G1 phase without inducing
apoptosis, and caused a modification in cellular morphology associated with a marked increase in
detached cells. The inhibition of adhesive ability onto different physiologic substrates and onto
endothelial cell monolayer was correlated with BJ-induced impairment of actin filaments and with the
reduction in the expression of the active form of FAK, in turn causing inhibition of cell migration [229].
Contrariwise, in human hepatocellular carcinoma HepG2 cells, we demonstrated that BJ reduces the
growth rate through the involvement of p53, p21, and NF-κB pathways, as well as the activation of
both intrinsic and extrinsic apoptotic pathways [230]. Moreover, we documented that the BJ-induced
reduction of both cell adhesiveness and motility could be responsible for the slight inhibitory effects on
lung metastasis colonization observed in an animal model of spontaneous neuroblastoma metastasis
formation in SCID mouse [231]. In order to assess which bioactive component of BJ was responsible for
its antitumor activity, we focused on the flavonoid-rich fraction from bergamot juice (BJe). Our results
suggested that BJe inhibits HT-29 human colorectal carcinoma cell growth and induces apoptosis
through multiple mechanisms. Molecular assays revealed that higher concentrations of BJe increase
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ROS production, which causes a loss of mitochondrial membrane potential and oxidative DNA
damage. Lower concentrations of BJe inhibited MAPK pathways and modified apoptosis-related
proteins, which in turn induced cell cycle arrest and apoptosis [232].
It is well known that chronic inflammation might lead to carcinogenesis, and that both inflammatory
cells and cytokines contribute to tumor growth, progression, and immunosuppression [233]. Moreover,
there is evidence to support the hypothesis that dysregulation of both inflammatory and redox
pathways in tumor cells and in their stromal environment play an essential role in tumorigenesis,
invasion, and systemic spread [234]. Furthermore, inflammatory pathways are constitutively active
in most cancers. Therefore, the use of medicines with antioxidant and anti-inflammatory activities is
desirable in oncological applications. In addition, although natural remedies are not risk free, they
are generally safer than both synthetic and biological drugs. In this context, we have recently shown
that BJe has antioxidant properties [235,236] and is able to suppress pro-inflammatory responses in
both in vitro [237,238] and in vivo models [239,240]. Interestingly, evidence showing that BJ did not
significantly affect the viability of normal human diploid fibroblast WI-38 cells [229], as well as not
provoking any apparent sign of systemic toxicity [231], together with its antimicrobial activity [241,242]
and favorable safety/efficacy balance [243], reveals the potential of BJe as an anti-cancer remedy,
highlighting that it could represent a novel strategic approach in oncology field.
Other studies have been performed using extracts of Citrus derivatives. For examples, Mak
and collaborators [244] reported that an extract from the pericarpium of Citrus reticulata inhibited
the proliferation of murine myeloid leukemia WEHI 3B cells and induced their differentiation into
macrophages and granulocytes, identifying nobiletin and tangeretin as the active components. Kim
and coworkers [245] reported the anti-proliferative and pro-apoptotic effects of a Citrus reticulata
Blanco peel extract on the human gastric cancer cell line SNU-668. Park et al. [246] used a flavonoid
extract from the peel of Korean Citrus aurantium L. and found it was able to induce cell cycle arrest
and apoptosis in A549 lung cancer cells, while Han and collaborators [247] suggested that a crude
methanol extract of Citrus aurantium L. peel should induce caspase-dependent apoptosis through the
inhibition of Akt in U937 human leukemia cells. Two animal studies using an orange peel extract
abundant in polymethoxyflavones, showed its ability to reduce the development of hyperplastic
lesions and to increase apoptosis in ductal epithelial cells of mouse mammary glands [55], and to
inhibit intestinal tumorigenesis in Apc(Min/+) mice [54]. Moreover, the ethanolic extract of peel from
Citrus aurantifolia increased the sensitivity of MCF-7 cells to doxorubicin, enhancing both cell cycle
arrest and apoptosis [248]. Similarly, total flavonoids from Citrus paradisi Macfadyen peel, when
combined with arsenic trioxide, produced a synergistic effect in reducing the proliferation of leukemia
cells and triggering apoptosis [249], suggesting that Citrus extracts could be used as co-adjuvants in
cancer therapy. Finally, we have shown that the bergamot essential oil (BEO) obtained by rasping
the peel of Citrus bergamia fruits decreased the growth rate of SH-SY5Y neuroblastoma cells [250] by
a mechanism correlated to both apoptotic and necrotic cell death [251]. Table 5 summarizes the main
characteristics of the above investigations into the anti-cancer properties of Citrus juices and extracts.
Table 5. Essential features of the studies evaluating the anti-cancer properties of Citrus juices
and extracts.
Citrus Juices and Extracts Experimental Model Reference
Citrus sinensis juice DMBA-injected rats [219]
Citrus sinensis juice DMBA-injected rats [220]
Citrus sinensis juice AOM-injected rats [221]
Citrus reticulata juice AOM-injected rats [222]
Citrus reticulata juice NNK-injected mice [223]
Citrus reticulata juice AOM-injected rats [225]
Citrus reticulata juice CAL-62, C-643, 8505C cells [226]
Lemon fruit extract MCF-7 cells [227]
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Table 5. Cont.
Citrus Juices and Extracts Experimental Model Reference
Lemon seed extracts MCF-7 cells [228]
Citrus bergamia juice SH-SY5Y cells [229]
Citrus bergamia juice HepG2 cells [230]
Citrus bergamia juice SK-N-SH/LAN-1 xenograft mice [231]
Flavonoid-rich extract of bergamot juice HT-29 cells [232]
Citrus reticulata pericarpium extract WEHI 3B cells [244]
Citrus reticulata Blanco peel extract SNU-668 cells [245]
Citrus aurantium peel extract A549 cells [246]
Citrus aurantium peel extract U937 cells [247]
Orange peel extract C57Bl/6 mice [55]
Orange peel extract Apc(Min/+) mice [54]
Citrus aurantifolia peel extract MCF-7 cells [248]
Citrus paradis peel extract Kasumi-1 cells [249]
Citrus bergamia essential oil SH-SY5Y cells [250]
Citrus bergamia essential oil SH-SY5Y cells [251]
AOM: azoxymethane; DMBA: 7,12-dimethylbenz(α)anthracene; NNK: 4-(methyl-nitrosoamino)-1-(3-pyridyl)-
1-butanone.
5. Epidemiological Studies
Over the last few decades, epidemiological and clinical studies have suggested that regular intake
of CF may protect against cancer development. The majority of the clinical evidence supporting
the potential anti-cancer effects of Citrus is derived from case–control studies. One of the first
population-based case-control studies evaluating whether Citrus intake is associated with a reduced
cancer risk was carried out in Shanghai at the end of the 1990s. The aim of this study was to
investigate the association between dietary factors and risk of nasopharyngeal carcinoma (NPC),
Yuan et al. [252] found that high intake of oranges and tangerines was associated with a statistically
significant reduction in the risk of NPC. The study included 935 NPC patients aged 15 to 74 years
interviewed by a questionnaire. Authors concluded that oranges and tangerines are a rich source of
vitamin C that can block nitrosamine formation, thereby offering a biological rationale for the anti-NPC
effect. In the 1990s, Bosetti et al. [253] conducted a hospital-based case–control study in three areas of
northern Italy on 304 patients affected by a squamous cell carcinoma of the esophagus and 743 controls
who were asked to complete a questionnaire. The results of this observational study provide further
evidence to support the theory that consumption of CF is inversely related to esophageal cancer risk.
Steevens et al. [254] reached the same conclusions when studying a Netherlands cohort. High intake
of CF has also been associated with reduced risk of cancer of the oral cavity and pharynx [255]. Some
years later, the same research group, performed a population-based case control study recruiting
subjects in Northern Italy and Swiss Canton of Vaud in the 1990s showed that intake of CF may also
reduce laryngeal cancer [256]. In line with these findings, a prospective study on 42,311 US men in the
Health Professionals Follow-up Study [257] reported that histologically-diagnosed oral premalignant
lesions were suppressed by consumption of CF and CF juices (30% to 40% lower risk), thus upholding
results previously obtained in Europe on smaller subject groups. Interestingly, a meta-analysis showed
that the CF consumption exerts the strongest protective effect against oral cancer compared to all other
kinds of fruits [258]. Pourfarzi et al. [259] reported that regular intake of fruits could reduce the risk of
gastric cancer by more than half. In particular, consumption of CF was more protective than all other
fruits, and subjects eating them more than three times per week had about a 70% lower risk than those
who never or infrequently ate CF. The beneficial effects of CF with respect to stomach cancer prevention
were confirmed by a more recent cohort study performed in Netherlands [254]. Epidemiological data
from a network of case–control studies strengthen the hypothesis that increasing consumption of
CF may reduce the risk of cancers of the digestive and upper respiratory tract [260]. Gonzalez and
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co-workers [261] also observed a significant inverse correlation between total CF ingestion and gastric
cancer risk.
However, the possibility that intake of CF can prevent the development of colon cancer is quite
controversial [262,263]. A large population-based case–control study was conducted on Chinese
women in Shanghai by interview. Tangerines, oranges, and grapefruits were found to be inversely
associated with breast cancer risk among pre-menopausal women, but the same data was not found to
be statistically significant in post-menopausal women [264]. However, a more recent study revealed
a significant protective effect against breast cancer by oranges, orange juice, and other CF [265]. Intake
of either CF [266] or orange, grapefruit, and their juice [267] also reduced the risk of developing
pancreatic cancer. Moreover, CF intake also seems to be inversely associated with prostate cancer
risk [268], and high consumption of both tangerines and oranges was found to be protective against
melanoma [269]. Recently, a prospective study showed that Citrus consumption, especially if eaten
daily, was correlated with reduced incidence of all cancers, although significant results were only
obtained for prostate and pancreatic cancer [270]. About 40,000 Japanese patients of Ohsaki were
followed for up to 9 years to assess the Citrus consumption by a self-administered questionnaire.
This study overcomes the bias of other studies described above due to their retrospective nature,
confirming the ability of CF to reduce risk of first and second primary tumors [270]. Interestingly,
one prospective study indicated that high intake of CF may confer protection against the development
of second primary cancers, particularly in the lung [271].
Furthermore, meta-analyses have confirmed the relationship between CF intake and decreased
risk of cancers. In particular, Bae et al. [272] have provided evidence for the protective effects of
high CF ingestion against stomach cancer risk. Another quantitative systematic review [273] has
reported an inverse association between CF consumption and pancreatic cancer risk, although the
effect was limited due to the weakness of study design. More recently, different meta-analyses have
highlighted an inverse association between CF intake and the risk of various types of cancers, such as
breast cancer [274], bladder cancers [275–277], and esophageal cancer [278]. A very recent systematic
literature review of prospective studies on CF intake and risk of esophageal and gastric cancers
revealed only a marginally significant decreased risk of esophageal cancer and reported no significant
inverse association for gastric cardia cancer, but data are still limited [279].
However, some researchers have reported the ineffectiveness of CF in cancer prevention.
For instance, the results from a large European prospective cohort suggested that higher consumption
of fruits and vegetables is not associated with decreased risk of pancreatic cancer [280]. Moreover,
Bae and coworkers [273] found no association between CF intake and risk of prostate cancer.
The reasons for this variability are multi-factorial, but probably reflect the ability of Citrus
flavonoids to interact with their molecular targets, and are due to their poor bioavailability and issues
linked to the study design. The latter include: fluctuations in CF intake, the qualitative/quantitative
composition of CF, the relative concentration of bioactive molecules, the eventual standardization
(in the case of natural remedies), the patient’s compliance with the instructions provided by the
investigator, and other numerous possible confounding elements. Nevertheless, although evidence
linking CF intake and cancer prevention are conflicting, epidemiological data seem to support the
hypothesis of some protection against certain types of cancer by CF. Table 6 collects the studies
presented in this paragraph.
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Table 6. The main epidemiological and clinical studies, systematic review, and meta-analysis on the
anti-cancer effects of Citrus fruits.
Study Design Subjects Reference
Case–control study 935 nasopharyngeal carcinoma (NPC) patients aged 15 to74 years and 1032 community controls [252]
Case–control study 304 esophagus squamous cell carcinoma patients and743 hospital controls [253]
Cohort study 120,852 Dutch men and women aged 55–69 [254]
Case–control study 512 men and 86 women with cancer of the oral cavity andpharynx and 1008 men and 483 women controls [255]
Case–control study 527 incident, histologically confirmed cases and1297 frequency-matched controls [256]
Prospective study 42,311 US men [257]
Case–control study 217 people with gastric cancer and 394 controls [259]
Population-based case–control study 1459 incident breast cancer cases and 1556frequency-matched controls [264]
Clinic-based case–control study 384 cases of pancreatic cancer and 983 controls [266]
Population-based case–control study 532 cases of pancreatic cancer and 1701 controls [267]
Case–control study 130 incident patients with adenocarcinoma of theprostate and 274 controls [268]
Hospital-based case–control study 304 incident cases of cutaneous melanoma and 305 controls [269]
Cohort Study 42,470 Japanese adults with age ranging fron 40 to 79 years [270]
Population-based case–control study 876 male patients with laryngeal/hypopharyngeal carcinoma [271]
Systematic review Stomach cancer [272]
Systematic review Pancreatic cancer [273]
Systematic review Breast cancer [274]
Meta-analysis Bladder cancer [275]
Systematic review and meta-analysis Bladder cancer [276]
Meta-analysis Bladder cancer [277]
Meta-analysis Esophageal cancer [278]
Systematic review Esophageal and gastric cancers [279]
6. Concluding Remarks
Overall, knowledge about the effects of flavonoids on cancer development has progressively
grown over recent years, as well as people’s desire to maintain good health through increasing use
of nutraceuticals, functional foods, and natural remedies. Numerous in vitro and in vivo studies
have shown the ability of flavonoids to exert anti-cancer effect, and some epidemiological studies
support this hypothesis. Moreover, evidence showing that flavonoids act not only as free radical
scavengers but also as modulators of several key molecular events implicated in cell survival and death,
has heightened scientific interest in these plant secondary metabolites. The main sources of dietary
flavonoids for humans are fruits, especially Citrus fruits and their juices, along with vegetables, wine,
and tea. Over the last few decades, experimental research and epidemiological studies indicate that
CF and their flavonoids could have anti-tumor properties. The experimental results discussed in this
review have clearly shown that Citrus flavonoids may act as chemopreventive and chemotherapeutic
agents, either as single agents or as co-adjuvants for other drugs. However, the majority of studies
on the anti-cancer potential of Citrus extracts and their single components have been carried out in
in vitro and in vivo models, and the extrapolation of preclinical results for human use is difficult to
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achieve, particularly, but not solely, due to problems linked to pharmacokinetics. Indeed, the modest
bioavailability of flavonoids and their limited duration of action are the main obstacles restricting
their clinical use. Some flavonoids, such as quercetin and anthocyanins, can be absorbed at the gastric
level, while others—resistant to acid hydrolysis in the stomach— intact reach the intestine where
are absorbed. However, most of the flavonoids present in food are esters, glycosides, or polymers,
which are not absorbed in their native form because of their extensive modification by intestinal
enzymes such as β-glucosidases and lactase-phlorizin hydrolase present in the resident bacterial flora.
Moreover, flavonoids may be subjected to intestinal and hepatic first-pass extraction that can further
affect their bioavailability. However, some metabolic reactions lead to the formation of biologically
active metabolites. While some flavonoids undergo an extensive pre-systemic elimination, others are
less vulnerable, depending on their chemical structure. Inter-individual variations have also been
observed, probably due to the different composition of the colonic microflora which can affect their
metabolism in different ways. Nevertheless, despite bioavailability problems, numerous experimental
and clinical data have demonstrated the ability of Citrus flavonoids to exert important systemic
pharmacological effects [14,281,282]. In addition, Citrus flavonoids also display neuroprotective
effects [283,284], suggesting that they are able to cross the blood–brain barrier. One explanation for
the apparent discrepancy between the poor bioavailability of flavonoids and their biological activity
in humans would be to assume that a significant part of the biological actions exhibited by Citrus
flavonoids are due to their active metabolites. Another hypothesis is the underestimation of plasma
concentration and half-life due to their large volume of distribution values, to their relatively rapid
post-systemic metabolization, and to the limits of assay sensitivity. In addition, to the best of our
knowledge, there are few appropriately designed clinical trials to assess both pharmacological efficacy
and pharmacokinetic profile of the bioactive molecules contained in CF. However, clinical studies
evaluating the effectiveness of CF extracts or flavonoids mixtures in which one or more was from CF
are a little more numerous. This evidence, together with the findings of other Authors [10,218,285],
strengthens our thesis that given the multi-factorial pathogenesis of cancer, the complex mixture
of phytochemicals present in a whole extract acts better than a single constituent. This is because
all molecules present in a phytocomplex can simultaneously modulate different targets of action
in both human cells and microorganisms, leading to a pool of pharmacological effects contributing
together to improve the patient’s health. On the bases of several preclinical and epidemiological
studies summarized in this review, we believe that regular intake of CF and their derivatives, linked to
a healthy life style, might be an important way to reduce cancer risk.
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Abstract: The high incidence of breast cancer in developed and developing countries, and its
correlation to cancer-related deaths, has prompted concerned scientists to discover novel alternatives
to deal with this challenge. In this review, we will provide a brief overview of polyphenol structures
and classifications, as well as on the carcinogenic process. The biology of breast cancer cells will
also be discussed. The molecular mechanisms involved in the anti-cancer activities of numerous
polyphenols, against a wide range of breast cancer cells, in vitro and in vivo, will be explained in
detail. The interplay between autophagy and apoptosis in the anti-cancer activity of polyphenols will
also be highlighted. In addition, the potential of polyphenols to target cancer stem cells (CSCs) via
various mechanisms will be explained. Recently, the use of natural products as chemotherapeutics
and chemopreventive drugs to overcome the side effects and resistance that arise from using
chemical-based agents has garnered the attention of the scientific community. Polyphenol research is
considered a promising field in the treatment and prevention of breast cancer.
Keywords: polyphenols; breast cancer; anti-cancer activity; autophagy; apoptosis; cancer stem cells
1. Introduction
Currently, cancer is one of the most common life-threatening diseases worldwide, and breast
cancer has the highest rate of diagnosis amongst women. There are three main strategies to block and
postpone the stages of carcinogenesis [1–3]. The primary strategy considered is a preventive approach,
which blocks the toxic, as well as the mutagenic, effects, which consequently inhibits tumor initiation
and promotion. The secondary strategy presents anti-cancer potential during the early stages of
carcinogenesis via various mechanisms, such as control of signal transduction, blocking angiogenesis,
antioxidant mechanisms, hormones, and modulation of immunity, which finally result in the blockage
of cancer progression. The third strategy for cancer treatment and prevention involves blocking
the invasiveness and metastatic properties of a tumor via regulation of cell-adhesion molecules,
protection of the extracellular matrix (ECM) from degradation, and up-regulation of genes that block
metastasis [1,2].
The link between a diet that is rich in fruits and vegetables, and the prevention, as well as
the reduction, of the occurrence of health-daunting diseases has been evidenced, and is partially
ascribed to polyphenols [4–6]. The term polyphenol was first given to natural compounds bearing
multiple (poly) phenol rings, which are widespread in various fruits, vegetables, wine, nuts, tea,
coffee, and in many foods that are consumed daily by humans [7]. Polyphenols possess a broad
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spectrum of structural variations, which lead to a wide range of biological functions; among them,
anti-cancer functions. Polyphenols possess a broad spectrum of structural variations in the carbon
backbone chains, as well as alterations to primary and secondary structures due to methylation,
glycosylation, and hydroxylation [6,8]. These structural variations may be responsible for their
various health benefits, including antioxidant [9,10], anti-inflammatory, anti-angiogenic [11,12],
and anti-proliferative mechanisms, as well as regulation of key signaling protein and enzyme
functions [13].
2. Carcinogenesis: Overview and Molecular Basis
The tumorigenic process is complicated and occurs through a multistep procedure, including
initiation, promotion, and progression, as illustrated in Figure 1 [14,15]. Initiation includes the entrance
and distribution of cancer-causing agents in the cell, in particular, the nucleus, and interaction with
DNA that finally results in the mutagenesis and emergence of the toxic effect [16]. This stage is
irreversible, but can be prevented by phase I and phase II metabolizing enzymes, which transform the
carcinogens into less toxic and soluble products [17,18].
Figure 1. Schematic representation depicting the multistage process, including initiation, promotion,
and progression, of carcinogenesis, and the biological targets of polyphenols at each step.
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Polyphenols present preventive effects against tumor initiation via numerous mechanisms,
such as prevention of the formation of genotoxic molecules and blocking the activity of the
mutagens-transforming enzymes [19,20]; regulation of heme-containing phase I enzymes, such as
cytochrome P450s (CYPs) [21,22]; regulation of carcinogen-detoxifying phase II enzymes, such as
NADPH-quinone oxidoreductase-1 (NQO1), quinone reductase (QR), glutathione S-transferase (GST),
and uridine diphospho (UDP) glucuronosyl transferase (UGT) [23,24]; and prevention of the formation
of DNA adducts [25].
The promotion stage, which takes time, is related to the proliferation of tumor-initiating cells.
It is considered a reversible stage of tumorigenesis, and gives rise to pre-cancerous cells. The main
features of this stage are cell proliferation and apoptosis. The tumor progression stage is the stage
in which cells gradually transform to the malignant state. Metastasis and invasiveness also emerge
during this stage, via the angiogenesis process, with the growth of new blood capillaries in the tumor,
which is enhanced by the secretion of specific growth factors and growth factor receptors, such as
platelet-derived growth factor (PDGF), PDGF receptor (PDGFR), vascular endothelial growth factor
(VEGF), and VEGF receptor (VEGFR), leading to overgrowth and spread of the tumor [26].
Cathepsins, which belong to the lysosomal proteases superfamily, are implicated in tumor
progression [27]. Cathepsin D, an aspartic protease, is considered to be a candidate as a clinical marker
for breast cancer, and is involved in the activation of the inactive form of cathepsin B (procathepsin B) [28].
Cathepsin B is essential for the growth of breast cancer [29] and its down-regulation leads to a reduction
of tumor progression [30]. The up-regulation of cathepsin B is an indicator of cancer progression and is
a poor prognosis [31].
The urokinase plasminogen activator (uPA) system consists of serine protease uPA and
various serine protease inhibitors, such as plasminogen activator inhibitors 1 and 2 (PAI-1 and
PAI-2). Upon binding of uPA to urokinase plasminogen activator anchored receptor (uPAR),
the activation of plasminogen takes place and leads to the production of the broad spectrum protease,
plasmin [32]. Plasmin directly degrades the ECM, or indirectly via the activation of the zymogens of
metalloproteinases (MMPs) [33].
There are numerous polyphenols that show potent inhibitory effects on the invasiveness and
metastatic properties of cancer, which will be explained in detail in the following sections.
3. Overview on Breast Cancer and Cancer Stem Cells (CSCs)
Breast cancer represents about 25.2% of cancer cases in women, and commonly occurs in US
women at a rate of one in eight cases [34,35]. In 2012, approximately 522,000 deaths were due to breast
cancer [36]. Despite the success of emergent breast cancer therapeutics in decreasing mortality cases,
the prognosis, in particular for the stage IV cancer, remains poor and needs further improvement [37].
The presence of small populations of cells with unique tumor recurrence and metastases represents
a serious challenge during cancer therapy, and may be ascribed to the presence of a small population
of specialized malignant cells, which are believed to be cancer stem cells (CSCs) [38,39].
In 2003, Al-Hajj et al. discovered the presence of CSCs in breast cancer [40]. They carried out
fluorescence-activated cell sorting (FACS) analyses of primary breast cancer cells for the expression
of the following markers, cluster of differentiation 44 (CD44), cluster of differentiation 24 (CD24),
and epithelial specific antigen (ESA). They confirmed that CD44+ CD24−/low cells possess the same
characteristic features of CSCs, including self-renewal, differentiation, and high tumor induction
properties [40].
4. Therapeutic Approaches to Breast Cancer and Development of Resistance
The main approaches for the treatment of breast cancer are surgical intervention, hormonal
therapy, immunotherapy, chemotherapy, and radiotherapy. However, the recovery rate after
application of these conventional methods is about 60%–80% for primary cancers and about 50%
for metastatic ones [41,42].
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Previously, the heterogenic features of cancer were calibrated, based on the following parameters:
histological analysis, tumor grading, condition of lymph nodes, and specific markers, such as estrogen
receptor (ER), progesterone receptor (PR), and, recently, human epidermal growth factor receptor 2
(HER2) [43]. Furthermore, tumor heterogeneity was verified using gene expression analysis and cDNA
microarrays analysis [44].
There are four fundamental groups of patients with metastatic breast cancer that are subjected
to treatment, including hormone receptor (HR)-positive patients, who are classified into two classes:
luminal A type, with the highest invasiveness and the best prognosis, which is characterized by ER+,
PR+, HER2−, and low ki67, and luminal B, which is characterized by ER+, PR+, HER2+ or HER2−,
and high ki67 [45,46]. HR+ breast cancers have the best prognosis and can be treated with tamoxifen,
an ER antagonist, fulvestrant, which directly hampers ER synthesis, and aromatase inhibitors, namely,
anastrozole, exemestane, and letrozole [47].
HER2+, another subtype of metastatic breast cancer, is an ER− breast cancer, and, therefore,
is considered to be from the worst aggressive type of breast cancer [48,49]. To eliminate this type
of cancer, various therapeutic strategies have been developed, such as a drug targeting HER2
receptor using humanized monoclonal antibodies, including trastuzumab (herceptin), pertuzumab,
and lapatinib [49].
Triple-negative breast cancer (TNBC), voided of ER, PR, and HER2, is considered the worst type
of metastatic breast cancer and has highly invasive properties, a large tumor size, poor prognosis,
a high chance to relapse, is not responsive to hormonal therapy, and has lymph node involvement.
There are several approaches to counteract TNBC, such as neoadjuvant chemotherapy, anthracyclines,
taxanes, poly (ADP-ribose) polymerase protein (PARP) inhibitors, epidermal growth factor receptor
(EGFR) inhibitors, and platinum-containing chemotherapeutic agents [50–52].
Chemotherapy remains a crucial approach for cancer management in all patient groups. However,
HER2-positive tumor patients, and patients with TNBC, need endocrine therapy in addition to
chemotherapy [53]. Taken together, new, alternative therapeutics, in particular, natural products,
need to be explored using mammosphere culture in order to overcome this problem.
5. Overview on Polyphenols
Polyphenols, a broad category of natural compounds and plant metabolites, possess one,
or numerous, benzene rings that bear one, or several, hydroxyl groups. They are considered to be
complicated antioxidants that are abundantly present in our daily diet, in particular, they can be found
in fruits, legumes, spices, cocoa, vegetable, coffee, nuts, beer, wine, and olive oil [54]. Average daily
consumption of polyphenols is estimated to be around one gram [55]. In nature, polyphenols generally
exist conjugated with organic acids and sugars, and, accordingly, can be classified into two main
categories; flavonoids and non-flavonoids, as shown in Figure 2.
The flavonoid category consists of two benzene rings, linked by a heterocyclic pyrone
C-ring, and the non-flavonoid category contains more complicated molecules (benzoic acid,
hydroxycinnamates, stilbenes, lignans, gallic acids tannins, and gallotannins) [56,57].
Polyphenols have been reported to possess special activities that are beneficial for human
health, such as anti-oxidant [58], anti-infection [59–61], anti-cancer [62,63], neuroprotective [64],
and anti-inflammatory [65] effects. Their broad activity could be attributed to several mechanisms,
including interaction with, as well as modulation of, a wide range of proteins, enzymes, and membrane
receptors, regulation of gene expression, apoptosis induction, vasodilatation, and modulation of cell
signaling pathways [66–70].
There are similarities between some groups of flavonoids, such as isoflavones and lignans, and the
estrogens, and, accordingly, they are considered as a phytoestrogen. Their anti-estrogenic activity
has been exploited and applied in a wide range of studies [71]. Especially, the potent anti-cancer
activity of polyphenols can be ascribed to their targeting of aromatase, antioxidant mechanisms,
anti-inflammatory mechanisms, and anti-estrogenic mechanisms [72–76].
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Flavonoids are considered to be the largest category of the polyphenols, and are characterized by
their low molecular weight [77,78]. The structural characteristics of flavonoids can determine their
functions and bioavailability, and can be used for classification into various groups.
Figure 2. Diagram summarizing the classes of polyphenols and their basic chemical structures.
Polyphenols can be separated into two main classes: flavonoids and non-flavonoids. The flavonoid
class consists of two benzene rings, linked by a heterocyclic pyrone C-ring. The non-flavonoids
class contains more intricate molecules, namely, benzoic acid, hydroxycinnamates, stilbenes, lignans,
gallic acids tannins, and gallotannins.
The basic structure of flavonoids consists of a flavan nucleus (2-phenylchroman) containing
15 atoms that constitute three rings (A-ring (C6), B-ring (C6), and C-ring (C3)). The variation among
flavonoids depends on the following: changes in the C-ring (presence of the 3-hydroxyl group,
and double bond or 4-oxo group) and changes in the A- and B-rings, such as the difference in the
number and the position of the hydroxyl and methoxyl groups. If one or more sugar group binds to
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the flavonoid structure, they are called “flavonoid glycosides”, whereas flavonoids without a sugar
group are described as “aglycones”.
Dietary flavonoids are mainly “flavonoids glycosides”, except for flavanols. Moreover, our research
group revealed various aspects of the biological activities and health benefits of numerous flavonoids,
such as antioxidant, antiviral, and anti-cancer properties, which were evidenced in vitro and
in vivo [79–84].
Polyphenols are considered the main natural antioxidant component in fruits, vegetables, tea,
oils, and cereals. The wide range of health benefits of dietary polyphenols is ascribed to their potential
in reducing the risk, as well as preventing, serious diseases, such as cancer, metabolic diseases,
neurodegenerative diseases, and heart diseases, which threaten human life and negatively affect
quality of life, as summarized in Figure 3 [85].
Figure 3. Overview summarizing the main health benefits of polyphenols. Polyphenols play key roles
in the prevention of serious diseases that threaten human life and negatively affect quality of life,
such as cancer, metabolic diseases, neurodegenerative diseases, hypertension, and cardiac diseases.
There is a large body of literature that describes the impact of polyphenols on human health and
disease prevention [86,87]. Polyphenols are present in foods as intricate combinations of various
chemical formulations of several polyphenol compounds, such as oligomers, chlorogenic acid,
hydroxycinnamic acids, and epicatechin (in apples) [88]. Moreover, these dietary polyphenols are
present in combination with sugar residues that conjugate with hydroxyl groups and aromatic carbons,
can be combined with organic and carboxylic acids, and with amines [89]. In cereals, polyphenols
are conjugated with polysaccharides of the cell wall [90], and in fruits, the amount of conjugated
polyphenols is much higher than the amount of free polyphenols [91].
The absorption rate and site of polyphenols are modulated by their structures [92]. For instance,
glycosides can be absorbed in the small intestine, except for glycosides that link to the rhamnose
group metabolized by the enzyme, α-rhamnosidase, which is secreted by microflora in the colon [93].
Glycosides can be metabolized by several enzymes, including cytosolic β-glucosidase and the
membrane-located lactase phlorizin hydrolase [94,95].
On the other hand, the acylated polyphenol compounds, flavan-3-ols (epicatechin), are absorbed
directly into the enterocyte without hydrolysis [96]. Hydroxycinnamic acids, which are esterified with
organic acids, lipids, and sugar, are partially absorbed in the small intestine, and a major portion
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is metabolized by colonic microflora. The colon is considered a suitable site for the absorption of
polymeric proanthocyanidins.
6. Correlation between Polyphenols’ Anti-Cancer Activity and Autophagy
Autophagy is a cellular phenomenon that occurs as a response reaction against stress factors,
such as starvation, oxidative stress, and toxicity [97]. During the autophagy process, catabolic lysosomal
degradation takes place in order to maintain cellular homeostasis.
Autophagy-related genes (ATG) and their proteins are essential for the formation of the
double-membrane vesicles needed for the engulfment of damaged cellular organelles in the cytosol.
Beclin-1 (Atg6 in yeast), which is located on human chromosome 17q21, is considered one of the key
components of ATG proteins. It exhibits haploinsufficiency, and its identification may have unveiled
a crosslink between autophagy and human cancer. Its monoallelic deletion has been detected in breast,
ovary, and prostate cancers [98,99].
The crosslink between diet and autophagy is well-known, and dietary restriction or starvation
are related to autophagy induction and influence on health [100,101]. Autophagy induction is
modulated by the level of cellular ATP and energy, which are detected by the cellular energy
sensor, adenosine monophosphate kinase (AMPK). AMPK activation is enhanced as a response
to the low ratio of ATP/AMP and nutrient deprivation via its upstream kinase, liver kinase BQ (LKB1
kinase). AMPK inhibits the activity of the mammalian target of rapamycin 1 (mTORC1) directly via
phosphorylation of RAPTOR, or indirectly through activation of TSC1/2, which enhance the activity of
GTP-Rheb [102,103]. Inactivated mTOR is involved in autophagy induction via activation of complexes,
including ULK1, Atg13, and the FAK-family interacting protein of 200 kDa (FIP200) [104].
Below, we will discuss examples of polyphenols, and how autophagy signaling pathways and
transcription factors are involved in their anti-cancer potentials, as summarized in Figure 4.
Figure 4. Role of polyphenols in the modulation of autophagy in breast cancer. Polyphenols modulate the
autophagy process by regulating various signaling pathways, such as the PI3K/AKT, RAS/RAF/ERK,
PKCδ, and AMPK signaling pathways.
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6.1. Resveratrol
Resveratrol (3,4′,5-trihydroxy-trans-stilbene), the main polyphenol in grapes and peanuts,
exists in red wine at a concentration of about 0.1–1.8 g per 100 mL. In mice, resveratrol potently
mitigates the harmful consequences of a high-fat diet that influences longevity and lifespan [105].
This lifespan-increasing effect is attributed to the activation of sirtuin (SIRT1) via an autophagy-mediated
mechanism [106]. The crosslink between SIRT1 and autophagy is attributed to the potency of SIRT1
to deacetylate the core elements, such as Atg5, Atg7, and Atg8, of autophagy induction [107].
Resveratrol is a well-known polyphenol modulating SIRT1 [108]. The anti-cancer activity of resveratrol
has been proven in vitro and in vivo [109–111], and is mediated by numerous mechanisms, such as
apoptosis, cell cycle arrest, kinase signaling pathways, and autophagy [109,112].
The implication of resveratrol in the induction of autophagy via the accumulation of
autophagosomes has been proved in various cell lines [109,113,114]; however, resveratrol treatment
induces non-canonical autophagy, which is independent of Beclin-1, vacuolar protein sorting 34
(Vps34), and Atg-dependent autophagy in breast cancer cells [115].
Apoptosis-resistant cell lines, such as breast cancer MCF-7 cells, which are deficient in caspase-3,
showed sensitivity to resveratrol treatment, and, interestingly, activation of caspase-9, as well as
chromatin condensation, were detected in resveratrol-treated MCF-7 cells [116].
Recently, FoxO transcription factors have been shown to play an important role in apoptosis and
autophagy induced by resveratrol treatment [117]. In human colorectal cancer, resveratrol-induced cell
death was abolished upon genetic inhibition of the function of autophagy-related proteins, including
PI3K, Lamp2b, and Beclin1 [113]. In human epidermoid carcinoma cells, exposure to resveratrol led to
a decrease in the expression level of Rictor protein, and of mTORC2, and ultimately a reduction of
RhoA-GTPase [118].
Reactive oxygen species (ROS) mediate the significant up-regulation of AMPK upon resveratrol
treatment in etoposide-resistant HT-29 colon cancer cells, and, in turn, augment the potential of
etoposide to induce apoptosis [119]. In addition, resveratrol exposure increased ROS generation
and cleavage of caspase-8 and caspase-9, and ultimately induced autophagy via up-regulation of
microtubule-associated protein 1 light chain 3-II (LC3-II) expression in colon cancer [120].
Resveratrol leads to autophagy induction via the up-regulation of p62/sequestome-1 (SQSTM1),
and AMPK/mTOR-mediated, by JNK in imatinib-sensitive and imatinib-resistant chronic myelogenous
leukemia cells (CML) K562 [121].
6.2. Silibinin
Silibinin, which is a flavonolignan extracted from milk thistle (Silybum marianum), possesses
protective effects for the liver [122] and neurons [123,124]. Recently, the anti-cancer activity of silibinin
has been demonstrated in vitro and in vivo [125–127]. In human colon cancer cells, silibinin treatment
led to activation of the extrinsic (receptor-related) and intrinsic (mitochondria-related) apoptosis
pathways, as well as activation of the autophagic process [128]. Pharmacological inhibition of
autophagy with treatment of bafilomycin-A1 (Baf-A1) in silibinin-exposed human colon cancer cells
resulted in autophagy inhibition, which is accompanied by activation of cell death. Accordingly,
silibinin treatment of human cancer cells induced cytoprotective autophagy, and ROS was
a mediator in silibinin-induced apoptosis and autophagy in tumor cells [129,130]. On the other hand,
the ROS-scavenging activity of silibinin was also shown in vitro and in vivo [123,131].
An interesting study demonstrated the potential of silibinin to induce autophagic cell death in
breast cancer cells. This effect was confirmed by high expression of LC3-II, increase of Beclin-1,
high Atg-12-Atg-5, and down-regulation of Bcl-2 [132]. Upon treatment with pharmacological
inhibitors of autophagy, 3-methyladenine (3-MA) and Baf-A1, silibinin-induced breast cancer cell death
was mitigated. Silibinin treatment led to ROS generation, which was correlated with the disruption of
mitochondrial membrane potential and ATP depletion, which were further blocked by treatment of
N-acetyl cysteine (NAC) and ascorbic acid [132].
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Of note, silibinin-exposed breast cancer cells showed up-regulation of Bcl-2 adenovirus E1B
19-kDa-interacting protein 3 (BNIP3). Small interfering RNA (siRNA) targeting BNIP3 abrogated
silibinin-induced cell death, ROS generation, ATP depletion, and the disruption of mitochondrial
membrane potential [132].
Silibinin-induced autophagy and apoptosis in MCF-7 cells are concomitant with the down-
regulation of AKT, mTOR, and ERK [133]. Co-treatment of ERα antagonist, methyl-piperidinopyrazole
(MPP) dihydrochloride, with silibinin led to the aggravation of the apoptosis and autophagy induced by
silibinin treatment. These results indicate that ERα inhibition by silibinin mediates the down-regulation
of AKT, mTOR, and ERK, and the final induction of apoptosis and autophagy in MCF-7 cells [133].
6.3. Quercetin
Quercetin (3,3′,4′,5,7-pentahydroxyflavanone), a flavonol, exists in a wide range of fruits and
vegetables, such as onions, apples, and berries, and is considered one of the most common antioxidants
in the human diet [134]. The application of quercetin to inhibit tyrosine kinase has been approved
for clinical trials [135]. The anti-cancer potential of quercetin has been shown in various in vitro
and in vivo studies [136–139]. Down-regulation of mTOR activity, and the subsequent formation of
autophagosomes by quercetin treatment, have been evidenced [140].
In gastric cancer cells, quercetin induced cytoprotective autophagy that was abrogated upon
treatment with the lysosomal inhibitor, chloroquine, or silencing of Atg5 or Beclin-1 using siRNA,
and led to apoptotic cell death [141].
Hypoxia-induced factor 1α (HIF-1α) and Akt-mTOR signaling pathways are mediators of
quercetin-induced cytoprotective autophagy. The components of the mTOR signaling pathway,
in particular, mTORC1, play key roles in the maintenance of cellular homeostasis via modulation of
protein synthesis through p70S6 kinase, which activates the ribosomal S6 subunit, and phosphorylation
of 4E-BP1 (eIF4E binding protein 1) that inhibits the sequestration of the eukaryotic initiation factor
of protein biosynthesis (eIF4). In various cancer cell lines, quercetin modulates the mTOR signaling
pathway through down-regulation of the phosphorylation level of the ribosomal S6 subunit via p70S6
kinase, as well as via activation of 4E-BP1 [140].
6.4. Genistein
Genistein (4′,5,7-trihydroxyisoflavone), an isoflavone, is widely distributed in soybean and
presents a broad spectrum of in vitro and in vivo anti-cancer potential in numerous cancer cells,
through cell cycle arrest, induction of apoptosis, blocking of angiogenesis, inhibition of telomerase
activity, and blocking inhibition of DNA topoisomerase II [142–145].
In ovarian cancer cells, genistein treatment led to cell death, which is independent of caspase
signaling pathways and induced autophagy [146]. The autophagy induced by genistein treatment can
be recovered upon treatment with methyl pyruvate, the substrate for oxidative phosphorylation and
fatty acid synthesis.
Genistein-exposed ovarian cancer cells showed a marked reduction in glucose uptake that may
be attributed to the inactivation of AKT signaling [146]. Inhibition of the aggregate that is formed
by the interaction between cyclic AMP phosphodiesterase-4A4 (PDE4A4) and SQSTM1 protein (p62)
is essential for the induction of autophagy. This can be explained by the role of SQSTM1 protein
in interacting with LC3, which has a pivotal role in vesicle formation in autophagosomes [147].
Genistein-treated ovarian cancer cells showed marked autophagy due to inhibition of the formation of
PDE4A4 and SQSTM1 aggregates, activated by ERK and PKC inhibitors [148].
6.5. Curcumin
Curcumin, diferuloylmethane extracted from Curcuma longa, is the key constituent of turmeric,
and possesses various biological functions with minimal toxicity, such as antioxidant, anti-inflammatory,
and anti-cancer functions [149,150]. In malignant glioma cells, curcumin exposure led to cell cycle
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arrest and autophagy induction through up-regulation of the ERK1/2 signaling pathways and
down-regulation of the Akt/mTOR/p70S6K signaling pathways [151]. In bladder cancer cells,
curcumin dephosphorylated AKT, and, in turn, activated LC3-II [152].
The autophagy-inducing capacity of curcumin was exploited in cellular protection against
oxidative stress-induced cell death in human umbilical vein endothelial cells. This was mediated by
modulation of the autophagy machinery, including activation of LC3-II, inhibition of PI3K/Akt/mTOR
core signaling, and promotion of FOXO1 (autophagy mediator) [153]. In curcumin-exposed human
colon cancer cells, there was a significant increase in the conversion of LC3-I to LC3-II, as well as
degradation of SQSTM1 [154]. These effects were markedly abrogated after treatment with an ROS
scavenging compound, NAC, indicating that ROS is a mediator of curcumin-induced autophagosome
formation and cell death [154].
In malignant glioma cells, curcumin treatment induced autophagy that is attributed to the
up-regulation of ERK signaling, which is concomitant with the down-regulation of the Akt/mTOR/p70
ribosomal protein S6 kinase (p70S6K) pathway [155]. Moreover, SIRT1 was modulated by curcumin in
the regulation of autophagy and other cellular events [108].
Curcumin remarkably enhanced the expression of AMPK, accompanied by p38 signaling-mediated
cell death in ovarian cancer cells [156]. Similarly, curcumin induced ROS generation at the beginning
of apoptosis and autophagy in oral squamous cell carcinoma, and NAC treatment abolished
curcumin-mediated autophagosome formation [157]. In addition to the induction of autophagy,
curcumin exposure led to apoptosis via inactivation of Bcl-2 protein and down-regulation of NF-κB in
cancer cells [158,159].
6.6. Rottlerin
Rottlerin, also called mallotoxin, is one of the active components of the Kamala tree
(Mallotus philippensis), which grows widely in Southeast Asia. In 1994, the pharmacological effects of
rottlerin were revealed, after its potential to specifically inhibit the activity of protein kinase C delta
(PKCδ) was demonstrated [160]. Therefore, the potency of rottlerin to block PKCδ activity has been
exploited in various biological functions related to PKCδ [161].
Recently, rottlerin was shown to exhibit various biological activities, including human T-cell
response inhibition [162], potassium channel activation [163], in vitro and in vivo neuroprotection [164],
antioxidant activity [165], antihistaminic activity [166], and anti-cancer activity [167]. The crosslink
between tissue transglutaminase (TG2) and NF-κB was evidenced [168]. Moreover, implication of
NF-κB in the autophagy process was proven [169].
In pancreatic cancer cells, rottlerin, as well as PKCδ siRNA treatment, led to a drastic decrease
in cell proliferation, which was accompanied by a significant reduction in mRNA and protein levels
of TG2, without showing any apoptotic changes [170]. However, rottlerin-treated pancreatic cancer
cells showed significant autophagy, which was evidenced by cytoplasmic acidic vacuoles and the
up-regulation of LC3-II, similar to that of TG2-specific siRNA-treated cells. Belin-1 knockdown
abrogated the potential of rottlerin and TG2 siRNA to induce autophagy in pancreatic cancer cells.
In human pancreatic CSCs, rottlerin treatment led to early autophagy, evidenced by the formation
of autophagosomes, LC3-II formation, up-regulation of Atg7 and Beclin-1, as well as down-regulation
of the pro-apoptotic proteins, Bcl-2 and Bcl-XL [171]. Treatment of 3-MA or genetic inhibition of
autophagy via silencing of the autophagy-specific genes, Atg7 and Beclin-1, blocked the potential of
rottlerin to induce autophagy and enhanced rottlerin-induced apoptosis [171].
In human breast cancer cells, rottlerin treatment showed TSC2-dependent inhibition of the
mTORC1 signaling pathway and the accumulation of autophagosomes as a consequence [172].
Taken together, we described the mechanisms of polyphenols in autophagy modulation in terms of their
anti-cancer functions. However, these findings need to be scrutinized in depth with respect to breast
cancer and in vivo using animal models that possess genetic modifications of autophagy-related genes.
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7. Anti-Cancer Activity of Polyphenols against Breast Cancer: Molecular Mechanisms
The anti-cancer activities of polyphenols against a wide range of cancers, such as breast cancer [173],
prostate cancer [174], colorectal cancer [175], pancreatic cancer, lung cancer, colorectal fibrosarcoma,
and leukemia, have been proven [176]. The possible mechanisms underlying the anticancer activity of
polyphenols against breast cancer are summarized in Figure 5, and the possible molecular mechanisms
by which polyphenols kill breast cancer are described below.
Figure 5. Comprehensive representation summarizing the possible mechanisms of action of
polyphenols against breast cancer. The anti-cancer activity of polyphenols is mediated via the regulation
of various signaling pathways, such as intrinsic and extrinsic apoptotic pathways, estrogen-related
signaling pathways, cell cycle arrest, and inflammation-related signaling pathways. RES, resveratrol;
CUR, curcumin; GENI, genistein; QUR, quercetin; APIG, apigenin.
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7.1. Modulation of ROS
In fruits, polyphenols represent a major portion of the antioxidants compared to vitamin C [177].
Antioxidant activity is one of the key mechanisms that contribute to the protective effect of polyphenols
against oxidative damage.
Cellular redox balance can be maintained by cellular antioxidant enzymes, including superoxide
dismutase (SOD), peroxiredoxins (PRXs), catalase (CAT), glutathione peroxidase (GPx), and glutathione
reductase (GR) [178]. However, mitigation of excessive generation of ROS by the cellular antioxidant
enzymes is difficult [179].
Polyphenols are directly involved in the reduction of the Fenton reaction, via chelation of iron,
thereby protecting cells from oxidation from highly reactive hydroxyl radicals [180–182]. The potent
antioxidant activity of polyphenols is attributed to their ability to scavenge a broad spectrum of
highly reactive species, such as ROS, reactive nitrogen species (NOS), chlorine species, peroxynitrous
acid (ONOOH), and hypochlorous acid (HOCl) [183]; they also block the chain reactions of lipid
peroxidation (chain breakers) as a consequence [180,184]. The antioxidant activity of flavonoid
compounds is also mediated by targeting NFκB- and MAPK-related signaling pathways [185].
Polyphenols can work as co-antioxidants, as they show synergistic activity with other antioxidants,
such as α-tocopherol (vitamin E), leading to the regeneration of vitamin E [186].
The polyphenols structures, such as the hydroxyl group’s number and position, hydroxylation
degree, and distance between the aromatic ring and the carbonyl group, play a pivotal role in
its antioxidant activity and metal chelating property. For instance, within the flavonol group,
quercetin showed the most potent antioxidant activity due to its 3-hydroxy group [187]. Additionally,
polyphenol potential for metal chelation and scavenging of free radicals could be elevated with a B-ring
bearing catechol moiety, C-ring bearing 4-oxo group, and the presence of a double bond [188].
Cinnamic acid and its derivatives showed relatively better antioxidant properties compared
to benzoic acid, due to the longer distance between the aromatic ring and the carbonyl group.
Additionally, the presence of the hydroxyl group at the para and/or ortho position on the benzoic ring
enhances antioxidant potential compared to the presence of the hydroxyl group at other positions [189].
Biochanin A, an isoflavonoid purified from red clover (Trifolium pratense) showed preventive
activity against the incidence of mammary gland cancer, after exposure to carcinogenic agents in
prepubertal rat [190]. It potentially counteracted oxidative stress through a significant up-regulation
of SOD, CAT, GPx, GST, and DT-diaphorase (DTD), as well as a remarkable reduction of lactate
dehydrogenase (LDH) and lipid peroxidation (LPO) activities.
The protective action of resveratrol against 17β-estradiol (E2)-induced carcinogenesis was
evidenced in vitro and in vivo, and was mediated by a significant increase in the expression of nuclear
factor erythroid-related factor-2 (Nrf-2), which consequently up-regulated the expression of antioxidant
genes, including NQO1, SOD3, and 8-oxoguanine DNA glycosylase 1 (OGG1) [191].
Green tea is composed of four main catechins, (−)-epicatechin (EC), (−)-epicatechin gallate (ECG),
(−)-epigallocatechin (EGC), and (−)-epigallocatechin-3-gallate (EGCG). EGCG, the most abundant
polyphenolic catechin, is considered the most active catechin, possessing various biological functions
in vitro and in vivo [15,192]. Low concentrations of EGCG resulted in significant reduction in ROS
generation, which was induced on exposure to environmental carcinogens [193]. However, it had
no significant effect on the regulation of the antioxidant enzymes (SOD and CAT) in MCF-7 breast
cancer cell lines, but showed up-regulated expression of NQO1, the main detoxification enzyme of
phase II [193].
Genistein showed significant antioxidant action and better mitochondrial function in T47D with
low ERα/ERβ ratios, whereas no significant antioxidant effect was shown in MCF-7 cells with high
ERα/ERβ ratios [194]. Therefore, ERβ is essential for the antioxidant potential of genistein [194].
Curcumin-treated breast cancer cells showed a significant decrease in cell proliferation,
mediated by Nrf-2 nuclear translocation, associated with the down-regulation of Flap endonuclease 1
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(Fen1), which is a nuclease involved in DNA repair [195]. It also showed ROS scavenging actions in
MCF-7 breast cancer cells exposed to nickel oxide nanoparticles [196].
On the other hand, polyphenols presented a pro-oxidant action that was determined by the
application of high concentrations, or the presence of, metal ions that mediate the formation of
chelates and the oxidation of polyphenols [197–199]. The pro-oxidant effects of polyphenols are
involved in their anti-cancer activity. For example, the pro-oxidant activity of polyphenols was
correlated with mitochondrial dysfunction and DNA damage mediated by high oxidative stress,
and, in turn, resulted in apoptosis [200,201]. In breast cancer cells, 50 μM of soy isoflavone,
genistein, showed a pro-oxidant action via mobilization of copper ions that led to DNA damage,
an increase in ROS generation, and apoptosis [202]. The pro-oxidant effect of curcumin via
ROS generation, in a time-dependent manner, in MCF-7 and MDA-MB-231 breast cancer cell lines,
was demonstrated [203]. Additionally, high concentration of EGCG showed a marked increase in
ROS generation in Hs578T breast cancer cells [204]. In vivo studies are needed to confirm, as well as
explain, the contradictory findings of the antioxidant and the pro-oxidant effects of polyphenols.
7.2. Modulation of Inflammation-Related Factors
Cancer occurs at sites of chronic inflammation, and is proved by the presence of inflammatory
cells in cancer [205]. For instance, inflammatory responses from microbial infection represent 15%–20%
of cancer death cases worldwide [205], and, therefore, non-steroidal, anti-inflammatory drugs are one
option to mitigate cancer deaths arising from inflammatory responses [206,207]. Chronic inflammation
can give rise to an aggressive type of breast cancer, inflammatory breast cancer (IBC), which represents
5% of breast cancers and is associated with 8%–10% of breast cancer deaths [208,209].
Polyphenols from blueberry powder present potent in vitro and in vivo inhibitory properties
against breast cancer proliferation and metastasis by regulation of interlukin-6 (IL-6) [210].
Polyphenol-enriched blueberry preparation (PEBP) potently inhibited breast cancer proliferation,
cell movement, and migration, by targeting inflammatory signaling cascades, including the ERK, AKT,
and STAT3 pathways [211]. In this regard, the anti-inflammatory activity of polyphenols may be important
mechanisms underlying their anti-cancer and chemopreventive potentials. The anti-inflammatory
activity of polyphenols is attributed to their ability to block properties against NF-κB [212],
cyclooxygenase (COX-2) [213], and lipoxygenase (LOX) [214] activities.
NF-κB plays a pivotal role in the control of the expression level of inflammation-related cytokines,
TNFα and IL-1 [215], as well as up-regulation of COX-2, which is an inducible prostaglandin G/H
synthase that is highly expressed in numerous tumor cells [216]. The possible mechanisms by which
dietary polyphenols block the up-regulation of NF-κB involve the inhibition of phosphorylation and/or
proteasomal degradation of IκBs, inhibition of the liberation of NF-κB dimers from the cytoplasm into
the nucleus, and hampering the interaction between NF-κB and target DNA [217,218]. Curcumin [219],
green tea rich polyphenols [220], quercetin [221], and resveratrol [222] showed potent anti-cancer
activities by blocking the expression level of NF-κB.
The potential of curcumin to inhibit cancer metastasis has been confirmed in vitro using breast
cancer cells, as well as in vivo, using immunodeficient mice. In this study, the authors showed the
crosslink between curcumin and the inhibition of the expression level of MMPs via down-regulation of
the expression level of NF-κB and transcription factor AP-1, as well as inhibition of the phosphorylation
of NF-κB, in turn, reducing the phosphorylation of IκB and p65 [223]. The anti-metastatic action of
curcumin in breast cancer cells is explained by its inhibition of the nuclear translocation of NF-κB via
dephosphorylation of IκB, resulting in the down-regulation of inflammation-related cytokines, such as
CXCL1/2 [224].
Green tea catechin, EGCG, stimulated apoptosis in γ-radiation-exposed breast cancer cells,
and was associated with the inactivation of NF-κB [225]. Combined treatment with EGCG and
curcumin potently reduced the expression of the BCSC marker, CD44, via dephosphorylation of
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STAT3, and, in turn, prevented its nuclear translocation and its interaction with NF-κB for activation
of target transcription factors [226].
The activation of STAT3 is essential for the proliferation and metastasis of a wide range of
cancer, and its high expression is indicative of a poor prognosis. Targeting the STAT3 pathway is
considered one of the key therapeutic approaches to block cancer proliferation and metastasis [227,228].
The inhibitory activity of silibinin against the phosphorylation of STAT3 has been demonstrated
in preclinical studies in various cancers [229]; however, further clinical trials are needed to fully
characterize silibinin activity as a STAT3 inhibitor.
In nude mice inoculated with MCF-7 cells, oral administration of xanthohumol, a prenylated
flavonoid that was purified from hops (Humulus lupulus L.), resulted in a significant reduction in
infiltration of mononuclear and polymorphonuclear inflammatory cells, an increase in the percentage
of apoptosis, a reduction in the density of microvessels, and a decrease in nuclear and cytoplasmic
NF-κβ expression and cytoplasmic staining of Pi-Iκβα, compared to tumors in untreated control
mice [230].
7.3. Modulation of the Estrogen Receptor
Estrogens are a commonly-listed human carcinogen, and high exposure to estrogen is highly
related to the incidence of breast cancer, via increased cell proliferation through interaction with
ER [231]. Patients with breast cancer show a high level of estrogen in the circulating blood [232].
Simply, breast cancer could be treated by inhibition of this action, as well as the production of estrogens,
or interference, in the binding to ER [233,234]. ER targeting can be performed using classical drugs,
such as raloxifene and tamoxifen, which are collectively called selective estrogen receptor modulators
(SERMs) and are effectively applied in pre-and post-menopausal women [235].
Two types of ER, ERα and ERβ, are differentially expressed in organs, and ERα is highly expressed
in the uterus and is involved in the proliferation of the endometrium, whereas ERβ is abundant in
mammary glands, ovary, and the hypothalamus [236]. ERβ was involved in the induction of various
transcription factors that are related to the modulation of cell proliferation and death, the cell cycle,
and differentiation [237,238].
Owing to the similarity in the structure of non-steroidal compounds or phytoestrogens and E2,
several phytoestrogens were shown to bind to ERα and ERβ. The binding affinity of genistein to ERβ
is about 7–48-fold higher than to ERα [239–241]. In contrast, a flavonoid, xanthohumol, showed potent
anti-cancer activity against luminal-type breast cancer by inhibiting the interaction between the growth
of luminal-type guanine nucleotide-exchange protein 3 (BIG3) and tumor suppressor prohibitin 2
(PHB2) [242]. The released PHB2 binds to the nuclear and cytoplasmic ERα, and blocks E2-associated
signaling pathways, thereby inhibiting the proliferation of ERα-positive breast cancer cells in vitro
and in vivo.
The flavonoid compound, ellagic acid, which is widely distributed in berries, grapes, and nuts,
possesses phenolic rings and ortho-dihydroxyl groups involved in the recognition of ER receptors [243].
Ellagic acid significantly reduced cancer size and occurrence in ACI rats exposed to estrogen with
decreased CYP1A1 activity [244].
Similar to most flavones, including fisetin, apigenin, and kaempferol, morin (3,5,7,2′,4′-
pentahydroxyflavone), a flavonol compound that is found in copious amounts in onion, mill (Prunus dulcis),
and fig (Chlorophora tinctoria), showed strong inhibitory effects against oxidative stress [245].
Morin possesses hydroxyl groups in the 7- and 4′-positions, parallel to the 3- and 4′-positions,
on synthetic estrogen diethylstilbestrol (DES), and is therefore considered a phytoestrogen [246].
Luteolin (3′,4′,5,7-tetrahydroxyflavone) potentially decreased the expression of insulin-like growth
factor-1 (IGF-1), which correlated with MCF-7 proliferation. This effect was attributed to the capacity
of luteolin to down-regulate ERα expression [247]. Knockdown of ERα led to the abolishment of the
potency of luteolin to inhibit MCF-7 cell proliferation.
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The chemical structure (2 hydroxyl groups and phenolic ring) of quercetin is akin to the structure
of estrogen and it is considered a phytoestrogen that potentially binds to ER and modulates cell cycle
progression. It also presents anti-cancer actions via estrogen-related pathways [248,249].
Resveratrol inhibits the growth of various breast cancer cells (MCF-7 and MBA-MB-231) via
modulation of the expression level of various transcription factors associated with cell cycle regulation,
apoptosis, metastasis, and angiogenesis. These actions were more pronounced in ER+ cells than in
ER− cells, assuring the importance of the binding to ER in the enhancement of the anti-cancer activity
of resveratrol against breast cancer [250].
In ERα-positive MCF-7 cell lines, the physiological dose of EGCG induced a significant reduction
in cell growth, which was correlated with the reduction in the protein levels of ERα and IGF-1 receptor
(IGF-1R), as well as the up-regulation of p53 and p21 [251]. Whereas, in ERα-positive T47D cell lines
expressing mutated p53, EGCG treatment had no significant inhibitory effects on cell growth; however,
EGCG treatment enhanced the expression of ERα, and increased the sensitivity of cells to treatment
with an ERα antagonist, tamoxifen. Moreover, EGCG-exposed ERα-negative MDA-MB-231 cell lines,
expressing mutated p53, showed a marked decrease in cell growth and up-regulation of ERα and
IGF-1R, which resulted in an increased responsiveness of the cell to tamoxifen treatment [251].
There are paradoxical findings on the effect of genistein on the proliferation of ER+ and ER−
breast cancer cells that are associated with concentration of genistein [252,253]. For instance, ER+ and
ER− breast cancer cells treated with a high concentration of genistein showed a significant reduction
in growth rate, while lower concentrations enhanced their growth rate. Similarly, tamoxifen and
SERMs showed controversial effects, which correlated with the applied concentration and the type of
tissue [254].
Taken together, the application of phytoestrogens is intricate, due to the controversial effects
attributed to variations in doses [255]. Therefore, further comprehensive research is needed to
characterize the side effects of using these phytoestrogens, which may be beneficial for endocrine
disorder-related public health in the future.
7.4. Modulation of the Aromatase Activity
Aromatase, an estrogen synthase, belongs to the cytochrome P450 enzyme family [256,257]. It is
highly expressed in breast cancer tissue compared to normal breast tissue [232]. Aromatase inhibitors
showed a better capacity for the treatment of breast cancer when compared to tamoxifen [258].
Aromatase stimulation is correlated with ER-independent malignancy [259]. The efficiency of various
synthetic aromatase inhibitors in the clinical application of breast cancer treatment, in ER+ patients at
the postmenopausal stage, was demonstrated [260].
Owing to the similarity between the A and C rings of flavonoids with D and C rings of
androstenedione, which is the substrate of aromatase, as well as to the potential of the C4 position’s
oxo-group to interact with the heme group of the aromatase, flavonoid compounds potently inhibit
aromatase activity [261]. Flavones and isoflavones were reported to bind to estrogen receptors and to
the active sites of the aromatase [262]. The potential of flavonoids to influence the promoter activity
of aromatase was demonstrated [263,264], additionally their role in the regulation of breast cancer’s
aromatase expression has been proven [265].
Aromatase activity is markedly inhibited by luteolin [266], but is up-regulated by hesperetin
(3′,5,7-trihydroxy-4-methoxyflavanone) [265]. The imidazolyl quinoline derivative of flavonoids,
XHN27, a potent aromatase inhibitor, significantly suppresses the proliferation of breast cancer T47D
cells, determined after screening a library of 7000 compounds [267].
7.5. Modulation of the Cell Cycle
During carcinogenesis, there is an imbalance between the action of cell cycle progression proteins
and cell cycle arrest proteins, resulting in marked cell division and proliferation. Cell cycle progression
can be mediated by cyclins and cyclin-dependent kinases (CDK), and its arrest is mediated by CDK
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inhibitors (CDKi), such as p15, p16, p21, p27, p53, and retinoblastoma tumor suppressor protein (RB).
Loss of function of RB, a tumor suppressor gene, is involved in resistance to chemotherapeutic drugs,
such as tamoxifen.
Numerous polyphenol-treated cancer cells showed down-regulation of CDK, as well as modulation
of CDKi, consequently leading to cell cycle arrest and apoptosis at the G2/M phase [268,269]. In breast
cancer cells, the synergy between E2 and IGF-1 is essential for cell cycle progression via up-regulation
of Cdk2, Cdk4, and cyclin D1 [270].
In breast and colon cancer cells, ginnalins A–C polyphenols isolated from Acer saccharum Marsh.
sugar and red maple (Acer rubrum L.) species showed remarkable anti-cancer activities via induction
of cell cycle arrest, in particular, in the S- and G2/M-phases, as well as down-regulation of cyclins A
and D1 proteins [268].
The potency of quercetin-3-methyl ether was exploited to induce cell cycle arrest in the G2/M
phase, and up-regulation of the phosphorylation level of cyclin B1 (Ser 147) to potently block the
growth of breast cancer cells that are resistant or sensitive to lapatinib, a reversible inhibitor of EGFR
and HER2 [271]. Therefore, quercetin-3-methyl ether is considered a naturally occurring polyphenol
that overcomes the resistance against the common anti-breast-cancer drug, lapatinib. In addition,
quercetin-exposed MDA-MB-453 breast cancer cells showed a marked increase in the number of cells
in the G2/M phase and a reduction in cell populations in the G1 phase [138].
Quercetin led to down-regulation of cyclin A and cyclin B, and a significant up-regulation of CDK
inhibitors, including p53, p21CIP1/waf1, and p27Kip1 [272,273]. As a part of its anti-cancer activities,
resveratrol also resulted in the modulation of cell cycle and apoptosis [274].
Curcumin possesses anti-cancer activities via the modulation of apoptosis and the cell cycle [275].
Curcumin-treated human MCF-7 breast cancer cells showed a drastic reduction in proliferation,
mediated by cell-cycle arrest in the G2/M phase [275]. Curcumin treatment led to apoptotic cell death,
which was confirmed by the detection of a high fraction of cells accumulated in the G0/G1 phase,
as well as by the up-regulation of Bax through a p53-dependent mechanism [276]. It was evidenced
that curcumin can induce the monopolar spindle formation, accumulation of mitotic arrest deficient 2
(Mad2), and Mad3/BubR1, thereby activating the mitotic checkpoint [277].
Apigenin (4′,5,7-trihydroxyflavone), a flavone, significantly inhibited the proliferation of SK-BR-3
breast cancer cells through inhibition of cell cycle progression at the G2M phase, with the up-regulation
of p21Cip1, as well as down-regulation of CDK1 and cyclin A and B [278].
EGCG inhibited the division and growth of cancer cells via dephosphorylation of the myosin II
regulatory light chain (MRLC), which is essential for contractile ring formation [279]. Consequently,
EGCG-treated cells showed high percentages of cell population in the G2/M phase and a decrease in
cell growth and division. Of note, EGCG-induced dephosphorylation of MRLC was attributed to its
interaction with metastasis-associated 67 kDa laminin receptor (67LR) [279].
7.6. Modulation of Apoptosis
Apoptosis is a type of programmed cell death, which is essential for various physiological
processes, such as homeostasis and development. Intrinsic or mitochondrial type apoptosis is
modulated by the B cell lymphoma (Bcl-2) family proteins [280]. The extrinsic apoptotic pathway is
activated by binding of death receptors with their ligands, such as binding of tumor necrosis factor
receptor 1 (TNFR1) and tumor necrosis factor (TNF), and the recruitment of receptor-interacting
protein (RIP), TNFR1-associated death domain protein (TRADD), and TNFR-associated factor (TRAF),
or binding of death-inducing signaling complexes [280].
Apoptosis plays important roles in the potential of quercetin to inhibit the proliferation of human
MDA-MB-453 breast cancer cells that are mediated by up-regulation of BAX and down-regulation of
Bcl-2 expression, as well as cleavage of caspase-3 and PARP proteins [138]. Quercetin-exposed MCF-7
breast cancer cells showed apoptotic cell death with a reduction in mitochondrial membrane potential,
down-regulation of Bcl-2 protein, and activation of the initiator caspases, caspase-8 and caspase-9,
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and the effector caspase, caspase-6, which were attributed to the binding of quercetin to the Fas/CD95
receptor [273]. Moreover, quercetin significantly inhibited MD-MBA-231 breast cancer cells through
the activation of caspase-3/-8/-9 [281].
Apigenin-treated SK-BR-3 breast cancer cells showed apoptotic cell death, evidenced by the
up-regulation of p53 and its downstream effectors, BAX and cytochrome c [278]. A recent study
detected a dramatic decrease in cell proliferation, as well as significant stimulation of apoptosis
signaling pathways, such as PARP cleavage and caspase-8 and -9 cleavages in apigenin-treated SKBR3
breast cancer cells [282]. This study concluded that STAT3 inhibition mediated apigenin-enhanced
apoptosis signaling pathways in SKBR3 cells.
On treatment with green tea polyphenols and EGCG, a significant reduction in cell growth
associated with apoptotic changes, such as stimulation of BAX, cleavage of PARP, and down-regulation
of Bcl-2, was observed in MD-MB-231 human breast cancer cells [283].
Resveratrol treatment led to apoptotic cell death in T47D breast cancer cells via activation of
CD95L, which is involved in the extrinsic apoptotic pathway [284], as well as activation of p53 [285].
PARP cleavage was significantly induced in resveratrol-treated MDA-MB-231 cells, and was correlated
with the activation of caspase-3 [286]. Moreover, resveratrol induced apoptosis in various malignant
cells (including MDA-MB-231 and MDA-MB-468 cell lines), via inhibition of Src tyrosine kinase activity
and blockage of STAT3 activation [287]. In estrogen-positive breast cancer cells, resveratrol markedly
reduced growth rate by stimulating apoptosis through reduction of the ratio of Bcl2/BAX, which was
independent of the presence of E2 [288]. Therefore, resveratrol is considered a potential and safe
chemopreventive alternative to hormone replacement therapy (HRT), in particular, in postmenopausal
women, and against hormone-dependent breast cancer.
Genistein-exposed MCF-7 cells showed up-regulation of BAX and reduction of Bcl-2 at the protein
and mRNA levels, resulting in a reduction in the Bcl-2/BAX ratio [289]. This effect is mediated by
blocking the activation of the IGF receptor (IGFR), as well as the phosphorylation of AKT.
Fisetin (3,3′,4′,7-tetrahydroxyflavone), a flavonoid, which is widely distributed in fruits and
vegetables, induced an uncommon form of apoptosis in caspase-voided MCF-7 cells characterized
by the activation of caspase-7/-8/-9, cleaved PARP, mitochondrial membrane depolarization,
up-regulation of p53, and break in the plasma membrane, while no change was detected in DNA
or phosphatidylserine (PS) [290]. These apoptotic changes were abolished upon treatment with
a pan-caspase inhibitor, z-VAD-fmk.
7.7. Modulation of the Multidrug Resistance (MDR)
Despite the potency of anti-cancer drugs in decreasing cancer size, a few populations of CSCs
potently resist chemotherapy and lead to tumor recurrence and MDR [291]. The crosslink between the
virulence of CSCs and MDR is correlated with reduction of intracellular concentrations of anti-cancer
drugs, continual growth, and cancer relapse [292].
The emergence of MDR is linked to over-expression of the ATP-binding cassette (ABC)
transporters family, which is composed of energy-dependent transporter proteins, which act as pumps.
ABC transporters are involved in drug efflux, thereby decreasing in intracellular concentrations [293].
Transporter proteins include various proteins, such as multidrug resistant-associated proteins (MRPs),
mitoxantrone resistance protein (MXR or ABCG2), and P-glycoprotein (P-gp) or ABCB1.
EGCG treatment leads to the accumulation of rhodamine-123 dye in MDR cell lines and an increase
in the intracellular concentration of anti-cancer drugs [294]. Moreover, a group of six common
polyphenols (naringenin, silymarin, daidzein, quercetin, resveratrol, and hesperetin) potently inhibit
the activity of MRP family proteins, thereby inhibiting efflux [295].
Curcumin treatment leads to down-regulation of MDR-1b expression by its interaction with
PI3K/AKT/NF-κB signaling [296]. Moreover, it enhances the sensitivity of MDR cell lines to
chemotherapeutic agents, such as cisplatin, vincristine, doxorubicin, tamoxifen, and mitoxantrone [297].
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7.8. Modulation of Signaling Pathways Related to Self-Renewal Capacity and Transformation of CSCs
CD44+/CD24low BCSCs showed a high degree of tumorigenicity with enhanced sphere formation
and self-renewal capacities [298,299]. Embryonic development-related signaling pathways, such as
Notch, Wnt/β-catenin, and Hedgehog, were significantly implicated in the self-renewal property
of BCSCs [300]. We will discuss the potential of polyphenols to interfere with the stemness-related
signaling pathways below.
7.8.1. Hedgehog (Hh) Signaling Pathway
Hh, encoding secreted proteins, modulates cellular differentiation, proliferation, and development
processes via autocrine- and paracrine-mediated signaling pathways [301]. There are three main
mammalian homologs of the Hh gene, namely Sonic hedgehog (Shh), Indian hedgehog, and Desert
hedgehog [302]. The interaction of the Hh proteins with the transmembrane protein, patched (PTC),
leads to activation or phosphorylation of another transmembrane protein, smoothened (SMO) [303].
The Hh pathway is correlated with the development and maintenance of CSCs in breast cancer, myeloid
leukaemia, glioma, gastric cancer, and multiple myeloma [304–307]. Therefore, the discovery of new
inhibitors targeting the Hh signaling pathway is a potent anti-cancer strategy and is under clinical
trials (phases I and II) [308].
Cyclopamine, extracted from Veratrum californicum or corn lily, was the first discovered
phytochemical that inhibits Hh signaling pathways by inactivation of SMO [306,309]. Cyclopamine
inhibits breast CSC proliferation and mammosphere formation [304].
Genistein potently inhibits the growth of CD44+/CD24−BCSCs by the notable down-regulation
of mRNA levels and the protein levels of SMO and Gli1, which are key factors for modulation of
Hedgehog-Gli1 signaling [310].
7.8.2. Notch Signaling Pathway
Notch proteins are composed of four transmembrane glycoproteins, namely, Notch1, Notch2,
Notch3, and Notch4, and also have five ligands, Delta-like1, Delta-like3, Delta-like4, Jagged1,
and Jagged2 [311]. The Notch signaling pathway is involved in cellular proliferation and
differentiation [312]. Its activation is mediated by the interaction between the extracellular domains
of receptors with ligands and the release of the Notch intracellular domain (NICD) into the nucleus
through proteolytic cleavage.
Resveratrol leads to down-regulation of Notch proteins only at the post-translational level,
a decrease in mRNA levels of pre-TCRα and HES1, an increase in p53, and a reduction of PI3K/AKT
signaling in MOLT-4 acute lymphoblastic leukemia cells [313].
7.8.3. Wingless/Integration 1 (Wnt) and the β-Catenin Signaling Pathway
The Wnt/β-Catenin signaling pathway is considered one of the essential signaling pathways for
the self-renewal of BCSCs [314]. β-Catenin is an integral effector of the Wnt signaling pathway in the
nucleus. In response to Wnt activation, stabilized β-catenin moves to the nucleus and activates target
genes by its interaction with the TC/LEF transcription factor [314,315]. Glycogen synthase kinase3β
(GSK3β), axin, casein kinase1α, and adenomatous polyposis coli (APC) protein complex are linked to
regulation of the intracellular level of β-Catenin.
EGCG significantly inhibits the formation and invasiveness of breast cancer by suppressing
the Wnt signaling pathway and reducing c-myc expression [316]; additionally, it potently reduces
nuclear β-Catenin [317]. Curcumin also targets β-Catenin in the caspase-mediated mechanism in
colon cancer [318]. Sulforaphane, a product of the conversion of glucoraphanin, which is the main
glucosinolate in broccoli and its sprouts, has potent chemoprevention activity against a wide range of
cancers [319–321].
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Sulforaphane-exposed human cervical carcinoma and hepatocarcinoma cell lines show a significant
increase in apoptosis by degradation of the β-Catenin protein [322]. Sulforaphane potently eliminates
BCSCs in vitro and in vivo by targeting the Wnt/β-Catenin-mediated self-renewal property of
BCSCs [321].
Piperine, an alkaloid isolated from black pepper (Piper nigrum) and long pepper (Piper longum),
shows potent in vivo reduction of lung metastasis [323]; in addition, it inhibits the self-renewal
property of BCSCs through down-regulation of the Wnt signaling pathway [324].
Oxymatrine, an alkaloid isolated from Sophora japonica, markedly decreases the proliferation
of breast cancer and its drastic reduction of the growth of the sorted side population (SP) of CSCs
was demonstrated [325]. In addition, it significantly reduced the activity of the Wnt/β-catenin
signaling pathway.
7.9. Modulation of Autophagy
Autophagy plays a pivotal role in maintaining stem cell characteristics. Conditional deletion of
Atg7 leads to a loss in properties, and disturbance in hematopoietic stem cell function [326]. In BCSCs,
a high basal level of autophagy was detected in ALDH1+ cell populations [327]. Autophagy is essential
for the enhancement of the invasiveness and metastatic properties of glioblastoma stem cells, which are
mediated by DRAM1 and p62 [328].
Rottlerin significantly inhibits the growth of human BCSCs and induces autophagy via
up-regulation of Atg12 and Beclin-1, and conversion of LC3-I into LC3-II [329]. Up-regulation of
BAX, reduction in phosphorylation of AKT, mTOR, and AMPK, and a significant decrease in the
expression of anti-apoptotic factors, were demonstrated over a long period of time of rottlerin
treatment. shRNAs targeting Atg7 and Beclin-1 abrogated the capacity of rottlerin to induce autophagy.
Autophagy inhibitors, 3-MA, Baf-A1, and cycloheximide, alleviate rottlerin-induced apoptosis and
phosphorylation of AMPK. Inactivation of AMPK was concomitant with the down-regulation of
Beclin-1, Atg12, and LC3.
Resveratrol blocks the growth of BCSCs and number of mammospheres [330]. It showed
significant up-regulation of LC3-II, Atg7, and Beclin1, which is concomitant with cell toxicity.
7.10. Modulation of the Epithelial Mesenchymal Transition (EMT)
EMT is an intricate developmental process, in which special differentiated polarized epithelial
cells undergo morphogenesis via loss of their differentiation characteristics, such as cell–cell adhesion,
cell polarity, immotile status, and the transformation into mesenchymal cells with invasive and
migratory properties [331,332].
During EMT, there is a decrease in the expression of epithelial markers, such as γ-catenin and
E-cadherin, and up-regulation of mesenchymal markers, including vimentin, N-cadherin, fibronectin,
and MMP-2/9. In contrast, mesenchymal-epithelial transition (MET) takes place after the migration
and invasion of cells to their designated sites [333]. E-cadherin, encoded by CDH1, plays a pivotal role
in the inhibition of tumor invasiveness and malignancy, as well as suppression of EMT.
There are various transcription factors, the Snail superfamily of zinc-finger transcriptional repressors,
such as Snail 1 and Snail 2 (also known as slug); the ZEB family, such as ZEB1 (also known as TCF8 and
δEF1) and ZEB2 (also known as Smad-interacting protein 1 (SIP1); and basic helix-loop-helix (bHLH),
such as E47 (also known as TCF3), TCF4 (also known as E2-2), and TWIST1 [331], which represent
transcription repressors of the CDH1 gene, and, thereby, inhibit tumor malignancy and invasiveness.
Up-regulation of the EMT transcription repressor is induced by a complicated signaling network
that is enhanced by receptor tyrosine kinases (RTKs) and transforming growth factor β (TGFβ) [334].
The NF-κB signaling pathway is involved in the activation of Snail, Slug, ZEB-1/2, and Twist, as well
as the up-regulation of mesenchymal markers, including MMPs, fibronectin, and vimentin [335].
Resveratrol treatment triggers apoptosis and recovers the expression of γ-catenin and E-cadherin
in tamoxifen-resistant breast cancer cells (MCF-7/TR) via targeting of TGFβ and its downstream
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effector, Smad [336]. Moreover, resveratrol recovered epithelial characteristics in EGF-transformed
breast cancer cell lines via repression of the ERK1/2 signaling pathways [337].
Baicalin and baicalein, the main flavones isolated from Scutellaria baicalensis, potently inhibit EMT
by targeting TGF-β1, and the inactivation of NF-κB-induced activation of Slug [338]. Furthermore,
Chrysin (5,7-dihydroxyflavone), a flavone isolated from passion flower (Passiflora caerulea) and
honeycomb of Apis mellifera, significantly inhibits the metastatic and invasive characteristics of TNBC
through down-regulation of Slug, Snail, and Vimentin, and inhibition of MMP-10 via blocking of the
PI3K-AKT signaling pathway [339].
Honokiol, isolated from seed cones from Magnolia grandiflora led to inhibition of EMT, which was
mediated by inactivation of STAT3 and, in turn, blocked off the repressive action of ZEB1 on
E-cadherin [340].
To sum up, several interesting studies have showed the capacity of polyphenols to potently
restore epithelial characteristics in transformed breast cancer cells, and prevented the emergence of
CSC phenotype and drug resistance.
8. Conclusions and Perspectives
In this review, we provide detailed information on the broad spectrum of mechanistic actions
of polyphenols against breast cancer and CSCs. Many studies revealed that apoptosis- and/or
autophagy-related signaling pathways are modulated by polyphenol treatment. Pharmacological
inhibition of autophagy plays a pivotal role in polyphenol-induced cell death. We also explained the
potential of polyphenols to target breast cancer and CSCs via modulation of various stemness-related
signaling pathways and transcription factors.
This review provides useful information that will guide future research, which will provide
strategies for efficient, polyphenol-based prevention, or treatment, of breast cancer. Further efforts
are needed to resolve several remaining hurdles, such as the variations in applied dose, the large
discrepancy between the in vitro and in vivo doses, and exposure time. Moreover, a better
understanding of the interconnection between apoptosis and autophagy in the polyphenol-mediated
treatment of breast cancer is needed to characterize the key factors involved in the actions of
polyphenols. However, the progress in technology continues to provide answers to unresolved
questions. To determine the potential of polyphenols in curing breast cancer in clinical trials,
discovered polyphenols need to be elucidated. Chemotherapy remains.
In fact, there is a paucity of information related to the application of polyphenols as
chemopreventive compounds. What lies ahead is the application of previously-discovered polyphenols
in the treatment of breast cancer in clinical trials. Collectively, the therapeutic applications of
polyphenols in breast cancer are promising, as these compounds present various mechanistic actions
and their clinical applications need to be tested.
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3. Mocanu, M.M.; Nagy, P.; Szöllősi, J. Chemoprevention of breast cancer by dietary polyphenols. Molecules
2015, 20, 22578–22620. [CrossRef] [PubMed]
4. Ui, A.; Kuriyama, S.; Kakizaki, M.; Sone, T.; Nakaya, N.; Ohmori-Matsuda, K.; Hozawa, A.; Nishino, Y.; Tsuji, I.
Green tea consumption and the risk of liver cancer in Japan: The Ohsaki Cohort study. Cancer Causes Control
2009, 20, 1939–1945. [CrossRef] [PubMed]
5. Wu, Y.; Zhang, L.; Na, R.; Xu, J.; Xiong, Z.; Zhang, N.; Dai, W.; Jiang, H.; Ding, Q. Plasma genistein and risk
of prostate cancer in Chinese population. Int. Urol. Nephrol. 2015, 47, 965–970. [CrossRef] [PubMed]
6. Crozier, A.; Jaganath, I.B.; Clifford, M.N. Dietary phenolics: Chemistry, bioavailability and effects on health.
Natl. Prod. Rep. 2009, 26, 1001–1043. [CrossRef] [PubMed]
7. Sharma, R. Polyphenols in health and disease: Practice and mechanisms of benefits. Polyphen. Hum. Health
Dis. Acad. San Diego 2014, 757–778.
8. Halbwirth, H. The creation and physiological relevance of divergent hydroxylation patterns in the flavonoid
pathway. Int. J. Mol. Sci. 2010, 11, 595–621. [CrossRef] [PubMed]
9. Danesi, F.; Kroon, P.A.; Saha, S.; de Biase, D.; D’Antuono, L.F.; Bordoni, A. Mixed pro-and anti-oxidative
effects of pomegranate polyphenols in cultured cells. Int. J. Mol. Sci. 2014, 15, 19458–19471. [CrossRef]
[PubMed]
10. Hsieh, S.R.; Cheng, W.C.; Su, Y.M.; Chiu, C.H.; Liou, Y.M. Molecular targets for anti-oxidative protection of
green tea polyphenols against myocardial ischemic injury. BioMedicine 2014, 4, 23. [CrossRef] [PubMed]
11. Lewandowska, U.; Szewczyk, K.; Owczarek, K.; Hrabec, Z.; Podsędek, A.; Sosnowska, D.; Hrabec, E.
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Abstract: Cancer is one of the leading causes of deaths worldwide. Compounds derived from
traditional Chinese medicines have been an important source of anticancer drugs and adjuvant agents
to potentiate the efficacy of chemotherapeutic drugs and improve the side effects of chemotherapy.
Herba Epimedii is one of most popular herbs used in China traditionally for the treatment of multiple
diseases, including osteoporosis, sexual dysfunction, hypertension and common inflammatory
diseases. Studies show Herba Epimedii also possesses anticancer activity. Flavonol glycosides icariin
and icariside II are the main bioactive components of Herba Epimedii. They have been found to
possess anticancer activities against various human cancer cell lines in vitro and mouse tumor
models in vivo via their effects on multiple biological pathways, including cell cycle regulation,
apoptosis, angiogenesis, and metastasis, and a variety of signaling pathways including JAK2-STAT3,
MAPK-ERK, and PI3k-Akt-mTOR. The review is aimed to provide an overview of the current
research results supporting their therapeutic effects and to highlight the molecular targets and
action mechanisms.
Keywords: anticancer properties; Herba Epimedii; icariin; icariside II
1. Introduction
Cancer is a complex genetic disease involving abnormal cell growth and is continue to be one of
the major causes of deaths in both developed and developing countries [1]. According to statistics,
there are approximately 14.1 million new cancer cases and 8.2 million deaths in 2012 [2]. It is estimated
that new cancer cases will increase to 20 million by 2025. Cancer has been recognized as one of the most
crucial health problems all over the world due to its great increased incidence and significant mortality.
Plants have a long history of use in the treatment of cancer and it is reported that more than
3000 plant species have been used [3,4]. The search for anticancer drugs from plant sources started
as early as the 1950s, and at present over 60% of anticancer drugs currently used are derived directly
or indirectly from natural sources, including plants, marine organisms and micro-organisms [5,6].
One of the successful stories is the discovery and development of the vinca alkaloids, vinblastine and
vincristine, isolated from Catharanthusroseus G. Don (Apocynaceae) [7], which are the first plant-derived
anticancer agents applied to clinical use for the treatment of various cancers [8,9].
Herba Epimedii (Common name: Yin-yang-huo in China, Figure 1) is the dried leaf of Epimedium
brevicornu Maxim., Epimedium sagittatum (Sieb. EtZucc.) Maxim., Epimedium pubescens Maxim. or
Epimedium koreanum Nakaias as recorded in the Chinese Pharmacopoeia (Figure 1) [10]. There are more
than 40 kinds of Epimedium plants all over the world, mainly distributed in the southwest and central
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regions of China, although some are found in the temperate and subtropical regions of Asia, Middle
East as well as Europe [11]. Herba Epimedii has been recorded in the Chinese medical classics Shen Nong
Ben Cao Jing 400 years ago and has been used in various traditional Chinese formulations. The herb
is believed to “nourishing the kidney and reinforcing the Yang” and is proven to have remarkably
therapeutic activities. In China and Japan, Herba Epimedii alone, or in the formulations, have been
widely used for treatment of osteoporosis [12,13], sexual dysfunction [14], hypertension [15] and
common inflammatory diseases, such as chronic obstructive pulmonary disease [16]. In addition,
Herba Epimedii has been shown to exert anticancer effect on cancer cell lines in vitro and also in vivo in
mouse tumor model [17].
Figure 1. Natural sources and chemical structures of icariin and icariside II [18,19]. Herba Epimedii is
made up of the dried leaves of E. brevicornu, E. sagittatum, E. pubescens or E. koreanum.
More than 260 constituents have been detected from Herba Epimedii with 141 flavonoids,
31 lignins and multiple other kinds of compounds [11], and the flavonoid glycosides have been
confirmed to be the fundamental pharmacologically active constituents [20]. Icariin (Figure 1) is
the major active constituent and has been chosen as the chemical marker for quality control of
Herba Epimedii in Chinese Pharmacopeia. It is specified that the contents of icariin and the total
flavonoids are no less than 0.5% and 5.0%, respectively [10]. Icariin has been found to possess
a variety of pharmacological activities, including anti-osteoporosis [21], anti-inflammatory [22,23],
antioxidant [24], antihepatotoxic [25], antidepressant [26] and neuroprotective effects [27]. It was
also demonstrated to improve sexual disorder and to protect against cardiac ischemia/reperfusion
injury [28,29] and atherosclerosis [30]. Besides, icariin was reported to exhibit anticancer activity
against a series of human cancer cell lines.
Icariside II (Figure 1), another active flavonoid glycoside derived from Herba Epimedii, is the major
pharmacological metabolite of icariin in vivo and has been reported to be obtained from icariin through
enzymatic hydrolysis [31]. Icariside II has been shown to promote osteogenic differentiation of bone
marrow derived stromal cells [32]. It shows protective effects on cognitive deficits [33] and cerebral
ischemia-reperfusion injury [34] at least in part due to the inhibition of NF-kappaB. Additionally,
icariside II has also been demonstrated to possess cytotoxic and cytostatic activities against various
cancer cell lines.
The topic of this review will emphasize on the antitumor activities of Herba Epimudii and its two
main active constituents and the mechanisms of action discovered so far.
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2. Anticancer Effects of Herba Epimedii in Vitro and in Vivo
Recent studies showed that Herba Epimedii could restrain the proliferation of human breast
cancer cell lines in vitro as well as inhibit tumor growth in rat model of bone metastasis from breast
cancer. The antiproliferative activities of the ethanol extracts from Herba Epimedii on two different
types of human breast cancer cells were investigated [35]. The 95% ethanol extract significantly
inhibited the proliferation of human breast cancer MCF-7 cells in the range of 100–800 μg/mL in a dose
dependent manner with an IC50 of 528 μg/mL after 72 h treatment. The 70% ethanol extract exhibited
a certain activity on the growth of MCF-7 cells, whereas the 20% and 40% ethanol extracts showed no
significant antiproliferation activity. The four different ethanol extracts of Herba Epimedii showed no
obvious antiproliferative activity on human breast cancer MDA-MB-231 cells. In the rat model of bone
metastasis from breast cancer, significant increase of 50% Paw withdrawn threshold (50% PWT) and
reduction of tumor sizes were observed after oral administration of the decoction of Herba Epimedii
at a dose of 5 g/kg daily for 20 days. In addition, the bone structural mineral density (BMD) and
bone mineral capacity (BMC) were significantly enhanced [36]. In another study, it was found that
the Epimedium sagittatum extract inhibited the proliferation of various hepatoma and leukemia cell
lines, including SK-Hep1, PLC/PRF/5, K562, U937, P3H1 and Raji, with IC50 values of 15, 57, 74, 221,
40 and 80 μg/mL, respectively, whereas it showed no inhibition effects to HepG2 and Hep3B cell lines
(IC50 > 500 μg/mL). The Hep3B was found to be less sensitive to the extract compared with other cell
lines, consistent with the reported result that cells with the p53 gene deleted, just like Hep3B cell line,
were more resistant to drugs [17].
3. Anticancer Effects of Icariin and Icariside II in Vitro and in Vivo
As for anticancer effects, studies have been performed in various human cancer cell lines. Icariin
and icariside are proved to inhibit the growth of human cancer cells in vitro through intervening with
multiple signaling pathways which are crucial to tumor growth, progression, invasion and apoptosis.
Different concentrations of icariin and icariside II were used in the studies, depending on the types of
cancer cell lines. The anticancer activity of icariin and icariside II and the molecular targets on various
cancer cell lines were summarized in Table 1.
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Icariin and icariside II have been demonstrated to exhibit in vivo suppressive effects both
on tumor weight and tumor volume on a variety of mouse tumor models without obvious side
effects (Table 2). Intraperitoneal administration of icariin at the doses of 15–150 mg/kg significantly
inhibited tumor growth in xenografted mice models with almost no or very low toxicity to animals.
Oral administration of 65 mg/kg icariin was shown to inhibit the growth of melanoma tumor and to
inhibit the metastasis of B16 melanoma cells, and the lifespan was apparently pro-longed [45]. At the
doses of 10–100 mg/kg, icariside II resulted in significant decrease in tumor weight and volume in
cancer cell bearing mice models. All these data suggested that icariin and icariside II indeed have
therapeutic potential against cancers.
Table 2. In vivo evaluation of icariin and icariside II in mouse tumor models.
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55.6% inhibition in tumor
weight; 47.2% inhibition in
tumor volume
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30 mg/kg everyday for
9 days
33.0%, 51.3%, and 62.6%
reduction in tumor weight,
respectively
[52]
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Icariside II Livercarcinoma H22 Inoculation
Given by i.v.10, 20,
30 mg/kg everyday for
9 days
Inhibit tumor growth [53]




Given by i.p. 10, 20 and
30 mg/kg everyday for
10 days
Inhibit tumor proliferation [54]




Given by i.p. 50 mg/kg
and 100 mg/kg 3 times for
a week
41% and 49% decrease in
tumor volume [47]
4. Icariin and Icariside II as Adjuvant Therapy
While icariin and icariside II as single agent exhibited antitumor activities towards diverse human
cancers, their potentials of potentiating the antitumor activity of a variety of chemotherapeutic drugs as
adjuvant agents have shown perspectives in recent years. The combination treatment with the natural
bioactive components and the chemotherapeutic drugs could facilitate chemotherapy for patients with
cancers and provide a higher efficacy remedy.
Icariin has been shown to potentiate the antitumor activity of arsenic trioxide, temozolomide,
doxorubicin, 5-fluorouracil and gemcitabine on a variety of human cancer cell lines, including acute
promyelocytic leukemia, glioblastomamultiforme, hepatocellular carcinoma, osteosarcoma, colorectal
cancer and gallbladder cancer cell lines, as well as in xenograft murine models (Table 3).
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Arsenic trioxide (ATO), a traditional Chinese medicine, has been wildly used for the treatment of
acute myeloid leukemia (AML) since 1970s in China and has been recommended as the front-line agent.
In addition, ATO has exhibited antitumor activity against various solid tumor cell lines. Icariin has
demonstrated to potentiate the antitumor activity of ATO in treating AML and hepatocellular
carcinoma, at least partially correlated with the increase in the accumulation of intracellular reactive
oxygen species (ROS). Of note, the sensitivity of APL cell line NB4 to ATO dues to the reduced
glutathione content and the increased ROS production. Adjuvant agent, which promotes the
accumulation of ROS, such as icariin, could potentiate the antitumor activity of ATO against APL [63].
Moreover, co-treatment with ATO and icariin resulted in a significant inhibition of tumor growth in
xenograft murine model of Hep G2 compared to the treatment with either agent alone by promoting
the generation of ROS and suppressing NF-κB without systemic toxicity [64].
Icariin potentiated the anti-tumor activity of temozolimide in glioblastomamultiforme cell line
U87MG [62]. The cytotoxicity of doxorubin was enhanced by icariin via the inhibition of ABC1 and
down regulation of PI3K/Akt pathway [65]. The combination of icariin and 5-fluorouracil led to the
inhibition of tumor growth by suppressing NF-κB activity [66]. Icariin also potentiated the anti-tumor
activity of gemcitabine in the treatment of gallbladder cancer by inhibiting NF-κB [67].
Icariside II has been demonstrated an increased inhibitory effect on human melanoma cells
and multiple myeloma U266 cells when combined with paclitaxel and bortezomib/thalidomide,
respectively (Table 3).
Paclitaxel is a widely used cancer chemotherapeutic drug and exhibits antitumor activity in
a variety of human malignancies. It was revealed to induce the activation of the toll-like receptor
4 (TLR4) signaling pathway, which was functionally associated with tumor growth, invasion and
chemoresistance [68]. Inhibition of the activation of TLR4-MyD88 has been considered as a novel
approach for reversing chemoresistance of paclitaxel. Data from our laboratory demonstrated that
Icariside II enhanced paclitaxel-induced apoptosis in human melanoma cells, which might be due to
its inhibition on paclitaxel-induced activation of TLR4-MyD88-ERK signaling [48].
Bortezomib (a proteasome inhibitor) and thalidomide (an inhibitor of TNF expression) have been
reported to be used for the treatment of multiple myeloma patients. Icariside II has been found to
induce the suppression of survival proteins such as Bcl-xL and surviving as well as cleavages of PARP
and caspase-3. Co-treatment of icariside II with bortezomib or thalidomide significantly improved
the cytotoxic effects of bortezomib and thalidomide from 25% and 20% to 60% and 50% in U266 cells,
respectively, accompanied by the further increase of caspase-3 activation and PARP cleavage [59].
Icariin and icariside II have played an excellent adjuvant effects without causing systemic
toxicity in the chemotherapeutic treatment of several tumors by interfering with multiple molecular
targets in tumor cells. They might be considered as the potential candidates for treating tumors in
combination with common chemotherapeutic drugs, thus contributing to the development of the
successful therapeutic strategies.
5. Molecular Mechanisms of Anticancer Activity of Icariin and Icariside II
Multiple studies have been performed to investigate the mechanisms by which icariin and
icariside II exert their anti-tumor effects. The mechanisms are comprehensive and diverse, involving
the regulation of a variety of targets, which play a particularly important role in the process of tumor
proliferation, invasion, angiogenesis, metastasis and apoptosis. Besides the effects of icariin and
icariside II on numerous signaling proteins and transcription factors, they also regulate the stages of
the tumor cells by inhibiting proliferation and inducing apoptosis. In addition, they could play their
anti-tumor effect through improving the tumor inflammatory microenvironment (Figure 2). Icariin and
icariside II might be considered as potential chemotherapeutic agents for the treatment of various
human cancers due to their multiple targets on the cell growth processes.
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Figure 2. Overview of the anti-cancer effects of icariin and icariside II. Icariin and icariside II stimulate
the cell cycle arrest via upregulation of p38, p53, and p21. Icariin and icariside II are involved in the
induction of apoptosis and inhibit tumor angiogenesis and metastasis via suppression of multiple
signaling pathways. They also have anti-inflammatory effects via downregulation of several factors,
such as IFN-γ, iNOs, and COX-2, (← activation; ⊥ inhibition; ↑, up-regulation; ↓, down-regulation).
5.1. Effect on Cell Cycle Regulation
Cell division is divided into two stages: Mitosis (M) and the interlude between two M phases,
including G1, S, and G2 phases. In addition, cells in G1 can enter a resting state called G0 just
before the DNA replication [69,70]. In normal cells, the cell cycle is a highly regulated event,
which is accurately regulated by cyclin dependent kinases (CDKs). The CDKs interact with various
corresponding cyclins to form active complexes to ensure that the process at each stage is completely
accomplished [71]. Tumor suppressor gene p53 is a vital cell cycle checkpoint regulator at the G1/S and
G2/M checkpoints and serves to monitor the accuracy of vital events [72,73]. p38 MARK activation
leads to the accumulation of p53 and the p53-induced cell cycle arrest is primarily mediated by the
activation of p21 [74].
As shown in Figure 3, there are five active CDKs during the cell cycle, CDK2, CDK4 and CDK6
for G1, CDK2 for S, and CDK1 for both G2 and M. The complexes of cyclin D with CDK4 or CDK6
promote the progression through G1, cyclin E/CDK2 activates G1 into S, cyclin A/CDK2 promotes
S progression, cyclin A/CDK1 activates G2 into M, while cyclin B/CDK1 stimulates the mitotic
phase [75]. Disorders in the regulatory control of cell cycle could lead to the formation of tumors,
characterized by the unlimited cell proliferation and abnormal apoptosis. Overexpression of cyclin D1
has been recognized as one of the distinct features in many types of human tumors [76]. Suppression of
deregulated cell cycle progression in cancer cells by inhibiting the activities of CDKs or the cyclins
have been considered as an effective strategy to inhibit the proliferation of the tumors [77].
Icariin has been reported to arrest the cell cycle at G0/G1 phase on the HepG2 cells.
Icariin treatment for 72 h significantly increased the proportion of cells in G0/G1 phase, while the
proportion of cells in S phases was remarkably lower (21.07%, p < 0.01) than that of the control group
(28.62%) (Figure 3) [37]. Icariin also showed a weak G1 phase arrest accompanied by a mitochondrial
transmembrane potential drop by decreasing cyclin D1 and CDK4 in human prostate carcinoma PC-3
cell line [39]. In another report, icariin stimulated S phase arrest in medulloblastoma cells by regulating
the cell cycle regulators cyclin A, CDK2 and cyclin B1 [51].
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Figure 3. The cell cycle arrest induced by icariin and icariside II. Icariin and icariside II stimulate cell
cycle arrest via suppression of the CDKs and cyclins at different stages, (← activation; ⊥ inhibition).
Our study demonstrated that icariside II induced cell cycle arrest at G0/G1 and G2/M phases in
A375 human melanoma cell line (Figure 3). After treatment with icariside II at a series of concentrations
0, 25, 50 and 100 μM, the percentage of cells in G0/G1 phase significantly increased with the increase
of icariside II concentration and peaked at 100 μM (69.51%), as compared to the control group (44.01%).
The cell cycle arrest of A375 cells at G0/G1 phase was found to be correlated with the decreased
expression of cyclin E and CDK2, and the arrest at G2/M phase was associated with decreased
expression of cyclin B1/CDK1 complex. It was determined that IS inhibits cell proliferation and
induces cell cycle arrest through the generation of reactive oxygen species and activation of p38 and
p53. These findings were further supported by the evidence that pretreatment with N-acetyl-L-cysteine,
SB203580 or pifithrin-α significantly blocked icariside II-induced reduction of cell viability, increase of
cell death and cell cycle arrest. Crucially, it was confirmed that these effects were mediated at least in
part by activating the ROS-p38-p53 pathway [46].
5.2. Effect on Apoptosis
Apoptosis occurs normally during development to maintain the cell population in normal tissues
or occurs as a defense mechanism to selectively eliminate the defective or unwanted cells which are
damaged by disease [78]. It has been recognized as a necessary complementary to proliferation and
plays a vital role in the development and regulation of the immune system, as well as the removal of
damaged cells, and what’s more, the disruption of apoptosis is implicated in tumors development [79].
It is well established that there are two main apoptotic pathways: The extrinsic (receptor mediated)
and the intrinsic (mitochondrial mediated) signaling pathway (Figure 4). The extrinsic signaling
pathway is initiated by the ligation of ligands and corresponding death receptors of the tumor necrosis
factor (TNF) receptor subfamily, such as FasL/FasR and TNF-α/TNFR1 [80]. The formation of
death-inducing signaling complex (DISC) leads to the autocatalytic activation of procaspase-8 [81].
The intrinsic apoptotic pathway is triggered by cellular stress factors including the negative signals
involving the absence of some growth factors, hormones and cytokines and positive signals, including
radiation, toxins, hypoxia, viral infections, and free radicals. These stimuli at on the mitochondrial
membrane and result in change of themitochondrial permeability transition (MPT), loss of the
mitochondrialtransmembrane potential and release of the pro-apopto ticproteins such as cytochrome c
and apoptosis inducing factor (AIF) from mitochondria into the cytosol [82]. The released cytochrome
c activates Apaf-1 and procaspase-9, resulting in the formation of apopto some [83]. The mitochondrial
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mediated apoptotic pathway is regulated by the members of the Bcl-2 family proteins [84], which
are reported to be implicated with the tumor suppressor protein p53 and comprise two groups of
proteins with the opposite function, the anti-apoptotic proteins (e.g., Bcl-2, Bcl-x and Bcl-xL) and the
pro-apoptotic proteins (e.g., Bax, Bid, Bak, Bim and Bik) [85]. The extrinsic pathway can be linked
with the intrinsic pathway through caspase-8 by inducing the activation of Bid, in turn, acting on the
mitochondrial membrane leading to the release of cytochrome c (Figure 4) [86].
Figure 4. Apoptosis signaling pathways induced by icariin and icariside II. Icariin and icariside II
induce apoptosis of tumor cells through two pathways, extrinsic (receptor-mediated) pathway and
intrinsic (mitochondria-mediated) pathway. The binding of TNF-α with TNFR1 leads to the formation
of TRADD and RIP, then the two factors combine with FADD and procaspase-8, which are resulted
from FasL/FasR pathway, leading to the formation of death inducing signaling complex (DISC) and
activating caspase-8. Activated caspase-8 stimulates the downstream caspase-3 and PARP, resulting
in apoptosis, or cleaves Bid, which is the link between extrinsic pathway and intrinsic pathway,
leading to the activation of intrinsic pathway. The cellular stress, activation of t-Bid, or modulation of
Bax/Bcl-2 result in the downregulation of mitochondrial membrane potential and subsequent release of
cytochrome c. Once released to cytosol, cytochrome c interacts with Apaf-1, resulting in the activation
of caspase-9, which then activates caspase-3 resulting in cell death. Activation of NF-κB leads to the
activation of several anti-apoptotic factors, which subsequently block the mitochondria-mediated
pathway. Tumor cells produce ROS at higher levels, leading to the activation of p38 and p53, and
subsequent apoptosis, (← activation; ⊥ inhibition).
Multiple studies have shown that icariin and icariside II can selectively kill cancer cells
without apparent toxicity on normal cells by inducing apoptosis in many cancers, including
hepatocellular carcinoma, prostate carcinoma, esophageal squamous cell carcinoma, ovarian cancer,
lung cancer, melanoma, leydig cell tumor, gastric adenocarcinoma, promyelocytic leukemia, sarcoma,
hepatoblastoma, medulloblastoma, osteosarcoma, epidermoid carcinoma, acute myeloid leukemia,
breast cancer, and multiple myeloma. It seems that icariin and icariside II induce apoptosis via both
extrinsic (caspase induced) and intrinsic (mitochondrial induced) signaling pathways.
Icariside II has been reported to increase the expression of Fas and the Fas-associated death
domain (FADD) without changing the level of Daxx, which is also an Fas binding protein inducing
apoptosis by activating the JNK pathway, and activate caspase-8 and caspase-3 in MCF-7 breast cancer
cells, indicating the involvement of extrinsic apoptosis pathway [58]. It was speculated that the
apoptosis induced by icariside II might be occurred by stimulating Fas/FADD signaling independently
of FasL and subsequently activating caspase-8. Moreover, the extrinsic signaling pathway might exert
its effects on the icariside II-treated MCF-7 cells independent of the intrinsic pathway for the absence
truncated Bid (tBid), which is the key molecule linking the two apoptosis pathways.
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Several studies have revealed that icariin and icariside II exert their anti-tumor effects by
inducing apoptosis via mitochondrial induced signaling pathway, mainly characterized by the loss
of mithchondrial membrane potential, release of cytochrome c, activation of caspase-9, caspase-3
and PARP, and elevation of intracellular reactive oxygen species (ROS), which played vital role
in cell apoptosis (Table 1). In addition, icariside II has also been shown to induce the release of
the apoptosis-inducing factor (AIF) and cytochrome c, and the activation of caspase-9, which are
characteristic features of intrinsic apoptosis pathway [58].
Nuclear factor-kappaB (NF-κB), an inducible transcription factor, and its downstream genes were
suggested to play an important role in cell proliferation, invasion, apoptosis and chemoresistance [87].
Recent studies have shown that icariin exhibits antitumor activity and potentiates the antitumor
effect of several chemotherapeutic drugs via down-regulation of NF-κB in various human cancer cells,
generally accompanied by the down-regulation of Bcl-2 and Bcl-xL [62,64,66,67]. Icariside II has been
shown to prohibit invasion of lung cancer A549 and H1299 cells through suppression of Akt/NF-κB
pathway [44].
5.3. Effect on Angiogenesis and Metastasis
The formation of new blood vessel is one of the key factors responsible for tumor growth and
metastasis, not only supply nutrients for the metabolic needs of rapidly proliferating cancer cells
but also provide conditions for cancer spread, resulting in malignant tumor growth, invasion and
metastasis. Microvascular density in primary tumors is implicated in the numbers of tumor cells
entered into the circulation in many tumors. Angiogenesis is regulated by multiple pro-angiogenic
genes and signaling molecules including vascular endothelial growth factor (VEGF), basic fibroblast
growth factor (bFGF), epidermal growth factor (EGF), platelet-derived growth factors (PDGF),
angiopoetin (Ang), hypoxia-inducible factors, and matrix metal oproteinases [88].
Icariin has been shown to significantly prohibit the proliferation of vascular smooth muscle cells
(VSMCs) and the activation of ERK1/2. Moreover, icariin also induced G1/S phase cell cycle arrest
and decreased the expression of PCNA in VSMCs [89]. Based on these results, it was proposed that the
inhibitory effect of icariin on the proliferation of VSMCs might be responsible for the suppression of
tumor metastasis.
Effects of icariin and icariside II treatments on the adhesion and metastasis have been investigated
in various human tumor cells, including esophageal carcinoma EC109 and TE1 [41], gastric
adenocarcinoma BGC-823 [50], and lung cancer A549 and H1299 cell lines [44].
The adhesion and migration of icariin-treated EC109 and TE1 cells were evaluated after incubation
in 15 μM ICA for 24 h [41]. The cell adhesion ratio decreased significantly to 47.23% ± 8.97% of that
of the control in EC109 cells and 45.98% ± 6.72% of that of the control in TE1 cells, respectively
(p < 0.05). Similarly, the scratch wound distance significantly increased by 159.23% ± 13.27% in EC109
cells and 179.26% ± 15.14% in TE1 cells, respectively (p < 0.05) [41]. Icariin was also reported to
significantly inhibit tumor cells migration and invasion of human gastric adenocarcinoma cell line
BGC-823 via the down-regulation of Rac1 and VASP [50]. The combination of icariin and the selective
siRNA targeting Rac1 and VASP promoted the inhibitory effects. In addition, transfection with Rac1
plasmids pcDNA3-EGFP-Rac1-Q61L resulted in the improvement of expression levels of both Rac1
and VASP. Based on these results, it could be concluded that icariin inhibit the tumor cell invasion
and migration through the Rac1-dependent VASP pathway [50]. A study has showed that icariside II
prohibited the migration and epithelial-mesenchymal transition (EMT) via the inhibition of N-cadherin
and vimentin up-regulation, and E-cadherin down-regulation induced by THP-1-CM in lung cancer
A549 and H1299 cells [44].
5.4. Effect on Multiple Signaling Pathways
Multiple signaling pathways played vital role in cell survival, apoptosis and metastasis.
Targeting various signaling pathways has been considered as a successful option in the treatment of
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cancer for its potential to avoid drug resistance, which is one of the major drawbacks of most anticancer
drugs. Epidermal growth factor receptor (EGFR) is overexpressed in various types of human cancers
and its expression is implicated with poor clinical prognosis [90]. Several small molecular kinase
inhibitors and antibodies targeting on EGFR have been approved by FDA to treat diverse types of
tumors. Activated EGFR recruits a variety of downstream signaling molecules, leading to the activation
of major signaling pathways such as JAK2-STAT3, MAPK-ERK, and PI3k-Akt-mTOR, which play vital
role in tumor growth, progression, and survival [91].
The inhibitory effects of icariside II on EGFR signaling have been investigated in human
epidermoid carcinoma A431 cells [56] and in human osteosarcoma MG-63 and Saos-2 cells [54]. In our
study, icariside II was found to inhibit the cell viability of A431 cells, accompanied by the decrease of
phosphorylated EGFR. Pretreatment with LY294002 (a phosphatidylinositol 3-kinase (PI3K) inhibitor),
EGF (an EGFR agonist) and AG1478 (an EGFR inhibitor) partially reversed the icariside II-induced
decrease in cell viability, indicating icariside II effectively inhibited the EGF-induced activation of the
EGFR pathway [56]. Icariside II was also found to decrease cell proliferation in MG-63 and Saos-2 cells
by inactivating EGFR/mTOR signaling pathway and the decreased cell viability could be reversed
partially by the pretreatment of EGF [54].
STAT3 is activated in a broad spectrum of human cancers, such as prostate cancers [92], breast
cancer [93], and nasopharyngeal carcinoma [94], and has been implicated as a potential therapeutic
target for multiple human cancers. Icariside II exhibited inhibitory effect on STAT3 signaling pathway
in human melanoma A375 and SK-MEL-5 cells [47], epidermoid carcinoma A431 cells [56], acute
myeloid leukemia U937 cells [57] and multiple myeloma U266 cells [59].
The phosphorylation of STATs is principally mediated via the activation of non-receptor protein
tyrosine kinases called as JAK. Data from our laboratory showed that Icariside II dramatically
inhibited the proliferation of melanoma A375 and SK-MEL-5 cells in vivo and in vitro by inhibiting
the activation of the JAK-STAT3 and MAPK pathways but promoting an unsustained activation peak
of the PI3K-AKT pathway [47]. Moreover, we also found icariside II induced apoptosis through
inhibition of EGF-induced activation of STAT3 in A431 cells [56]. In U937 and U266 cells, Icariside
II decreased the phosphorylation of JAK2 and c-Src, the upstream activators of the STAT pathway,
and increased the expression of PTPs such as PTEN and protein tyrosine phosphatase (PTP) SH2
domain-containing phosphatase (SHP)-1 [57,59]. Sodium pervanadate (a PTP inhibitor) prevented
Icariside II-induced apoptosis as well as STAT3 inactivation in U937 cells. Furthermore, silencing SHP-1
using specific siRNA significantly blocked STAT3 inactivation and apoptosis induced by Icariside
II in U937 cells. All these results support a key role of SHP-1 in the suppression of STAT signaling
pathways. In addition, icariside II was proved to reduce the level of STAT3 in MDA-MB-231 (breast
adenocarcinoma) and DU145 (prostate carcinoma) cells, in which STAT3 is constitutively active [57].
The mitogen-activated protein kinase (MAPK-ERK, also known as Raf-MEK-ERK) pathway
consisted several signal factors and the extracellular signal-regulated kinase-1 and 2 (ERK1/2) are
extremely important in human cancers, which then activate ERK [95]. The importance of MAPK-ERK
pathways in cancer progression and proliferation has been supported by Shield et al. [96]. Icariside II
has been shown to inhibit the activation of ERK in melanoma A375 cells [47,48] and epidermoid
carcinoma A431 cells [56]. Our data showed that icariside II treatment could effectively inhibit
paclitaxel-induced activation of TLR4-MyD88-ERK signaling pathway in human melanoma A375
cells, which is proposed to be a novel target for reversing chemoresistance to paclitaxel. What’s more,
icariside II decreased cell proliferation and inactivated Raf-MEK-ERK signaling in osteosarcoma MG-63
and Saos-2 cells [54].
Phosphatidylinostinositol-3-kinase/protein kinase B (PI3K-AKT) signaling was found to play
a key role in cell proliferation and is overexpressed in multiple human cancers [97]. As the downstream
of PI3K-AKT, the mammalian target of rapamycin (mTOR), is a master growth regulator that
senses the presence of growth factors by regulating p70S6K and 4E-binding protein 1 (4E-BP1) [98].
Icariside II, a natural mTOR inhibitor, was found to decrease the phosphorylation of PI3K-PDK1 and
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dephosphorylated Akt at Thr308 and Ser473 in osteosarcoma MG-63 and Saos-2 cells [54]. Akt activates
mTOR by relieving proline-rich Akt substrate 40 (PRAS40)-mediated inhibition of mTOR. In addition,
icariside II activated GSK3β, the direct target of Akt, by dephosphorylation atSer9, weakening the
stability of transcription factors and cycle-related proteins. The suppression of icariside II on the
phosphorylation of PI3K, Akt, PRAS40 was approved by mice bearing osteosarcoma sarcoma-180 cells.
In conclusion, icariside II treatment moderated EGF-induced activation of PI3K/Akt/PRAS40 pathway
in vitro as well as in vivo [54]. Icariside II was also shown to suppress aberrant energy homeostasis
in osteosarcoma U2OS, fibrosarcoma S180 and chondrosarcoma SW1535 cells via suppression of
mTORC1 by regulating mTORC1-4E-BP1 axis, suggesting a potential application of icariside II in
sarcoma therapy [52]. In addition, icariin was reported to enhance cytotoxicity of doxorubin in the
human osteosarcoma doxorubicin (DOX)-resistant MG-63/DOX cell line through down-regulation of
PI3K-Akt pathway [65].
5.5. Anti-Inflammatory Activity
The hypothesis that chronic inflammation promoted cancer development and progression is
strongly supported by the findings that individuals with chronic inflammation of the specific organ
are significantly more susceptible to some organ-specific cancers [99]. The induction of myeloid
suppressor cells (MDSC), one of the major factors mediating tumor-associated immune suppression,
undermines the immune surveillance, thereby providing an environment favorable for tumor growth
and allowing proliferation of malignant cells [100]. If inflammation facilitates tumor progression
through the induction of more suppressive MDSCby signaling through the toll-like receptor 4 (TLR4)
pathway, then it is possible that a decreased pro-inflammatory microenvironment may reduce the
potency of MDSC. Data from our laboratory showed that icariin treatment reduced the expression
of MRP8/MRP14 and TLR4 on human PBMCs [60]. Administration of icariin inhibited the tumor
growth in 4T1-Neu tumor-bearing mice by reducing splenic MDSC accumulation and activation
restoration of the functionality of effector CD8+ Tcells [60]. Furthermore, icariin significantly decreased
the amounts of nitric oxide and reactive oxygen species in MDSC in vivo. Further, we saw a restoration
of IFN-γ production by CD8+T cells and the drops of nitric oxide and reactive oxygen species in tumor
bearing mice.
Recent findings demonstrated that cyclooxygenzase-2 (COX-2) is over-expressed in various
cancers, including pancreatic cancer [101], gastric carcinoma [102], and prostate cancer [103].
Prostaglandin E2 (PGE2), the proflammatory product of elevated COX-2, has been shown to play
a crucial role in the progression of malignant tumor. Since COX-2 is increased in inflammatory
microenvironment, it is considered as a molecular target for cancer prevention and treatment.
The mechanism of icariside II induced apoptosis in hormone-independent prostate carcinoma
PC-3 cells was studied in association with COX-2 [40]. Data showed that Icariside II exerted cytotoxicity
with IC50 of approximately 20 μM on PC-3 cells. Furthermore, icariside II induced apoptosis via the
suppression of COX-2, inducible NO synthase (iNOS), vascular endothelial growth factor (VEGF) and
mitochondrial membrane potential, release of cytochrome c, and activation of caspase-8, -9 and, -3
expressions, and cleaved PARP. Moreover, exogeneous PGE2 inhibited PARP cleavage and knockdown
of COX-2 enhanced PARP cleavage. These results indicated that icariside II induced mitochondrial
dependent apoptosis by initiating the inhibition of COX-2/PGE2 pathway in PC-3 prostate [40].
The apoptosis induced by icariside II in acute myeloid leukemia U937 and multiple myeloma U266
was also found to be associated with the decrease of COX-2 [57,59].
6. Conclusions
A renewed interest emerges in the study of alternative and less toxic remedies for the treatment of
many diseases, including cancer. Maximizing efficacy and minimizing side-effects has been recognized
as the major goal of the treatment of cancers. Herba Epimedii has been traditionally used in clinical due
to its multi-purpose activity and low toxicity. Collective data indicate that icariin and icariside II are
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the main bioactive components of Herba Epimedii and are potential anticancer agents towards a broad
spectrum of human cancers. They exhibit broad toxicity to various types of human cancer cells by
interfering with multiple mechanisms, inhibiting multiple signaling pathways, as well as regulating
inflammatory microenvironment. Moreover, icariin and icariside II could be used as chemotherapeutic
adjuvant agents in combination with standard drugs to improve the treatment effects and avoid drug
resistance. In view of these demonstrated effects, icariin and icariside II could be potential therapeutic
intervention agents alone or in combination with current chemotherapeutic drugs for cancers.
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Abstract: Polyphenols, found abundantly in plants, display many anticarcinogenic properties
including their inhibitory effects on cancer cell proliferation, tumor growth, angiogenesis, metastasis,
and inflammation as well as inducing apoptosis. In addition, they can modulate immune system
response and protect normal cells against free radicals damage. Most investigations on anticancer
mechanisms of polyphenols were conducted with individual compounds. However, several studies,
including ours, have indicated that anti-cancer efficacy and scope of action can be further enhanced
by combining them synergistically with chemically similar or different compounds. While most
studies investigated the anti-cancer effects of combinations of two or three compounds, we used
more comprehensive mixtures of specific polyphenols and mixtures of polyphenols with vitamins,
amino acids and other micronutrients. The mixture containing quercetin, curcumin, green tea,
cruciferex, and resveratrol (PB) demonstrated significant inhibition of the growth of Fanconi anemia
head and neck squamous cell carcinoma and dose-dependent inhibition of cell proliferation, matrix
metalloproteinase (MMP)-2 and -9 secretion, cell migration and invasion through Matrigel. PB was
found effective in inhibition of fibrosarcoma HT-1080 and melanoma A2058 cell proliferation, MMP-2
and -9 expression, invasion through Matrigel and inducing apoptosis, important parameters for
cancer prevention. A combination of polyphenols (quercetin and green tea extract) with vitamin
C, amino acids and other micronutrients (EPQ) demonstrated significant suppression of ovarian
cancer ES-2 xenograft tumor growth and suppression of ovarian tumor growth and lung metastasis
from IP injection of ovarian cancer A-2780 cells. The EPQ mixture without quercetin (NM) also
has shown potent anticancer activity in vivo and in vitro in a few dozen cancer cell lines by
inhibiting tumor growth and metastasis, MMP-2 and -9 secretion, invasion, angiogenesis, and
cell growth as well as induction of apoptosis. The presence of vitamin C, amino acids and other
micronutrients could enhance inhibitory effect of epigallocatechin gallate (EGCG) on secretion of
MMPs. In addition, enrichment of NM with quercetin (EPQ mix) enhanced anticancer activity
of NM in vivo. In conclusion, polyphenols, especially in combination with other polyphenols or
micronutrients, have been shown to be effective against multiple targets in cancer development
and progression, and should be considered as safe and effective approaches in cancer prevention
and therapy.
Keywords: polyphenols; tumor growth; metastasis; Matrigel invasion
1. Introduction
Polyphenols comprise a diverse group of secondary metabolites abundant in plants, where
they play key roles in regulating growth, metabolism, protecting against UV radiation and
various pathogens. More than 8000 polyphenolic compounds have been identified in various plant
species. Polyphenols have been subjected to numerous studies, investigating their potential health
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benefits, including protection against oxidative stress, cardiovascular disease, diabetes, asthma,
neurodegenerative disease and even aging [1]. Particular interest in these naturally occurring plant
components has been kindled by the search for new chemopreventive agents that are more effective
and less toxic than conventional therapies. As such, this group of substances has been studied
for anticarcinogenic properties, such as modulating cell proliferation, tumor growth, angiogenesis,
metastasis, inflammation and apoptosis [2,3].
Polyphenols are classified based on the number of phenol rings and the structural elements
that bind these rings to one another. The groups include: phenolic acids, stilbenes, lignans, and
flavonoids. Flavonoids, which have both antioxidant and anti-inflammatory properties, are found in
fruits, vegetables, legumes, red wine, and green tea. They are subdivided into six classes: flavonols,
flavones, isoflavones, flavanones, anthocyanidins, and flavanols (catechins and proanthocyanidins) [4].
Flavonols, the most ubiquitous flavonoids in foods, are generally present at relatively low
concentrations. Quercetin and kaempferol are the main representatives, and their richest sources
are onions, curly kale, leeks, broccoli, and blueberries [4].
Flavones, consisting mainly of glycosides of luteolin and apigenin, are less common than flavonols
in fruit and vegetables; parsley and celery are the main edible sources of flavones [4]. Flavanones,
present in tomatoes and certain aromatic plants such as mint, are present in high concentrations only in
citrus fruit. Isoflavones, flavonoids with structural similarities to estrogens, have the ability to bind to
estrogen receptors, and thus are classified as phytoestrogens. They are found almost exclusively
in leguminous plants. Flavanols occur as catechins (a monomer form) and proanthocyanidins
(the polymer form).
Catechins are found in many types of fruit, red wine, green tea and chocolate. Gallocatechin,
epigallocatechin, and epigallocatechin gallate (EGCG) are found in teas, seeds of leguminous plants
and grapes [5,6]. Green tea, a rich source, contains up to 200 mg catechins in a cup of tea [7]. Flavanols
are not glycosylated in foods as are other classes of flavonoids; thus tea epicatechins remain very stable
when exposed to heat under acidic pH. Only 15% of these substances are degraded after 7 h in boiling
water at pH 5 [8].
Among phenolic acids, hydroxybenzoic acids are found in tea and more common hydroxycinnamic
acids are found in cinnamon, coffee, blueberries, kiwis, plums, apples, and cherries [4]. These acids are
mostly found as glycosylated derivatives of esters of quinic acid, shikimic acid and tartaric acid [4].
Ferrulic acid is the most abundant phenolic acid found in cereal grains and in wheat; it may represent
up to about 90% polyphenols [9].
Stilbenes are found in low quantities in our diet, which may be not sufficient to exercise significant
health effects; larger quantities can be provided in concentrated extracts or in the form of purified
compounds. Resveratrol is a key stilbene, found especially in red wine and peanuts, which has been
extensively studied for its anticarcinogenic and other health effects [10].
Lignans are found in flax seeds, legumes, cereals, grains, fruits, algae, and certain vegetables [4].
Their concentration in linseed is about 1000 times as high as in other food sources [11]. Plant lignin,
secoisolariciresinol diglycoside (SDG) and its metabolites have shown promise in reducing carcinogenic
tumors, in particular hormone-sensitive ones such as breast, endometrium and prostate tumors [12].
2. Aspects Associated with Bioavailability of Polyphenols
Bioavailability defines the amount of nutrient that is digested, absorbed and metabolized in
normal biochemical pathways. Most polyphenols are present in food in the form of esters, glycosides
or polymers, and are metabolized by a common pathway. Before absorption, most polyphenols have to
be hydrolyzed by intestinal enzymes or microflora present in colon. Only aglycones can be absorbed via
the small intestine [13]. Subsequently, during absorption, polyphenols undergo extensive modification
by conjugation in the intestinal cells and further processing in the liver through methylation, sulfation
and glucuronidation [13]. Therefore, their forms detected in the blood and tissues differ from the ones
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present in food. In addition, the most biologically active polyphenols are not necessarily the most
common ones in the diet.
Metabolic activity of polyphenols is dependent on intrinsic activity, relative absorption from the
intestine, rate of metabolism and of elimination. In addition, digestive or hepatic metabolic activity
may render the metabolites that reach the blood and target organs to differ in biological activity from
their native form. Polyphenol metabolites circulate in the blood bound to proteins, mainly albumin,
with binding affinity largely defined by their structural properties [14]. Protein binding can affect the
rate of their delivery to cells and tissues.
Polyphenols are able to penetrate tissues, in particular the intestine and liver, where they are
metabolized. Their excretion occurs through urine (mainly small conjugates) and more extensively
conjugated metabolites are secreted in bile. It appears that the amount of metabolite in urine roughly
corresponds to its maximum concentration in plasma. It is quite high for citrus fruit flavanones and
decreases from isoflavones to flavonols. Thus, understanding polyphenol bioavailability is essential
for determining their health effects.
3. Antitumor Effects of Select Polyphenols
Development of cancer is a multi-stage process that involves initiation, promotion and progression.
Dietary polyphenols can affect and modulate multiple diverse biochemical processes and pathways
involved in carcinogenesis [15]. In addition, they can act as biological response modifiers supporting
immune system function, as well as protecting living cells against damage from free radicals. Although
polyphenols in fruits and vegetables are widely implicated in cancer prevention, few protective effects
of individual compounds have been firmly confirmed in clinical trials due to differences in dosing,
timing and other confounding factors.
Several cancer preventive mechanisms have been identified as affected by polyphenols,
including prevention of oxidation, detoxification of xenobiotics, induction of apoptosis, as well as
estrogenic/anti-estrogenic activity, stimulating effects on immune system function, anti-inflammatory
properties and their effects on the cellular signaling system. Among these are effects on nuclear factors,
such as NF-κB or activator protein 1 (AP-1), which play central roles in cellular signaling cascades,
regulating DNA transcription, gene expression in response to different stimuli, cell proliferation and
survival [16,17]. Most investigations have been conducted with individual polyphenols in order
to increase our understanding of biological and cellular mechanisms of their anticancer efficacy.
However, final effects of these compounds are largely influenced by their interactions with other
natural components, both at the cellular and organ levels. These aspects have been rarely evaluated and
studied. Below we will discuss key studies investigating anti-cancer effects of individual polyphenols,
as well as their efficacy when used in various combinations, the approach which has been promoted in
our research.
3.1. Curcumin
This active ingredient of a rhizome of turmeric has been known for its anti-oxidant properties
and many health benefits. It has been demonstrated in different cancer models that curcumin can
inhibit cellular proliferation and angiogenesis, block cell cycle progression in tumor cells, and induce
apoptosis [18–20]. Aoki et al. demonstrated inhibition of glioma cell xenograft tumor growth by
curcumin [21]. Studies by Anand indicate that in addition to modulating cancer cell proliferation,
angiogenesis and inducing apoptosis, curcumin can affect cancer invasion, and metastasis [22].
The anti-cancer efficacy of curcumin may involve a variety of mechanisms. Study of pancreatic
cancer in nude mice has shown that curcumin can suppress pancreatic cancer cell proliferation and
angiogenesis by inhibiting NF-kB-regulated gene products such as cyclin D1, cmyc, Bcl-2, Bcl-xL,
and apoptosis protein-1, COX-2, MMP, and vascular endothelial growth factor (VEGF) [18]. Various
studies, including the use of lung models, point to curcumin affecting the mechanisms involving
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inhibition of the signal transducer and activation of transcription Stat3 pathways [23], as well as matrix
metalloproteinases and VEGF [18].
Curcumin’s anti-tumor effects may also be due to its interactions with arachidonate metabolism
and in vivo anti-angiogenic properties [24]. Some studies indicate curcumin interacts with vitamin D
receptors, which would explain its preventive properties against colon cancer where vitamin D
has strong anti-cancer effects [25]. Curcumin also appears to work in synergy with isoflavones in
suppressing prostate specific antigen (PSA) production in prostate cells [26]. Gupta et al. have reviewed
clinical trial research on curcumin and have concluded that curcumin, either alone or in combination
with other agents, has demonstrated potential against various cancers, including colorectal, pancreatic,
breast, prostate, lung, multiple myeloma, and head and neck squamous cell carcinoma [27]. Overall,
chemoprevention and anticancer effects of curcumin are multimodal and complex. Molecular pathways
and targets modulated by curcumin have been discussed in details in other review articles [28,29].
3.2. Quercetin
Cancer preventive effects of quercetin include induction of cell cycle arrest, apoptosis and
antioxidant functions [30]. Induction of apoptosis by quercetin in cancer cells during different cell
cycle stages without affecting normal cells has been documented in various cancers in vivo and
in vitro [30]. Quercetin has been reported to reduce both the risk and progression of cancer through
their free radical scavenging activity [31,32]. It protects cells from oxidative stress, inflammation,
and DNA damage due to its antioxidant properties and modulates growth of many cancer cell lines
by blocking cell cycle progression and tumor cell proliferation and by inducing apoptosis [33–36].
In addition, quercetin provided protection against liver cancer development in rats injected with a
cancer inducer [37]. Furthermore, injection of quercetin directly into breast tumors led to a significant
reduction of their mass [38]. Epidemiological studies report that intake of quercetin-rich food reduced
the risk of gastric cancer by 43% [31] and colon cancer by 32% [39]. Consumption of quercetin was
also reported to reduce lung cancer risk by 51% and even in heavy smokers by 65% [32]. Intravenous
administration of quercetin in patients with different types of cancer demonstrated decreased activity of
the enzyme tyrosine kinase, an enzyme required for tumor growth, in nine of 11 patients [40]. There is
a growing interest among scientists in exploring synergistic interactions of quercetin with standard
chemotherapeutics. Both in vitro and in vivo studies have shown that quercetin can potentiate the
efficacy of concomitant drugs by enhancing their bioavailability and accumulation, and by sensitizing
cancer cells to these chemotherapeutics [41]. From a clinical perspective, this would allow dose
reduction of toxic drugs, thereby alleviating their severe side effects.
3.3. Resveratrol
Resveratrol has demonstrated to be effective in preventing all stages of cancer development
and has been found effective in most cancers including prostate, breast, stomach, colon, lung,
thyroid and pancreatic cancer cell lines [42]. Bishayee et al. reported that resveratrol can affect
carcinogenesis by modulating signal transduction pathways that control cell division and growth,
apoptosis, inflammation, angiogenesis and metastasis [43]. In vivo, resveratrol has shown efficacy in
preventing and treating skin, esophageal, intestinal, and colon tumors [44]. Various anti-cancer cellular
mechanisms of resveratrol have been suggested, including inhibition of angiogenesis, metastasis and
induction of apoptosis [38]. Resveratrol has been studied in patients with colon cancer to evaluate
the pharmacokinetic and metabolite profiles in these patients [45]. In addition, resveratrol studied in
healthy volunteers demonstrated that it is well tolerated and modulates enzyme systems involved
in carcinogen activation and detoxification [46]. Resveratrol has promising anti-cancer potential but,
because of its poor bioavailability, the best efficacy has been limited to tumors it can come into direct
contact with (e.g., skin cancers or gastrointestinal tract cancers).
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3.4. Cruciferous Plant Extracts
Cruciferous vegetables of the Brassica genus, such as broccoli, cabbage, cauliflower and others
contain a number of nutrients and phytochemicals with cancer preventive properties, including
carotenoids, chlorophyll and fibers. Their unique anti-cancer characteristic relates to being a source of
large quantities of sulfur containing natural compounds known as glucosinolates [47]. After hydrolysis
they form bioactive isothiocyanates and indole-3-carbinol [48,49]. By 2011 more than 132 glucosinolates
with their unique hydrolysis products had been identified in plants [50]. Epidemiological evidence
suggests that high intake of cruciferous vegetables can lower risk of some cancers, including colon
and lung cancers [48]. Numerous in vitro and in vivo studies suggest that dietary compounds from
cruciferous plants may have potent chemopreventive properties by acting through different molecular
mechanisms [51–56]. This includes many studies, which have shown that cruciferous vegetables can
help prevent the onset and inhibit the progression of colon, breast, prostate, thyroid, cervical, and other
cancers [57–66]. It has been shown that cruciferous bioactive components can facilitate detoxification
and excretion of carcinogens, protect against oxidative stress, inhibit cancer cell proliferation and
increase apoptosis, resulting in inhibition of tumor growth [67].
3.5. Green Tea
Green tea extract, rich in catechins, has been subjected to numerous studies and shown to
modulate cancer cell growth, metastasis, angiogenesis, and other aspects of cancer progression
by affecting different mechanisms [68–73]. The four principal tea catechins are epicatechin (EC),
epicatechin-3-gallate (ECG), epigallocatechin (EGC) and epigallocatechin-3-gallate (EGCG) [74]. It has
been shown that three of these catechins, EGCG, EGC and ECG, have anticancer preventive activity,
and that their combination with an inactive EC has synergistic effect on prostate cancer cells PC-9, by
inducing apoptosis and inhibiting proliferation [75].
The most studied of all green tea catechins in relation to cancer is EGCG, which is found at
the highest concentration in green tea (10%–15%) [75]. Gupta et al. demonstrated that EGCG
potently induced apoptosis and suppressed cell growth in vitro by modulating expression of cell
cycle regulatory proteins, activating killer caspases, and suppressing activation of NF-κB [76]. Harakeh
et al. demonstrated the anti-proliferative and pro-apoptotic effects of EGCG in HTLV-1-positive and
-negative cells. These effects included down-regulation of TGF-alpha, up-regulation of TGF-beta2,
increased cell distribution in pre-G(1) phase and upregulation of p53, Bax and p21 proteins expression
while down-regulating Bcl-2alpha [73]. EGCG was reported to control and promote IL-23 dependent
DNA repair, enhance cytotoxic T-cell activities and block cancer development by inhibiting carcinogenic
signal transduction pathways [77]. EGCG was also shown to modulate several biological pathways,
including growth factor-mediated pathway, the mitogen activated protein kinase-dependent pathway,
and ubiquitin/proteasome degradation pathways [78]. Clinically, in a study of over 8000 individuals,
daily consumption of green tea demonstrated delayed cancer onset; furthermore, breast cancer patients
experienced a lower recurrence rate and longer remission [75]. Another clinical study found that oral
ingestion of EGCG (200 mg per os) for 12 weeks was effective in patients with human papilloma
virus-infected cervical lesions [79].
While EGCG is the most studied catechin in cancer, the in vitro study in human pancreatic ductal
adenocarcinoma (PDAC) cells showed that two minor green tea catechins, ECG and EG, had much
stronger anti proliferative and anti-inflammatory effects, including inhibition of NF-κB, IL8 and uPA,
than EGCG [80].
Epigallocatechin gallate (EGCG) has poor bioavailability in rats and humans due to oxidation,
metabolism and its efflux. In addition, specific interactions with other polyphenolic compounds can
modulate its metabolic efficacy. However, a study by Kale et al. [81] showed that green tea extract
consumed together with onion, which is rich in quercetin, can significantly enhance bioavailability
of EGCG in humans. Wang et al. confirmed this effect, showing that quercetin affects EGCG by
decreasing its methylation [82]. EGCG-quercetin interactions resulted in enhanced anti-proliferative
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effects of EGCG in androgen-dependent and androgen-independent prostate cancer cells [83]. EGCG
bioavailability is affected by numerous compounds as its consumption with cereal and milk resulted
in lower EGCG blood levels [84]. This indicates that proper selection of compounds and their
combinations are important in achieving the desired biological effect.
4. Benefits of Nutrient Combinations—Pleiotropic Effects
Numerous in vitro and in vivo studies provide support for use of polyphenols in cancer
prevention by applying them in combinations with other micronutrients for achieving pleiotropic
effects. As mentioned previously, one of major problems with using polyphenols as anticancer agents
individually is their poor bioavailability in the human body. In addition, their interactions with other
natural compounds in a diet may hinder or complicate consistency of their efficacy [85]. Therefore,
specifically designed combinations of several polyphenols or combinations of polyphenols with other
natural agents aimed at defined biological targets will expand metabolic effects of constituents of such
mixtures in controlled and reproducible ways. In addition, proper combinations of micronutrients
enable use of lower doses of individual components without compromising their efficacy, rather than
expanding the scope of cellular mechanisms affected. This novel approach opens up a possibility of
developing more effective strategies against various human pathologies, including cancer.
Several in vitro and in vivo studies have shown that combinations of two or three polyphenols
were more effective in inhibiting cancer growth than treatment with a single compound. Our research
has demonstrated that multi-nutrient combinations, through their reciprocal interactions, including
synergy, can modulate bioavailability of natural compounds and exercise pleiotropic effects by affecting
multiple metabolic pathways involved in carcinogenesis simultaneously. Below we present a few
examples of specific and effective anti-cancer nutrient mixtures. They include a combination of
different polyphenols and combinations of polyphenols with vitamins and other micronutrients, which
were selected to specifically target defined key cellular mechanisms involved in carcinogenesis.
4.1. Anticancer Effects of a Combination of Different Polyphenols
Several studies investigated the efficacy of mixtures containing two or three different polyphenols.
These include combinations of EGCG with quercetin in prostate cancer cells [86,87], and EGCG with
resveratrol in prostate cancer cell lines [88] and breast cancer MCF-7 cell line [89]. Combinations studied
also included curcumin with EGCG and EC in lung cancer cell lines [90,91], curcumin with EGCG in
human B-cell chronic leukemia [92] and in xenograft mouse models implanted with MDA-MB-231
breast cancer cells [93] and lung A549 cells [91]. Piao et al. [94] demonstrated anti-cancer effects
of a tri-nutrient combination composed of curcumin, resveratrol and epicatechin gallate on cell
viability, clonogenic survival, apoptosis and tumor growth in HPV-positive head and neck squamous
cell carcinoma.
These findings indicate that more comprehensive mixtures of nutrients with similar or complementary
anti-cancer mechanisms would allow for enhanced complementary or synergistic interactions between
these compounds, thereby expanding different cancer mechanisms simultaneously and in a controlled
fashion. Therefore, we combined the compounds previously investigated in combinations and
cruciferous extract in order to enhance and expand their anti-cancer mechanisms through additive
and synergistic effects. This mixture of nutrients (PB) included: quercetin, 400 mg; Cruciferex™
(prioprietary extract from cabbage, cauliflower, broccoli and carrots), 400 mg; turmeric root extract
containing 95% curcuminoids, 300 mg; resveratrol, 50 mg; and standardized green tea extract
(80% polyphenols), 300 mg. See Table 1 for summary of PB studies using in vitro and in vivo
approaches. These included human Fanconi anemia head and neck squamous cell carcinoma
(HNSCC), which with acute myeloid leukemia, are the major causes of mortality and morbidity in
Fanconi anemia patients. We found that nude mice injected with OHSU-974 cells and subsequently
fed a diet supplemented with 1% PB demonstrated inhibition of tumor growth by 67.6% (p < 0.0001)
and tumor burden by 63.6% (p < 0.0001) [95]. In vitro study demonstrated dose-dependent inhibition
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of OSHU-974 cell proliferation, with cell toxicity detected at 27% (p = 0.0003) and 48% (p = 0.0004) at
PB concentrations of 75 and 100 μg/mL, respectively [95]. These cells constitutively secrete matrix
metalloproteinase (MMP)-2 and, after stimulation by phorbyl 12-myristate (PMA), also MMP-9.
The secretion of MMPs by both stimulated and unstimulated cells was suppressed by PB in a
dose-dependent manner, with total block of both at 50 μg/mL, which is below PB’s toxicity level [95].
This concentration was also effective in inhibiting cancer cell migration (by scratch test) and invasion
through Matrigel, apparently not related to cell toxicity, as no visible morphological changes were
detected at this and lower concentrations [95].
Table 1. Anticancer effect of polyphenol mixture containing quercetin, curcumin, green tea,
Cruciferex™, and resveratrol (PB) on cancer cell lines.
Cancer Cell Line and in Vivo Design Tumor Growth Inhibition In Vitro Inhibition
FA HNSCC
Athymic male nude mice injected SQ
with 3 × 106 OHSU-974 cells
Control group fed regular murine diet
and PB group diet supplemented with
PB 1% × 4 weeks [95]
Tumor weight by 67.6%
(p < 0.0001)
Tumor burden by 63.6%
Cell proliferation inhibited by 48% at 100 μg/mL PB; MMP-2 and -9
completely blocked at 50 μg/mL PB; cell migration and Matrigel
invasion blocked at 50 μg/mL PB
Fibrosarcoma HT-1080 [96] N/A
HT-1080 cell proliferation inhibited by 80% at 50 μg/mL PB; MMP-2
and -9 completely blocked at 50 μg/mL PB; Matrigel invasion
blocked at 25 μg/mL PB; induction of dose-dependent apoptosis
Melanoma A-2058 [97] N/A
A-2058 cell proliferation inhibited by 80% at 25 μg/mL PB; MMP-2
and -9 completely blocked at 50 μg/mL PB; Matrigel invasion
blocked at 50 μg/mL PB; induction of dose-dependent apoptosis
The inhibitory effects of PB were also observed in fibrosarcoma, which is an aggressive and
highly metastatic cancer of connective tissue, and in melanoma, which causes the majority of skin
cancer-related deaths, secondary to metastasis. The in vitro studies used human fibrosarcoma cell line
HT-1080 [96] and melanoma A2058 cells [97]. The study showed that PB inhibited cell proliferation of
human fibrosarcoma cells by 60% at 25 μg/mL and 80% at 50 μg/mL, and inhibited both MMP-2 and
-9 secretion in a dose-dependent manner, with total inhibition at 50 μg/mL [96]. At PB concentration
of 25 μg/mL, invasion of HT-1080 cells through Matrigel was totally blocked [96]. Melanoma cells
were more sensitive to PB, as their proliferation was inhibited by 80% at 25 ug/mL and MMP-2 and -9
secretion and Matrigel cell invasion blocked completely at 50 μg/mL, indicating strong anti-invasive
properties of this polyphenol mixture [97]. PB also induced cell apoptosis in both cell lines in a
dose-dependent fashion.
4.2. Anticancer Effects of Combinations of Polyphenols, with Vitamins and Other Compounds
Combinations of polyphenols with mixtures of vitamins, amino acids and other micronutrients
are rarely utilized in cancer research. We initiated this multi-targeted approach over a decade ago,
demonstrating that a combination of EGCG with specific micronutrients showed anti-proliferative
and anti-invasive effects in human breast (MDA-MB-231), colon (HCT 116) and melanoma (A-2058)
cancer cells [98]. The investigated combination included EGCG from green tea together with ascorbic
acid, lysine, proline, arginine, N-acetyl cysteine, selenium, copper and manganese. This mixture,
designated as NM, was tested in vitro and in vivo against a few dozen human cancer cell lines.
The composition of this specific micronutrient mixture exemplifies the importance of extracellular
matrix-mediated processes in developing a general strategy of effective control of cancer. While most
of natural compound combinations target intracellular regulatory mechanisms of tumorigenesis, our
approach expands it to include connective tissue integrity as a common element involved in tumor
growth, invasion and metastasis. The role of this natural anti-cancer barrier is frequently overlooked in
therapeutic approaches to cancer. However, all critical metabolic steps in cancer require degradation of
basement membrane and extracellular matrix components as the physical barrier restraining growth,
migration and invasion of tumor cells. Increased activity of proteinases, such as MMPs and plasmin,
accompanied by down-regulation of their natural inhibitors has been correlated with aggressiveness
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of cancer and angiogenesis, associated with neovascularization of tumors [99,100]. This new approach
to curbing cancer growth by strengthening the connective tissue in the body was introduced by
Rath in the 1990s [101]. This can be achieved with micronutrients essential for the synthesis and
structure of connective tissue (vitamin C, lysine, proline, and copper manganese) and inhibitors of
enzymatic breakdown of collagen facilitated by malignant cells (i.e., lysine). In addition to its essential
role in collagen production, vitamin C has shown to be an effective anti-cancer agent (pro-oxidant
effects) [102,103] and in cancer prevention (antioxidant effects) [104]. The presence of polyphenols in
this mixture, in addition to selenium, N-acetylcysteine and arginine allows for expanding biological
targets and enhancing several cellular mechanisms important in controlling cancer, such as immune
system function. The mixture was formulated in two variants in regard to its polyphenol components:
including both EGCG and quercetin (EPQ) and containing EGCG (NM) as the sole polyphenol. Both
compositions were tested against several human and murine cancer cell lines both in vivo and in vitro.
4.2.1. EGCG in Combination with Vitamin C, Amino Acids and Other Micronutrients
The multiple aspects of anticancer efficacy of the combination of green tea extract rich in EGCG
with ascorbic acid, lysine, proline, arginine, N-acetylcysteine, selenium, copper and manganese (NM)
on several cancer cell lines in vivo and in vitro were presented in a review article [105].
This unique mixture demonstrated potent, significant suppression of hepatic and pulmonary
metastasis in a murine model resulting in significant reduction in tumor size and tumor burden in all
human cancer cell lines tested. In vitro studies demonstrated that NM was very effective in inhibition
of cell proliferation (by MTT assay), MMP secretion (by gelatinase zymography), cell invasion (through
Matrigel), cell migration (by scratch test), angiogenesis (VEGF and other angiogenic models), induction
of apoptosis (by live green caspase) and induction of pro-apoptotic genes in many diverse cancer cell
lines. A more recent study conducted with the NM mixture illustrates its efficacy against multiple
parameters of cancer growth and progression in vivo and in vitro. We used an orthotopic breast cancer
model to evaluate the development of tumors and metastasis, challenging mice with breast cancer
4T1 cells into the mammary pad, and also studied in vitro activity of NM on cell proliferation, MMP
secretion, cell migration and invasion [106]. See Table 2 for summary of results. In contrast to human
tumor cell models, murine tumor cell models often metastasize more effectively and display metastatic
characteristics more similar to those observed in cancer patients. The 4T1 mammary carcinoma model
was chosen since the primary tumor grows in the anatomically correct site and, as in human breast
cancer, 4T1 metastatic disease develops spontaneously from the primary tumor. In addition, metastatic
spread of 4T1 metastases to other organs and the draining lymph nodes is similar to that of human
mammary cancer. The results showed that NM inhibited tumor weight and burden by 50% (p = 0.02)
and 53.4% (p < 0.0001), respectively, and metastasis, by reducing mean number of colonies by 87%
(p < 0.0001) and mean weight of lungs by 60% (p = 0.0001) compared to Control mice [106]. Metastasis
to liver, spleen, kidney and heart was significantly reduced with NM supplementation [106].
Table 2. Anticancer effect of the combination of green tea extract with ascorbic acid, lysine, proline,
arginine, N-acetyl cysteine, selenium, copper and manganese (NM) on breast 4T1 tumor [106].
Tumor Cell Line/In Vivo Design Tumor Growth and Metastasis In Vitro Results
Orthotopic injection of 5 × 105 breast
cancer 4T1 cells into the mammary
pad of Balb C mice
Control group fed regular murine diet
and NM group diet supplemented
with NM 0.5% × 4 weeks
Tumor weight reduced by 50%
(p = 0.02) and tumor burden by
53.4% (p < 0.0001) in NM mice
compared to Control mice
Lung metastasis inhibited by 87%
(p < 0.0001) in NM mice compared
to Control mice
Mean weight of lungs reduced by
60% (p = 0.0001)
Metastasis to liver, spleen, kidney
and heart significantly reduced in
NM group compared to Control
Cell proliferation reduced by 50% at
250 μg/mL NM
MMP-2 and -9 completely blocked at
1000 μg/mL NM
Cell migration and Matrigel invasion
blocked at 250 μg/mL NM
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4.2.2. Inhibitory Effects of EGCG Applied Individually, and in Combination with Other Micronutrients
on MMPs
In a previous study, we compared the anticancer effects of EGCG alone, in green tea and in
combinations with micronutrients on the critical aspect of malignancy. Since type IV collagenase
matrix metalloproteinases, especially MMP-2 and MMP-9, have been found to promote invasion and
metastasis of malignant tumors, we investigated the relative inhibitory effects in MMP-2 and -9 by
EGCG, the main polyphenol in green tea extract (GTE) to that of GTE and to that of NM as a whole
using four cancer cell lines expressing MMP-2, MMP-9 or both, to determine if there is an additive
or synergistic effect from combinations of these agents [107]. The cell lines tested included human
fibrosarcoma (HT-1080), hepatocellular carcinoma (SK-Hep-1), glioblastoma (T-98G) and uterine
leiomyosarcoma (SK-UT-1). The cells were also treated with PMA 100 ng/mL to study enhanced
expression of MMP-9. Secretion of MMPs was assessed by gelatinase zymography. Fibrosarcoma and
hepatocellular carcinoma cells expressed both MMP-2 and MMP-9, glioblastoma cells MMP-2 and
PMA-induced MMP-9, and uterine leimyosarcoma cells only PMA-induced MMP-9. NM was the most
potent dose-dependent inhibitor of MMPs, followed by green tea extract and EGCG. See Table 3 for
summary of results. These results suggest the enhanced efficacy of nutrients working in synergy to
modulate complex pathways such as MMP expression.
Table 3. Comparative cumulative expression of MMP-2 and -9 in cell lines treated with epigallocatechin
gallate (EGCG), green tea extract (GTE) and the nutrient mixture (NM) [107].
EGCG GTE NM EGCG + PMA GTE + PMA NM + PMA
Fibrosarcoma HT-1080
MMP-2 7.88 7.47 3.29 0.21 0.20 0
MMP-9 5.74 3.02 1.58 209.06 139.84 93.54
Hepatocellular carcinoma Sk-Hep-1
MMP-2 1.21 1.10 0 0.77 0.55 0.29
MMP-9 256.51 187.28 26.59 611.90 593.80 508.28
Glioblastoma T-98G
MMP-2 109.97 86.63 65.84 178.16 140.09 53.20
MMP-9 0.37 0.37 0.10 92.69 82.67 52.50
Uterine leimyosarcoma SK-UT-1
MMP-2 0 0 0 51.36 49.97 34.30
MMP-9 0 0 0 87.42 87.30 77.95
4.2.3. Quercetin in Enhancing the Micronutrient Mixture Efficacy in Established Breast Cancer Tumors
We observed that including quercetin in the nutrient mixture containing EGCG has beneficial
effects when administered to rats at early stages of breast tumor growth. Breast tumors were induced
by IP administration of N-methyl-N-nitrosourea to Wistar rats [108]. After tumors were evident in all
rats, the animals were divided into groups and fed one of the following regimens for 60 days: control
diet; 30 mg green tea extract alone; 30 mg green tea extract in combination with NM; or a diet containing
30 mg of green tea extract, NM and quercetin. The results showed that tumor size/rat was significantly
lower in all supplemented groups than in the Control group. The rats on the diet containing NM and
quercetin showed significantly lower values for tumor incidence, mean tumor volume and mean tumor
weight compared to the Control, the green tea extract and the NM groups [108]. Rats in the Control
group developed 24 carcinomas (mostly of grade III severity), contrasted with six carcinomas (all of
which were of grade II severity) in the NM supplemented group containing quercetin. The incidence,
mean tumor volume and mean tumor weight of the green tea extract group alone (2.0, 7.27 cc, and
5.33 g, respectively) were higher than those of the NM group (1.4, 3.39 cc, and 1.71 g, respectively), and
that was greater than that of the quercetin + NM group (1.0, 2.69 cc, and 1.35 g, respectively); however,
the differences did not reach statistical significance. Higher anti-cancer efficacy of the mixture in the
presence of quercetin might be related to its effects on EGCG bioavailability, as the results showed
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that administration of EGCG in the mixture with vitamins, amino acids and trace element (NM)
resulted in a modest increase of its plasma concentration to 45.81 ng/mL from 35.84 ng/mL with
EGCG administered alone. The enrichment of this mixture with quercetin resulted in increased plasma
EGCG level to 65.94 ng/mL.
4.2.4. Anticancer Effects of EGCG plus Quercetin in the Micronutrient Mixture
The studies presented below illustrate the anti-cancer potential of EGCG and quercetin in
combination with the micronutrient mixture against ovarian cancer using two different cell lines
(ES-2 and A-2780) [109,110]. See Table 4 for summary of results. EPQ contains the following nutrients
in the relative amounts indicated: vitamin C (as ascorbic acid and as Mg, Ca ascorbates, and ascorbyl
palmitate) 700 mg; L-lysine 1000 mg; L-proline 750 mg; L-arginine 500 mg; N-acetyl cysteine 200 mg;
standardized green tea extract (80% polyphenol) 1000 mg; quercetin as quercetin dihydrate, from
Saphora japonica 50 mg; selenium 30 μg; copper 2 mg; manganese 1 mg.
Table 4. Anticancer effect of mixture containing polyphenols quercetin and green tea extract with
ascorbic acid, lysine, proline, arginine, N-acetyl cysteine, selenium, copper and manganese (EPQ).
Cancer Cell Line and in Vivo Design Tumor Growth and Metastasis Inhibition In Vitro Inhibition
Athymic female mice inoculated
subcutaneously with 3 × 106 ovarian
ES-2 cells
Control group fed regular murine diet
and EPQ group diet supplemented
with EPQ 0.5% × 4 weeks [109]
Tumor weight reduced by 59.2% (p < 0.0001) and
tumor burden by 59.7% p < 0.0001) in EPQ mice
ES-2 cell proliferation inhibited by
35% at 1000 μg/mL EPQ; MMP-2
virtual total block at 1000 μg/mL EPQ;
cell migration and Matrigel invasion
blocked at 500 μg/mL EPQ
Athymic female mice inoculated
intraperitoneally with 2 × 106 ovarian
A-2780 cells
Control group fed regular murine diet
and EPQ group diet supplemented
with EPQ 0.5% × 4 weeks [110]
Incidence of ovarian tumors reduced to 1 small
tumor in EPQ group contrasted with Control group
mice which all developed large ovarian tumors;
tumor growth suppressed by 87% (p < 0.0001);
lung metastasis completely suppressed in EPQ
mice, but 100% present in Control mice
A-2780 cell proliferation inhibited by
80% at 1000 μg/mL EPQ; MMP-9
virtual total block at 250 μg/mL EPQ;
Matrigel invasion blocked at
250 μg/mL EPQ
Epithelial ovarian carcinoma is the leading cause of death from gynecological malignancy due to
metastasis and recurrence. Our previous publication on athymic female mice inoculated with ES-2
ovarian cancer cells showed that dietary intake of EPQ (0.5%, w/w) inhibited weight and burden of
tumors by 59.2% (p < 0.0001) and 59.7% (p < 0.0001), respectively [109] (see Figure 1). A subsequent
study on ovarian carcinoma used IP injection of ovarian cancer A-2780 cells into athymic female mice
and focused on ovarian tumor growth and lung metastasis [110]. In the A-2780 study, all Control
mice developed large ovarian tumors, whereas five out of six mice in the EPQ group developed
no tumors, and one, only a small tumor [110]. EPQ suppressed tumor growth by 87% (p < 0.0001).
In addition, all animals in the Control group had lung metastasis while, in contrast, no metastasis
was observed in the EPQ group of mice [110]. In vitro, the effects of EPQ on cell proliferation, MMP
secretion, invasion through Matrigel, migration by scratch test and morphology were evaluated in
ES-2 [109] and A2780 [110] cells. EPQ exhibited 35% toxicity over the control in ES-2 cells [109] and
80% in A-2780 cells [110] at 1000 μg/mL concentration. ES-2 cells demonstrated only MMP-2, with
and without PMA, which was inhibited by EPQ in a dose dependent fashion, with near total inhibition
at 1000 μg/mL [109]. A-2780 cells demonstrated only MMP-9 expression, which EPQ inhibited in
a dose dependent fashion, with virtual total block at 250 μg/mL concentration [110]. Migration of
ES-2 cells by scratch test and invasion through Matrigel were inhibited in a dose dependent manner
with total block of invasion and migration at 500 μg/mL [109]. Invasion through Matrigel of A-2780
cells was completely inhibited by EPQ at 250 μg/mL [110]. H&E staining showed no morphological
changes below 500 μg/mL EPQ in A-2780 cells [110] and below 1000 μg/mL EPQ in ES-2 cells [109].
See Table 4 for summary of results.
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Figure 1. Gross photographs of representative tumors from Control and EPQ groups of mice inoculated
with ovarian cancer ES-2 cells. Mean tumor weight and burden of EPQ group tumors were inhibited
by 59.2% (p < 0.0001) and 59.7% (p < 0.0001) compared to Control group, respectively.
An earlier study investigated the efficacy of a combination of polyphenols, quercetin and green
tea, on prostate cancer xenograft tumor growth. The results confirmed the synergistic effects of this
nutrient combination resulting in tumor growth inhibition by 45%, compared to 15% with quercetin
and 21% with green tea only [111]. Although the experimental design and tumor type differed in
the Wang studies from our research, both investigations point out to enhance anticancer effects of
various nutrient combinations and the importance of connective tissue in confining tumor growth
and metastasis.
5. Conclusions
Current cancer therapies based on chemotherapy and radiation are associated with significant
side effects. Therefore, there is an urgent need for developing alternate or adjuvant approaches.
Polyphenolic compounds, which are abundant from dietary sources, show great promise in cancer
treatment, especially considering their safe use. Due to their ability to modulate multiple biological
mechanisms involved in cancer initiation and progression, they offer more comprehensive therapeutic
effects than single drugs. Bioavailability, as well as curative and preventive properties of these
nutrients, can be enhanced and expanded in combination therapies that include natural compounds
of the same or different chemical class. Combinations of polyphenols with micronutrients essential
for maintaining integrity and stability of extracellular matrix offer expanded anti-cancer benefits.
They include targeting complementary metabolic pathways important in curtailing cancer invasion
and metastasis. Therefore, future research directions should expand to using natural compounds,
especially in combinations, as safe, effective and affordable therapeutic approaches to cancer.
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Abstract: Evidence from numerous observational and clinical studies suggest that polyphenolic
phytochemicals such as phenolic acids in olive oil, flavonols in tea, chocolate and grapes, and
isoflavones in soy products reduce the risk of breast cancer. A dietary food pattern naturally rich
in polyphenols is the Mediterranean diet and evidence suggests those of Mediterranean descent
have a lower breast cancer incidence. Whilst dietary polyphenols have been the subject of breast
cancer risk-reduction, this review will focus on the clinical effects of polyphenols on reducing
recurrence. Overall, we recommend breast cancer patients consume a diet naturally high in flavonol
polyphenols including tea, vegetables (onion, broccoli), and fruit (apples, citrus). At least five servings
of vegetables and fruit daily appear protective. Moderate soy protein consumption (5–10 g daily) and
the Mediterranean dietary pattern show the most promise for breast cancer patients. In this review,
we present an overview of clinical trials on supplementary polyphenols of dietary patterns rich in
polyphenols on breast cancer recurrence, mechanistic data, and novel delivery systems currently
being researched.
Keywords: polyphenols; breast cancer; human trials
1. Introduction
Breast cancer is the most commonly diagnosed cancer in females worldwide [1]. Diet-related
factors are thought to account for around 30% of all cancer in developed countries, with breast cancer
being no exception. Obesity, a lack of physical activity, and, to a lesser extent, alcohol increase the
risk of breast cancer [2], whereas consumption of vegetables, fruits, legumes, grains, and green tea
appear to be protective [3]. In particular, several plant components especially phytochemicals may
protect against DNA damage and block specific carcinogen pathways. There are a multitude of in vitro
studies outlining the effect specific dietary components have on breast cancer; however, interpretation
and clinical application of such studies is problematic, as cell-based studies fail to account for human
absorption and metabolism. Presently, there are very few evidence-based nutrition guidelines for
breast cancer survivors to follow and many are confused about nutrition support post-diagnosis.
Secondary prevention or adjunct therapy through dietary intervention is a cost-effective alternative
for preventing the large burden of healthcare associated with breast cancer treatment. In the past
decade, epidemiologic and preclinical evidence suggest that polyphenolic phytochemicals present in
many plant foods possess chemo-preventive properties against breast cancer [2]. Epidemiological data
suggests dietary patterns naturally rich in polyphenols are protective against breast cancer. Whilst
data on the nutritional aspect of cancer prevention and the reduction of risk are important, the degree
to which the outcomes that can be applied to reducing cancer recurrence is questionable. Increasing
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evidence suggests that diets providing a variety of polyphenols are useful with regard to breast cancer
prevention and cessation.
The health benefits of polyphenols have been linked mostly to their antioxidant effects. Although
this is an important contributor, polyphenol phytochemicals also interact with other pathways,
especially receptor signalling. Polyphenols have been reported to reduce inflammation and cancer
recurrence by (a) acting as an antioxidant or increasing antioxidant gene or protein expression;
(b) decreasing cancer cell proliferation; (c) blocking pro-inflammatory cytokines or endotoxin-mediated
kinases and transcription factors involved in cancer progression; (d) increasing histone deacetylase
activity; or (e) activating transcription factors that antagonize chronic inflammation [4,5]. Polyphenol
phytochemicals can interfere with both estrogen receptor (ER) and tyrosine kinase receptor (TKR)
signalling, thereby inducing apoptotic and/or autophagy cell death. Estrogen receptors are central to
the development of primary and secondary breast cancers. Estrogen binds membrane-initiated steroid
signalling (MISS) or TKR to initiate a cascade of effects via estrogen response elements (ERE), AP-1,
SP1, and other transcription factors to activate pro-apoptotic genes [6]. There are some indications that
polyphenols can bind ER with varying affinities. Thus, it is clear that targeting these ER pathways
using dietary polyphenols may affect the development of both primary and secondary breast cancer.
The importance of other dietary factors, including meat, fibre, and vitamins, is not yet clear [7]. There
has been interest in the potential of naturally occurring cancer chemo-preventive agents, such as
polyphenols, to curb the increasing burden of breast cancer treatment [8,9]. Dietary polyphenols may
support current medical treatment options to improve prognosis.
This article reviews the current literature on breast cancer clinical trials of polyphenolic
phytochemicals with an aim to identify potential nutritional strategies for breast cancer
patients, post-diagnosis.
2. Methods
The current review discusses the evidence on dietary polyphenols and food patterns naturally high
in polyphenols and breast cancer recurrence or relevant biomarkers. In selecting the literature to review,
studies that addressed the prognosis and recurrence of breast cancer in survivors were identified.
Inclusion criteria included any breast cancer stage and type, human trials only, and intervention
commenced after breast cancer diagnosis. Particular attention has been given to human randomised
control trials and observational studies on breast cancer survivors. Studies included in Table 1 were
human data and must have investigated polyphenol-rich dietary intake or supplements. For inclusion,
our definition of a “polyphenol rich diet” were those investigating vegetables (onion, broccoli) and
fruit (apples, citrus). Articles from any date of publication or language were considered. PubMed,
Google Scholar, and PEN—Practice-Based Nutrition Database—were searched using various key
terms, including “breast cancer”, “nutrition”, “polyphenol”, and “human”. Abstracts were reviewed
for relevant material.
Table 1. Clinical studies of polyphenols in breast cancer patients. Table includes human studies only






Rock, Natarajan et al.,
2009 [10]
Design; Observational. Assessed
intake of vegetables, fruit and




Greater intake of fruit and vegetables
naturally high in polyphenols and
carotenoids, was associated with
improved likelihood of breast
cancer–free survival regardless of study
group assignment. HR = 0.67
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dietary intake of fruit and
vegetable consumption. Outcome:
risk of breast cancer
5707 BCa patients;
6389 Controls
A high consumption of fruit and
vegetables naturally high in
polyphenols and carotenoids may
reduce the risk of premenopausal but
not postmenopausal breast cancer,
particularly among smokers
Baglietto, Krishnan
et al., 2011 [12]
Design: Observational. Assessed
dietary intake patterns. Outcome:




A dietary pattern rich in fruit and
salad might protect against invasive
breast cancer and that the effect might




Caan, B.J. et al.,
2007 [13]
Design: Intervention Education to
promote 5 servings of fruit and




Among survivors of early stage breast
cancer, adoption of a diet that was very
high in vegetables, fruit, and fibre and
low in fat did not reduce additional
breast cancer events or mortality during
a 7.3-year follow-up period.
Unfortunately, the control group also
received written education material
Sartippour M.R.,
Rao J.Y., Apple S.,
Wu et al., 2004 [14]
Design: Intervention. 200 mg
isoflavones for 2-weeks.
Assessment: Direct breast tissue
samples from patients were
assessed for cancer growth
17 BCa patients;
26 Controls No change in apoptosis/mitosis ratio
DiSilvestro R.A.,
Goodman, J., Dy, E.,
Lavalle, G. 2005 [15]
Design: Intervention. 138 mg
isoflavones for 24-days.
Assessment: Blood samples were
assessed for oxidative status
7 BCa patients,
crossover design
Increased SOD activity. No change in
oxidative stress markers
Inoue, M., Tajima, K.,





1160 women of which
133 develop BCa
3+ cups of green tea daily was
associated with lower BCa recurrence in
early stages (HR = 0.69, 95%
Cl 0.47–1.00)
3. Discussion
3.1. Dietary Amelioration of Inflammation Associated with Breast Cancer
Many studies suggest that low-grade inflammation is mitigated by healthy dietary habits, such
as polyphenols and the Mediterranean food pattern, resulting in lower circulating concentrations
of inflammatory markers [17]. Western-type or meat-based patterns are positively associated
with low-grade inflammation [18]. Among the components of a healthy diet, whole grains,
vegetables and fruits, and fish are all associated with lower inflammation, and a limited number
of observational studies suggested a pro-inflammatory action of diets rich in saturated fatty
acids or trans-monounsaturated fats [19]. The association between inflammation and cancer has
been reported elsewhere [20], citing major mediators nuclear factor kappa B (NF-κB), tumour
necrosis factor (TNF), and cyclooxygenase-2 (COX-2), given the combined role in inflammation, cell
proliferation, angiogenesis, and metastasis. Inhibition of COX-2 thus blocking the inhibition cascade
may be an important mechanism by which polyphenols exert benefit to the breast cancer patient.
The consumption of polyphenol-rich foods is thought to have an effect in modulating low-grade
inflammation [21].
The inflammatory environment that promotes breast cancer tumour growth links to obesity and
metabolic syndrome. Women who gain weight in adulthood and overweight postmenopausal women
have a greater risk for breast cancer than lean women [22]. However, there are inconsistencies regarding
the effect modification of menopausal status. In contrast, evidence exists showing that overweight and
obesity is associated with reduced risk in premenopausal women [23]. Metabolic syndrome (clinically
defined as having three of the following factors: Abdominal obesity, hypertension, hyperglycemia,
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high triglycerides, or low HDL cholesterol [24] has been associated with a 2.6 times higher risk of
breast cancer in postmenopausal women [25]. It can be deduced that a range of factors, including
age, hormone levels, and obesity and overweight, affect breast cancer risk. Because overweight and
obesity are powerful modifiable risk factors [26], interventions, including dietary intervention, should
be investigated further. Whilst clear evidence links metabolic syndrome with increased risk of breast
cancer, it is also clear that post-diagnosis weight gain occurs in 50%–95% of patients and is associated
with poor prognosis. Excess weight gain is associated with elevated inflammatory markers, against
which polyphenols may protect.
According to a study conducted on rats, dietary supplementation of a high-fat diet and
polyphenols led to dramatic changes in gut microbial community structure [27]. Cranberry polyphenols
protected mice on a high-fat, high-sucrose diet against oxidative stress, inflammation, weight gain, and
markers of metabolic syndrome [28]. Chronic low-grade inflammation promoted by an individual’s
diet and their functioning gut microbiota may influence cancer progression.
Dietary polyphenols may protect against breast cancer progression, despite limited absorption
and digestion, raising questions about their mechanism of action. As discussed, polyphenols appear
to alter gut microbiota in rats and mice and has also been demonstrated in human studies. It was
found that a moderate intake of red wine had positive effects on the composition of the gut microbiota
and a reduction in the inflammatory markers [29]. Polyphenols may assist the breast cancer patient
by minimizing weight gain, improving the inflammatory profile and altering gut microbiota activity,
thus reducing tumour growth.
3.2. Antioxidant Action of Polyphenolics
Polyphenols are secondary metabolites of plants and are generally involved in defense against
ultraviolet radiation or aggression due to their physiological effects and structure [30]. Many of
the biological actions of polyphenols have been attributed to their antioxidant properties; however,
recent research has suggested that polyphenols may affect several cellular pathways, thereby exerting
a pleiotropic effect [31]. Cellular pathways initiated by polyphenols may delay and reduce the
carcinogenic processes in breast tissue [32,33]. Oxidative stress is known to alter the cellular redox
status, resulting in altered gene expression by the activation of several redox-sensitive transcription
factors. This signaling cascade affects both cell growth and cell death. An increased rate of reactive
oxygen species (ROS) production occurs in highly proliferative cancer cells, owing to oncogenic
mutations that promote aberrant metabolism. The ability of dietary polyphenols to modulate cellular
signal transduction pathways, through the activation or repression of multiple redox-sensitive
transcription factors, has been claimed for their potential therapeutic use as chemo-preventive
agents [34].
Red wine polyphenols reduce breast cancer cell proliferation in a dose-dependent manner by
specifically targeting steroid receptors and modifying the production of ROS [4]. However, it should
be noted that it would not be prudent to advise the breast cancer patient to consume alcohol, given
the potentially damaging effects. Phenolic phytochemicals have a strong antioxidant potential due to
the hydroxyl groups associated with their aromatic rings. Phenolic phytochemicals have been shown
to increase the levels of anti-inflammatory genes such as superoxide dismutase (SOD), glutathione
peroxidase (GPx), and heme oxygenase (HO)-1 via activation of the transcription factor nuclear
factor-erythroid 2 (NF-E2)-related factor 2 (Nrf2). Thus, polyphenols have an inherent capacity
to reduce ROS and other free radicals, thereby preventing their activation of oxidative stress and
inflammation [35]. Polyphenols are effective free radical scavengers and their antioxidant properties
should not be overlooked. In a recent meta-analysis of data from 7500 participants, those who reported
a high polyphenol intake, especially of stilbenes and lignans, showed a reduced risk of overall mortality
compared to those with lower intakes [36]. Polyphenols where found to be protective against chronic
disease, implying a change in oxidative status. The antioxidant properties of polyphenols are thought
to delay and to fight the carcinogenic processes in breast tissue [32,33]. Further studies will likely
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provide additional insights into the mechanism of redox control of breast cancer. Whilst polyphenols
appear to reduce oxidative stress, the degree to which breast cancer prognosis is improved is unclear.
3.3. Polyphenols Protect DNA from the Carcinogen-Induced Damage
Chronic activation of inflammatory processes is widely regarded as an enabling characteristic
towards the development of cancer. We know that chronic inflammation can drive tumour growth and
the production of ROS [37]. In turn, ROS can cause DNA damage. Production of ROS, together
with deficiencies in the capacity to repair DNA (genotype dependent), can interact to increase
carcinogenic capabilities [37,38]. Base-excision repair genes, such as XRCC1 G399A [37] and OGG1
C326G, are associated with reduced repair of DNA lesions associated with ROS [39].
The mutagen sensitivity assay (MSA) can be used as a marker of the ability of DNA to respond to
and repair DNA damage and hence it has been used to test response to mutagens and bioactives [38].
The Comet and Micronucleus assays have also been extensively used to determine the extent of DNA
strand breaks and repair [40–42], and there are a number of other methods, including RAD1 focus
formation [43], PCR, and the TUNEL assay, as well as numerous others [44].
Germline mutations in DNA mismatch repair genes (BRCA1, BRCA2, CHEK2, ERCC4, FAAP100,
and TP53BP1, amongst others) are associated with breast cancer susceptibility [45,46]. In some
cases, it may be possible to modify diet to help decrease the risk of breast cancer and breast cancer
recurrence [45]. In a study of triple negative breast cancer (TNBC) patients, Lee et al. assessed 16 single
nucleotide polymorphisms (SNPs) associated with DNA repair [45]. The authors found that the risk
of TNBC was associated with six of the SNPs and that this risk was modified by zinc, folate, and
β-carotene levels such that low levels increased risk [45]. These effects were additive. In other studies,
it has been reported that high plasma levels of β-carotene, or the consumption of a carotenoid rich diet,
were associated with lower levels of breast cancer or breast cancer recurrence [10,11] or a reduction in
oxidative stress in those previously treated for breast cancer [47]. Others found that diets rich in fruits
and salads, a food pattern traditionally high in polyphenols, was associated with a reduced risk of
breast cancer, particularly estrogen and progesterone receptor negative breast cancers [12].
Polyphenols can act as pro- and anti-oxidants, depending on the experimental or environmental
conditions [41], and may modify the interaction between carcinogenic capabilities and breast cancer
risk. In addition, polyphenols may enhance repair or change methylation status of promoter regions
to favour DNA repair, or protect against DNA damage. Adams et al. found that polyphenols from
blueberries inhibited cell proliferation and cell migration in human TNBC cell lines [48] and decreased
tumour size and inhibited metastasis in a TNBC xenograft study in mice [49]. Similarly, Meeran et al.
assessed the effect of Epigallocatechin-3-gallate (EGCG) and sulforaphane, an isothiocynate derived
predominantly from plants of the order Brassicales and known to have strong chemo-preventative
and anti-inflammatory properties on breast cancer cell lines [50,51]. They found that sulforaphane
and EGCG inhibited cell proliferation, telomerase activity, and human telomerase reverse transcriptase
(hTERT) gene expression [50,51]. hTERT is widely expressed in cancers, but not in normal cells, and
downregulation of hTERT in breast cancer can lead to the inhibition of cell proliferation and the
induction of apoptosis. Food or dietary compound induced changes in hTERT expression, which,
in many cases, are due to epigenetic modifications [50–52].
3.4. Dietary Sources of Polyphenols
Following the systematic search, a small subset of polyphenol types emerged as having
human-derived evidence with regard to breast cancer recurrence. This review focuses on the
human-derived evidence on breast cancer, and we focus the discussion on phenolic acids, flavonols,
and isoflavones. Whilst cell line data on polyphenols such as curcumin and resveratrol are promising,
very little has been conducted in human clinical trials.
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3.4.1. Phenolic Acids
One of the major dietary sources of dietary phenolic is olive oil, which contains caffeic, oleuropein,
and hydroxytyrosol, amongst others. Previous research attributes the health effects of olive oil to
its high content in oleic acid. Nowadays, the health benefits of olive oil are also attributed to its
phenolic content, namely olepurenoil [53]. Researchers have indicated that the antioxidant capacity of
polyphenols in olive oil may reduce the risk of developing cardiovascular diseases and cancer [54].
Studies have indicated that the biological activity of polyphenols in olive oil is higher when
they are part of the diet than when these molecules are administered as food supplements [54,55].
The processing of olive oil also determines the variability and availability of polyphenol content in this
product. The polyphenol content of olive oil is important, not only for the delivery of compounds with
strong anti-oxidant capacity, but also because it exists in conjunction with fatty acids that are potentially
oxidised [54]. The phenolic composition of olive oils varies in quantity and quality depending on the
olive variety, the age of the tree, and the agricultural techniques used in cultivation.
Recent data suggest a polyphenolic compound found in olive oil, known as oleocanthal,
can selectively kill cancerous breast cells while leaving healthy cells intact [56]. Oleocanthal ruptures
the lysosome of cancerous cells by inhibiting acid sphingomyelinase activity, which destabilizes
the interaction between proteins required for lysosomal membrane stability [56]. The ruptured cell
renders the cancer to usual enzymatic degradation and programmed cell death. Further research is
needed to confirm findings in human trials, but results are promising. Researchers suggest those on a
Mediterranean diet may benefit from the higher consumption of olive oil [56].
Coffee contains numerous compounds, potentially beneficial as well as harmful. With regard to
breast cancer, coffee drinking may even have a protective effect. Coffee contains various polyphenols,
which inhibit harmful oxidation processes in the body, while the latter include acrylamide, whose high
intake in daily diet may have carcinogenic action [57]. In mechanistic cell studies, coffee polyphenols
change the expression of STAT5B and ATF-2 modifying cyclin D1 levels in cancer cells [58]. Whilst
in vitro studies suggest coffee may offer protection against breast cancer, the overall effect requires
clarification, given the paucity of clinical trials.
3.4.2. Flavonols
Flavonols are the major polyphenolic sub-group of flavonoids, which are present in tea, onions,
broccoli, and various common fruits. Example polyphenol flavonols include quercetin, kaempferol,
myricetin, and isorhamnetin, with an estimated intake of 12.9 mg/day in a typical Western diet [59].
Flavonols may act through anti-oxidant, pro-oxidant, anti-estrogenic, cell signalling pathway
modulation, or mitochondrial toxicity to inhibit breast carcinogenesis. One study investigating
the effect of flavonols of breast cancer risk reported a risk ratio of 0.94 (0.72, 1.22; p-value for test
of trend = 0.54) for the sum of flavonol-rich foods. Among the major food sources of flavonols,
a significant inverse association with the intake of beans or lentils was reported, but not with tea,
onions, apples, string beans, broccoli, green pepper, or blueberries [60]. Despite no overall association
between intake of flavonols and risk of breast cancer, there was an inverse association with the intake
of beans or lentils. In contrast, a recent meta-analysis of flavonoid intake and breast cancer risk
suggested that dietary flavonols and flavones, but not other flavonoid subclasses or total flavonoids,
was associated with a decreased risk of breast cancer, especially among post-menopausal women [59].
Given the large range in polyphenols present in the flavonol sub-group, definitive recommendations
are difficult; however, it is safe to assume a diet high in beans and legumes and a range of flavonols
including onions, apples, citrus, tea, and broccoli are likely to be protective.
3.4.3. Isoflavones
Estrogen is believed to play a role in breast cancer development and progression, and any
nutritional intervention that blocks the production or reduces the hormone action is likely to be
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effective in improving clinical outcomes in breast cancer survivors. Soy food consumption has been
attributed to protection against breast cancer, primarily because of the soybean isoflavones (genistein,
daidzein, and glycitein), which are natural estrogen receptor modulators. In vitro studies show that
genistein inhibits the growth of breast cancer cells, including hormone-dependent and independent
cell types at higher concentrations (10–50 μmol/L), while stimulating growth at lower concentrations
(<10 μmol/L) [61]. Whilst the structure of soy isoflavones mimics estrogen, the majority of human
research fails to detect any clinically relevant estrogenic activity, as determined by estradiol, estrone,
and sex hormone binding globulin [62]. In one of the key human intervention studies on soy protein,
results were stratified by the amount of soy consumed and showed a dose-response relationship
between decreasing risk of breast cancer with an increased soy food intake, translating to a 16% risk
reduction per 10 mg of daily isoflavone consumed [63]. However, concerns remain regarding optimal
dose of soy foods to ensure improved survival in breast cancer sufferers, and further clinical trials are
needed. Soybeans contain a number of anticarcinogens, suggesting that consumption may protect
against breast cancer, with non-fermented products such as tofu and soymilk showing more promise.
Unfortunately, clinical outcomes in animal and human epidemiological studies are varied, with
65% of studies reporting no effect or slightly protective against breast cancer risk. A recent review
demonstrated the protective effect soy consumption has on breast cancer development, recurrence, and
mortality [62]. At this stage, soy phytoestrogens require further research [64]. The protective association
of soy food appears more pronounced in postmenopausal women. However, the reduced risk of
recurrence results should be interpreted with caution given the modest effect and wide confidence
intervals for most studies and the lack of dose response relationship in one positive study.
Both the breast cancer treatment drug Tamoxifen and dietary phytoestrogens bind estrogen
receptors, and many have theorised that soy consumption will reduce drug efficacy. In a study on
investigating the association of soy food consumption and survival in breast cancer sufferers, women
in the highest soy food intake groups had the lowest mortality and recurrence rate compared with
women in the lowest intake group, regardless of tamoxifen use. Among women whose soy intake was
in the highest quartile, tamoxifen did not confer additional health benefits [65]. Based on this limited
epidemiological data, it follows that moderate soy protein consumption (5–10 g/day) in combination
with Tamoxifen use represents the optimal treatment combination for relevant breast cancer patients.
Within nutrition science, the critical concept of food synergy recognises that nutrients exist in
a purposeful biological sense within foods, delivering them in combinations that reflect biological
functionality [66]. Thus, while it is difficult to separate out the effects of foods within a total diet, it is
also difficult to study the effects of nutrients and bioactive substances in the isolation of foods [67].
3.5. Polyphenol-Rich Dietary Pattern and Breast Cancer Progression
The Mediterranean diet has been shown to reduce body weight by 4.4% over a year and improve
the inflammatory profile in cardiac and diabetic groups. Given the tendency for breast cancer
survivors to gain weight and risk metabolic syndrome, the Mediterranean diet may assist with
weight loss and provide specific benefits over and above the usual low-fat, healthy diet intervention.
The Mediterranean diet is a plant-based dietary pattern characterized by a high intake of olive oil,
legumes, whole grains, fruit, vegetables, nuts, seeds, fish, and is rich in dietary polyphenols. The diet
has been linked to a decreased risk of developing breast cancer [48]. The Mediterranean diet contains
a wide range of various polyphenols, particularly from nuts, fruit, and coffee [68], and represents
a potential population approach to increasing the intake of polyphenols. Epidemiological evidence
strongly suggests that long-term consumption of diets rich in plant polyphenols, much like that of the
Mediterranean diet, can offer protection against development of major chronic and neurodegenerative
diseases [69,70]. Suggested mechanisms through which the Mediterranean diet may impact breast
cancer initiation and proliferation include increased insulin sensitivity and reduction of excess insulin
production, anti-inflammatory and antioxidant effects of the diet, high fibre content, and an association
356
Nutrients 2016, 8, 547
with reduced risk of excess weight gain and obesity [48]. The health benefits of the Mediterranean diet
are likely a synergistic effect of weight loss, polyphenol intake, and improved glycemic control.
There are three main randomised trials investigating the effect of following a Mediterranean
diet pattern and the prognosis following treatment for breast cancer. The results, however, are
mixed. In 2007, The Women’s Healthy Eating and Living (WHEL) Randomised Trial found that a
diet high in vegetable, fruit, and fibre and low in fat intake did not reduce additional breast cancer
events or mortality over a relatively long follow-up period [13]. These results are at odds with the
Women’s Intervention Nutrition Study (WINS), a randomised trial that focused on a low-fat diet and
weight loss, reporting that this diet was associated with longer relapse-free survival of breast cancer
patients [71]. Follow up times and differences in menopausal status between studies may explain
outcomes. Difficulties in ascertaining the polyphenol content of these diets make conclusions regarding
efficacy difficult.
Another reason for the difference in the results of these trials may be that, in WINS, the women
lost weight in the randomised group, whereas those women in the WHEL study had an iso-caloric diet
by design, and the women in the intervention group gained around 1 kg. The results from previous
observational studies suggesting calorie reduction and weight loss are beneficial in breast cancer
prognosis may add context to this situation and show why the results of the WHEL study were to no
effect. Such an interpretation is verified by the relatively consistent observations that overweight and
obese breast cancer patients have a worse prognosis than lean patients [1,72–74]. The Mediterranean
diet has been shown to support weight loss in participants and as such may offer multiple benefits in
polyphenol intake and weight loss.
The most recent randomised trial investigating the effects of a Mediterranean macrobiotic lifestyle
on breast cancer prognosis is the DIANA-5 trial [75]. It demonstrated that dietary modification based
on Mediterranean and macrobiotic dietary principles can reduce body weight, and the bioavailability
of sex hormones and growth factors may promote tumour growth [76,77]. The diet consisted of low
consumption of fats, refined carbohydrates and animal products, and the high consumption of whole
grain cereals, legumes, and vegetables.
Chemotherapy works to significantly decrease recurrences and improve survival in women with
early breast cancer, but a major side effect is weight gain which, as discussed, is associated with a
poorer prognosis [78]. The trial showed this specific diet significantly decreases body weight and waist
circumference, thereby improving insulin sensitivity [79]. Like the WINS trial, only post-menopausal
women were included in the study. The results may have differed for pre-menopausal women if they
were also included.
Overall, the DIANA-5 trial has the potential to provide a clear answer to the hypothesis that
a comprehensive modification of diet can lead to a longer event-free survival among women after
breast cancer treatment [75]. Intervention has been shown to be effective in changing lifestyle in terms
of diet and weight loss. Combined with other modifiable factors, a Mediterranean diet that focuses
on weight loss and reducing insulin resistance may have substantial benefits for women previously
treated for breast cancer. All of these studies have pieced together components that warrant further
investigation to the role of a Mediterranean-based diet and breast cancer prognosis, event-free survival,
and mortality.
3.6. Disease Characteristics and Biomarkers
A reduction in breast cancer incidence and mortality is the gold standard criteria for success in
a clinical trial; however, this approach is expensive and ethically difficult to implement. The use of
surrogate breast cancer biomarkers is an appealing alternative. Breast cancer biomarkers useful
for investigating the efficacy of polyphenols include specific oncogenic pathways (e.g., COX-2,
or prostaglandin E2, a product of COX mediated catalysis), levels of circulating disease related proteins,
such as ostrodial or estrogen, changes in breast cancer histology and cytology, genomic alterations
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A major challenge in the treatment of breast cancer is its high heterogeneity from patient to
patient, which initiated its classification into three major molecular subtypes—estrogen receptors (ER),
progesterone receptors (PR), and HER2, hormone receptor positive with luminal A (ER+PR+HER2−)
and luminal B (ER+PR+HER2+) phenotypes, HER2 positive (ER−PR−HER2+), and triple negative/
basal-like (ER−PR−HER2−) [80–82]. About 70% of breast cancers are estrogen receptor positive [83].
Recent data suggest that molecular subtypes differ substantially in the intracellular pathways
responsible for cell growth and metastatic spread, suggesting a wide array of potential molecular
targets of polyphenols [84]. The efficacy of polyphenolic therapy is likely to differ pending the breast
cancer stage and subtype.
3.7. Epigenetic Potential of Polyphenolic Phytochemicals
Epigenetics refers to heritable changes in DNA that are involved in the control of gene expression.
Epigenetic mechanisms include changes in DNA methylation, histone modification, and non-coding
RNAs [84]. While epigenetic characteristics are sometimes inherited they can also be modified by
environmental and dietary factors. Inflammatory pathways can trigger epigenetic switches from
nontransformed to metastatic cancer cells via signalling involving NF κB and STAT3 transcription
factors, microRNAs (Lin28 and let-7), and IL-6 cytokines [85]. Moreover, the polyphenols resveratrol
and quercetin decreased miRNA-155 and inhibited NF-κB-involved inflammation in a cancer cell line
study. Increasing evidence suggests polyphenols are capable of influencing epigenetic characteristics
relevant to cancer progression. It is beyond the scope of this review to outline all the research
of all aspects of the epigenetic potential of polyphenols; other reviews have been completed [85].
Of the more notable epigenetic modification by polyphenols, epigenetically modified genes can be
restored, inactivated methylated genes can be demethylated, and histone complexes can be rendered
transcriptionally active by dietary intervention. Common to cancer initiation is the inhibition of
tumour suppressor genes by DNA methylation of transcription factors. DNA methyltransferase
(DNMT) inhibitors can undergo such methylation, which polyphenols have been demonstrated to
reverse [86].
Polyphenols can also alter heritable gene expression, activity of epigenetic machinery and
decreases micro-RNAs related to inflammation and cancer growth. So far, it is not clear whether
the occasional or typical dietary intake of polyphenols results in long-term epigenetic regulation of
gene expression, downstream chemo-preventative effects, or both.
3.8. Bioavailability of Polyphenols
Biological properties of polyphenols depend on their bioavailability. The chemical structure of
polyphenols determines their rate and extent of intestinal absorption, as well as the nature of the
metabolites circulating in the plasma. For most flavonoids absorbed in the small intestine, the plasma
concentration rapidly decreases (elimination half-life period of 1–2 h). The elimination half-life period
for quercetin is much higher (24 h) probably due to its particularly high affinity for plasma albumin [87].
Flavonols, isoflavones, flavones, and anthocyanins are usually glycosylated. Following high-dose
polyphenol administration, metabolism occurs primarily in the liver, whereas, when smaller doses
were administered, metabolism took place first at the intestinal mucosa, the liver playing a secondary
role to further modify the conjugated polyphenol. This implies that the intestine is an important site
for metabolism of food-derived polyphenols [88]. Intestinal microbiological fermentation decreases
the bioavailability of the many polyphenols; however, it also gives rise to metabolites that may be
more bioactive than the native polyphenols [88]. Metabolic responses based on dose also suggest that
any potential benefit will vary based on the polyphenol dose used. Studies on ideal dose and delivery
route are needed.
To circumvent poor bioavailability of polyphenols, a current area of promising research is using
nanotechnology. One such nanotechnology, titled “Nano emulsions”, are a class of extremely small
droplets that allow polyphenol phytochemicals to be transported through the cell membranes more
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easily, resulting in an increased concentration in plasma and improved bioavailability. Curcumin Nano
emulsions show 85% inhibition of 12-O-Tetradecanoylphorbol-13-acetate (TPA)-induced mouse ear
inflammation as well as the inhibition of cyclin D1 expression. In addition, dibenzoylmethane (DBM)
Nano emulsions improve oral bioavailability of curcumin 3-fold, compared with the conventional
DBM emulsions [89]. The degree to which improved bioavailability improves survival in breast cancer
patients is still to be determined, as there is likely a dose-response that is still to be ascertained.
3.9. Limitations (Toxicity, Bioavailability, Challenges and Weaknesses Associated with Human Trials, etc.)
Several factors have been proposed to explain differences observed between the positive
effects of polyphenol consumption reported in epidemiological studies and the unclear to negative
findings reported in intervention trials with supplements. These factors include the following:
(1) differing doses of administered compounds; (2) additive or synergistic effects, such as those
between polyphenols and other antioxidants, present in whole foods but not in supplements; and
(3) differences in bioavailability and metabolism [88]. Results from randomised clinical trials vary to
those of in vitro studies largely as a result of these factors.
With any human dietary study, interpreting outcomes and defining appropriate dietary
recommendations can be extremely difficult. Studies typically involve many methodological
considerations such as dietary pattern differences across populations, accurately measuring food
intake, biological mechanisms, genetic variations, food definitions, bias, and other confounding
factors [90]. Adding further complication is that many studies between cancer and diet provide weak
associations, whereby confounding factors, exposure misclassification, and other biases, even modest
ones, can have a large impact on the overall conclusions [91]. To best answer questions regarding
efficacy of dietary polyphenols, in vitro studies of polyphenol metabolites should be followed up
with human clinical trials and we would recommend that further studies use placebo controlled,
double-blind trials that extend over many years with a sufficient sample size. Unfortunately, such
studies are expensive to conduct.
4. Conclusions
Whilst recognizing the broad nature of investigating the efficacy of polyphenols for breast cancer
patients, we can conclude the following based on clinical and observational studies. Early diagnosed
breast cancer patients should consume at least five servings of vegetables and fruit, and we recommend
those high in flavonols such as onions, broccoli, apples, and citrus, amongst others. Both green and
black tea consumption is protective, with 3+ cups of green tea being particularly helpful. We would
recommend women diagnosed with breast cancer to adopt a moderate soy protein consumption
(5–10 g/day) from non-fermented soy products such as soymilk and tofu.
The Mediterranean diet appears useful in assisting with weight control and improving metabolic
syndrome. It is a dietary pattern naturally high in legumes and olive oil, both of which have been
independently reported to improve in vitro and in vivo breast cancer recurrence and biomarkers of
disease. Foods rich in polyphenols are the preferred methods of delivery over supplements, until more
is known. Further research should include specific dietary foods in large randomized control trials,
which, the authors recognize, are expensive to conduct.
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Abstract: Quercetin, a medicinally important member of the flavonoid family, is one of the most
prominent dietary antioxidants. It is present in a variety of foods—including fruits, vegetables, tea,
wine, as well as other dietary supplements—and is responsible for various health benefits. Numerous
pharmacological effects of quercetin include protection against diseases, such as osteoporosis, certain
forms of malignant tumors, and pulmonary and cardiovascular disorders. Quercetin has the special
ability of scavenging highly reactive species, such as hydrogen peroxide, superoxide anion, and
hydroxyl radicals. These oxygen radicals are called reactive oxygen species, which can cause oxidative
damage to cellular components, such as proteins, lipids, and deoxyribonucleic acid. Various oxygen
radicals play important roles in pathophysiological and degenerative processes, such as aging.
Subsequently, several studies have been performed to evaluate possible advantageous health effects
of quercetin and to collect scientific evidence for these beneficial health claims. These studies also
gather data in order to evaluate the exact mechanism(s) of action and toxicological effects of quercetin.
The purpose of this review is to present and critically analyze molecular pathways underlying the
anticancer effects of quercetin. Current limitations and future directions of research on this bioactive
dietary polyphenol are also critically discussed.
Keywords: quercetin; cancer prevention; diet; bioavailability; DNA damage; polyphenols
1. Introduction
During the last decade, the proportion of scientific studies based on non-nutritive components
of diet has increased. Such components are present in diet and have the ability to protect the body
from the harmful effects of degenerative diseases, cancer, and cardiovascular ailments. Carotenoids
and flavonoids, two distinct groups of phytochemicals, represent valuable constituents of food.
Other dietary agents—such as phytoalexins, phenolic acids, indole-3-carbinol, and organosulfur
compounds—are also important phytochemicals with interesting biological activities [1,2]. Phytochemicals
are generally present in a variety of foods, fruits, vegetables, beverages, and many other food
products and medicinally important herbal preparations. The important point that brings the
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attention of the scientists towards the naturally occurring compounds for the purpose of testing
is the presence of numerous phytochemicals existing in plant-derived foods. There are a wide
variety of biological activities which are still unknown for the majority of these compounds [3].
Plant-derived phytochemicals activate various cell signaling pathways that play key roles in the
prevention of physiological disorders in the body, which are mainly responsible for the development
of cancers, neurodegenerative and cardiovascular diseases [4,5]. Various scientific studies conducted
on experimental animal models for the assessment of the exact mechanisms through which
phytochemicals exert their actions provide a good and valuable description of how food supplements
containing abundant amounts of phytochemicals exhibit protective roles against degenerative
disorders [6]. It is noteworthy to find out that such plant-derived medicinally important constituents
have the ability to demonstrate preventive and protective measures against pathological disorders.
Flavonoids are mostly present in nature in the form of benzo-γ-pyrone derivatives. These
compounds are mostly present in a variety of plants, vegetables, and flowers. Flavonoids have diverse
structural frameworks and play important roles in the body’s defense system. The beneficial effects
of flavonoid-rich foods have been demonstrated by various studies [7]. Data collected from different
clinical trials have tried to underscore the exact mode of action exerted by flavonoids. There is a need
to evaluate new possible ways to understand the beneficial activities associated with the consumption
of flavonoid-rich food in order to advance our knowledge about the possible beneficial action of plant
extracts. There are 4000 types of different flavonoids found in nature with diverse subcategories, such
as flavones, isoflavones, flavonones, and chalcones. Flavonoids possess important biological activities,
such as anti-inflammatory, antioxidant, hepatoprotective, and antimicrobial properties [8].
Quercetin is a key member of the polyphenol family and is largely found in various vegetables and
fruits, such as capers, lovage, dill, cilantro, onions, various berries (e.g., chokeberries, cranberries, and
lingonberries), and apples. Quercetin is well known for its anticarcinogenic potential. The anticancer
property of quercetin is due to various cell signaling mechanisms and its ability to inhibit enzymes
responsible for the activation of carcinogens. Moreover, quercetin exerts anticancer effect by binding
to cellular receptors and proteins [9,10].
Several previous publications [11–16] present an excellent overview of research related to the
therapeutic application of quercetin in cancer prevention and treatment. Nevertheless, there exists
a need for a systematic, up-to-date, and critical evaluation of literature to understand biochemical
and molecular mechanisms of the anticancer action of quercetin. In this review article, first we
focused on chemical reactivity of quercetin and related analogs. Secondly, we discussed the molecular
targets as well as signaling pathways implicated in anticancer and cancer preventive potential of
quercetin. Thirdly, we presented epidemiological evidences regarding quercetin consumption and
cancer occurrence. Finally, we discussed future directions of research to understand the full potential
of quercetin in cancer prevention and treatment.
2. Bibliographic Search
The scientific information gathered in this review was collected by widespread search of several
electronic databases, including PubMed, Scopus, Medline, Web of Science, EBASE, and Google Scholar.
The criteria for the exclusion of articles was the language of reports being other than English, reports
with unavailable abstracts, studies related to quercetin effects apart from its anticancer profile, and
studies which showed the linkage between cancer and cancer risk factors, such as tobacco smoking
and alcohol consumption. Various appropriate articles not indexed by PubMed were also considered,
and 27 such reports which fulfilled the criteria for inclusion were further recovered from Google
Scholar. Therefore, the total number of included articles in this review is 127 (Figure 1).
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Data retrieved from
PubMed, Scopus and
Google Scholar (n = 190)
Supplementary data searched





Full text articles screened
(n = 192)
Total articles cited (n = 127)
Articles excluded because
of languages other than




factors such as tobacco




PubMed papers (n = 27)
Total remained data
(n = 165)
Figure 1. Flow diagram of included studies. The number of citations and resource materials that have
been screened, excluded and/or included in this review is indicated in parenthesis.
3. Chemistry of Quercetin and Its Analogs
Quercetin is a polyphenolic secondary metabolite that belongs to the flavonol class of flavonoids. It
is characterized by a benzo-(γ)-pyrone skeletal structure with C6-C3-C6 carbon framework, consisting
of two benzene rings, A and B, linked by a three-carbon pyrone ring C as shown in Figure 2 [17].
Quercetin is referred to as pentahydroxyflavonol due to the presence of five hydroxyl groups on its
flavonol skeletal framework at 3, 3′, 4′, 5, and 7 carbons [12]. The wide range of biochemical and
pharmacological activities of quercetin and its metabolites is due to the relative substitution of various
functional groups on the flavonol molecule [18].
Phytochemical investigations of various plant extracts have revealed that quercetin can exist in
a free state as an aglycone, or as its derivative by conjugating with: (1) carbohydrates as quercetin
glycosides, (2) lipids as prenylated quercetin, (3) alcohols as quercetin ethers, and (4) a sulfate group
as quercetin sulfate [19].
Quercetin glycosides are formed through the O-glycosidic bond between a sugar and the
hydroxyl group of quercetin molecule, and the general glycosylation site on the quercetin molecule
is at the 3-hydroxyl position. However, glycosylation of other hydroxyl groups has also been
reported [20]. The sugar moieties can be monosaccharides, disaccharides, or polysaccharides, and the
most common carbohydrate substituents are glucose, galactose, rhamnose, and xylose. Isoquercetin,
hyperoside, quercitrin, and rutin are a few of the most abundant and well-studied quercetin glycosides
(Figure 2) [21].
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Figure 2. Structures of quercetin and its derivatives [19–24].
Quercetin methyl ethers are one of the most widely studied natural pigments, and they are formed
through the conjugation of the quercetin hydroxyl group with alcohol, generally methanol. Quercetin
ethers can exist in various configurations, from mono-ethers to penta-ethers, with substitution on
all the hydroxyl groups of quercetin molecule. Rhamnetin, isorhamnetin, and rhamnazin are a few
representatives of quercetin ether analogs [19].
Prenylflavonols are an important group of molecules belonging to the flavonol subclass. They
are well-known for their wide range of biological activities, such as antioxidant, antibacterial,
anti-inflammatory, and anticancer properties [22]. Structurally, in C-prenylflavonols, prenyl groups
are attached to the carbon atom of the flavonol skeleton. In the past few years, prenylated quercetin
analogs, such as solophenol D and uralenol, have gained a lot of attention due to their antibacterial
properties. It has been reported that prenylation may enhance the biological functions of quercetin by
increasing its hydrophobicity and bioavailability [23,24].
In addition to the sugar, lipid, and alcohol derivatives, quercetin also exists as sulfate conjugate in
nature. Quercetin 3,7,3′,4′-tetrasulfate, isolated from the leaves Flaveria bidentis, has shown remarkable
anticoagulant properties [25]. The multisubstituted derivatives, such as icaritin, isorhamnetin
3-O-glucoside, quercetin-3,4′-di-O-glucoside, and dorsmannin, can form from the combination of
same or different functional groups. The number and nature of these functional group substitutions
have profound effects on the physicochemical properties and biological effects of quercetin analogs [26].
The best described biochemical property of quercetin is its ability to act as an antioxidant.
The antioxidant activity and free radical scavenging properties of quercetin are attributed to its
chemical structure [27]. There are three important structural features: (1) catechol functionality
(ortho-dihydroxyl) on B ring, (2) a Δ2 double bond adjacent to a 4-oxo group in pyrone C ring,
and (3) hydroxyl groups at C-3 and C-5 carbons in the benzopyrone AC ring [28]. The structural
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variables—such as configuration, substitution, and number of hydroxyl groups—greatly influence the
mechanisms involved in antioxidant activity, like their ability to scavenge radical species and their
ability to chelate metals [29].
Quercetin also inhibits the lipid peroxidation process, a common consequence of oxidative stress,
and consequently protects against lipid membrane damage [30]. Due to its lower redox potential,
quercetin is able to reduce highly oxidizing free radicals, such as superoxide and peroxide radicals.
Because of its ability to chelate metal ions, quercetin can inhibit the generation of free radicals [28].
4. Bioavailability and Metabolism of Quercetin
In order to estimate the efficacy of quercetin in terms of its anticarcinogenic effect, it is important
to understand the bioavailability of quercetin as well as its intestinal absorption and metabolism
conversion rate. When quercetin was administered intravenously to rodents, it immediately
disappeared from the plasma. It was evident from this experiment that quercetin was rapidly
metabolized and eliminated from the body through urine and no evidence was observed regarding
the storage of quercetin inside the tissues and body fluids. Previously, there was a common belief
about the excretion of quercetin into feces without being absorbed by the intestine, but it is evident
from recent studies that an excessive amount of quercetin found in foods is likely to be absorbed from
the intestine and subsequently converted to its respective metabolites [31]. In the transportation of
the metabolites of quercetin, the body’s lymphatic system is also involved [32]. Repeated intake of
onion resulted in accumulation of quercetin metabolites in various tissues and blood, which reached a
total plasma concentration of 0.6 μM after 1 week. Hence, it is important to keep the plasma quercetin
metabolite concentration at an acceptable and significant level [33].
It is evident from studies conducted recently that the metabolites of quercetin were rapidly
distributed among various organs at low levels after intake of dietary quercetin for a long time [34].
It is also evident that regular consumption of dietary quercetin results in the storage of metabolites
throughout the body [35]. Generally, the conversion of quercetin to its metabolic derivatives decreases
its free radical scavenging activity, but there are some metabolic derivatives of quercetin, which are
capable of removing the reactive species from the body. Moreover, during the process of inflammation,
quercetin-3-glucuronide is metabolized, resulting in the accumulation of quercetin aglycone [36].
Recent studies showed that glucuronide, a more active form of aglycone metabolite of quercetin,
was used for the incorporation into macrophages [34]. This study showed those actions of quercetin
metabolites which are mostly site-specific in nature and are recommended for inflammatory conditions.
The modified forms of quercetin are present in human blood and stored in inactive forms, which are
further converted into active residues and ultimately converted into the active constituents to exert
their actions at specific target sites.
5. Protective Effects of Quercetin
Quercetin and its metabolites are crucial due to their physiological functions as well as their role
in the elimination of cancerous cells. Therefore, it is important to further investigate this specialized
aspect of quercetin in terms of protection against cancer and other degenerative disorders, as these
ailments are the leading causes of death throughout the world.
It was investigated recently that by influencing the pentose phosphate pathway with the
production of CYP450, the preventive environment for cytochrome c-mediated apoptosis can be
maintained. This cytochrome is an important part of the electron transport chain and is released
from mitochondria during the apoptosis process. Therefore, the cancerous cells keep constant control
over cell death through the release of cytochrome c [37]. These metabolic changes are important for
the survival of cells for a longer time and also for the spreading of cancer cells [38]. Various studies
have been performed to evaluate the pharmacological actions of quercetin in biological systems in
order to investigate the precise mode of action of quercetin [39,40]. Therefore, it is evident from these
studies that quercetin and its metabolites, which are present in various plants, play crucial roles in the
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protection against cancer and oxidative stress. When PC-12 cells were treated with nerve growth factor
(NGF), the cells ceased to multiply and began to extend branching varicose processes similar to those
produced by sympathetic neurons in primary cell culture [41]. Quercetin exhibited NGF-like action
when it came in contact with PC-12 cells. Quercetin also causes cell differentiation similar to that caused
by NGF [42]. Although the exact mechanism is still unclear, the well-characterized NGF-inducing
capacity is more likely related to the differentiation-inducing effects of quercetin [43]. The protective
effects of quercetin have also been observed in primary cultures [39]. Quercetin increased the rate of
survival of cells when it was administered 24 h before the oxidative stress. In a cell culture model,
it was reported that quercetin internalization into neurons happened rapidly, and a neuroprotective
pathway involved Nrf2-dependent variation of the GSH redox system was observed [44].
When the aqueous quercetin was administered in experimental animals, there was a significant
reduction in brain ischemic lesions [45]. Quercetin has been used in a variety of studies to evaluate
its protective effects. In one study, the anticancer effects of quercetin were studied in animal
models. The investigators examined the physiological changes after they administered colchicine by
intracerebroventricular route [46].
In a similar study, quercetin was administered to mice for a period of seven days through
intraperitoneal (i.p.) route. After administration of quercetin, memory improvement was observed in
mice [47]. In this study the developmental changes were linked with the inhibition of cyclooxygenase 2
enzyme. It was observed that there was a noteworthy improvement in the learning ability of mice in
comparison with the control group of mice [48]. Quercetin also increased the activity of superoxide
dismutase (SOD) and lowered the level of malondialdehyde. Quercetin and other flavonoids acted as
prodrugs and were metabolized into active hydroxyphenyl acetic acid metabolites by microflora in
the intestine [49]. The protective effects of quercetin were observed in rats with known evidence of
cerebral ischemia [50]. By administering two consecutive doses of quercetin, the memory problem in
rats—which was induced by repeated cerebral ischemia—was improved and the level of cell death
was reduced in the region I of hippocampus proper area (CA1). In another study, when quercetin was
administered through i.p. route to rats with spinal cord injuries for a period of 10 days, half of the rats
started walking [51].
In a study evaluating the penetration of quercetin across the blood–brain barrier, it was observed
that quercetin induced various changes within different brain regions based on an in situ brain
perfusion model in rats [52].
6. Molecular Mechanisms of Quercetin
Quercetin is used for therapeutic purposes in various disorders due to its antioxidant capability
The reactive oxygen species (ROS) scavenging activity is attributed to a change in OH− ions, which
has a relation to electron exchange [53]. Catechol oxidative agents, such as semiquinones and quinones
formed due to quercetin, alter redox homeostasis and inhibit primary positive effects [27]. In vitro
study predicted that due to this special feature quercetin has a protective role in the nervous system.
In the current scenario, the neuroprotective activity of quercetin cannot be ignored and additional
in vivo studies should be investigated with different humanized animal models to translate the efficacy.
Quercetin exerts its antioxidant activity by competitively inhibiting the xanthine oxidase enzyme and
noncompetitively blocking the xanthine dehydrogenase enzyme. The inhibitory capabilities are due to
its flavonoid structure rather than to its antioxidant potential [54].
6.1. HMGB1 Signaling Pathway
High-mobility group box protein 1 (HMGB1) is a nuclear protein which is highly preserved. It is
secreted by the action of macrophages previously activated and it works as a crucial “late” facilitator of
fatal endotoxemia and sepsis formation [55]. The HMGB1 protein, which is present outside the cell, can
motivate the release of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and other inflammatory
mediators from monocytes [55,56]. Quercetin stimulates the inhibition of HMGB1-induced TNF-α
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and IL-1β mRNA expression, which suggests that quercetin modulates cell signaling that in turn
regulates the action of proinflammatory cytokines. The activation of mitogen-activated protein kinase
(MAPK) signaling pathway is a significant step in the HMGB1-induced gene expression process,
which causes the release of inflammatory cytokines—such as TNF-α, and IL-1β—inside macrophages,
neutrophils, and endothelial cells. HMGB1-induced cytokine release partially interferes with MAPK
pathways. HMGB1 or lipopolysaccharides (LPS) time-dependently induce phosphorylation of p38,
c-Jun N–terminal kinase, and extracellular signal-regulated kinase in macrophages. Quercetin
considerably inhibits HMGB1- or LPS-induced phosphorylation of each kinase [57]. Apart from
MAPK activation, the nuclear factor-κB (NF-κB) signal transduction pathway is also involved in
HMGB1-induced cellular activation, and NF-κB-dependent transcriptional activity is very important
for cytokine expression [58,59]. In cells, NF-κB subunits (p50 and p65) exist as inactive trimers in the
cytosol through the interaction with IκBα, which is the most important member of the IκB family [60].
Quercetin significantly inhibits IκBα degradation and nuclear translocation of NF-κB p65. Therefore,
after stimulation with HMGB1 or LPS, p65, the key activator of NF-κB-regulated transcription, becomes
available to NF-κB-regulated genes in the nucleus and nuclear localization is most effectively inhibited
by quercetin.
6.2. Thymic Stromal Lymphopoietin (TSLP) Activation
The level of TSLP, which is an epithelial-derived cytokine with a role in T helper (Th) cells’ Type-2
immunity, is considerably increased in human skin as well as blood. The TSLP signaling process is
initiated through proteins, including 1L-7 chain of receptor, which has potential to enhance the B
lymphocyte activation and dendritic cells [61]. Primary skin keratinocytes are mostly responsible for
expressing the TSLP in smooth muscle and lung connective tissues. TSLP contributes its main biological
role by influencing various cells [62]. It is evident that TSLP has the potential to activate both CD4+ T
and CD8+ cells along with other B lymphocytes’ differentiation, which in turn promotes the release and
activation of chemokines. Additionally, it can enhance the secretory mechanism of the Th2 cytokines
from mast cells. During the binding of TSLP with respective receptors, various signaling pathways
are activated [63]. It has been reported in a recent study that due to the activation of these receptors,
there is a marked promotion in the phosphorylation process of Janus kinase-signal transducers and
activators of transcription (JAK-STAT) signaling, which further causes skin inflammation [64]. Thus,
targeting the above signaling pathway is a viable approach to design a treatment plan for various
inflammatory diseases, including cancer.
6.3. JAK-STAT Signaling Pathway
JAK-STAT signaling pathway is a typical signal transduction pathway for various types of
inflammatory cytokines and growth regulatory factors. The binding of ligands to their respective
receptors leads to the activation of JAK, which further increases the phosphorylation process and hence
leads to the activation of STAT. The STATs, which are already activated, enter the nucleus, where they
start the regulation of gene expression [65]. Studies have shown that the activated mast cells stimulate
the formation of the Th2 cytokines and decrease the secretory mechanism of Th1 cytokines. JAK-STAT
signaling is activated by mast cells, which in turn activate the IL-13 production in the Th2 cell line [66].
Quercetin has the ability to actively inhibit the JAK-STAT signaling pathway in various
inflammatory disorders. Furthermore, treatment of activated T cells with quercetin in vitro inhibited
the interleukin-12 (IL-12)-induced phosphorylation of JAK2, tyrosine kinase-2 (TYK2), STAT3, and
STAT4, which result in decreased levels of T cell propagation and Th1 variation [67]. Therefore,
these anti-inflammatory and antiapoptotic properties of quercetin have a key role in the reduction
of cancer by controlling the toll-like receptor-2 (TLR2) and JAK2/STAT3 pathway and causing
the inhibition of STAT3 tyrosine phosphorylation within inflammatory cells [68]. Pretreatment of
cholangiocarcinoma cells with quercetin inhibited the cytokine-mediated upregulation of inducible
nitric oxide synthase (iNOS) and expression of intercellular adhesion molecule-1 (ICAM-1) in the
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JAK/STAT cascade pathway. Also, quercetin blocked the activation of inflammatory cytokine
interleukin-6 and interferon-γ [69]. It was reported that LPS-induced STAT1 activation was inhibited
by quercetin in combination with its profound inhibitory effects on iNOS and NF-κB expression, which
are persistently involved in activation of interleukin-2 (IL-2) as shown in Figure 3 [70].
Figure 3. Anticancer pathways and mechanisms of quercetin.
7. Anticancer Effects of Quercetin
Vegetables and fruits are rich sources of phytochemicals with significant potential to prevent
cancer due to the presence of abundant antioxidants. Among polyphenols, quercetin is the most
important and naturally occurring cancer-preventing agent. The importance of dietary quercetin is due
to its antioxidant potential and anti-inflammatory effects [47]. The cancer preventive and therapeutic
effects of quercetin have been demonstrated through in vitro (Table 1) as well as in vivo (Table 2)
experimental findings.
Table 1. In vitro anticancer effects of quercetin and its analogs.
Compound
tested





















Quercetin LNCaP, PC-3 Inhibitedproliferation
↓VEGF secretion,
↓mRNA levels [74]
Quercetin HepG2 Inhibitedproliferation ↓PI3K,↓PKC [75]
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Cell lines Effects Mechanisms References
Rutin ACC Inhibitedproliferation ↓PI3K,↓Akt,↓IKK-α,↓NF-κB [76]
Rutin SKOV3 Inhibited cellgrowth ↓Cyclin D1 [77]
Rutin HeLa Inhibited cellgrowth ↑p53,↓NF-κB [78]
Quercetin A549 Inhibited cellgrowth ↓cdk1,↓cyclin B [79]
Quercetin JB6 P+ Inhibited cellmigration Regulation of p13K/Akt [5]
Quercetin U373MG Inhibited cellmigration ↑caspase-7,↑JNK,↑p53 [80]
Quercetin, when used in pharmacologically safe doses, inhibits the phosphatidylinositol 3-kinase
(PI3K)-Akt/PKB (protein kinase B) pathway in cancer cells [81]. Both Raf and MAPK/extracellular
signal-regulated kinase (ERK) kinase (MEK) act as direct targets for quercetin, leading to the potential
to decrease MEK1 activity more powerfully when compared to PD098059, which is a specific MEK
inhibitor. Quercetin donates a hydrogen bond to the main amide group of Ser-212, which is known
to stabilize the inactive conformation of the activated loop of MEK1 [82]. When a dose of 10 g
quercetin/kg was administered to rats for 11 weeks, physiological changes were observed inside the
rats’ colons. This study indicated that quercetin extensively downregulated the potential oncogenic
MAPK signaling in vivo [83]. Various in vitro studies have demonstrated that quercetin plays a key
role in cancer prevention and tumor suppression in different cell lines [84]. The doses of quercetin that
showed anticancer effects in vitro were ranging from 3 to 50 μM [85]. The cancer prevention properties
of quercetin in vivo studies have been confirmed in colon cancer [11]. Furthermore, quercetin has been
shown to exhibit anticancer effects in melanoma [86]. The inhibition of tumor growth by quercetin
was evaluated when it was administered as a food supplement to experimental models. However,
contradictory results have been reported in the literature [87].


























































i.p., intraperitoneal; i.v., intravenous; p.o., per os.
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7.1. Binding Ability of Quercetin to SEK1–JNK1/2 and MEK1–ERK1/2
Studies have shown that various pathways are the possible molecular targets of quercetin to
inhibit inflammatory responses as shown in Figure 3. Quercetin chemically binds to protein kinase as
evidenced by the bead-bound pull-down assay, which has been recognized as a potent screening tool.
Quercetin binds with SAPK/ERK kinase 1 (SEK1), c-Jun N-terminal kinase 1/2 (JNK1/2), MEK1 and
ERK1/2 [93].
Several studies have provided useful evidences that there are many hydrogen bonds between
different hydroxyl groups of quercetin and amino acid residues of SEK1–JNK1/2 and MEK1–ERK1/2.
The ERK1/2 is part of a MAPK cascade, which consists of consecutively functioning kinases, such
as Raf, MEK, and ERK1/2 [94]. The active ERK1/2 induces reprogramming events related to gene
expression by actively phosphorylating diverse intracellular molecular target proteins and other
transcription factors, and hence potentiates cellular growth, spreading, and antiapoptotic properties.
7.2. Cellular Senescence Induction and Telomerase Inhibition
It is a process of irreversible cell aging that occurs in most of the normal cells in response
to the restriction of telomerase enzymes or due to changes in the three-dimensional structure of
telomerase. The cellular death activity is also associated with oncogenic activation or stress caused by
oxidation [95]. The process of senescence induction by phytochemicals is a new alternative approach
to chemoprevention. In a recent study, it was confirmed that both quercetin and resveratrol induced
the cell death process even in very low doses in cells which showed resistance to glioma formation [96].
Despite the fact that there was no proper identification of a molecular target, there was a marked
decrease in Akt phosphorylation. In the senescence induction process, quercetin also targeted the
telomerase induction in eluding the replicate immortality.
Telomerases are specialized DNA polymerases having the ability to join the repeating parts of
the telomerase enzymes with the ends of the DNA strands. The enzyme telomerase is significantly
expressed at certain intervals in the majority of the cells, including the excessively proliferating human
cells. The presence of telomerase activity is closely related to cell death resistance [95]. Quercetin and
other polyphenols, including epigallocatechin-3-gallate (EGCG), inhibit the activity of telomerase in a
cell-free system. The telomerase inhibitory effect was confirmed using adenocarcinoma and breast
carcinoma patients [97].
7.3. Cell Death Induction Activity
Programmed cell death is an important mechanism which is activated to eliminate cancer cells
in the body [95]. There are extrinsic and intrinsic pathways which control the cell death activity in
the body, and these pathways are under the influence of cytokines, which act by binding with tumor
necrosis factor receptors (TNF-R). The cytokines are large molecules which are mostly involved in the
development of immunity [98].
Quercetin bypasses the cell damage resistance through various mechanisms. One example of
quercetin action is evident in lymphocytic leukemia cell line. Quercetin is introduced to the body
with minimum toxic concentrations to induce the apoptotic process. From this study, it is evident
that quercetin induces the apoptotic process when combined with antibodies for the enhancement of
immunity [99].
At molecular levels, quercetin acts by lowering the ROS inside the cell. This property of
scavenging free radical species is a unique function of quercetin among flavonoid derivatives [100].
Apoptosis-inducing activity of quercetin has been confirmed in leukemia and also in cells which are
resistant to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis [101].
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7.4. Interactions of Quercetin with Cellular Receptors
Quercetin binds with different receptors present throughout the body and shows its anticancer
properties. In a recent study, it was concluded that both Raf and MEK are molecular targets of
quercetin in the prevention and treatment of cancer [102]. Whether quercetin has direct interactions
with cell receptors is still unclear, but there are reports that aryl hydrocarbon receptor (AhR) is a known
molecular target receptor for the majority of flavonoids, including quercetin. The AhR receptor is
a ligand-gated transcription factor which is activated by the interaction with synthetic and natural
chemicals [45,103]. Similarly, AhR is responsible for the regulation and expression of cytochrome P-450
(CYP) 1 family, and this family is fully capable of activating procarcinogens. In the biotransformation
of polycyclic aromatic hydrocarbons (PAHs) to metabolites, which are carcinogenic in nature, the CYP1
family members are actively involved [104]. The process of biotransformation is closely associated
with cancer development in the lung. Also, a high level of CYP1 is responsible for colon cancer, a
major cause of cancer-related death [105].
Quercetin inhibits the transformation of AhR and protects the cells from the toxicity induced by
dioxins [106]. The IC50 values of quercetin 3-O-β-D-glucuronide and quercetin 4′-O-β-D-glucuronide
were 42.6 and 181 μM, respectively. It is indicated from this result that aglycones have
stronger antagonistic activity than glucuronides and other metabolites. Quercetin also blocks the
biotransformation of AhR in rat hepatocytes. It is noteworthy that the inhibitory effect of quercetin is
much stronger than the effects of α-naphthoflavone, a well-known antagonist for AhR [107]. It
is evident from these results that quercetin is a strong antagonist for AhR and hence exerts its
pharmacological effects against carcinogenicity developed by PAHs. Quercetin also interacts with other
receptors, which are involved in the prevention of cancer, but the exact mechanism is still unclear [108].
Quercetin has no role in the increase or decrease and distribution of estrogen receptors-beta isoforms
in breast cancer [109]. Quercetin has been shown to possess inhibitory effects in human prostate cancer,
and this effect is linked to the expression of androgen receptors [110]. It has been suggested in a
recent report that a transcription factor is involved in quercetin-mediated inhibition of androgenic
receptor [111].
7.5. Signal Transduction Modification
There are various reports which document modulatory effects of quercetin and other flavonoids
on signal transduction pathways. The use of quercetin enhances the cell death process in HepG2
human hepatoma cells. There are two mechanisms involved in this process; one is the activation
of caspase-3 and caspase-9, but not caspase-8. The other mechanism involves an increase in the
translocation of proapoptotic Bax to the membrane of mitochondria [112]. In a similar study, it has
been shown that quercetin causes the cleavage of polymerase and also potentiates the upregulation of
Bax (Figure 4). Quercetin decreases the levels of key oncogenic protein Ras in cancer cells and blocks
the cell proliferation and survival [113].
Quercetin has been shown to cause changes in apoptosis in mesangial cells by inhibiting the
activation of JNK and other ERKs pathways. It is also clear that there is no significant effect on the
level of p38 MAPK [114]. In a similar study, it is reported that quercetin caused the inhibition of
phosphorylation of p38 and Bcl2. This property of quercetin is useful as it may stop the apoptotic
process [115]. The action of quercetin may be considered as short-term or long-term. The short-term
effect causes scavenging of free radicals and it is mostly antioxidative and antiapoptotic in nature, while
the long term effect is pro-oxidative [116]. The proapoptotic action of quercetin is linked mostly to a
decreased level of glutamate-stimulating hormones (GSH). It is evident that GSH plays an important
role in determining the antioxidant nature of flavonoids. The action of quercetin may depend upon
the concentrations of quercetin in cell culture medium [117].
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Figure 4. Modulation of mitochondrial apoptotic signaling pathways by quercetin. Quercetin induces
p53 activation resulting in upregulation of Bax and downregulation of Bcl-2 in tumor cells. This leads
to caspase activation and ultimately apoptotic cell death.
How to determine the accurate mechanism through which quercetin exerts its effect in controlling
the signal transduction pathway is still unclear. There are few studies on the mechanisms of action
of quercetin, and the specific targets of quercetin are not well known [118]. Apart from the findings
mentioned above, it has been reported that the MEK/ERK pathway is activated by quercetin during
the process of programmed cell death in human lung cancer. This contradiction may be because of the
basic difference in investigational conditions, including the use of various cell lines [119]. Quercetin
is important in the regulation of signal transduction pathways, and such pathways are crucial in the
production of inflammatory mediators. Quercetin also decreases the LPS formation of cytokinase,
and this enzyme causes the inhibition of iNOS by further suppressing ERK and p38 MAPK [120].
Moreover, quercetin significantly reduces the half-life of Ras protein, which is oncogenic in nature, but
no significant action was reported when the cells were treated with proteasome inhibitor [113].
8. Epidemiological Studies about Quercetin
Emerging studies suggest that intake of fruits and vegetables decrease the risk of human
carcinomas, including colon, breast, bladder, stomach, and lung cancer [121]. A plethora of
phytochemicals present in plant-based food products are consumed by humans on a daily basis.
However, it is still unknown which one among these phytoconstituents is responsible for protective
action against cancer. The most studied phytochemicals for anticancer potential are flavonoids [122].
A few studies indicate an opposite relation among the dietary consumption of polyphenols and cancer
risk [123]. However, Hertog and his coworkers [124] assert that there is no association between the
intake of flavonol or flavone derivatives and cancer-related mortality rates.
Regarding quercetin, an opposite co-relation exists between the consumption of quercetin found
in foods and the development of lung cancer caused by smoking [125]. A recent multiethnic clinical
study has provided evidence about the cancer preventive effects of quercetin in the progression of
pancreatic cancer in individuals who were chain smokers and nonsmokers. However, the effect was
more pronounced in smokers compared to nonsmokers, as quercetin imparted its antioxidant activity
in smokers who had increased oxidative stress relative to nonsmokers [126]. It is evident from many
studies that quercetin has beneficial effects against cancer risks. In a study, Gates and coworkers [127]
evaluated the relationship between the intake of quercetin and the incidence rate of the ovarian cancer
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among the nursing staff. The data collected from these results revealed that quercetin intake had
a nonsignificant 29% decrease in ovarian cancer risk compared to women with the lowest intake
of quercetin.
9. Conclusion and Future Perspectives
The studies presented here suggest the potential effects of quercetin in cancer therapy. Numerous
in vitro and in vivo experiments have shown various mechanisms of action that could suppress
multiple oncogenic signaling pathways. Quercetin is safe with no reported toxicity when applied for
the treatment of human cancer. Since quercetin and its derivatives have great benefits, it is the need of
the hour to investigate further the effects of these molecules in the prevention and intervention of cancer.
However, there is still no conclusive evidence regarding its exact mode of action in order to enhance
its clinical application in the treatment of human cancer. Therefore, the future perspective of research
should concentrate on the evaluation of quercetin’s precise mechanisms of action. Similarly, it is
necessary to perform more clinical studies on the efficacy and bioavailability of quercetin in biological
systems for the future use in human population, especially in the treatment of cancer. Moreover,
the conversions of quercetin to its metabolites must be considered while assessing the efficacy and
bioavailability of quercetin for further pharmacological use. The conjugation of xenobiotics with
quercetin alters the reactivity of quercetin, but there are some metabolites of quercetin in conjugated
form which showed beneficial biological activities. It is important to investigate further mechanisms of
action of quercetin, especially in terms of suppressing carcinogenicity in rodents. The results obtained
from the current epidemiological studies shows that there is shortage of evidence of quercetin intake
for the prevention of human cancer. There is a need to conduct further epidemiological studies to
evaluate the role of quercetin in human cancer prevention. Updating the database related to dietary
flavonoids will deliver significant information for future epidemiological studies. The use of quercetin
in the field of pharmaceuticals is limited because of its poor water solubility and oral bioavailability. In
order to enhance the solubility and bioavailability of quercetin inside human body, various scientific
approaches have been taken into consideration, including the application of novel drug delivery
systems such as nanoparticles and liposomes. These and additional approaches may help us to
understand the full potential of quercetin in cancer prevention and therapy.
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Abstract: There is much epidemiological evidence that a diet rich in fruits and vegetables could lower
the risk of certain cancers. The effect has been attributed, in part, to natural polyphenols. Besides,
numerous studies have demonstrated that natural polyphenols could be used for the prevention and
treatment of cancer. Potential mechanisms included antioxidant, anti-inflammation as well as the
modulation of multiple molecular events involved in carcinogenesis. The current review summarized
the anticancer efficacy of major polyphenol classes (flavonoids, phenolic acids, lignans and stilbenes)
and discussed the potential mechanisms of action, which were based on epidemiological, in vitro,
in vivo and clinical studies within the past five years.
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1. Introduction
Globally, there were approximately 14.1 million new cancer cases in 2012, and the number was
estimated to reach 25 million in 2032. Aside from the high incidence, cancer is also one of the leading
causes of death. In 2012 alone, there were about 8.2 million cancer-related deaths, which were mainly
attributed to lung, gastric, colorectal, liver, breast, prostate and cervical cancer [1]. The situation urges
the research of cancer prevention and treatment. In the last two decades, the anticancer effects of natural
polyphenols have become a hot topic in many laboratories. Meanwhile, polyphenols are potential
candidates for the discovery of anticancer drugs. Polyphenols are defined as compounds having at least
one aromatic ring with one or more hydroxyl functional groups attached. Natural polyphenols refer
to a large group of plant secondary metabolites ranging from small molecules to highly polymerized
compounds [2]. Polyphenols are widely present in foods and beverages of plant origins (e.g., fruits,
vegetables, spices, soy, nuts, tea and wine) [3–5]. Based on chemical structures, natural polyphenols
can be divided into five classes, including flavonoids, phenolic acids, lignans, stilbenes and other
polyphenols. Flavonoids and phenolic acids are the most common classes, and account for about 60%
and 30% of all natural polyphenols, respectively (Table 1) [6]. A plethora of studies have documented
the anticancer effects of natural polyphenols [7–11]. Noteworthy examples include anthocyanins from
blueberries, epigallocatechin gallate (EGCG) from green tea, resveratrol from red wine and isoflavones
from soy. The anticancer efficacy of natural polyphenols has largely been attributed to their potent
antioxidant and anti-inflammatory activities as well as their abilities to modulate molecular targets and
signaling pathways, which were associated with cell survival, proliferation, differentiation, migration,
angiogenesis, hormone activities, detoxification enzymes, immune responses, etc. [12,13].
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The present review summarized recent discoveries about the anti-carcinogenic properties of
natural polyphenols and discussed the mechanisms of action, which were based on evidence from
epidemiological studies, laboratory experiments and clinical trials.
Table 1. The classification of natural polyphenols.
Classification Representative Members Major Dietary Sources
flavonoids
anthocyanins delphinidin, pelargonidin,cyanidin, malvidin
berries, grapes, cherries,
plums, pomegranates
flavanols epicatechin, epigallocatechin,EGCG, procyanidins
apples, pears, legumes, tea,
cocoa, wine
flavanones hesperidin, naringenin citrus fruits
flavones apigenin, chrysin, luteolin, parsley, celery, orange,onions, tea, honey, spices
flavonols quercetin, kaempferol, myricetin,isorhamnetin, galangin
berries, apples, broccoli,
beans, tea
isoflavonoids genistein, daidzein soy
phenolic acids




hydroxycinnamic acid ferulic acid, chlorogenic acid coffee, cereal grains
lignans sesamin, secoisolariciresinoldiglucoside flaxseeds, sesame
stilbenes resveratrol, pterostilbene,piceatannol grapes, berries, red wine
2. Epidemiological Studies
Evidence from epidemiological studies is inconsistent, especially when considering the results of
prospective cohort studies (Table 2). A case-control study in Canada reported favorable effects of a high
dietary intake of total flavonoids on lung cancer risks [14]. Apart from this, in a Korean study, for
women, the intake of total flavonoids, as well as flavones and anthocyanidins, was inversely associated
with the risk of gastric cancer [15]. However, another study in America found no significant association
between flavonoids intake and the incidence or survival of gastric cancer [16]. For colorectal cancer,
a meta-analysis showed protective roles of high dietary isoflavone intake [17]. Besides, a Spanish
case-control study suggested that the dietary intake of total flavonoids (especially certain subclasses)
and lignans might decrease colorectal cancer risks [18]. However, large prospective cohorts showed that
high habitual consumption of flavonoids could not protect against colorectal cancer [19]. In addition,
the Fukuoka study reported no association between total dietary polyphenols and colorectal cancer
risks [20]. For hepatocellular carcinoma (HCC), the European Prospective Investigation into Cancer
and Nutrition suggested that a high intake of dietary flavanols, but not total flavonoids, might
modestly decrease HCC risks [21,22]. In addition, according to a meta-analysis, the risk of breast
cancer was reduced in women with a high intake of flavonols and flavones [23]. Studies also suggested
that soy isoflavone intake reduced breast cancer risk for Asian women, which was more potent
for post-menopausal women (OR 0.46, 95% CI 0.28–0.78) than for premenopausal women (OR 0.63,
95% CI 0.50–0.80). However, for women in Western countries, no significant association could be
found, which might due to low levels of isoflavone consumption in the Western population [24,25].
In addition, the estrogen receptor (ER) status might modify the association. For example, a U.S.
prospective cohort study showed that a modest inverse trend existed for dietary flavanols intake and
the risk of ER-negative breast cancer, but not ER-positive cancer [26]. For prostate cancer, data from a
Netherlands cohort study showed that dietary flavonoid intake was correlated with decreased risks of
advanced stage prostate cancer but not overall or non-advanced prostate cancer [27]. On the contrary,
in a prospective cohort study, the intake of total flavonoids as well as flavan-3-ols, isoflavones, and
proanthocyanidins, increased prostate cancer risks [28].
386
Nutrients 2016, 8, 515
It should be noted that the assessment of polyphenol intakes in many epidemiological studies
was based on food questionnaires, which could not provide the exact composition of foods. Therefore,
it might be difficult for them to reflect the real impact of natural polyphenols on cancer. In this case, the
experimental study in cell culture or animal modes might be a more direct way to assess the anticancer
efficacy of natural polyphenols as well as to examine the possible mechanisms involved in this process.
Table 2. Dietary polyphenol intake and cancer risks.
Cancer Polyphenols Study Type Risk Estimates (95% CI) References
lung cancer flavonoids case-control study 0.63 (0.47–0.85) [14]
gastric cancer
flavonoids case-control study no significant association [16]
flavonoids case-control study 0.33 (0.15–0.73) [15]
colorectal cancer
flavonoids cohort study no significant association [19]
flavonoids and
lignans case-control study
total flavonoids 0.59 (0.35–0.99);
lignans 0.59 (0.34–0.99) [18]
polyphenols case-control study no significant association [20]
isoflavones meta-analysis 0.76 (0.59–0.98) [17]





no significant association for total
flavonoids or other subclasses
[23]
isoflavones meta-analysis 0.68 (0.52–0.89) [25]
flavanols cohort study 0.81 (0.67–0.97) [26]
prostate cancer
flavonoids cohort study 1.15 (1.04–1.27) [28]
flavonoids cohort study






Accumulating evidence from laboratory studies has supported the anticancer properties of natural
polyphenols. Given the vast number of studies, a search of PubMed and Web of Science was conducted
to identify relevant peer-reviewed articles published in English within 5 years.
3.1. Anthocyanins
Anthocyanins (Figure 1), which occur ubiquitously throughout the plant kingdom, are the basis
for the bright attractive red, blue and purple colors of fruits and vegetables. In plants, anthocyanins are
usually glycosylated with glucose, galactose, arabinose, rutinose, etc. The aglycone forms are known as








Figure 1. The chemical structures of cyanidin (R1 = OH, R2 = H), delphinidin (R1 = R2 = OH), peonidin
(R1 = OCH3, R2 = H), petunidin (R1 = OCH3, R2 = OH), pelargonidin (R1 = R2 = H) and malvidin
(R1 = R2 = OCH3).
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Among anthocyanins, delphinidin possesses strong anticancer activities. Studies have shown that
delphinidin treatment induced apoptosis and cell cycle arrest in several types of cancer. This effect
might be due to suppression of the NF-κB pathway [30,31]. The over-expression of human epidermal
growth factor receptor 2 (HER2) is usually associated with poor prognosis. A study found that
two anthocyanins extracted from black rice, peonidin-3-glucoside and cyaniding-3-glucoside, could
induce apoptosis and selectively decrease cell proliferation and tumor growth of HER2 positive
breast cancer [32]. In addition, peonidin-3-glucoside treatment significantly suppressed invasion and
metastasis of lung cancer cells by down-regulating the matrix metalloproteinase (MMP) [33]. In similar
ways, cyanidin-3-O-sambubioside from Acanthopanax sessiliflorus fruit inhibited angiogenesis and
invasion of breast cancer cells [34]. Though anthocyanins are usually considered as antioxidants,
a study showed that certain anthocyanins (cyanidin and delphinidin) exhibited oxidative stress-based
cytotoxicity to colorectal cancer cells [35]. Another study evaluated the impact of chemical structures
on chemopreventive activities of anthocyanins in colon cancer cells. Data indicated that nonacylated
monoglycosylated anthocyanins were more potent in inhibiting cancer cell growth, while anthocyanins
with pelargonidin aglycone and triglycosylation were weak [36]. On the other hand, it was suggested
that a mixture of different anthocyanins might be better than a single one in cancer treatment.
For example, a combination of sub-optimal concentration of anthocyanidins synergistically suppressed
the growth of lung cancer cells. Meanwhile, in a mice model of lung cancer, a mixture of anthocyanidins
from bilberry (0.5 mg/mouse) or delphinidin (1.5 mg/mouse) all inhibited tumor growth, and
the effective concentration of delphinidin in the mixture was eight-fold lower than the purified
compound [7].
3.2. Xanthohumol
Xanthohumol (Figure 2) is a major prenylated chalcone isolated from hops (Humulus lupulus).
The compound can also be found in beer, but to a much less extent. In some cancers, the
xanthohumol-induced cell death was accompanied by apoptosis and S phase cell cycle arrest [37,38].
A study suggested that the apoptosis induced by treatment of xanthohumol (10–40 μM) to HepG2 liver
cancer cells was due to modulation of the NF-κB/p53 signaling pathway [39]. Another study reported
that xanthohumol treatment (>5 μM) mediated anticancer activity in human liver cancer cells through
suppression of the Notch1 signaling pathway [40]. In addition, xanthohumol could block the estrogen
signaling pathway. By doing so, it selectively suppressed the growth of ERα-positive breast cancer
both in vitro and in vivo [41]. Cysteine X Cysteine chemokine receptor 4 (CXCR4) is over-expressed in
many cancers and mediates metastasis of cancer cells to sites expressing its cognate ligand CXCL12.
A study demonstrated that xanthohumol treatment dose- and time-dependently decreased expression
of CXCR4, thus inhibiting cell invasion induced by CXCL12 in breast and colon cancer cells [42].
In another study, by promoting production of reactive oxygen species (ROS), xanthohumol treatment
inhibited the progression of advanced tumor and the growth of poorly differentiated prostate cancer







Figure 2. The chemical structure of xanthohumol.
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3.3. Flavanols
Flavanols, also known as flavan-3-ols, have the most complex structures among subclasses of
flavonoid. Flavanols include simple monomers (catechins) as well as oligomers and polymers, the latter
two are known as proanthocyanidins or condensed tannins. Flavanols can be commonly found in
foodstuffs [29].
3.3.1. EGCG
Smoking is a well-established risk factor of lung cancer. A study showed that EGCG (Figure 3)
treatment suppressed nicotine-induced migration and invasion of A549 lung cancer cells in vitro as
well as in mice through inhibiting angiogenesis and epithelial-mesenchymal transition (EMT) [9].
The effects of EGCG varied with dose. In CL1-5 lung cancer cells, at concentration of 5–20 μM, EGCG
effectively suppressed the invasion and migration through suppressing MMP-2 expression. While at
higher concentration (>20 μM), it exhibited anti-proliferation activities through induction of G2/M
cell cycle arrest but not apoptosis [44]. Another study found that several gastric cancer cell lines were
sensitive to EGCG (100 μM) induced apoptosis due to inhibition of survivin, a potent anti-apoptotic
protein [45]. Many signaling pathways might be affected by EGCG treatment. A study showed that
EGCG (20 μM) exerted anti-proliferative effects in gastric cancer cell by preventing the β-catenin
oncogenic signaling pathway [46]. Another study on colon cancer suggested that the Akt, extracellular
signal-related kinase (ERK) 1/2 and alternative p38MAPK signaling pathways were involved in the
chemopreventive effects of EGCG [47]. Besides, there is a growing interest in cancer epigenetics in
recent years mainly due to the reversibility of epigenetic alterations. Major epigenetic alterations
involve DNA methylation, histone modifications and miRNAs [48]. The combination of EGCG
and sodium butyrate inhibited DNA methytransferases and class I histone deacetylases (HDACs)
in colorectal cancer cells, thus modulating global DNA methylation and histone modifications [49].
In addition, the cancer stem cell plays a key role in chemoresistance and recurrence. Both in vitro
and in vivo studies showed that EGCG could suppress cancer stem cell growth of colorectal cancer
as well as breast cancer [50,51]. The anticancer activities of EGCG might involve modulation of
hormone activities. It is known that exposure to estrogen is an important risk factor of breast cancer.
A study found that EGCG (1 μM) could suppress estrogen (estradiol, E2)-induced breast cancer
cell proliferation [52]. In addition, EGCG treatment down-regulated ERα in ER+/PR+ breast cancer
cells [53]. Treatment of EGCG (20 μM) also inhibited metastasis of breast cancer cells by restoring the
balance between MMP and the tissue inhibitor of matrix metalloproteinase (TIMP). Mechanistic studies
suggested that the epigenetic induction of TIMP-3 was a key event in this process, which involved
modifying the enhancer of zeste homolog 2 and HDAC1 [54]. Androgen deprivation is a main therapy
for prostate cancer. It was reported that EGCG could functionally antagonize androgen, leading to












Figure 3. The chemical structure of EGCG.
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3.3.2. Procyanidins
A study suggested that procyanidin C1 from Cinnamomi cortex might be able to prevent
TGF-β-induced EMT in the A549 lung cancer cells [56]. Another study found that hexmer form
of procyanidins from cocoa inhibited the proliferation (50 and 100 μM), induced apoptosis and G2/M
cell cycle arrest in several colorectal cancer cells, which was possibly mediated by the Akt pathway [57].
Procyanidins from Japanese quince also showed pro-apoptotic effects on Caco-2 colon cancer cells,
with the oligomer enriched extract showing a more potent pro-apoptotic activity [58]. Besides, data
shows that in breast cancer cells, treatment of procyanidins from evening primrose (25–100 μM
gallic acid equivalents) decreased cell viability by promoting apoptosis and reduced cell invasion by
suppressing angiogenesis propensity [59].
3.4. Flavanones
Flavanones (Figure 4) are abundant in citrus fruits, especially the solid parts of fruit.
















Figure 4. The chemical structures of naringenin (a) and hesperetin (b).
3.4.1. Naringenin
In A549 lung cancer cells, naringenin treatment enhanced TRAIL-mediated apoptosis by
up-regulating the expression of death receptor 5 [60]. Besides, in SGC-7901 gastric cancer cells,
naringenin treatment inhibited cancer cell proliferation, invasion, and migration and induced apoptosis,
which might be related to its inhibition of the Akt signaling pathway [61]. Another study in
colon cancer cells suggested that the pro-apoptotic activity of naringenin was mediated by the
p38-dependent pathway [62]. In HCC cells, naringenin could suppress TPA-induced cancer cell
invasion by down-regulating multiple signaling pathways, such as the NF-κB pathway, the ERK and
c-Jun N-terminal kinase (JNK) signaling pathway [63]. Besides, naringenin treatment to HepG2 liver
cancer cells induced mitochondrial-mediated apoptosis and cell cycle arrest through up-regulation of
p53 [64]. In breast cancer cells, naringenin demonstrated anti-estrogenic activity in estrogen-rich status
and estrogenic activity in estrogen-deficient status [65]. In addition, oral administration of naringenin
suppressed breast cancer metastases after surgery by modulating the host immunity [66].
3.4.2. Hesperetin
In gastric cancer cells, hesperetin treatment (100–400 μM) decreased cell proliferation and induced
mitochondria-mediated apoptosis via promoting intracellular ROS accumulation. Meanwhile, the
compound (i.p. 20–40 mg/kg thrice a week) significantly suppressed the growth of xenograft tumors
in mice model of gastric cancer [67]. Besides, dietary hesperetin showed anti-proliferative activities
against chemical-induced colon carcinogenesis. Oral supplements of hesperetin (20 mg/kg/day)
reduced the proliferating cell nuclear antigen, the formation of aberrant crypt foci induced by
1,2-dimethylhydrazine in rat [68]. In breast cancer cells, hesperetin (40–200 μM) induced growth
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inhibition also involved mitochondria-mediated apoptosis, increased ROS and activation of ASK1/JNK
pathway [69]. Cancer cells usually have high levels of glucose uptake and metabolism, which
plays an important role in tumor growth. A study suggested that the anti-proliferative effects of
hesperetin (50–100 μM) on breast cancer were possibly due to the suppression of glucose uptake [70].
Another study found that hesperetin treatment (IC50 40–90 μM) decreased proliferation and induced
apoptosis in PC-3 prostate cancer cells, which was likely mediated by inhibition of the NF-κB
pathway [71]. In addition, hesperetin (IC50 650 μM) exhibited potential anticancer effects on cervical
cancer cells through the induction of both extrinsic and intrinsic apoptosis [72].
3.5. Flavones
Flavones (Figure 5) in food are usually the glycosides of apigenin and luteolin. Important dietary





Figure 5. The chemical structures of apigenin (R1 = OH, R2 = H), chrysin (R1 = R2 = H) and luteolin
(R1 = R2 = OH).
3.5.1. Apigenin
Apigenin is a common flavonoid widely distributed in plant-based food, such as orange,
parsley, onions, tea and wheat sprouts [73]. In H460 lung cancer cells, treatment of apigenin
(40–160 μM) induced apoptosis and DNA damage, which was accompanied by increased production
of ROS and Ca2+ as well as a change of the Bax/Bcl-2 ratio [74]. Apigenin (20 μg/mL) also
induced apoptosis in gastric cancer cells, especially in the undifferentiated gastric cancer cells,
while showed little cytotoxicity to normal gastric cells [75]. Helicobacter pylori infection is known
to cause ulcers and is possibly linked to gastric cancer. Atrophic gastritis was suggested to be
a critical step in Helicobacter pylori-induced carcinogenesis. A study found that apigenin administration
(30–60 mg/kg/week) could prevent Helicobacter pylori-induced atrophic gastritis as well as gastric
cancer development in Mongolian gerbils [76]. Additionally, apigenin treatment (20–120 μM)
suppressed proliferation, invasion and migration of several colorectal cancer cell lines. The compound
(50 mg/kg) also inhibited tumor growth and metastasis in the orthotopic colorectal cancer model [77].
About 20% of breast cancer cases are HER2-positive, with amplification of human epidermal
growth factor receptor (HER2) or over-expression of HER2 protein. These cancers are usually more
aggressive and more resistant to hormone treatment than other types of breast cancer. A study
found that apigenin treatment (20–100 μM) significantly suppressed growth and caused apoptosis in
HER2-positive breast cancer cells, which was possibly mediated by inhibition of the signal transducer
and activator of transcription 3 (STAT3) signaling pathway [78]. Another study reported anticancer
effects of apigenin on MDA-MB-231 breast cancer cells in vitro (10–40 μM) and in vivo (5 and
25 mg/kg). Possible mechanisms included induction of G2/M cell cycle arrest and epigenetic
alterations. Apigenin inhibited HDACs, which induced acetylation of histone H3 in the p21WAF1/CIP1
promoter region, leading to enhanced transcription of p21WAF1/CIP1 [79]. Similar epigenetic effects
were also found in prostate cancer. Apigenin inhibited HDACs, especially HDAC1 and HDAC3
expression. In this way apigenin treatment (20–40 μM) induced cell cycle arrest and apoptosis in
prostate cancer cells and markedly inhibited tumor growth in mice (oral administration: 20 and
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50 μg/mouse/day) [80]. In addition, apigenin treatment to mice (20 and 50 μg/mouse/day) markedly
decreased tumor volumes of the prostate, inhibited angiogenesis and completely prevented distant
organ metastasis, which at least in part, was mediated by the PI3K/Akt/Forkhead box O (FoxO)
signaling pathway [81].
3.5.2. Chrysin
Chrysin is a naturally occurring flavone present in honey and propolis as well as the passion flower
(Passiflora caerulea), and has displayed a variety of bioactivities, such as antioxidant, anti-inflammatory
and anticancer activities [82]. AMPK activation is associated with cancer cell apoptosis. A study
suggested that AMPK activation might be involved in the growth inhibition and apoptosis induced by
chrysin treatment (10 μM) in lung cancer cells, and ROS might be a key regulator in this process [83].
Chrysin (50–100 μM) also exhibited chemopreventive effects in colorectal cancer cells, mainly as a result
of TNF-mediated apoptotic cell death, and the aryl hydrocarbon receptor, a transcriptional factor,
seemed to modulate this process [84]. Besides, in human triple-negative breast cancer cells, chrysin
treatment (5, 10 and 20 μM) dose-dependently inhibited the potential of cancer cells to invasion and
migration by down-regulating MMP-10, EMT and the PI3K/Akt signaling pathway [82].
3.5.3. Luteolin
Luteolin is abundant in artichoke as well as several spices, including sage, thyme and oregano.
In A549 lung cancer cells, luteolin exhibited significant cytotoxic effects (IC50 40.2 μM) through induction
of G2 cell cycle arrest and apoptosis. The apoptosis was induced in a mitochondria-dependent
pathway and was associated with activation of JNK and inhibition of NF-κB (p65) translocation [85].
The micro-environment around cancer cells is highly involved in cancer progression. It was
reported that luteolin (1–10 μM) effectively suppressed IL-4 induced polarization of tumor-associated
macrophages (major components of cancer cell micro-environment) and consequently inhibited
monocyte recruitment and migration of Lewis lung cancer cells [86]. Hypoxia is another important
component of cancer micro-environment. In non-small lung cancer cells, high levels of hypoxia are
usually related to EMT. Luteolin treatment (5–50 μM) to non-small lung cancer cells could inhibit
hypoxia-induced EMT as well as cell viability, proliferation and motility. The effect was at least
partly through suppressing the expression of integrin β1 and FAK [87]. More importantly, luteolin
administration (i.p. 10 and 30 mg/kg/day) effectively suppressed tumor growth in a lung cancer mice
model with EGF receptor mutation and drug resistance [88].
In a human gastric cancer xenograft model, luteolin treatment (i.p. 10 mg/kg/day) significantly
suppressed tumor growth, without causing apparent toxicity or weight loss [89]. Luteolin treatment
(20–100 μM) also exhibited cytotoxic effect on several colon cancer cell lines through induction
of apoptosis and cell cycle arrest. Meantime, the same treatment exerted no evident toxicity
on normal differentiated enterocytes [90,91]. These effects of luteolin might be associated with
down-regulation of the IGF-1-mediated PI3K/Akt and ERK1/2 pathways, and suppression of synthesis
of sphingosine-1-phosphate and ceramide traffic [90,91]. Besides, it was indicated that ERα was
a possible target of luteolin. By down-regulating the expression of ERα, luteolin treatment (10–40 μM)
suppressed IGF-1-mediated PI3K/Akt pathway, leading to growth inhibition of MCF-7 breast cancer
cells accompanied by cell cycle arrest and apoptosis [92]. In the MDA-MB-231 ER-negative breast
cancer cells, luteolin treatment also induced cell cycle arrest and apoptosis possibly mediated by EGFR.
In addition, luteolin-supplemented diet (0.01% or 0.05%) effectively reduced tumor burden in mice
inoculated with MDA-MB-231 cells [93]. Besides, in LNCaP prostate cancer cells, luteolin treatment
(30 μM) arrested the cell cycle at G1/S phase, induced cell apoptosis and inhibited cell invasion. The
possible mechanism might be down-regulated expression of prostate-specific antigen by luteolin [94].
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3.6. Flavonols
Flavonols (Figure 6) are probably the most widely distributed flavonoids in foods, but they are
usually present at relatively low concentrations [2]. Representatives of this subclass are quercetin,







Figure 6. The chemical structures of quercetin (R1 = H, R2 = R3 = OH), kaempferol (R1 = R3 = H,
R2 = OH), myricetin (R1 = R2 = R3 = OH), galangin (R1 = R2 = R3 = H) and isorhamnetin (R1 = H,
R2 = OH, R3 = OCH3).
3.6.1. Quercetin
Quercetin treatment (IC50 2.30 ± 0.26 μM) to A549 lung cancer cells induced growth inhibition
via apoptosis. In similar ways, quercetin (8.4 mg/kg) inhibited the growth of transplanted lung
cancer in nude mice [95]. On the other hand, though exposure of gastric cancer cells to quercetin
(IC50 40 and 160 μM in two cell lines respectively) led to pronounced apoptosis, the treatment also
induced protective autophagy, which impaired the anticancer effects of quercetin [96]. AMPK-mediated
signaling pathway, which participates in regulation of energy homeostasis, is important for the adaptive
responses of cancer cells and might be critical for the effects of quercetin. A study found that quercetin
treatment (i.p. 50 mg/kg/day) significantly decreased tumor volume in the HCT116 colon cancer
xenograft model by reducing AMPK activity. Similarly, by inhibiting AMPK, the apoptosis induced
by quercetin (100 μM) was more pronounced under hypoxic conditions than normoxic conditions
in HCT116 colon cancer cells [97]. Besides, in a mouse model of colorectal cancer, dietary quercetin
supplementation (25 mg/kg/day) alleviated several symptoms of cachexia such as body weight, grip
strength and muscle mass [98]. Another study found that quercetin treatment (0.05–0.15 mM) to HCC
cells effectively inhibited proliferation and induced apoptosis through up-regulation of Bad and Bax,
and concomitant down-regulating Bcl-2 and survivin. Importantly, quercetin (i.p. 40 mg/kg/day) also
exhibited excellent inhibition effects on tumor growth in mice [99].
The exposure of MCF-7 breast cancer cells to quercetin (50–200 μM) caused a dose- and
time-dependent decrease of proliferation through induction of apoptosis, which was accompanied by
up-regulation of Bax and down-regulation of Bcl-2 [100]. The inhibition of insulin receptor signaling
by quercetin (100 μM) also impairs proliferation of MDA-MB-231 breast cancer cells. Quercetin
feeding (50 μg/mouse/day) resulted in a significant decrease of tumor growth in mice model of breast
cancer [101]. In another study, quercetin (1–100 μM) inhibited breast cancer cells growth and migration
via reversing EMT, which was linked with the modulation of β-catenin as well as its target genes
(e.g., cyclin D1 and c-Myc) [102]. VEGFR2-mediated pathway participates in the angiogenesis in
cancer development. Quercetin (34 mg/kg/day) inhibited angiogenesis of breast cancer xenograft
in mice, which was performed through suppressing this pathway [103]. Besides, dietary quercetin
(200 mg/kg body weight thrice a week) protected against prostate carcinogenesis induced by hormone
(testosterone) and carcinogen (N-methyl-N-nitrosourea) in rats [104]. In another preclinical rat model
of prostate cancer, oral administration of quercetin (200 mg/kg/day) prevented cancer development
by down-regulating the cell survival, proliferative and anti-apoptotic proteins [105]. In HeLa cervical
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cancer cells, quercetin treatment (110.38 ± 0.66 μM) led to ROS accumulation to induce apoptosis and
G2/M cell cycle arrest [106].
3.6.2. Kaempferol
Kaempferol is a natural flavonol broadly distributed in apples, strawberries, broccoli and
beans, and exhibits a wide range of beneficial properties, such as cardioprotective, anti-diabetic, and
anti-allergic effects [107]. In A549 lung cancer cells, kaempferol treatment inhibited TGF-β1-induced
EMT and migration through suppressing the phosphorylation of smad3 mediated by Akt1 [107].
Another study reported that kaempferol treatment exhibited significant anti-proliferative effects on
MKN28 and SGC7901 gastric cancer cells without apparent cytotoxicity to normal gastric epithelial cells.
The possible mechanism might be induction of apoptosis and G2/M cell cycle arrest. More importantly,
administration of kaempferol suppressed gastric cancer growth in vivo [108]. In HT-29 colon cancer
cells, the treatment of kaempferol (0–60 μM) provoked apoptosis by activating the death receptor
pathway and mitochondrial pathway [109]. Another study in SK-HEP-1 human liver cancer cells
found G2/M cell cycle arrest and autophagy following kaempferol treatment, which might be the
result of the modulation of CDK1/cyclin B expression and AMPK and AKT signaling pathways [110].
Kaempferol induced apoptosis in MCF-7 breast cancer cells [111]. In the same cell line, treatment of
kaempferol (100 μM) also significantly suppressed glucose uptake mediated by GLUT1, which might
be another mechanism underlying its anti-proliferative effects [112]. Besides, both in vitro and
in vivo study revealed that kaempferol could prevent breast cancer induced by 17β-estradiol or
triclosn, an exogenous estrogen [113]. Kaempferol treatment also inhibited breast cell invasion
through down-regulating the expression and activity of MMP-9 by blocking the PKCδ/MAPK/AP-1
cascades [114].
3.6.3. Myricetin
Myricetin is rich in berries, walnuts and herbs. Myricetin treatment to gastric cancer cells exhibited
anti-proliferative effects by inducing apoptosis and cell cycle arrest [115]. In HCT-15 human colon
cancer cells, myricetin treatment induced apoptotic cell death by modulating the Bax/Bcl-2-dependent
pathway [116]. Similarly, myricetin also decreased the expression of anti-apoptotic survivin and Bcl-2
and increased the expression of pro-apoptotic Bax in HCC cells and in vivo [117].
3.6.4. Galangin
Galangin is a naturally occurring flavonoid rich in oregano as well as in Alpinis officinarum,
a common spice in Asia. Galangin treatment (50–200 μM) to SNU-484 human gastric cancer cells
dose- and time-dependently inhibited cell proliferation through induction of apoptosis [118]. Besides,
in hepG2 liver cancer cells, galangin treatment (10–30 μM) significantly inhibited chemical-induced
cell invasion and metastasis by modulating the PKC/ERK pathway [119]. Another study suggested
that galangin (79.8–134 μM) could promote ER stress to suppress the proliferation of HCC cells [120].
3.6.5. Isorhamnetin
Isorhamnetin is a natural flavonoid rich in fruits and vegetables as well as tea, and is also
an immediate metabolite of quercetin, which has drawn attention for its excellent anti-inflammatory
and anticancer activities [121,122].
Treatment of isorhamnetin to A549 lung cancer cells induced apoptotic cell death, which was
accompanied by the up-regulation of capase-3, Bax, p53 and the down-regulation of Bcl-2, cyclin
D1 and PCNA protein. More importantly, isorhamnetin administration to tumor-bearing mice
significantly suppressed tumor growth [123]. Additionally, isorhamnetin suppressed gastric cancer
proliferation and invasion, and induced apoptosis by modulating the peroxisome proliferator-activated
receptor γ (PPAR γ)-mediated pathway in vitro and in vivo [124]. Another study investigated the
anti-proliferative activity of isorhamnetin in several human colorectal cancer cell lines (HT29, HCT116
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and SW480), and found that the compound inhibited proliferation of all tested cancer cells by blocking
the PI3K/Akt/mTOR pathway [125]. Both in vitro and in vivo experiments suggested that the
anticancer property of isorhamnetin in colon cancer involved inhibition of inflammation as well
as oncogenic Src activity and consequential loss of nuclear β-catenin [126]. Another study documented
the anti-proliferative and pro-apoptotic activities of isorhamnetin in breast cancer cells, which was
probably mediated by the Akt and MAPK kinase signaling pathways [121]. Besides, in MDA-MB-231
breast cancer cells, isorhamnetin treatment significantly suppressed cell invasion by down-regulating
MMP-2 and MMP-9, which might be associated with the inhibition of p38 MAPK and STAT3 [122].
3.7. Isoflavones
Due to structural similarities to estrogen, isoflavones (Figure 7) have been classified as
phytoestrogen, another important class of phytochemicals. Genistein and daidzein from soy are




Figure 7. The chemical structures of daidzein (R = H) and genistein (R = OH).
3.7.1. Daidzein
Data indicated that daidzein was an apoptosis inducer in liver cancer cells and treatment of
daidzein (200–600 μM) caused mitochondrial-dependent apoptosis mediated by the Bcl-2 family [127].
In an in vitro study, daidzein (50 μM) as well as its metabolites R-equol and S-equol, suppressed
the invasion of MDA-MB-231 human breast cancer cells at least partly through the down-regulation
of MMP-2 expression [128]. However, another study reported that daidzein treatment (3–10 μM)
up-regulated proto-oncogene BRF2 in ER-positive breast cancer cells but not ER-negative cells.
Female mice treated with a high-isoflavone commercial diet showed significantly increased BRF2
expression [129].
3.7.2. Genistein
Genistein is the most abundant isoflavonoid contained in soy as well as soy products and is also
a major active component of hormonal supplements for menopausal women [10]. In H446 lung cancer
cells, genistein treatment (25–75 μM) effectively suppressed the cell proliferation and migration, which
was accompanied by induction of apoptosis and G2/M cell cycle arrest. Importantly, the treatment
also suppressed the expression of Forehead box protein M1 and its target genes regulating cell cycle
or apoptosis, such as survivin, cyclin B1 and Cdc25. Therefore, the effects of genistein were at least
partly mediated by Forkhead box protein M1 [130]. In addition, genistein treatment (15 μM) to gastric
cancer cells suppressed the cancer cell stem-like abilities, includingself-renewal, drug resistance and
carcinogenicity, which might be due to down-regulation of stemness related genes as well as drug
resistance gene ABCG2. Meantime, genistein (i.p. 1.5 mg/kg/day) significantly decreased the weight
and size of gastric cancer inoculated in nude mice [131]. Besides, genistein (25–100 μM) exhibited
anti-proliferative and pro-apoptotic effects on colon cancer cells. The study indicated that inhibition of
oncogenic miR-95, Akt and SGK as well as phosphorylation of Akt could be involved in these anticancer
effects. Moreover, genistein treatment (i.p. 20, 50, 80 mg/kg/day) to mice significantly decreased
the weight and size of transplanted colorectal cancer [132]. Oral administration of genistein also
inhibited angiogenesis and suppressed metastasis of colorectal cancer to distant organs in mice [133].
395
Nutrients 2016, 8, 515
According to in vitro studies, the anticancer effects of genistein on colorectal cancer might involve
the suppression of Wnt, NF-κB signaling pathways [134,135]. Additionally, in nude mice inoculated
with liver cancer cells, oral administration of genistein (50 mg/kg/day) significantly suppressed the
intrahepatic metastasis [136].
Genistein treatment (5, 10 or 20 μM) elicited growth inhibition of MDA-MB-231 breast cancer
cells, which was accompanied by apoptosis and G2/M cell cycle arrest. This effect might be mediated
by down-regulation of the NF-κB activity via the Notch-1 pathway [137]. In MCf-7 breast cancer cells,
genistein treatment (15 and 30 μM) also inhibited cell growth, induced apoptosis and decreased the
CD44+CD24− cancer stem cells. Importantly, genistein (i.p. 20 and 50 mg/kg/day) could also target
breast cancer stem cells to reduce the volume and weight of xenograft tumors in nude mice. The effects
might be correlated with down-regulation of Hedgehog-Gli1 signaling pathway [138]. However, some
studies found that genistein has adverse effects on breast cancer treatment. A study suggested that the
ERα/ERβ ratio could be a determinant of genistein functions in breast cancer. In breast cancer with
a low ERα/ERβ ratio (e.g., T4D7 cells), genistein treatment might be harmless or even beneficial, while
in breast cancer with a high ratio (e.g., MCF-7 cells), the treatment might be counterproductive [139].
Genistein (10 μM) could also affect the expression and function of ATP-binding cassette drug
transporters in breast cancer cells. The effect resulted in an increase of efflux and resistance of
chemotherapeutic drugs (doxorubicin and mitoxantrone) in MCF-7 cells [10]. Moreover, in athymic
mice model of breast cancer, a low dose long-term treatment of genistein (≤500 ppm) led to tumor
growth as well as more aggressive and advanced phenotypes [140]. Genistein was also reported to
have different effects on prostate cancer cells. In LAPC-4 cells with wild androgen receptor, genistein
treatment (0.5–50 μM) dose dependently suppressed cell proliferation and androgen receptor. However,
in LNCaP cells with T877A mutant androgen receptor, genistein promoted cancer cell growth and
androgen receptor at physiological concentration (0.5–5 μM), but showed inhibitory activities at higher
concentration. Similar biphasic activities of genistein were also observed in PC-3 cells transfected
with androgen receptor mutants [141]. In addition, the exposure of HeLa cervical cancer cells to
genistein (IC50 100 μM) led to growth inhibition mediated by apoptosis and G2/M cell cycle arrest and
suppressed cell migration by modulating MMP-9 and TIMP-1 [142].
3.8. Phenolic Acids
Phenolic acids (Figure 8) can be mainly classified into two groups, hydroxybenzoic acid and
hydroxycinnamic acid. Hydroxybenzoic acids present in few edible plants and are not considered to
be of high nutritional interest. The other group is more common in food, but its consumption is highly


















Figure 8. The chemical structures of (a) ellagic acid; (b) gallic acid and (c) ferulic acid.
3.8.1. Ellagic Acid
Ellagic acid is a dietary flavonoid abundantly in pomegranate, grapes, strawberries and
walnuts [143]. Ellagic acid (50–200 μM) exerted anti-proliferative and pro-apoptotic effects in colon
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cancer cell lines in a concentration dependent manner [144]. Besides, in a chemical-induced liver
cancer rat model, oral administration of ellagic acid (30 mg/kg/day) normalized the permeability of
mitochondrial outer membrane and alleviated inflammation-mediated cancer cell proliferation [145].
Ellagic acid (10–40 μg/mL) also showed growth inhibitory effects on MCF-7 breast cancer cells, which
was accompanied by G0/G1 cell cycle arrest. The modulation of the TGF-β/Smads signaling pathway
was suggested to be the potential mechanism [143]. Furthermore, exposure to ellagic acid (i.p. 50 and
100 mg/kg/day) suppressed tumor growth and angiogenesis in mice implanted with breast cancer
cells [146]. In another study, non-cytotoxic dose of ellagic acid (25 and 50 μM) to androgen independent
prostate cancer cells markedly suppressed the cell invasion and motility. The effect might be the result
of down-regulation of MMPs [147]. Besides, at higher dose (10–100 μM), ellagic acid treatment was
found to induce growth inhibition and caspase-dependent apoptosis in PC3 prostate cancer cells in
a dose responsive manner [148].
3.8.2. Gallic Acid
Gallic acid is widely distributed in plant-based food in free forms as well as part of hydrolyzable
tannins. Blackberry, raspberry, walnuts, chocolate, wine, green tea and vinegar are rich sources
of the compound. Gallic acid possesses various pharmacological activities, such as anti-microbial,
anti-inflammatory and anticancer activities [149,150]. Exposure to gallic acid (3.5 μM) inhibited
migration of AGS gastric cancer cells, which was possibly mediated by up-regulation of RhoB as well
as down-regulation of AKT/small GTPase signals and NF-κB activity. In addition to this, compared
with the control, feeding with gallic acid solution (0.25% and 0.5%) significantly decreased tumor size
and weight in mice models of gastric cancer [151]. The ROS-dependent pro-apoptotic effects of gallic
acid led to decreased viability of different cancer cells, such as HCT-15 colon cancer cells (200 μM) and
LNCaP prostate cancer cells (80 μg/mL) [149,152]. Besides, gallic acid treatment selectively inhibited
growth of liver cancer cells through the mitochondria-mediated apoptotic pathways (IC50 for cancer
cells 28.5 ± 1.6 μg/mL and 22.1 ± 1.4 μg/mL, for normal human hepatocytes 80.9 ± 4.6 μg/mL) [153].
Studies on MCF-7 breast cancer cells also showed that gallic acid treatment inhibited cell proliferation
(IC50 80.5 μM) and induced apoptosis via both the extrinsic and intrinsic pathways [150]. Additionally,
exposure to gallic acid (25 and 50 μM) suppressed the invasion and migration of PC-3 prostate cancer
cells through down-regulation of MMP-2 and MMP-9 [154]. In another study, gallic acid (50, 100,
and 200 μM) in PC-3 prostate cancer cells provoked DNA damage and inhibited expression of DNA
repair genes, which contributed to gallic-induced growth inhibition [155]. Treatment with gallic acid
(10–40 μg/mL) decreased cell viability, proliferation, invasion and angiogenesis HeLa and HTB-35
cervical cancer cells, but showed less cytotoxicity on normal cells (HUVEC), indicating a potential role
of the compound in cervical cancer treatment [156].
3.8.3. Ferulic Acid
The main dietary sources of ferulic acid are cereal grains, particularly the outer parts of grain.
The compound has attracted great attention due to its therapeutic activities against various diseases,
such as cancer, cardiovascular and neurodegenerative diseases [157,158].
It was reported that ferulic acid was a pro-oxidant at high concentration or in the presence of metal
ions such as copper. Since the increased level of copper was observed in many cancers, and cancer cells
are usually under greater oxidative stress than normal cells, the pro-oxidant ability of ferulic acid might
lead to selective cytotoxicity to cancer cells [157]. Ferulic acid (10 μg/mL) also decreased cell viability
and enhanced efficacy of radiotherapy in two cervical cancer cell lines (HeLa and ME-180), possibly
through promotion of ROS [159]. Another study on prostate cancer found that the effects of ferulic
acid varied with cell types. Ferulic acid treatment caused cell cycle arrest in PC-3 cells (IC50 300 μM),
and led to apoptosis in LNCaP cells (IC50 500 μM) [158].
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3.9. Lignans
Lignans (Figure 9) are widely present in plants, such as flaxseed, sesame, and seeds of
Arctium lappa. Secoisolariciresinol diglucoside (SDG) is a natural lignan rich in flaxseed, and can
be converted into more biologically active lignans (enterodiol and enterolactone) by human colon
bacteria. These lignans are structurally similar to estradiol; thus, they may have anticancer effects for
hormone-related cancers, such as breast, prostate and colon cancer. For example, SDG was reported to
possess selective estrogen receptor modulating effects and display anti-estrogenic activity in a high
estrogen environment. Treatment with SDG (100 ppm in diet) normalized some biomarkers changed
by carcinogen in mammary gland tissue of mice [160]. In another study, enterolactone modulated
expression of genes involved in cell proliferation and cell cycle of MDA-MB-231 breast cancer cells





















Figure 9. The chemical structures of (a) Secoisolariciresinol diglucoside and (b) sesamin.
Sesamin is a major lipid soluble lignan from sesame oil. Sesamin treatment (1, 10 and 50 μM)
dose-dependently decreased cell viability and increased apoptosis in MCF-7 breast cancer cells.
The lignan (10–100 μM) also inhibited the pro-angiogenic activity of macrophages in MCF-7 cells by
down-regulating VEGF and MMP-9 [162]. Besides, it was suggested that STAT3 played an important
role in sesamin (25–125 μM) induced G2/M cell cycle arrest and apoptosis in HepG2 cells [163].
Sesamin (10–100 μg/mL) could suppress lipopolysaccharide-induced proliferation and invasion of
PC3 prostate cancer cells by modulating the p38-MAPK and NF-κB signaling pathways. Likewise,
sesamin pretreatment (10 mg/kg every three days, injection) suppressed PC3 cells-derived tumor
growth triggered by lipopolysaccharide in mice [164].
3.10. Stilbenes
Natural stilbenes (Figure 10) are another important group of polyphenols. Though they only exist
in a limited group of plant families, the prominent health benefits of resveratrol, an important member
of this class, have attracted a lot of studies into natural stilbenes.
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Figure 10. The chemical structures of resveratrol (R1 = R2 = R3 = H), pterostilbene (R1 = R2 = CH3,
R3 = OH), piceatannol (R1 = R2 = H, R3 = OH).
3.10.1. Resveratrol
Resveratrol is predominantly found in red wine, grapes and berries. X-ray repair cross
complement group 1 (XRCC1) participates in base excision repair. It was reported that resveratrol
treatment (5–50 μM) could suppress XRCC1 expression, thus leading to enhanced chemosensitivity to
etoposide (a topoisomerase II inhibitor) of human non-small-cell lung cancer cell lines [165]. Besides,
it was reported that 20 μM resveratrol treatment significantly suppressed invasion and metastasis of
A549 lung cancer cells by inhibiting EMT [11].
In gastric cancer cells, resveratrol treatment (25 and 50 μM) arrested cancer cells in the G1 phase,
resulting in senescence instead of apoptosis. In similar ways, resveratrol (40 mg/kg/day) inhibited
gastric cancer development in nude mice [166]. However, at higher concentrations (50–200 μM),
resveratrol induced DNA damage and apoptosis in human gastric adenocarcinoma cells via promoting
generation of ROS [167]. Resveratrol induced apoptosis in different colon cancer cell lines via
modulating diverse targets. For example, resveratrol induced caspase-8 and -3 dependent apoptosis
via ROS-triggered autophagy in HT-29 (IC50 150 μM) and COLO 201 (IC50 75 μM) human colon
cancer cells [168]. A study reported that the indirect DNA-damaging effects of resveratrol (30 μM)
in colon cancer cells were mainly caused by overproduction of ROS [169]. Another study suggested
that the DNA damage induced by resveratrol (25 μM) was due to topoisomerase II poisoning
rather than promoting ROS production [170]. Besides, resveratrol (50 μM) suppressed expression of
multi-drug resistance protein 1 (MDR1) and drug efflux in drug-resistant colorectal cancer cells [171].
Activating mutations in Kras contribute to sporadic colorectal cancer. An in vivo study found that
dietary supplements of resveratrol (equivalent to 105 and 210 mg daily for humans) protected against
formation and growth of colorectal cancer by suppressing expression of Kras [172]. In addition,
in colorectal cancer patients, following oral administration of resveratrol, high concentrations of
resveratrol conjugates (mainly RSV-3-O-sulfate, RSV-3-O-glucuronide and RSV-4′-O-glucuronide)
were found in the colorectum. Mixture of these conjugates exhibited synergistic anticancer effects
by inducing DNA damage and apoptosis in human colorectal cancer cells. Therefore, despite the
low bioavailability of resveratrol, the anti-carcinogenic properties could also be achieved by its
main metabolites [173]. Cancer stem cells possess the ability to self-renew and are important for
tumor generation. Three signaling pathways regulated the self-renewal of breast cancer stem cells
are Wnt, Notch and Hedgehog. It was reported that resveratrol could inhibit the Wnt/β-catenin
signaling pathway in breast cancer stem cells. Accordingly, resveratrol treatment (i.v. 100 mg/kg/day)
to mice significantly suppressed tumor growth as well as the breast cancer stem cells in primary
xenografts [174]. Resveratrol is also a powerful chemopreventive agent against liver cancer. At low
concentration, resveratrol treatment (25–100 μM) inhibited metastasis of HCC cells and decreased
expression of urokinase-type plasminogen activator (u-PA), which involved down-regulation of the
SP-1 signaling pathway [175]. Besides, in N-nitrosodiethylamine treated rat, the oral administration
of resveratrol (20 mg/kg/day) either at early or advanced stages of liver carcinogenesis was equally
effective, possibly mediated by apoptosis [176]. In androgen independent prostate cancer cells,
resveratrol treatment (25–100 μM) induced autophagy-mediated cell death [177]. In addition,
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oral administration of resveratrol (30 mg/kg thrice a week) to mice inhibited proliferation, induced
apoptosis, and suppressed angiogenesis and metastasis of prostate cancer [178]. In several cervical
cancer cells, resveratrol treatment (150–250 μM) caused cell cycle arrest and apoptosis [179].
3.10.2. Pterostilbene
Pterostilbene is a natural dimethoxylated analog of resveratrol mainly found in blueberries.
The hydroxyl group substitution with methoxyl groups gives pterostilbene greater lipophilicity,
oral bioavailability and biological half-life than resveratrol.
Pinostilbene is a major metabolite of pterostilbene in the colon of mice. At physiologically relevant
concentrations (20 and 40 μM), it significantly inhibited cell growth, and induced apoptosis and S phase
arrest of human colon cancer cells. Therefore, pinostilbene might be important for the anticancer effects
of orally administered pterostilbene [180]. In addition, pterostilbene treatment (25–75 μM) was able
to induce apoptosis in breast cancer cells via Bax activation and over-expression [181]. MicroRNAs
(miRNAs) are small non-coding RNAs, which control post-transcriptional expression of genes. It was
suggested that miRNAs are highly involved in the development of cancer [48]. A study reported that
pterostilbene treatment inhibited EMT and metastasis of breast cancer cells (2.5–10 μM). Mechanistic
investigations also showed an up-regulation of miR-205 following pterostilbene treatment, which
inhibited the Src/Fak signaling and suppressed tumor growth and metastasis in MDA-MB-231-bearing
NOD/SCID mice (i.p. 10 mg/kg thrice a week) [182]. Another study found that pterostilbene treatment
selectively killed breast cancer stem cells (IC50 25 μM) and sensitized these cells to chemotherapeutic
drug paclitaxel [183]. Besides, pterostilbene treatment (80 μM) activated AMPK in both p53 positive
and negative human prostate cancer cells, but the cell fate following AMPK activation was affected
by p53 status. In p53 positive LNCaP cells, pterostilbene caused G1 cell cycle arrest by increasing
p53 expression, while in p53 negative PC3 cells, pterostilbene treatment induced apoptosis [184].
In another study, pterostilbene (i.p. 50 mg/kg/day) inhibited tumor growth in mice models of prostate
cancer [185].
3.10.3. Piceatannol
Piceatannol is a hydroxylated analog of resveratrol present in a variety of foods, for example,
grapes, berries, passion fruit, and white tea. In colorectal cancer cells, piceatannol treatment (30 μM)
induced apoptosis by up-regulating miR-129, and thus down-regulating Bcl-2, which is a known
target of miR-129 [186]. Besides, in prostate cancer cells, treatment with piceatannol (25 and 50 μM)
inhibited proliferation, and induced cell cycle arrest and apoptosis, which might be associated with
down-regulated mTOR [187]. Piceatannol was also a potential anti-invasive and anti-metastasis
agent on prostate cancer cells. The oral administration of piceatannol (20 mg/kg/day) significantly
suppressed the metastasis of prostate cancer to lung in mice [188].
The anticancer activities and potential mechanisms of the polyphenols reviewed in this section
were summarized in Table 3 and Figure 11. Due to the critical role of cancer stem cells in cancer
development and treatment, the anti-cancer stem cell effects of polyphenols were summarized in
Table 4. It should be noted that curcumin is not discussed in this section because it has been extensively
reviewed [189–191]. Besides, the bioavailability of many polyphenols is low, which might hamper
their application in cancer treatment (Table 5) [6].
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Table 3. The in vitro and in vivo anticancer activities of natural polyphenols.
Polyphenol Study Type Dose Main Effects References
Lung Cancer
peonidin-3-glucoside in vitro 10–40 μM inhibiting cancer cell invasion, motility,secretion of MMPs and u-PA [33]
anthocyanidins in vivo 0.5 mg/mouse inhibiting tumor growth [7]
xanthohumol in vitro 14–42 μM inducing apoptosis and cell cycle arrest [38]
EGCG in vitro 5–20 μM suppressing cancer cell invasion,migration, MMP-2 [44]
EGCG in vivo NA 1 suppressing nicotine-induced angiogenesis [9]
procyanidin C1 in vitro 1.25–40 μg/mL inhibiting TGF-β-induced EMT [56]
naringenin in vitro 100 μM enhancing TRAIL-mediated apoptosis [60]
apigenin in vitro 40–160 μM inducing apoptosis and DNA damage [74]
chrysin in vitro 10 μM inducing apoptosis, AMPK activation, ROS [83]
luteolin in vitro 5–50 μM




luteolin in vivo 10–30 mg/kg suppressing tumor growth [88]
quercetin in vivo 8.4 mg/kg suppressing tumor growth [95]
kaempferol in vitro 10–50 μM inhibiting TGF-β1-induced EMTand migration [107]
isorhamnetin in vivo NA suppressing tumor growth [123]
genistein in vitro 25–75 μM
suppressing cancer cell proliferation and
migration, accompanied by apoptosis and
cell cycle arrest
[130]
resveratrol in vitro 5–50 μM





EGCG in vitro 20–100 μM inducing apoptosis, down-regulatingsurvivin, the β-catenin signaling pathway [45,46]
naringenin in vitro 20–80 μM
inducing apoptosis, inhibiting cancer cell
proliferation, invasion, migration and the
AKT pathway
[61]
hesperetin in vivo 20–40 mg/kg suppressing tumor growth [67]
apigenin in vitro 20 μg/mL inducing apoptosis [75]
apigenin in vivo 30–60 mg/kg preventing Helicobacter pylori-inducedatrophic gastritis and carcinogenesis [76]
luteolin in vivo 10 mg/kg suppressing tumor growth [89]
quercetin in vitro 40–160 μM inducing apoptosis andprotective autophagy [96]
kaempferol in vivo 20 mg/kg suppressing tumor growth [108]
myricetin in vitro 20–40 μM inducing apoptosis and cell cycle arrest [115]
galangin in vitro 50–200 μM inducing apoptosis [118]
isorhamnetin in vivo 1 mg/kg increasing PPAR-γ, decreasing Bcl-2 andCD31 [124]
gallic acid in vivo 0.25% and 0.5%in water decreasing tumor size and weight [151]
resveratrol in vitro 50–200 μM inducing apoptosis, DNA damage,ROS production [167]
resveratrol in vivo 40 mg/kg suppressing tumor growth [166]
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Table 3. Cont.
Polyphenol Study Type Dose Main Effects References
Colorectal Cancer
delphinidin in vitro 30–240 μM inducing apoptosis, cell cycle arrest,oxidative stress [30]
cyanidin in vitro 100 μM inducing oxidative stress [35]
EGCG in vitro 1–50 μM inducing epigenetic alteration, apoptosis,MAPK and Akt pathways activation [47,49]
procyanidins in vitro 50 and 100 μM inducing apoptosis and cell cycle arrest [57]
naringenin in vitro 50–200 μM inducing apoptosis [62]
hesperetin in vivo 20 mg/kg suppressing chemical-inducedcarcinogenesis [68]
apigenin in vivo 50 mg/kg inhibiting tumor growth and metastasis [77]
chrysin in vitro 50–100 μM inducing TNF-mediated apoptoticcell death [84]
luteolin in vitro 20-100 μM inducing apoptosis and cell cycle arrest [90]
quercetin in vivo 25–50 mg/kg
suppressing tumor growth by reducing
AMPK activity and alleviating
cachexia symptoms
[97,98]
kaempferol in vitro 0–60 μM inducing apoptosis [109]
myricetin in vitro NA inducing apoptosis [116]
isorhamnetin in vivo 200 g/kg in diet
suppressing mortality, tumor number,
tumor burden and chemical-induced
inflammatory responses
[126]
genistein in vivo 20–80 mg/kg
decreasing the weight and size of
transplanted tumor, inhibiting angiogenesis
and metastasis
[132,133]
ellagic acid in vitro 50–200 μM inducing apoptosis [144]
gallic acid in vitro 200 μM inducing apoptosis [149]
resveratrol in vitro 25–150 μM inducing apoptosis, DNA damage andsuppressing drug resistance [168–171]
resveratrol in vivo equal to 105 and210 mg for human
suppressing tumor development by
modulation of Kras [172]
piceatannol in vitro 30 μM inducing apoptosis mediated by miR-129 [186]
Liver Cancer
xanthohumol in vitro 5–40 μM
inducing apoptosis, modulating the
NF-κB/p53 and the Notch1
signaling pathways
[39,40]
naringenin in vitro 25–200 μM
suppressing TPA-induced cancer cell
invasion, inducing apoptosis and cell
cycle arrest
[63,64]
quercetin in vivo 40 mg/kg suppressing tumor growth [99]
kaempferol in vitro 25–100 μM inducing cell cycle arrest and autophagy [110]
myricetin in vivo 100 mg/kg suppressing chemical-inducedcarcinogenesis [117]
galangin in vitro 10–134 μM inhibiting chemical-induced cell invasion,metastasis, promoting ER stress [119,120]
daidzein in vitro 200–600 μM inducing apoptosis [127]
genistein in vivo 50 mg/kg suppressing the intrahepatic metastasis [136]
ellagic acid in vivo 30 mg/kg suppressing chemical-inducedcarcinogenesis [145]
gallic acid in vitro 22.1–28.5 μg/mL inducing apoptosis [153]
sesamin in vitro 25–125 μM inducing apoptosis and cell cycle arrestmediated by STAT3 [163]
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Liver Cancer
resveratrol in vitro 25–100 μM
inhibiting metastasis, decreasing
expression of u-PA, down-regulating the
SP-1 signaling pathway
[175]
resveratrol in vivo 20 mg/kg suppressing chemical-inducedcarcinogenesis [176]
Breast Cancer
anthocyanins in vivo 6 mg/kg suppressing the growth ofHER2-positive tumor [32]
cyanidin-3-
O-sambubioside in vitro 1–30 μM inhibiting angiogenesis and invasion [34]
xanthohumol in vitro NA decreasing expression of CXCR4, inhibitingcell invasion induced by CXCL12 [42]
xanthohumol in vivo 0.3 and 1.0 mg/kg
blocking the estrogen singling pathway,
selectively suppressing the growth of
ERα-positive breast cancer
[41]
EGCG in vitro 1–40 μM
suppressing estrogen-induced cancer cell
proliferation, down-regulating ERα ,
inhibiting metastasis by restoring the
balance between MMP and TIMP
[52–54]
procyanidins in vitro 25–100 μM inducing apoptosis, reducinginvasion, angiogenesis [59]
naringenin in vivo 100 mg/kg suppressing lung metastases by thehost immunity [66]
hesperetin in vitro 40–200 μM
inducing apoptosis, ROS production and
activation of ASK1/JNK pathway,
suppressing glucose uptake
[69,70]
apigenin in vitro 20–100 μM
suppressing growth and causing apoptosis
possibly mediated by the STAT3
signaling pathway
[78]
apigenin in vivo 5–25 mg/kg inducing cell cycle arrest throughepigenetic change [79]
chrysin in vitro 5–20 μM inhibiting cancer cell invasionand migration [84]
luteolin in vitro 10–40 μM down-regulating ERα expression, inducingapoptosis and cell cycle arrest [92]
luteolin in vivo 0.01%–0.05%in diet reducing tumor burden [93]
quercetin in vitro 1–200 μM inducing apoptosis, suppressing the insulinreceptor signaling and EMT [100–102]
quercetin in vivo 34 mg/kg inhibiting angiogenesis [103]
kaempferol in vitro 100 μM inducing apoptosis and suppressingglucose uptake [111,112]
kaempferol in vivo 100 mg/kg preventing cancer development inducedby estrogen [113]
isorhamnetin in vitro 10–40 μM inhibiting cancer cell adhesion,migration, invasion [122]
daidzein in vitro 3–50 μM
decreasing invasion, MMP-2 expression,
up-regulating proto-oncogene BRF2 in
ER-positive cancer cells
[128,129]
genistein in vitro 5–20 μM inducing apoptosis, cell cycle arrest,increasing drug resistance [10,137]
genistein in vivo ≤500 ppm enhancing tumor growth [140]
ellagic acid in vitro 10–40 μg/mL inducing cell cycle arrest [143]
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Breast Cancer
ellagic acid in vivo 50–100 mg/kg suppressing tumor growthand angiogenesis [146]
gallic acid in vitro 80.5 μM inducing apoptosis [150]
SDG in vivo 100 ppm in diet normalizing some biomarkers changedby carcinogen [160]
enterolactone in vitro 261.9 ± 10.5 μM modulating expression of genes involved incell proliferation and cell cycle [161]
sesamin in vitro 1–100 μM inducing apoptosis and inhibiting thepro-angiogenic activity of macrophages [162]
pterostilbene in vitro 25–75 μM inducing apoptosis [181]
pterostilbene in vivo 10 mg/kg suppressing tumor growth and metastasis [182]
Prostate Cancer
delphinidin in vitro 3–90 μM inducing apoptosis and cell cycle arrest [31]
xanthohumol in vivo 50 μg/mouse suppressing tumor growth and progression [43]
EGCG in vivo 1 mg 3×/week antagonizing androgen, suppressingtumor growth [55]
hesperetin in vitro 40–90 μM inducing apoptosis, inhibiting theNF-κB pathway [71]
apigenin in vivo 20 and50 μg/mouse
suppressing tumor growth,
angiogenesis, metastasis [81]
luteolin in vitro 30 μM inducing apoptosis, cell cycle arrest,inhibiting invasion [94]
quercetin in vivo 200 mg/kg inhibiting carcinogenesis induced byhormone and carcinogen [104]
genistein in vitro 0.5–50 μM different effects dependent onandrogen receptor [141]
ellagic acid in vitro 10–100 μM inducing apoptosis, inhibiting cellinvasion, motility [147,148]
gallic acid in vitro 25–200 μM provoking DNA damage, down-regulatingDNA repair genes, invasion and migration [154,155]
ferulic acid in vitro 300–500 μM inducing apoptosis and cell cycle arrest [158]
sesamin in vivo 10 mg/kg suppressed tumor growth induced by LPS [164]
resveratrol in vitro 25–100 μM inducing autophagy-mediated cell death [177]
resveratrol in vivo 30 mg/kg inducing apoptosis, suppressingangiogenesis and metastasis [178]
pterostilbene in vitro 80 μM inducing apoptosis and cell cycle arrest [184]
pterostilbene in vivo 50 mg/kg suppressing tumor growth [185]
piceatannol in vitro 25 and 50 μM inducing apoptosis and cell cycle arrest [187]
piceatannol in vivo 20 mg/kg suppressing lung metastasis [188]
Cervical Cancer
hesperetin in vitro 650 μM inducing apoptosis [72]
quercetin in vitro 110.38 μM inducing apoptosis and cell cycle arrest [106]
genistein in vitro 100 μM inducing apoptosis, cell cycle arrest,suppressing cell migration [142]
gallic acid in vitro 10–40 μg/mL decreasing cell proliferation,invasion, angiogenesis [156]
ferulic acid in vitro 10 μg/mL enhancing efficacy of radiotherapy [159]
resveratrol in vitro 150–250 μM inducing apoptosis and cell cycle arrest [179]
1 NA, stands for not available.
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Figure 11. Mechanisms of the anticancer activities of natural polyphenols → stands for activation, – for
regulation, ⊥ for inhibition.
Table 4. The anti-cancer stem cell effects of polyphenols.
Compound Cancer Study Type Dose Effect References
EGCG
colorectal
cancer in vivo 100 μM




breast cancer in vivo 16.5 mg/kg
decreasing tumor growth, the





gastric cancer in vivo 1.5 mg/kg decreasing tumor weight and size [131]
breast cancer in vivo 20–50 mg/kg
targeting breast cancer stem cells





resveratrol breast cancer in vivo 100 mg/kg
inhibited the Wnt/β-catenin
signaling pathway, tumor growth
and cancer stem cells
[174]
pterostilbene breast cancer in vitro 25 μM decreasing cancer stem cells anddrug resistance [183]
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Table 5. The bioavailability of some natural polyphenols.
Compound Subject Treatment Urine Concentration Plasm Concentration





EGCG human 2 mg/kg NA mean Cmax 0.09 μmol/L,Tmax 2 h
naringenin human fresh orange segments 150 g (11.8mg/150 g fresh weight) *
mean urinary
excretion 12.5%
mean Cmax 0.08 μmol/L,
Tmax 5.88 h
hesperetin human fresh orange segments 150 g (79.7mg/150 g fresh weight) *
mean urinary
excretion 4.53%
mean Cmax 0.09 μmol/L,
Tmax 7 h
quercetin human dry shallot skin 1.4 mg/kg(4.93 μmol/g fresh weight) * NA
mean Cmax 3.95 μmol/L,
Tmax 2.78 h
isorhamnetin rat 0.25 mg/kg NA mean Cmax 0.18 μmol/L,Tmax 8 h
daidzein human soy milk 750 mL/day(5.4 mg/250 mL) *
148.35 μmol/24 h
after 5 days 196.1 nmol/L after 5 days
genistein human soy milk 750 mL/day(16.98 mg/250 mL) *
2077.7 μmol/24 h
after 5 days 797.04 nmol/L after 5 days
ellagic acid human freeze-dried black raspberry45 g/day (0.3 mg/g dry weight) * NA
mean Cmax 0.01 μmol/L,
Tmax 1.98 h
gallic acid human grape skin extract 18 g (0.7 mg/gdry weight) * 5.9 μmol after 24 h NA
ferulic acid rat 5.15 mg/kg mean urinaryexcretion 43.4%
mean Cmax 1.68 μmol/L,
Tmax 1 h
resveratrol human 1 mg/kg trans-resveratrol mean urinaryexcretion 26% 0.75 μg/mL after 1.5 h
* Indicates content of the compound in food; NA, stands for not available.
4. Clinical Trials
Though numerous studies have demonstrated that natural polyphenol could be potential
candidates for anticancer therapy, clinical studies in this area are relatively few and the therapeutic
efficacy is sometimes non-significant. A review of early clinical investigations on polyphenolic
phytochemicals suggested tea polyphenols could be used for the prevention of premalignancy,
but evidence was less convincing for curcumin and soy isoflavones [192]. Table 6 summarized
some clinical evidence about the use of natural polyphenol in cancer treatment. The clinical trials in
this section were identified from the PubMed database using the MeSH term “neoplasms” combined
with “polyphenols”.
Table 6. Summary of clinical trials with polyphenols in various cancers.
Subject Treatment Outcome References
54 patients with localized
prostate cancer
synthetic genistein (30 mg)
daily for 3–6 weeks
decreasing level of serum
prostate specific antigen (PSA) [193]
158 men aged 50–75 with
rising prostate
specific antigen
isoflavone (60 mg) daily for
12 months
reducing prostate cancer
incidence for patients aged 65
or more
[194]
86 patients with localized
prostate cancer
soy isoflavone (80 mg total
isoflavones, 51 mg aglucon
units) daily for 6 weeks




10 breast cancer patients
undergoing radiotherapy
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Table 6. Cont.
Subject Treatment Outcome References
147 patients with
prostate cancer





enterolactone and Ki67 in the
tumor tissue
[197]
87 patients with resected
colorectal cancer
or polypectomy
flavonoid mixture (20 mg
apigenin and 20 mg EGCG)
for 3–4 years
reducing recurrence rate of
colon neoplasia in patients





curcumin (480 mg) and
quercetin (20 mg) thrice
daily for 6 months
reducing polyp number and





isoflavones (40 mg) and
curcumin (100 mg) daily for
6 months
decreasing level of serum PSA [200]
44 smokers with 8 or more
aberrant crypt foci
curcumin (2 or 4 g) daily for
30 days




curcumin (360 mg) thrice
daily for 10–30 days
increasing body weight and
expression of p53, suppressing
serum level of TNF-α
[202]
5. Conclusions
The epidemiological studies about the relationship between dietary polyphenol consumption
and cancer risks yielded different results. The difficult in assessing intake of dietary polyphenols
and the diversity of polyphenols might contribute to the inconsistent results. On the other hand,
the vast majority of laboratory studies supported anticancer activities of natural polyphenols,
such as anthocyanins, EGCG, resveratrol and curcumin. The mechanisms of action mainly
included modulation of molecular events and signaling pathways associated with cell survival,
proliferation, differentiation, migration, angiogenesis, hormone activities, detoxification enzymes,
immune responses, etc. Besides, the anticancer effects of polyphenol varied with cancer types, cell lines
and doses. It is of note that some polyphenols, such as genistein and daidzein, have been suggested
to have adverse effects on hormone-related cancer. Therefore, the use of these polyphenols in cancer
treatment should be cautious. In addition, clinical trials about the anticancer actions of polyphenol
are limited. In the future, more epidemiological studies employing biomarkers of polyphenols are
needed to assess the impact of dietary polyphenols on cancer risks. Besides, the anticancer activities of
more polyphenols need to be assessed and compared, and the mechanisms of action require further
study. Larger, randomized clinical trials need to be carried out to provide more reliable evidence.
Additionally, the bioavailability of polyphenols should be evaluated and improved. Special attention
should be paid to the safety of polyphenols.
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Abstract: The traditional Mediterranean diet (MD) is associated with long life and lower prevalence
of cardiovascular disease and cancers. The main components of this diet include high intake of fruit,
vegetables, red wine, extra virgin olive oil (EVOO) and fish, low intake of dairy and red meat. Olive
oil has gained support as a key effector of health benefits and there is evidence that this relates to the
polyphenol content. Olive leaf extract (OLE) contains a higher quantity and variety of polyphenols
than those found in EVOO. There are also important structural differences between polyphenols
from olive leaf and those from olive fruit that may improve the capacity of OLE to enhance health
outcomes. Olive polyphenols have been claimed to play an important protective role in cancer and
other inflammation-related diseases. Both inflammatory and cancer cell models have shown that
olive leaf polyphenols are anti-inflammatory and protect against DNA damage initiated by free
radicals. The various bioactive properties of olive leaf polyphenols are a plausible explanation for
the inhibition of progression and development of cancers. The pathways and signaling cascades
manipulated include the NF-κB inflammatory response and the oxidative stress response, but the
effects of these bioactive components may also result from their action as a phytoestrogen. Due to the
similar structure of the olive polyphenols to oestrogens, these have been hypothesized to interact with
oestrogen receptors, thereby reducing the prevalence and progression of hormone related cancers.
Evidence for the protective effect of olive polyphenols for cancer in humans remains anecdotal and
clinical trials are required to substantiate these claims idea. This review aims to amalgamate the
current literature regarding bioavailability and mechanisms involved in the potential anti-cancer
action of olive leaf polyphenols.
Keywords: olive leaf; oleuropein; oxidative stress; inflammation; Mediterranean diet; Cyclooxygenase-2
1. Introduction
Cancer is a group of diseases involving proliferation of mutated cells [1]. In 2012, over 14 million
new cases of cancer were reported [2], triggering a push to further develop treatments and preventative
strategies. Cancer is predominantly an age-related disease, therefore with better conditions of life and
increased longevity it is likely to continue increasing in prevalence. However, there are clearly factors
other than age that contribute to its development. The traditional Mediterranean diet (MD) has gained
robust scientific support for providing protection against some cancers [3,4]. The MD has shown an
ability to influence the inflammatory response, which plays a pivotal role in aging and in reducing its
age-associated non-communicable diseases such as cancer. However, the mechanisms of action behind
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the effects of the MD on inflammation are not entirely clear [5–7]. It has been suggested that the NF-κB
inflammatory response, eicosanoid pathways and oxidative stress via free radical formation, have
been suggested to play a role in MD related health benefits [5,8,9]. The diet, as a whole, has shown a
protective role in cancer, however, the distribution of people still consuming it is gradually receding
due to the spread of the western-type urban society, globalization and consumption [10]. Because
of this, it is important to understand whether any beneficial effects ascribed to the MD are due to a
particular component of the diet, rather than the whole diet. As one example, polyphenol bioactive
components have shown particular promise and have therefore been a research focus.
Extra virgin olive oil (EVOO) is typically used as a traditional component of the MD and has
also been correlated with improved cardiovascular disease and cancer outcomes [11,12]. EVOO is
manufactured by pressing olives to create a paste, which is churned to amalgamate oil droplets which
are then extracted. There is a considerable variation in EVOO characteristics that can be attributed
to the olive variety, the geographical location the olives were derived from [13] and the method of
oil extraction [14]. Intake of both MD and EVOO has been shown to correlate with a reduced overall
risk of cancer and is more specifically associated with reduced risk of cancers of the digestive system,
prostate and breast [12].
EVOO is primarily a monounsaturated fatty acid (MUFA) in the form of oleic acid, with minor
components including various phenolics [15]. It has been recognised that the polyphenol content plays
an important role in health benefits. The European Food Safety Authority (EFSA) have approved
the use of the general claim “olive oil polyphenols contribute to the protection of blood lipids from
oxidative stress” when oil contains no less than 5 mg of hydroxytyrosol (HT) and its derivatives
(such as tyrosol and oleuropein) per 20 mL OO [16] (Figure 1). There are several studies that have
shown that EVOO with higher phenolic content provides stronger anti-inflammatory and antioxidant
effects than OO with a lower phenolic content [17,18]. This suggests the phenolic component, rather
than the fat in the oil, is the effector.
Figure 1. The olive polyphenol hydroxytyrosol and its derivatives, oleuropein and tyrosol (adapted
from [19]).
Olive tree leaves (Olea europaea) are widely used in traditional medicine in the Mediterranean
region [20]. In the Bible, the olive plant is referenced numerous times for its medicinal
use [21]. The bioactive properties of the leaf have created a foundation for use as an antioxidant,
anti-hypertensive, anti-atherogenic, anti-inflammatory, hypoglycemic, and hypocholesterolemic
treatment [20]. Olive tree leaves contain similar polyphenols to those found in EVOO or the fruit itself,
albeit at a much higher concentration [20,22]. Consequently, olive leaf extract (OLE) may hold an even
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greater potential than EVOO for improving health outcomes. During EVOO processing leaves can
unintentionally be left in the mixture if the separation methods are inadequate, alternately leaves can
also be added to EVOO mixtures to provide health benefits and improve flavor [23]. The addition
of leaves increase the phenolic and chlorophyll content of the oil but also the organoleptic traits as
measured in volunteer taste tests [24]. Components of OLE that are not detected in the oil from the
fruit include several flavonoids, namely luteolin and apigenin, which have demonstrated anti-cancer
properties [25–29]. In addition, the structure of phenolics differs between the olive fruit and leaf, with
OLE containing a higher proportion with a glycoside moiety (Figure 2 and Table 1) [19]. The presence
of a glucose molecule could play an important role in respect to both bioavailability and bioactive
potential of the polyphenols, thereby impacting the health benefits for humans.
Figure 2. Most abundant phenolics present in OLE. Structures (a) and (b) are flavonoids. Structures
(d) and (e) are esters of (c) which is a simple phenolic. The glucoside moieties are circled. This figure is
adapted from [19].
Table 1. Comparison of phenolic compounds found in olive leaf extract and olive oil, with values
reported in mg/kg [30]. Luteolin, apigenin, verbascoside and oleuropein all have a glucoside moiety.












131.77 ± 32 ND ND ND ND 17.24 ± 1.15 [30]
3.0 ± 0.2 ND ND ND 0.08 ± 0.02 NM [31]
12.5 ND NM NM NM NM [32]
4.3–9.9 ND 4.0–7.6 1.5–2.6 ND 67.7–136.4 [33]




NM 26,471.4 ± 1760.2 4208.9 ± 97.8 2333.1 ± 74.7 966.1 ± 18.1 NM [35]
ND 19,050 ± 880 155 ± 10 207 ± 10 1428 ± 46 NM [31]
NM 19,860 ± 54 NM NM 200 ± 40 NM [36]
NM 22,610 ± 632 970 ± 43 1072 ± 38 488 ± 21 NM [37]
NM 5173–12,921 219–444 192–488 213–501 NM [38]
Abbreviations: not detected: ND; not measured: NM.
Although there is a large body of research that has investigated the phenolic components of olive
products and the benefits they provide to human health [39–42], there are currently no approved
claims in regard to OLE. OLE not only contains a higher quantity and variety of polyphenols than
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those found in EVOO, but many of the polyphenols also contain a glucose moiety. This structural
difference in the polyphenols may have important consequences by altering their capacity to improve
health outcomes [43,44]. In previous work, OLE polyphenols have demonstrated the ability to inhibit
proliferation of several cancer cell lines including pancreatic [45], leukaemia [46] and breast [28,47].
Cellular models for breast and prostate cancers have been inhibited by the olive polyphenols oleuropein
and HT [48–51]. Importantly, oleuropein and HT have consistently been reported to discriminate
between cancer and normal cells; inhibiting proliferation and inducing apoptosis only in cancer cells.
The intake of polyphenols in observational studies is difficult to quantify and therefore assign effect
and intervention studies in regards to cancer have not been carried out, therefore the relationship
between polyphenols and cancer outcomes in humans has not been substantiated.
Research into the anti-cancer properties of olive polyphenols is abundant with a focus on the
health effects of EVOO. Evidence suggests that the bioactive components of OLE, although similar to
EVOO, may be more potent and therefore show more potential for improving health outcomes. This
review aims to amalgamate the current literature regarding bioavailability and anti-cancer mechanisms
involved in OLE polyphenol action. The literature identified for this review was found using the
search engines PubMed-NCBI, Scopus and ScienceDirect with a combination of block searching and
pearl-growing. Key words used for the search were olive leaf extract, polyphenols, cancer, oleuropein,
hydroxytyrosol, Mediterranean diet, inflammation, and bioavailability. The key components from the
research articles pivotal to this review have been summarized in Supplementary Table S1.
2. Olive Leaf Polyphenols
The Mediterranean region, where olive trees are predominantly grown, is characterized by
extended periods of sunlight and high rates of pathogen and insect attack. To combat these stressors,
olive trees synthesize high volumes of polyphenols which are largely stored in their thick leaves [52].
The concentration and variety of polyphenols present in the leaves will be influenced by many factors
such as geographical location, cultivar of tree, and the age of the tree [49]. Polyphenols comprise
multiple phenolic groups, each consisting of an aromatic ring with a varying number of hydroxyl
groups [19]. The polyphenols predominantly occur in a conjugated form, with one or several sugars
attached to the hydroxyl group [53]. The number and structure of phenol rings in a polyphenol are
used for classification and will determine its bioactive properties. The main phenolic compounds
are the secoiridoids (namely oleuropein) and flavonoids (Figure 2), these have shown the ability to
influence human and animal inflammatory and metabolic biomarkers [41,54–56].
Secoiridoids are a group of compounds found exclusively in plants of the Olearaceae family,
and make up the majority of olive polyphenols (~85% of olive leaf polyphenols) [57]. In OLE the
secoiridoid, oleuropein is the most abundant polyphenol (Figure 2), while its derivatives oleuropein
aglycone, oleoside, and ligstroside aglycone are also present at varying concentrations [19]. The
research surrounding oleuropein is abundant. It has been associated with numerous health benefits
including the ability to: lower blood pressure in rats [58], decrease plasma glucose concentrations
in rats [55], inhibit the growth of microbes grown on agar plates [59], inhibit cultured parasitic
protozoans [60] and has also shown the ability to induce apoptosis in cancer cell models: colorectal [61],
breast ([61–63] and prostate [48]. Human trials looking into the effect of OLE on cancer do not yet exist.
Hydrolysis of oleuropein gives rise to oleuropein aglycone, elenolic acid, HT and a glucose
molecule (Figure 3) [64]. HT is a phenolic alcohol and the second most abundant phenolic acid
in olive leaf. Tyrosol is another phenolic acid derived from oleuropein, but is found in low
concentrations in the leaf (Table 1). Other related compounds include verbascoside, which also
has demonstrated anti-inflammatory, anti-oxidant and antineoplastic properties similar to the other
olive leaf bioactives [65], as well as caffeic acid (220.5 ± 23.3 mg/kg) [35] and p-coumaric acid.
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Figure 3. Glycosylation of oleuropein to its aglycone this gives rise to elenolic acid and hydroxytyrosol.
Tyrosol in turn is hydrolysed from hydroxytyrosol (modified from Granados-Principal et al., 2010 [64]).
OLE consists of a number of flavonoids (~2% of olive leaf polyphenols) including luteolin,
apigenin (Table 1), rutin (495.9 ± 12.2 mg/kg) [35], catechin (19.3–32.6 mg/g dried extract) [66] and
diosmetin (8.70 mg/g dried extract) [22]. Luteolin is able to suppress inflammatory expression in
macrophages and adipocytes [67]. Apigenin is present at relatively low concentrations within olive
leaf, but it has also been linked to anti-inflammatory, anti-cancer and anti-oxidising properties [68].
Other components of OLE that occur in smaller concentrations include oleanolic acid [69], vanillin
and vanillic acid, [59], as well as tocopherols and β carotene [70]. In human studies, α tocopherols
have been correlated to lower prostate cancer mortality, but β carotene at high concentrations, has
been correlated to increased mortality of lung cancer patients [71].
Thousands of phytochemicals with differing attributes have been identified and isolated, but a
point which is often overlooked is that it can be a combination of compounds that induce health
benefits [72–74]. Within plants, polyphenols are present in mixtures and not as independent
compounds; the polyphenols have evolved together, generally for the purpose of deterring insect
feeding and the levels of the different bioactives with these mixtures need to be considered when
looking at bioactive properties for human health. While the evolutionary purpose for the polyphenol
mixtures it not for human benefit, the nature of the mixtures may nevertheless be important for
human health. Several studies have demonstrated that the phenolic compounds from OLE may
display a synergistic effect when in the same proportions as occurring naturally in the olive leaf. The
secoiridoids, flavonoids and other phenols in OLE provide a stronger anti-microbial and antioxidant
effect when working together, as opposed to the phenolics independently [59,75,76]. Through the use
of different antioxidant assays it was determined that OLE flavonoids, simple phenols and secoiridoids
utilize different mechanisms to exert an anti-oxidant effect [75], which at least in part explains their
additive effect.
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3. Bioavailability of Olive Leaf Polyphenols
In nutrition, bioavailability refers to the amount of compound/nutrient extracted from a food or
supplement that is capable of being absorbed and made available for physiological use by the body [77].
There are many factors that will influence the bioavailability of a compound including the vector, time
taken for absorption, structure of compound/bioactive target or the individual person [78]. The matrix
that the olive leaf is consumed and maintained may also have an impact on the bioavailability of
the active components. The leaves can be consumed in tea, as a powder or in an extract form As an
example, De Bock and co-authors demonstrated that the polyphenol derivatives measured in plasma
differed when the OLE was administered as a safflower oil compared to a glycerol matrix [79].
The ability to produce health benefits in different organs throughout the body requires that the
bioactive olive leaf polyphenols, or their metabolites, are able to infiltrate these areas. After an acute
load of olive phenolic (3 g phenolic extract from olive cake/kg of body weight) extract in mice, samples
demonstrated that phenolic derivatives and conjugates (oleuropein, tyrosol, HT and luteolin) were
absorbed, metabolised and present in the plasma (oleuropein derivative: max 4 h: 24 nmol/L and HT:
max 2 h: 5.2 nmol/L), the heart (luteolin derivative at 1 h: 0.47 nmol/g), kidney (luteolin derivative
1 h: 0.04 nmol/g, HT max 4 h: 3.8 nmol/g), testicles (olueropein derivative Cmax 2 h: 0.07 nmol/g and
HT max 2 h: 2.7 nmol/g) and had even passed the blood brain barrier (olueropein derivative at 2 h:
2.8 nmol/g) [80].
The research looking into bioavailability of polyphenols from OLE in commercial glycerol
formulations consistently show that oleuropein is bioavailable in humans but there is differing evidence
regarding the metabolites found in plasma [79,81]. De Bock reported the primary metabolite recovered
to be glucoronidated and sulphated HT [79]. In contrast, Kendall’s group reported that no HT was
detected in urine samples, but glucuronic acid conjugates, derived from oleuropein aglycone were
detected [81]. In rats fed oleuropein, liquid chromatography-mass spectrometry (LC-MS) detected
oleuropein, oleuropein aglycone, elenolic acid and HT both within faeces and urine at 24 h [82]. This
demonstrates the stability of these compounds and therefore the potential ability to reach other parts
of the body intact and in an active form.
Corona et al. (2006) reported HT and tyrosol traversed the perfused small intestine membrane of
rats but oleuropein did not, and would therefore likely reach the large intestine intact [83]. Incubating
with anaerobic human microbiota with olueropein resulted in rapid and extensive microbiota
degradation of oleuropein to HT and other metabolites [83]. Specifically the gastrointestinal bacterium
Lactobacillus planatarum has the ability to metabolize oleuropein to HT [84]. The microbiota acting
to break down oleuropein to HT would have an important impact on bioavailability if oleuropein
cannot traverse membranes, but HT and other metabolites can, as reported by Corona et al. 2006.
Another study has since found that oleuropein orally administered to rats resulted in the production of
oleuropein metabolites from the gastrointestinal tract as well as metabolites in the blood [82]. The most
recent research looking into the metabolism of oleuropein verses oleuropein aglycone in rodents (5 mg
phenol/kg/day) found that oleuropein resulted in the greatest bioavailabilty (measured by the highest
content of HT excreted in urine) and a greater diversity of microbial metabolites due to its superior
ability to reach the colon intact [44].
Glycosylation of Polyphenols
The glucose moiety that is present on many of the olive leaf polyphenols could have an important
impact on their bioactive properties. The glucose molecule significantly increases the molar mass of
the polyphenol; oleuropein is 540.51 g/mol, where the oleuropein aglycone is 394 g/mol. The glucose
molecule may improve stability and bioavailability, and facilitate cell entry but it also may impede
bioactive properties.
Through collection and processing methods of olives and leaves, different glycosylation enzymes
are activated [85]. The transformation of oleuropein is dependent on the type of glycosylation enzyme
acting (β-glucosidase, hemicellulase, tannase, neutral protease, cellulase, glucoamylase, papain,
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alkaline protease, amylase, β-glucanase) and this will result in varied concentrations and ratios
of HT, oleuropein aglycone, elonolic acid and total phenolics [86,87]. The combination of polyphenols
may improve the OLE biostability, insuring polyphenols are still present in the olive leaf extract when
consumed by humans but also improving the polyphenols ability to reach different areas of the body
intact. For example oxidoreductase enzymes reduce the abundance of oleuropein in OLE, but the
presence of HT is able to inhibit their action [86].
Olive leaf polyphenols containing a glucose moiety have been suggested to play an important
role in relation to cancer cell treatment. A study looking at oleuropein found removal of the glucose
moiety reduced its ability to inhibit proliferation of cancer cells [43]. This indicated that the hydrophilic
glucose may be enabling oleuropein to enter cells via GLUT transporters to create the anti-cancer affect.
GLUT mRNA expression is often increased in cancer cells and is correlated to cancer progression [88].
The glucose moiety in oleuropein may facilitate its diffusion into these cells in precedence to normal
cells and therefore result in a greater inhibitory effect on cancer versus normal cells. Another study
has indicated that the olive flavonoid apigenin is able to reduce the expression of GLUT1 in prostate
cancer cell lines thereby inhibiting proliferation of the cancer [29].
Another study looking at the effect of oleuropein (dissolved in water) verses oleuropein aglycone
(dissolved in ethanol 100%) (6 to 100 μM) in MCF-7 found the aglycone to be more effective at reducing
cell viability [89]. This would suggest that the glycoside is essential for anti-cancer effects.
Protective effects of the MD and EVOO against cancers, as discussed in the introduction, are
primarily associated with cancers of the digestive system. This could be due to the bioavailability
of the polyphenols, with the polyphenol constituents creating the anti-cancer effects not being able
to reach other parts of the body to have an impact. Consequently if the glucose moiety, a prominent
characteristic of olive leaf polyphenols improves bioavailability it may also improve protective effects
for different cancers.
4. OLE and Evidence of the Ability of Olive Leaf Polyphenols to Scavenge Nitric Oxide and
Quench Reactive Oxygen Species
Reactive oxygen species (ROS) and nitrogen species (NOS) are essential for cell function. They are
involved in energy supply, detoxification, chemical signaling and immune response. However, when
overproduced they can create stress by damaging DNA, lipids and proteins and they are widely
accepted to play an important role in pathologies and aging [20,90]. Chronic disease is associated with
oxidative stress, therefore an increased antioxidant intake or intake of compounds that enhance the
body’s own antioxidant system is expected to reduce the risk of these diseases. It was this hypothesis
that has led to an increased interest in antioxidants and their bioactive properties. Phenolics are one
group for which there is robust evidence supporting the health promoting effects of antioxidants.
There is a general consensus that olive leaf phenolics have a strong ability to scavenge nitric oxide
(NO) and quench ROS [91,92].
Antioxidant properties have been an important focus of research into polyphenols and are a
widely accepted mechanism for their health benefits. However, it has been suggested that several
constraints impede polyphenol in vivo scavenging of radicals, and that they would be inefficient at
mounting an antioxidant defense [93]. Concerns that have been highlighted include bioavailability
(the anti-oxidizing agent must reach these radicals in an active form to quench them) and kinetic
constraints for antioxidant scavenging (radicals may actually react with other biological molecules
such as DNA and lipids in the cell at the same rate as the antioxidants) [93]. This could mean
that a very high concentration of polyphenols would need to be ingested to perceive any effect
in humans. Instead it is suggested that antioxidant compounds, such as polyphenols, are able to
activate transcription factors such as nuclear factor (erythroid-derived 2)-like 2 (Nrf2) that bind to
the Electrophile Response Element (EpRE) and thereby transcribe genes for protective enzymes that
provide the health benefits (Forman et al., 2014 and Figure 4). Several in vitro studies using humans
cells and animal in vivo studies investigating olive polyphenols have supported Nrf2 activation and
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its consequential expression of protective genes [72,94]. Conversely, a recent human intervention
study has shown no evidence of altered phase II enzyme expression (the downstream product of Nrf2
activation) in peripheral blood mononuclear cells following consumption of HT (5 mg and 25 mg per
day in olive mill waste water) [95]. The olive mill waste water was tested to confirm oleuropein was
not present.
Figure 4. Polyphenol interaction with Nrf2 and activation of EpRE genes. The polyphenol (HT) reacts
with Keap1 permitting Nrf2 to escape. Nrf2 requires phosphorylation before it is able to enter the
nucleus. This schematic is modified from [93].
The Xenohormesis hypothesis suggests the stress-induced secondary metabolite production
in plants is recognized by humans upon consumption, and these signals initiate stress response
pathways [72,73]. Similarities in the human and plant extracellular signal-regulated kinase (ERK)
pathways (these are able to activate many transcription factors and play an important role in cell
regulation functions) show that polyphenols are able to activate pathways, such as AMP-activated
protein kinase (AMPK) and hold the potential to modulate redox and mitochondrial signaling [96,97].
During eukaryotic evolution, glucose was the preferred carbon source. Rapid cell growth was the best
way to utilize glucose, and AMPK activation provided the off switch mechanism in this process [72].
Therefore, AMPK activation (or similar pathways) could result in decreased ATP and increases in
mitochondrial free radicals, implicating protection from chronic disease and aging [72]. Evidence for
this theory was provided by microarray analysis of gene expression after EVOO treatment of breast
cancer cells. These results demonstrated up-regulation of AMPK, and the top Canonical pathway
regulated was the Nrf2 Mediated Oxidative stress pathway [72].
HT in vitro studies using human cell lines has been shown to up-regulate the expression of
endogenous antioxidant genes (Heme Oxygenase 1 (HO-1), NAD(P)H-quinone oxidoreductase
(NQO1), Glutathione (GSH)) via Nrf2 overexpression. The c-Jun N-terminal kinase (JNK) pathway
plays an important role in inflammatory signaling. The JNK pathway was up-regulated following
treatment with HT and inhibiting this pathway established its requirement for GSH and p62 regulation.
However, HO-1 or NQ-1 were unaffected [94]. p62 inactivates Keap1, increasing Nrf2 in the nucleus
and consequently increasing the expression of oxidation defense enzyme genes [98]. Oleuropein in
a human in vitro model has also been shown to activate Nrf2 and HO-1 expression [99]. However,
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in vivo human trials with HT have failed to find an up-regulation of phase 2 enzymes which are the
by-product of EpRE and Nrf2 stimulation [95].
5. Olive Leaf Properties That Protect against Development and Progression of Cancer
Genetic changes are involved in the prevalence of cancers, however it is environmental
and lifestyle factors such as obesity [100], unbalanced diet, tobacco, lack of exercise and alcohol
consumption that account for the majority of the attributing cause [101]. Olive leaf contains strong
anti-oxidants, it would be logical to conclude that these would help in mitigating the effect of genetic
lesions that give rise to cancer. However, olive leaf has also attracted attention as a potential cancer
treatment [28,46,102,103]. In previous work, olive leaf polyphenols have demonstrated the ability
to inhibit the proliferation of several cancer cell lines including pancreatic [45], leukaemia [46],
breast [28,47,49], prostate [48] and colorectal [61]. Importantly, oleuropein and HT have consistently
been reported to discriminate between cancer and normal cells; inhibiting proliferation and inducing
apoptosis only in cancer cells [48,49]. The challenge with relating the anti-cancer effects in cell models
to in vivo arises when considering bioavailability of the polyphenols. This could explain why OO
protective effects in humans show a strong association with cancers of the digestive system [12].
In other cancers OO phenolics has been suggested to act as phytoestrogens and anti-inflammatory
agents, thus producing a protective effect.
A higher risk of breast cancer is linked to over-exposure to oestrogen [104,105] and growth of
breast cancer can be stimulated by estradiol, which binds to the oestrogen receptor (ER). This receptor
is an important biomarker and target for breast cancer prevention and treatment [106]. Work with
breast cancer cell lines and OLE polyphenols have indicated potential mechanisms of action that
include action as a phytoestrogen. Oleuropein and HT both possess an aromatic ring that is similar to
that in estradiol, therefore these compounds are hypothesized to compete with oestrogens for receptor
binding sites [50,107]. In the MCF-7 breast cancer cell line, HT and oleuropein (at doses between 10 and
75 μM) dose-dependently prevented cell proliferation through inhibition of the oestrogen activated
ERK1/2 signaling pathway but did not show a direct effect on the mediation of ER gene expression [50].
It was later shown that oestrogen responses were also mediated by the GPER/GPER30 receptors, of
which HT and oleuropein are agonists [108]. Despite both oestrogen and the polyphenols showing the
same mechanism of receptor binding, they have opposite effects. Oestrogen leads to cell proliferation,
while polyphenols lead to apoptosis or cell death. Both activate the ERK1/2 pathways but it has been
proposed that the length of activation could influence the effect, with prolonged activation leading to
apoptosis, and short-term to cell proliferation [108]. Sustained ERK activation has previously been
demonstrated to result in inhibition of MCF-7 cell growth [109]. In vivo studies looking at olive leaf
polyphenols also appear to support an anti-cancer effect. Oleuropein (125 mg/kg of diet) slowed
tumor growth and inhibited cancer metastasis after MCF-7 cell xenograft establishment in mice [110].
OLE dissolved in water (150 and 225 mg/kg/day) reduced tumour volume and weight in mice after
breast cancer xenograft [111].
The aromatase (CYP19) enzyme is the catalyst for the rate determining reaction in oestrogen
synthesis. Inhibiting CYP19 effectively prevents oestrogen synthesis and because high levels of
oestrogen are linked to breast cancer, this holds potential as a treatment [112]. A recent clinical
study has shown that amylase inhibitors taken daily for 5 years were successfully able to reduce
the incidence of breast cancer in high-risk postmenopausal women [113]. In MCF-7 cells, luteolin
suppressed CYP19 transcription potentially via activator protein-1 (AP1) and C/EBP binding to the
aromatase promoter [26].
The olive flavones apigenin and luteolin have been shown to act as aryl hydrocarbon receptor
(AhR) antagonists in mouse cell lines [114]. Upon ligand binding, AhR is translocated to the nucleus
where it activates response elements in the DNA sequence and consequent production of xenobiotic
enzymes [115]. Other work has found that AhR in cancer cell lines acts as a tumour suppressor through
diminished DNA replication and G0/G1 arrest [116]. Another study has reported that apigenin
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suppresses the growth of MCF-7 cells, inhibiting the NF-κB signaling pathway, the phosphorylation
of IkBα, and nuclear translocation of p65 within the nucleus [27]. Apigenin was not found to inhibit
cell survival signaling through mediators such as AKT, ERK, JNK, or p38, but it decreased STAT3
transcriptional activity in the cells, indicating that this compound induces growth-suppressive activity.
The transcription factor STAT3 is more specifically involved in inflammatory signaling within cancer
tumours and interacts with cytokines [117], thus by inhibiting STAT3, luteolin could also be having
an anti-inflammatory effect. In another study oleuropein was cytotoxic to MDA-MB-231 and MCF-7
cells, avoiding damage to normal cells, with apoptosis taking place via induction of the mitochondrial
pathway [49]. MCF-7 cell proliferation was inhibited by oleuropein at the S-phase of the cell cycle by
an up-regulation of the p21 gene, and inhibition of NF-κB and its target D1 gene expression.
In PC3 and DU145 prostate cancer cell lines, HT has demonstrated the ability to interfere with
cell proliferation [51]. HT also activated mitogen-activated protein kinase (MAPK), ERK, p38 MAPK
and JNK. However, when inhibited by specific antagonists, HT was still able to inhibit cell growth.
The authors concluded that HT was able to induce apoptosis in cancer cells via the generation of
superoxide dismutase (SOD) and extracellular ROS.
Work using the prostate cancer cell lines, LNCaP and DU145, found that oleuropein was
pro-oxidative, causing loss of viability, but in non-malignant cells (a benign hyperplastic prostatic
epithelial cell line) oleuropein acted as an anti-oxidant [48]. The downstream products of EpRE
activation were all increased with oleuropein; pAkt, y-glutamylcysteine (y-GCS), heme oxygenase-1
(HO-1) and ROS. Interference with pAkt was proposed as the mechanism enabling cell apoptosis in
these prostate cancer cell lines [48].
5.1. Anti-Inflammatory Properties of Olive Leaf Polyphenols and Their Effects on Cancer
Inflammation is the natural defense mechanism against foreign threats, and its mechanisms
are essential for survival. However, chronic inflammation, even at low levels, has been correlated
to many health complications and age-associated diseases, including but not limited to cancer and
cardiovascular disease [118]. The NF-κB signaling pathways play a pivotal role in inflammatory
response and are an attractive target for preventing inflammation. NF-κB resides inactive within the
cytoplasm due to the presence of IκB kinase, an inhibitor enzyme, therefore it can be activated very
quickly to initiate cytokine and prostanoid production. There is strong evidence that olive polyphenols
are able to interact with these pathways [119–121].
The cyclooxygenase 2 (COX-2) enzyme plays an important role in inflammation as the catalyst
for the synthesis for prostanoids and hence an inflammatory response [122]. Cellular studies with
OLE polyphenols have found a protective effect in relation to inflammation; a down-regulation of
NO and COX-2 [120,123–125]. Inhibition of the Toll-like receptor (TLR) signaling induced by LPS was
demonstrated not only by down-regulation of iNOS and COX2, but also by a decrease in ERK1/2,
JNK and nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha (IκBα)
phosphorylation in vitro after oleuropein treatment [120] (Figure 5). In down-regulating this pathway
the pro-inflammatory enzymes interleukin 6 (IL-6) and interleukin 1β (IL-1β) and the gene AP-1
were also down-regulated. In human monocytes HT inhibited LPS induced COX-2 and prostanoid
production, however, it increased TNF-α. In contrast in human cell models tyrosol down-regulated
TNF-α and induced NF-κB, JNK and ERK phosphorylation and COX-2 expression [126] (Figure 5).
Lastly the olive flavonoid luteolin regulated IL-1β induced COX-2 expression via ERK, JNK and
NF-κB [127].
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Figure 5. Olive leaf polyphenols may interact with gene and protein expression directly or via an
interaction with receptors on the cell membrane. Toll-like receptor (TLR) and tumour necrosis factor
receptor (TNFR) activation results in inflammatory gene expression (COX2, IL-6, IL-6 and IL-1β) and
prostanoid production. This illustration shows the potential points at which OLE polyphenols could
interact if able to enter the cell membrane.
5.2. Cancer, Inflammation and COX2 Expression
An overexpression of COX-2 has been linked to invasiveness of many cancers including human
breast cancer [128,129], prostate [130] and colorectal [131]. Drugs that inhibit COX-2 enzymes are able
to reduce the risk of breast cancer [132], and have pro-apoptotic effects in the MCF-7 cell line [133]
and prostate cancer cell lines [134]. Luteolin, when administered with the COX-2 inhibitor celecoxib,
created a synergistic effect in MCF-7 and three other breast cancer cell lines. Interestingly, the ERK1/2
levels were inhibited in the oestrogen receptor positive cell lines, but were increased in the negative
cell lines [135]. Down-regulation of the phosphatidylinositide 3-kinase (P13K)/Akt pathway inhibits
phosphorylated Akt levels, which in turn stimulates apoptosis. Phosphorylated Akt levels were
decreased in all cell lines [135].
A review on breast cancer found all stages of cancer progression corresponded to COX-2
expression [129]. COX-2 is a down-stream product of NF-κB which was down-regulated in MCF-7
treated with oleuropein [49]. In mouse models, COX-2 driven prostaglandin E2 (PGE2) expression in
mammary tissue led to an increase of CYP19 and aromatase-catalysed oestrogen biosynthesis [136].
Samples taken from patients with breast cancer showed a correlation between transcription of CYP19
and both gene and protein expressions of COX-2 and PGE2 [137]. In a previous study the authors
hypothesized that HT and oleuropein were able to inhibit proliferation via competing for oestrogen
binding sites [50]. These studies suggest that OLE polyphenols may be acting in MCF-7 to block
oestrogen receptor binding and to inhibit COX-2 expression, which appears to down-regulate CYP19
expression [136].
Another gene that COX-2 can regulate is p53. Work in human mammary tissue has demonstrated
that COX-2 represses p53 transcription thereby inhibiting cell apoptosis [138] and it has since been
demonstrated that p53 down-regulates aromatase expression in breast adipose stromal cells [139].
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Work looking at the effects of oleuropein in MCF-7 has shown that it is able to induce apoptosis via
up-regulating p53, and consequently the transcription of Bax/Bcl-2 apoptotic genes [62]. Other studies
have also measured a change in p53 and Bax expression with oleuropein inhibition of cervical cancer
cells [140] and p53 pathway up-regulation with oleuropein inhibition of colorectal cancer cells [61].
In vivo, luteolin (10 mg/kg/day) reduced both volume and weight of tumors in a prostate
xenograft mouse model and in vitro, using the prostate cancer cells PC-3, it down-regulated VEGF
phosphorylation of VEGF2 receptor and its downstream inflammatory markers IL-8 and IL-6 [25].
If VEGF is correlated to PGE2, as in the breast cancer models mentioned above, then it could be a
downstream effect of COX-2 inhibition.
PGE2 expression pushes the immune response from a T-helper 1 (Th1) (including cells
such as Natural killer (NK) cells) to a Th2 (such as mast cells) and Th17 mediated response,
which is less effective at fighting off infections or protecting from cancer [141]. This potentiates
acute, local inflammation driven by phagocytes, which is less aggressive than the Th1/Th17
response [141]. By down-regulating COX-2, the balance will shift back to Th1, which may improve
immune-competence. For example COX-2 knock out in breast cancer cells inhibited tumour growth by
enhancing T-cell survival and immune surveillance in tumours [142].
The tumour microenvironment has an important impact on tumour progression and metastasis,
therefore its manipulation has been suggested as a target for cancer therapy [143]. It has been
demonstrated in breast cancer MCF-7 cells that tumour associated macrophages are able to enhance
COX-2 levels in the tumour. Conversely inhibiting COX-2 in macrophages was able to inhibit levels in
the tumour [144]. In several human intervention studies with olive polyphenols, COX-2 expression
in immune cells was down-regulated [145,146]. In cancer patients this could potentially lead to a
down-regulation of COX-2 in tumours and thereby inhibit tumour progression. In other intervention
studies the inflammatory markers NF-κB, p65, IKKβ, and IKKα [147] and NF-κB, IL-6 and IL-1β [148]
have been down-regulated with olive polyphenols. These studies measured changes after single
40 mL doses of EVOO (containing the olive polyphenols), quantities achievable in an individual's
standard diet.
5.3. Quinone Hypothesis for Anti-Cancer Properties of Olive Leaf
As quinones, olive leaf polyphenols could bind to the cysteine residues of NF-κB in cancer
cells and manipulate gene expression. This would explain the observed gene expression in in vitro
models [46,120,126]. A recent study has indicated olive leaf polyphenols in a quinone form could
interact with Topoisomerase IIα [149]. The olive leaf polyphenols oleuropein, verbascoside, and HT
were categorized by Vann et al. as Topoisomerase IIα poisons. Topoisomerase IIα is an enzyme
essential for cell survival, catalysing the breaking and re-joining of the DNA helix to remove tangles
and playing an important role in cell replication. Acting as Topoisomerase IIα poisons the polyphenols
increased DNA cleavage, this effect was 10–100 times stronger in the presence of an oxidant [149].
This is consistent with the idea that the polyphenols have been transformed into quinone electrophiles,
which are then able to bind to cysteine residues. This study also demonstrated that the olive leaf
polyphenol tyrosol was unable to act as a poison consistent with its inability to form a quinone and
bind to the cysteine residue within Topoisomerase IIα.
Although potentially dangerous in normal cells, Topisomerase IIα is an important target for cancer
treatment. Due to the requirement of an oxidant environment, this might explain why no toxicity has
been shown in normal cells in comparison to tumour cell models; the quinones were not formed.
6. Conclusions
There is strong evidence from cell models which demonstrates that olive polyphenols, and
specifically the combination found in olive leaf, are able to modulate and interact with molecular
pathways and in doing so may inhibit the progression and development of cancer. However, it is
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important to acknowledge that cell models are very different from the complex human body and
applying these findings to cancer outcomes in humans is difficult.
Meta-analysis correlating the consumption of a MD and OO in humans to protection from
digestive system, prostate and breast cancers [4,12], suggest that the effects may be constrained by
bioavailability but also directs to a phytoestrogenic mechanism of action. Not only are the reduced risk
of oestrogen related cancers in females correlated to protective effects of phytoestrogens, but a recent
meta-analysis has correlated a lower risk of prostate cancer with phytoestrogen consumption [150].
The evidence suggests that olive polyphenols may act differently when in different combinations
and at different concentrations. The presence of a glucose molecule, one factor that differentiates olive
leaf polyphenols from OO polyphenols, is likely to affect the bioavailability and therefore bioactive
properties. Changes to microbiota and microbiota-mediated degradation of polyphenols, demonstrate
the glucose molecule has an effect.
Both cell models and human intervention studies demonstrate olive polyphenols are creating an
anti-inflammatory change involving NF-κB inhibition. The down-stream products of NF-κB: including
COX-2, IL-6, IL-8, IL-1β are expressed at lower levels creating a tumour micro-environment that no
longer facilitates progression or development of cancers. This may account for the lower prevalence of
cancer in people consuming a MD.
To answer the question “does OLE protect against cancer?” is difficult. Evidence is available in
cell and animal models to support the conclusion that OLE does have beneficial effects and there is
anecdotal evidence that olive polyphenols have a protective effect against cancer in humans. People
consuming the MD have a lower prevalence of cancer, the MD consists of a high content of polyphenols,
and olive leaf is an excellent source of many of these polyphenols. However, in order to prove that
OLE improves cancer outcomes in humans, clinical trials would be required.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/8/8/513/s1,
Table S1: Olive leaf polyphenol treatment in different cancer models; in vivo and in vitro.
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The following abbreviations are used in this manuscript:
AhR Aryl hydrocarbon receptor
AP1 Activator protein-1
EVOO Extra Virgin Olive oil
HT Hydroxytyrosol
JNK c-Jun N-terminal kinase
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MAPK Mitogen-activated protein kinase
Nrf2 Nuclear factor (erythroid-derived 2)-like 2
NO Nitric oxide
OLE Olive leaf extract
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ROS Reactive oxygen species
TLR Toll-like receptor
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Abstract: Tea leaf (Camellia sinensis) is rich in catechins, which endow tea with various health benefits.
There are more than ten catechin compounds in tea, among which epigallocatechingallate (EGCG) is
the most abundant. Epidemiological studies on the association between tea consumption and the risk
of breast cancer were summarized, and the inhibitory effects of tea catechins on breast cancer, with
EGCG as a representative compound, were reviewed in the present paper. The controversial results
regarding the role of tea in breast cancer and areas for further study were discussed.
Keywords: Camellia sinensis; anticancer; antioxidant; signaling pathway; anti-proliferation; DNA
methylation; metastasis
1. Introduction
Breast cancer is a common cancer in women. There were an estimated 1.7 million new cases (25%
of all cancers in women) and 0.5 million cancer deaths (15% of all cancer deaths in women) in 2012 [1].
Though there have been great advances in the treatment of breast cancer, mortality from breast cancer
is still high, and it is the second leading cause of cancer-related death among women in the United
States [2]. Diet is considered to be an important factor preventing breast cancer [2,3].
Tea is one of the most popular beverages consumed all over the world. Tea leaves
are rich in catechins, a group of polyphenols that endow tea with many health benefits.
(´)-Epigallocatechingallate (EGCG), (´)-epicatechingallate (ECG), (´)-epigallocatechin (EGC), and
(´)-epicatechin (EC) are the major catechins in fresh tea leaf, while more than ten catechins are usually
detected in various kinds of processed teas, owing to the isomerization of epi-type catechins during
tea processing [4]. Teas are classified into fully-fermented black tea, semi-fermented Oolong tea, and
unfermented green tea, based on the degree of fermentation, during which catechins are oxidized.
EGCG is the most abundant catechin in tea, and it accounts for more than 40% of total catechins in green
tea leaves [5]. The total concentration of catechins is 58.0–183.9 mg/g in green tea [4], 74.8–105.7 mg/g
in oolong tea [6], and 11.7–55.3 mg/g in black tea [7]. Green tea polyphenols (GTP) are considered to be
a potential candidate for further development as a chemoprotective factor for the primary prevention
of age-related eye diseases [8]. There have been epidemiological and in vitro studies regarding the
association of tea consumption with depression among breast cancer survivors [9]. Drinking tea or
green tea was not associated with overall breast cancer risk [10]. However, the effects of tea and its
catechins on the prevention of breast cancer are still inconclusive and controversial [11,12]. The present
review will highlight the recent advances in the effects of tea and its catechins on breast cancer,
including epidemiological, in vivo, and in vitro studies. The controversial results from in vitro and
in vivo studies, as well as directions for further study are also discussed in the present paper.
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2. Epidemiological Evidence
As early as 1997, an epidemiological study carried out in Japan showed that drinking green
tea had a potentially preventive effect on breast cancer, especially among women who drank more
than 10 cups of green tea per day [13]. Many cohort studies or case-control studies on the association
between tea consumption and breast cancer risk have been carried out since then. Cohort studies in
China and the USA showed that habitual drinking of green tea was weakly associated with a decreased
risk of breast cancer [14,15]. There was a time-dependent interaction between green tea consumption
and age of breast cancer onset (p for interaction = 0.03). Women who started drinking tea at the age
of 25 or younger had a hazard ratio (HR) of 0.69 (95% confidence interval (CI): 0.41–1.17) to develop
premenopausal breast cancer, compared with non-tea drinkers [16]. Tea drinking was also helpful to
the treatment of breast cancer patients. Habitual tea-drinking (more than 100 g dried tea per month)
was inversely associated with depression among patients who were diagnosed with stage 0 to III breast
cancer, with odds ratio (OR) 0.39 and 95% CI ranging from 0.19 to 0.84 [9]. Drinking tea or green tea
was not associated with overall breast cancer risk [10].
The association between tea consumption and decreased risk of breast cancer was also confirmed
by population-based case-control studies carried out in China [10,12,17], the USA [18–20], and
Singapore [21,22]. There were studies showing that green tea consumption significantly reduced
the risk of breast cancer [18] and the women who drank three or more cups of tea per day had a
37% reduced breast cancer risk than their counterparts that did not drink tea [20]. Differences in the
efficacy of tea consumption on breast cancer were observed between various populations. Among
women with high-activity of the angiotensin-converting enzyme (ACE) genotype, green tea intake
frequency significantly decreased the risk of breast cancer (p = 0.039) [21]. Among women with low
folate intake or high-activity MTHFR/TYMS (methylene tetrahydrofolate reductase /thymidylate
synthetase) genotypes, green tea consumption was inversely associated with breast cancer risk [22],
suggesting that folate pathway inhibition might be one of the mechanisms for the protection that
green tea provides against breast cancer in humans. A significant association between regular tea
consumption and lower risk for breast cancer [12] was observed among premenopausal Chinese
women (OR = 0.62, 95% CI: 0.40–0.97) [10], but an increased risk was seen in postmenopausal women
(OR = 1.40, 95% CI: 1.00–1.96) [10]. An inverse association between tea consumption and breast cancer
was observed among younger women (less than 50 years old), which was consistent for in situ and
invasive breast cancer and ductal and lobular breast cancer [20]. Combined intake of green tea and
mushroom showed an additional decreased risk of breast cancer [17]. Table 1 lists the epidemiological
evidence for the association between tea intake and the risk of breast cancer.
443































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Nutrients 2016, 8, 458
3. Mechanism of Tea Catechins in Suppressing Breast Cancer
3.1. Suppressing Carcinogen-Induced ROS Elevation and DNA Damage
ROS (reactive oxygen species) are a group of chemically-reactive molecules, including hydrogen
peroxide, superoxide anion radical, singlet oxygen, and hydroxyl radicals, which are crucially
involved in multiple stages of carcinogenesis [24]. The anti-carcinogenic activity of tea catechins
is considered to be related to their protection of DNA from ROS-induced damages by alleviating
ROS stress. It was shown that short-term exposure of breast cancer cells to 4-(methylnitrosamino)-1-
(3-pyridyl)-1-butanone (NNK) and benzo[a]pyrene (B[a]P) would increase the level of ROS, resulting
in the activation of the extracellular signal-regulated kinase (ERK) pathway and subsequent induction
of DNA damage [25]. In vitro [26] and in vivo [27] studies showed that tea catechins prevented breast
carcinogenesis by alleviating ROS stress. Ten μg/mL EGCG suppressed chronically-induced cellular
carcinogenesis by blocking carcinogen-induced ROS elevation [25]. Tea polyphenols, such as green
tea catechins and black tea theaflavins, could inhibit DNA cleavage induced by the combination of
hydrogen peroxide and cytochrome c [26]. Green tea catechins or black tea theaflavins delay mammary
carcinogenesis in the TAg mouse model, which is accompanied by an antioxidant effect in the target
organ, as reflected by levels of M1dG (malondialdehyde–deoxyganosine) adducts [27] which is a
prevalent guanine adduct formed by a condensation reaction between guanosine. Furthermore, the
combination of catechins with anticancer drugs such as tamoxifen (TAM) showed an etiological
role in the abrogation of TAM-induced toxicity by relieving oxidative stress and biochemical
perturbations [28].
The mechanism for the alleviation of ROS stress by catechins includes their increasing of the
activity of anti-oxidases such as catalase, superoxide dismutase (SOD), and glutathione peroxidase
(GHS-px) [29] directly scavenging ROS [25], preventing the iron-induced generation of hydroxyl free
radicals via Haber–Weiss and Fenton reactions by chelating ferrous iron. The potent antioxidant and
anti-inflammatory activities of EGCG are also beneficial to the modulation of mitochondrial functions,
impacting mitochondrial bioenergetic control, cell cycle, and mitochondria-related apoptosis [30].
3.2. Regulating Cell Signaling Pathways
The PI3K/Akt/mTOR (phosphoinositide-3-kinase/protein kinase B/mammalian target of
rapamycin) signaling pathway is a commonly activated signaling pathway in human cancer. The
important nodes in this pathway are used as key therapeutic targets for cancer treatments. EGCG was
confirmed to be an ATP-competitive inhibitor of both PI3K and mTOR in breast cancer cells MDA-MB-231,
with Ki values ranging 380 nM to 320 nM, respectively [30]. Molecular docking studies showed
that EGCG binds well to the PI3K kinase domain active site, showing ATP-competitive activity [31].
Tumor-associated fatty acid synthase (FAS) is implicated in breast carcinoma and is connected to the
epidermal growth factor receptor (EGFR) signaling pathway. Suppression of FAS in cancer cells may
lead to growth inhibition and the apoptosis of breast cancer cells. EGCG suppressed EGFR signaling
and downstream phosphatidylinositol 3-kinase (PI3K)/Akt activation in the MCF-7 breast cancer cell
line, resulting in down-regulation of FAS expression. It is considered that EGCG may be useful in the
chemoprevention of breast carcinoma in which FAS over-expression results from signaling of human
epidermal growth factor receptor 2 (HER2) or/and HER3, two members of EGFR family [32]. Exposure
to carcinogens such as 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and benzo[a]pyrene
(B[a]P) will result in an elevation of ROS, leading to activation of the Raf-independent extracellular
signal-regulated kinase (ERK) pathway, which will induce DNA damage. Green tea extract (GTE)
was confirmed to inhibit the activation of the ERK pathway by blocking carcinogen-induced ROS
elevation, resulting in the suppression of chronically-induced breast cell carcinogenesis [25]. Wnt
(wingless integrated) proteins are a group of highly conserved secreted signaling molecules which play
critical roles during embryonic development and in the regeneration of adult tissues. Mutations in
Wnt genes or Wnt pathway components lead to developmental defects and many cancers are caused
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by abnormal Wnt signaling. EGCG induced HMG-box transcription factor 1 (HBP1) transcriptional
repressor, resulting in blockage of the Wnt/β-catenin pathway and inhibition of both breast cancer cell
tumorigenic proliferation and invasiveness [33]. Met, a hepatocyte growth factor (HGF) receptor, is a
strong prognostic indicator of breast cancer patient outcome and survival. Therapies targeting Met will
have beneficial clinic outcomes. Catechins with R1 galloyl and R2 hydroxyl groups had a strong ability
to inhibit HGF/Met signaling and block invasive breast cancer [34].
3.3. Interacting with Target Proteins
Estrogen is associated with the initiation and growth of breast cancer due to its action on
proto-oncogenes and breast cell proliferation [35]. The interactions between estrogen and its specific
estrogen receptor (ERs) proteins are increasingly drawing research interest in breast cancer etiology and
clinical therapy studies. The ERs are classified into nuclear ERs and membrane ERs [36,37]. ERα and
ERβ are two important subtypes of nuclear ERs, and they are used as reference for clinical diagnosis
and therapy decisions regarding breast cancer [35,37]. Synthetic ER antagonists were designed to
occupy the ligand-binding pocket to block the access of estrogen to the ERs, which have been used
clinically in the treatment of ER-positive breast cancer [37]. The interaction between catechins and ERs
showed anti-estrogenic activity, and so catechins are considered for use as potential phytoestrogens
to replace synthetic ER antagonists in clinical use [32,38,39]. EGCG could reactivate ERα expression
in ERα-negative breast cancer cells by its remodeling effect on the chromatin structure of the ERα
promoter through altering histone acetylation and methylation status [40]. These results support
further preclinical and clinical evaluation of EGCG as a therapeutic option for ER-negative breast
cancer. Furthermore, EGCG can bind with high affinity to many other target proteins in cancer cells,
such as 70 kDa zeta-associated protein (Zap-70) [41], 67-kDa laminin receptor [42], phosphoinositide 3
kinase (PI3K) [31], Ras-GTPase activating protein (GAP), SH3 domain-binding protein 1 (G3BP1) [43],
insulin-like growth factor 1 receptor (IGF-1R) [44], vimentin [45], Bcl-2 and Bcl-xL [46], GRP78 [47],
and Fyn [48], resulting in the inhibition of breast cancer. EGCG interacts with target proteins via
hydrogen bonding, during which the hydroxyl groups of EGCG serve as hydrogen bond donors.
3.4. Inhibiting DNA Methylation
DNA methylation is an important epigenetic mechanism for the inactivation of many genes
related to tumor suppressors and DNA repair enzymes [49]. DNA methylation is catalyzed
by specific DNA methyltransferase (DNMT) or catechol-O-methyltransferase (COMT), in which
S-adenosyl-L-methionine (SAM) is the methyl donor. S-adenosyl-L-homocysteine (SAH)—a potent
noncompetitive inhibitor of DNMTs—is formed when the methyl group of SAM combines with
the DNA substrate. Recent studies showed that tea catechins inhibited human DNMT-mediated
DNA methylation through two mechanisms—i.e., the direct inhibition of DNMTs by catechins and
the indirect inhibition of DNMTs by increasing the SAH level. Their inhibitory potency is in the
rank order of EGCG > ECG > EGC > EC, based on the concentration for 50% inhibition (IC50) [50].
EGCG interacted with DNMT enzyme by forming hydrogen bonds with proline1223, glutamate1265,
cysteine1225, serine1229, and arginine1309 in the catalytic pocket of DNMT, and the B and D ring moieties
of EGCG played important roles [51]. Synthetic analog of EGCG had the same effect on COMT as
EGCG [52]. Methylated EGCG led to decreased proteasome-inhibitory activity and cancer-preventive
effects of EGCG [53]. The suppressive effects of EGCG on DNA methylation were closely associated
with its anti-tumor activity [54].
3.5. Inhibiting Tumor Angiogenesis
Angiogenesis, which is essential for tumor growth, can provide nutrients and oxygen for
tumor growth [55]. Vascular endothelial growth factor (VEGF), the most effective angiogenesis
factor, has been reported to stimulate endothelial cells in the proliferation of tumor blood vessels.
Subsequently, the proliferation of endothelial cells prompts the formation of new blood vessels [55,56].
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Thus, inhibiting angiogenesis would be conducive to tumor suppression. Tea catechins—especially
EGCG—exert prominent antiangiogenic activity [57–59], which results in decreased breast cancer risk.
Catechins could effectively inhibit VEGF expression in breast cancer cells, leading to the suppression
of endothelial cell formation and angiogenesis. GTE or EGCG suppressed VEGF protein secretion
by inhibiting VEGF promoter activity, resulting in decreased expression of VEGF transcript, c-jun
transcript, c-fos transcript, and protein kinase C (PKC) [60].
The antiangiogenic mechanism of catechins is closely related to VEGF signaling intervention. The
VEGF-induced angiogenesis signal pathway is initiated through a multi-component receptor complex
composed of VEGF-2, β-bcatenin, VE-cadherin, and PI3-kinase. Catechins inhibited the formation
of the multi-component receptor complex, resulting in the interference of VEGF signaling and the
inhibition of endothelial cell formation [61].
3.6. Anti-Proliferation and Inducing Breast Cancer Cell Apoptosis
The mechanism of action of anticancer drugs is based on their ability to induce apoptosis in
cancer cells. Tea catechins such as EGCG, gallocatechin gallate (GCG), and gallocatechin (GC) showed
100%, 97%, and 95% inhibition of breast cancer cell proliferation, respectively at a concentration of
50 μM, [62]. Tea catechins suppress proliferation and induce apoptosis of breast cancer cells via several
pathways, including: (1) Inducing cell cycle arrest. The cell growth of human breast cancer cell line
T47D was arrested at the G(2)/M phase in a dose-dependent manner by EGCG. The mechanism is
that catechins phosphorylate c-jun N-terminal kinase/stress activated protein kinase (JNK/SAPK)
and p38. The phosphorylated JNK/SAPK and p38 inhibit the phosphorylation of cell division cycle
2 (cdc2) and regulate the expression of cyclin A, cyclin B1, and cyclin-dependent kinase proteins,
resulting in G(2) arrest [63]; (2) Promoting tumor protein P53 (TP53)/caspase-mediated apoptosis.
Catechin hydrate (CH) is a strong antioxidant and an efficient scavenger of free radicals. CH exhibits
anticancer effects by inhibiting the proliferation of breast cancer cells and inducing the apoptosis of
cancer cells, partially through suppression of the expression of caspase-3, caspase-8, caspase-9, and
TP53 [64]; (3) Down-regulating anti-apoptotic factors. Catechins such as catechin, GC, and catechin
gallate (CG) induced breast cancer cell apoptosis by suppressing the expression of anti-apoptotic
factors such as B cell lymphoma 2 (Bcl-2), Bcl-xL, and survivin, accompanied by the inhibition of NFκB,
JAK/STAT, and PI3K pathways [65]. Oligonol—a catechin-rich preparation—triggered apoptosis
in estrogen-responsive MCF-7 and estrogen-unresponsive MDA-MB-231 breast cancer cells through
the modulation of pro-apoptotic Bcl-2 family proteins and MEK/ERK signaling pathway [66]; (4)
Inhibiting fatty acid synthase (FAS). FAS is a breast cancer-associated enzyme connected to human
epidermal growth factor receptor (HER). Suppression of FAS may lead to cancer cell apoptosis.
EGCG down-regulated FAS by suppressing HER2 or/and HER3 signaling and downstream PI3K/Akt
activation in the MCF-7 breast cancer cell line [32]; (5) Regulating NO/NOS system. Catechins
(10´7 M) inhibited proliferation of human breast cancer cell T47D, with cells being arrested at the S
phase of cell cycle. The anti-proliferative activity of catechins is considered to be involved in the nitric
oxide/nitric oxide synthase (NO/NOS) system because catechin treatment decreased NOS, resulting
in NO reduction [67]. However, the role of NO in regulating the anti-proliferative effect of catechins
is ambiguous, and the regulation mechanism of catechins on the NO/NOS system is not fully clear
yet; (6) Inducing Ca2+-associated apoptosis. EGCG induced an increase in endoplasmic reticulum
calcium ([Ca2+]ER) and a decrease in cytosolic Ca2+ by inhibiting Bcl-2 mediated Ca2+ leakage from
the endoplasmic reticulum in MCF-7 breast cancer cells [68]. EGCG acts via the signaling pathways
related to cell membrane and endoplasmic reticulum stress to suppress cell proliferation or provoke
apoptosis [69].
3.7. Anti-Metastasis of Breast Cancer Cells
The metastasis of cancer cells includes three key steps; i.e., adhesion, migration, and invasion.
EGCG can effectively inhibit the invasion and migration of breast cancer cells, resulting in decreased
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lung and liver metastasis [70]. Tea catechins showed an inhibitory effect on the migratory and invasive
potential of breast cancer cells [71,72]. Catechins inhibit metastasis by modulating the activity of
proteolytic enzymes, regulating the signaling pathway and growth factor/receptor, suppressing the
epithelial-to-mesenchymal transition (EMT) process and inhibiting angiogenesis [72,73].
Degradation of extracellular matrix components by matrix metalloproteinases (MMPs) and other
proteolytic enzymes is critical in tumor invasion and metastasis behavior. Pro-MMP-2 is a proenzyme
involved in the malignant progression of tumors. Membrane type-1 matrix metalloproteinase
(MT1-MMP) cleaves the N-terminal prodomain of pro-MMP-2, which generates the active intermediate
that is modified into the fully active enzyme MMP-2 afterwards. EGCG down-regulated MT1-MMP
transcription, resulting in the inhibition of the MT1-MMP-driven migration of breast cancer cells [73].
Catechins can modulate the secretion of urokinase plasminogen activator (uPA), which is closely
related to proteolytic enzymes in breast cancer cells and inhibits their invasive behavior by suppressing
the transcription factors AP-1 and NF-κB [71]. EGCG can also remarkably attenuate lipopolysaccharide
(LPS)-induced cell migration by a significant internalization of 67KD laminin receptor (67LR) [42,73].
EGCG also plays important roles in inhibiting tumor metastasis through the modulation of
signaling pathways, including the modulation of β1 integrin-mediated signaling [74], down regulation
of vasodilator-stimulated phosphoprotein (VASP) expression via the Rac1 pathway [72], enhancing
the expression of α1-antitrypsin by regulating the PI3K/AKT pathway [75], and down-regulating the
EGFR signaling pathway [76].
4. Inconsistent Results and Further Study Suggestions
4.1. Inconsistent Results
Although animal and in vitro studies showed that tea catechins were associated with a protective
role against breast cancer, evidence from in vivo and human epidemiological studies is inconsistent.
Increased green tea consumption (>3 cups/day) was inversely associated with recurrence (Pooled
RR = 0.73, 95% CI: 0.56–0.96). An analysis of case–control studies investigating incidence suggested an
inverse association, with a pooled RR of 0.81 (95% CI: 0.75, 0.88), while no association was found among
cohort studies of incidence [23,77,78]. There are many factors leading to the controversial results.
First, the suppressive effects of tea on breast cancer differed between various kinds of tea.
The reduction in breast cancer risk was usually associated with green tea consumption, rather than
black tea consumption [10,11,15,17,79]. The major bioactive components in tea are catechins, especially
EGCG. Black tea is a fully-fermented tea, and about 80% of tea catechins are oxidized and converted
into orange and red tea pigments (theaflavins and thearubigins) during fermentation. This may explain
why black tea consumption was not associated with the decreased risk of breast cancer.
Second, contradictory results arose from different populations investigated. An epidemiological
study showed that daily tea consumption was significantly associated with a lower risk in the
population of premenopausal women (OR = 0.62, 95% CI: 0.40–0.97), but an increased risk for
breast cancer in the population of postmenopausal women (OR = 1.40, 95% CI: 1.00–1.96). The
relationship between drinking green tea with the risk of breast cancer differed between ER-negative
(OR = 1.22, 95% CI: 0.43–3.43) and ER-positive (OR = 0.61, 95% CI: 0.25–1.49) populations among
postmenopausal women [10]. The observations of men and women gave different results. Tea drinking
showed a strong association with increased risk for breast cancer in men, but no association with the
development of breast cancer in women [80]. There was a significant association between the intake
frequency of green tea and the decrease in risk of breast cancer among women with high-activity of
the angiotensin-converting enzyme (ACE) genotype. However, no association was observed between
the intake frequency of green tea and the risk of breast cancer among women with the low-activity
ACE genotype [21]. These controversial results might be due to the differences in physiological status
between various populations, which gave different responses to the bioactive components in tea.
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Third, contradictory results between in vitro and in vivo studies arose from low bioavailability
and biotransformation in vivo. When EGCG was incubated with rat liver microsomes at 1–100
μM for 30 min in vitro, EGCG selectively bound to COMT [81]. However, in vivo tests showed
that supplementation with a high dose of EGCG does not impair the activity of COMT [82].
A bioavailability test using 3H-EGCG in mice revealed a wide distribution of radioactivity in target
organs, including digestive tract, liver, lung, pancreas, mammary gland, brain, kidney, uterus,
and ovary. However, radioactivity in the blood was low, being about 2% of total administered
radioactivity at 6 h after administration, and the status was sustained for 24 h. However, 37.1% of
total administered radioactivity was excreted in feces and 6.6% in urine within 24 h [83]. Chemical
modification of tea catechins occurring in the digestive tract might lead to their low bioavailability.
Under physiological conditions, COMT can metabolize EGCG to 4”-O-methyl-EGCG (MeEGCG) and
41,4”-di-O-methyl-EGCG (DiMeEGCG), resulting in a reduction of the oral bioavailability of EGCG
and reduced cancer-related biological activities of EGCG. Combination of EGCG and Tolcapone
(TOL) (a COMT inhibitor) was found to improve the bioavailability of EGCG and to synergistically
enhance the cancer suppressive effect of EGCG by inhibiting the COMT-mediated methylation of
EGCG in vivo [84]. The authors deduced that the differences in the suppressive effect of catechins on
breast cancer between various populations might be related to the differentiation in the bioavailability
of catechins between different populations, owing to variations in physiological status.
4.2. Further Study Suggestions
Improvement of the bioavailability of the bioactive catechins will be an important research
topic in the future. The development of methods to improve the stability of tea catechins will
enhance their oral bioavailability. The usage of stabilizers and/or encapsulation of EGCG into
particulate systems such as nanoparticles or microparticles can significantly increase its stability [85].
It was reported that encapsulation of tea extract in chitosan encapsulation in nanoparticles (NPs)
was beneficial in stabilizing catechins including EGCG and catechin (C) in vivo, resulting in a
significant improvement of their intestinal absorption [86]. Encapsulation of catechin and epicatechin
(EC) in bovine serum albumin NPs (BSA-NPs) could also improve their stability and antioxidant
potential in cell line A549 [87]. Antitumor activity of folate-conjugated chitosan-coated EGCG NPs
(FCS-EGCG-NPs)—prepared by ionic gelation method using folic acid-modified carboxymethyl
chitosan—gave a greater tumor inhibitory effect on cancer cells than free EGCG, especially in the cancer
cells with a strong expression of folic acid receptors on the cell surface [88]. Loading EGCG in cationic
lipid nanoparticles (LNs) is recognized as a promising strategy for prolonging EGCG release [89].
Developing complex formulations using various tea catechins and other bioactive components
will also improve the stability and bioavailability of tea catechins. Although EC did not induce
apoptosis of lung cancer cell line PC-9, co-treatment of EGCG with 100 μM EC reduced the IC50
of EGCG from 60 μM to 15 μM, suggesting that EC enhanced the anti-cancer activity of EGCG [83].
The combination of 75 μM EGCG with the cancer preventive agent Sulindac (10 μM or 100 μM) induced
apoptosis of PC-9 cells over 10 times more strongly than Sulindac alone [83]. The cellular accumulation
of EC was increased by co-administrating with other catechins, especially gallated catechins [90].
Green tea catechins, formulated with xylitol and vitamin C and then encapsulated in g-cyclodextrin
(g-CD) or coated with hydroxypropyl methyl cellulose phthalate (HPMCP), provided a synergistic
effect to significantly enhance the intestinal absorption of catechins [91]. Encapsulation of hydrophilic
catechin and hydrophobic curcumin within a water-in-oil-in-water (W/O/W) double emulsion by
a two-step emulsification method significantly increased their stability in simulated gastrointestinal
fluid and gave a four-fold augmentation in their bio-accessibility, compared to that of freely-suspended
curcumin and catechin solutions [92]. When EGCG was loaded into hydrogel prepared by ionic
interaction gelatin and γ-polyglutamic acid with ethylcarbodiimide as the crosslinker, EGCG was
more stable in the harsh gastrointestinal tract environment than free EGCG [93].
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However, encapsulated EGCG should be taken without food in order to maximize its systemic
absorption, because the co-administration of EGCG with foods such as a light breakfast or strawberry
sorbet reduced systemic or plasma EGCG [94].
5. Conclusions
Though the role of tea in breast cancer is uncertain, there have been many in vitro and in vivo
studies showing the association between green tea consumption and the decreased risk of breast
cancer. There are more than ten catechin compounds in tea, among which EGCG is the most abundant
and shows the most active suppressing effects on breast cancer. Catechins are a group of natural
antioxidants, and they suppress carcinogen-induced ROS and DNA damage by enhancing antioxidant
enzymes, scavenging ROS, and promoting the repair of damaged DNA. Catechins such as EGCG
regulate cell signaling pathways relating to breast carcinogenesis, such as PI3k/Akt/mTOR, EGFR,
ERK, Wnt/β-catenin, and HGF/Met pathways. EGCG interacts with target proteins in the breast
cancer cells, such as ERα, Zap-70, PI3K, G3BP1, IGF-1R, vimentin, Bcl-2, Bcl-xL, GRP78, and Fyn
via hydrogen bonding, which plays a role in the inhibition of breast cancer. Catechins inhibit DNA
methylation by suppressing DNMTs and increasing SAH levels. GTE or EGCG suppressed the secretion
of VEGF protein by inhibiting VEGF promoter activity, resulting in the inhibition of tumor angiogenesis.
Catechins suppress proliferation and induce apoptosis of breast cancer cells by inducing cell cycle
arrest and Ca2+-associated apoptosis, promoting TP53/caspase-mediated apoptosis, down-regulating
anti-apoptotic factors, inhibiting FAS, and regulating the NO/NOS system. Tea catechins inhibit
metastasis of breast cancer cells via the modulation of proteolytic enzymes, suppressing the EMT, and
down-regulating MT1-MMP transcription (Figure 1).
Figure 1. Effects of tea catechins on breast cancer. Akt: protein kinase B; DNMT: DNA
methyltransferase; EGFR: epidermal growth factor receptor; EMT: epithelial-to-mesenchymal transition;
ERα: estrogen receptor alpha; ERK: extracellular signal-regulated kinase; FAS: fatty acid synthase;
G3BP1: SH3 domain-binding protein 1; HGF: hepatocyte growth factor; IGF-1R: insulin-like growth
factor 1 receptor; MT1-MMP: membrane type-1 matrix metalloproteinase; mTOR: mammalian
target of rapamycin; NO/NOS: nitric oxide/nitric oxide synthase; PI3K: phosphoinositide-3-kinase;
ROS: reactive oxygen species; SAH: S-adenosyl-L-homocysteine; TP53: tumor protein P53; VEGF:
vascular endothelial growth factor; Zap-70: 70 kDa zeta-associated protein.
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The inconsistent results between in vitro and in vivo studies are considered to arise from the low
oral bioavailability and the biotransformation of catechins in vivo. Further studies on the development
of methods to stabilize catechins in the digestive tract and complex formulation with synergistic
effects between catechins and other ingredients will be beneficial to improve oral bioavailability
and anti-tumor effects of tea catechins. Overall, tea catechins show a potential role in suppressing
breast cancer.
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Abstract: Pancreatic cancer (PC) is one of the deadliest cancers worldwide. Surgical resection remains
the only curative therapeutic treatment for this disease, although only the minority of patients can
be resected due to late diagnosis. Systemic gemcitabine-based chemotherapy plus nab-paclitaxel
are used as the gold-standard therapy for patients with advanced PC; although this treatment is
associated with a better overall survival compared to the old treatment, many side effects and poor
results are still present. Therefore, new alternative therapies have been considered for treatment of
advanced PC. Several preclinical studies have demonstrated that curcumin, a naturally occurring
polyphenolic compound, has anticancer effects against different types of cancer, including PC, by
modulating many molecular targets. Regarding PC, in vitro studies have shown potent cytotoxic
effects of curcumin on different PC cell lines including MiaPaCa-2, Panc-1, AsPC-1, and BxPC-3.
In addition, in vivo studies on PC models have shown that the anti-proliferative effects of curcumin
are caused by the inhibition of oxidative stress and angiogenesis and are due to the induction of
apoptosis. On the basis of these results, several researchers tested the anticancer effects of curcumin in
clinical trials, trying to overcome the poor bioavailability of this agent by developing new bioavailable
forms of curcumin. In this article, we review the results of pre-clinical and clinical studies on the
effects of curcumin in the treatment of PC.
Keywords: curcumin; natural compound; pancreatic cancer; therapy
1. Introduction
Pancreatic cancer is one of the deadliest cancer worldwide [1]. Surgical resection remains the
only curative therapeutic treatment for this disease, although only the minority of patients can be
resected due to late diagnosis [2]. Systemic gemcitabine-based chemotherapy has been used as the
standard therapy for patients with advanced PC, although this treatment is associated with many side
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effects and poor overall survival [3,4]. In order to improve the overall survival of patients with PC,
many studies combined the use of gemcitabine with different agents, although the results were not
encouraging [5–11]. For these reasons, new alternative therapies involving natural compounds with
minimal toxicity, such as curcumin, have been considered for treatment of PC. Curcumin, a naturally
occurring polyphenolic compound, derives from turmeric (Curcuma longa). It has been commonly
used as a food additive or dietary pigment and in traditional medicine [12–16]. Preclinical in vitro
and in vivo studies have demonstrated that curcumin has several pharmacologic effects, including
antioxidant, anti-inflammatory, and anticancer activities, in different types of cancer, including PC,
by modulating multiple signaling pathways [15,17–44]. Taken together, these results suggest that
curcumin can be considered a new therapeutic drug in PC treatment [45]. In addition it has many
advantages for patients, such as safety and minimal toxicity. Several researchers tested the anticancer
effects of curcumin in clinical trials, trying to overcome the poor bioavailability of this agent by
developing new bioavailable forms of curcumin [15,46–57]. In this article, we review the results of
pre-clinical and clinical studies on the effects of curcumin in the treatment of pancreatic cancer.
2. Effects of Curcumin in Treatment of PC
(a) In Vitro Studies: Dissecting the Molecular Mechanism Underlying the Antitumor Effects of Curcumin in
PC Cell Growth
Several preclinical studies showed that curcumin has antitumor effects by modulating
multiple cell-signaling pathways in different types of cancers, including colorectal [28,33,58],
pancreatic [17,18,22,27–31,34,35,42,43,59–67], breast [26], lung [32], hepatic [20], ovarian [25], head
and neck [68], and prostate [24].
Regarding PC, in vitro studies on the effects of curcumin have been performed on different PC
cells lines including MiaPaCa-2, MPanc-96, BxPC-3, Panc-1, AsPC-1, and L3.6pL. Results from these
studies showed that the anti-proliferative effects of curcumin are mainly due to the inhibition of
oxidative stress and angiogenesis and the induction of apoptosis [17,18,22,29,34,42,43,59,60,65,69–73].
The first report on the antitumor effect of curcumin in PC was described by Li et al. [17]. The authors
demonstrated that curcumin down-regulated Nuclear factor kappa-light-chain-enhancer of activated
B cells (NF-κB) and growth control molecules induced by NF-κB in human pancreatic cells in a time-
and dose-dependent manner. These effects were accompanied by marked growth inhibition and
apoptosis. Similar results were obtained by Wang et al. [22]. Then authors demonstrated that the
Notch-1 signaling pathway was associated with NF-κB activity during curcumin-induced cell growth
inhibition and apoptosis of pancreatic cells, suggesting that the down-regulation of Notch signaling by
curcumin could represent a novel strategy for the treatment of patients with PC. In another study, it was
demonstrated that curcumin treatment inhibited the proliferation of BxPC-3 human pancreatic cancer
cells by DNA damage-mediated G2/M cell cycle arrest, by inhibition of cyclin B1/Cyclin-dependent
kinase 1 (Cdk1) expression and by the activation of ataxia tel-angiectasia mutated (ATM)/Checkpoint
kinase 1(Chk1)/Cell Division Cycle 25C (Cdc25C) [29]. Jutooru et al. showed that curcumin inhibited
NF-κB expression and Panc-1 and L3.6pL cancer cell growth by down-regulation of the specificity
protein Sp1 [59]. We also demonstrated that curcumin inhibited the proliferation and enhanced the
apoptosis of MIA PaCa-2 cells, through the suppression of NF-κB-activation [18]. Recent findings
showed that curcumin induced apoptosis in PC cells through the induction of forkhead box O1 (FOXO1)
and the inhibition of the phosphatidylinositol 3-kinase/phosphatidylinositol 3-kinase (PI3K/Akt)
pathway [43]. The antitumor role of curcumin in PC was also demonstrated by Diaz et al. in Panc-1
cells. The authors showed that curcumin induced pancreatic adenocarcinoma cell death via the
reduction of the inhibitors of apoptosis (IAP) [42]. Finally, very recently, it was demonstrated that a
small-molecule tolfenamic acid and dietary spice curcumin treatment enhanced the anti-proliferative
effect in PC cells L3.6pl and MIA PaCa-2 through Sp1 suppression, NF-κB disruption of translocation
to the nucleus and cell cycle phase distribution [34].
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These results suggest that curcumin exerts its antitumor effect on PC by acting on different
molecular mechanisms. Specifically, other studies showed that treatment of PC cells with curcumin
has been associated with reduced migration and invasiveness of tumor cells, inhibition of cancer stem
cell function, reversal of the epithelial-mesenchymal transition (EMT), and suppression of miR-221,
Cyclooxygenase 2 (COX-2) and their effectors and pro-inflammatory cytokines [69,70]. In addition, it
has been demonstrated that curcumin can also block signal transducer and activator of transcription 1
(STAT1) and signal transducer and activator of transcription 3 (STAT3) phosphorylation, and epidermal
growth factor receptor (EGFR) and (neurogenic locus notch homolog protein-1) Notch-1 signaling
pathways, which play important roles in pancreatic tumor growth [74]. It has been also demonstrated
that siRNA/shRNA, small-molecule kinase inhibitors, and curcumin targeting these tumor stem cell
markers and tumor suppressor miRNAs could be the perfect therapeutic agents for the treatment of
PC [31,67,69,75–77] (Figure 1).
Figure 1. A schematization of molecular targets in PC regulated by curcumin. NF-κB:
Nuclear factor kappa-light-chain-enhancer of activated B cells; COX2: Cyclooxygenase 2; Hes-1:
Cyclin-dependent kinase 1; Akt: Protein kinase B; Stat3: Signal transducer and activator of
transcription 3; PI3K: phosphatidylinositol 3-kinase; Notch-1: Neurogenic locus notch homolog
protein-1; c-myc: C-mycproto-oncogene; Jak: Janus kinase. P21: Cyclin-dependent kinase inhibitor;
P27: Cyclin-dependent kinase inhibitor; BCL-xL: B-cell lymphoma-extra large.
In order to ameliorate the aqueous solubility of curcumin, different derivatives of this compound
or delivery system have been developed [78,79]. One curcumin analogue used in in vitro experiments
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is the 3,4-difluorobenzylidene curcumin (CDF). This compound has a higher tendency to accumulate
in the pancreas than normal curcumin [74,80]. Although it has been demonstrated that CDF has
cytotoxic effects on both resistant and nonresistant pancreatic tumor cell lines with respect to
curcumin, this curcumin derivative still presents low aqueous solubility. To bypass this problem,
researchers developed a new delivery system based on nanoparticles, such as hyaluronic acid
(HA)-conjugated polyamidoamine dendrimers and hyaluronic acid (HA) and styrene-maleic
acid-engineered nanomicelles of CDF. Results from studies performed with these systems gained
improvements of aqueous solubility, stability, release profile and antitumor effects on PC cells lines
with respect to unformulated CDF [56,63,81]. Table 1 summarizes the most relevant in vitro studies on
the antitumor effect of curcumin in PC cells.
Table 1. A summary of in vitro studies on the role of curcumin in Pancreatic Cancer cell growth.
Cell Lines Dose of Curcumin (μM) Molecular Targets Reference
MiaPaCa-2; BxPC-3; Panc-1; MPanc-96 ě25 NF-κBÓ;VEGFÓ [71]
MiaPaCa-2 50 NF-κBÓ [18]
BxPC-3 2.5 Cdk1Ó; cyclin B1Ó [29]
Panc-28; L3.6p ě25 NF-κBÓ, Sp-1, Sp-3, Sp4Ó [59]
Miapaca-E; Miapaca-M; BxPC-3 ě4 miR-220Ò; miR-21Ó [31]
Panc-1 ě25 IAPÓ [42]
L3.6pl; MIA PaCa-2 5–25 NF-κBÓ, Sp-1, Sp-3, Sp4Ó [34]
PANC-1 10–30 ShhÓ, GLI1Ó, E-cadherinÓ, vimentinÓ [70]
NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells; VEGF: Vascular endothelial growth
factor; Cdk1: Cyclin-dependent kinase 1; Sp-1: Specificity protein 1; Sp-3: Specificity protein 3; Sp4: Specificity
protein 4; IAP: inhibitors of apoptosis; Shh: Sonic hedgehog, GLI1: Glioma-associated oncogene homologue 1;
E-cadherin: Epithelial cadherin.
(b) In Vivo Studies: Effects of Curcumin in Mouse Model of PC
The antitumor effect of curcumin and its analogues on PC has been demonstrated in in vivo
experiments on mouse models of PC [18,27,59,71,74,82–88]. The first in vivo study was reported
by Kunnumakara et al. [71]. The authors demonstrated that curcumin (1 g/kg orally) potentiated
the antitumor activity of gemcitabine (25 mg/kg via intraperitoneal injection) in an orthotopic
mouse model of PC [15] through the suppression of proliferation, angiogenesis, and inhibition
of NF-κB-regulated gene products. Our research group also reported similar results. In fact, we
demonstrated with the generation of an orthotropic mouse model of PC that tumors from mice injected
with MIA PaCa-2 cells and placed on a diet containing curcumin at 0.6% for six weeks were smaller
than those observed in controls. We also showed a down-regulation of the NF-κB-regulated gene
products, suggesting that curcumin had great potential in the treatment of human PC, through the
modulation of the NF-κB pathway [18]. Mach et al., in a xenograft human PC model, established the
minimum effective dose (MED, 20 mg/kg) and optimal dosing schedule for liposomal curcumin [88].
In another study, the in vivo antitumorigenic activity of curcumin was investigated in athymic nude
bearing L36pL cells as xenografts. The authors demonstrated that curcumin (dose of 100 mg/kg/days)
inhibited tumor growth and tumor weight by down-regulation of the Sp transcription factor [59].
In order to potentiate the effects of curcumin on PC in vivo, several studies were performed
using different forms of curcumin. Bao et al. demonstrated that CDF (2.5 mg/mouse/days; 5
mg/mouse/days; intragastric once daily for three weeks), an analogue of curcumin analogue, inhibited
pancreatic tumor growth by switching on suppressor microRNAs and attenuating the expression of
histone methyltransferase enhancer of zeste homolog 2, EZH2 [74]. Similar effects were reported for
synthetic curcumin analogues EF31 and UBS109. The authors demonstrated, both in vitro and in vivo,
that these analogues were potent DNA hypomethylating agents in PC [86]. The efficacy of liposomal
curcumin in human PC was also reported by Ranjan et al. The authors showed that in xenograft
tumors in nude mice, liposomal curcumin (20 mg/kg i.p. three times a week for four weeks) induced
a suppression of tumor growth compared to untreated controls, indicating that this agent could be
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beneficial in patients with PC [85]. Similar results have been reported by recent studies in which the
efficacy of curcuminoids and nanomicelles in treatment of PC was demonstrated [81,82]. It is important
to underline that in all studies performed with curcumin derivatives and or a delivery system, the
antitumor effects have been reported to be greater with respect to those observed with conventional
curcumin. On the basis of these results, researchers tested the anticancer effects of curcumin in clinical
trials, trying to overcome the poor bioavailability of this agent by developing new bioavailable forms
of curcumin. Table 2 summarizes preclinical in vivo studies on the anticancer effects of curcumin
against PC.
Table 2. Preclinical in vivo studies on the anticancer effects of curcumin against PC.




Gemcitabine 1 g/kg (orally)
Suppression of proliferation,




(MIA PaCa-2 cells) Curcumin 0.6% for 6 weeks (dietary food)
Tumor growth inhibition and




(L36pL cells) Curcumin 100 mg/kg/days
Tumor growth and Tumor
weight inhibition [59]
Orthotopic mouse model
(MIA PaCa-2 cells) CDF
2.5 mg/mouse/days;
5 mg/mouse/days; intragastric
once daily for 3 weeks
Tumor growth inhibition,





20 mg/kg i.p. three-times a
week for four weeks Tumor growth inhibition [85]
(c) Clinical Trials
In order to translate the preclinical antitumor effects of curcumin into clinical practice, few clinical
trials have been performed so far. Healthy volunteers and cancer patients were treated with curcumin,
administered orally, in different clinical trials (phase I and pharmacokinetic studies). No dose-limiting
toxicity (DLT) of up to at least 12 g/day was observed in patients, although nausea and diarrhea have
been reported [48,89,90]. It was established that the daily oral dose of curcumin of 8 g or less is the
most commonly used in clinical trials, due to its poor bioavailability.
Several phase II clinical trials on the antitumor effects of curcumin in PC were conducted [91–93].
Dhillon et al. conducted the first trial [91] and successfully tested the safety and the efficacy of
curcumin used as a monotherapy in 25 patients of PC. Another group conducted a phase I/II
clinical trial of curcumin in 21 patients with PC (resistant to gemcitabine-based chemotherapy),
combining gemcitabine-based chemotherapy with curcumin treatment (8 g daily oral dose) [92].
Results from this study indicated that combination therapy using 8 g oral curcumin daily with
gemcitabine-based chemotherapy was safe and feasible in patients with PC. Another interesting study
tested the efficacy and feasibility of curcumin (8 g daily oral dose) in combination with gemcitabine
monotherapy (standard dose and schedule) in 17 chemo-naive patients with PC. Differently from
previous studies, increased gastrointestinal toxicity was observed in seven patients treated with this
therapy, probably due to the elevated dose of curcumin combined with gemcitabine. For this reason,
the dose of curcumin was reduced from 8 to 4 g [93]. From this study emerged the problem of the
poor bioavailability of curcumin, which strongly limited its application in clinical practice. To solve
this problem, new curcumin analogs and new drug delivery systems have been developed [46–55].
Interesting results have been reported by dose escalation and pharmacokinetic studies performed
with Theracurcumin, a nanoparticle-based curcumin [55]. These studies demonstrated that the plasma
curcumin levels observed after Theracurcumin ingestion were higher with respect to those obtained
with conventional curcumin. The phase I clinical trial involving Theracurcumin (level 1 group: 200 mg
oral/daily; level 2 group: 400 mg oral/daily) was conducted on 16 patients with PC resistant to
gemcitabine-based chemotherapy [94]. The results from this study showed that repetitive systemic
exposure to high concentrations of Theracurmin did not increase the incidence of side effects in cancer
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patients receiving gemcitabine-based chemotherapy, indicating that this agent could represent a new
agent for PC treatments.
New clinical trials are needed to test the therapeutic effects of curcumin and its analogues in
patients with PC.
3. Conclusions
Several preclinical studies have demonstrated that curcumin, a naturally occurring polyphenolic
compound, has anticancer effects against different types of cancer, including PC, by modulating many
molecular targets. On the basis of these results, several researchers tested the anticancer effects of
curcumin in clinical trials, trying to overcome the poor bioavailability of this agent, which limited its
clinical application. New bioavailable forms of curcumin have been developed and the results from
clinical trials on patients with PC suggest that these agents could represent promising new treatments
for PC, although more clinical studies will be still needed.
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Nuclear factor kappa-light-chain-enhancer of
activated B cells
Cdk1 Cyclin-dependent kinase 1
ATM Ataxia tel-angiectasia
Chk1 Checkpoint kinase 1
Cdc25C Cell division cycle 25C




IAP Inhibitors of apoptosis
EMT epithelial-mesenchymal transition
STAT1 Activator of transcription 1
STAT3 Signal transducer and activator of transcription 3
EGFR Epidermal growth factor receptor
Notch-1 Neurogenic locus notch homolog protein-1
COX2 Cyclooxygenase 2
Hes-1 Cyclin-dependent kinase 1
Akt Protein kinase B
Stat3 Signal transducer and activator of transcription 3
PI3K phosphatidylinositol 3-kinase
Notch-1 Neurogenic locus notch homolog protein-1
c-myc C-mycproto-oncogene
Jak Janus kinase
P21 Cyclin-dependent kinase inhibitor
P27 Cyclin-dependent kinase inhibitor
BCL-xL B-cell lymphoma-extra large
CDF 3, 4-difluorobenzylidene curcumin
HA hyaluronic acid
Sp-3 Specificity protein 3
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Sp4 Specificity protein 4
Shh Sonic hedgehog
GLI1 Glioma-associated oncogene homologue 1
E-cadherin Epithelial cadherin
EZH2 enhancer of zeste homolog 2
MED minimum effective dose
DLT dose-limiting toxicity
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Abstract: Mangiferin, a bioactive compound derived primarily from Anacardiaceae and Gentianaceae
families and found in mangoes and honeybush tea, has been extensively studied for its therapeutic
properties. Mangiferin has shown promising chemotherapeutic and chemopreventative potential.
This review focuses on the effect of mangiferin on: (1) inflammation, with respect to NFκB, PPAR
and the immune system; (2) cell cycle, the MAPK pathway G2/M checkpoint; (3) proliferation
and metastasis, and implications on β-catenin, MMPs, EMT, angiogenesis and tumour volume;
(4) apoptosis, with a focus on Bax/Bcl ratios, intrinsic/extrinsic apoptotic pathways and telomerase
activity; (5) oxidative stress, through Nrf2/ARE signalling, ROS elimination and catalase activity; and
(6) efficacy of chemotherapeutic agents, such as oxaliplatin, etoposide and doxorubicin. In addition,
the need to enhance the bioavailability and delivery of mangiferin are briefly addressed, as well as
the potential for toxicity.
Keywords: mangiferin; cancer; inflammation; NFκB; oxidative stress; cell cycle; combination therapy;
nutraceuticals; bioavailability; hallmarks of cancer
1. Introduction
Cancer has been identified as the leading cause of non-communicable disease mortality
globally [1], and is responsible for significant morbidity and costs to healthcare systems. Cancer
incidence and mortality has been increasing at a greater rate than population growth alone could
account for. The International Agency for Research on Cancer (IARC) reported 14.1 million cases
and over 8.2 million mortalities due to cancer in 2012 compared to 10 million cases and six million
mortalities in 2000 [2] in a baseline population of 7.1 billion and 6.1 billion, respectively [3]. Much of
this increase is due to rising cancer burden in less developed countries (LDCs), with 57% of new cases,
and 65% of cancer related deaths occurring in LDCs [2]. When standardized by age, the total number
of cases per 100,000 population is greater in more developed countries (MDCs) than LDCs (overall age
standardized rate: 268 and 148 respectively) [4]. One exception to this pattern is infection-attributable
cancers, which are responsible for 26% of the cancer burden in LDCs but only 8% in MDCs [5].
Cancer is less likely to be identified early or treated successfully in LDCs due to reduced access to
screening tools and chemotherapeutic drugs. Previously, cancer has been regarded as a MDC disease.
However, through the adoption of a more Westernised lifestyle, cancer incidence has been steadily
increasing in LDCs. From the data published by Parkin et al., it can be seen that 40%–45% of cancers
can be attributable to lifestyle factors such as diet, smoking status, alcohol consumption and lack of
physical activity [6]. Some compounds naturally present in the diet, such as mangiferin in mangoes
and honeybush tea, are thought to modulate risk of cancer and retard cancer progression.
Mangiferin (1,3,6,7-tetrahydroxyxanthone-C2-β-D glucoside) [7–11] is a polyphenol [8,11–15]
found in many plant species, in particular, those from the Anacardiaceae [7,9,16–20] and Gentianaceae
Nutrients 2016, 8, 396 468 www.mdpi.com/journal/nutrients
Nutrients 2016, 8, 396
families [7,9,13,17,18,20]. For an extensive breakdown of plant sources of mangiferin and mangiferin
content, see Matkowski et al. [21].
Mangiferin is not only present in everyday foods, but utilised in a number of natural medicines.
In traditional medicine, different cultures have cultivated and processed mangiferin rich plants
for the treatment of a range of illnesses including cardiovascular disease, diabetes, infection and
cancer [22–24]. In India, Ayurvedic practitioners [22] have used Salicia chinesis (saptarangi) [21,25,26]
and Mangifera indica (mango), which are two species that contain high levels of mangiferin.
Salicia chinesis has been used for its hypo-lipidaemic, anti-diabetic, hepatoprotective and antioxidant
properties. Salicia chinesis has now been over-exploited and research is being conducted into how
this plant may be grown in a more sustainable way to meet demands [27]. Mangifera indica is used
not only in Ayurvedic medicine but also used in Cuba [23], China [21,24] and throughout East
Asia [21] for its anti-inflammatory, anti-viral, anti-diabetic and anti-cancer properties. Mangifera indica,
a member of the Gentianaceae family, contains mangiferin [10,20,21,28–30] in its bark (18.33 g/kg
dry weight [31]), leaves [15] (old leaves 36.9 g/kg and young leaves 58.12 g/kg dry weight [31]) and
root along with the seed, pulp (0 to 2.65 mg/kg dry weight, depending on the variety [32]) and skin
of the fruit [7,8,12,20,33–35] (4.94 g/kg dry weight [31]). However, the concentration of mangiferin
in the pulp is unlikely to be sufficient to provide significant health benefits, and can vary greatly
depending on variety and the maturity of the fruit [32]. Although somewhat lower than levels found
in bark and leaves, the mangiferin in the skin [36] and seed/kernel [31], which are usually considered
waste products, may provide a promising sustainable option for mangiferin extraction. To date, these
mango by-products have been used to enhance the nutritional density of pasta, biscuits, muffins and
pancakes [37–40]. Although the phenolic content of these food items increased 2.8–3.9 fold [37,39],
the mangiferin content was not reported. However, in the results detailed in the sections hereafter,
the concentrations used or administered varied from 12.5 to 100 μg/mL in in vitro studies [12] and
approximately 100 mg/kg body weight in in vivo studies [7]. Clearly, the consumption of such
quantities is not achievable by consuming fresh mango pulp, but maybe achievable by adding a leaf,
bark, and/or seed extract as a supplement to food, or consuming as a liquid (if palatable).
In Cuba, aqueous extracts of Mangifera indica bark have become popular [7,12,41,42] for treatment
of not only cancer but gastric and dermatological disorders, AIDS and asthma [43]. Stem bark extracts
contain polyphenols, terpenoids, steroids, fatty acids and trace elements alongside mangiferin [21,23].
The natural medicine, Vimang® [7,12,42], produced from aqueous extracts of Mangifera indica, contains
~20% mangiferin [23] and is available in tablets, creams and syrups. Vimang® is registered as
an “anti-inflammatory phytomedicine” by the Cuban Regulatory Health Authorities and is primarily
used by those with multiple and different types of cancer. In China, mango leaves [21,24] and
Dobinea delavayi (Baill.) leaves [44], which both contain mangiferin, are often used in traditional
medicines. The greatest dietary source of mangiferin is Honeybush tea, popular in South Africa
and obtained from Cyclopia sp. [21]. Honeybush tea leaves have been found to consist of up to 4%
mangiferin by dry weight [21].
Research into mangiferin has resulted in the identification of a similar compound, namely
mangiferin aglycone or norathyriol, which appears to have greater biological activity in some instances.
The compound mangiferin aglycone can be artificially synthesized, bypassing any sustainability
concerns surrounding mangiferin. The structure of mangiferin and mangiferin aglycone are shown in
Figure 1. Mangiferin aglycone has shown greater biological activity in some targets than mangiferin,
possibly due to greater water solubility [28], and the former appears to reduce UV-induced skin
cancer [8]. Further studies are required to elucidate the degree of similarity in action of mangiferin
and mangiferin aglycone.
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Figure 1. The molecular structure of: (A) mangiferin [45]; and (B) mangiferin aglycone [46].
Evidence suggests that mangiferin could prove to be a useful, inexpensive compound to not only
maintain and improve health in the worried well, but also to significantly improve the outlook for
those with certain cancers (e.g., breast cancer [41]) and reduce the likelihood of developing cancer.
This is of particular relevance to LDCs, where the more expensive chemotherapeutic drugs may be
inaccessible, while mangiferin containing plants are abundant. In MDCs, the potential enhanced
synergistic effect seen with major chemotherapeutic drugs may allow for lower dosages of drugs, thus
reducing toxicity and providing greater selective toxicity to malignant cells, reducing the extent of
side effects [47]. However, it is acknowledged that the quantity of fruit required in order to achieve
clinically relevant levels of mangiferin may be unreasonably high. For this reason substitution of flour
and sugar with mango processing by product [37,39] may prove an additional and useful method of
increasing mangiferin intake.
The anti-cancer properties of mangiferin have been extensively studied over the past few decades.
This review article seeks to consolidate the most recent research on the anti-neoplastic properties of
mangiferin, with a focus on molecular pathways and uses of mangiferin, in conjunction with known
chemotherapeutic agents, to aid further research on this topic.
2. Molecular Mechanisms of the Anti-Cancer Action of Mangiferin
Mangiferin acts through a myriad of mechanisms to exert anti-inflammatory [11,14,20–24,28,29,42,48],
immunomodulatory [8,9,14,19,20,23,24,28,29,49], cell cycle arrest, anti-proliferative, anti-apoptotic [48],
anti-oxidative [8,11,14,15,19,20,22–24,28–30,36,42,48–51], anti-genotoxic [30] and anti-viral [11,15,20,48]
effects which cumulatively result in anti-tumour activity [9,11,15,19–21,23,24,29,41,50]. Mangiferin
has demonstrated broad-spectrum efficacy against an array of different cancers in in vitro and in vivo
studies [8,11,12,14,21]. To date, evidence suggests that the side effects of mangiferin vary from mild to
non-existent [52]; however, there may be some variation according to source of mangiferin.
2.1. Inflammation
The chronic activation of inflammatory processes is widely regarded as an enabling characteristic
towards the acquisition of cancer [53]. Approximately 20% of cancers are attributable to chronic
inflammation [54], which may be induced by bacterial or viral infections, autoimmune disease,
or constant exposure to irritants. Chronic inflammation can drive tumour growth by providing
a favourable environment, rich in inflammatory mediators, to enhance cell growth and survival [53,55].
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In addition, inflammation involves the production of reactive oxygen species (ROS), which can cause
DNA damage, enhancing carcinogenic capabilities [56]. Mangiferin is thought to dampen down
the inflammatory response primarily by interference with Nuclear Factor κ-light-chain-enhancer of
activated B cells (NFκB) [34].
By reducing inflammation, mangiferin not only provides unfavourable conditions for cancer, but
can provide anti-diabetic effects [11,15,19,21,23,24,28,29,50] and reduce risk of cardiovascular disease.
Mangiferin also reduces serum glucose levels and lipid levels [8,14,30], further decreasing development
and severity of diabetes and cardiovascular disease. Thus, while many medications used to treat these
widespread non-communicable diseases may create adverse conditions in the body that may lead to
other diseases, mangiferin provides broad spectrum benefits across a range of diseases such as cancers,
cardiovascular disease and diabetes [26,33,35,39].
2.1.1. Nuclear Factor κ-Light-Chain-Enhancer of Activated B Cells Activity
The transcription factor NFκB regulates many important processes in inflammation, including the
expression of pro-inflammatory cytokines, migration molecules, growth factors and other genes
involved in proliferation and survival [34]. NFκB is up-regulated during inflammation. Under
inflammatory conditions, ligands bind and activate Toll-like receptors (TLRs) and Interleukin-1
Receptors (IL-1R), triggering the Myeloid Differentiation Primary Response Gene 88 (Myd88) to
recruit Interleukin-1 Receptor Activated Kinase 1 (IRAK1) to this receptor-signalling complex for
phosphorylation [57,58]. Association of IRAK1 with Myd88 allows phosphorylation by IRAK4
and subsequent autophosphorylation. In its phosphorylated form, IRAK1 interacts with Tumour
necrosis factor Receptor-Associated Factor 6 (TRAF6) to form a complex, which signals sequentially
through Transforming growth factor beta-activated kinase 1/Transforming growth factor beta-activated
kinase 1-binding protein 1 and 2 (TAK1/TAB1/TAB2), NFκB Essential Modulator/Inhibitor of NFκB
Kinase subunit-β/Inhibitor of NFκB Kinase subunit-α (NEMO/IKK-β/IKK-α) and Inhibitor of κB
(IκB)/p50/p65 complexes to ultimately activate NFκB [57]. Recent findings suggest mangiferin inhibits
NFκB activation at various steps in the pathway (Figure 2A,B) [11,47]. NFκB can be activated via the
classical or alternative pathways. The classical pathway is regulated by the IκB kinase complex and
p50, while the alternative pathway is regulated by IKKα and p52 [59].
Figure 2. Cont.
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Figure 2. Inhibition of NFκB via the (A) classical and (B) alternative pathways by mangiferin and
Vimang (adapted from [11,45,55]) (abbreviations: Mng, mangiferin; V, Vimang®).
Initial Stimulus for NFκB Activation
When studied, it was found that mangiferin blocks Tumour Necrosis Factor (TNF) [8],
lipopolysaccharide (LPS), peptidoglycan (PDG) [60], phorbol-12-myristate-13-acetate (PMA) [11]
or hydrogen peroxide (H2O2) mediated NFκB activation by inhibiting ROS production [61]. This effect
has been demonstrated in U-937 (lymphoma), HeLa (cervical cancer), MCF-7 (breast cancer) and IRB3
AN27 (human foetal neuronal) cell lines [11]. Jeong et al. [60] demonstrated that the inhibitory effect of
mangiferin on NFκB expression when induced by LPS and PDG in peritoneal macrophages was elicited
in part by inhibition of IRAK1 phosphorylation and consequently activation. In parallel, mangiferin
impedes NFκB activation via inflammatory genes [11,48]. Inhibition of IRAK1 by mangiferin may
reduce development of resistance to chemotherapeutic drugs. In particular, triple negative breast
cancers have been associated with overexpression of IRAK1, and it is reported that inhibition of IRAK1,
through the p38-MCL1 pathway, may reverse paclitaxel resistance [62]. Mangiferin, as a component of
combination therapy, will be addressed in Section 4.
Subsequent studies have implicated mangiferin in suppressing the TNF signal transduction
pathway [11,48], where under normal conditions, canonic interactions of TNF Receptor (TNFR)
with Tumour Necrosis Factor Receptor type-1-Associated Death Domain protein (TRADD),
TNFR-Associated Factor 2 (TRAF2) and NCK Interacting Kinase (NIK) along with subsequent
phosphorylation and degradation of IκBα initiates NFκB activation (Figure 2A) [11]. To identify
the site of action, U-937 cells were transfected with TNFR1, TRADD, TRAF2, NIK, IKK and p65
plasmids. Secreted Embryonic Alkaline Phosphatase (SEAP) was used as a reporter gene for NFκB
and expression levels were monitored in treated and un-treated cells. Mangiferin inhibited TNFR1,
TRADD, TRAF2, NIK and IKK induced SEAP expression but did not have a significant effect on p65
induced SEAP expression. Consequently, mangiferin must act downstream from IKK [11].
Signal Transduction to Activate NFκB
In a study carried out by García-Rivera et al. on estrogen negative MDA-MB231 breast cancer
cells, the efficacy of Vimang® (aqueous extract from Mangifera indica) was investigated and compared
to treatment with either mangiferin only or gallic acid only (another bioactive present in Vimang®) [41].
At baseline, MDA-MB231 cells, which have a mutated p53 gene, demonstrate high NFκB activity [41].
When cells were pre-treated for 4 h with 200 μg/mL Vimang® or 100 μg/mL of mangiferin, there was no
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change in IKKα expression, but reduced phosphorylation of IKKα and IKKβ was observed [41]. These
proteins must be phosphorylated in order to transduce the signal and activate NFκB, thus mangiferin
attenuated signal transduction. These authors also report that time taken for IκB phosphorylation
and consequently degradation in response to TNF stimulation was doubled and time taken for IκB
resynthesis was significantly reduced [41]. The action of mangiferin on IκB degradation has also been
reported in a number of other studies [11,41,47,48,63]. Once IκBα is degraded, its inhibitory effect on
the NFκB activation pathway is diminished [63] and thus NFκB can freely bind to DNA, allowing
transcription and translation of the respective genes and proteins that it regulates [64]. Additionally,
mangiferin and Vimang® were found to reduce phosphorylation and translocation of p65 into the
nucleus and impeded NFκB/DNA binding in response to TNF [41]. Other studies have also reported
that mangiferin affects IκBα and p65 in this way [8,11,48]. García-Rivera et al. revealed that Vimang®,
but not mangiferin alone was found to prevent parallel NFκB transactivation [41], emphasising the
beneficial effects provided by other bioactive constituents of this aqueous extract.
It is clear that mangiferin is likely to attenuate NFκB expression in a multifaceted way, [34,47]
with additional mechanisms yet to be elucidated.
Consequential Effects of NFκB Downregulation
NFκB is implicit in regulating expression of Cyclooxygenase-2 (COX-2), Intercellular Adhesion
Molecule-1 (ICAM-1), B Cell Lymphoma-2 (bcl-2), Interleukin-6 (IL-6), Interleukin-8 (IL-8), C-X-C
Chemokine Receptor type-4 (CXCR4), X linked Inhibitor of Apoptosis Protein (XIAP) and Vascular
Endothelial Growth Factor (VEGF), which are all involved in inflammation, metastasis, cell survival
and angiogenesis [11,29,42,48] (more on COX-2 below). As a downregulator of NFκB, mangiferin
consequentially reduces expression of the genes listed above [41] and increases apoptosis [8].
IL-6 and IL-8 are both inflammatory cytokines that enhance cell proliferation. In MDA-MB231 cells,
proliferation is conditional on autocrine synthesis of inflammatory cytokines and growth factors [41].
Vimang® and mangiferin have each been found to down-regulate IL-6 and IL-8 production when
stimulated by TNF [41], thus reducing the inflammatory response.
2.1.2. Peroxisome Proliferator-Activated Receptor (PPAR )
PPAR is a nuclear receptor that also functions as a transcription factor, regulating expression of
genes involved in cell differentiation and tumourigenesis [65]. Under normal circumstances, when
the corresponding ligand binds to PPAR , transcriptional activation of COX-2 is suppressed through
a number of mechanisms [66]. COX-2 is one of the key drivers of chronic inflammation through the
production of prostaglandins leading to further activation of inflammatory processes [67], and thus
COX-2 overexpression favours cancer progression [29]. PPAR also has a pleiotropic effect on blood
glucose levels. PPAR agonists such as thiazolidinediones are widely used in management of diabetes
and have a hypoglycaemic effect [65]. Hyperglycaemia is regarded as an emerging risk factor for
cancer development [65]. Mangiferin, like thiazolidinedione may also act to reduce hyperglycaemia,
benefiting diabetics and decreasing cancer risk.
Mangiferin increases mRNA expression of the PPAR gene [68] and thus decreases transcriptional
activation of COX-2. This reduces inflammation and creates a less favourable environment for
acquisition and proliferation of malignant cells. Mangiferin also impedes expression of COX-2 [41]
via upregulation of TGF-β and downregulation of NFκB. Mangiferin may play a beneficial role in
modulating PPAR and COX-2 regulation as evidenced by in vitro studies in MDA-MB231 breast
cancer cells [43].
2.1.3. Immune Response
Cancer cells can sometimes escape detection and avoid the immune system, which would
otherwise destroy abnormal cells. Cancer cells not only express immune checkpoint proteins that
dampen the immune response, but they may also release cytokines and growth factors that promote
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tumour cell proliferation and minimize apoptosis. By enhancing a patient’s immune response a better
outcome can be achieved. In in vivo studies, mangiferin has been found to enhance the number and
activity of immune cells [9,10].
Rajendran et al. found that in mice treated with benzo(a)pyrene (B(a)P) to induce lung cancer,
dosing with mangiferin influenced the types of immune cells present and concentrations of various
immunoglobulins [9]. Mangiferin treatment resulted in higher numbers of lymphocytes and
neutrophils [9]. Mangiferin treatment of B(a)P mice increased levels of IgG and IgM immunoglobulins
and decreased levels of IgA immunoglobulins, relative to animals only receiving B(a)P treatment [9].
In addition, mangiferin inhibited phagocytic capacity and nitric oxide production of macrophages
when stimulated with LPS and IFN [9]. Thus, with respect to the inflammatory response, less
collateral damage is likely to occur. In a later study, it was found that in tumour bearing Swiss mice,
mangiferin promoted cytotoxic behaviour of lymphocytes and macrophages against malignant cells,
and thus the incidence of fibrosarcoma was reduced [7].
2.2. Cell Cycle
Maintenance of a normal cell cycle is essential for homeostasis. It allows cells to be replaced at the
same rate as they are lost. Often in cancer, the length of the cell cycle is reduced, allowing aberrant
proliferation of malignant cells.
Findings suggest that mangiferin influences the Mitogen Activated Protein Kinase (MAPK)
pathway and progression from the G2/M checkpoint, thus maintaining a more normal cell cycle length,
or cell cycle arrest at the appropriate checkpoint [8,13,52].
2.2.1. Mitogen Activated Protein Kinase Pathway
The MAPK pathway is frequently implicated in tumourigenesis as it plays a role in processes
such as cell proliferation, growth, differentiation, apoptosis and migration [69]. Mangiferin attenuates
MAPK signalling [34] by inhibiting MAPKs p38, Extracellular signal-Regulated Kinase (ERK) and
c Jun N-terminal Kinase phosphorylation [60]. Li et al. found that mangiferin aglycone, a metabolite of
mangiferin, formed through deglycosylationin vivo, also inhibited ERK1/2 when phosphorylation was
induced by UVB [70]. In this study, mangiferin aglycone was found to significantly reduce UV-induced
skin cancers in mice, primarily through this interaction with ERK [70]. While further study is required,
this suggests a beneficial effect against skin cancer.
2.2.2. G2/M Checkpoint
Under normal conditions, cells with mutations are not able to undergo mitosis, as there are
a number of checkpoints in the cycle that prevent mutated DNA from replicating [71]. Cancer cells
must acquire characteristics that allow them to bypass these checkpoints in order to survive and
proliferate [71].
The G2/M checkpoint occurs during the transition from G2 to mitotic entry. The G2 phase
involves rapid growth of a cell as it prepares for mitosis. Cell progression from the G2/M checkpoint
only occurs in the absence of DNA damage signals [72]. DNA damage can be sensed by Ataxia
telangiectasia mutated protein (ATM) and Ataxia Telangiectasia and Rad3-related protein (ATR) which
signal via Checkpoint kinase 1 (Chk1) and Checkpoint Kinase 2 (Chk2) to cause degradation of
M-phase inducer phosphatase 1 (cdc25a), which results in inhibition of the Cyclin-Dependent Kinase 1
(CDK1)-cyclinB1 complex and thus cell cycle arrest [71,72] (see Figure 3). The cdc2-cyclinB1 complex
is often overexpressed in malignant cells, enhancing entry into mitosis in eukaryotic cells. Malignant
cells may acquire characteristics, which enable them to escape cell cycle arrest regardless of mutations.
Chemotherapeutic agents such as etoposide target malignant cells at the G2/M checkpoint, thus
when cell cycle progression is inhibited, the efficacy of etoposide at inducing apoptosis is increased.
Mangiferin is thought to induce G2/M phase arrest [8], reducing proliferation of malignant cells and
increasing efficacy of chemotherapeutic agents that target this phase.
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Figure 3. Mangiferin affects the molecular events leading to cell cycle G2/M phase arrest (Figure
adapted from [71]).
Mangiferin has been shown to arrest cell cycle progression in a time dependent manner at the
G2/M phase through suppression of the cdc2-cyclin B1 signalling pathway in MCF-7 cells [8]. This was
observed through analysis of cell cycle distribution through flow cytometry, where a greater number
of cells were found in the G2/M phase after incubation with mangiferin [13,52]. These findings are
in keeping with results from the Peng et al. study in HL-60 cells [8]. Peng et al. [52] also found that
in HL-60 leukaemia cells, gene expression of Chk1, cdc25 and Wee1 was elevated when exposed to
low concentrations of mangiferin, but at higher concentrations, Chk1 and cdc25 gene expression was
reduced at the mRNA level. Mangiferin has been shown to significantly inhibit phosphorylation of
ATR, Chk1 and other proteins with anti-proliferative properties such as Wee1, Akt and Erk1/2, while
increasing phosphorylation of cdc2 and cyclinB1 [52]. Lv et al. used a Western blot assay to identify
a reduction in cdc2 (cdk1) and cyclinB1 [8] protein levels in response to treatment with mangiferin.
Findings suggest that inhibition of the ATR-Chk1 stress response DNA damage pathway by mangiferin
is responsible for cell cycle arrest.
While G2/M phase arrest has been identified in response to mangiferin treatment in a number
of cancer cell lines (MCF-7, HL-60, BEL-7404 and CNE2) [16,18,35,52,73], further study is required to
determine dosages of mangiferin required to elicit an effect. In addition to G2/M phase arrest, Lv et al.
also suggest that mangiferin may induce G0/G1 cell cycle arrest in MCF7 cells [8].
2.3. Proliferation/Metastasis
Under normal circumstances, the rate of cell replication and cell death is matched to maintain
homeostasis. In cancer cells, the mediators of these processes may be deregulated, allowing cells
to proliferate continuously, exceeding rates of cell death. Cancer cells may develop a more motile
phenotype, due to deregulation of cell adhesion pathways. Loss of adhesion allows cells to escape
their site of origin and spread to other sites, causing secondary malignancies.
Mangiferin is thought to reduce cell proliferation [16] through modulation of β-catenin
and consequently metalloproteinase-7 (MMP-7), MMP-9, and EMT (epithelial to mesenchymal
transition) [14]. Through NFκB, mangiferin may influence VEGF-A transcription to modulate
angiogenesis. Additionally, in in vivo experiments, mangiferin has shown efficacy at reducing tumour
volume in mice [14].
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In a variety of breast cancer cell lines, mangiferin has been implicated in reduced cell proliferation
(MDA-MB-231, BT-549, MCF-7 and T47D) [8,14] and reduced metastasis (MDA-MB-231 and BT-549)
in a dose-dependent manner [14]. In HL-60 cells, Li et al. reinforced that mangiferin reduced
proliferation [14]. In contrast, Wilkinson et al. found that mangiferin did not suppress proliferation
in MCF-7 cells, while mangiferin aglycone did [74]. This may be a result of differential activation of
estrogen receptors [74]. Kim et al. also reported no significant effect on proliferation when HeLa cells
were treated with 25–200 μM of mangiferin [36] and Garcia-Rivera et al. found no significant inhibition
of proliferation in MDA-MB231 cells when treated with mangiferin, but proliferation was inhibited by
Vimang® [41]. Thus, further evidence is required to ascertain an effect.
2.3.1. Glycogen Synthase Kinase-3β/β-Catenin
In cancer, aberrant activation of β-catenin is often observed [14]. High levels of expression of
β-catenin are associated with proliferation and metastasis. Glycogen synthase kinase -3β (GSK-3β) is
capable of phosphorylating and degrading β-catenin [14]. GSK-3β may be inhibited by a number of
signals. Mangiferin is hypothesised to suppress the β-catenin pathway [14].
Using a Western blot assay to analyse protein expression in breast cancer cell lines, mangiferin was
found to down-regulate β-catenin and decrease levels of inactive GSK-3β, indicating suppression of
the β-catenin pathway, which in turn down-regulates MMP-7, MMP-9 and snail expression [14]. Snail
can be used as an epithelial/mesenchymal phenotye indicator [14], thus lower levels of snail, which
are seen on exposure to mangiferin, favour a more epithelial, less mobile phenotype, while higher
expression of snail would indicate a more motile phenotype, allowing malignant cells to metastasise.
2.3.2. Matrix Metalloproteinases
Activation of matrix MMPs is a crucial step towards metastasis as these enzymes facilitate cell
escape from the initial site of the malignancy, through degradation of the extracellular matrix. As above,
mangiferin has been linked to downregulation of NFκB, which in turn influences downstream
expression of MMPs [64,75].
In breast cancer, the matrix metalloproteinases MMP-2, -7 and -9 are often up-regulated [14].
Li et al. have demonstrated through a Western blot assay that of these three enzymes, MMP-2
was not significantly affected while MMP-7 and MMP-9 were down-regulated by mangiferin [14].
MMP-7 and -9 strongly promote cancer progression by allowing malignant cells to metastasise [76].
In LNCaP prostate cancer cells, activation of NFκB by TNF-α increases levels of MMP-9 mRNA and
protein present in the cell [75]. Mangiferin is capable of attenuating this effect, ultimately reducing
metastasis [75]. In addition to this pathway of MMP-9 activation, Xiao et al. (2015) discovered
that mangiferin stimulates miR-15b expression, which in turn down-regulates MMP-9 expression
in U87 glioma cells [16], thus reducing the capability of malignant cells to escape the extracellular
matrix and metastasise. In the study by Jung et al., mangiferin prevented PMA induced MMP-9
expression without influencing other MMP expression in human astroglioma cell lines: U87MG,
U373MG and CRT-MG [19]. MMP-1, -2, -3 and -14 expressions were not influenced by mangiferin [19].
Mangiferin is thought to act by suppressing NFκB and AP-1 binding to the promoter region of
MMP-9 and prevents phosphorylation of Akt and MAP kinases (see above section) induced by
PMA [19]. Jung et al. also suggest that mangiferin acts on MMP-9 suppressors, Tissue Inhibitor of
Metalloproteinase -1 and -2 (TIMP-1 and -2). TIMP-1 and TIMP-2 mRNA levels were enhanced by the
presence of mangiferin, implying another favourable quality of mangiferin [19]. Jung et al. suggest
that mangiferin, through these mechanisms, may reduce glioma invasiveness [19]. Overall, published
studies indicate that mangiferin may play an important role in reducing expression of MMP-9, limiting
cancer invasiveness [16,19].
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2.3.3. Epithelial to Mesenchymal Transition
EMT involves the loss of adherence and gain of a motile phenotype and resistance to apoptosis,
which may allow motile cancer cells to migrate from their site of origin and survive, causing secondary
metastases [53]. β-catenin signalling may also play a role in EMT [14]. Mangiferin appears to enhance
epithelial characteristics in breast cancer cell lines and thus help protect against metastasis [14].
Li et al. [14] investigated the effect of mangiferin on EMT through analysis of two
mesenchymal-like breast cancer cell lines (MDA-MB-231 and BT-549). Mesenchymal characteristics
were reduced upon treatment with mangiferin, whereby cells obtained a more epithelial-like
morphology. Associated with these physical observations, increased expression of the epithelial
phenotype marker, E-cadherin, and decreased expression of mesenchymal phenotype markers,
vimentin, snail and slug were seen [14]. In MDA-MB-231 xenograft mice treated with mangiferin,
Western blot analysis revealed the same shift in expression in epithelial and mesenchymal markers
with lower expression of active β-catenin, MMP-7, MMP-9 and vimentin (mesenchymal markers)
and higher expression of E-cadherin (an epithelial marker) [14], reinforcing the in vitro results. While
these results are promising in breast cancer cells, investigation in a more diverse range of cell lines is
required to determine if these findings may be applicable to a broader range of breast cancer cell lines
as well as other cancer cell lines.
2.3.4. Angiogenesis
Sustained angiogenesis is widely regarded as an enabling characteristic of cancer, as tumours
are unable to survive beyond a certain size without their own blood supply [53]. Angiogenic
tumours are able to grow and proliferate using nutrients and oxygen from their own blood supply.
The VEGF-A protein is known to stimulate angiogenesis [53]. Both mangiferin and Vimang® extracts
have demonstrated inhibitory effects on TNF-induced transcription of VEGF-A in MDA-MB231
cells [41]. However, this experiment was carried out over a short time period. Further investigation
over longer time periods and evidence from in vivo/ex vivo studies are required to further determine
the effect of mangiferin on angiogenesis.
2.3.5. Tumour Volume
Duringin vivo experiments in mice, mangiferin has been found to reduce tumour volume.
In C57BL/6J mice inoculated with MCF-7 cells on the neck, a reduction of 89.4% in tumour volume
relative to control was seen when mice were medicated with 100 mg/kg of mangiferin. This value
was closely comparable to the results obtained from cisplatin treatment (91.5%), an established
chemotherapeutic drug [8]. In a similar experiment, the lifespan of these mice was extended at
dosages from 10 mg/kg mangiferin and above and 60% of mice survived until the end of the assay
period [8], while in the no treatment group, there were no mice surviving after day 40 following
MCF-7 inoculation. A high dosage of mangiferin (100 mg/kg) extended lifespan to the same degree as
cisplatin, with no significant difference (p < 0.05) being observed between these treatments [8]. Dose
dependency was observed [8].
These results show that mangiferin can act as a potent chemotherapeutic agent in mice and thus
further investigation into mangiferin-based products could benefit treatment of cancer in humans.
2.4. Apoptosis
In order to survive and proliferate, cancer cells must be able to evade apoptosis, despite
carrying malignant characteristics [53]. Under normal circumstances, either the intrinsic pathway
via the mitochondria, or the extrinsic pathway involving death receptors, can induce apoptosis.
The intrinsic pathway generally involves increased permeability of the mitochondrial membrane and
the release of cytochrome C to activate initiator procaspase-9, while the extrinsic pathway involves
Fas Associated Death Domain (FADD) and procaspase-8 [36] (Figure 4). Apoptosis is the preferred
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pathway of cell death, as necrotic cell death may induce inflammatory changes due to the release of
immune-stimulatory molecules. In order to eradicate cancer, many chemotherapeutic agents seek
to induce apoptosis in malignant cells. From the peer reviewed literature, it can be concluded that
mangiferin has promising apoptosis inducing properties in a number of cell lines and is involved in
regulating apoptosis via multiple targets [8,14,36].
Figure 4. Effect of Mangiferin on proteins implicated in apoptosis.
In 2013, two studies were published that demonstrated a dose dependent increase in apoptosis
in response to increasing mangiferin concentration in MDAMB-231, BT-549, MCF7 and T47D breast
cancer cell lines [8,14]. Kim et al. reported similar findings in HeLa cells in response to treatment with
ethanolic extracts of mango skin or flesh [36]. There are a number of suggested mechanisms by which
an increase in apoptosis in these cancer cells may be potentiated. As discussed earlier, mangiferin
down-regulates the transcription factor NFκB. It is hypothesized that this dampening of NFκB activity
is likely to be responsible for increased apoptosis in HL-60 acute myeloid leukaemia (AML) cells,
MCF7 cells and HeLa cells [8,13,35,77].
2.4.1. Mangiferin and Hesperidin in Cyclopia Sp. Extracts
Bartoszewski et al. showed in HeLa cells that treatment with Cyclopia sp. tea extracts, which
are high in mangiferin and hesperidin, caused up-regulation of TRADD and TNFR superfamily
member 25 (TRAMP), which are involved in signalling of the extrinsic apoptotic pathway [77].
However, when compared to mangiferin only and hesperidin only, it would appear that hesperidin is
a more potent activator of apoptosis in HeLa cells than mangiferin [77]. Regardless, mangiferin did
enhance the activity of hesperidin, even when added in low concentrations. Mangiferin itself caused
down-regulation of Baculoviral IAP Repeat Containing 7 (BIRC7), which sensitizes cells to death by
the extrinsic apoptotic pathway [77].
2.4.2. Bax/Bcl-2
The Bcl-2 protein acts to block programmed cell death while the Bcl-2 associated X protein (Bax)
protein favours apoptosis. When the ratio of Bax:Bcl-2 is increased, a cell’s sensitivity to apoptosis is
increased [78], and consequently malignant cells are less likely to survive. Current literature suggests
that the effect of mangiferin on the Bax:Bcl-2 ratio is dependent on cell type, dosage and perhaps the
form of mangiferin used [35,79].
Pan et al. found that when CNE2 nasopharyngeal carcinoma cells were treated with mangiferin,
the mRNA and protein expression levels of Bcl-2 were consistently down-regulated while Bax
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was up-regulated [35]. As a consequence, these cells were primed for apoptosis. Bcl-2 was also
down-regulated upon treatment with an ethanolic extract of mango skins, which contained mangiferin,
mangiferin gallate and isomangiferin gallate [36]. This ultimately resulted in activation of caspase-3, -6,
-8 and -9 alongside poly (ADP-ribose) polymerase (PARP) protein [36], favouring cell death. However,
Klavitha et al. [22] have found that the reverse applies in the context of excitotoxicity in neurons,
whereby mangiferin blocks upregulation of Bax, thus attenuating cell death, making it a promising
compound for further research with regard to Parkinson’s disease [22]. Furthermore, Bartoszewski
et al. demonstrated that on analysis of green fermented Cyclopia sp. extracts (in which the primary
compounds were mangiferin and hesperidin), there were no significant changes in Bax/Bcl2 mRNA
levels or protein levels [77], although Bartoszewski et al. acknowledge that the most likely cause of
this disparate finding was low dosage.
In addition to the Bax/Bcl2 ratio, Zhang et al. and Pan et al. reported that apoptosis could be
triggered by mangiferin in HL-60 cells due to changes in levels of similar proteins [13,35]. HL-60 cells
responded to mangiferin by decreasing levels of Bcl-extra large (Bcl-xL) and XIAP [13,35], resulting in
increased apoptosis.
Further experimentation in a wider range of cell lines is required to elucidate what dosage of
mangiferin is likely to provide an effect.
2.4.3. Intrinsic/Extrinsic Apoptotic Pathway
To identify whether mangiferin was acting on the intrinsic or extrinsic apoptotic pathway, Kim
et al. performed a Western blot experiment to assess expression levels of proteins involved in either
the intrinsic pathway, extrinsic pathway or both pathways [36]. Results indicated that there was
slightly lower expression levels of BH3 interacting domain (Bid), pro-caspase-3 and pro-caspase-8,
but increased expression of cleaved, active forms of PARP, caspase-7 and caspase-9 [36], when HeLa
cells were treated with an ethanolic extract of mango peel. Consequently, it is likely that the ethanolic
extracts of mango pulp and skin influenced both apoptotic pathways, which is crucial for effective
apoptosis. Lv et al. further strengthened the evidence for the role of mangiferin in the intrinsic
apoptotic pathway by considering cytochrome C [8]. They found that when MCF-7 cells were treated
with mangiferin, cytochrome C concentration in the mitochondria was reduced, while a corresponding
increase in cytochrome C concentration was observed in the cytosol. This indicates that cytochrome
C was released from the mitochondria in response to mangiferin treatment and thus apoptosis may
be induced via the mitochondrial pathway [8]. In addition to these findings, increased expression
of caspase-3, -8 and -9, and decreased expression of procaspase-3, -8 and -9 expression was noted,
suggesting activation of both intrinsic and extrinsic apoptotic pathways [8]. Based on results from
their study, du Plessis-Stoman et al. have suggested that mangiferin may favour apoptotic cell death
over necrotic cell death, which has potential to reduce inflammation [48].
2.4.4. Telomerase
Aside from the study of various pathways of apoptosis, in the literature it is reported that
mangiferin can inhibit telomerase activity in K562 human leukaemia cells with dose- and time-
dependent behaviour [8,35,80], promoting apoptosis. It has been suggested that this may be due to
increased fas gene expression and protein levels of fas [8]. Enhanced telomerase activity is found in
a variety of cancers and is permissive and required for sustained growth of late cancers. Almost all
cancers exhibit some form of telomerase reactivation [81]. By reducing telomerase activity, mangiferin
can be used to reduce the progression of existing cancers and create an environment in which malignant
cells are unlikely to survive.
Mangiferin has demonstrated pro-apoptotic activity in a number of cancer cell lines including
K562 leukaemia, MCF-7 breast cancer and CNE2 nasopharyngeal cells [8,35].
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2.5. Oxidative Stress
Oxidative stress occurs when the burden of ROS is not balanced by antioxidants and detoxification
systems. The presence of these excess reactive species can result in cellular damage, particularly to
DNA, lipids and proteins. Over time, oxidative stress increases the risk of developing cancer and may
exacerbate inflammation. Mangiferin is thought to play a role in: (1) modulating the Nrf2/antioxidant
response element (ARE) detoxification pathway (Figure 5); (2) directly detoxifying reactive species;
and (3) activating detoxification enzymes such as catalase.
Figure 5. Effect of Mangiferin on the Nrf2/ARE Detoxification Pathway.
2.5.1. Nrf2/ARE Detoxification Pathway
Under normal conditions, Nrf2 gene transcription is inhibited by Kelch-like ECH-associated
protein-1 (KEAP-1). However, oxidative stress, dietary components and synthetic chemicals can
induce Nrf2 transcription [18]. Consequently, Nrf2 protein can accumulate in the nucleus where it
forms heterodimers with musculoaponeurotic fibrosarcoma (maf) protein. This heterodimer signals
through the ARE to initiate transcription of a number of phase II detoxification enzymes [17], such
as NAD(P)H: quinine reductases (NQO1), glutathione S-transferase (GSH) and heme oxygenase
(HO-1) [18]. HO-1, when activated, can translocate into the nucleus to further activate transcription
factors relevant to the stimulus [82]. Ultimately, this pathway provides activation of detoxification
enzymes when oxidative stresses are presented. Mangiferin manipulates this pathway in such a way
that the survival of healthy cells but not malignant cells is enhanced. Mangiferin modulated this
Nrf2/ARE signaling pathway at multiple steps [13,17,18].
While mangiferin does not directly influence Nrf2 transcription rates, Zhao et al. have
demonstrated that the half-life of Nrf2 is increased due to impaired ubiquitination and thus degradation
of the protein [18], which results in higher levels of the protein being present within the cell. Zhang et
al. also reported similar findings in human umbilical cord mononuclear blood cells, where mangiferin
increased the quantity of Nrf2 accumulating in the nucleus in a time dependent manner [17]. Protein
quantity was assessed by microscopy and verified by Western blotting [17]. Additionally, mangiferin
increased the binding of Nrf2 to ARE which in turn was shown to increase downstream production of
NQO1 (a prominent antioxidant enzyme) when assessed in a Western blot assay [13,17].
Nrf-ARE signaling can provide protection against agents that are chemotherapeutic to
normal cells [13] (more on synergistic effects of mangiferin and chemotheraputics later). Similarly,
overexpression of Nrf2 in cancer cells can promote resistance to therapy, through up-regulation of
antiapoptotic bcl-xL. Mangiferin seems able to differentiate between malignant cells and healthy
cells, promoting Nrf2 activation in healthy cells (human umbilical cord mononuclear blood cells) but
480
Nutrients 2016, 8, 396
not cancerous cells (HL-60). Thus, survival is aided in healthy cells by enhanced efficiency of the
Nrf2/ARE detoxification pathway while the development of resistance to chemotherapeutics is not
permitted in malignant cells [13]. To date, mangiferin is the only known Nrf2 activator that does not
confer protection to malignant cells against chemotherapeutic agents [13], making it a promising agent
for cancer therapy.
Downstream effects in the Nrf2/ARE detoxification pathway have been further studied upon
treatment with Vimang®. Treatment of MDA-MB231 breast cancer cells with 200–400 μL/mL of
Vimang® was found to significantly increase HO-1 transcription. However, when treated with
mangiferin alone, there was no significant increase in HO-1 transcription [41]. From this result, one
may deduce that the Nrf2/ARE detoxification pathway may not have been activated by mangiferin, as
was reported earlier in the HL-60 cancer cell line. It is possible that an alternative bioactive, found
in Vimang® may be responsible for the up-regulation of HO-1 transcription in the MDA-MB231
breast cancer cells. Overall, results would suggest that mangiferin may provide some benefit through
activation of the Nrf-ARE detoxification pathway.
2.5.2. Elimination of Reactive Species
Reactive species must be eliminated promptly to avoid damage to important biological molecules.
This may be done directly by antioxidant species, or by inducing and up-regulating detoxification
pathways. Mangiferin is an established antioxidant that is able to neutralize a range of reactive species
and influence expression and activity of key detoxification enzymes. By performing these actions,
oxidative stress and inflammation are reduced.
Mangiferin is able to directly protect against hydroxyl [28], 2,2-diphenyl-1-picrylhydrazyl (DPPH),
superoxide, hydrogen peroxide [51], and peroxynitrite free radicals, lipid peroxides [9,21], hypochlorus
acid [28] and heavy metal induced reactive oxygen species [15]. Findings from numerous studies can
be used to reinforce the notion that mangiferin has greater or comparative antioxidative capacity to
other known antioxidants, such as quercetin, baicalein, catechins, phenylpropanoic acids [21], vitamin
C, vitamin E and β-carotene [28]. Alongside its antioxidative potential, mangiferin influences ROS
production through modulating Fenton-type reactions. Fenton-type reactions usually involve the
production of a hydroxyl radical and the oxidation of Fe2+ to Fe3+. In the presence of mangiferin,
Fenton-type reactions are inhibited by chelating Fe2+ ions, reducing production of subsequent
ROS [15,29,51]. Additionally, Duang et al. have suggested that mangiferin protects against lipid
peroxidation [29]. This protection may in part be responsible for reduced DNA damage and
amelioration of cytotoxic action seen in response to ionising radiation in healthy cells [9,83].
Both in vitro and in vivo evidence suggests that mangiferin up-regulates expression of various
detoxifying enzymes, resulting in enhanced clearance of ROS. In N2A neuroblastoma cells,
Kavintha et al. implicated mangiferin in reducing oxidative stress by providing protection against
1-methyl-4-phenylpyridine (MPP+) induced cytotoxicity, due to its capability to restore glutathione
action and reduce expression of superoxide (SOD) and catalase [22]. In addition to these findings,
Matkowski et al. also reported that mangiferin influenced SOD, catalase and glutathione peroxidase
in such a way that it halts ROS centred apoptotic pathways through dampening endogenous ROS
production [21]. Sarker et al. demonstrated the relationship between mangiferin and glutathione
levels by showing that mangiferin increased levels of GSH more than 2ˆ the amount observed
on treatment with other anti-oxidants [11]. It has been suggested that mangiferin increases GSH
levels by up-regulation of -Glutamylcysteine Synthetase ( -GCS), the enzyme controlling the rate
limiting step of GSH synthesis [11]. In vivo studies demonstrate a similar pattern of increased
detoxification enzyme activity. In experiments using B(a)P-treated mice, B(a)P attenuated SOD
and catalase (see below for more on catalase) activity in lymphocytes, polymorphonuclear cells
and macrophages [9]. However, mangiferin co-administration provided a protective effect against
these events. Rajendran et al. also found that mangiferin reduced the production of H2O2 in B(a)P
treated animals [9]. In animals with lung cancer, enhanced activity of glutathione transferase [48],
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quinine reductase and uridine 5’-diphosphate-glucuronosyl transferase activity has been demonstrated
upon treatment with mangiferin [8]. These events each contribute to a reduction in oxidative stress
through increased capacity to deal with assault from reactive species. Sarker et al. further suggest
that the ability of mangiferin to reduce oxidative stress may also be linked to NFκB down-regulating
capabilities, which reduces TNF-induced reactive oxygen intermediate generation [11].
2.5.3. Catalase
Catalase is a detoxification enzyme present in most organisms exposed to oxygen that converts
H2O2 into water and oxygen. H2O2 can cause oxidative damage if not rapidly converted into less
toxic species. Mangiferin may directly increase the efficiency of the catalase enzyme by interacting
directly with the enzyme, thus reducing oxidative damage that can be done prior to detoxification of
H2O2 [61]. Increased activity of catalase may modulate downstream signalling pathways that favour
an environment that does not promote cancer development and survival. However, not all published
findings are consistent with the notion that mangiferin increases catalase activity [11,61].
In silico docking studies using AutoDock and PyMol predict that mangiferin has the capacity
to bind to the active site of catalase, but not other oxidase enzymes [61]. The binding of mangiferin
to catalase enhanced the activity of catalase by 44% during the in vitro studies conducted by
Sahoo et al. [61]. An earlier study by Sarkar et al. reported disparate findings, where mangiferin
caused a 0%–23% increase in activity when compared to untreated cells, and did not influence the
quantity of enzyme present [11]. In both experiments, U-937 cells were treated alongside other cell
lines with 10 μg/mL of mangiferin for 3 h [11].
To further elucidate the effect of mangiferin on catalase activity, Sahoo et al. conducted
fluorescent spectrophotometry experiments on catalase in the unbound state (peak at 330 nm, excitation
wavelength 280 nm) and subsequently, increasing concentrations of mangiferin were added [61]. As the
concentration of mangiferin was increased, the peak at 330 nm decreased in magnitude, suggesting
interaction with mangiferin. When the binding constant was calculated (3.1 ˆ 10´7 M´1), this indicated
a strong binding affinity between catalase and mangiferin [61]. Mangiferin also proved capable of
overriding aminotriazole (ATZ) inhibition of catalase in lipid peroxidation assays [61]. Sahoo et al.
further demonstrated that direct quenching of H2O2 by mangiferin was not significant, implying that
the entire 44% difference found may be attributable to enhanced activity of the catalase enzyme [61].
It has been suggested that increased catalase activity may dampen excessive activation of
MAPK/AKT, which is commonly found in malignant cells [61] (See above for MAKP/AKT).
Sarker et al. suggested that high expression of catalase would reduce NFκB levels [11]. However,
evidence does not support any change in catalase expression, only in the efficiency of this
enzyme [11,61]. Increased catalase activity could reduce oxidative stress and inflammation, thus
favouring a chemopreventative environment.
2.6. DNA Damage
DNA damage facilitates mutations in the genetic material of a cell. Mutation is required to
initiate the development of cancer and also expedites the acquisition of characteristics required for
a malignant cell to survive. Thus, a higher susceptibility to DNA damage results in a higher incidence
of mutation and the development of cancer [84]. The role of mangiferin with regard to DNA damage
is controversial.
Studies have reported that mangiferin is capable of protecting not only DNA [42] but also
deoxyribose, phospholipids, polyunsaturated fatty acids and proteins [21]. However, Rodeiro et al. [12]
found that when aqueous extracts from Mangifera indica bark were applied to lymphocytes and
lymphoblastic cells, DNA damage was induced. When this effect was further investigated with
the compound mangiferin alone, there was a reduction in DNA damage, thus there is likely to be
an alternative compound in the extract that is inducing DNA damage [12]. In addition, Rodeiro et al.
found that when DNA damage was induced by γ-radiation, the aqueous extract was protective against
DNA damage [12].
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Radiation Damage
Ionising radiation has been shown to induce DNA damage. In patients undergoing radiotherapy,
many healthy cells acquire collateral damage. Mangiferin and mangiferin aglycone have demonstrated
protective effects against radiation damage during in vitro studies [28].
Lei et al. demonstrated that pre-treatment of human intestinal epithelial cells with mangiferin
aglycone reduced the percentage of cells with double strand breakages in their DNA by 47% when
treated with ionizing radiation [28]. This was more effective than the 40% reduction seen following
mangiferin pre-treatment. Currently, there are few radioprotective agents, and these agents tend to be
associated with high levels of toxicity [28]. Mangiferin may provide some protection to cancer patients
undergoing chemotherapy as well as improve efficiency of anti-cancer treatments.
3. Synergistic Effects
The use of many chemotherapeutic agents induces a range of side effects, which can cause
serious illness. Mangiferin shows potential to reduce or negate these side effects by selectively
targeting malignant cells for cell death and enhancing survival of healthy cells. Mangiferin may
potentiate cell death by existing drugs through modulation of NFκB activity [11] and causing cell cycle
arrest in malignant cells at the G2/M checkpoint, leaving cells susceptible to apoptosis induced by
chemotherapeutic agents such as etoposide [13]. Through NFκB inhibition, mangiferin is likely to
reduce resistance to chemotherapeutic agents in cancer cells [13,48]. Studies using pro-apoptotic agents
such as oxaliplatin, etoposide, doxorubicin and paclitaxel have documented additional beneficial
effects when co-administered with mangiferin (Table 1).
Table 1. Summary of proposed beneficial effects of co-administration of mangiferin alongside
chemotherapeutic agents.
Chemotherapeutic Agent Cell Line Reference Evidence
Oxaliplatin HeLa, HT29, HL60 [48] Reduction in oxaliplatin IC50 values; counteractsresistance to oxaliplatin.
Etoposide HL60, U937 [11,13]
Reduces oxidative stress. Protects normal cells without
reducing sensitivity of HL60 to etoposide [13]. Activity
of the drug is enhanced by mangiferin [11].
Doxorubicin MCF7, U937 [13,33]
At high concentrations mangiferin can inhibit
P-glycoprotein expression and chemosensitise for
doxorubicin therapy [33]. Activity of the drug is
enhanced by mangiferin [11].
Paclitaxel Triple negativebreast cancer [60,62]
IRAK1 overexpression confers a growth advantage [62].
Mangiferin may inhibit IRAK1 activation [60,62].
Cisplatin U937 [11]
Inhibits ROS production [8]. Activity of the drug is
enhanced by mangiferin; Impedes NFκB activation;
Enhanced cell death in the presence of TNF [11].
Vincristine U937 [11]
Inhibits ROS production [8]. Activity of the drug is
enhanced by mangiferin; Impedes NFκB activation;
Enhanced cell death in the presence of TNF [11].
Adriamycin U937 [11]
Inhibits ROS production [8]. Activity of the drug is
enhanced by mangiferin; Impedes NFκB activation;
Enhanced cell death in the presence of TNF [11].
AraC U937 [11]
Inhibits ROS production [8]. Activity of the drug is
enhanced by mangiferin; Impedes NFκB activation;
Enhanced cell death in the presence of TNF [11].
3.1. Pro-Apoptotic Agents
While mangiferin (at a concentration of 10 μg/mL) does not trigger apoptotic cell death itself [11],
it may enhance action of chemotherapeutic pro-apoptotic agents. Sarker et al. [11] demonstrated that
this was due to down-regulation of NFκB by transfecting U-937 cells with an IκBα-double negative
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construct, blocking NFκB activation and also transfecting with a p65 construct and observing cell
death after 36 h by MTT assay, using the Live/Dead cell assay. In IκBα-double negative transfected
cells, cell death increased by 12% and increased cell death with TNF from 42% to 53%. Cell death in
the presence of mangiferin was increased a further 4%. In p65 overexpressing cells, cell death was not
observed in response to treatment with TNF or TNF and mangiferin. By considering SEAP as a reporter
gene, IκBα-double negative cells were shown to down-regulate NFκB and p65 overexpressing cells
up-regulated NFκB. Thus, it was found that down-regulation of NFκB primes cells for cytotoxic
agents [11].
Sarkar et al. reported that the activity of the pro-apoptotic agents cisplatin, vincristine, doxorubicin,
etoposide, Adriamycin and AraC was enhanced significantly by co-administration of mangiferin in
U-937 cells [11]. Unlike other antioxidants, mangiferin was not found to be toxic to the cells, as it only
enhanced cell death when exposed to TNF [11].
Oxidative damage induced by chemotherapeutic drugs correlates with the development of
secondary malignancies such as acute myeloid leukaemia (AML). Mangiferin reduces oxidative stress
induced by these agents and thus reduces likelihood of developing secondary malignancies [13].
By enhancing apoptotic activity against malignant cells upon treatment with chemotherapeutic
agents, lower dosages may be required when co-administered with mangiferin, which may reduce the
side effects associated with toxicity.
3.1.1. Oxaliplatin
Oxaliplatin is a platinum-based anti-neoplastic agent used for the treatment of colon or rectal
cancer once metastasised. It is often given in conjunction with other chemotherapeutic agents. Common
side effects, occurring in >30% of patients, include nausea, vomiting, fatigue, loss of appetite, mouth
sores, low blood count, diarrhoea and peripheral neuropathy [85]. Apoptotic efficacy of oxaliplatin is
enhanced by the addition of mangiferin, as mangiferin inhibits NFκB (see above) [13,14,48,77] and is
thought to increase the sensitivity of malignant cells to apoptotic cell death [48].
Du Plessis-Stoman et al. demonstrated the positive effect of mangiferin on oxaliplatin action in
HeLa cells and HT29 cells through use of IC50 assays [48]. When stained with tryptan blue, cells treated
with oxaliplatin and mangiferin displayed fewer non-viable cells than those treated with oxaliplatin
only, indicating that there was less necrosis, suggesting the apoptotic pathway for cell death was
preferred [48]. Co-administration of mangiferin with oxaliplatin increased caspase 3 activation in HeLa
and HT29 cell lines relative to cells that only received oxaliplatin, further implicating the apoptotic
pathway of cell death was favoured, thus reducing inflammation [48].
Du Plessis-Stoman et al. have suggested that mangiferin only exhibits NFκB inhibition when used
with platinum containing complexes, as they found that treatment of normal cells with mangiferin
alone resulted in increased NFκB activity [48]. When treated with mangiferin and oxaliplatin, the
level of NFκB inhibition was similar to cells treated with oxaliplatin alone. However, in the presence
of mangiferin, the oxaliplatin IC50 was 3.4 times lower in the cells receiving both treatments [48].
In addition, when assessing changes in cell cycle, mangiferin caused a delay in S-phase only when
used in conjunction with oxaliplatin [48]. On treatment with oxaliplatin or mangiferin alone, a G2/M
phase cell cycle arrest was noted.
Both oxaliplatin and mangiferin are implicated in the mitochondrial pathway of apoptosis
through reduction of mitochondrial membrane potential. However, cells treated with mangiferin and
oxaliplatin did not show a significantly different mitochondrial membrane potential to those treated
with oxaliplatin alone [48].
Evidence indicates that mangiferin increases the efficacy of oxaliplatin at inducing cell death in
malignant cells.
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3.1.2. Etoposide
As discussed above (Section 2.5.1 on Nrf2), mangiferin protects against etoposide induced
oxidative damage in human umbilical cord blood mononuclear cells by promoting Nrf2 signalling
to activate a number of antioxidant enzymes [13]. Side effects such as myelo-suppression are also
reduced. As discussed earlier, literature indicated that mangiferin causes G2/M phase cell cycle arrest.
Etoposide targets cells in this phase [86]. In addition, oxidative damage in response to etoposide may
result in p53 activation. However, when the effect of mangiferin on etoposide efficacy was studied,
HL-60 cells were used, which lack wild type p53, thus further experimentation is required to elucidate
this effect [13].
3.1.3. Doxorubicin
Louisa et al. (2014) reported that mangiferin increased the efficacy of doxorubicin in MCF-7 [33].
Cells were initially incubated with a low concentration of doxorubicin for 10 days. The apoptotic rate
was measured and found to be reduced, indicating the development of drug resistance. Thereafter, cells
were treated with mangiferin and at high concentrations mangiferin significantly reduced cell viability
through reduced expression of P-glycoprotein, which acts as a multidrug transporter. The efficacy of
mangiferin increased in a concentration dependent manner [33]. In this study it was found that mRNA
levels associated with multidrug resistance associated protein-1 and breast cancer resistance protein
were unaffected by mangiferin, unlike P-glycoprotein [33].
4. Bioavailability and Delivery of Mangiferin
Extraction, quantification, solubility and bioavailability of polyphenols, including mangiferin, are
of relevance to clinical success. Bioavailability is dependent on bioaccessibility (quantity of compound
released from the food matrix), solubility in gastrointestinal fluids, cellular uptake, compound
metabolism and efficiency of the circulatory system [87,88]. Like many other polyphenols, the optimal
health benefits of mangiferin are not fully realised due to poor water solubility and oral bioavailability
(1.2% in rats) [89].
Using HPLC-MS, Hou et al. evaluated the pharmacokinetics (PK) of mangiferin following oral
administration (0.1 g. 0.3 g and 0.9 g) in healthy male volunteers [90]. The point of maximum plasma
concentration (38.64 ng/mL´1) was at approximately 1 h, and was surprisingly low considering the
dose of 0.9 g. This outcome supports other published findings such as those reported by [89,91]
in rats. Maximal plasma concentrations, both quantity and time, were enhanced when mangiferin
was orally administered to rats as a polyherbal formulation, rather than as mangiferin alone [92].
Similarly, Ma et al., in a rat model, found that permeability and plasma concentrations were improved
following administration of a phospholipid complex containing mangiferin, relative to administration
of mangiferin alone [93]. However, in addition to whole body PK, intratumoral PK, influenced by
packing density of solid tumour cells and components of the extracellular matrix, is also important [94],
and these challenges could be addressed by co-formulation and innovative delivery modes.
Bioavailability can be influenced by the properties of the food matrix (composition and structure)
and hence the oral bioavailability of bioactive compounds, in this case, mangiferin could be improved
if the major limiting factors were characterised [88] and modes of delivery designed accordingly.
McClements et al. developed a new system for the classification of factors limiting oral bioavailability
of nutraceuticals such that the design of food matrices can be optimised for each nutraceutical.
The classification system is largely based on bioaccessibility (liberation, solubilisation and interactions),
absorption (mucus layer, bilayer permeability and tight-, active- and efflux- transporters), and
transformation (chemical degradation and metabolism) [88]. Such a system assists with determining
an optimal food matrix design that will maximise oral bioavailability e.g., the encapsulation of
a compound with low bilayer permeability or the addition of components that may protect a compound,
that is sensitive to metabolism, against enzymes in the gut [88]. Many of these characteristics need to
be assessed for mangiferin in order to improve oral bioavailability.
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Encapsulation of compounds has improved PK properties in general, and is particularly suitable
for compounds such as mangiferin, that are poorly water soluble [50]. Spray-drying formulations
can impact on retention of mangiferin in the particle as demonstrated by the comparison of a pectin
formulation versus a chitosan polysaccharide, with pectin being found to have a better retention of
mangiferin in the particles than a chitosan formulation [50]. Numerous types of nanovehicles have
been developed, and many polysaccharide-based nanovehicles have been used for the delivery of
anti-cancer drugs, some of which may interact with membrane receptors. (See Caro and Pozo for
an overview on the application of polysaccharides as nanovehicles in cancer therapy [95]). Specialised
polysaccharide-based nanovehicles may be suitable for the delivery of mangiferin. It is clear that
further work is required with respect to improving bioavailability and delivery methods of mangiferin
from fruit or supplement to tumour site. The design of a “smart vehicle” for the delivery of mangiferin
to the tumour cells, rather than healthy cells, and for avoidance or minimisation of a delivery gradient
within the solid tumour, the “smart vehicle” will likely need to be unique to mangiferin and possibly
to the cancer type.
5. Toxicity
In addition to bioavailability and delivery of bioactive compound to enhance health, it is critical
to consider toxicity of the compound. Being a natural compound, mangiferin exhibits minimal
toxicity [34] and is generally regarded as non-toxic [28]. Stem-bark extract from Mangifera indica
has only shown toxicity in animals when injected intra-peritoneally and after acute exposure [12].
Mangiferin’s reported toxic dose in mice is 400 mg/kg [28,50]. In experiments involving blood
peripheral lymphocytes and hepatocytes of rats, mangiferin did not induce cytotoxicity, genotoxicity
or mutagenicity [12]. However, in a more recent study by Prado et al. [96], oral administration
of mangiferin in rodents demonstrated low acute and sub-chronic toxicity. Nonetheless, it is still
anticipated that there is a wide safety margin for this compound when taken orally [96]. Due to the
polyphenolic structure of mangiferin, it is likely to undergo biotransformation in the liver, and for
this reason it is suggested that further investigation into the safety of mangiferin metabolites may be
required [23].
6. Conclusions
Evidence strongly supports the link between mangiferin treatment and modulation of
many molecular pathways to prevent the development and progression of cancer. Mangiferin
is primarily implicated in down-regulating inflammation, causing cell cycle arrest, reducing
proliferation/metastasis, promoting apoptosis in malignant cells and protecting against oxidative
stress and DNA damage. Perhaps the most promising anti-proliferative effect observed on treatment
with mangiferin was that seen during in vivo experiments where mangiferin reduced tumour volume
to a similar extent as treatment with cisplatin. Literature consistently shows that mangiferin enhances
the efficacy of pro-apoptotic chemotherapeutic agents, with the most evidence supporting synergistic
effects with oxaliplatin, etoposide and doxorubicin. This is of particular interest when we consider
that mangiferin exhibits low toxicity and has a wide oral safety margin, unlike other compounds with
similar activity. However, the bioavailability and delivery of mangiferin requires further research
and development.
Ultimately, there is strong evidence, in a number of pathways, for a protective effect of mangiferin.
However, in some cases, there may be variation in effect due to dosage, origin of extract or cell line used.
Furthermore, low water solubility as well as low oral bioavailability are two factors that limit clinical
use at present, and further research efforts targeting appropriate delivery systems are required in order
to improve clinical efficacy. In addition, investigations into in vivo effects are required to determine
the significance of these results to human health. Clinical trials in humans could substantially improve
our understanding of the macroscopic effects of mangiferin. Additionally, further investigation into
mangiferin aglycone, may uncover a more sustainable way of achieving greater efficiency than that
observed with mangiferin alone.
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Abbreviations
The following abbreviations are used in this manuscript:
AML acute myeloid leukaemia
ARE antioxidant response element
ATM Ataxia telangiectasia mutated protein
ATR Ataxia Telangiectasia and Rad3-related protein
ATZ aminotriazole
Bax Bcl-2 associated X protein
bcl-2 B Cell Lymphoma-2
bcl-xL B Cell Lymphoma-extra large
B(a)P benzo(a)pyrene
Bid BH3 interacting domain
BIRC7 Baculoviral IAP Repeat Containing 7
Chk1 Checkpoint kinase 1
CHk2 Checkpoint Kinase 2
CDK1 Cyclin-Dependent Kinase 1
COX Cyclooxygenase-2
CXCR4 C-X-C Chemokine Receptor type-4
DPPH 2,2-diphenyl-1-picrylhydrazyl
EMT Epithelial to Mesenchymal Transition
ERK Extracellular signal-Regulated Kinase




IARC International Agency for Research on Cancer
ICAM-1 Intercellular Adhesion Molecule-1
IκB Inhibitor of κB
IKK-α Inhibitor of NFκB Kinase subunit-α




IRAK1 Interleukin-1 Receptor Activated Kinase 1
IRAK4 Interleukin-1 Receptor Activated Kinase 4
KEAP-1 Kelch-like ECH-associated protein-1
LDC Less Developed Countries
LPS lipopolysaccharide
maf musculoaponeurotic fibrosarcoma
MAPK Mitogen Activated Protein Kinase




Myd88 Myeloid Differentiation Primary Response Gene 88
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NEMO NFκB Essential Modulator
NFκB Nuclear Factor κ-light-chain-enhancer of activated B cells
NIK NCK Interacting Kinase
NQO1 NAD(P)H: quinine reductases




PPAR Peroxisome Proliferator-Activated Receptor
ROS Reactive oxygen species
SEAP Secreted Embryonic Alkaline Phosphatase
SOD superoxide
TAB1 Transforming growth factor beta-activated kinase 1-binding protein 1
TAB2 Transforming growth factor beta-activated kinase 1-binding protein 2
TAK1 Transforming growth factor beta-activated kinase 1
TLRs Toll-like receptors
TNF Tumour Necrosis Factor
TNFR Tumour Necrosis Factor Receptor
TRADD TNFR with Tumour Necrosis Factor Receptor type-1-Associated Death Domain protein
TRAF2 Tumour Necrosis Factor Receptor-Associated Factor 2
TRAF6 Tumour necrosis factor Receptor-Associated Factor 6
VEGF Vascular Endothelial Growth Factor
XIAP X linked Inhibitor of Apoptosis Protein
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Malignant Mesothelioma (MM) is a rare form of cancer that affects the thin cell wall lining of
the body’s internal organs and structures. MM has a particularly poor outcome following standard
treatment options. MM is found in the pleura, the peritoneum, and more rarely in the heart. MM is
known only to be caused by exposure to asbestos fibres either directly, or through someone who was
exposed, and this risk may be modified by genotype [1]. The disease develops through a multistep
process resulting from chronic inflammation, DNA damage and dysregulation of the immune system.
Benvenuto and colleagues from the University of Rome recently published an article of great public
interest in the Nutrients Special Issue: Polyphenols for Cancer Treatment or Prevention, wherein
they present current knowledge on the properties of polyphenols and protective effects against
asbestos-mediated MM [2].
Polyphenols are commonly found in edible plants, are known to improve the immune function,
reduce chronic inflammation [2], modify aberrant intraperitoneal cytokine levels [3] and reduce growth
of cancer cells [2]. Benvenuto et al. list the various subclasses of polyphenols and their sources, and in
addition, highlight the fact that a reduction in chronic inflammation may be the key to the prevention
and/or stunted progression of MM [2].
Interestingly, Benvenuto et al. [2] provide a “profile” of up and down regulated cytokines for
healthy subjects vs. asbestos exposed vs. MM patients. Upon further refinement, such profiles may be
useful as a biomarker for MM risk and progression.
Despite the health benefits associated with polyphenols, the bioavailability of many polyphenol
bioactives limits their effect. Problems with poor absorption, fast-metabolism and food preparation
techniques, amongst others, remain to be solved. Importantly, Benvenuto et al. [2] have summarised
the relevant published literature and suggest administering polyphenols to the serous cavity, so as to
avoid problems associated with bioavailability and to deliver a clinically relevant dose to the tumour
site. The location of MM tumours makes intratumoral administration feasible.
Bioavailability is a common problem whether we are considering the action of drugs or the
clinical application of bioactives in foods. Granja and colleagues, from the University of Porto,
Portugal, in a recent publication in the same Nutrients Special Issue, also recognise the need to
improve stability and bioavailability of food bioactives that have shown promising anti-cancer activity
in vitro. They reviewed published data and summarised various delivery systems for the polyphenol
(´)-Epigallocatechin-3-gallate (EGCG). EGCG is most commonly associated with green tea, and is
believed to work in synergy with various anti-cancer drugs [4]. Granja et al. [4] provide an overview of
the nanotechnologies employed to overcome the poor pharmacokinetic and pharmacodynamics of this
promising anti-cancer agent. In particular, gold nanoparticles; biodegradable, polymeric nanoparticles,
functionalised with cell surface specific antibodies; as well as nanoliposomes [4], hold much promise
for the delivery or co-delivery (with FDA approved anti-cancer drugs) of polyphenols as anti-cancer
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agents. Further research is required, but such an approach is likely to solve many of the challenges
surrounding absorption and bioavailability of polyphenols to aid in the prevention and treatment of
numerous cancers, as well as their treatment related side-effects.
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Abstract: Cancer is one of the leading causes of morbidity and mortality all over the world.
Conventional treatments, such as chemotherapy, are generally expensive, highly toxic and lack
efficiency. Cancer chemoprevention using phytochemicals is emerging as a promising approach for
the treatment of early carcinogenic processes. (´)-Epigallocatechin-3-gallate (EGCG) is the major
bioactive constituent in green tea with numerous health benefits including anti-cancer activity,
which has been intensively studied. Besides its potential for chemoprevention, EGCG has also
been shown to synergize with common anti-cancer agents, which makes it a suitable adjuvant in
chemotherapy. However, limitations in terms of stability and bioavailability have hampered its
application in clinical settings. Nanotechnology may have an important role in improving the
pharmacokinetic and pharmacodynamics of EGCG. Indeed, several studies have already reported
the use of nanoparticles as delivery vehicles of EGCG for cancer therapy. The aim of this article is
to discuss the EGCG molecule and its associated health benefits, particularly its anti-cancer activity
and provide an overview of the studies that have employed nanotechnology strategies to enhance
EGCG’s properties and potentiate its anti-tumoral activity.
Keywords: green tea; EGCG; cancer; nanotechnology; nanochemoprevention; anti-cancer therapy
1. Introduction
Cancer is a disease characterized by an excessive and uncontrolled growth of cells that can
metastasize to several organs and eventually cause death of the host [1]. This disease is one of the
leading causes of morbidity and mortality all over the world [2]. In 2012, approximately 14.1 million
new cases were diagnosed and 8.2 million cancer-related deaths occurred worldwide [3]. By 2025,
19.3 million new cases are expected to emerge each year [4]. The costs associated with cancer are
also a major matter of concern. In 2013, the total healthcare expenditure associated with cancer in the
US was $74.8 billion [1]. Conventional treatments for the disease include surgery, hormone therapy,
radiation and chemotherapy [1]. Chemotherapy is the main treatment for most cancers in advanced
stage [5]. This therapeutic has, however, several limitations such as high costs, lack of efficiency and
elevated toxicity, causing various side effects, including anemia, exhaustion, nausea and hair loss,
which greatly impacts quality of life [5–7]. Therefore, it is essential to explore and develop novel
strategies to minimize the undesirable effects of chemotherapy and increase its anti-cancer efficacy [5].
The use of natural compounds, such as phytochemicals has emerged as a potential strategy for
cancer management. These compounds are of great interest due to their high spectrum of biological
activity, low cost and minimal side effects [8,9]. One popular phytochemical with great potential is
found in green tea, which is a healthy beverage consumed worldwide and produced from the leaves
of Camellia sinensis [8,10]. (´)-Epigallocatechin-3-gallate (EGCG) is the most abundant and the most
biologically active catechin in green tea and its role in cancer treatment has been intensively studied [11].
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EGCG chemopreventive and chemotherapeutic activity has been demonstrated in several in vitro and
in vivo animal studies [12–16]. The results have also been corroborated by various epidemiological
and preclinical studies, which demonstrated a correlation between green tea regular consumption
and cancer prevention and the inhibition of tumor progression [17–21]. In addition, EGCG offers
several advantages over conventional therapies since it is widely available and inexpensive to
isolate from green tea, it can be administered orally and it has an acceptable safety profile [22].
Despite its enormous potential as an anti-cancer agent, EGCG has a short half-life, low stability
and low bioavailability, greatly limiting its use in clinical settings [8,23]. In a study developed by
Nakagawa et al. [24] EGCG levels detected in plasma corresponded to only 0.2%–2% of the ingested
amount. In addition, the effective anti-tumoral concentration of EGCG in vitro is generally an order
of magnitude higher than the levels measured in vivo, which restricts its effectiveness [8]. Moreover,
EGCG lacks target specificity [23]. Therefore, a strategy that increases EGCG stability and bioavailability
and simultaneously targets cancer cells is necessary. Recently, the concept of nanochemoprevention was
introduced [25]. This strategy consists of the use of nanotechnology to improve the pharmacokinetic and
pharmacodynamic of chemopreventive agents in order to prevent, slow-down or revert cancer [25]. EGCG
encapsulation into a specific nanocarrier can increase its solubility and bioavailability, protect it from
premature degradation, prolong its circulation time and induce higher levels of target specificity due to the
possibility of nanoparticle (NP) surface functionalization [25]. Several studies have already implemented
this strategy encapsulating EGCG into different types of nanoparticles for cancer treatment [25].
The aim of this article is to provide a critical review of the EGCG molecule and its associated health
benefits with a special focus on its anti-cancer activity. In addition, an overview of the applications
that used nanotechnology strategies to deliver EGCG to cancer cells will also be given.
2. EGCG
2.1. Source and Chemical Structure
Green tea is composed of different chemical compounds, such as amino acids, vitamins, inorganic
elements, carbohydrates, lipids, caffeine and tea polyphenols [26]. Polyphenols constitute about 30%
of the dry weight of green tea leaves and are the main compound responsible for its health promoting
effects [27]. Catechins form the major group of polyphenols found in green tea and comprise different
molecules such as (´)-Epicatechin (EC), (´)-Epicatechin-3-gallate (ECG), (´)-Epigallocatechin (EGC),
and (´)-Epigallocatechin-3-gallate (EGCG) [28]. The chemical structures of catechins are represented
in Figure 1.
Figure 1. Chemical structure of (´)-Epicatechin (EC), (´)-Epicatechin-3-gallate (ECG), (´)-Epigallocatechin
(EGC) and (´)-Epigallocatechin-3-gallate (EGCG).
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These molecules are composed of a polyphenolic structure that allows electron delocalization,
enabling the quenching of free radicals [29]. Catechins are characterized by a dihydroxyl or trihydroxyl
substitution on the B ring, a meta-5, 7-dihydroxyl substitutions on the A ring and, in the case of
the galloylated catechins ECG and EGCG, the trihydroxyl substitutions on the D ring [29]. EGCG
is the major catechin and the most biologically active compound, accounting for 50%–80% of the
total catechins in green tea [5,12]. This molecule has a trihydroxyl substitution on the B ring
and a gallate moiety esterified at carbon 3 on the C ring [28]. These structural characteristics
contribute to its increased anti-oxidant and iron-chelating activities [28]. Tea catechins, particularly
EGCG, have several pharmacological and biological properties, such as anti-oxidant, free radical
scavenging [30,31], anti-bacterial [32,33], anti-viral [34–36], anti-diabetic [37–40], cardioprotective,
anti-atherosclerotic, anti-inflammatory [41–46], anti-obesity [47], neuroprotective [48–50] and
anti-carcinogenic effects [12–21]. The latter, in particular, has been intensively studied [12–21].
Figure 2. Cancer-related cell mechanisms modulated by EGCG: (1) Inhibition of DNA
hypermethylation by direct blocking of DNA methyltransferase (DNMT); (2) Repression of telomerase
activity; (3) Inhibition of angiogenesis by repression of transcription factors Hypoxia-inducible factor
1-α (HIF-1α) and Nuclear factor kappa B (NF-κB); (4) Blocking of cell metastasis by inhibition of
Matrix metalloproteinases (MMPs) -2, -9 and -3; (5) Promotion of cancer cell apoptosis by induction
of pro-apoptotic proteins BCL-2-associated X protein (BAX) and BCL-2 homologous antagonist killer
(BAK) and repression of anti-apoptotic proteins B-cell lymphoma 2 (BCL-2) and B cell lymphoma-extra
large (BCL-XL); (6) Induction of tumor suppressor genes p53 and Phosphatase and tensin homolog (PTEN)
and inhibition of oncogenes Human epidermal growth factor receptor 2 (HER2) and Epidermal growth factor
receptor (EGFR); (7) Inhibition of NF-κB and subsequent events of cell inflammation, proliferation,
metastasis and angiogenesis; and (8) Anti-proliferative activity by inhibition of Mitogen-activated
protein kinases (MAPK) pathway and Insulin-like growth factor I receptor (IGFIR).
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2.2. Anti-Cancer Activity
EGCG has been shown to play a significant role as an anti-cancer agent. Cancer is a disease
characterized by an abnormal growth of cells, which generates excessive cell proliferation over cell
death [51]. This imbalance culminates in the formation of a group of cells that can invade tissues and
metastasize to distant regions, causing morbidity and, eventually, death of the host [51]. Cancer is
associated with multiple changes in gene expression, which affect the normal mechanisms of cell
division and differentiation [51]. The factors that trigger these alterations are not clearly defined in
most cases, however, it is established that both external (such as an unhealthy diet, chemicals, tobacco
and radiation) and internal (such as inherited genetic mutations and immune conditions) factors may
have an impact in the onset of the disease [51]. EGCG’s anti-tumoral effects have been demonstrated
both in cell culture and animal experiments and in epidemiological and clinical studies [12–21].
EGCG is involved in numerous signaling pathways and biological mechanisms related with
cancer development and progression (Figure 2), discussed in more detail below.
2.2.1. DNA Hypermethylation
DNA methylation is a biochemical modification that consists of the addition of a methyl group
to a cytosine within a CpG site, a process that is performed by the enzyme DNA methyltransferase
(DNMT) [52]. Hypermethylation usually inhibits the binding of the transcription factors to the
promoter region, which induces gene silencing [53]. This process occurs frequently during cancer
development with inhibition of cell cycle regulator, receptor and apoptotic genes [54]. It has been
demonstrated that EGCG has the ability to directly block DNMTs, and consequently, restore the
expression of these genes, which may have an impact on cancer progression [55].
2.2.2. Telomerase Activity
Telomeres are regions localized at the end of eukaryotic chromosomes responsible for DNA
protection and genomic stability [56]. Telomerase is a reverse transcriptase responsible for telomere
preservation [56]. These enzymes were found to be upregulated in various types of tumors [57].
Different studies demonstrated the capacity of EGCG to inhibit telomerase activity in different cancer
cell lines including lung carcinoma [58], cervical cancer [59], leukemia and adenocarcinoma cells [60],
thus emphasizing its potential to block the development and progression of these tumors.
2.2.3. Angiogenesis
Tumor angiogenesis is one of the hallmarks of cancer with a huge impact on tumor
progression [61]. It consists of the recruitment of blood vessels to the tumor site, to assure oxygen
and nutrient supply [62]. Angiogenesis is stimulated by several different factors, including Vascular
Endothelial Growth Factor (VEGF) [63]. Various studies described that EGCG can significantly inhibit
VEGF expression through repression of transcription factors Hypoxia-inducible factor 1-α (HIF-1α)
and Nuclear factor kappa B (NF-κB), thus suppressing angiogenesis [64–66]. In vivo studies using
nude mice also corroborated this capacity, showing an inhibition of vascularity and tumor growth and
proliferation after treatment with EGCG [65,67].
2.2.4. Metastasis
Another cancer hallmark is cell metastasis, which is an extension of cell invasion [62].
After invasion, cancer cells can pass through the extracellular matrix and enter into the bloodstream,
being able to disseminate and create a new niche in another location, forming a metastatic focus [61].
To metastasize, tumor cells have to degrade the basement membrane and the stroma, which is
possible through the secretion of specific proteases called Matrix metalloproteinases (MMPs) [61].
Inhibition of these MMPs has been revealed to inhibit metastasis and tumor growth in mouse xenograft
models [61]. EGCG has demonstrated ability to prevent cancer cell metastasis, due to inhibition of
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matrix MMPs -2, -3 and -9, which play an important role in metastasis, via direct binding and gene
expression repression [68–71].
2.2.5. Cancer Cell Apoptosis
Apoptosis is the process of programmed cell death that often culminates in the activation of
cysteine-aspartic proteases (caspases), which are responsible for the cleavage of intra-cellular proteins
triggering sequential events that will culminate into induction of cell death [72]. Two main pathways
can induce this event: extrinsic and intrinsic pathway [72]. In the extrinsic pathway, apoptosis is
triggered by the binding of death ligands to death receptors, which induces intra-cellular signaling
mechanisms that activate caspases [72]. In the intrinsic pathway, activation of pro-apoptotic proteins
BCL-2-associated X protein (BAX) and BCL-2 homologous antagonist killer (BAK) promotes the release
of proteins from the mitochondria leading to the formation of the apoptosome and culminating in the
activation of caspases [72]. The regulation of this pathway is done by apoptosis inhibitors, such as
B-cell lymphoma 2 (BCL-2) and B cell lymphoma-extra large (BCL-XL), which antagonize with BAX
and BAK [72]. The apoptotic pathways described above are often downregulated in cancer [72,73].
As a consequence, apoptosis has been widely studied as a target for anti-cancer therapies [72]. Different
studies have demonstrated that EGCG can inhibit the expression of the anti-apoptotic proteins BCL-2
and BCL-XL and induce the expression of apoptotic proteins BAX and BAK, with subsequent activation
of caspases in several types of cancers [73–76]. In addition, EGCG has revealed ability to induce H2O2
production [77], block cell cycle progression [78] and inhibit NF-κB [79,80], events which will also
induce apoptosis.
2.2.6. Tumor Suppressor Genes and Oncogenes Expression
Tumor suppressor genes are genes that reduce the probability of a normal cell to become a tumor
cell [81]. These genes are usually associated with cell cycle arrest and apoptosis induction triggered by
DNA damage [81]. Mutations in tumor suppressor genes severely increase the probability of cancer
development [81]. In fact, their inactivation has been observed in several types of tumors [81]. EGCG
has revealed capacity to increase the expression of tumor suppressor gene p53 [82,83] and Phosphatase
and tensin homolog (PTEN) [84] and cyclin-dependent kinase inhibitors p21 and p27 [83,85] in different
cancer cell lines, including breast, pancreas and prostate cancer. Oncogenes are mutated genes that
have influence on the development of cancer [86]. There are several types of oncogenes, whose function
is usually associated with cell proliferation, such as Epidermal growth factor receptor (EGFR) and Human
epidermal growth factor receptor 2 (HER2). These genes are frequently overexpressed in several types of
cancers [87,88]. Some studies revealed that EGCG is able to inhibit the activation of HER2 and EGFR in
different cancer cells lines, such as, lung, thyroid, breast cancer and squamous-cell carcinoma [89–92].
2.2.7. NF-κB Activation and Nuclear Translocation
NF-κB is a family of transcription factors activated by numerous stimuli, amongst them
free radicals, inflammatory signals, cytokines, carcinogens, UV-light and tumor promoters [93].
After activation, NF-κB migrates to the nucleus and induces the expression of genes responsible
for the suppression of apoptosis, inflammation, proliferation and metastasis [93]. Different studies
showed that EGCG can efficiently inhibit the activation and nuclear translocation of this transcription
factor, preventing the subsequent events related to cancer progression in different types of tumor
cell lines, including epidermoid carcinoma cells [94], bladder [95], breast, and head and neck [96]
cancer cells.
2.2.8. Anti-Proliferative Activity
EGCG revealed anti-proliferative ability on cancer cells by inhibiting mitogenic signal transduction
pathways. Mitogen-activated protein kinases (MAPK) are protein kinases involved in the cytoplasmic
phase of the signaling pathway initiated by the binding of growth factor to a transmembrane
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receptor [97]. These pathways are responsible for cell survival and proliferation and are highly
related to cancer development [97]. EGCG has proven its ability to inhibit MAPK pathway in different
cancer cell types, such as colon [98], endometrial [99] and leukemia [100]. In addition EGCG was
shown to directly bind and inhibit Insulin-like growth factor I receptor (IGFIR) activity, which is one of
the receptors than can lead to activation of the MAPK pathway and plays an important role in cell
proliferation [101,102].
2.2.9. Protein Binding
The anticancer effects of EGCG may be explained in part due to its capacity to bind directly to
several proteins involved in different cell mechanisms such as proliferation, apoptosis and metastasis.
Suzuki et al. showed that EGCG can bind to plasma protein fibrinogen and cell adhesive proteins
fibronectin and laminin [103,104]. These interactions may be related to the capacity of EGCG to
inhibit metastasis [105]. EGCG has also been shown to directly bind to Fas, triggering Fas-mediated
apoptosis [106]. This may be one of the main mechanisms by which EGCG induces apoptosis in cancer
cells [106]. Tachibana et al. identified 67-kDa laminin receptor as a mediator of EGCG anticancer effects
(67LR) [107]. Ermakova et al. [108] demonstrated that EGCG binds to vimentin, a protein responsible
for mitosis, locomotion and structural integrity, and inhibits its phosphorylation, decreasing cell
proliferation. The same authors found other relevant proteins inhibited by EGCG via direct binding
such as the chaperone protein glucose-regulated protein 78 (GRP78), whose anti-apoptotic effects are
related to chemotherapeutic drug resistance [109], IGFIR, highly associated with cell proliferation and
cancer development [102] and the tyrosine kinases Fyn [110] and ZAP-70 [111]. Other EGCG-binding
proteins were also identified such as Ras-GTPase-activating protein SH3 domain-binding protein 1
(G3BP1) [112] and peptidyl prolyl cis/trans isomerase (Pin1) [113], both involved in oncogenic cell
signaling pathways.
2.2.10. In Vivo Experiments
Inhibition of tumorigenesis by EGCG was also demonstrated in vivo in mice models for different
types of cancer, including breast [13], lung [14], intestine [15], skin [16] and prostate [114].
2.2.11. Clinical Studies
Different clinical studies have corroborated the in vitro results. Patients with papilloma
virus-infected cervical lesions were treated with 200 mg capsules of EGCG or green tea extracts and
the treatment demonstrated effectiveness, with a 69% response rate [115]. Bettuzzi et al. demonstrated
that daily administration of 600 mg of EGCG was effective in treating premalignant lesions in men
with high-grade prostate intraepithelial neoplasia [18]. Consistent with this, McLarty et al. developed a
phase II clinical trial in prostate carcinoma patients demonstrating a significant reduction in the levels
of different cancer-related biomarkers in serum after oral administration of 800 mg of EGCG [116].
On the other hand, in a phase II study after administration of daily doses of EGCG to 42 androgen
independent prostate cancer patients, only limited antineoplasic activity was detected [117].
2.2.12. Epidemiological Data
Different epidemiological studies have addressed the effects of green tea and particularly EGCG,
in prevention and treatment of cancer, further supporting the in vitro and in vivo results. A prospective
cohort study with over 8000 individuals found that daily consumption of green tea delayed cancer
onset [17]. Additionally, a follow up study with stages I and II breast cancer patients, determined lower
recurrence rate and longer disease-free period after daily consumption of green tea [17]. Green tea daily
consumption has also demonstrated a preventive effect against prostate cancer [19]. A prospective
cohort study also revealed that green tea consumption is inversely associated with distal gastric cancer
occurrence among women [20]. In this study, participants who consumed five or more cups per day
had 49% less risk of having gastric tumors in the distal portion compared with the ones who drank
501
Nutrients 2016, 8, 307
less than 1 cup per day [20]. More recently, the protective role of green tea against stomach cancer was
also demonstrated in a meta-analysis, where a reduction of 14% in the risk of stomach cancer with
high green tea consumption was determined [21]. On the other hand, there are also many studies
where weak or no association between cancer risk and green tea consumption was found as reported
by Zhou et al. [118], Lin et al. [119] and Sasazuki et al. [120] For a more detailed review on this subject,
see [121]. These differences in results may be explained in part by the low levels of EGCG present in
the blood following green tea consumption, which may be insufficient to induce a chemopreventive
effect [121].
The vast majority of these studies highlight the importance of EGCG in cancer and the pertinence
of exploiting it in anti-tumoral therapy. Conventional treatments against cancer often consist of the
administration of cytostatic drugs, which present several limitations. One of the most relevant is the
lack of precision, which implies that only a small part of the drug reaches the tumor region, reducing
the efficacy of the drug and causing systemic toxicity [122]. Another drawback is the fact that the
drugs are also toxic to healthy cells, including bone marrow and gastrointestinal cells [122]. All these
factors contribute to the well-known side effects associated with chemotherapy such as nausea, fatigue
and hair loss [122]. EGCG can be used as an adjuvant in chemotherapy [123] lowering the doses of the
cytostatic drugs used in chemotherapy and, consequently, the associated toxicity and side effects.
3. Nanotechnology and Nanochemoprevention
Nanotechnology is an interdisciplinary field that comprises the areas of biology, engineering,
chemistry and medicine and relies on the use of nanosystems, which are man-made devices with at
least one dimension in the range of 1–100 nanometers [124]. Nanotechnology is currently being studied
and implemented in diagnosis and treatment of cancer, with the development of nanosensor devices
and nanovectors [124]. Nanovectors include nanoparticles (NPs) for loading drugs or imaging agents
and subsequent delivery and targeting to tumor cells [124]. A wide variety of different nanoparticles
may be applied to develop anti-cancer drug delivery systems, including liposomes, magnetic NPs,
polymeric NPs, among many others [124]. The potential of nanoparticles as anti-cancer drug delivery
systems is enormous since they increase the absorption, solubility and bioavailability of the drug,
protect it from premature degradation and extend its circulation time [23,124,125]. In addition, NPs
can increase drug retention in tumor tissues, due to the enhanced permeability and retention effect
(EPR), facilitate intra-cellular penetration, increase target specificity due to the possibility of surface
functionalization and minimize drug toxic effects [23]. Furthermore, they enable oral administration of
the drug, which is the preferred delivery route in terms of patient compliance and convenience [126].
Chemoprevention is a promising strategy that consists of the use of natural and synthetic
compounds, such as EGCG, as a strategy for cancer prevention, slowdown or reversion [124]. Despite
its potential, the efficiency of this approach is still limited due to toxicity and ineffective systemic
delivery and bioavailability [25]. To overcome these limitations, Siddiqui et al. [25] introduced
the concept of nanochemoprevention, which consists of the use of nanotechnology to improve
the pharmacokinetic and pharmacodynamic of chemopreventive agents in order to manage cancer.
In addition to chemopreventive applications, EGCG may also have a relevant role as an adjuvant in
chemotherapy. Indeed, EGCG has already been shown to synergize with common anti-cancer agents
such as doxorubicin, tamoxifen and paclitaxel in multiple cell lines [123]. Several studies reported in
the literature have already applied nanotechnology strategies, using different types of nanoparticles as
delivery vehicles of EGCG to target different types of cancer both in vitro and in vivo. These reports
are discussed below in more detail grouped according to the type of nanoparticle used. The main
strategies followed are schematically represented in Figure 3.
502















Figure 3. Summary of EGCG delivery approaches for cancer therapy reported in the literature:
(1) incorporation of ligands (small molecules, peptides and antibodies) at the surface of the nanoparticle
to target specific cancer cell receptors or antigens; (2) use of EGCG as a capping agent; (3) surface
functionalization with specific polymers to enhance drug release properties, cell uptake and intestinal
absorption; and (4) co-encapsulation with common cytostatic drugs such as paclitaxel.
3.1. Gold Nanoparticles
Gold nanoparticles present unique physicochemical properties, such as small size, plasmon
resonance, capacity to bind amine and thiol groups, high atomic number and biocompatibility [127].
Synthesis of these NPs usually involves the reduction of Au (III) derivatives, such as Chloroauric acid
(HAuCl4) [127]. Generally, an aqueous solution of HAuCl4 is mixed with an aqueous solution of a
reducing agent, which leads to the reduction of Au3+ and formation of gold nanoparticles [127].
Polyphenols may act as both reducing and capping agents of this process as reported by
Nune et al. [128]. This approach avoids the use of an additional synthetic chemical reagent, which
makes it a green chemistry process [128].
Due to their distinctive properties, gold NPs have been exploited in several biomedical
applications as biosensors, contrast agents, drug delivery vehicles and anti-tumoral agents [125,129].
Gold NPs are suitable anti-cancer agents mainly due to their small size, which enables them to
penetrate in the tissues and accumulate in the tumor site and their optical properties, which allow their
use in photothermal anti-cancer therapies [125].
Several reports have described the effect of gold NPs in conjugation with EGCG for cancer
treatment. The main results of these studies, including nanoparticle type, size, zeta potential, loading
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capacity (LC) encapsulation efficiency (EE) and in vitro and in vivo evaluation are summarized in
Table 1.
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64.7 ´3.36 27 N/A intra-tumoral
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Reduction in tumor volume in
a mouse melanoma model
[125]
Gold 25.55 ˘ 7.26 N/A N/A N/A N/A
Retention of EGCG’s
anti-oxidant activity




Gold 45 +43 N/A N/A N/A
High toxicity towards EAC
cells and protection of normal
mouse hepatocytes
[11]
Hsieh et al. [130] coated gold NPs with EGCG (EGCG-pNG) through an ultrasonication process
and tested their effect in the treatment of bladder cancer both in vitro and in vivo. Their results showed
that this strategy induced high levels of cytotoxicity in bladder cancer cells (MBT-2) without affecting
the viability of normal cells (Vero cells). Treatment with EGCG-pNG was shown to induce apoptosis
through triggering the intrinsic apoptotic pathway via the activation of caspases-3 and -7. In vivo
tests confirmed these results. C3H/HeN mice subcutaneously implanted with MBT-2 cells revealed a
significantly higher reduction in tumor volume after oral administration of EGCG-pNG in comparison
with free EGCG. In addition, NPs were also administered via intra-tumoral and intra-peritoneal.
These previous two administration routes were more effective than oral administration in suppressing
tumor growth. In a more recent work, the same group [125] tested the efficiency of similar NPs
against melanoma both in vivo and in vitro. In vitro results showed that gold NPs induced 4.91 times
higher levels of apoptosis in B16F10 murine melanoma cells compared to non-encapsulated EGCG.
Apoptosis was caused by activation of a mitochondrial-mediated pathway. This nanocarrier also
demonstrated a high biocompatibility, inducing low damage to human red blood cells. In vivo results
demonstrated that intra-tumoral injection of EGCG NPs induced a reduction in the tumor volume of a
mouse melanoma model compared with the control treatment. This ability to inhibit tumor growth
was 1.66 times higher when EGCG was encapsulated compared to free EGCG.
Sanna et al. [131] synthesized gold NPs using a similar process to the one described
by Nune et al. [128]. EGCG-conjugated gold nanoparticles revealed high stability in simulated
biological fluids and were able to retain EGCG’s anti-oxidant activity [131]. In addition, the
nanoparticles were efficient in inducing apoptosis (through activation of caspase-3) in neuroblastoma
SH-SY5Y-CFP-DEVD-YFP cells in a concentration dependent-manner after 72 h of exposure.
The authors concluded that the efficiency of EGCG was maintained after adsorption to the surface
of gold NPs. The same chemical process for the synthesis of gold NPs was replicated recently by
Mukherjee et al. also with encouraging results [11]. EGCG-conjugated gold NPs revealed higher
anti-oxidant activity, cellular internalization and cytotoxicity towards tumor cells than EGCG in
a free form. At the same dose (20 μg/mL), EGCG NPs induced 30% more cell death in Ehrlich’s
Ascites Carcinoma (EAC) cells than native EGCG. Apoptosis was induced due to an increase in lipid
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peroxidation and in the levels of ROS. A reduction in the levels of anti-oxidant enzymes, such as
glutathione was observed as well as an inhibition of the nuclear translocation of the transcription factor
NF-κB and subsequent activation of its downstream survival molecules. On the other hand, in normal
primary mouse hepatocytes, EGCG NPs promoted an increase in the levels of anti-oxidant enzymes,
protecting the cells against tumor-induced cellular damage. The results revealed that these NPs are
able to induce tumor cell apoptosis and simultaneously protect hepatocytes against undesirable effects.
3.2. Polymeric Nanoparticles
Polymeric NPs present important characteristics, which make them suitable for biomedical
applications, such as biocompatibility, biodegradability, with the possibility of controlling the rate of
polymer degradation, mechanical strength, and high structure versatility [132,133].
Several polymers, natural or synthetic, can be employed to produce polymeric NPs, the most
common include polycaprolactone (PCL), polylactic acid (PLA), poly (lactic-co-glycolic acid) (PLGA),
chitosan and gelatin [134]. PLA and PLGA are approved and recognized as safe by the US Food
and Drug Administration (FDA) for human applications and are metabolized in the organism into
biodegradable biocompatible monomers (lactic and glycolic acid) [134]. Intravenous injection of PLGA
and PLA usually leads to their rapid clearance by the immune system [25]. To increase their circulation
time, NPs are frequently coated with PEG, also approved by the FDA, which stabilizes and avoids their
recognition by the immune system [25]. Chitosan is a natural polymer characterized by its non-toxic,
non-immunogenic and mucoadhesive properties in the gastrointestinal tract, which makes it suitable
for oral routes of administration [126]. Gelatin is intensively used in food and medical products and
it is also a non-toxic biodegradable polymer [134]. It is characterized by its mechanical, thermal and
swelling properties, which are highly dependent on the degree of crosslinking [134]. Several groups
have already encapsulated EGCG into different polymeric NPs for cancer therapy. The main findings
from these studies are shown in Table 2.
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Sanna et al. [135] designed EGCG-loaded PLGA-PEG NPs for treatment against prostate cancer.
In this study, the function of the NPs was enhanced with a prostate-specific membrane antigen (PSMA)
ligand (DCL). These NPs allowed a greater control of the rate of release of EGCG relative to that
of free EGCG. Encapsulation and functionalization with DCL increased the cytotoxicity of the NPs
towards LNCaP prostate cancer cell line, which were PSMA-positive. On the other hand, no significant
inhibition of cell growth inhibition was detected in HUVECs (human umbilical vein endothelial cells).
These results suggest that PLA-PEG-DCL EGCG-loaded NPs were able to efficiently kill PSMA-positive
prostate cancer cells without influencing the viability of normal cells.
Alotaibi et al. [132] also prepared PLGA NPs for EGCG encapsulation. The DNA damage effect
of these NPs was tested against lymphocytes of healthy and colorectal cancer patients pretreated
with oxaliplatin of satraplatin. The obtained results suggest that encapsulated EGCG significantly
intensified DNA damage levels in a dose-dependent way. In contrast, free EGCG promoted a reduction
in DNA damage. The authors suggested that this catechin might alternate between an anti-oxidant
(bulk form) and a pro-oxidant (encapsulated form) state.
Narayanan et al. [136] synthesized PLGA-casein NPs constituted by a core and a shell, where
paclitaxel and EGCG, respectively, were entrapped. This organization enabled a sequential and
controlled release of both drugs. Nanocarriers revealed a longer circulatory lifespan and increased
biocompatibility both in vitro and in vivo. In a more recent study, the same authors tested the
chemotherapeutic effect against breast cancer cells (MDA-MB-231 cells and patient-derived tumor
cells) [137]. With that purpose some of the NPs were functionalized with antibodies specific for the
cell surface receptors anti-EGFR and anti-HER2. The results showed an enhanced cellular uptake by
MDA-MB-231 cells and a higher rate of apoptosis compared with individually encapsulated paclitaxel
and EGCG. Both results were improved when NPs were functionalized with anti-EGFR. This therapy
also showed an inhibitory effect in the protein levels of NF-κB, a signaling molecule activated by
paclitaxel that may interfere with chemotherapy effectiveness, promoting angiogenesis, metastasis and
drug resistance. Combination treatment functionalized with both EGFR and HER2 antibodies towards
breast cancer samples from patients also showed significantly higher anti-tumoral activity.
Siddiqui et al. [25] reported the use of PLA-PEG NPs to encapsulate EGCG. The efficiency of
NPs against human prostate cancer was determined both in vitro and in vivo. The in vitro results
showed that EGCG NPs induced the same extent of cellular death in human prostate cancer PC3
cells as non-encapsulated EGCG with an over 10-fold dose advantage. These NPs promoted an
increase in pro-apoptotic molecules, such as BAX and a decrease in anti-apoptotic molecules, such
as BCL-2 confirming the ability that the NPs have to retain EGCG’s biological activity even at
very low concentrations. Furthermore, EGCG-loaded NPs were also able to efficiently inhibit
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angiogenesis. This data was validated by in vivo results where it was observed that treatment with
EGCG NPs induced a significant decrease in the tumor volume of athymic nude mice injected with
androgen-responsive 22Rν1 cells with a 10-fold lower dose. More recently the same group [126],
developed an EGCG nanocarrier specifically designed for oral administration using water-soluble
chitosan. In this study, chitosan NPs revealed stability in an acidic environment, inducing a very
slow release of EGCG in simulated gastric juice and a faster release in neutral pH (simulated
intestinal fluid). The in vivo results determined in a prostate cancer xenograft model showed a
significantly higher inhibition of tumor growth compared with both control and free EGCG-treated
groups. This inhibition was found to be dose-dependent. Other relevant in vivo results include:
inhibition of serum prostate cancer marker PSA; activation of DNA damage-related protein PARP;
activation of mitochondrial pathway of apoptosis, with increase in the levels of pro-apototic protein
BAX, decrease in the levels of anti-apoptotic protein BCL-2 and activation of caspases -3, -8 and -9,
inhibition of cell proliferation markers (Ki-67 and PCNA) and angiogenesis markers (CD31 and VEGF).
This oral nanoformulation with EGCG also demonstrated efficiency against melanoma cells [138].
After treatment with EGCG-encapsulated chitosan NPs, a higher cytotoxic effect against Mel 928
human melanoma cells was observed with regulation of intrinsic apoptotic pathways and induction of
cell cycle arrest with a dose advantage over free EGCG. These results were supported by the in vivo
tests performed in a melanoma xenograft model where it was shown that oral administration of
encapsulated EGCG was able to inhibit tumor growth and induce the intrinsic apoptotic pathway and
cell cycle arrest.
Hu et al. [139] reported the use of genipicin-crosslinked caseinophosphopeptide (CPP)–chitosan
NPs for encapsulation of EGCG. Cross-linking of the NPs with genipicin increased the stability of
the nanocarriers at different pH values, and at simulated gastric and intestinal fluid (SGF and SIF).
Alterations in the crosslinking degree of the NP enabled the modulation of the release profile of
EGCG. This release rate was found to be higher in the SIF than in the SGF, which is appropriate for
an oral delivery system. In vitro test with gastrointestinal cancer cell line BGC823 demonstrated that
encapsulated EGCG retained its anti-tumoral activity.
Shutava et al. [8] synthesized gelatin-based NPs with or without a coating of polyelectrolytes
polystyrene sulfonate/polyallylamine hydrochloride produced through the layer-by-layer technique.
Gelatin NPs revealed a more sustained release of EGCG as compared with uncoated NPs. Encapsulated
EGCG maintained its biological activity, being able to inhibit hepatocyte growth factor (HGF) and
subsequent activation of cell signaling pathways responsible for cell invasion in breast cancer cell line
MDA-MD-23.
3.3. Liposomes
Liposomes are vesicles forming a membrane-like phospholipid bilayer enclosing an aqueous
compartment [140]. These structural properties enable the encapsulation of both lipophilic and
hydrophilic drugs [141]. In addition, liposomes are biodegradable and present minimal levels of
toxicity [140]. Few studies have used these nanocarriers for delivery of EGCG to cancer cells. Results
are summarized in Table 3.
Fang et al. [142] developed liposomal formulations with EGCG and other catechins for topical
and intra-tumoral administration to treat BCC (basal cell carcinoma) in female nude mice. The
authors concluded that intra-tumoral injection of liposomes was the most effective route to
reach cancer cells, promoting a great amount of EGCG deposition in tumor tissues. The same
group reported the use of liposomal formulations for BCCs treatment in vivo after intra-tumoral
administration [140]. Nanoencapsulation significantly increased EGCG stability compared to free
drug, which, according to the authors, may indicate that liposomes protect EGCG from oxidation and
degradation. The synthesized liposomes also enabled higher EGCG accumulation in tumor tissues
and induced higher levels of BCC cell death compared to the non-encapsulated EGCG treatment at
lower concentrations [140].
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LC (%) EE (%)
Route of
Administration
In Vitro/In Vivo Results Reference
Liposomes





Great amount of EGCG
deposition in tumor tissues
in BCC model in female
nude mice
[142]







accumulation in BCCs cells
and higher apoptosis
induction compared to free
EGCG
[140]
´36.1 ˘ 1.7 84.6 ˘ 3.8
Chitosan-coated
liposomes 85 ˘ 6.6 16.4 ˘ 2.8 3 90 N/A
High anti-proliferative and
pro-apoptotic effects in
MCF7 breast cancer cell
line
[23]
Liposomes 126.7 ˘ 4.3 ´37.5 N/A 60.21 ˘ 1.59 N/A
MDA-MB-231 breast cancer
cell apoptosis and cell
invasion inhibition
[141]
In work published by de Pace et al. [23], EGCG was encapsulated in the hydrophilic core of
nanoliposomes formed by cholesterol and phosphatidylcholine and coated with 0.2% of chitosan.
In vitro results demonstrated that these NPs significantly enhanced EGCG stability and prevented its
premature degradation in both PBS and cell culture mediums, when compared to free EGCG which
was degraded much faster. In addition, nanoencapsulation promoted a more extended release and a
higher EGCG content in MCF7 breast cancer cells compared to free EGCG. Differences in EGCG cellular
content were also detected after treatment with both chitosan-coated and non-coated nanoliposomes
suggesting that chitosan increases cell absorption. A dose of 10 mM of chitosan-coated liposomes also
revealed significant anti-proliferative and pro-apoptotic effects with a decrease of 40% of MCF7 cells’
proliferation compared with native EGCG and induction of 27% of MCF7 cell apoptosis.
More recently, Ramadass et al. [141] developed a liposomal co-delivery system comprising EGCG
and paclitaxel for invasive cancer therapy using MDA-MB-231 breast cancer cell line. The results
proved that this synergistic combination was effective in inducing cancer cell apoptosis and inhibiting
cell invasion, which was demonstrated by an increase in caspase-3 activity and a decrease in MMP
expression. These effects were higher in comparison with both paclitaxel and EGCG individual effects.
3.4. Other Type of NPs
A large variety of other different materials can be used for the design of nanoparticles.
Encapsulation of EGCG for the purpose of cancer therapy using different materials, including
carbohydrates, transition metals, inorganic materials and lipids are summarized in Table 4.





LC (%) EE (%)
Route of
Administration
In Vitro/In Vivo Results Reference
Maltodextrin-gum
arabic 120 ˘ 28 ´12.3 ˘ 0.8 N/A 85 ˘ 3 N/A
Higher reduction in cell
viability in Du145 human
prostate cancer cells
[143]
Ruthenium 73.59 ´17.9 N/A N/A Intra-tumoral
Induction of cancer cell
apoptosis, oxidative stress
and inhibition of migration
Tumor growth inhibition in
liver cancer xenograft model
[144]
Ca/Al-NO3
LDH N/A +30.6 N/A N/A N/A
Enhanced anti-tumoral
activity of EGCG in PC3
prostate cancer cell line
[5]
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Rocha et al. [143] reported the encapsulation of EGCG into carbohydrate NPs composed of
gum arabic and maltodextrin, whose properties enables them to protect the drug from oxidation.
This nanocarrier promoted a reduction in cell viability in Du145 human prostate cancer cells and an
induction of caspase-3 activation, and hence, apoptosis. These effects were higher comparing to free
EGCG at low concentrations.
Zhou et al. [144] developed an anti-liver cancer therapy based on ruthenium NPs loaded with
luminescent ruthenium complexes using EGCG as reducing and capping agent. Functionalization
with EGCG was performed due to its high affinity to 67LR overexpressed in Hepatocellular carcinoma
cells (HCC). In vitro results showed that the synthesized NPs had high specificity to liver cancer cells
(SMMC-7721 HCCs) and their route of internalization was endocytosis mediated by 67LR. These NPs
induced high levels of cytotoxicity, cell migration inhibition and induction of oxidative stress in HCC,
while no harmful effects were detected in normal L-02 cells. The in vivo assay performed in a liver
tumor xenograft model showed that intra-tumoral injection of EGCG functionalized nanocarriers
could significantly inhibit tumor growth.
In a recent study developed by Shafiei et al. [5] EGCG was incorporated in Ca/Al-NO3 Layered
double hydroxide (LDH) NPs using co-precipitation and ion-exchange techniques. The in vitro results
revealed a higher anti-tumoral activity of the EGCG-LDH nanohybrid in a prostate cancer cell line
(PC3), with a five-fold dose advantage over native ECGC and a longer release period compared to
physical mixture of LDH and EGCG.
In these studies different types of nanoparticles were used including gold, polymeric, liposomes,
metallic and carbohydrate-based. The majority of the studies have focused on polymeric NPs and
liposomes, possibly due to their beneficial properties such as biocompatibility. A wide range of sizes
was found varying from 20 to 1200 nm, although the majority of NPs were smaller than 250 nm.
Different zeta potentials were also found, varying from positive (+30) to negative (´41). Encapsulation
efficiencies were in general high, above 60%. EGCG anticancer activity was tested mainly in breast and
prostate cancer models. Overall, the different types of nanoparticles promoted an enhancement
of EGCG’s bioavailability, stability and release profile as well as improvement of its anticancer
activity compared to free catechin. In some studies, surface functionalization increased some of these
characteristics particularly the release profile and the bioavailability. Moreover, the use of targeting
ligands described on some of the works, contributed to increase EGCG specificity and anti-tumoral
activity. Two of the studies have addressed an interesting topic, which is the combination of EGCG
with common cytostatic drugs, demonstrating their synergistic effect, which is encouraging for future
chemotherapy approaches. Most studies, however, have not revealed whether the nanoparticles
could protect EGCG from degradation and oxidation. This would be particularly relevant since this
compound is very susceptible to oxidation, specially in alkaline environments [145,146]. Future studies
should address this issue and evaluate the capacity that different nanoparticles have to protect EGCG
from oxidation and premature degradation.
4. Conclusions
EGCG is the major bioactive component in green tea with many health benefits, including
anti-cancer activity, which has been demonstrated in in vitro and in vivo models and corroborated by
some clinical and epidemiological studies. Despite that, this catechin is still not currently used in
clinical settings due to its limited bioavailability and stability. In order to overcome these limitations,
several studies have been developed applying the concept of nanochemoprevention, the use of
nanotechnology to improve the pharmacokinetic and pharmacodynamic of chemopreventive agents to
manage cancer. In these studies, different types of nanoparticles including gold, polymeric, metallic,
carbohydrate-based and liposomes were used as delivery vehicles of EGCG. In the majority of these
studies, the size of the nanoparticles was below 250 nm and encapsulation efficiencies were higher
than 60%. The results revealed that EGCG nanoparticles promoted prolonged circulation time in
blood, increased cell internalization in tumor sites and inhibited tumor growth both in vitro and in vivo
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predominantly in breast and prostate cancer models. Surface functionalization was employed to
enhance drug release, cell uptake and intestinal absorption. The use of targeting ligands further
increased cancer cell specificity and improved the anti-tumor effects of EGCG. Some studies reported
the combination therapy of EGCG with cytostatic agents, emphasizing the synergistic effect of
the two compounds. These advances in EGCG nanodelivery systems highlight the importance
of nanotechnology in the enhancement of EGCG anti-cancer activities and hold great promise for
upcoming clinical applications. With this approach, it is expected that, in the future, EGCG could be
commercially produced by nutraceutical and dietary supplement industries as innovative supplements
for cancer prevention. In addition, when combined with conventional cytostatic drugs, EGCG may
provide a useful contribution to cancer treatments. This synergistic association is expected to increase
the effectiveness of the drug and decrease the administered doses, hence, minimizing its adverse side
effects, which will greatly improve the efficiency of future cancer therapies and the quality of life of
cancer patients.
Acknowledgments: This work received financial support from the European Union (FEDER funds) and National
Funds (FCT/MEC, Fundação para a Ciência e Tecnologia and Ministério da Educação e Ciência) under the
Partnership Agreement PT2020 UID/MULTI/04378/2013-POCI/01/0145/FEDER/007728. MP thanks FCT
(Fundação para a Ciência e Tecnologia) and POPH (Programa Operacional Potencial Humano) for her Post-Doc
grant SFRH/BPD/99124/2013.
Author Contributions: Marina Pinheiro and Salette Reis conceived the searching strategy, the structure and the
information eligible for the review; Andreia Granja conducted the research, analyzed the information and wrote
the paper; and Marina Pinheiro and Salette Reis revised the subsequent drafts and approved the manuscript
for submission.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Cancer Facts & Figures 2016. American Cancer Society. Available online: http://www.cancer.org/research/
cancerfactsstatistics/cancerfactsfigures2016/ (accessed on 7 February 2016).
2. Stewart, B.W.; Wild, C.P. World Cancer Report 2014. International Agency for Research on Cancer; World Health
Organization: Geneva, Swizerland, 2014.
3. Worldwide Cancer Statistics. Cancer Research UK. Available online: http://www.cancerresearchuk.org/
health-professional/cancer-statistics/worldwide-cancer#heading-Zero (accessed on 20 January 2016).
4. CDC—Global Cancer Statistics. Available online: http://www.cdc.gov/cancer/international/statistics.htm
(accessed on 21 January 2016).
5. Shafiei, S.S.; Solati-Hashjin, M.; Samadikuchaksaraei, A.; Kalantarinejad, R.; Asadi-Eydivand, M.;
Abu Osman, N.A. Epigallocatechin gallate/layered double hydroxide nanohybrids: Preparation,
characterization, and In vitro anti-tumor study. PLoS ONE 2015, 10, e0136530. [CrossRef] [PubMed]
6. Morgan, G.; Ward, R.; Barton, M. The contribution of cytotoxic chemotherapy to 5-year survival in adult
malignancies. Clin. Oncol. J. (R. Coll. Radiol.) 2004, 16, 549–560. [CrossRef]
7. Siddiqui, M.; Rajkumar, S.V. The high cost of cancer drugs and what we can do about it. Mayo Clin. Proc.
2012, 87, 935–943. [CrossRef] [PubMed]
8. Shutava, T.G.; Balkundi, S.S.; Vangala, P.; Steffan, J.J.; Bigelow, R.L.; Cardelli, J.A.; O’Neal, D.P.; Lvov, Y.M.
Layer-by-layer-coated gelatin nanoparticles as a vehicle for delivery of natural polyphenols. ACS Nano 2009,
3, 1877–1885. [CrossRef] [PubMed]
9. Nyamai, D.W.; Arika, W.; Ogola, P.E.; Njagi, E.N.M.; Ngugi, M.P. Medicinally Important Phytochemicals:
An Untapped Research Avenue. Res. Rev. J. Pharmacogn. Phytochem. 2016, 4, 35–49.
10. Xiao, L.; Mertens, M.; Wortmann, L.; Kremer, S.; Valldor, M.; Lammers, T.; Kiessling, F.; Mathur, S. Enhanced
in vitro and in vivo cellular imaging with green tea coated water-soluble iron oxide nanocrystals. ACS Appl.
Mater. Interfaces 2015, 7, 6530–6540. [CrossRef] [PubMed]
11. Mukherjee, S.; Ghosh, S.; Das, D.K.; Chakraborty, P.; Choudhury, S.; Gupta, P.; Adhikary, A.; Dey, S.;
Chattopadhyay, S. Gold-conjugated green tea nanoparticles for enhanced anti-tumor activities and
hepatoprotection—Synthesis, characterization and in vitro evaluation. J. Nutr. Biochem. 2015, 26, 1283–1297.
[CrossRef] [PubMed]
510
Nutrients 2016, 8, 307
12. Rahmani, A.H.; Al Shabrmi, F.M.; Allemailem, K.S.; Aly, S.M.; Khan, M.A. Implications of green tea and its
constituents in the prevention of cancer via the modulation of cell signalling pathway. BioMed Res. Int. 2015,
2015. [CrossRef] [PubMed]
13. Thangapazham, R.L.; Singh, A.K.; Sharma, A.; Warren, J.; Gaddipati, J.P.; Maheshwari, R.K. Green tea
polyphenols and its constituent Epigallocatechin gallate inhibits proliferation of human breast cancer cells
in vitro and in vivo. Cancer Lett. 2007, 245, 232–241. [CrossRef] [PubMed]
14. Xu, Y.; Ho, C.T.; Amin, S.G.; Han, C.; Chung, F.L. Inhibition of tobacco-specific nitrosamine-induced lung
tumorigenesis in A/J mice by green tea and its major polyphenol as antioxidants. Cancer Res. 1992, 52,
3875–3879. [PubMed]
15. Ju, J.; Hong, J.; Zhou, J.; Pan, Z.; Bose, M.; Liao, J.; Yang, G.; Liu, Y.Y.; Hou, Z.; Lin, Y.; et al. Inhibition of
intestinal tumorigenesis in Apcmin/+ mice by (´)-Epigallocatechin-3-gallate, the major catechin in green
tea. Cancer Res. 2005, 65, 10623–10631. [CrossRef] [PubMed]
16. Lu, Y.P.; Lou, Y.R.; Xie, J.G.; Peng, Q.Y.; Liao, J.; Yang, C.S.; Huang, M.T.; Conney, A.H. Topical applications
of caffeine or (´)-Epigallocatechin gallate (EGCG) inhibit carcinogenesis and selectively increase apoptosis
in UVB-induced skin tumors in mice. Proc. Natl. Acad. Sci. USA 2002, 99, 12455–12460. [CrossRef] [PubMed]
17. Fujiki, H. Two stages of cancer prevention with green tea. J. Cancer Res. Clin. Oncol. 1999, 125, 589–597.
[CrossRef] [PubMed]
18. Bettuzzi, S.; Brausi, M.; Rizzi, F.; Castagnetti, G.; Peracchia, G.; Corti, A. Chemoprevention of human prostate
cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial
neoplasia: A preliminary report from a one-year proof-of-principle study. Cancer Res. 2006, 66, 1234–1240.
[CrossRef] [PubMed]
19. Kurahashi, N.; Sasazuki, S.; Iwasaki, M.; Inoue, M.; Tsugane, S. Green tea consumption and prostate cancer
risk in Japanese men: A prospective study. Am. J. Epidemiol. 2008, 167, 71–77. [CrossRef] [PubMed]
20. Sasazuki, S.; Inoue, M.; Hanaoka, T.; Yamamoto, S.; Sobue, T.; Tsugane, S. Green tea consumption and
subsequent risk of gastric cancer by subsite: The JPHC Study. Cancer Causes Control. 2004, 15, 483–491.
[CrossRef] [PubMed]
21. Kang, H.; Rha, S.Y.; Oh, K.W.; Nam, C.M. Green tea consumption and stomach cancer risk: A meta-analysis.
Epidemiol. Health 2010, 32, e2010001. [CrossRef] [PubMed]
22. Singh, B.N.; Shankar, S.; Srivastava, R.K. Green tea catechin, Epigallocatechin-3-gallate (EGCG): Mechanisms,
perspectives and clinical applications. Biochem. Pharmacol. 2011, 82, 1807–1821. [CrossRef] [PubMed]
23. De Pace, R.C.C.; Liu, X.; Sun, M.; Nie, S.; Zhang, J.; Cai, Q.; Gao, W.; Pan, X.; Fan, Z.; Wang, S.
Anticancer activities of (´)-Epigallocatechin-3-gallate encapsulated nanoliposomes in MCF7 breast cancer
cells. J. Liposome Res. 2013, 23, 187–196. [CrossRef] [PubMed]
24. Nakagawa, K.; Okuda, S.; Miyazawa, T. Dose-dependent incorporation of tea catechins,
(´)-Epigallocatechin-3-gallate and (´)-Epigallocatechin, into human plasma. Biosci. Biotechnol. Biochem.
1997, 61, 1981–1985. [CrossRef] [PubMed]
25. Siddiqui, I.A.; Adhami, V.M.; Bharali, D.J.; Hafeez, B.B.; Asim, M.; Khwaja, S.I.; Ahmad, N.; Cui, H.;
Mousa, S.A.; Mukhtar, H. Introducing nanochemoprevention as a novel approach for cancer control: Proof of
principle with green tea polyphenol Epigallocatechin-3-gallate. Cancer Res. 2009, 69, 1712–1716. [CrossRef]
[PubMed]
26. Yamamoto, T.; Juneja, L.R.; Chu, sDjong-C.; Kim, M. Chemistry and Applications of Green Tea; CRC Press: Boca
Raton, FL, USA, 1997.
27. Ahmad, N.; Mukhtar, H. Green tea polyphenols and cancer: Biologic mechanisms and practical implications.
Nutr. Rev. 1999, 57, 78–83. [CrossRef] [PubMed]
28. O’Grady, M.N.; Kerry, J.P. Using antioxidants and nutraceuticals as dietary supplements to improve the
quality and shelf-life of fresh meat. In Improving the Sensory and Nutritional Quality of Fresh Meat; Woodhead
Publishing Limited: Cambridge, UK, 2009; pp. 356–386.
29. Velickovic, T.C.; Gavrovic-Jankulovic, M. Food Allergens: Biochemistry and Molecular Nutrition; Springer:
New York, NY, USA, 2014.
30. Nakagawa, T.; Yokozawa, T. Direct scavenging of nitric oxide and superoxide by green tea. Food Chem. Toxicol.
2002, 40, 1745–1750. [CrossRef]
31. Ho, C.T.; Chen, Q.; Shi, H.; Zhang, K.Q.; Rosen, R.T. Antioxidative effect of polyphenol extract prepared
from various Chinese teas. Prev. Med. (Baltim.) 1992, 21, 520–525. [CrossRef]
511
Nutrients 2016, 8, 307
32. Betts, J.W.; Wareham, D.W. In vitro activity of curcumin in combination with Epigallocatechin gallate (EGCG)
versus multidrug-resistant Acinetobacter baumannii. BMC Microbiol. 2014, 14, 172. [CrossRef] [PubMed]
33. Steinmann, J.; Buer, J.; Pietschmann, T.; Steinmann, E. Anti-infective properties of Epigallocatechin-3-gallate
(EGCG), a component of green tea. Br. J. Pharmacol. 2013, 168, 1059–1073. [CrossRef] [PubMed]
34. Huang, H.C.; Tao, M.H.; Hung, T.M.; Chen, J.C.; Lin, Z.J.; Huang, C. (´)-Epigallocatechin-3-gallate inhibits
entry of hepatitis B virus into hepatocytes. Antivir. Res. 2014, 111, 100–111. [CrossRef] [PubMed]
35. Calland, N.; Albecka, A.; Belouzard, S.; Wychowski, C.; Duverlie, G.; Descamps, V.; Hober, D.; Dubuisson, J.;
Rouillé, Y.; Séron, K. (´)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Hepatology
2012, 55, 720–729. [CrossRef] [PubMed]
36. Weber, C.; Sliva, K.; von Rhein, C.; Kümmerer, B.M.; Schnierle, B.S. The green tea catechin, Epigallocatechin
gallate inhibits chikungunya virus infection. Antivir. Res. 2015, 113, 1–3. [CrossRef] [PubMed]
37. Munir, K.M.; Chandrasekaran, S.; Gao, F.; Quon, M.J. Mechanisms for food polyphenols to ameliorate
insulin resistance and endothelial dysfunction: Therapeutic implications for diabetes and its cardiovascular
complications. Am. J. Physiol. Endocrinol. Metab. 2013, 305, E679–E686. [CrossRef] [PubMed]
38. Babu, P.V.A.; Liu, D.; Gilbert, E.R. Recent advances in understanding the anti-diabetic actions of dietary
flavonoids. J. Nutr. Biochem. 2013, 24, 1777–1789. [CrossRef] [PubMed]
39. Iso, H. The relationship between green tea and total caffeine intake and risk for self-reported type 2 diabetes
among japanese adults. Ann. Intern. Med. 2006, 144, 554–562. [CrossRef] [PubMed]
40. Panagiotakos, D.B.; Lionis, C.; Zeimbekis, A.; Gelastopoulou, K.; Papairakleous, N.; Das, U.N.;
Polychronopoulos, E. Long-term tea intake is associated with reduced prevalence of (type 2) diabetes
mellitus among elderly people from Mediterranean islands: MEDIS epidemiological study. Yonsei Med. J.
2009, 50, 31–38. [CrossRef] [PubMed]
41. Khurana, S.; Venkataraman, K.; Hollingsworth, A.; Piche, M.; Tai, T.C. Polyphenols: Benefits to the
cardiovascular system in health and in aging. Nutrients 2013, 5, 3779–3827. [CrossRef] [PubMed]
42. Osada, K.; Takahashi, M.; Hoshina, S.; Nakamura, M.; Nakamura, S.; Sugano, M. Tea catechins inhibit
cholesterol oxidation accompanying oxidation of low density lipoprotein in vitro. Comp. Biochem. Physiol. C
Toxicol. Pharmacol. 2001, 128, 153–164. [CrossRef]
43. Kuriyama, S.; Shimazu, T.; Ohmori, K.; Kikuchi, N.; Nakaya, N.; Nishino, Y.; Tsubono, Y.; Tsuji, I. Green tea
consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: The Ohsaki study.
JAMA 2006, 296, 1255–1265. [CrossRef] [PubMed]
44. Geleijnse, J.M.; Launer, L.J.; Van der Kuip, D.A.M.; Hofman, A.; Witteman, J.C.M. Inverse association of tea
and flavonoid intakes with incident myocardial infarction: The Rotterdam Study. Am. J. Clin. Nutr. 2002, 75,
880–886. [PubMed]
45. Yang, Y.C.; Lu, F.H.; Wu, J.S.; Wu, C.H.; Chang, C.J. The protective effect of habitual tea consumption on
hypertension. Arch. Intern. Med. 2004, 164, 1534–1540. [CrossRef] [PubMed]
46. Geleijnse, J.M.; Launer, L.J.; Hofman, A.; Pols, H.A.; Witteman, J.C. Tea flavonoids may protect against
atherosclerosis: The Rotterdam Study. Arch. Intern. Med. 1999, 159, 2170–2174. [CrossRef] [PubMed]
47. Diepvens, K.; Westerterp, K.R.; Westerterp-Plantenga, M.S. Obesity and thermogenesis related to the
consumption of caffeine, ephedrine, capsaicin, and green tea. Am. J. Physiol. Regul. Integr. Comp. Physiol.
2006, 292, R77–R85. [CrossRef] [PubMed]
48. Lim, H.J.; Shim, S.B.; Jee, S.W.; Lee, S.H.; Lim, C.J.; Hong, J.T.; Sheen, Y.Y.; Hwang, D.Y. Green tea catechin
leads to global improvement among Alzheimer’s disease—Related phenotypes in NSE/hAPP-C105 Tg mice.
J. Nutr. Biochem. 2013, 24, 1302–1313. [CrossRef] [PubMed]
49. Mandel, S.A.; Amit, T.; Weinreb, O.; Youdim, M.B.H. Understanding the broad-spectrum neuroprotective
action profile of green tea polyphenols in aging and neurodegenerative diseases. J. Alzheimers Dis. 2011, 25,
187–208. [PubMed]
50. Rigacci, S.; Stefani, M. Nutraceuticals and amyloid neurodegenerative diseases: A focus on natural phenols.
Expert Rev. Neurother. 2015, 15, 41–52. [CrossRef] [PubMed]
51. Ruddon, R.W. Cancer Biology; Oxford University Press: New York, NY, USA, 2007.
52. Mikeska, T.; Craig, J.M. DNA methylation biomarkers: Cancer and beyond. Genes 2014, 5, 821–864. [CrossRef]
[PubMed]
53. Jones, P.A.; Baylin, S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002, 3, 415–428.
[PubMed]
512
Nutrients 2016, 8, 307
54. Baylin, S.B. DNA methylation and gene silencing in cancer. Nat. Clin. Pract. Oncol. 2005, 2 (Suppl. 1), S4–S11.
[CrossRef] [PubMed]
55. Fang, M.Z.; Wang, Y.; Ai, N.; Hou, Z.; Sun, Y.; Lu, H.; Welsh, W.; Yang, C.S. Tea polyphenol
(´)-Epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes
in cancer cell lines. Cancer Res. 2003, 63, 7563–7570. [PubMed]
56. Gavory, G.; Farrow, M.; Balasubramanian, S. Minimum length requirement of the alignment domain of
human telomerase RNA to sustain catalytic activity in vitro. Nucleic Acids Res. 2002, 30, 4470–4480. [CrossRef]
[PubMed]
57. Kim, N.W.; Piatyszek, M.A.; Prowse, K.R.; Harley, C.B.; West, M.D.; Ho, P.L.; Coviello, G.M.; Wright, W.E.;
Weinrich, S.L.; Shay, J.W. Specific association of human telomerase activity with immortal cells and cancer.
Science 1994, 266, 2011–2015. [CrossRef] [PubMed]
58. Sadava, D.; Whitlock, E.; Kane, S.E. The green tea polyphenol, Epigallocatechin-3-gallate inhibits telomerase
and induces apoptosis in drug-resistant lung cancer cells. Biochem. Biophys. Res. Commun. 2007, 360, 233–237.
[CrossRef] [PubMed]
59. Yokoyama, M.; Noguchi, M.; Nakao, Y.; Pater, A.; Iwasaka, T. The tea polyphenol, (´)-Epigallocatechin
gallate effects on growth, apoptosis, and telomerase activity in cervical cell lines. Gynecol. Oncol. 2004, 92,
197–204. [CrossRef] [PubMed]
60. Naasani, I.; Seimiya, H.; Tsuruo, T. Telomerase Inhibition, Telomere Shortening, and Senescence of Cancer
Cells by Tea Catechins. Biochem. Biophys. Res. Commun. 1998, 249, 391–396. [CrossRef] [PubMed]
61. Sledge, G.; Miller, K. Exploiting the hallmarks of cancer. Eur. J. Cancer 2003, 39, 1668–1675. [CrossRef]
62. Roudsari, L.C.; West, J.L. Studying the influence of angiogenesis in in vitro cancer model systems. Adv. Drug
Deliv. Rev. 2015, 97, 250–259. [CrossRef] [PubMed]
63. Byrne, A.M.; Bouchier-Hayes, D.J.; Harmey, J.H. Angiogenic and cell survival functions of vascular
endothelial growth factor (VEGF). J. Cell. Mol. Med. 2005, 9, 777–794. [CrossRef] [PubMed]
64. Wang, H.; Bian, S.; Yang, C.S. Green tea polyphenol EGCG suppresses lung cancer cell growth through
upregulating miR-210 expression caused by stabilizing HIF-1α. Carcinogenesis 2011, 32, 1881–1889. [CrossRef]
[PubMed]
65. Gu, J.-W.; Makey, K.L.; Tucker, K.B.; Chinchar, E.; Mao, X.; Pei, I.; Thomas, E.Y.; Miele, L. EGCG, a major
green tea catechin suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1α
and NFκB, and VEGF expression. Vasc. Cell 2013, 5, 9. [CrossRef] [PubMed]
66. Li, X.; Feng, Y.; Liu, J.; Feng, X.; Zhou, K.; Tang, X. Epigallocatechin-3-gallate inhibits IGF-I-stimulated
lung cancer angiogenesis through downregulation of HIF-1α and VEGF expression. J. Nutr. Nutr. 2013, 6,
169–178.
67. Shankar, S.; Ganapathy, S.; Hingorani, S.R.; Srivastava, R.K. EGCG inhibits growth, invasion, angiogenesis
and metastasis of pancreatic cancer. Front. Biosci. 2008, 13, 440–452. [CrossRef] [PubMed]
68. Isemura, M.; Saeki, K.; Kimura, T.; Hayakawa, S.; Minami, T.; Sazuka, M. Tea catechins and related
polyphenols as anti-cancer agents. Biofactors 2000, 13, 81–85. [CrossRef] [PubMed]
69. Garbisa, S.; Biggin, S.; Cavallarin, N.; Sartor, L.; Benelli, R.; Albini, A. Tumor invasion: Molecular shears
blunted by green tea. Nat. Med. 1999, 5, 1216. [CrossRef] [PubMed]
70. Demeule, M.; Brossard, M.; Pagé, M.; Gingras, D.; Béliveau, R. Matrix metalloproteinase inhibition by green
tea catechins. Biochim. Biophys. Acta 2000, 1478, 51–60. [CrossRef]
71. Zhen, M.; Huang, X.; Wang, Q.; Sun, K.; Liu, Y.; Li, W.; Zhang, L.; Cao, L.; Chen, X. Green tea polyphenol
Epigallocatechin-3-gallate suppresses rat hepatic stellate cell invasion by inhibition of MMP-2 expression
and its activation. Acta Pharmacol. Sin. 2006, 27, 1600–1607. [CrossRef] [PubMed]
72. Koff, J.; Ramachandiran, S.; Bernal-Mizrachi, L. A Time to Kill: Targeting Apoptosis in Cancer. Int. J. Mol. Sci.
2015, 16, 2942–2955. [CrossRef] [PubMed]
73. Shankar, S.; Suthakar, G.; Srivastava, R.K. Epigallocatechin-3-gallate inhibits cell cycle and induces apoptosis
in pancreatic cancer. Front. Biosci. 2007, 12, 5039–5051. [CrossRef] [PubMed]
74. Leone, M.; Zhai, D.; Sareth, S.; Kitada, S.; Reed, J.C.; Pellecchia, M. Cancer prevention by tea polyphenols
is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res. 2003, 63, 8118–8121.
[PubMed]
75. Sonoda, J.I.; Ikeda, R.; Baba, Y.; Narumi, K.; Kawachi, A.; Tomishige, E.; Nishihara, K.; Takeda, Y.; Yamada, K.;
Sato, K.; et al. Green tea catechin, Epigallocatechin-3-gallate, attenuates the cell viability of human
513
Nutrients 2016, 8, 307
non-small-cell lung cancer A549 cells via reducing Bcl-xL expression. Exp. Ther. Med. 2014, 8, 59–63.
[CrossRef] [PubMed]
76. Yang, W.H.; Fong, Y.C.; Lee, C.Y.; Jin, T.R.; Tzen, J.T.; Li, T.M.; Tang, C.H. Epigallocatechin-3-gallate
induces cell apoptosis of human chondrosarcoma cells through apoptosis signal-regulating kinase 1 pathway.
J. Cell. Biochem. 2011, 112, 1601–1611. [CrossRef] [PubMed]
77. Yang, G.Y.; Liao, J.; Li, C.; Chung, J.; Yurkow, E.J.; Ho, C.T.; Yang, C.S. Effect of black and green tea
polyphenols on c-jun phosphorylation and H(2)O(2) production in transformed and non-transformed human
bronchial cell lines: Possible mechanisms of cell growth inhibition and apoptosis induction. Carcinogenesis
2000, 21, 2035–2039. [CrossRef] [PubMed]
78. Ahmad, N.; Cheng, P.; Mukhtar, H. Cell cycle dysregulation by green tea polyphenol
Epigallocatechin-3-gallate. Biochem. Biophys. Res. Commun. 2000, 275, 328–334. [CrossRef] [PubMed]
79. Fatemi, A.; Safa, M.; Kazemi, A. MST-312 induces G2/M cell cycle arrest and apoptosis in APL cells through
inhibition of telomerase activity and suppression of NF-κB pathway. Tumour Biol. 2015, 36, 8425–8437.
[CrossRef] [PubMed]
80. Singh, M.; Singh, R.; Bhui, K.; Tyagi, S.; Mahmood, Z.; Shukla, Y. Tea polyphenols induce apoptosis through
mitochondrial pathway and by inhibiting nuclear factor-kappaB and Akt activation in human cervical cancer
cells. Oncol. Res. 2011, 19, 245–257. [CrossRef] [PubMed]
81. Polinsky, K.R. Tumor Suppressor Genes; Nova Publishers: Hauppauge, NY, USA, 2007.
82. Thakur, V.S.; Gupta, K.; Gupta, S. Green tea polyphenols increase p53 transcriptional activity and acetylation
by suppressing class I histone deacetylases. Int. J. Oncol. 2012, 41, 353–361. [PubMed]
83. Hastak, K.; Agarwal, M.K.; Mukhtar, H.; Agarwal, M.L. Ablation of either p21 or Bax prevents p53-dependent
apoptosis induced by green tea polyphenol Epigallocatechin-3-gallate. FASEB J. 2005, 19, 789–791. [CrossRef]
[PubMed]
84. Liu, S.; Wang, X.J.; Liu, Y.; Cui, Y.F. PI3K/AKT/mTOR signaling is involved in (´)-Epigallocatechin-3-
gallate-induced apoptosis of human pancreatic carcinoma cells. Am. J. Chin. Med. 2013, 41, 629–642.
[CrossRef] [PubMed]
85. Liang, Y.C.; Lin-Shiau, S.Y.; Chen, C.F.; Lin, J.K. Inhibition of cyclin-dependent kinases 2 and 4 activities as
well as induction of Cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by
(´)-Epigallocatechin-3-gallate. J. Cell. Biochem. 1999, 75, 1–12. [CrossRef]
86. Ozols, R.F. Ovarian Cancer; BC Decker Inc: Hamilton, ON, Canada, 2003; Volume 1.
87. Iqbal, N.; Iqbal, N. Human epidermal growth factor receptor 2 (HER2) in cancers: Overexpression and
therapeutic implications. Mol. Biol. Int. 2014. [CrossRef] [PubMed]
88. Milanezi, F.; Carvalho, S.; Schmitt, F.C. EGFR/HER2 in breast cancer: A biological approach for molecular
diagnosis and therapy. Expert Rev. Mol. Diagn. 2008, 8, 417–434. [CrossRef] [PubMed]
89. Ma, Y.C.; Li, C.; Gao, F.; Xu, Y.; Jiang, Z.B.; Liu, J.X.; Jin, L.Y. Epigallocatechin gallate inhibits the growth
of human lung cancer by directly targeting the EGFR signaling pathway. Oncol. Rep. 2014, 31, 1343–1349.
[PubMed]
90. Lim, Y.C.; Cha, Y.Y. Epigallocatechin-3-gallate induces growth inhibition and apoptosis of human anaplastic
thyroid carcinoma cells through suppression of EGFR/ERK pathway and cyclin B1/CDK1 complex.
J. Surg. Oncol. 2011, 104, 776–780. [CrossRef] [PubMed]
91. Masuda, M.; Suzui, M.; Lim, J.T.E.; Weinstein, I.B. Epigallocatechin-3-gallate inhibits activation of HER-2/neu
and downstream signaling pathways in human head and neck and breast carcinoma cells. Clin. Cancer Res.
2003, 9, 3486–3491. [PubMed]
92. Pianetti, S.; Guo, S.; Kavanagh, K.T.; Sonenshein, G.E. Green tea polyphenol Epigallocatechin-3 gallate
inhibits Her-2/neu signaling, proliferation, and transformed phenotype of breast cancer cells. Cancer Res.
2002, 62, 652–655. [PubMed]
93. Aggarwal, B.B.; Shishodia, S. Molecular targets of dietary agents for prevention and therapy of cancer.
Biochem. Pharmacol. 2006, 71, 1397–1421. [CrossRef] [PubMed]
94. Ahmad, N.; Gupta, S.; Mukhtar, H. Green tea polyphenol Epigallocatechin-3-gallate differentially modulates
nuclear factor kappaB in cancer cells versus normal cells. Arch. Biochem. Biophys. 2000, 376, 338–346.
[CrossRef] [PubMed]
514
Nutrients 2016, 8, 307
95. Qin, J.; Wang, Y.; Bai, Y.; Yang, K.; Mao, Q.; Lin, Y.; Kong, D.; Zheng, X.; Xie, L. Epigallocatechin-3-gallate
inhibits bladder cancer cell invasion via suppression of NF-κB-mediated matrix metalloproteinase-9
expression. Mol. Med. Rep. 2012, 6, 1040–1044. [PubMed]
96. Masuda, M.; Suzui, M.; Lim, J.T.E.; Deguchi, A.; Soh, J.W.; Weinstein, I.B. Epigallocatechin-3-gallate decreases
VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of
signal transduction. J. Exp. Ther. Oncol. 2002, 2, 350–359. [CrossRef] [PubMed]
97. Seger, R.; Krebs, E.G. The MAPK signaling cascade. FASEB J. 1995, 9, 726–735. [PubMed]
98. Cerezo-Guisado, M.I.; Zur, R.; Lorenzo, M.J.; Risco, A.; Martín-Serrano, M.A.; Alvarez-Barrientos, A.;
Cuenda, A.; Centeno, F. Implication of Akt, ERK1/2 and alternative p38MAPK signalling pathways in
human colon cancer cell apoptosis induced by green tea EGCG. Food Chem. Toxicol. 2015, 84, 125–132.
[CrossRef] [PubMed]
99. Park, S.B.; Bae, J.W.; Kim, J.M.; Lee, S.G.; Han, M. Antiproliferative and apoptotic effect of Epigallocatechin-3-
gallate on Ishikawa cells is accompanied by sex steroid receptor downregulation. Int. J. Mol. Med. 2012, 30,
1211–1218. [PubMed]
100. Ly, B.T.K.; Chi, H.T.; Yamagishi, M.; Kano, Y.; Hara, Y.; Nakano, K.; Sato, Y.; Watanabe, T. Inhibition of
FLT3 expression by green tea catechins in FLT3 mutated-AML cells. PLoS ONE 2013, 8, e66378. [CrossRef]
[PubMed]
101. Adhami, V.M.; Siddiqui, I.A.; Ahmad, N.; Gupta, S.; Mukhtar, H. Oral consumption of green tea polyphenols
inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer.
Cancer Res. 2004, 64, 8715–8522. [CrossRef] [PubMed]
102. Li, M.; He, Z.; Ermakova, S.; Zheng, D.; Tang, F.; Cho, Y.Y.; Zhu, F.; Ma, W.Y.; Sham, Y.; Rogozin, E.A.; et al.
Direct inhibition of insulin-like growth factor-I receptor kinase activity by (´)-Epigallocatechin-3-gallate
regulates cell transformation. Cancer Epidemiol. Biomark. Prev. 2007, 16, 598–605. [CrossRef] [PubMed]
103. Sazuka, M.; Itoi, T.; Suzuki, Y.; Odani, S.; Koide, T.; Isemura, M. Evidence for the interaction between
(´)-Epigallocatechin gallate and human plasma proteins fibronectin, fibrinogen, and histidine-rich
glycoprotein. Biosci. Biotechnol. Biochem. 1996, 60, 1317–1319. [CrossRef] [PubMed]
104. Suzuki, Y.; Isemura, M. Inhibitory effect of Epigallocatechin gallate on adhesion of murine melanoma cells to
laminin. Cancer Lett. 2001, 173, 15–20. [CrossRef]
105. Suzuki, Y.; Isemura, M. Binding interaction between (´)-Epigallocatechin gallate causes impaired spreading
of cancer cells on fibrinogen. Biomed. Res. 2013, 34, 301–308. [CrossRef] [PubMed]
106. Hayakawa, S.; Saeki, K.; Sazuka, M.; Suzuki, Y.; Shoji, Y.; Ohta, T.; Kaji, K.; Yuo, A.; Isemura, M. Apoptosis
induction by Epigallocatechin gallate involves its binding to Fas. Biochem. Biophys. Res. Commun. 2001, 285,
1102–1106. [CrossRef] [PubMed]
107. Tachibana, H.; Koga, K.; Fujimura, Y.; Yamada, K. A receptor for green tea polyphenol EGCG. Nat. Struct.
Mol. Biol. 2004, 11, 380–381. [CrossRef] [PubMed]
108. Ermakova, S.; Choi, B.Y.; Choi, H.S.; Kang, B.S.; Bode, A.M.; Dong, Z. The intermediate filament protein
vimentin is a new target for Epigallocatechin gallate. J. Biol. Chem. 2005, 280, 16882–16890. [CrossRef]
[PubMed]
109. Ermakova, S.P.; Kang, B.S.; Choi, B.Y.; Choi, H.S.; Schuster, T.F.; Ma, W.Y.; Bode, A.M.; Dong, Z.
(´)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular
chaperone glucose-regulated protein 78. Cancer Res. 2006, 66, 9260–9269. [CrossRef] [PubMed]
110. He, Z.; Tang, F.; Ermakova, S.; Li, M.; Zhao, Q.; Cho, Y.Y.; Ma, W.Y.; Choi, H.S.; Bode, A.M.; Yang, C.S.;
et al. Fyn is a novel target of (´)-Epigallocatechin gallate in the inhibition of JB6 Cl41 cell transformation.
Mol. Carcinog. 2008, 47, 172–183. [CrossRef] [PubMed]
111. Shim, J.H.; Choi, H.S.; Pugliese, A.; Lee, S.Y.; Chae, J.I.; Choi, B.Y.; Bode, A.M.; Dong, Z. (´)-Epigallocatechin
gallate regulates CD3-mediated T cell receptor signaling in leukemia through the inhibition of ZAP-70 kinase.
J. Biol. Chem. 2008, 283, 28370–28379. [CrossRef] [PubMed]
112. Shim, J.H.; Su, Z.Y.; Chae, J.I.; Kim, D.J.; Zhu, F.; Ma, W.Y.; Bode, A.M.; Yang, C.S.; Dong, Z. Epigallocatechin
gallate suppresses lung cancer cell growth through Ras-GTPase-activating protein SH3 domain-binding
protein 1. Cancer Prev. Res. (Phila.) 2010, 3, 670–679. [CrossRef] [PubMed]
113. Urusova, D.V.; Shim, J.H.; Kim, D.J.; Jung, S.K.; Zykova, T.A.; Carper, A.; Bode, A.M.; Dong, Z.
Epigallocatechin- gallate suppresses tumorigenesis by directly targeting Pin1. Cancer Prev. Res. (Phila.) 2011,
4, 1366–1377. [CrossRef] [PubMed]
515
Nutrients 2016, 8, 307
114. Liao, S.; Umekita, Y.; Guo, J.; Kokontis, J.M.; Hiipakka, R.A. Growth inhibition and regression of human
prostate and breast tumors in athymic mice by tea Epigallocatechin gallate. Cancer Lett. 1995, 96, 239–243.
[CrossRef]
115. Ahn, W.S.; Yoo, J.; Huh, S.W.; Kim, C.K.; Lee, J.M.; Namkoong, S.E.; Bae, S.M.; Lee, I.P. Protective effects
of green tea extracts (polyphenon E and EGCG) on human cervical lesions. Eur. J. Cancer Prev. 2003, 12,
383–390. [CrossRef] [PubMed]
116. McLarty, J.; Bigelow, R.L.H.; Smith, M.; Elmajian, D.; Ankem, M.; Cardelli, J.A. Tea polyphenols decrease
serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in
prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth
factor in vitro. Cancer Prev. Res. (Phila.) 2009, 2, 673–682. [PubMed]
117. Jatoi, A.; Ellison, N.; Burch, P.A.; Sloan, J.A.; Dakhil, S.R.; Novotny, P.; Tan, W.; Fitch, T.R.; Rowland, K.M.;
Young, C.Y.F.; et al. phase II trial of green tea in the treatment of patients with androgen independent
metastatic prostate carcinoma. Cancer 2003, 97, 1442–1446. [CrossRef] [PubMed]
118. Zhou, Y.; Li, N.; Zhuang, W.; Liu, G.; Wu, T.; Yao, X.; Du, L.; Wei, M.; Wu, X. Green tea and gastric cancer
risk: Meta-analysis of epidemiologic studies. Asia Pac. J. Clin. Nutr. 2008, 17, 159–165. [PubMed]
119. Lin, Y.; Kikuchi, S.; Tamakoshi, A.; Yagyu, K.; Obata, Y.; Kurosawa, M.; Inaba, Y.; Kawamura, T.; Motohashi, Y.;
Ishibashi, T. Green tea consumption and the risk of pancreatic cancer in Japanese adults. Pancreas 2008, 37,
25–30. [CrossRef] [PubMed]
120. Sasazuki, S.; Tamakoshi, A.; Matsuo, K.; Ito, H.; Wakai, K.; Nagata, C.; Mizoue, T.; Tanaka, K.; Tsuji, I.;
Inoue, M.; et al. Green tea consumption and gastric cancer risk: An evaluation based on a systematic review
of epidemiologic evidence among the Japanese population. Jpn. J. Clin. Oncol. 2012, 42, 335–346. [CrossRef]
[PubMed]
121. Wang, H.; Zhou, H.; Yang, C.S. Cancer prevention with green tea polyphenols. In Cancer Chemoprevention
and Treatment by Diet Therapy; Springer: Dordrecht, The Netherlands, 2013; pp. 91–119.
122. Selvamuthukumar, S.; Velmurugan, R. Nanostructured lipid carriers: A potential drug carrier for cancer
chemotherapy. Lipids Health Dis. 2012, 11, 159. [CrossRef] [PubMed]
123. Lecumberri, E.; Dupertuis, Y.M.; Miralbell, R.; Pichard, C. Green tea polyphenol Epigallocatechin-3-gallate
(EGCG) as adjuvant in cancer therapy. Clin. Nutr. 2013, 32, 894–903. [CrossRef] [PubMed]
124. Siddiqui, I.A.; Adhami, V.M.; Ahmad, N.; Mukhtar, H. Nanochemoprevention: Sustained release of bioactive
food components for cancer prevention. Nutr. Cancer 2010, 62, 883–890. [CrossRef] [PubMed]
125. Chen, C.C.; Hsieh, D.S.; Huang, K.J.; Chan, Y.L.; Hong, P.D.; Yeh, M.K.; Wu, C.J. Improving anticancer
efficacy of (´)-Epigallocatechin-3-gallate gold nanoparticles in murine B16F10 melanoma cells. Drug Des.
Dev. Ther. 2014, 8, 459–473.
126. Khan, N.; Bharali, D.J.; Adhami, V.M.; Siddiqui, I.A.; Cui, H.; Shabana, S.M.; Mousa, S.A.; Mukhtar, H.
Oral administration of naturally occurring chitosan-based nanoformulated green tea polyphenol EGCG
effectively inhibits prostate cancer cell growth in a xenograft model. Carcinogenesis 2014, 35, 415–423.
[CrossRef] [PubMed]
127. Jain, S.; Hirst, D.G.; O’Sullivan, J.M. Gold nanoparticles as novel agents for cancer therapy. Br. J. Radiol. 2012,
85, 101–113. [CrossRef] [PubMed]
128. Nune, S.K.; Chanda, N.; Shukla, R.; Katti, K.; Kulkarni, R.R.; Thilakavathy, S.; Mekapothula, S.; Kannan, R.;
Katti, K.V. Green nanotechnology from tea: Phytochemicals in tea as building blocks for production of
biocompatible gold nanoparticles. J. Mater. Chem. 2009, 19, 2912. [CrossRef] [PubMed]
129. Nie, L.; Liu, F.; Ma, P.; Xiao, X. Applications of gold nanoparticles in optical biosensors. J. Biomed. Nanotechnol.
2014, 10, 2700–2721. [CrossRef] [PubMed]
130. Hsieh, D.S.; Wang, H.; Tan, S.W.; Huang, Y.H.; Tsai, C.Y.; Yeh, M.K.; Wu, C.J. The treatment of bladder
cancer in a mouse model by Epigallocatechin-3-gallate-gold nanoparticles. Biomaterials 2011, 32, 7633–7640.
[CrossRef] [PubMed]
131. Sanna, V.; Pala, N.; Dessi, G.; Manconi, P.; Mariani, A.; Dedola, S.; Rassu, M.; Crosio, C.; Iaccarino, C.;
Sechi, M. Single-step green synthesis and characterization of gold-conjugated polyphenol nanoparticles with
antioxidant and biological activities. Int. J. Nanomedicine 2014, 9, 4935–4951. [PubMed]
132. Alotaibi, A.; Bhatnagar, P.; Najafzadeh, M.; Gupta, K.C.; Anderson, D. Tea phenols in bulk and nanoparticle
form modify DNA damage in human lymphocytes from colon cancer patients and healthy individuals treated
516
Nutrients 2016, 8, 307
in vitro with platinum based-chemotherapeutic drugs. Nanomedicine (Lond.) 2013, 8, 389–401. [CrossRef]
[PubMed]
133. Elsabahy, M.; Wooley, K.L. Design of polymeric nanoparticles for biomedical delivery applications.
Chem. Soc. Rev. 2012, 41, 2545–2561. [CrossRef] [PubMed]
134. Kumari, A.; Yadav, S.K.; Yadav, S.C. Biodegradable polymeric nanoparticles based drug delivery systems.
Colloids Surf. B. Biointerfaces 2010, 75, 1–18. [CrossRef] [PubMed]
135. Sanna, V.; Pintus, G.; Roggio, A.M.; Punzoni, S.; Posadino, A.M.; Arca, A.; Marceddu, S.; Bandiera, P.;
Uzzau, S.; Sechi, M. Targeted biocompatible nanoparticles for the delivery of (´)-Epigallocatechin 3-gallate
to prostate cancer cells. J. Med. Chem. 2011, 54, 1321–1332. [CrossRef] [PubMed]
136. Narayanan, S.; Pavithran, M.; Viswanath, A.; Narayanan, D.; Mohan, C.C.; Manzoor, K.; Menon, D.
Sequentially releasing dual-drug-loaded PLGA–casein core/shell nanomedicine: Design, synthesis,
biocompatibility and pharmacokinetics. Acta Biomater. 2014, 10, 2112–2124. [CrossRef] [PubMed]
137. Narayanan, S.; Mony, U.; Vijaykumar, D.K.; Koyakutty, M.; Paul-Prasanth, B.; Menon, D. Sequential release of
Epigallocatechin gallate and paclitaxel from PLGA-casein core/shell nanoparticles sensitizes drug-resistant
breast cancer cells. Nanomedicine 2015, 11, 1399–1406. [CrossRef] [PubMed]
138. Siddiqui, I.A.; Bharali, D.J.; Nihal, M.; Adhami, V.M.; Khan, N.; Chamcheu, J.C.; Khan, M.I.;
Shabana, S.; Mousa, S.A.; Mukhtar, H. Excellent anti-proliferative and pro-apoptotic effects of
(´)-Epigallocatechin-3-gallate encapsulated in chitosan nanoparticles on human melanoma cell growth both
in vitro and in vivo. Nanomedicine 2014, 10, 1619–1626. [CrossRef] [PubMed]
139. Hu, B.; Xie, M.; Zhang, C.; Zeng, X. Genipin-structured peptide-polysaccharide nanoparticles with
significantly improved resistance to harsh gastrointestinal environments and their potential for oral delivery
of polyphenols. J. Agric. Food Chem. 2014, 62, 12443–12452. [CrossRef] [PubMed]
140. Fang, J.Y.; Lee, W.R.; Shen, S.C.; Huang, Y.L. Effect of liposome encapsulation of tea catechins on their
accumulation in basal cell carcinomas. J. Dermatol. Sci. 2006, 42, 101–109. [CrossRef] [PubMed]
141. Ramadass, S.K.; Anantharaman, N.V.; Subramanian, S.; Sivasubramanian, S.; Madhan, B.
Paclitaxel/Epigallocatechin gallate coloaded liposome: A synergistic delivery to control the invasiveness of
MDA-MB-231 breast cancer cells. Colloids Surf. B Biointerfaces 2015, 125, 65–72. [CrossRef] [PubMed]
142. Fang, J.Y.; Hung, C.F.; Hwang, T.L.; Huang, Y.L. Physicochemical characteristics and in vivo deposition of
liposome-encapsulated tea catechins by topical and intratumor administrations. J. Drug Target. 2005, 13,
19–27. [CrossRef] [PubMed]
143. Rocha, S.; Generalov, R.; Peres, I.; Juzenas, P. Epigallocatechin gallate-loaded polysaccharide nanoparticles
for prostate cancer chemoprevention. Nanomedicine (Lond.) 2011, 6, 79–87. [CrossRef] [PubMed]
144. Zhou, Y.; Yu, Q.; Qin, X.; Bhavsar, D.; Yang, L.; Chen, Q.; Zheng, W.; Chen, L.; Liu, J. Improving the Anticancer
Efficacy of Laminin Receptor-Specific Therapeutic Ruthenium Nanoparticles (RuBB-Loaded EGCG-RuNPs)
via ROS-Dependent Apoptosis in SMMC-7721 Cells. ACS Appl. Mater. Interfaces 2015. [CrossRef] [PubMed]
145. Janeiro, P.; Oliveira Brett, A.M. Catechin electrochemical oxidation mechanisms. Anal. Chim. Acta 2004, 518,
109–115. [CrossRef]
146. Dube, A.; Ng, K.; Nicolazzo, J.A.; Larson, I. Effective use of reducing agents and nanoparticle encapsulation
in stabilizing catechins in alkaline solution. Food Chem. 2010, 122, 662–667. [CrossRef]
© 2016 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




The Potential Protective Effects of Polyphenols in
Asbestos-Mediated Inflammation and Carcinogenesis
of Mesothelium
Monica Benvenuto 1,†, Rosanna Mattera 1,†, Gloria Taffera 1, Maria Gabriella Giganti 1,
Paolo Lido 2, Laura Masuelli 3, Andrea Modesti 1 and Roberto Bei 1,*
1 Department of Clinical Sciences and Translational Medicine, University of Rome “Tor Vergata”, Rome 00133,
Italy; monicab4@hotmail.it (M.B.); rosannamatter@gmail.com (R.M.); g.taffera@gmail.com (G.T.);
giganti@med.uniroma2.it (M.G.G.); modesti@med.uniroma2.it (A.M.)
2 Internal Medicine Residency Program, University of Rome “Tor Vergata”, Rome 00133, Italy;
paulshore@virgilio.it
3 Department of Experimental Medicine, University of Rome “Sapienza”, Rome 00164, Italy;
Laura.masuelli@uniroma1.it
* Correspondence: bei@med.uniroma2.it; Tel.: +39-06-7259-6522
† These authors contributed equally to this work.
Received: 24 March 2016; Accepted: 4 May 2016; Published: 9 May 2016
Abstract: Malignant Mesothelioma (MM) is a tumor of the serous membranes linked to exposure to
asbestos. A chronic inflammatory response orchestrated by mesothelial cells contributes to the
development and progression of MM. The evidence that: (a) multiple signaling pathways are
aberrantly activated in MM cells; (b) asbestos mediated-chronic inflammation has a key role in
MM carcinogenesis; (c) the deregulation of the immune system might favor the development of
MM; and (d) a drug might have a better efficacy when injected into a serous cavity thus bypassing
biotransformation and reaching an effective dose has prompted investigations to evaluate the effects
of polyphenols for the therapy and prevention of MM. Dietary polyphenols are able to inhibit cancer
cell growth by targeting multiple signaling pathways, reducing inflammation, and modulating
immune response. The ability of polyphenols to modulate the production of pro-inflammatory
molecules by targeting signaling pathways or ROS might represent a key mechanism to prevent
and/or to contrast the development of MM. In this review, we will report the current knowledge
on the ability of polyphenols to modulate the immune system and production of mediators of
inflammation, thus revealing an important tool in preventing and/or counteracting the growth
of MM.
Keywords: malignant mesothelioma; inflammation; immune system; ROS and RNS; polyphenols;
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1. Introduction
Malignant Mesothelioma (MM) is a rare primary tumor arising from the mesothelial cell linings
of the serous membranes, most commonly involving the pleural and peritoneal spaces [1]. The
development of MM consists of a multi-step process driven by cellular DNA damage and tumor cell
promotion, in which genetically modified mesothelial cells are prone to grow, and tumor progression,
in which mesothelial cells develop a more aggressive phenotype and eventually acquire the ability to
metastasize and invade other tissues. The immune system’s involvement in the development of MM is
complex and multifaceted and is likely to involve both the innate and adaptive immune systems [2–4].
A chronic inflammatory response orchestrated by mesothelial cells contributes to the development
and progression of mesothelial cells into MM [2–4].
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Cisplatin and antifolate-based combination chemotherapy represent the standard first-line
treatment for advanced and unresectable MM patients [5]. However, taking into account the poor
outcome and toxicity of chemotherapy, novel approaches based on targeting abnormally activated
signaling pathways in MM cells were employed to improve survival in MM patients, as described in
the review by Remon et al. [5]. Clinical trials have employed antiangiogenic and vascular disrupting
agents, PI3K/AKT/mTOR pathway inhibitors, heat shock protein S90 inhibitors and arginine depletory
molecule, and immunotherapy. However, although some of these clinical trials sustain further studies,
the absolute response rates (RRs) are limited compared to other tumors [5].
The knowledge of MM pathophysiology might influence novel approaches [6–9].
The evidence that: (a) multiple signaling pathways are aberrantly activated in MM cells [10];
(b) asbestos-mediated chronic inflammation through the release of reactive oxygen species (ROS),
nitrogen species (RNS) and cytokines has a key role in MM carcinogenesis [11]; (c) the deregulation of
the immune system might favor the onset of MM [9]; and (d) a drug might have a better efficacy when
injected into a serous cavity, thus bypassing biotransformation and reaching an effective dose [12],
have prompted investigations to evaluate the effects of polyphenols for the therapy and prevention of
MM. Dietary polyphenols possess pleiotropic properties capable of being able to (a) inhibit cancer cell
growth by targeting multiple signaling pathways; (b) reduce inflammation and (c) modulate immune
response [13–17].
The ability to reduce chronic inflammation might represent a key mechanism to contrast the
development and/or to prevent MM. Accordingly, the local or systemic administration of polyphenols
might reduce the production of pro-inflammatory molecules by targeting signal transduction pathways
or ROS and RNS. In addition, the pro-oxidant activity of polyphenols could be a strategy to kill cancer
cells and thus to limit tumor growth [14].
In this review we will report the current knowledge on the ability of polyphenols to modulate the
immune system and production of mediators of inflammation in MM, thus revealing an important
tool to prevent and/or to counteract the growth of MM.
2. Polyphenols
Polyphenols, a large group of phytochemicals ubiquitously found in plants, are secondary
metabolites that perform functions in the host’s defense against pathogens, ultraviolet radiation,
and signal transduction [18]. Polyphenols are present in food and beverages of plant origin, such as
fruits, vegetables, cereals, spices, legumes, nuts, olives, tea, coffee, and wine [19]. These compounds
exhibit anti-inflammatory, antimicrobial, anticancer, and immunomodulatory activities, and thus are
beneficial for human health [20].
Polyphenols have a characteristic phenolic structure and are classified according to the number of
phenol rings that they contain and by the structural elements that bind these rings to one another. The
main classes of polyphenols are flavonoids, phenolic acids, stilbenes, and lignans [18,21].
Among flavonoids, the most important subclasses are flavonols, flavones, flavan-3-ols,
anthocyanins, flavanones, and isoflavones. The flavonoid subclasses dihydroflavonols, flavan-3,4-diols,
chalcones, dihydrochalcones, and aurones are minor components of our diet [22].
Quercetin, kaempferol, and myricetin, found mostly in fruits, edible plants, wine, and tea,
are the main flavonols [18]. The most abundant flavones in foods are apigenin (parsley, celery,
onion, garlic, pepper, chamomile tea) and luteolin (Thai chili, onion leaves, celery) [20]. The
flavan-3-ol subclass includes a wide range of compounds with different chemical structures that
can be divided in monomers, (+)-catechin, (´)-epicatechin, (+)-gallocatechin, (´)-epigallocatechin,
(´)-epicatechin-3-O-gallate, (´)-epigallocatechin-3-O-gallate, and polymers (proanthocyanidins) and
are found mainly in fruits, berries, cereals, nuts, chocolate, red wine, and tea [20]. The most
abundant anthocyanins (cyanidin, pelargonidin, delphinidin, peonidin, petunidin, and malvidin)
are found mainly in berries, cherries, red grapes, and currants [23]. Flavanones are present in
citrus fruit and the most important are hesperetin and naringenin and their correspondent glycated
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forms (naringin (naringenin-7-O-neohesperidoside), neohesperidin (hesperetin-7-O-neohesperidoside),
narirutin (naringenin-7-O-rutinoside), and hesperidin (hesperetin-7-O-rutinoside)) [21,24]. Daidzein,
genistein, and glyciten are the most common members of isoflavones, found mainly in soybeans, soy
products, and leguminous plants [25].
Among phenolic acids, the hydroxybenzoic acids (protocatechuic acid and gallic acid) are found
in few edible plants, while hydroxycinnamic acids (caffeic acid, ferulic acid, p-coumaric acid, and
sinapic acid) are found in fruits, coffee, and cereal grains [18].
The main member of stilbenes is resveratrol (3,5,41-trihydroxystilbene) and is present in
grapes, berries, plums, peanuts, and pine nuts [21]. Lignans (ecoisolariciresinol, matairesinol,
medioresinol, pinoresinol, and lariciresinol) are found in high concentration in linseed and in
minor concentration in algae, leguminous plants, cereals, vegetables, and fruits [18]. Curcumin
(1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione), a member of the curcuminoid family,
is another polyphenol compound found in turmeric, a spice produced from the rhizome of
Curcuma longa [26].
Polyphenols have important anti-inflammatory effects by regulating innate and adaptive
immunity through the modulation of different cytokines and also by acting as an immune surveillance
mechanism against cancers through the regulation of apoptosis [14]. Polyphenols also possess
anti-oxidant and pro-oxydant activities [27–30] and are able to modulate multiple targets involved in
carcinogenesis through simultaneous direct interaction or modulation of gene expression [13]. It is
worth nothing that these compounds are able to inhibit the growth of cancer cells without having an
adverse effect on normal cells. In this way, polyphenols play selectively an antitumor role in cancer [14].
However, despite promising results obtained from in vitro studies, the use of polyphenols as anticancer
agents is yet limited in clinical practice due to their low bioavailability in the human body, which
affects the effective dose delivered to cancer cells. In fact, polyphenols have a poor absorption and
biodistribution and a fast metabolism and excretion in the human body. Only nano- or micromolar
concentrations of polyphenols and polyphenol metabolites are found in plasma (0–4 μM after an intake
of 50 mg of aglycone equivalents) [31]. Several mechanisms limit the bioavailability of polyphenols,
including their metabolism in the gastrointestinal tract and liver, their binding on the surfaces of
blood cells and microbial flora in the oral cavity and gut, and regulatory mechanisms that prevent
the toxic effects of high compound levels on mitochondria or other organelles [32]. In addition to
endogenous factors, dietary factors can affect the bioavailability of polyphenols, such as food matrix
and food preparation techniques [33]. Promising strategies for improving the in vivo anticancer effects
of polyphenols are the combination of polyphenols, or polyphenols and conventional cancer treatments,
and the intratumoral administration of polyphenols, in order to bypass biotransformation and reach
an effective dose directly available at the site of tumor [22]. Several pre-clinical and Phase I and Phase
II clinical trials are employing intratumoral administration to deliver different therapeutics such as
drugs, viral-based cancer vaccines, immune cell-based vaccines, cytokines, DNA, bacterial products,
nanoparticles, and natural compounds to the tumor site [34–39]. Thus, intratumoral delivery of cancer
therapeutics could be a more efficient route of administration for several agents in easily accessible
tumors, such as MM. An intratumoral route of administration is able to prevent the occurrence of
systemic side effects and makes the therapeutic agents directly available at the tumor site, allowing for
the highest concentration close to tumor cells [40].
3. Asbestos Fibers and MM
MM was broadly observed in the mid-to-late 1960s among workers whose asbestos exposure
began 30–40 years earlier [41]. Accordingly, the development of MM has been linked to exposure
to asbestos fibers [1]. Although the use of asbestos has by now been prohibited in 55 countries, the
occurrence of asbestos-related diseases cannot decrease due to: the long latency period of MM, the
continued use of asbestos in Third World Countries and the continued occupational exposure in
Western Countries, such as the US and Europe [5,42].
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Thermo-resistant magnesium and calcium silicate fibers were usually used as insulating materials
in buildings and are deposited in the alveoli upon inhalation. Asbestos fibers are genotoxic, causing
random chromosome breaks [43]. Asbestos is classified into two major categories (amphibole and
serpentine) [43]. There are five members of the amphibole category: crocidolite (blue asbestos), amosite
(brown asbestos), tremolite, anthophyllite, and actinolite. The serpentine class is made up of only one
member (chrysotile, white asbestos) [43]. The International Agency for Research on Cancer (IARC)
classifies asbestos as a Group I carcinogen, because of the ability of chrysotile, crocidolite, and amosite
to induce lung cancer or MM [44]. Fiber translocation into the pleural cavity can occur across the
alveolar surface or via pulmonary lymph flow [45].
Although the link between MM and asbestos is well established, other carcinogenic or
co-carcinogenic events must be involved in MM development because only 10% of all MM cases
occur in asbestos-exposed subjects [46].
4. Chronic Inflammation Affects MM Development
4.1. Overproduction of ROS and RNS
A key immune-mediated involvement in asbestos-related carcinogenesis is superimposed on
the fibers’ damage to the mesothelium integrity. Mesothelial cells offer the first defense against
chemical and biological injuries by building a mechanical barrier and also by activating inflammation
through the release of ROS, RNS, and cytokines [47–51]. In fact, mesothelial cells express on their
luminal surface a sialomucins veil that electrostatically repels bacteria, viruses, and chemicals and
mechanically decreases their adherence to the mesothelial layer [47]. In addition, serous spaces
are surrounded by several defensive molecules including lysozyme, IgA immunoglobulins, and
complement factors [47]. Mesothelial cells damaged by asbestos fibers release inflammatory mediators
that maintain an inflammatory environment [48–50].
Asbestos induces free radical production by mesothelial cells through the iron content of the
asbestos fibers which increases the hydroxyl radical formation from hydrogen peroxide through
iron catalysed reactions and by inflammatory cells such as pulmonary alveolar macrophages and
neutrophils [52]. Kinnula et al. reported that inflammatory cells are the essential cells responsible
for the free radical-mediated mesothelial cell injury during asbestos exposure in vivo [53,54]. During
the respiratory burst, leukocytes produce multiple ROS, including hydroxyl radical, superoxide
anions, and hydrogen peroxide [55]. Hansen et al. reported that the geometry and/or chemical
composition of asbestos is important for the release of superoxide anions by leucocytes during
frustrated phagocytosis [56,57]. Indeed, crocidolite and amosite induced significant ROS generation
by neutrophils with a peak at 10 min, whereas that of chrysotile was ~25% of the crocidolite/amosite
response [58].
Leukocytes and mesothelial cells are also able to overexpress nitric oxide synthase (NOS) in
response to a variety of stimuli [52]. Inflammatory cytokines and oxidant stress can each augment iNOS
expression and activity in pulmonary alveolar epithelial cells [52]. The inhalation of either chrysotile or
crocidolite asbestos fibers was shown to induce the production of nitric oxide in bronchoalveolar lavage
cells and the formation of nitrotyrosine within the lungs and pleura [59]. The majority of MM was
found to express high levels of iNOS, while its expression was occasionally found in non-neoplastic
healthy mesothelium [60]. Thus, RNS might have an important role in asbestos-mediated mesothelioma
oncogenesis [52]. Peroxynitrite can be produced by the reaction of ROS with RNS. The overproduction
of ROS and RNS in the inflammatory microenvironment can cause DNA damage to mesothelial cells,
thus leading to the development of MM [61].
Macrophages are recruited and activated to clear away asbestos fibers [48]. Vitronectin captures
crocidolite asbestos and enhances fiber phagocytosis by mesothelial cells via integrins [62]. Yang et al.
provided the mechanistic rationale that associates asbestos-mediated mesothelial cell necrosis to the
chronic inflammatory reaction that is, in turn, linked with asbestos-mediated tumorigenesis [63].
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The authors reported that exposure of mesothelial cells to crocidolite asbestos induces them to
activate poly(ADP-ribose) polymerase, to secrete hydrogen peroxide, to deplete ATP, and to secrete
high-mobility group box 1 protein (HMGB1) into the extracellular space. This latter stimulates
macrophages to secrete tumor necrosis factor-α (TNF-α) and the inflammatory response associated
with asbestos-mediated carcinogenesis [2].
The asbestos-mediated chronic inflammation can increase the genotoxic damage due to the
secretion of free radicals [48].
In addition, several studies have shown that asbestos fibers induce the activation of EGFR
(Epidermal growth factor receptor) and thus MAPK (Mitogen-activated protein kinase) pathway and
AP-1 (Activator protein-1), leading to cell proliferation [43] (Figure 1).
Figure 1. The asbestos-mediated long-lasting inflammation in mesothelial cells. Biological responses of
mesothelial cells to asbestos fiber injury. Abbreviations: ROS, Reactive Oxygen Species; RNS, Reactive
Nitrogen Species; HMGB1, High-Mobility Group Box 1 Protein; PDGF, Platelet-Derived Growth Factors;
FGF, Fibroblast Growth Factor; IGF-1, Insulin-Like Growth Factor-1; VEGF, Vascular Endothelial
Growth Factor; TGF-β, Transforming Growth Factor-β; GM-CSF, Granulocyte/Macrophage-Colony
Stimulating Factor; IL-6, Interleukin-6; ET-1, Endothelin-1; IL-1 α/β, Interleukin-1 α/β; TNF-α, Tumor
Necrosis Factor-α; ENA-78, Epithelial Neutrophil Activating Protein-78; NF-κB, Nuclear Factor-kB;
EGFR, Epidermal Growth Factor Receptor; AP-1, Activator Protein-1.
4.2. Inflammasome Activation and Cytokines Secretion
It was reported that exposure to asbestos induces mesothelial cell necrosis and the release of
HMGB1 into the extracellular space [2]. HMGB1 is a key mediator of chronic inflammation in MM,
leading to Nalp3 inflammasome activation, macrophages accumulation, interleukin (IL)-1β and TNF-α
secretion, and thus to activation of the NF-κB pathway, which increases cell survival and tumor growth
after asbestos exposure [50]. A recent study reported that HMGB1 localization was regulated by its
acetylation. In fact, HMGB1 is localized in the nucleus to stabilize nucleosomes when it is in the
nonacetylated form. When HMGB1 is hyperacetylated, it is actively secreted into the extracellular
space. The authors indicated that HMGB1 hyperacetylation could be a sensitive and specific biomarker
to discriminate MM patients from asbestos-exposed individuals and from healthy unexposed controls.
They demonstrated that hyperacetylated HMGB1 was significantly higher in MM patients compared
with asbestos-exposed individuals and healthy controls, and did not vary with tumor stage [4].
Accordingly, asbestos fibers induce NLRP3 priming and activation, thus leading to increased
transcription of pro-inflammatory cytokines [63,64]. The inflammasome is a constituent of the
inflammation machinery which includes NOD-like receptors (NLRs) whose activation induces the
activation of caspase-1 and of the mature form pro-inflammatory cytokines, such as IL-1β and
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IL-18 [65,66]. It was reported that the NLRP3 inflammasome is necessary for early inflammatory
responses to asbestos, but it is not indispensable for asbestos-induced MM [64]. Hillegass et al. linked
NLRP3 activation to the release of several pro-inflammatory cytokines (IL-1β, IL-6 and IL-8) and the
vascular endothelial growth factor (VEGF) by fiber-stimulated human mesothelial cells in vitro [63].
They showed that mesothelial cells secrete IL-1β in response to asbestos/erionite and that through an
autocrine stimulation they undergo transformation [63]. In addition, the authors demonstrated that
treatment of MM tumor-bearing SCID mice with IL-1R (Interleukin-1 receptor) antagonist (Anakinra)
decreased the levels of IL-8 and VEGF in peritoneal lavage fluid, thus indicating that IL-1 has a key
role in regulating the production of other cytokines, thus affecting the tumorigenesis of mesothelial
cells [63]. A combination of IL-1β and TNF-α and erionite, or at least two cytokines together without
erionite, for at least four months, induced transformation of the immortalized, non-tumorigenic human
mesothelial cell line (MeT-5A) in vitro [67].
Accordingly, the release of cytokines driving inflammation represents a hallmark of exposure
to asbestos. Mesothelial inflammatory processes were reported to occur both in animal models and
in the lungs of patients exposed to asbestos. The production of different cytokines by mesothelial
cells indicates the particular transcriptional aptitude of mesothelial cells [68]. A cytokine network
is established in the serous membranes after mesothelial cell injury. Among the other cytokines,
chemokines produced by mesothelial cells can recruit leukocytes [68] (Figure 1). Driscoll et al. showed
that alveolar macrophages release TNF-α and IL-1 in rats exposed to crocidolite fibers [69]. In
addition, crocidolite enhanced the production of mitochondrial-derived hydrogen peroxide which in
turn contributes to crocidolite activation of NF-κB and increased MIP-2 (Macrophage Inflammatory
protein-2) gene expression in rat alveolar Type II cells [70]. Recently, Acencio et al. performed
an in vitro experiment to determine the acute inflammatory response of mesothelial cells damaged
by asbestos fibers. They showed that mesothelial cells exposed to either crocidolite or chrysotile
produced high levels of IL-6, IL-1β, MIP-2 and that these cytokines, when acting together with
asbestos, increased cell death of pleural mesothelial cells [49]. Indeed, they showed that anti-IL-1β
and anti-IL-6 antibodies significantly inhibited necrosis and apoptosis of mesothelial cells exposed
to crocidolite [49]. High levels of cytokines, including transforming growth factor beta (TGF-β), IL-6,
IL-1 and TNF-α were produced during MM development in an in vivo mouse model by the MM
cells and/or tumor infiltrating leukocytes [71]. TNF-α, IL-6, TGF-β, and IL-10 have been shown to
participate in cancer initiation and progression [72]. TGF-β counteracts proliferation and differentiation
of different immune cells, thus inducing immunosuppression and favoring cancer cell growth [73].
IL-1β may confer a proliferative advantage to cancer cells through autocrine mechanisms [74]. The
pro-inflammatory cytokines IL-1β, IL-6, IL-8, and VEGF promote tumor angiogenesis [75].
Fox et al. investigated the expression of CC and CXC chemokine genes I response to cytokines in
MM and mesothelial cell cultures derived from two different mouse strains (BALB/c and CBA/CaH).
They found that monocyte chemoattractant protein-1 (MCP-1)/JE, GRO-α/KC and RANTES were
expressed in mouse MM and mesothelial cells, whereas MIP-1α and MIP-2 were infrequently expressed
in these cell lines. MCP-1 was up-regulated in response to TNF-α and other cytokines [76]. MCP-1 and
RANTES have been shown to induce cell growth and to act as monocyte attractants [77]. GRO-α/KC
mRNA was overexpressed in cancer cells [76].
In vivo human studies were performed as well. The study of the RENAPE (French Network for
Rare Peritoneal Malignancies) aimed to evaluate the intraperitoneal levels of IL-6, IL-8, IL-10, TNF-α,
and sICAM (soluble intercellular adhesion molecule) in patients with pseudomyxoma peritonei and
peritoneal mesothelioma. They found that cancer patients had significantly higher intraperitoneal
cytokine levels than non-cancer patients. Cytokines peritoneal levels were significantly higher in
peritoneal fluids compared with matched sera, thus indicating the cytokines production from either
peritoneal cells or immune cells. In addition, they found a correlation between cytokine peritoneal
levels and aggressiveness of peritoneal surface malignancies [78].
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Comar et al., employing Luminex Multiplex Panel Technology, measured the serum levels
of a large panel of cytokines and growth factors from workers previously exposed to asbestos
(Asb-workers). They found that interferon (IFN)-α, EOTAXIN, and RANTES were highly expressed in
Asb-workers while IL-12(p40), IL-3, IL-1α, MCP-3, β-NGF (nerve growth factor), TNF-β, and RANTES
were highly produced in MM patients [79].
Xu et al. found that the amount of CCL3 in the serum of healthy subjects potentially exposed to
asbestos was significantly higher than for the control group. In addition, they observed that the pleural
plaque, benign hydrothorax asbestosis, and lung cancer patients had serum CCL3 levels similar to
that of healthy subjects potentially exposed to asbestos. They detected the CCL3 chemokine in the
serum of nine of the 10 patients diagnosed with MM and three patients with MM showed very high
CCL3 levels [80]. The elevated levels of CCL3 are very likely produced by macrophages chronically
interacting with asbestos fibers [80].
4.3. Innate Immunity and Cytokines in the Development of MM: MM-Driven Immunoediting
The activation of an adaptive immune response and/or cell proliferation by inflammasome
effectors is dependent on the cell type and tissue microenvironment [81]. The creation of a local
cytokine-based microenvironment is employed by MM to avoid the specific immune response. IL-1β
and IL-18 released by epithelial cells promote a Th2 response and recruitment of suppressive immune
cells in the absence of IL-12 rather than activating Th1 and Th17 cells. In addition, the release
of growth factors will favor angiogenesis and tumor invasiveness [81]. Indeed, IL-1β promotes
carcinogenesis and induces the invasive potential of malignant cells by favoring the expression
of matrix metalloproteinases, VEGF, chemokines, growth factors, and TGF-β in chronic inflamed
tissue [82]. However, inflammasome’s activation in dendritic cells (DCs) and macrophages can
bias Th1, Th17 immune response ability to reduce tumor growth in the presence of an appropriate
microenvironment [81]. We recently demonstrated that macrophages and CD4+ T-cells were polarized
by MM to produce IL-17, and that this cytokine exerts multiple tumor-supporting effects on both cell
growth and invasiveness [83].
Many MM-derived factors can skew monocyte development through the recruitment of
tumor-supporting cells, as reported by the presence of myeloid-derived suppressor cells (MDSCs)
in murine models of MM. Employing a mouse model of transplanted diffuse MM, it was reported
that MDSCs arise simultaneously with the recruitment of inflammatory cells in tumor foci. The
presence of MDSCs came before the accumulation of macrophages and regulatory T lymphocytes
which suppress T-cell function [84]. The cytokine profile three weeks after MM injection induced a
tumor microenvironment that suppressed immune surveillance and antitumor immunity. At that
stage, high expression levels of CXCL12, a chemotactic factor for MDSC, CCL9, and CXCL5, were
observed [84]. Veltman et al. demonstrated that BALB/c mice carrying MM have PMN-MDSCs that
induce immunosuppressive activity by releasing ROS via a cyclooxygenase-2 (COX-2)-dependent
mechanism, which then induces T-cell immunosuppression [85]. The same authors inoculated mice
with MM cells and treated them with celecoxib, a COX-2 inhibitor. They observed that treatment
of tumor-bearing mice with the celecoxib prevented the local and systemic expansion of all MDSC
subtypes [86]. However, a recent study by Yang et al. also reported that aspirin (a COX inhibitor)
exerted a protective effect against MM growth through a COX-2-independent mechanism. In fact,
the authors demonstrated that aspirin inhibited MM growth in a xenograft model by inhibiting the
activities of HMGB1. The authors concluded that aspirin could be administered to people who were
exposed to asbestos or erionite to prevent or delay MM development and progression [87].
Tumor-associated macrophages (TAMs) represent a major link between inflammation and
cancer [88]. M1 macrophages have immunostimulatory Th1-activating properties while M2 cells
have poor antigen-presenting capacity and suppress Th1 adaptive immunity [88]. Prostaglandin E2
(PGE2), TGF-β, IL-6, and IL-10 promote M2 macrophage polarization. Inhibition of the antitumor
responses is achieved not only by the secretion of immunosuppressive cytokines but also by the
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selective recruitment of naive T-cells, trough CCL18, and of Th2 and Treg, through CCL17 and
CCL22 [88]. The majority of TAMs in MM have the M2 phenotype. By retrospectively reviewing 667
tumor specimens of patients with MM it was found that, within the tumors, macrophages comprised
27% of the tumor area and had an immunosuppressive phenotype [89]. Hegmans et al. detected in
pleural effusion of MM patients several cytokines involved in immune suppression and angiogenesis,
including TGF-β. In addition, they demonstrated that human MM tissue contained a high number
of Foxp3+ CD4+ CD25+ regulatory T-cells and when the CD25+ regulatory T-cells were depleted
in an in vivo mouse model, mice survival increased [90]. The expression profile of cytokines and
chemokines in mice transplanted with MM cells was consistent with M2-polarized cells [91]. They
found elevated IL-10 and IL-10RA expression as well as expression of CXCL13, CCL22, CCL24, and
their respective receptors [91]. In a recent report by Napolitano et al., it was also observed that mice
with germline BAP1 (BRCA1-associated protein-1) mutations (BAP1+/´ mice) exposed to low-dose
asbestos fibers had alterations in the peritoneal inflammatory response. In fact, BAP1+/´ mice showed
higher levels of pro-tumorigenic M2 macrophages and lower levels of M1 macrophages, cytokines
(IL-6, leukemia inhibitory factor), and chemokines (MCP-1, keratinocyte-derived chemokine). Thus,
these mice showed higher MM incidence after exposure to very low doses of asbestos, doses that
rarely induced MM in wild-type mice. The authors suggested that patients with this mutation have an
increased risk of developing MM, even after a minimal exposure of asbestos, due to alterations of the
inflammatory response [92].
Asbestos induces partially functional decreases in T helper (Th) cells, natural killer (NK) cells,
and cytotoxic T lymphocytes (CTLs) in patients with MM [93]. To elucidate the antitumor immune
interference of asbestos caused to CD4+ T-cells, Maeda et al. established an in vitro T-cell model
of long-term and low-level exposure to chrysotile asbestos from a human adult T-cell leukemia
virus-1-immortalized human polyclonal CD4+ T-cell line (MT-2). They observed a decreased expression
of CXCR3, IFN-γ, and CXCL10/IP10 in the MT-2 cell line, thus suggesting that exposure to asbestos
may impair the antitumor immune responses [94]. They also found that chrysotile asbestos reduces the
chemokine receptor CXCR3 expression in human peripheral CD4+ T-cells, thus suggesting that immune
response might be impaired in patients with asbestos-related disease because the low expression
of CXCR3 might reduce chemotaxis [95]. In addition, in a recent report, the same authors showed
that an asbestos-induced apoptosis-resistant subline (MT-2Rst), which was established from a human
adult T-cell leukemia virus-immortalized T-cell line (MT-2Org) by continuous exposure to asbestos
chrysotile-B, produced high levels of TGF-β1 through phosphorylation of p38 MAPK, and acquire
resistance to inhibition of cell growth by TGF-β1 [96]. It was observed that asbestos can trigger a cascade
of biological events including the increase of IL-10 expression and Bcl-2 overexpression in human T-cell
leukemia virus-immortalized T-cell line and that CD4+ T lymphocytes from MM patients had significant
up-regulation of Bcl-2 expression thus affecting their survival. The Bcl-2 up-regulation might affect the
Treg population thus contributing to immunosuppression in cancer patients [97] (Figure 2).
Figure 2. Role of the innate immunity in the development of MM. Tumor-associated macrophages
(TAMs) represent a major link between inflammation and cancer. The majority of TAMs in MM have the
M2 phenotype. M2 TAMs have poor antigen-presenting capacity, suppress T-cells adaptive immunity,
and support MM growth.
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5. Effects of Polyphenols in MM
5.1. Effects of Polyphenols on ROS in MM
Epidemiological studies indicate the existence of an inverse correlation between the consumption
of polyphenols and the incidence of various chronic diseases and cancer. In fact, polyphenols
possess anti-oxidant activities and thus are able to protect cells from oxidative stress, providing
an anti-inflammatory effect [98–100]. For instance, flavonoids are able to scavenge ROS generated
by neutrophils and macrophages and to impair ROS production by inhibiting NADPH oxidase,
xanthine oxidase, and myeloperoxidase [27,29,30]. In addition, polyphenols modulate the activity
of ROS-generating enzymes, such as COX and lipoxygenase (LOX) [30,101,102]. Furthermore,
polyphenols inhibit NO production from activated macrophages [103,104] and also inducible nitric
oxide synthase (iNOS) protein and its mRNA expression [105].
However, polyphenols also possess a pro-oxidant activity, depending on their concentration and
chemical structure, cell type, or experimental conditions (pH, redox stress) [106,107]. The pro-oxidant
effect of polyphenols is important in cancer cells, since this effect leads to oxidative breaking of DNA,
inhibition of cell growth and apoptosis [14]. In fact, in the last few years the use of pro-oxidants against
cancer is an emerging topic of research, since it has been observed that ROS contribute to the cytotoxic
activity of some chemotherapeutics and that cancer cells are more susceptible to ROS than normal
cells [107].
As for MM, asbestos produces ROS and RNS, that act as second messengers to drive initiation and
progression of MM-carcinogenesis, through genetic alterations, activation of the survival pathways,
stimulation of matrix metalloproteinases (MMP), and angiogenic signaling. Furthermore, ROS mediate
extrinsic and intrinsic pathways of apoptosis, necrosis, and autophagy, thus ROS production is also
used as a therapy for MM, to limit tumor growth [51]. In this way, polyphenols, which also possess
pro- and anti-oxidant properties, are a promising tool to treat MM.
Several studies have explored the ability of different polyphenols as pro-oxidant agents in MM.
It has been demonstrated that curcumin (40 μM) increased ROS production in HMESO cells in vitro,
leading to caspase-1 activation and pyroptotic cell death of MM cells [108].
Satoh et al. demonstrated that the flavan-3-ol epigallocatechin-3-gallate (EGCG) induced ROS
production and impaired the mitochondrial membrane potential and these effects were responsible for
the induction of apoptosis in MM cells in vitro. In fact, the treatment of MM cells with ROS scavengers,
such as tempol and catalase, inhibited the apoptosis induced by EGCG [109]. A similar effect was
reported by Ranzato et al. They demonstrated that EGCG induced both apoptotic and necrotic cell
death in MM cells. In particular, it has been shown that EGCG had a pro-oxidant effect and induced
cell death by the release of H2O2 outside of cells [110]. Similarly, a recent study showed that EGCG,
when added to culture medium, induced H2O2 formation and decreased proliferation both in MM
cells and MET5A cells (normal cells). Due to EGCG instability that causes H2O2 formation in culture
medium, ECGC was added to cells in presence of catalase (CAT) and exogenous superoxide dismutase
(SOD). In this way, EGCG decreased cell proliferation only in MM cells and induced mitochondrial
apoptosis [111].
The increased levels of ROS induce the nuclear translocation and activation of Nrf2 (nuclear factor
E2-related factor 2) in MM. Normally, Nrf2 is sequestered in cytosol by its inhibitor Keap-1 (Kelch-like
ECH-associated protein 1); when MM arises, the ROS levels increase and one or multiple cysteines
bind to Keap-1, which undergoes a conformational change releasing Nrf2. Next, Nrf2 translocates to
the nucleus and activates the transcription of downstream genes, as HO-1. The high levels of Nrf2
create an anti-oxidant environment which is resistant to MM-therapy. It has been demonstrated that
the combined treatment of clofarabine and resveratrol inhibited the Nrf2 pathway by reducing nuclear
localization of Nrf2 and by decreasing Nrf2 and HO-1 protein levels in vitro. Lee et al. hypothesized that
resveratrol with clofarabine decreased the chemoresistance of MM, modulating the levels of proteins
activated by ROS, as Nrf2 [112]. In addition, the same authors demonstrated that the combined
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treatment of clofarabine and resveratrol increased the nuclear expression of phospho-p53. Hence,
p53 induced the expression of pro-apoptotic proteins, as Bax, Puma, and Noxa [113]. Faraonio et al.
indicated the possibility of crosstalk between p53 and Nrf2. p53 could prevent the generation of an
anti-oxidant environment counteracting the effect of Nrf2 and inducing apoptosis [114].
A recent study by Pietrofesa et al. reported the in vitro ability of LGM2605 (a synthetic lignan
secoisolariciresinol diglucoside) to reduce asbestos-induced cytotoxicity and ROS generation and to
induce phase II anti-oxidant enzymes stimulated by Nrf2 (HO-1 and Nqo1) in murine peritoneal
macrophages. LGM2605 acted as a direct free radical scavenger and anti-oxidant in a dose-dependent
manner. They hypothesized the possible use of this synthetic lignan as a chemopreventive agent in the
development of asbestos-induced MM [115].
Kostyuk et al. have conducted several studies on the efficacy of different polyphenols in preventing
asbestos-induced injury of peritoneal macrophages and red blood cells. They demonstrated that
quercetin and rutin were able to reduce peritoneal macrophages injury caused by asbestos and
to scavenge ROS. They suggested that quercetin and rutin could be promising drug candidates
for a prophylactic asbestos-induced disease [116]. Similarly, in another study they explored the
efficacy of the main polyphenolic constituents of green tea extract, (´)-epicatechin gallate (ECG)
and (´)-epigallocatechin gallate (EGCG). They observed that ECG and EGCG had a protective effect
against chrysotile and crocidolite-induced cell injuries in peritoneal macrophages, and this effect was
attributed to the scavenger properties towards the superoxide anion and the ability of polyphenols to
chelate iron ions [117]. They also concluded in a comparative study that the protective effect increased
in the following series: rutin < dihydroquercetin < quercetin < ECG < EGCG [118].
Effects of polyphenols on ROS in MM are summarized in Table 1.
Table 1. Effects of polyphenols on ROS production and scavenging in MM.




Ò Pyroptotic cell death
EGCG
ACC-meso 1, Y-meso 8A,
EHMES-10, EHMES-1,
MSTO-211H, REN,
MM98, BR95, E198 cells
Ò ROS
[109–111]
Ò H2O2 outside of cells













Ò Phase II anti-oxidant
enzymes














Ó: decrease; Ò: increase.
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5.2. Effects of Polyphenols on Mediators of Inflammation in MM
Inflammation plays a critical role in the process of carcinogenesis by regulating the different
stages of initiation, promotion, progression, and metastasis, and also the responses to therapies [119].
In this regard, it has been observed that the tumor microenvironment is infiltrated by innate and
adaptive immune cells, such as macrophages, neutrophils, mast cells, myeloid-derived suppressor
cells, dendritic cells, NKcells, and T and B lymphocytes that communicate to each other through the
production of cytokines [119].
Polyphenols possess the ability to directly modulate innate and also adaptive immune cells that
infiltrate the tumor. In fact, it has been demonstrated that different polyphenols, such as genistein,
EGCG, curcumin, and resveratrol, are able to modulate these immune cells to enhance an antitumor
response or to suppress the immune escape of tumors [14].
In addition, it has been demonstrated that polyphenols possess the ability to control the
inflammatory process by inhibiting the secretion of pro-inflammatory cytokines (IL-1β, IL-2, IL-6,
IFN-γ, TNF-α) and chemokines [20]. The inhibition of the production of these cytokines also led to
inhibition of ROS, since cytokines trigger ROS production [120]. Several studies have reported this
ability of polyphenols. For instance, curcumin and different flavonoids, such as flavones, EGCG, and
flavonols, are able to inhibit the secretion of TNF-α, IL-6, IL-1β, IL-8, and IFN-γ from various cell
types [121–129].
By the activation of different transcription factors, such as NF-κB, AP-1, STAT-3, SMAD, and
caspases, cytokines can promote or inhibit tumor progression [119]. It has been demonstrated
that polyphenols, such as resveratrol, flavones, flavonols, EGCG, anthocyanins, isoflavones, and
curcumin, are able to modulate NF-κB [130–138]. Curcumin, resveratrol, and EGCG also inhibit STAT-3
activation [139–142].
Inflammation, and thus the production of inflammasome, has an essential role in the development
of MM [143]. As previously described, the active inflammasome induces the activation of caspase-1
and mature form of pro-inflammatory cytokines IL-1β and IL-18 and thus the inflammatory cell death
pyroptosis [144].
In this regard, the anti-inflammatory effect of polyphenols, by regulating innate and adaptive
immunity through the modulation of different cytokines, chemokines, and transcription factors could
be a promising strategy to contrast development of this type of cancer [14].
Miller et al. has observed that curcumin was able to kill MM cells via pyroptosis without the
classical inflammasome-related cytokines, IL-1β and IL-18. They observed that curcumin increased the
concentration of caspase-1 but did not increase IL-1β and IL-18 expression. Furthermore, they observed
a higher concentration of pro-IL-1β, indicating a block of the maturation of cytokine. Curcumin
treatment increased the expression of NLRP3, which alone induces a decreased NF-κB expression.
Curcumin reduced the inflammasome-related gene expression, NF-κB, TLR and IL-1 pathway. In
addition, curcumin down-regulated the expression of MYD88, NLRC4, and TXNIP and up-regulated
HSP90AA1 (heat shock protein 90 kDa alpha class A member 1), IL-12, IL-6. Hence, curcumin has an
anti-inflammatory effect on MM cells by blocking cytokine processing of IL-1β and genes involved in
the NF-κB pathway [108].
Wang et al. demonstrated that curcumin also suppressed MM cell growth in vitro and in vivo
(oral administration) and enhanced the efficacy of cisplatin. In particular, curcumin inhibited cell
growth through activation of p38 kinase, caspases 9 and 3, increased pro-apoptotic protein Bax levels,
stimulated PARP cleavage, and induced apoptosis. In addition, curcumin stimulated expression of
novel transducers of cell growth suppression, such as CARP-1, XAF1, and SULF1 proteins [145].
It has been shown that the activated NF-κB and high levels of the activated phosphorylated
STAT-3 are present in MM. Cioce et al. showed that butein (3,4,21,41-tetrahydroxychalcone), a natural
inhibitor of NF-κB and STAT-3, inhibits the migration of MM cells and strongly affects the clonogenicity
of MM cells in vitro by inhibiting the phosphorylation of STAT-3, the nuclear localization of NF-κB
and the interaction of NF-κB and phospho-STAT-3. Different genes involved in cancer progression of
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pro-angiogenic cytokines (VEGF) and of IL-6 and IL-8 were also down-regulated. Furthermore, they
showed that butein was able to severely affect tumor engraftment and to potentiate the anticancer
effects of pemetrexed in mouse xenograft models in vivo. Intraperitoneal treatment with butein was
safe, since butein does not significantly affect the viability of human untransformed mesothelial cells
in vitro or the survival of tumor-free mice in vivo [146].
The activation of STAT-3 is associated to PIAS-3 expression levels in MM cell lines. PIAS-3
specifically interacts with phospho-STAT-3 and decreases the STAT-3 DNA-binding capacity and
transcriptional activity. The overexpression of PIAS-3 can inhibit STAT-3 transcriptional activity and
induces apoptosis in vitro [147]. Dabir et al. demonstrated that an inverse correlation between PIAS-3
and STAT-3 is present in MM cells. In fact, they showed that high levels of phospho-STAT-3 and low
levels of PIAS-3 are present. Furthermore, they observed that treatment with curcumin (1.0 μM) was
able to increase PIAS-3 levels and thereby decreased STAT-3 phosphorylation and cell viability in MM
cells [148].
Flaxseed lignans, enriched in secoisolariciresinol diglucoside (SDG), have been investigated for
the prevention of asbestos-induced peritoneal inflammation in a mouse model of accelerated MM
development that recapitulates many of the molecular, genetic, and cell-signaling features of human
MM after asbestos injection. Mice were supplemented with a diet containing lignans seven days before
an intraperitoneal injection of crocidolite asbestos and three days after asbestos exposure; they were
evaluated for abdominal inflammation, pro-inflammatory/pro-fibrogenic cytokine release, WBC gene
expression changes, and oxidative and nitrosative stress in peritoneal lavage fluid. The results showed
that dietary lignan administration diminished acute inflammation by decreasing the number of WBCs
and the release of IL-1β, IL-6, HMGB1, and TNF-α pro-inflammatory cytokines and pro-fibrogenic
active TGF-β1. Furthermore, lignan acted as an anti-oxidant by decreasing mRNA levels of inducible
nitric oxide synthase, and thus nitrosative and oxidative stress, and by increasing the expression of the
Nrf2-regulated anti-oxidant enzymes, HO-1, Nqo1 and Gstm1 [42].
In a preliminary study, Martinotti et al. demonstrated that the combined treatment with EGCG,
ascorbate, and gemcitabine (AND) synergistically affected the viability of MM cells [149]. Next, the
same authors showed that AND treatment increased DAPK2 (Death-Associated Protein Kinase 2), a
calcium- and calmodulin-dependent regulator of apoptosis and tumor suppressor, and TNSFR11B
expression. The TNSFR11B gene encodes a cytokine receptor belonging to the TNF receptor family,
called osteoprotegerin (OPG). OPG acts as receptor for RANK ligand, inhibiting RANK-dependent
activation of NF-κB. Furthermore, they observed a decreased expression of TNFAIP3 (tumor necrosis
factor-α-induced protein 3), an inhibitor of NF-κB activation and TNF-mediated apoptosis, typically
up-regulated in inflammation and in tumors. In this study, they found a down-regulated TNFAIP3
expression because AND treatment decreased p65 subunit of NF-κB. Hence, the combined treatment
induced a non-inflammatory apoptosis [150].
The transcription factor Specificity protein 1 (Sp1) is highly expressed in different cancers and is
associated with poor prognosis. Sp1 modulates the expression of oncogenes and tumor suppressors,
as well as genes involved in proliferation, differentiation, the DNA damage response, apoptosis,
senescence, and angiogenesis and it is also implicated in inflammation and genomic instability [151].
Lee et al. showed that resveratrol decreased the Sp1 expression and down-regulated
Sp1-dependent gene expression in MM. They observed a decreased tumor volume and an increased
number of caspase-3-positive cells after intraperitoneal treatment with resveratrol [152]. In another
study, it has been demonstrated that the combined treatment of clofarabine and resveratrol decreased
levels of Sp1, p-Akt, c-Met, cyclin D1, and p21 [153].
Similarly, Chae et al. found that 20–80 μM quercetin suppressed the Sp1 expression and modulated
the target genes, as cyclin D1, Mcl-1 (myeloid cell leukemia), and survivin in MM. Furthermore,
quercetin induced apoptosis through the Bid, caspase-3, and PARP cleavage, the up-regulation of Bax,
and down-regulation of Bcl-xL in MSTO-211H cells [154].
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In another study, the same authors focused on the anticancer effects of honokiol (HNK), a
pharmacologically active component found in the traditional Chinese medicinal herb, Magnolia species.
It has been observed that HNK inhibited MM cell growth, down-regulated Sp1 expression and Sp1
target transcription factors, including cyclin D1, Mcl-1, and survivin, and induced the apoptosis by
increasing Bax, reducing Bid and Bcl-xL and activating caspase-3 and PARP [155].
Kim et al. found that licochalcone A (LCA), a natural product derived from the Glycyrrhiza inflata,
regulated the cell growth and down-regulated the Sp1 expression in MSTO-211H and H28 cell lines.
Furthermore, LCA down-regulated the expression of Sp1 downstream genes, as cyclin D1, Mcl1 and
survivin. Like quercetin and honokiol, LCA increased Bax and decreased Bcl-2 expression, inducing
the mitochondrial apoptotic pathway [156].
Lee et al. demonstrated that hesperidin, a flavanone presents in citrus fruits, inhibited the
cell growth and down-regulated the SP1 expression in MSTO-211H cells. Hesperidin significantly
suppressed mRNA and protein levels of Sp1 and regulated the expression of p27, p21, cyclin D1,
Mcl-1, and survivin. Furthermore, hesperidin induced the apoptosis pathway through cleavages of
Bid, caspase-3, and PARP, and up-regulation of Bax and down-regulation of Bcl-xL [157]. Similarly,
the same authors showed that cafestol and kahweol, two diterpenes present in the typical bean of
Coffea Arabica, induced apoptosis and suppressed the Sp1 protein levels in MSTO-211H cells. These
compounds modulated the expression of genes regulated by Sp1, including cyclin D1, Mcl-1, and
survivin. Furthermore, the cafestol treatment induced the cleavage of Bid, caspase-3, and PARP, and
the kahweol treatment up-regulated Bax and down-regulated Bcl-xL [158].
The effect of a novel mixture containing lysine, proline, ascorbic acid, and green tea extract has
been investigated by Roomi et al. in MM cell line MSTO-211H. They demonstrated that this mixture
was able to inhibit MMP secretion and invasion and thus is a promising candidate for therapeutic use
in the treatment of MM [159].
Effects of polyphenols on mediators of inflammation in MM are summarized in Table 2.
Table 2. Effects of polyphenols on production of mediators of inflammation in MM.
Polyphenols
Cell Type or Animal
Model







Ò pro-IL-1β and block of maturation
of IL-1 β
Ò NLRP3








Flaxseed Lignans MM-prone Nf2
+/mut
mice




EGCG + Ascorbate +














[153]Ó c-Met, cyclin D1, p21
530
Nutrients 2016, 8, 275
Table 2. Cont.
Polyphenols
Cell Type or Animal
Model
Effects on Inflammation Ref.
Quercetin MSTO-211H cells




[155]Ó cyclin D1, Mcl-1, survivin
Ò Apoptosis
Licochalcone A MSTO-211H and H28
cells
Ó Sp1




[157]Ó p27, p21, cyclin D1, Mcl-1,
survivin
Ò Apoptosis
Cafestol and kahweol MSTO-211H cells
Ó Sp1, cyclin D1, Mcl-1, survivin
[158]Ò Apoptosis
Ó: decrease; Ò: increase.
6. Conclusions
The immune system, and in particular inflammation, has an essential role in the development
of MM. A long-lasting inflammatory response orchestrated by mesothelial cells contributes to the
initiation, promotion, and progression of mesothelial cells into MM. Polyphenols possess important
anti-inflammatory properties by regulating innate and adaptive immunity through the modulation of
different mediators of inflammation and also by acting as an immune surveillance mechanism against
cancers through the regulation of apoptosis. Furthermore, polyphenols possess a pro-oxidant activity,
which could be used against cancer. In fact, in the last few years the use of ROS-generating agents
against cancer is an emerging strategy to kill cancer cells, since it has been observed that ROS contribute
to the cytotoxic activity of some chemotherapeutics and that cancer cells are more susceptible to ROS
than normal cells.
Accordingly, the local or systemic administration of polyphenols might reduce the production of
pro-inflammatory molecules by targeting signal transduction pathways or ROS and RNS in order to
prevent MM. On the other hand, the administration of polyphenols might also induce MM cell death
to limit tumor growth.
Furthermore, MM is a tumor arising from the mesothelial cell linings of the serous membranes,
thus the local administration of polyphenols in the serous cavity might be a better strategy to treat
MM, because in this way polyphenols could bypass biotransformation and could reach an effective
dose directly available at the site of tumor.
Thus the use of polyphenols might represent a promising strategy to contrast the development
and/or to prevent MM.
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